<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002898.pub5" GROUP_ID="EYES" ID="789399071908463424" MERGED_FROM="" MODIFIED="2015-01-09 14:00:08 +0000" MODIFIED_BY="Anupa Shah" REVIEW_NO="KIWI01" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-01-09 14:00:08 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2013-09-24 19:45:03 +0100" MODIFIED_BY="[Empty name]">Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis</TITLE>
<CONTACT MODIFIED="2015-01-09 14:00:08 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="8890" ROLE="AUTHOR"><FIRST_NAME>Kirk</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Wilhelmus</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>kirkw@bcm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Cullen Eye Institute, Department of Ophthalmology</DEPARTMENT><ORGANISATION>Baylor College of Medicine</ORGANISATION><CITY>Houston</CITY><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 713 798 5952</PHONE_1><FAX_1>+1 713 798 4142</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2015-01-09 14:00:08 +0000" MODIFIED_BY="Anupa Shah"><PERSON ID="8890" ROLE="AUTHOR"><FIRST_NAME>Kirk</FIRST_NAME><MIDDLE_INITIALS>R</MIDDLE_INITIALS><LAST_NAME>Wilhelmus</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>kirkw@bcm.edu</EMAIL_1><ADDRESS><DEPARTMENT>Cullen Eye Institute, Department of Ophthalmology</DEPARTMENT><ORGANISATION>Baylor College of Medicine</ORGANISATION><CITY>Houston</CITY><REGION>Texas</REGION><COUNTRY CODE="US">USA</COUNTRY><PHONE_1>+1 713 798 5952</PHONE_1><FAX_1>+1 713 798 4142</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2015-01-09 10:42:47 +0000" MODIFIED_BY="Anupa Shah">
<UP_TO_DATE>
<DATE DAY="31" MONTH="12" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="12" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="12" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-01-09 11:13:27 +0000" MODIFIED_BY="Anupa Shah">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-01-09 11:05:23 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="9" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Issue 1, 2015: Studies using the antiviral drug foscarnet have been included in this update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-09 11:13:27 +0000" MODIFIED_BY="Anupa Shah">
<DATE DAY="9" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Issue 1, 2015: Updated searches found 31 trials to include in the analysis (<LINK REF="STD-Cao-2001" TYPE="STUDY">Cao 2001</LINK>; <LINK REF="STD-Colin-1982" TYPE="STUDY">Colin 1982</LINK>; <LINK REF="STD-Dai-2009a" TYPE="STUDY">Dai 2009a</LINK>; <LINK REF="STD-Dai-2009b" TYPE="STUDY">Dai 2009b</LINK>; <LINK REF="STD-Fu-2012" TYPE="STUDY">Fu 2012</LINK>; <LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>; <LINK REF="STD-Han-2014" TYPE="STUDY">Han 2014</LINK>; <LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>; <LINK REF="STD-Li-2013a" TYPE="STUDY">Li 2013a</LINK>; <LINK REF="STD-Li-2013b" TYPE="STUDY">Li 2013b</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Lin-2014" TYPE="STUDY">Lin 2014</LINK>; <LINK REF="STD-Liu-2010" TYPE="STUDY">Liu 2010</LINK>; <LINK REF="STD-Liu-2011" TYPE="STUDY">Liu 2011</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Liu-2014a" TYPE="STUDY">Liu 2014a</LINK>; <LINK REF="STD-Maichuk-1980" TYPE="STUDY">Maichuk 1980</LINK>; <LINK REF="STD-Ramirez-2002" TYPE="STUDY">Ramirez 2002</LINK>; <LINK REF="STD-Shen-2014" TYPE="STUDY">Shen 2014</LINK>; <LINK REF="STD-Sun-2013a" TYPE="STUDY">Sun 2013a</LINK>; <LINK REF="STD-Tanaka-1988a" TYPE="STUDY">Tanaka 1988a</LINK>; <LINK REF="STD-Tanaka-1988b" TYPE="STUDY">Tanaka 1988b</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Yang-2008" TYPE="STUDY">Yang 2008</LINK>; <LINK REF="STD-Yu-2012a" TYPE="STUDY">Yu 2012a</LINK>; <LINK REF="STD-Zhang-2014" TYPE="STUDY">Zhang 2014</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>; <LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>; <LINK REF="STD-Zheng-2010" TYPE="STUDY">Zheng 2010</LINK>; <LINK REF="STD-Zhu-2012" TYPE="STUDY">Zhu 2012</LINK>); a secondary citation of an existing study (<LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>); an additional 46 excluded studies (<LINK REF="STD-Cao-2012" TYPE="STUDY">Cao 2012</LINK>; <LINK REF="STD-Cao-2013" TYPE="STUDY">Cao 2013</LINK>; <LINK REF="STD-Gong-2013" TYPE="STUDY">Gong 2013</LINK>; <LINK REF="STD-Gulinuer-2011" TYPE="STUDY">Gulinuer 2011</LINK>; <LINK REF="STD-He-2014" TYPE="STUDY">He 2014</LINK>; <LINK REF="STD-Hu-2013" TYPE="STUDY">Hu 2013</LINK>; <LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>; <LINK REF="STD-Huang-2013" TYPE="STUDY">Huang 2013</LINK>; <LINK REF="STD-Jiang-2011" TYPE="STUDY">Jiang 2011</LINK>; <LINK REF="STD-Jing-2010" TYPE="STUDY">Jing 2010</LINK>; <LINK REF="STD-Li-2012" TYPE="STUDY">Li 2012</LINK>; <LINK REF="STD-Li-2013c" TYPE="STUDY">Li 2013c</LINK>; <LINK REF="STD-Li-2014a" TYPE="STUDY">Li 2014a</LINK>; <LINK REF="STD-Li-2014b" TYPE="STUDY">Li 2014b</LINK>; <LINK REF="STD-Li-2014c" TYPE="STUDY">Li 2014c</LINK>; <LINK REF="STD-Lin-2013a" TYPE="STUDY">Lin 2013a</LINK>; <LINK REF="STD-Lin-2013b" TYPE="STUDY">Lin 2013b</LINK>; <LINK REF="STD-Liu-2014b" TYPE="STUDY">Liu 2014b</LINK>; <LINK REF="STD-Long-2011" TYPE="STUDY">Long 2011</LINK>; <LINK REF="STD-Ma-2010" TYPE="STUDY">Ma 2010</LINK>; <LINK REF="STD-Ma-2011" TYPE="STUDY">Ma 2011</LINK>; <LINK REF="STD-Ma-2013" TYPE="STUDY">Ma 2013</LINK>; <LINK REF="STD-Rykun-1988" TYPE="STUDY">Rykun 1988</LINK>; <LINK REF="STD-Su-2010" TYPE="STUDY">Su 2010</LINK>; <LINK REF="STD-Sun-2012" TYPE="STUDY">Sun 2012</LINK>; <LINK REF="STD-Sun-2014" TYPE="STUDY">Sun 2014</LINK>; <LINK REF="STD-Wan-2014" TYPE="STUDY">Wan 2014</LINK>; <LINK REF="STD-Wang-2010a" TYPE="STUDY">Wang 2010a</LINK>; <LINK REF="STD-Wang-2010b" TYPE="STUDY">Wang 2010b</LINK>; <LINK REF="STD-Wang-2011" TYPE="STUDY">Wang 2011</LINK>; <LINK REF="STD-Wang-2014b" TYPE="STUDY">Wang 2014b</LINK>; <LINK REF="STD-Wei-2012" TYPE="STUDY">Wei 2012</LINK>; <LINK REF="STD-Wen-2011" TYPE="STUDY">Wen 2011</LINK>; <LINK REF="STD-Weng-2014" TYPE="STUDY">Weng 2014</LINK>; <LINK REF="STD-Xu-2012" TYPE="STUDY">Xu 2012</LINK>; <LINK REF="STD-Yang-2012" TYPE="STUDY">Yang 2012</LINK>; <LINK REF="STD-Yi-2011" TYPE="STUDY">Yi 2011</LINK>; <LINK REF="STD-Yu-2012b" TYPE="STUDY">Yu 2012b</LINK>; <LINK REF="STD-Yu-2014" TYPE="STUDY">Yu 2014</LINK>; <LINK REF="STD-Yuan-2011" TYPE="STUDY">Yuan 2011</LINK>; <LINK REF="STD-Zhan-2011" TYPE="STUDY">Zhan 2011</LINK>; <LINK REF="STD-Zhang-2010" TYPE="STUDY">Zhang 2010</LINK>; <LINK REF="STD-Zhao-2010" TYPE="STUDY">Zhao 2010</LINK>; <LINK REF="STD-Zhao-2013" TYPE="STUDY">Zhao 2013</LINK>; <LINK REF="STD-Zheng-2014" TYPE="STUDY">Zheng 2014</LINK>; <LINK REF="STD-Zhong-2003" TYPE="STUDY">Zhong 2003</LINK>); and an unpublished registered trial (<LINK REF="STD-Ajanta-Pharma-2013" TYPE="STUDY">Ajanta Pharma 2013</LINK>). A recent systematic review comparing acyclovir and ganciclovir was incorporated (<LINK REF="REF-Li-2014d" TYPE="REFERENCE">Li 2014d</LINK>).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-05 21:40:07 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-05 21:38:35 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Issue 7, 2011: The review was edited. While new searches were not done for this interim update, two citations (<LINK REF="REF-Croxtall-2011" TYPE="REFERENCE">Croxtall 2011</LINK>; <LINK REF="REF-Guess-2010" TYPE="REFERENCE">Guess 2010</LINK>) were added to the '<LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK>' section. Satpathy 2010 citation updated to <LINK REF="REF-Satpathy-2011" TYPE="REFERENCE">Satpathy 2011</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-05 21:39:13 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="11" YEAR="2010"/>
<DESCRIPTION>
<P>Issue 12, 2010: This review was substantively updated with the following changes:</P>
<UL>
<LI>The original title of 'Therapeutic interventions for herpes simplex virus epithelial keratitis' was changed to 'Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.'</LI>
<LI>Six new studies comparing ganciclovir and acyclovir were added (<LINK REF="STD-Chen-2008" TYPE="STUDY">Chen 2008</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Liu-2009a" TYPE="STUDY">Liu 2009a</LINK>; <LINK REF="STD-Xu-2009a" TYPE="STUDY">Xu 2009a</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>).</LI>
<LI>Risk of bias tables were completed for all included studies.</LI>
<LI>Trials of botanicals and traditional Chinese medicines were added to excluded studies.</LI>
<LI>Data on adverse drug-related effects added (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</LI>
<LI>Hazard ratios from healing curves were incorporated into the results (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</LI>
<LI>
<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> was added to describe studies excluded because of insufficient data.</LI>
<LI>A literature flow diagram was included (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</LI>
</UL>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2013-08-17 14:38:04 +0100" MODIFIED_BY="Anupa Shah">
<DATE DAY="6" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-01-05 21:39:58 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>Issue 1, 2008: two new studies (<LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK> and <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>) added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_MINOR" MODIFIED="2015-01-05 21:40:07 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>Issue 1, 2007: one new study (<LINK REF="STD-Kitano-1985" TYPE="STUDY">Kitano 1985</LINK>) added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2014-10-14 14:04:31 +0100" MODIFIED_BY="Anupa Shah">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2014-10-14 14:04:31 +0100" MODIFIED_BY="Anupa Shah">
<SOURCE MODIFIED="2014-09-08 18:20:04 +0100" MODIFIED_BY="[Empty name]">
<NAME>Grant 1 U01 EY020522 National Eye Institute, National Institutes of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION>
<P>Methodological support provided by the Cochrane Eyes and Vision Group, US Project</P>
</DESCRIPTION>
</SOURCE>
<SOURCE>
<NAME>Research to Prevent Blindness, Inc</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Sid W Richardson Foundation</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2014-10-14 14:04:31 +0100" MODIFIED_BY="Anupa Shah">
<NAME>National Institute for Health Research</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<UL>
<LI>Richard Wormald, Co-ordinating Editor for the Cochrane Eyes and Vision Group (CEVG) acknowledges financial support for his CEVG research sessions from the Department of Health through the award made by the National Institute for Health Research to Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology.</LI>
<LI>The NIHR also funds the CEVG Editorial Base in London.</LI>
</UL>
<P>The views expressed in this publication are those of the authors and not necessarily those of the NIHR, NHS, or the Department of Health.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-01-09 10:45:04 +0000" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2015-01-09 10:45:04 +0000" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2015-01-04 14:48:17 +0000" MODIFIED_BY="Anupa Shah">Antiviral medicines, interferon, and corneal surface removal in the treatment of herpes simplex virus infection of the eye</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-09 10:45:04 +0000" MODIFIED_BY="Anupa Shah">
<P>
<B>Review question</B>
<BR/>We compared different treatments of people's eyes infected with herpes simplex virus (HSV).</P>
<P>
<B>Background</B>
<BR/>HSV infection of the eye causes pain and hazy vision. Antiviral eye medicines, interferon drops, and superficial wiping have been used to cure HSV infection of the corneal surface.</P>
<P>
<B>Study characteristics</B>
<BR/>This update, current to December 2014, uses a network of 137 studies of 8333 eyes to compare antiviral medicines and to find out if interferon or debridement would help. Between one and 28 studies were available to compare seven ophthalmic antiviral drugs, an antiviral taken by mouth, interferon, office procedures to remove the eye's infected surface, and other medicines.</P>
<P>
<B>Key results</B>
<BR/>The first antivirals, idoxuridine and vidarabine, seem better than no treatment in healing HSV dendritic keratitis within two weeks. Topically applied trifluridine, acyclovir, or brivudine are better and safer than idoxuridine, cure about 90% of treated eyes within two weeks, and have no significant differences in effectiveness. The evidence is conflicting whether ganciclovir is as good as or better than acyclovir. Determining the role of antiviral pills is limited by few studies and inconsistent findings. Interferon, a natural part of the immune system that can be given as an eye drop, is active against HSV infection of the cornea. The integrated use of interferon and an antiviral drug might be slightly better than an antiviral drug by itself. Another treatment is to rub off the infected surface of the eye, but using a wiping method followed by an antiviral drug is not consistently better than just an antiviral medication.</P>
<P>
<B>Quality of the evidence</B>
<BR/>Comparisons of one ophthalmic antiviral drug to another have a moderate quality of evidence, except for the appraisal comparing ganciclovir and acyclovir where studies are inconsistent. The quality of the evidence is moderate to low when an ophthalmic antiviral drug was compared to combined antiviral and interferon treatments or to combined antiviral treatment and debridement. Evidence is scarce or poor for placebo-controlled comparisons, comparisons of antiviral treatment to interferon or to debridement, and evaluations of antiviral pills. Proper randomisation could not be assured in nearly a quarter of the studies. Patients or examiners could have known which treatment was assigned in at least half of the studies.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-05 22:05:05 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-12-06 15:30:36 +0000" MODIFIED_BY="[Empty name]">
<P>Eye disease due to herpes simplex virus (HSV) commonly presents as epithelial keratitis which, though usually self-limiting, may persist or progress without treatment.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-24 12:44:29 +0100" MODIFIED_BY="[Empty name]">
<P>To compare the relative effectiveness of antiviral agents, interferon, and corneal debridement in the treatment of HSV epithelial keratitis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-05 22:05:05 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (2014, Issue 12), PubMed (January 1946 to 31 December 2014), EMBASE (January 1980 to 31 December 2014), Latin American and Caribbean Health Sciences Literature Database (LILACS) (January 1982 to 31 December 2014), System for Information on Grey Literature in Europe (OpenGrey) (January 1995 to 31 December 2014), BIOSIS (January 1926 to 5 May 2014), Scopus (January 1966 to 31 December 2014), Japan Science and Technology Institute (J-Global) (January 1975 to 31 December 2014), China National Knowledge Infrastructure (CNKI) (January 1979 to 31 December 2014), British Library's Electronic Table of Contents (Zetoc) (January 1993 to 7 May 2014). We looked for trials listed on the the <I>meta</I>Register of Controlled Trials (<A HREF="http://www.controlled-trials.com/">www.controlled-trials.com</A>), ClinicalTrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/search/en">www.who.int/ictrp/search/en</A>), Chinese Clinical Trial Registry, the U.S. Food and Drug Administration (FDA) (<A HREF="http://www.fda.gov/">www.fda.gov/</A>), National Institute for Health and Clinical Excellence (NICE) (<A HREF="http://www.evidence.nhs.uk/">www.evidence.nhs.uk</A>) and the European Medicines Agency (EMA) (<A HREF="http://www.ema.europa.eu/ema/">www.ema.europa.eu/ema/</A>) as of 31 December 2014. There were no language or date restrictions in the search for trials. We also culled literature digests and conference proceedings as of 15 April 2014. There were no language or date restrictions in the search for trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-12-09 23:47:47 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised and quasi-randomised trials of HSV dendritic or geographic epithelial keratitis were included that reported the proportion of eyes healed at one week, two weeks, or both after enrolment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-12-26 21:00:36 +0000" MODIFIED_BY="[Empty name]">
<P>We tabulated data on study characteristics, risk of bias, and outcomes and used direct comparisons to estimate a risk ratio (RR) and, when feasible, a hazard ratio (HR) with a 95% confidence interval (CI). Heterogeneity was assessed by an inconsistency index. A multiple treatment comparison meta-analysis consolidated direct and indirect comparisons of relative healing at 14 days.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-12-26 21:04:31 +0000" MODIFIED_BY="[Empty name]">
<P>One hundred thirty-seven studies involving 8333 eyes met the inclusion criteria. Placebo-controlled studies were heterogeneous in comparison with idoxuridine (RR 1.74; 95% CI 1.03 to 2.91) and few in number for vidarabine (RR 1.81; 95% CI 1.09 to 3.01), interferon (RR 1.32; 95% CI 1.06 to 1.64), and debridement. Vidarabine (RR 1.13; 95% CI 1.02 to 1.25), trifluridine (RR 1.30; 95% CI 1.18 to 1.43), acyclovir (RR 1.23; 95% CI 1.14 to 1.34), and brivudine (RR 1.34; 95% CI 1.18 to 1.51) were more effective than idoxuridine. Trifluridine (RR 1.17; 95% CI 1.03 to 1.32) and acyclovir (RR 1.11; 95% CI 1.03 to 1.19) were more effective than vidarabine. No significant differences in healing emerged among trifluridine, acyclovir, brivudine, and foscarnet although few studies compared brivudine or foscarnet with other antivirals. Any potential advantage of ganciclovir compared to acyclovir was mitigated by study heterogeneity and possible publication bias. Only one study evaluated the joint use of two topical antivirals. In a limited number of studies, oral acyclovir (RR 0.92; 95% CI 0.79 to 1.07) or the combination of oral acyclovir with a topical antiviral (RR 1.36; 95% CI 0.68 to 2.74) appeared as effective as a single topical antiviral agent. Compared to topical antiviral monotherapy, the combination of an antiviral with either interferon or debridement had inconsistent effects on expediting healing and improving outcome.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-12-26 21:05:47 +0000" MODIFIED_BY="[Empty name]">
<P>Placebo-controlled studies of HSV epithelial keratitis are limited to superseded interventions. Trifluridine and acyclovir are more effective than idoxuridine or vidarabine and similar in therapeutic effectiveness. Brivudine and foscarnet do not substantially differ in effectiveness from trifluridine or acyclovir. Ganciclovir is at least as effective as acyclovir. The addition of interferon to a nucleoside antiviral agent and the combination of debridement with antiviral treatment need to be further assessed to substantiate any possible advantage in healing.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-05 22:00:53 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-01-04 16:37:13 +0000" MODIFIED_BY="Anupa Shah">
<P>Herpes simplex virus (HSV) affects most people (<LINK REF="REF-Smith-2002" TYPE="REFERENCE">Smith 2002</LINK>). Upon initial exposure, HSV type 1 often infects subclinically but sometimes produces a primary viral syndrome afflicting the eyelids and ocular surface. After establishing latency within neurons of the trigeminal ganglion, periodic shedding of HSV into the tear film is commonly asymptomatic. On occasion, usually years to decades after initial exposure, reactivation of latent HSV erupts into infection and inflammation of the eye. Epithelial keratitis is its most frequent and conspicuous manifestation.</P>
<CONDITION MODIFIED="2015-01-04 16:37:13 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Epidemiology</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Public health importance</HEADING>
<P>HSV is an epidemiologically important cause of infectious and inflammatory eye disease among children, adolescents, adults, and the elderly (<LINK REF="REF-Liesegang-2001" TYPE="REFERENCE">Liesegang 2001</LINK>; <LINK REF="REF-Wilhelmus-2008a" TYPE="REFERENCE">Wilhelmus 2008a</LINK>). The incidence of first-episode ocular HSV in population studies from Europe, North America, and South America is 4 to 13 per 100,000 person-years (<LINK REF="REF-Adhin-2012" TYPE="REFERENCE">Adhin 2012</LINK>; <LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989b" TYPE="REFERENCE">Liesegang 1989b</LINK>; <LINK REF="REF-Mortensen-1979" TYPE="REFERENCE">Mortensen 1979</LINK>; <LINK REF="REF-Ribaric-1976" TYPE="REFERENCE">Ribaric 1976</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>). The incidence of subsequent HSV keratitis is 6 to 18 per 100,000 person-years (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989b" TYPE="REFERENCE">Liesegang 1989b</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>). The joint incidence of new or recurrent HSV keratitis is 12.5 to 31.5 people per 100,000 person-years (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989b" TYPE="REFERENCE">Liesegang 1989b</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>). Worldwide, an estimated 1.5 million people experience HSV keratitis each year (<LINK REF="REF-Farooq-2012" TYPE="REFERENCE">Farooq 2012</LINK>).</P>
<P>The prevalence of a history of ocular HSV disease is about 2 to 15 per 10,000 in the U.S. population (<LINK REF="REF-Liesegang-1989a" TYPE="REFERENCE">Liesegang 1989a</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>). Approximately 3% have visual acuity of the previously diseased eye worse than 20/200 (<LINK REF="REF-Wilhelmus-1981b" TYPE="REFERENCE">Wilhelmus 1981b</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>). Globally, between one and ten million persons have had herpetic eye disease, and many are left with severely impaired vision of the affected eye. Ocular herpes is an important infective cause of corneal blindness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Epithelial keratitis</HEADING>
<P>Epithelial keratitis is the most common form of HSV eye disease, accounting for 50% to 80% of ocular herpes (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989a" TYPE="REFERENCE">Liesegang 1989a</LINK>; <LINK REF="REF-Uchio-1994" TYPE="REFERENCE">Uchio 1994</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>). The incidence of new or recurrent HSV epithelial keratitis is estimated at 5 to 22 people per 100,000 person-years (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989b" TYPE="REFERENCE">Liesegang 1989b</LINK>; <LINK REF="REF-Mortensen-1979" TYPE="REFERENCE">Mortensen 1979</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>). On a global scale, about one million people suffer a new or repeat episode of HSV epithelial keratitis each year.</P>
<P>Dendritic epithelial keratitis, a branching pattern of painful infection affecting the corneal surface, is the customary configuration (<LINK REF="REF-Tabery-2010" TYPE="REFERENCE">Tabery 2010</LINK>). Geographic epithelial keratitis is a macroulcerative form of corneal HSV infection that complicates topical corticosteroid use or systemic immunosuppression.</P>
<P>HSV epithelial keratitis is typically unilateral. The contralateral eye is infrequently affected, either simultaneously or subsequently (<LINK REF="REF-Liesegang-2001" TYPE="REFERENCE">Liesegang 2001</LINK>), in healthy individuals. People with atopy or an immune deviation may be predisposed to HSV epithelial keratitis of both eyes (<LINK REF="REF-Souza-2003" TYPE="REFERENCE">Souza 2003</LINK>; <LINK REF="REF-Wilhelmus-1981c" TYPE="REFERENCE">Wilhelmus 1981c</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Etiology</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Clinical virology</HEADING>
<P>Branching corneal disease was first mentioned in a 10<SUP>th</SUP>-century medical text (<LINK REF="REF-Wood-1936" TYPE="REFERENCE">Wood 1936</LINK>) and redescribed in the 19<SUP>th</SUP> century with febrile illness (<LINK REF="REF-Kipp-1880" TYPE="REFERENCE">Kipp 1880</LINK>) or as a spontaneous episode (<LINK REF="REF-Hansen-Grut-1886" TYPE="REFERENCE">Hansen Grut 1886</LINK>) to which the term "keratitis dendritica" was given (<LINK REF="REF-Emmert-1885" TYPE="REFERENCE">Emmert 1885</LINK>). Onset of dendritic corneal inflammation was realised to be part of an acute syndrome (<LINK REF="REF-Horner-1871" TYPE="REFERENCE">Horner 1871</LINK>; <LINK REF="REF-Verhoeff-1909" TYPE="REFERENCE">Verhoeff 1909</LINK>) and by 1920 was shown to be due to a transmissible virus (<LINK REF="REF-Gr_x00fc_ter-1920" TYPE="REFERENCE">Grüter 1920</LINK>).</P>
<P>HSV-1 is the cause of nearly all infective dendritic epithelial keratitis. HSV-2 is much less commonly isolated from the cornea than HSV-1 (<LINK REF="REF-Kaneko-2008" TYPE="REFERENCE">Kaneko 2008</LINK>; <LINK REF="REF-Neumann_x002d_Haefelin-1978" TYPE="REFERENCE">Neumann-Haefelin 1978</LINK>; <LINK REF="STD-Vannini-1986" TYPE="STUDY">Vannini 1986</LINK>). Varicella-zoster virus epithelial keratitis can resemble HSV epithelial keratitis (<LINK REF="REF-Bierly-1994" TYPE="REFERENCE">Bierly 1994</LINK>; <LINK REF="REF-Hu-2010" TYPE="REFERENCE">Hu 2010</LINK>; <LINK REF="REF-Pavan_x002d_Langston-1973" TYPE="REFERENCE">Pavan-Langston 1973</LINK>) and may occur with or without dermatoblepharitis during chickenpox or shingles. Rare causes of dendritic epithelial keratitis include cytomegalovirus (<LINK REF="REF-Wilhelmus-1996b" TYPE="REFERENCE">Wilhelmus 1996b</LINK>), Epstein-Barr virus (<LINK REF="REF-Pflugfelder-1990" TYPE="REFERENCE">Pflugfelder 1990</LINK>), human herpesvirus 6 (<LINK REF="REF-Boto_x002d_de_x002d_los_x002d_Bueis-2013" TYPE="REFERENCE">Boto-de-los-Bueis 2013</LINK>; <LINK REF="REF-Okuno-2011" TYPE="REFERENCE">Okuno 2011</LINK>), and adenovirus (<LINK REF="REF-Chodosh-1995" TYPE="REFERENCE">Chodosh 1995</LINK>). Laboratory testing can help to establish the etiology of atypical cases (<LINK REF="REF-Chanzy-2002" TYPE="REFERENCE">Chanzy 2002</LINK>; <LINK REF="REF-Farhatullah-2004" TYPE="REFERENCE">Farhatullah 2004</LINK>; <LINK REF="REF-Kowalski-1993" TYPE="REFERENCE">Kowalski 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Differential diagnosis</HEADING>
<P>Dendritiform keratopathy is a condition of the corneal surface characterized by a curvilinear or arborescent pattern that may simulate HSV epithelial keratitis but is due to various noninfective causes. Ramous epithelial changes can be associated with various disorders of the ocular surface. For example, a pseudodendrite can be made up of regenerating or hypertrophic epithelium. Whorling epithelial granularity may be due to dysfunction of the limbal stem cells. Intraepithelial deposits and drug-induced changes can also take on a vortex formation. Fungal and am&#339;bic infections of the cornea have been mistaken as HSV keratitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reactivation and recurrence</HEADING>
<P>Primary ocular herpes may cause dendritic keratitis in susceptible children and adults (<LINK REF="REF-Darougar-1985" TYPE="REFERENCE">Darougar 1985</LINK>). HSV epithelial keratitis can occur following primary transmission from mother to neonate (<LINK REF="REF-Liesegang-2001" TYPE="REFERENCE">Liesegang 2001</LINK>) and from donor to corneal transplant recipient (<LINK REF="REF-Borderie-2004" TYPE="REFERENCE">Borderie 2004</LINK>; <LINK REF="REF-Hassan-2009" TYPE="REFERENCE">Hassan 2009</LINK>; <LINK REF="REF-Remeijer-1997" TYPE="REFERENCE">Remeijer 1997</LINK>; <LINK REF="REF-Robert-2005" TYPE="REFERENCE">Robert 2005</LINK>). Reinfection with a different HSV strain is also possible (<LINK REF="REF-Remeijer-2002" TYPE="REFERENCE">Remeijer 2002</LINK>). Much more commonly, HSV epithelial keratitis follows viral reactivation in a latently infected person. After a recurrence, 5% to 10% of people develop a subsequent recurrence of epithelial keratitis each year (<LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>), regardless of gender or ethnicity (<LINK REF="REF-HEDS-Group-2001" TYPE="REFERENCE">HEDS Group 2001</LINK>). Events that induce viral reactivation and shedding or that enhance susceptibility of the eye to viral infection can precipitate an infective episode (<LINK REF="REF-Webre-2012" TYPE="REFERENCE">Webre 2012</LINK>). Identifying triggers is difficult since any suspected causal association that is made in hindsight is liable to be faulty. For example, a suspected link between psychological stress and herpetic keratitis remains indecisive (<LINK REF="REF-HEDS-Group-2000a" TYPE="REFERENCE">HEDS Group 2000a</LINK>; <LINK REF="REF-Kip-2001" TYPE="REFERENCE">Kip 2001</LINK>). With the caveat of recall bias, the following are situations thought to instigate HSV epithelial keratitis:</P>
<SUBSECTION>
<HEADING LEVEL="5">Reactivation of latent virus</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Altered homeostasis</HEADING>
<UL>
<LI>Fever (<LINK REF="REF-Ashaye-2008" TYPE="REFERENCE">Ashaye 2008</LINK>; <LINK REF="REF-Yorston-1992" TYPE="REFERENCE">Yorston 1992</LINK>)</LI>
<LI>Advancing age (<LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Radiation exposure</HEADING>
<UL>
<LI>Excess sunlight (<LINK REF="REF-Ludema-2014a" TYPE="REFERENCE">Ludema 2014a</LINK>; <LINK REF="REF-Stan-2000" TYPE="REFERENCE">Stan 2000</LINK>)</LI>
<LI>Photodynamic therapy of corneal neovascularisation (<LINK REF="REF-Dantas-1997" TYPE="REFERENCE">Dantas 1997</LINK>; <LINK REF="REF-Yoon-2010" TYPE="REFERENCE">Yoon 2010</LINK>)</LI>
<LI>Corneal cross-linking with ultraviolet light (<LINK REF="REF-Kymionis-2007" TYPE="REFERENCE">Kymionis 2007</LINK>; <LINK REF="REF-Yuksel-2011" TYPE="REFERENCE">Yuksel 2011</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Ocular irritants or injections</HEADING>
<UL>
<LI>Contact lens wear (<LINK REF="REF-Hamroush-2014" TYPE="REFERENCE">Hamroush 2014</LINK>; <LINK REF="REF-Mucci-2009" TYPE="REFERENCE">Mucci 2009</LINK>)</LI>
<LI>Corneal injury with a foreign body (<LINK REF="REF-Sundmacher-1986" TYPE="REFERENCE">Sundmacher 1986</LINK>)</LI>
<LI>Periocular injection (<LINK REF="REF-Lingua-1985" TYPE="REFERENCE">Lingua 1985</LINK>)</LI>
<LI>Intraocular injection (<LINK REF="REF-Khalili-2009" TYPE="REFERENCE">Khalili 2009</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Topical ophthalmic drugs</HEADING>
<UL>
<LI>Prostaglandin analogues and other glaucoma drugs (<LINK REF="REF-Alm-2008" TYPE="REFERENCE">Alm 2008</LINK>; <LINK REF="REF-Villegas-2008" TYPE="REFERENCE">Villegas 2008</LINK>)</LI>
<LI>Mitomycin-C and other cytotoxic agents (<LINK REF="REF-Rao-2009" TYPE="REFERENCE">Rao 2009</LINK>; <LINK REF="REF-Siddique-2011" TYPE="REFERENCE">Siddique 2011</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Anterior segment surgery</HEADING>
<UL>
<LI>Laser iridotomy (<LINK REF="REF-Hou-2004" TYPE="REFERENCE">Hou 2004</LINK>)</LI>
<LI>Cataract extraction (<LINK REF="REF-Du-2010" TYPE="REFERENCE">Du 2010</LINK>; <LINK REF="REF-Gu-2014" TYPE="REFERENCE">Gu 2014</LINK>; <LINK REF="REF-Lu-2011" TYPE="REFERENCE">Lu 2011</LINK>; <LINK REF="REF-Patel-2009" TYPE="REFERENCE">Patel 2009</LINK>; <LINK REF="REF-Sun-2013b" TYPE="REFERENCE">Sun 2013b</LINK>; <LINK REF="REF-Yang-2011" TYPE="REFERENCE">Yang 2011</LINK>)</LI>
<LI>Keratorefractive surgery (<LINK REF="REF-Santos-1983" TYPE="REFERENCE">Santos 1983</LINK>)</LI>
<LI>Laser-assisted in situ keratomileusis (LASIK), photorefractive keratectomy (PRK), laser astigmatic keratotomy, and phototherapeutic keratectomy (PTK) (<LINK REF="REF-Di-2011" TYPE="REFERENCE">Di 2011</LINK>; <LINK REF="REF-G_x00f3_mez-Garc_x00ed_a-2004" TYPE="REFERENCE">Gómez García 2004</LINK>; <LINK REF="REF-Hamoudi-2013" TYPE="REFERENCE">Hamoudi 2013</LINK>; <LINK REF="REF-Lu-2006" TYPE="REFERENCE">Lu 2006</LINK>; <LINK REF="REF-Nagy-2003" TYPE="REFERENCE">Nagy 2003</LINK>; <LINK REF="REF-Nataneli-2013" TYPE="REFERENCE">Nataneli 2013</LINK>)</LI>
<LI>Lamellar keratoplasty (<LINK REF="REF-Jezegabel-1967" TYPE="REFERENCE">Jezegabel 1967</LINK>)</LI>
<LI>Penetrating keratoplasty (<LINK REF="REF-Ambr_x00f3_sio-2001" TYPE="REFERENCE">Ambrósio 2001</LINK>; <LINK REF="REF-Miyajima-2003" TYPE="REFERENCE">Miyajima 2003</LINK>; <LINK REF="REF-Rezende-2004" TYPE="REFERENCE">Rezende 2004</LINK>)</LI>
<LI>Endothelial keratoplasty (<LINK REF="REF-Prasher-2009" TYPE="REFERENCE">Prasher 2009</LINK>)</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Susceptibility to reactivated virus</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Ophthalmic corticosteroids</HEADING>
<UL>
<LI>Topical corticosteroid (<LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>; <LINK REF="REF-Sundmacher-1978c" TYPE="REFERENCE">Sundmacher 1978c</LINK>; <LINK REF="REF-Williams-1977" TYPE="REFERENCE">Williams 1977</LINK>)</LI>
<LI>Subconjunctival or subtenon corticosteroid (<LINK REF="REF-Hashizume-2009" TYPE="REFERENCE">Hashizume 2009</LINK>; <LINK REF="REF-Inoue-2014" TYPE="REFERENCE">Inoue 2014</LINK>)</LI>
<LI>Intravitreal corticosteroid (<LINK REF="REF-Gulkilik-2007" TYPE="REFERENCE">Gulkilik 2007</LINK>; <LINK REF="REF-Shtein-2007" TYPE="REFERENCE">Shtein 2007</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Other immunosuppressive treatment</HEADING>
<UL>
<LI>Topical ophthalmic calcineurin inhibitor (<LINK REF="REF-Field-1995" TYPE="REFERENCE">Field 1995</LINK>; <LINK REF="REF-Joseph-2005" TYPE="REFERENCE">Joseph 2005</LINK>)</LI>
<LI>Inhaled corticosteroid (<LINK REF="REF-Garcia_x002d_Medina-2011" TYPE="REFERENCE">Garcia-Medina 2011</LINK>; <LINK REF="REF-McDonald-2015" TYPE="REFERENCE">McDonald 2015</LINK>)</LI>
<LI>Systemic immunosuppressants following organ or bone marrow transplantation (<LINK REF="REF-Hayashi-2008" TYPE="REFERENCE">Hayashi 2008</LINK>; <LINK REF="REF-Kremer-1991" TYPE="REFERENCE">Kremer 1991</LINK>; <LINK REF="REF-Ng-1998" TYPE="REFERENCE">Ng 1998</LINK>)</LI>
<LI>Systemic immunosuppressants given for autoimmune disorders (<LINK REF="REF-Larra_x00f1_aga-Fragoso-2015" TYPE="REFERENCE">Larrañaga Fragoso 2015</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Immune dysregulation</HEADING>
<UL>
<LI>Atopy (<LINK REF="REF-Borkar-2014" TYPE="REFERENCE">Borkar 2014</LINK>; <LINK REF="REF-Kaiserman-2006" TYPE="REFERENCE">Kaiserman 2006</LINK>; <LINK REF="REF-Prabriputaloong-2006" TYPE="REFERENCE">Prabriputaloong 2006</LINK>; <LINK REF="REF-Rezende-2006" TYPE="REFERENCE">Rezende 2006</LINK>)</LI>
<LI>HIV infection (<LINK REF="REF-Hodge-1997" TYPE="REFERENCE">Hodge 1997</LINK>)</LI>
<LI>Diabetes mellitus (<LINK REF="REF-Kaiserman-2005" TYPE="REFERENCE">Kaiserman 2005</LINK>)</LI>
<LI>Malnutrition (<LINK REF="REF-Ukety-1991" TYPE="REFERENCE">Ukety 1991</LINK>)</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Natural history</HEADING>
<P>Without treatment, dendritic epithelial keratitis tends to be self-limited (<LINK REF="REF-Thygeson-1976" TYPE="REFERENCE">Thygeson 1976</LINK>). Some eyes heal in a few days, but natural healing often takes longer than two weeks (<LINK REF="REF-Liesegang-1989a" TYPE="REFERENCE">Liesegang 1989a</LINK>). Inappropriate treatment can worsen corneal inflammation and contribute to visual loss. Any treatment that speeds healing would reduce the opportunity for unsuitable management (<LINK REF="REF-Kaufman-1972" TYPE="REFERENCE">Kaufman 1972</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-04 16:01:35 +0000" MODIFIED_BY="Anupa Shah">
<SUBSECTION>
<HEADING LEVEL="3">Antiviral drugs</HEADING>
<P>Antiviral compounds emerged as potential treatments for herpetic keratitis during the last half of the 20<SUP>th</SUP> century (<LINK REF="REF-Bauer-1985" TYPE="REFERENCE">Bauer 1985</LINK>; <LINK REF="STD-Graupner-1969" TYPE="STUDY">Graupner 1969</LINK>). In 1962 idoxuridine (iododeoxyuridine, IDU), a pyrimidine analogue, was the first effective antiherpetic drug (<LINK REF="REF-Kaufman-1962" TYPE="REFERENCE">Kaufman 1962</LINK>). In the following decade a purine analogue, vidarabine (adenine arabinoside, ARA-A), entered ophthalmic practice (<LINK REF="REF-Whitley-1980" TYPE="REFERENCE">Whitley 1980</LINK>). Idoxuridine and vidarabine were then progressively superseded by other nucleoside analogues: trifluridine (trifluorothymidine, TFT) (<LINK REF="REF-Carmine-1982" TYPE="REFERENCE">Carmine 1982</LINK>), acyclovir (acycloguanosine, ACV) (<LINK REF="REF-Richards-1983" TYPE="REFERENCE">Richards 1983</LINK>; <LINK REF="REF-Wagstaff-1994" TYPE="REFERENCE">Wagstaff 1994</LINK>), brivudine (bromovinyldeoxyuridine, BVDU) (<LINK REF="REF-De-Clerq-2005" TYPE="REFERENCE">De Clerq 2005</LINK>), and ganciclovir (dihydroxypropoxymethylguanine, DHPG) (<LINK REF="REF-Chou-2014" TYPE="REFERENCE">Chou 2014</LINK>; <LINK REF="REF-Croxtall-2011" TYPE="REFERENCE">Croxtall 2011</LINK>; <LINK REF="REF-Tabbara-2010" TYPE="REFERENCE">Tabbara 2010</LINK>). Cidofovir (hydroxyphosphonylmethoxypropylcytosine, HPMPC) is an acyclic nucleotide analogue. Foscarnet (phosphonoformic acid, PFA) is a non-nucleoside antiviral compound.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interferon</HEADING>
<P>As synthetic antivirals were under development, a cytokine that could interfere with viral replication was discovered in 1957. Interferon, found to be active against HSV in 1960, was first evaluated for HSV epithelial keratitis in 1963 (<LINK REF="STD-Tommila-1963" TYPE="STUDY">Tommila 1963</LINK>) and emerged as a novel management strategy for viral eye disease (<LINK REF="REF-Jones-1967" TYPE="REFERENCE">Jones 1967</LINK>). Comparative treatment trials of topical interferon that began in 1976 showed type I interferons&#65293;interferon-&#945; (leukocyte interferon) and interferon-&#946; (fibroblast interferon)&#65293;to be effective for treating HSV epithelial keratitis (<LINK REF="REF-Pollard-1982" TYPE="REFERENCE">Pollard 1982</LINK>; <LINK REF="REF-Sundmacher-1982" TYPE="REFERENCE">Sundmacher 1982</LINK>). Several formulations and dosages of exogenous interferon were tested: alone, with an antiviral nucleoside, and after debridement (<LINK REF="REF-Cantell-1995" TYPE="REFERENCE">Cantell 1995</LINK>; <LINK REF="REF-Sundmacher-1983" TYPE="REFERENCE">Sundmacher 1983</LINK>). Formerly available in limited amounts, purified interferon is now produced by recombinant DNA technology. Though not marketed for ophthalmic use, interferon eye drops can be prepared extemporaneously (<LINK REF="REF-Ruiz-2007" TYPE="REFERENCE">Ruiz 2007</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Corneal surface debridement</HEADING>
<P>Curettage and cauterisation of the ocular surface came into use in 1890 (<LINK REF="REF-Kipp-1890" TYPE="REFERENCE">Kipp 1890</LINK>), followed by the application of cytotoxic reagents in 1900 (<LINK REF="REF-Friedenwald-1900" TYPE="REFERENCE">Friedenwald 1900</LINK>). Corneal epithelial removal, usually by iodinisation or carbolisation, became a customary remedy for dendritic keratitis during the first half of the 20<SUP>th</SUP> century. Initial clinical trials of corneal epithelial removal involved the application of noxious solutions such as tincture of iodine (<LINK REF="STD-Austin-1974" TYPE="STUDY">Austin 1974</LINK>; <LINK REF="STD-Davidson-1964" TYPE="STUDY">Davidson 1964</LINK>; <LINK REF="STD-Graupner-1969" TYPE="STUDY">Graupner 1969</LINK>; <LINK REF="STD-Matth_x00e4_us-1970" TYPE="STUDY">Matthäus 1970</LINK>; <LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>) or phenol (<LINK REF="STD-Fulhorst-1972" TYPE="STUDY">Fulhorst 1972</LINK>; <LINK REF="STD-MacKenzie-1964" TYPE="STUDY">MacKenzie 1964</LINK>; <LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>; <LINK REF="STD-Patterson-1967b" TYPE="STUDY">Patterson 1967b</LINK>), sometimes in combination with mechanical scraping. Subsequent methods of corneal debridement included cryoapplication (<LINK REF="STD-Fulhorst-1972" TYPE="STUDY">Fulhorst 1972</LINK>; <LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>), photoinactivation (<LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>; <LINK REF="STD-Daniel-1972" TYPE="STUDY">Daniel 1972</LINK>; <LINK REF="STD-O_x0027_Day-1975" TYPE="STUDY">O'Day 1975</LINK>), and thermocautery (<LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>; <LINK REF="STD-Sundmacher-1976b" TYPE="STUDY">Sundmacher 1976b</LINK>; <LINK REF="STD-Sundmacher-1978a" TYPE="STUDY">Sundmacher 1978a</LINK>; <LINK REF="STD-Sundmacher-1978b" TYPE="STUDY">Sundmacher 1978b</LINK>). Minimal wiping debridement (<LINK REF="STD-Whitcher-1976" TYPE="STUDY">Whitcher 1976</LINK>) offered a simpler, safer procedure and was used in several clinical studies (<LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Coster-1977a" TYPE="STUDY">Coster 1977a</LINK>; <LINK REF="STD-Hung-1984" TYPE="STUDY">Hung 1984</LINK>; <LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-Kato-1979" TYPE="STUDY">Kato 1979</LINK>; <LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>; <LINK REF="STD-Richter-1986" TYPE="STUDY">Richter 1986</LINK>; <LINK REF="STD-Serifoglu-1987" TYPE="STUDY">Serifoglu 1987</LINK>; <LINK REF="STD-Uchida-1981" TYPE="STUDY">Uchida 1981</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>; <LINK REF="STD-Yamazaki-1984a" TYPE="STUDY">Yamazaki 1984a</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2014-12-10 16:23:35 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment of HSV epithelial keratitis aims to halt active viral infection of the cornea quickly and safely, thereby controlling symptoms and allowing a normal ocular surface to become re-established. Antiviral nucleosides include purine analogues such as vidarabine; pyrimidine analogues such as idoxuridine, trifluridine, and brivudine; and acyclic analogues such as acyclovir and ganciclovir. These prodrugs are phosphorylated by viral thymidine kinase and inhibit HSV replication by interfering with viral DNA synthesis during transcription of the viral genome. Foscarnet and cidofovir directly inhibit viral DNA polymerase. Mutations in viral genes encoding thymidine kinase or DNA polymerase can confer antiviral resistance. </P>
<P>Interferons are cytokines capable of activating an intracellular pathway that upregulates host genes affecting antiviral responses. Interferon and a nucleoside antiviral could have an additive or synergistic interaction. </P>
<P>Corneal epithelial debridement or chemical cauterisation removes or destroys virus-infected cells of the corneal surface and is followed by corneal epithelial regeneration if residual or persistently shed virus does not cause recrudescent ocular infection. A combination of debridement with either a nucleoside antiviral drug or interferon has been suggested to avert early recrudescence. An occlusion patch applied immediately after debridement could affect the epithelial healing rate (<LINK REF="REF-Turner-2006" TYPE="REFERENCE">Turner 2006</LINK>) or even raise the corneal temperature by a few degrees to hinder HSV replication (<LINK REF="REF-Wheeler-1959" TYPE="REFERENCE">Wheeler 1959</LINK>).</P>
<P>Ancillary topical ophthalmic agents such as lubricants or growth factors might facilitate corneal epithelial regeneration.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-04 14:48:39 +0000" MODIFIED_BY="[Empty name]">
<P>An antiviral agent is a favoured treatment for HSV epithelial keratitis (<LINK REF="REF-Sundmacher-2009" TYPE="REFERENCE">Sundmacher 2009</LINK>). However, controversies persist about the optimal antiviral agent, the role of interferon, and the effectiveness of debridement methods (<LINK REF="REF-Epstein-1989" TYPE="REFERENCE">Epstein 1989</LINK>; <LINK REF="REF-Guess-2007" TYPE="REFERENCE">Guess 2007</LINK>; <LINK REF="REF-Kastner-1984" TYPE="REFERENCE">Kastner 1984</LINK>). Surveys among ophthalmologists reveal some differences of opinion in treatment preferences for HSV epithelial keratitis (<LINK REF="REF-Guess-2010" TYPE="REFERENCE">Guess 2010</LINK>; <LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-McAllum-2003" TYPE="REFERENCE">McAllum 2003</LINK>; <LINK REF="REF-Sundmacher-1977" TYPE="REFERENCE">Sundmacher 1977</LINK>; <LINK REF="REF-Ziahosseini-2009" TYPE="REFERENCE">Ziahosseini 2009</LINK>). To provide an evidence-based analysis, this systematic review evaluates the collective evidence on the treatment of HSV epithelial keratitis.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-12-11 17:21:52 +0000" MODIFIED_BY="[Empty name]">
<P>To compare the relative effectiveness of antiviral agents, interferon, and corneal debridement in the treatment of HSV epithelial keratitis.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-05 22:00:53 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-12-27 20:36:14 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-11-27 21:51:50 +0000" MODIFIED_BY="[Empty name]">
<P>This review included clinical trials that compared the relative effectiveness of therapeutic interventions on the corneal epithelial healing of participants who had clinically diagnosed or virologically confirmed HSV epithelial keratitis. Trials limited to the prevention of recurrent herpetic eye disease were not considered in this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-11-27 21:51:36 +0000" MODIFIED_BY="[Empty name]">
<P>Participants had active dendritic or geographic epithelial keratitis. Punctate, stellate, or linear epithelial keratitis was considered to be a form of dendritic epithelial keratitis. Trials of herpes simplex virus stromal keratitis, keratouveitis, or uveitis were not considered in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-12-27 20:36:14 +0000" MODIFIED_BY="[Empty name]">
<P>Antiviral agents included idoxuridine, vidarabine, trifluridine, acyclovir, ganciclovir, brivudine, foscarnet, and cidofovir. Interferon preparations included interferon-&#945;, interferon-&#946;, and interferon inducers. Debridement of the corneal epithelium was done by wiping, scraping, chemical corrosion, cryotherapy, thermal application, or photoinactivation. Supplemental agents included lubricants, growth factors, anti-inflammatory medications, and immunomodulators. Trials of herbal extracts, traditional medicines, acupuncture, and other alternative interventions were not considered in this review. Studies of gene therapy were not part of this review (<LINK REF="REF-Elbadawy-2012" TYPE="REFERENCE">Elbadawy 2012</LINK>).</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-12-27 19:34:44 +0000" MODIFIED_BY="Anupa Shah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-04-25 23:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>The primary outcome was the proportion of eyes healed at 14 days after study entry.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-12-27 19:34:44 +0000" MODIFIED_BY="Anupa Shah">
<P>Two secondary outcomes were used to evaluate the pace of healing: the proportion healed at seven days after study entry and the comparative rate of healing between interventions as estimated by logrank analysis of survival curves or life tables. Ancillary measures that were recorded when available were the effect on viral recovery, the prevalence of adverse events during treatment, the occurrence of episodes of recrudescent keratitis during or immediately after treatment (arbitrarily defining recrudescence as reappearing epithelial keratitis occurring less than two weeks after completing short-term therapy), and the number of episodes of recurrent keratitis during follow up over the ensuing months (arbitrarily defining recurrence as a new episode of epithelial keratitis occurring two weeks or longer after completing short-term therapy).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-05 22:00:53 +0000" MODIFIED_BY="[Empty name]">
<P>We attempted to identify all relevant trials, regardless of language or publication status, using search strategies recommended by The Cochrane Collaboration. The search for studies was performed with the assistance of the Cochrane Eyes and Vision Group (<A HREF="http://eyes.cochrane.org">CEVG</A>) and the United States Cochrane Center (<A HREF="http://us.cochrane.org">USCC</A>). The author selected potentially relevant studies by reviewing the titles and abstracts of studies found by the searches. The full text was obtained for any report of a possibly relevant clinical trial. Articles were translated as needed. The sequence of searching and assessment of studies was in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (<A HREF="http://www.prisma-statement.org">PRISMA</A>).</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-01-05 22:00:53 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (<A HREF="http://crso.cochrane.org">CENTRAL</A>) (2014, Issue 12), PubMed (January 1946 to 31 December 2014), EMBASE (January 1980 to 31 December 2014), Latin American and Caribbean Health Sciences Literature Database (<A HREF="http://lilacs.bvsalud.org">LILACS</A>) (January 1982 to 31 December 2014), System for Information on Grey Literature in Europe (<A HREF="http://www.opengrey.eu">OpenGrey</A>) (January 1995 to 31 December 2014), BIOSIS (January 1926 to 5 May 2014), Scopus (January 1966 to 31 December 2014), Japan Science and Technology Institute (<A HREF="http://jglobal.jst.go.jp">J-Global</A>) (January 1975 to 31 December 2014), China National Knowledge Infrastructure (<A HREF="http://oversea.cnki.net">CNKI</A>) (January 1979 to 31 December 2014), and British Library's Electronic Table of Contents (Zetoc) (January 1993 to 7 May 2014). The following resources were last searched on 31 December 2014: the <I>meta</I>Register of Controlled Trials (<A HREF="http://www.controlled-trials.com">mRCT</A>), <A HREF="http://www.clinicaltrials.gov">ClinicalTrials.gov</A>, the World Health Organization (WHO) International Clinical Trials Registry Platform (<A HREF="http://www.who.int/ictrp/search/en">ICTRP</A>), and the Chinese Clinical Trial Registry (<A HREF="http://www.chictr.org">ChiCTR</A>). There were no language or date restrictions in the search for trials. Spanish, Portuguese, Japanese, and Chinese databases were searched with English language terms and with pertinent language terms.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), PubMed (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), OpenGrey (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>), BIOSIS (<LINK REF="APP-06" TYPE="APPENDIX">Appendix 6</LINK>), Scopus (<LINK REF="APP-07" TYPE="APPENDIX">Appendix 7</LINK>), J-Global (<LINK REF="APP-08" TYPE="APPENDIX">Appendix 8</LINK>), CNKI (<LINK REF="APP-09" TYPE="APPENDIX">Appendix 9</LINK>), Zetoc (<LINK REF="APP-10" TYPE="APPENDIX">Appendix 10</LINK>), <I>m</I>RCT (<LINK REF="APP-11" TYPE="APPENDIX">Appendix 11</LINK>), ClinicalTrials.gov (<LINK REF="APP-12" TYPE="APPENDIX">Appendix 12</LINK>), ICTRP (<LINK REF="APP-13" TYPE="APPENDIX">Appendix 13</LINK>), and ChiCTR (<LINK REF="APP-14" TYPE="APPENDIX">Appendix 14</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-12-27 15:01:10 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Handsearching</HEADING>
<P>Manual searching of printed databases, using the terms &#8216;cornea&#8217;, &#8216;herpes&#8217;, and &#8216;keratitis&#8217;, was undertaken for <I>Index Medicus</I> (1960 to 1965), <I>Excerpta Medica Ophthalmology</I> (1960 to 1973), and <I>Ophthalmic Literature</I> (1947 to 1998).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grey literature</HEADING>
<P>We searched titles and abstracts of presentations and posters from 1960 to 2014 for clinical reports of herpetic keratitis submitted to the following meetings: Association for Research in Vision and Ophthalmology (<A HREF="http://www.arvo.org">ARVO</A>), World Ophthalmology Congress, American Academy of Ophthalmology (<A HREF="http://www.aao.org/meetings/annual_meeting/program/past-archive.cfm">AAO</A>), Ocular Microbiology and Immunology Group (<A HREF="http://eyemicrobiology.upmc.com/OMIG.htm">OMIG</A>), and International Conference on Herpetic Eye Diseases. Websites of the U.S.Food and Drug Administration (<A HREF="http://www.fda.gov/">FDA</A>) (<LINK REF="APP-15" TYPE="APPENDIX">Appendix 15</LINK>), National Institute for Health and Clinical Excellence (<A HREF="http://www.evidence.nhs.uk">NICE</A>) (<LINK REF="APP-16" TYPE="APPENDIX">Appendix 16</LINK>), the European Medicines Agency (<A HREF="http://www.ema.europa.eu/ema/">EMA</A>) (<LINK REF="APP-17" TYPE="APPENDIX">Appendix 17</LINK>) were searched for unpublished or unregistered clinical trials on herpetic keratitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Reference lists</HEADING>
<P>The bibliographies of included study reports, ocular virology review articles, and corneal textbooks were surveyed for relevant publications that included the word &#8216;herpes&#8217; or &#8216;herpetic&#8217; and the word 'keratitis' in the article title.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Correspondence</HEADING>
<P>Selected authors were contacted, when feasible, if insufficient data were provided in the published report.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-04 14:49:12 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2014-12-10 17:04:13 +0000" MODIFIED_BY="[Empty name]">
<P>Human studies were selected based on study design, type of corneal disease, interventions, and outcome measures. Included studies had an impartial allocation of two or more interventions to participants who were clinically diagnosed or virologically confirmed, or both, with HSV epithelial keratitis and who were evaluated for corneal healing at seven or 14 days, or both, after study entry. Trials on the relative effectiveness of botanical or herbal preparations were not included in this review. For multiple publications that described all or part of the same study population the most detailed report with the largest sample was used (<LINK REF="REF-Wilhelmus-2007a" TYPE="REFERENCE">Wilhelmus 2007a</LINK>). This review did not examine the management of HSV stromal keratitis, endotheliitis, keratouveitis, or iritis (<LINK REF="REF-Knickelbein-2009" TYPE="REFERENCE">Knickelbein 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-12-10 17:04:58 +0000" MODIFIED_BY="[Empty name]">
<P>The author recorded relevant information for each included study onto a data collection form. Extracted data comprised attributes of study participants, method of treatment allocation, any co-interventions or adjunctive treatment, and the examination method used to evaluate healing. Data from trials restricted to geographic epithelial keratitis were incorporated into pooled comparisons but also tabulated separately.</P>
<P>The cumulative number of eyes that healed in each intervention group was recorded for each day of follow up, including days seven and 14. For reports using graphs of healing curves to describe outcome, plotted lines were projected onto the ordinate axis for each follow-up day along the abscissa to estimate the daily proportion healed in each treatment group. Adjustment for censoring was not part of the estimation of risk ratios but was considered when estimating hazard ratios.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-05-14 17:46:20 +0100" MODIFIED_BY="Anupa Shah">
<P>Appraisal of study design, analysis, and presentation considered potential sources of selection bias, performance bias, detection bias, and attrition bias. Selection bias was evaluated by examining randomisation of treatment allocation and concealment of assigned treatment group. Studies that did not explain the method of sequence generation but did describe a controlled clinical trial design were considered to have an unclear risk of bias for sequence generation. The remaining studies that did not identify a randomisation process were considered to have a high risk of bias for random sequence generation. Performance bias and detection bias were evaluated by noting the use of masking of participants, trialists, and outcome assessors and by the method that was used to ascertain corneal epithelial healing. Attrition bias was evaluated by the extent of withdrawals and other losses to follow up. Because the primary endpoint of corneal epithelial healing was measured within two weeks of enrolment, withdrawals and losses to follow up were expected to be relatively low. Studies were judged to be liable to have incomplete outcome reporting if the status was not provided for participants who did not achieve healing and who were not assessed at two weeks. Each component of internal validity (sequence generation, allocation concealment, masking, completeness of outcome data, outcome reporting, and other sources of bias) was categorically judged as having a low, unclear, or high risk of bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-12-27 15:01:57 +0000" MODIFIED_BY="[Empty name]">
<P>Relative measures of corneal healing between treatment groups were estimated by risk ratios at seven days and at 14 days after trial enrolment. A hazard ratio was also estimated when additional time-to-event data could be extracted from tables or cumulative healing curves. Ratios were reported with 95% confidence intervals. Reports of treatment comparisons that provided only the mean time to resolution were not used in estimating survival rates because all interventions did not yield consistently similar healing distributions (<LINK REF="REF-Michiels-2005" TYPE="REFERENCE">Michiels 2005</LINK>).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2015-01-04 14:49:12 +0000" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was the individual eye with HSV keratitis. If a person with bilateral or recurrent keratitis was enrolled more than once into a trial, the unit of analysis was the eye designated to receive study treatment for each episode. Potential correlation of outcomes between fellow eyes was not considered in pooled analyses.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-08-27 21:01:49 +0100" MODIFIED_BY="[Empty name]">
<P>Whenever possible, data on all participants were extracted from studies that reported sufficient information for an intention-to-treat analysis. Censoring was assumed to be non-informative and to occur at a constant rate during the initial two weeks of treatment.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-09-25 05:53:31 +0100" MODIFIED_BY="[Empty name]">
<P>Heterogeneity among trials evaluating similar interventions was investigated using forest plots. The I<SUP>2</SUP> statistic was used as an index of inconsistency among pooled comparisons of interventions (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002</LINK>). I<SUP>2 </SUP>greater than 50% indicated substantial heterogeneity. Any treatment comparison having high heterogeneity when estimating a pooled risk ratio at 14 days was re-analysed in a random-effects model.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-12-09 14:36:55 +0000" MODIFIED_BY="[Empty name]">
<P>Publication bias was explored by funnel plots for treatment comparisons that had at least ten trials.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-12-27 15:04:41 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Treatment comparisons</HEADING>
<P>Interventions were compared to inactive controls, to each other, or to combinations of interventions. Data from trials with multiple treatment groups were evaluated by selecting paired comparisons of two interventions or by combining data from similar treatment groups.</P>
<SUBSECTION>
<HEADING LEVEL="5">Placebo controls</HEADING>
<P>Some placebo-controlled trials used the vehicle of the relevant study drug for the inactive control. Other topical agents that were classified as inactive controls in this review included solutions of tissue-culture medium, neomycin, albumin, non-specific gamma-globulin, and low-dose interferon preparations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combining treatments within studies</HEADING>
<P>Interventions that were considered sufficiently similar and that were amalgamated within studies having more than two treatment groups were photoinactivation and carbolisation; cryotherapy and carbolisation; interferon-&#945; at either 1 million IU/ml or 10 million IU/ml; thermomechanical debridement and thermomechanical debridement with interferon-&#945; 62,500 IU/ml, a dosage probably too low to exert clinical effects; debridement with interferon-&#945; at either 11 million IU/ml or 33 million IU/ml; and trifluridine with interferon-&#945; at either one million IU/ml or 30 million IU/ml.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combining treatments between studies</HEADING>
<P>Different formulations of the same nucleoside antiviral agent (for example, idoxuridine solution and idoxuridine ointment; acyclovir ointment and acyclovir solution; and ganciclovir gel and ganciclovir solution) were combined in pooled analyses. Data for ganciclovir 0.15% gel rather than ganciclovir 0.05% gel were tabulated for comparison to topical acyclovir since ganciclovir 0.15% is the commercially available concentration. Multi-arm studies comparing more than two interventions were recombined into appropriate pairs of interventions in the data tables. One study (<LINK REF="STD-Li-2013a" TYPE="STUDY">Li 2013a</LINK>) that compared ganciclovir to acyclovir plus interferon was tabulated in the ganciclovir-acyclovir comparison.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Statistical estimation</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Direct risk ratio</HEADING>
<P>Tables were constructed of the cumulative number of eyes healed after trial enrolment for each treatment group. Direct comparisons between interventions estimated risk ratios (<LINK REF="REF-Deeks-2002" TYPE="REFERENCE">Deeks 2002</LINK>) at seven days and at 14 days using a fixed-effect model with the Mantel-Haenszel method. Pooled comparisons with I<SUP>2 </SUP>&gt; 50% for the 14-day outcome were re-estimated in a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Indirect risk ratio</HEADING>
<P>Treatment comparisons were organised into networks. Within the network of antiviral treatment trials, indirect risk ratios were estimated in which different antivirals could be compared by way of a mutual antiviral agent (<LINK REF="REF-Bucher-1997" TYPE="REFERENCE">Bucher 1997</LINK>; <LINK REF="REF-Glenny-2005" TYPE="REFERENCE">Glenny 2005</LINK>; <LINK REF="REF-Song-2009" TYPE="REFERENCE">Song 2009</LINK>). Using formulæ (<LINK REF="REF-Wells-2009" TYPE="REFERENCE">Wells 2009</LINK>) implemented in <A HREF="http://www.cadth.ca/en/publication/884">software</A> from the Canadian Agency for Drugs and Technologies in Health, indirect risk ratios and corresponding 95% confidence intervals were computed for topical antiviral treatment comparisons at 14 days. Consistency within a set of indirect risk ratios was examined with random-effects meta-regression (<LINK REF="REF-White-2012" TYPE="REFERENCE">White 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Combined direct and indirect risk ratio</HEADING>
<P>An adjusted risk ratio was estimated by pooling direct and indirect relative treatment effects (<LINK REF="REF-Song-2003" TYPE="REFERENCE">Song 2003</LINK>) in a software program using a random-effects model (<LINK REF="REF-Harris-2008" TYPE="REFERENCE">Harris 2008</LINK>). The I<SUP>2</SUP> statistic and graphs (<LINK REF="REF-Chaimani-2013" TYPE="REFERENCE">Chaimani 2013</LINK>) were used to interpret the network meta-analysis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hazard ratio</HEADING>
<P>Healing times were estimated for studies that reported outcomes at more than two time points within two weeks after enrolment by extracting healing and censoring data from reported survival curves and life tables. The observed (O) and the logrank expected (E) numbers of events were used to compute logrank statistics (O-E) and to estimate the hypergeometric variance (V) with formulæ (<LINK REF="REF-Tierney-2007" TYPE="REFERENCE">Tierney 2007</LINK>) implemented in a <A HREF="http://www.biomedcentral.com/content/supplementary/1745-6215-8-16-S1.xls">spreadsheet calculator</A>. Hazard ratios were then pooled with a fixed-effect model to describe the relative therapeutic effect of interventions over time (<LINK REF="REF-Parmar-1998" TYPE="REFERENCE">Parmar 1998</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Healing rate</HEADING>
<P>Studies providing healing curves were integrated into a graph to illustrate the relative rates of corneal re-epithelialisation over two weeks of treatment. The cumulative healing probability was estimated by collating participant-level data from a large antiviral treatment trial.</P>
</SUBSECTION>
</SUBSECTION>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-12-10 17:10:18 +0000" MODIFIED_BY="[Empty name]">
<P>Two trials that restricted enrolment to persons with geographic epithelial keratitis were tabulated with other trials but also analysed separately. Studies that enrolled eyes with either dendritic or geographic epithelial keratitis did not undergo stratified analysis by type of keratitis in this systematic review. Other characteristics evaluated as possible prognostic factors of corneal epithelial healing time in any <I>post hoc</I> analysis of individual trials were recorded.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-12-27 15:05:31 +0000" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses assessed the robustness of pooled relative effect measures and explored possible reasons for heterogeneity. In one sensitivity analysis, studies were selectively omitted from the meta-analysis if there was a potentially high risk of bias because of possible non-random sequence generation, unconcealed allocation, or lack of masking that could have influenced outcome assessment. Another sensitivity analysis used only studies with an explicit randomised, double-masked trial design. Studies that were excluded because cumulative healing proportions of the treatment arms were not given were tabulated to explore how their findings compared with the pooled results of included studies.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-04 14:38:07 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-04 14:38:07 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-12-27 15:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>Electronic and manual searches identified 2430 discrete reports of HSV keratitis. After screening, 280 therapeutic studies were identified that compared two or more interventions in the treatment of HSV epithelial keratitis (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). One hundred thirty-seven studies that met this review's inclusion criteria are tabulated in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> outlines which of the five main reasons why 143 studies were excluded along with the treatment groups of each excluded study. Two unpublished antiviral treatment trials are listed in <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-04 14:38:07 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Trials compared various pharmacological and non-pharmacological interventions. One hundred sixteen trials compared an intervention to a control or compared two interventions. The others had multiple treatment arms: 16 studies had three treatment groups (<LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>; <LINK REF="STD-Carmassi-1993" TYPE="STUDY">Carmassi 1993</LINK>; <LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK>; <LINK REF="STD-Coster-1977a" TYPE="STUDY">Coster 1977a</LINK>; <LINK REF="STD-Davidson-1964" TYPE="STUDY">Davidson 1964</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-MacKenzie-1964" TYPE="STUDY">MacKenzie 1964</LINK>; <LINK REF="STD-Maichuk-1988" TYPE="STUDY">Maichuk 1988</LINK>; <LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>; <LINK REF="STD-Meurs-1985" TYPE="STUDY">Meurs 1985</LINK>; <LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>; <LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>; <LINK REF="STD-Sundmacher-1981b" TYPE="STUDY">Sundmacher 1981b</LINK>; <LINK REF="STD-Uchida-1981" TYPE="STUDY">Uchida 1981</LINK>), four studies had four groups (<LINK REF="STD-Matth_x00e4_us-1970" TYPE="STUDY">Matthäus 1970</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>; <LINK REF="STD-Sundmacher-1987" TYPE="STUDY">Sundmacher 1987</LINK>), and one study had five groups (<LINK REF="STD-Fulhorst-1972" TYPE="STUDY">Fulhorst 1972</LINK>).</P>
<P>For this systematic review, treatment comparisons were organised into two-way comparisons and allocated into five categories: comparisons of topical antivirals, trials involving oral antiviral treatments, studies examining the effect of interferon, studies of corneal epithelial debridement, and trials of miscellaneous drugs. Among multiple treatment comparisons (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>), the number of direct, two-way comparisons ranged from one to 28 studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Supplemental medications</HEADING>
<P>Use of a topical cycloplegic agent was reported in 51 included trials: atropine in 29 studies, scopolamine in six, homatropine in five, and a non-specified cycloplegic or mydriatic agent in 11. A concomitant topical antibiotic was dispensed in 19 studies: ofloxacin in seven studies, chloramphenicol in four, gentamicin in one, micronomicin in one, and an unspecified antibiotic in six.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sample sizes and study statistics</HEADING>
<P>A total of 8333 eyes with HSV epithelial keratitis were enrolled and analysed in 137 studies included for analysis in this systematic review. Study sizes ranged from 15 to 287 participants, and the distribution of study sizes skewed toward small to moderately sized samples. The median number enrolled per study was 53 (interquartile range [IQR] 33 to 78). Multicentre studies enrolled more eyes: the median study size was 50 (IQR 32 to 76) among 118 single-centre studies and 64 (IQR 51 to 109) among 19 multicentre studies.</P>
<P>None of the studies reported a pretrial sample size estimation based on <I>a priori</I> assumptions, although one trial did provide a statistical computation that was used to plan enrolment based on recurrence risk rather than epithelial healing (<LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>). The statistical analysis of individual studies, when reported, was based on detecting a statistically significant difference between treatment groups in corneal epithelial healing. One study provided a <I>post hoc</I> non-inferiority analysis (<LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>). An independent committee monitored accrued data for some multicentre studies (<LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>; <LINK REF="STD-Tanaka-1988a" TYPE="STUDY">Tanaka 1988a</LINK>; <LINK REF="STD-Tanaka-1988b" TYPE="STUDY">Tanaka 1988b</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Study participants</HEADING>
<P>
<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> summarizes the characteristics of participants and interventions. Among 66 trials that described age statistics of enrolled participants (including one trial (<LINK REF="STD-Li-2013b" TYPE="STUDY">Li 2013b</LINK>) that gave median rather than mean age), the overall average age was 43 years (standard deviation (SD) 6 years). Of 78 trials reporting the gender of study participants (omitting one trial (<LINK REF="STD-Hart-1965" TYPE="STUDY">Hart 1965</LINK>) that only gave the gender of cured participants), 71 (91%) enrolled more men than women. The median male-female ratio was 1.5 (IQR 1.2 to 2.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>Seventy-one trials included in this review took place in Europe, 51 in Asia, 13 in North America (including one performed in the United States and the United Kingdom), one in Africa, and one in Australia. One hundred seventeen trials included in this review took place at a single centre. The primary report was published in the English language for 79 included trials, Chinese for 33, Japanese for seven, German for seven, French for six, Italian for two, Turkish for two, and Russian for one.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Type of epithelial keratitis</HEADING>
<P>Seventy-four trials specified dendritic epithelial keratitis as an eligibility criterion. Two other trials (<LINK REF="STD-Burns-1963" TYPE="STUDY">Burns 1963</LINK>; <LINK REF="STD-Davidson-1964" TYPE="STUDY">Davidson 1964</LINK>) provided insufficient information to confirm that all participants had dendritic epithelial keratitis. Fifty-nine trials enrolled participants with either dendritic or geographic epithelial keratitis. In these studies dendritic epithelial keratitis was, on average, five times more prevalent than geographic epithelial keratitis. Two trials were restricted to geographic epithelial keratitis (<LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Laboratory confirmation</HEADING>
<P>Viral isolation was performed in 34 included trials. Five trials enrolled only HSV culture-confirmed eyes (<LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-Meurs-1985" TYPE="STUDY">Meurs 1985</LINK>; <LINK REF="STD-Sundmacher-1981a" TYPE="STUDY">Sundmacher 1981a</LINK>; <LINK REF="STD-Sundmacher-1981b" TYPE="STUDY">Sundmacher 1981b</LINK>; <LINK REF="STD-Sundmacher-1984a" TYPE="STUDY">Sundmacher 1984a</LINK>). Four trials performed HSV isolation without providing the number of culture-positive eyes (<LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>; <LINK REF="STD-Hoang_x002d_Xuan-1984" TYPE="STUDY">Hoang-Xuan 1984</LINK>; <LINK REF="STD-Luntz-1963" TYPE="STUDY">Luntz 1963</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>). Of 25 trials that reported the prevalence of 759 positive viral culture results (including one trial that reported viral culture and immunofluorescent test results) among 1148 eyes tested at trial entry, the median prevalence of study participants who had laboratory-confirmed HSV ocular infection, from corneal or conjunctival samples, was 68% (IQR 50% to 78%). HSV-2 was rarely isolated (<LINK REF="STD-Vannini-1986" TYPE="STUDY">Vannini 1986</LINK>). No study reported whether a topical anæsthetic (<LINK REF="REF-Goldschmidt-2006" TYPE="REFERENCE">Goldschmidt 2006</LINK>; <LINK REF="REF-Weinberg-1977" TYPE="REFERENCE">Weinberg 1977</LINK>) or stain (<LINK REF="REF-Roat-1987" TYPE="REFERENCE">Roat 1987</LINK>; <LINK REF="REF-Seitzman-2006" TYPE="REFERENCE">Seitzman 2006</LINK>) might have curtailed viral detection.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome evaluation</HEADING>
<P>Outcome assessment was based on clinical observation using slit-lamp biomicroscopy, except for one study (<LINK REF="STD-Hart-1965" TYPE="STUDY">Hart 1965</LINK>) that used a magnifying loupe. Of 117 trials specifying the use of a stain, 96 (82%) used fluorescein (including one study stating only that a "stain" was used), nine used rose-Bengal, and 12 used both fluorescein and rose-Bengal.</P>
<P>The description of outcome assessment, when stated, assigned the day of healing as the time when re-epithelialisation of the corneal surface was first verified. If a topical dye was used then the day of healing was the first day when no confluent staining was observed. The following extracts exemplify overlapping ways by which the primary endpoint of resolution of active epithelial keratitis were expressed:</P>
<UL>
<LI>"Disappearance of [fluorescein] dendritic staining, despite the occasional persistence of fine, superficial punctate keratitis" (<LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>).</LI>
<LI>"Fluorescein-negative healing of the corneal epithelium, which was defined as complete closure of all erosions except for some single dye-positive micropunctations" (<LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>).</LI>
<LI>"Disappearance of specific Bengal-rose staining of the precise site of the healing dendritic ulceration...[not considering] fine microscopic punctate staining diffusely arranged on the epithelial surface" (<LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>).</LI>
<LI>"2 criteria for healing: (1) partial healing...defined as closure of the epithelial wound only, i.e., no staining with fluorescein; and (2) complete healing...defined as closure of the epithelial wound without any epithelial oedema or cystic changes in the area of the previous dendrite" (<LINK REF="STD-de-Koning-1982" TYPE="STUDY">de Koning 1982</LINK>).</LI>
<LI>"Healing was defined as the situation in which no staining with fluorescein was observed and no epithelial oedema and cystic changes were present in the epithelium covering the site of the original ulcer" (<LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>).</LI>
<LI>Following fluorescein 1% and rose-Bengal 1%, the initial dendritic pattern "was red, stained by rose bengal, and outlined by a green fluorescent double contour&#8230;. The red-stained dendriform pattern represented virus-affected cells, while the green double contour disclosed presence of epithelial defects as well. After on an average five days only uncharacteristic remains were left of the previous dendritic pattern in the form of accumulated vital-stained dots localized within parts of the previous pattern. Some such remains were fluorescein-stained epithelial defects and others rose-bengal-stained, degenerate epithelial cells&#8230;. This second phase was followed by a third one, during which punctate fluorescein and/or rose bengal staining might still be seen, but now only represented by a few dots, as a rule scattered over the whole cornea, also outside the original dendritic pattern" (<LINK REF="STD-Norn-1973" TYPE="STUDY">Norn 1973</LINK>).</LI>
</UL>
<P>The median time to healing of dendritic epithelial keratitis with trifluridine, acyclovir, brivudine, or ganciclovir was seven days. The median time to healing in both trials of antiviral-treated geographic epithelial keratitis was nine days (<LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>). Based on 49 trials that published survival graphs, the maximum separation of healing curves for different treatments occurred at a median of six days. The healing curve of one large antiviral treatment trial (<LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>) was examined in parametric statistical models and found to fit a log-logistic distribution (<LINK REF="REF-Wilhelmus-2000" TYPE="REFERENCE">Wilhelmus 2000</LINK>). In that study, the cumulative probability of corneal epithelial healing at each day (t) of trifluridine chemotherapy for dendritic epithelial keratitis could be estimated by [(7/t)<SUP>4</SUP> + 1]<SUP>-1</SUP>.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-12-27 15:32:23 +0000" MODIFIED_BY="[Empty name]">
<P>One hundred forty-three comparative treatment trials of HSV epithelial keratitis were excluded from analysis because study treatment, study design, or available data did not meet eligibility criteria (<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). One excluded study did not report the sample size (<LINK REF="STD-Kuyama-1979" TYPE="STUDY">Kuyama 1979</LINK>). A total of 12,367 participants with HSV epithelial keratitis were enrolled in the other 142 excluded studies that had study populations ranging from nine to 416 participants.</P>
<SUBSECTION>
<HEADING LEVEL="4">Alternative study treatment</HEADING>
<P>Fifty studies were ineligible because at least one of two treatment groups included an ethnobotanical preparation or traditional Chinese medication, used either alone or integrated with a synthetic antiviral agent. Several studies of complementary or alternative interventions were pre-emptively identified before full articles were reviewed for eligibility, precluded based on their titles or abstracts, and do not appear in this subtotal.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Ineligible study design</HEADING>
<P>Twenty-five studies were excluded because of non-concurrent or non-randomised treatment allocation. Seven studies were excluded because their eligibility criteria did not ensure that enrolled patients had active epithelial keratitis. Four studies were excluded because outcome was based on an endpoint other than epithelial healing.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Insufficient outcome information</HEADING>
<P>Fifty-seven studies were excluded because insufficient outcome data were available at seven and 14 days. Trials lacking survival data generally assessed relative outcome by comparing mean healing times or clinical scores of symptoms and signs (<LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Thirty-three studies reported mean healing times of treatment groups; 18 studies reported a P value for a different endpoint; and six studies provided neither outcome analysis.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-12-27 15:56:09 +0000" MODIFIED_BY="[Empty name]">
<P>Potential biases affected several studies (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). </P>
<ALLOCATION MODIFIED="2014-12-13 18:22:56 +0000" MODIFIED_BY="[Empty name]">
<P>Among 137 included trials, 107 (78%) stated that a randomisation process was used to allocate study interventions. Sixteen studies had an unclear method of generating the sequence of treatment assignment. Fourteen studies were considered to have a potentially high risk of bias of random sequence generation, including two studies that assigned study treatment to alternating participants (<LINK REF="STD-Daniel-1972" TYPE="STUDY">Daniel 1972</LINK>; <LINK REF="STD-Luntz-1963" TYPE="STUDY">Luntz 1963</LINK>) and two studies that apparently allocated treatment by availability (<LINK REF="STD-Abe-1987" TYPE="STUDY">Abe 1987</LINK>; <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>). Allocation concealment was judged to have a low risk of bias for 46 (34%) of the studies. Seventy-six studies had an unclear risk of bias of allocation concealment, and 15 were considered to have a high risk of bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2014-12-27 15:33:17 +0000" MODIFIED_BY="[Empty name]">
<P>Fifty-seven (42%) studies had a double-masked study design, including two triple-masked trials that used a different outcome assessor than the investigator who allocated treatment (<LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>; <LINK REF="STD-Sundmacher-1978a" TYPE="STUDY">Sundmacher 1978a</LINK>). Twenty-eight trials had a single-masked or unclear scheme, and 52 trials used an unmasked design.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2014-12-27 15:34:06 +0000" MODIFIED_BY="[Empty name]">
<P>Ninety (66%) of the studies were considered to have a low risk of attrition bias. Nineteen studies had an unclear risk of attrition bias. Among 28 studies considered to have a high risk of having incomplete outcome data, the percentage of missing data varied from 5% to 40%. Eight of these studies provided outcome data only for culture-positive eyes.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-12-27 15:53:46 +0000" MODIFIED_BY="[Empty name]">
<P>Eighty-eight (64%) of the studies had a low risk of reporting bias. Forty-eight studies had an unclear risk of selective reporting, mainly because study protocols were rarely available and the published report was used to determine relevant events within two weeks of follow up. One study judged to have a high risk of reporting bias apparently enrolled patients with bilateral keratitis but used participants rather than eyes as the unit of analysis (<LINK REF="STD-Dai-2009a" TYPE="STUDY">Dai 2009a</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2014-12-27 15:56:09 +0000" MODIFIED_BY="[Empty name]">
<P>Thirteen studies were judged to have a high risk of other sources of bias. Two trials added supplemental treatment during follow up: additional debridement in one trial (<LINK REF="STD-Sundmacher-1978a" TYPE="STUDY">Sundmacher 1978a</LINK>) and corticosteroid eye drops in another trial (<LINK REF="STD-Luntz-1963" TYPE="STUDY">Luntz 1963</LINK>). One trial allowed some participants to cross over to the other treatment arm (<LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>). Two trials were stopped early (<LINK REF="STD-Behrens_x002d_Baumann-1992" TYPE="STUDY">Behrens-Baumann 1992</LINK>; <LINK REF="STD-O_x0027_Day-1975" TYPE="STUDY">O'Day 1975</LINK>). In addition to one study that enrolled an unclear number of eyes with stromal keratitis (<LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>), seven studies randomised between 13% and 34% of study eyes having disciform or stromal keratitis; these studies did not separately report healing outcomes by type of keratitis (<LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Liu-2014a" TYPE="STUDY">Liu 2014a</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Investigation of heterogeneity</HEADING>
<P>Substantial heterogeneity (I<SUP>2 </SUP>&gt; 50%) among study findings was found for ten treatment comparisons at the 14-day outcome assessment, including one placebo-controlled comparison (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), three comparisons of topical nucleoside antivirals (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>; <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>), a comparison involving oral acyclovir (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), the comparison between interferon (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) or combined interferon and an antiviral (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) with nucleoside antivirals, and three comparisons examining debridement (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). Six of these comparisons also showed heterogeneous findings at seven days (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>; <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). Possible treatment-related reasons for inconsistency among studies were differences in dosage or formulation of topical study medicines, non-uniform methods of corneal debridement, dissimilar use of adjunctive drugs, and possible enrolment of some eyes that did not have HSV epithelial keratitis.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>After selectively omitting studies that had a potentially inadequate or indeterminate process of random treatment assignment, studies that may have had unconcealed allocation, and studies that used incomplete masking, precision declined but relative effect measures did not shift substantially (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). The findings of randomised, double-masked trials were also generally comparable to the results of all studies (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of publication bias</HEADING>
<P>Five treatment comparisons had enough studies to assess asymmetry in funnel plots. No obvious publication bias was found for the idoxuridine-placebo comparison. Publication bias may have existed in favour of acyclovir for the acyclovir-idoxuridine comparison at seven days, but no serious publication bias was apparent for the 14-day outcome. Publication bias was possible for the ganciclovir-acyclovir comparison (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), suggesting a bias toward publication of studies favouring ganciclovir. The comparisons between antiviral treatment and either interferon plus antiviral or debridement did not have apparent publication bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secular variation</HEADING>
<P>To explore whether response to therapy may have changed over time, outcome were examined for 59 studies in which topical acyclovir ointment or solution was assigned to one treatment arm. The 14-day cure rate with acyclovir averaged 91% (SD 10%) among 27 studies published between 1980 and 1989 (<LINK REF="STD-Abe-1987" TYPE="STUDY">Abe 1987</LINK>; <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Colin-1981" TYPE="STUDY">Colin 1981</LINK>; <LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-Colin-1987" TYPE="STUDY">Colin 1987</LINK>; <LINK REF="STD-Collum-1980" TYPE="STUDY">Collum 1980</LINK>; <LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Collum-1986" TYPE="STUDY">Collum 1986</LINK>; <LINK REF="STD-Coster-1980" TYPE="STUDY">Coster 1980</LINK>; <LINK REF="STD-de-Koning-1983" TYPE="STUDY">de Koning 1983</LINK>; <LINK REF="STD-Denis-1983" TYPE="STUDY">Denis 1983</LINK>; <LINK REF="STD-Gen_x00e9_e-1987" TYPE="STUDY">Genée 1987</LINK>; <LINK REF="STD-Hoang_x002d_Xuan-1984" TYPE="STUDY">Hoang-Xuan 1984</LINK>; <LINK REF="STD-H_x00f8_vding-1989" TYPE="STUDY">Høvding 1989</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-Kitano-1985" TYPE="STUDY">Kitano 1985</LINK>; <LINK REF="STD-Klauber-1982" TYPE="STUDY">Klauber 1982</LINK>; <LINK REF="STD-Kumar-1987" TYPE="STUDY">Kumar 1987</LINK>; <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK>; <LINK REF="STD-Maichuk-1988" TYPE="STUDY">Maichuk 1988</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Meurs-1985" TYPE="STUDY">Meurs 1985</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK>), 75% (SD 15%) for four studies published between 1990 and 1999 (<LINK REF="STD-Carmassi-1993" TYPE="STUDY">Carmassi 1993</LINK>; <LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-1997b" TYPE="STUDY">Colin 1997b</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>), 56% (SD 27%) for 15 studies published between 2000 and 2009 (<LINK REF="STD-Cao-2001" TYPE="STUDY">Cao 2001</LINK>; <LINK REF="STD-Chen-2008" TYPE="STUDY">Chen 2008</LINK>; <LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK>; <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>; <LINK REF="STD-Dai-2009a" TYPE="STUDY">Dai 2009a</LINK>; <LINK REF="STD-Dai-2009b" TYPE="STUDY">Dai 2009b</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>; <LINK REF="STD-Liu-2009a" TYPE="STUDY">Liu 2009a</LINK>; <LINK REF="STD-Ramirez-2002" TYPE="STUDY">Ramirez 2002</LINK>; <LINK REF="STD-Xu-2009a" TYPE="STUDY">Xu 2009a</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>; <LINK REF="STD-Yang-2008" TYPE="STUDY">Yang 2008</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>), and 46% (SD 24%) for 13 studies published between 2010 and 2014 (<LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>; <LINK REF="STD-Han-2014" TYPE="STUDY">Han 2014</LINK>; <LINK REF="STD-Li-2013a" TYPE="STUDY">Li 2013a</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Lin-2014" TYPE="STUDY">Lin 2014</LINK>; <LINK REF="STD-Liu-2010" TYPE="STUDY">Liu 2010</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Sun-2013a" TYPE="STUDY">Sun 2013a</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Zhang-2014" TYPE="STUDY">Zhang 2014</LINK>; <LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>). Among 32 studies evaluating ganciclovir gel, the 14-day outcome with ganciclovir averaged 83% (SD 0.5%) for two studies published in 1997 (<LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-1997b" TYPE="STUDY">Colin 1997b</LINK>), 73% (SD 18%) for 13 studies published between 2000 and 2009 (<LINK REF="STD-Chen-2008" TYPE="STUDY">Chen 2008</LINK>; <LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK>; <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>; <LINK REF="STD-Dai-2009a" TYPE="STUDY">Dai 2009a</LINK>; <LINK REF="STD-Dai-2009b" TYPE="STUDY">Dai 2009b</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Liu-2009a" TYPE="STUDY">Liu 2009a</LINK>; <LINK REF="STD-Ramirez-2002" TYPE="STUDY">Ramirez 2002</LINK>; <LINK REF="STD-Xu-2009a" TYPE="STUDY">Xu 2009a</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>; <LINK REF="STD-Yang-2008" TYPE="STUDY">Yang 2008</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>), and 73% (SD 20%) for 17 studies published between 2010 and 2014 (<LINK REF="STD-Fu-2012" TYPE="STUDY">Fu 2012</LINK>; <LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>; <LINK REF="STD-Han-2014" TYPE="STUDY">Han 2014</LINK>; <LINK REF="STD-Li-2013a" TYPE="STUDY">Li 2013a</LINK>; <LINK REF="STD-Li-2013b" TYPE="STUDY">Li 2013b</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Lin-2014" TYPE="STUDY">Lin 2014</LINK>; <LINK REF="STD-Liu-2010" TYPE="STUDY">Liu 2010</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Sun-2013a" TYPE="STUDY">Sun 2013a</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Yu-2012a" TYPE="STUDY">Yu 2012a</LINK>; <LINK REF="STD-Zhang-2014" TYPE="STUDY">Zhang 2014</LINK>; <LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>; <LINK REF="STD-Zheng-2010" TYPE="STUDY">Zheng 2010</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-12-27 16:04:23 +0000" MODIFIED_BY="[Empty name]">
<P>Interventions were divided into five categories: topical antiviral agents, oral antiviral therapy, interferon, corneal epithelial debridement, and adjunctive drugs. The primary treatment effect was assessed by a risk ratio at 14 days, adjusted by available indirect risk ratios for antiviral treatment comparisons (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Any difference in early resolution was examined by a risk ratio at seven days. The relative pace of healing was examined by a hazard ratio.</P>
<SUBSECTION>
<HEADING LEVEL="3">Topical antiviral therapy</HEADING>
<P>Eight-three studies made head-to-head comparisons among inactive control, idoxuridine, vidarabine, trifluridine, acyclovir, brivudine, ganciclovir, or foscarnet (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Idoxuridine and vidarabine</HEADING>
<P>The analyses of seven-day and 14-day outcomes (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and of relative healing rates (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) comparing idoxuridine to inactive control were limited by heterogeneity. In one trial, vidarabine was significantly better than inactive control at 14 days (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and increased the rate of healing (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). While direct comparisons of vidarabine to idoxuridine did not show a significant difference in healing outcome (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) or healing rate (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), a combined direct and indirect comparison using studies in which vidarabine and idoxuridine were compared to a mutual antiviral suggested that vidarabine might have better therapeutic effectiveness than idoxuridine (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Additionally, <I>para</I>-fluorophenylalanine, an amino acid analogue having antiviral activity, did not significantly differ from idoxuridine (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trifluridine, acyclovir, brivudine, and ganciclovir</HEADING>
<P>Compared to idoxuridine, trifluridine (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>), acyclovir (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>), and brivudine (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>) were significantly better, although the acyclovir-idoxuridine comparison had high heterogeneity and possible bias toward publication of trials that showed faster healing with acyclovir. One trial compared acyclovir to iododeoxycytidine, but a significant difference in healing outcome was not detected (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>.3). Network analysis indicated that healing outcomes of trifluridine, acyclovir, or brivudine were significantly better than for idoxuridine (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Assimilated healing curves also furnished evidence that trifluridine and acyclovir provided faster healing than idoxuridine (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). Trifluridine (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>) and acyclovir (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>), while not determined to be significantly different from vidarabine in direct comparisons, were more effective than vidarabine in network analyses (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). Neither acyclovir (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>; <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>) nor brivudine (<LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>; <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>) was found to be significantly different from trifluridine. Brivudine was not different from acyclovir in one trial (<LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>) and in network analysis (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). The direct comparison of ganciclovir with acyclovir was limited by heterogeneity among included studies (<LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK>) and a possible publication bias toward studies favouring ganciclovir (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Foscarnet</HEADING>
<P>Foscarnet was not significantly different from trifluridine in one trial (<LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>), from acyclovir in one trial (<LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>), or from ganciclovir in one trial (<LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>). Network analysis did not reveal statistically significant differences between foscarnet and trifluridine or ganciclovir (<LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). The indirect comparison of foscarnet and acyclovir involved a heterogeneous group of studies comparing acyclovir and ganciclovir.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antiviral combination</HEADING>
<P>Although dual antiviral treatment was more effective at seven days, the combination of topical acyclovir and vidarabine was not significantly different at 14 days than topical acyclovir in one trial (<LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Formulation and dosage of topical antivirals</HEADING>
<P>No differences were apparent among few studies that evaluated different vehicles (<LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>) or concentrations (<LINK REF="CMP-001.28" TYPE="ANALYSIS">Analysis 1.28</LINK>) of topical antiviral agents. No study compared different frequencies of administration of the same topical antiviral agent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety of topical antivirals</HEADING>
<P>Forty-four studies reported the prevalence of ocular adverse reactions other than stinging or discomfort that was attributable to topical antiviral medications. Treatment-related effects on the ocular surface that were reported in trials included in this review were allergic blepharoconjunctivitis, toxo-allergic follicular conjunctivitis, and superficial keratopathy. In these antiviral treatment trials the median percentage of eyes that developed superficial keratopathy or punctate epithelial erosions was 10% with idoxuridine, 11% with vidarabine, 4% with trifluridine, 10% with acyclovir, 0% with brivudine, and 4% with ganciclovir (<LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral antiviral therapy</HEADING>
<P>The comparison of oral antiviral to topical antiviral therapy (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) and the comparison of combined oral and topical antiviral to topical antiviral therapy (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) were limited by few trials that tended to be heterogeneous.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interferon therapy</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Interferon monotherapy</HEADING>
<P>Topical interferon therapy was significantly better than inactive control (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), but few studies were available. A higher interferon concentration (&#8805; 1 million IU/ml) was more effective than a low concentration (1000 IU/ml) (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>). Interferon-&#945; and interferon-&#946; did not differ significantly when used with debridement (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Recombinant interferon was not significantly different from naturally-derived interferon in combination with trifluridine (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interferon compared to nucleoside antivirals</HEADING>
<P>The comparison of topical interferon to a topical nucleoside antiviral agent (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>) was limited by heterogeneity among included studies. A topical interferon inducer did not differ significantly from a topical antiviral agent in a single study (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interferon-antiviral combination therapy</HEADING>
<P>The combination of interferon and an antiviral agent appeared to be significantly more effective than antiviral monotherapy (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>) and to offer earlier and significantly faster healing (<LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>), but these comparisons were limited by heterogeneity among studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety of topical interferons</HEADING>
<P>Adverse effects attributable to topical interferon were rarely mentioned in studies, although between 5% and 25% of treated patients had a mild, transient reaction (<LINK REF="STD-Tanaka-1988a" TYPE="STUDY">Tanaka 1988a</LINK>; <LINK REF="STD-Tanaka-1988b" TYPE="STUDY">Tanaka 1988b</LINK>). Adverse events described with the combined use of interferon and an antiviral drug were limited to punctate keratopathy (<LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-de-Koning-1983" TYPE="STUDY">de Koning 1983</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Debridement</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Methods of corneal debridement</HEADING>
<P>Few studies of limited duration compared physicochemical debridement with control (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). The comparison of debridement to topical antiviral therapy was limited by heterogeneity among studies (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). No clinically significant differences were found in the few studies that compared different methods of taking off the corneal epithelium (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Debridement and antiviral chemotherapy</HEADING>
<P>The comparison of physicochemical debridement followed by an antiviral agent compared to debridement alone was limited by heterogeneity among studies (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>). One trial comparing debridement and acyclovir to debridement and idoxuridine did not show a significant difference in the proportion of participants healed at seven or 14 days (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>). Heterogeneity was present among studies comparing combined debridement-antiviral treatment to antiviral therapy (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>). Evidence that combination therapy might allow faster healing was also constrained by heterogeneity among studies (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety of debridement</HEADING>
<P>Most studies that used a method of corneal debridement did not mention side effects. Four studies stated that no adverse reactions occurred (<LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>; <LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-Kato-1979" TYPE="STUDY">Kato 1979</LINK>; <LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>). Phototherapy was reported to be painful (<LINK REF="STD-Daniel-1972" TYPE="STUDY">Daniel 1972</LINK>) and was associated with superficial punctate keratopathy and iritis in one study (<LINK REF="STD-O_x0027_Day-1975" TYPE="STUDY">O'Day 1975</LINK>). Carbolisation produced superficial punctate keratopathy in 11% of patients in one study (<LINK REF="STD-MacKenzie-1964" TYPE="STUDY">MacKenzie 1964</LINK>) and one episode of shallow ulceration in another study (<LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Supplemental agents</HEADING>
<P>Hyaluronate contributed to healing at one week but did not yield a better outcome at two weeks in one trial (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). The combination of epidermal growth factor with an antiviral did not significantly enhance the antiviral agent's effect on corneal epithelial healing in one trial (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). Topical panthenol, a precursor to pantothenic acid that might promote epithelial wound healing, was not significantly different from <I>para</I>-fluorophenylalanine in one trial (<LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). Methyluracil, an antioxidant thought to facilitate cell proliferation, did not have an additive effect with interferon in one trial (<LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
<P>The addition of the nonsteroidal anti-inflammatory agent oxyphenbutazone to idoxuridine treatment did not differ from treatment with idoxuridine alone in one trial (<LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>). Inosine pranobex, an immune modulator (<LINK REF="REF-Campoli_x002d_Richards-1986" TYPE="REFERENCE">Campoli-Richards 1986</LINK>) that has been used both topically and orally (<LINK REF="STD-Sellitti-1982" TYPE="STUDY">Sellitti 1982</LINK>), had an uncertain effect on healing at one week and, without or with an antiviral agent, did not significantly affect the 14-day outcome in two included studies (<LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>). No adverse reactions were reported in this cluster of studies.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-04 16:38:18 +0000" MODIFIED_BY="[Empty name]">
<P>HSV infection is a prevalent and potentially damaging eye disease that inflicts personal distress and socioeconomic costs. Safe, effective treatment aims to alleviate symptoms, to enable corneal healing, and to expedite visual recovery. This systematic review synthesises an interconnected web of clinical trials comparing therapeutic options for HSV infection of the corneal surface (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>) and presents the direct and indirect evidence on the relative effectiveness of antivirals, interferon, and debridement in the treatment of HSV epithelial keratitis (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-12-27 19:51:27 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Antiviral therapy</HEADING>
<P>Placebo-controlled studies were inconsistent for idoxuridine and sparse for vidarabine. No significant difference in effectiveness was found between idoxuridine and vidarabine (<LINK REF="STD-Pavan_x002d_Langston-1972" TYPE="STUDY">Pavan-Langston 1972</LINK>). Another out-of-use compound, <I>para</I>-fluorophenylalanine, did not significantly differ from idoxuridine (<LINK REF="STD-Pietruschka-1968" TYPE="STUDY">Pietruschka 1968</LINK>). Trifluridine and acyclovir were more effective than either idoxuridine or vidarabine. Excluded studies also suggested that trifluridine was better than idoxuridine (<LINK REF="STD-Assetto-1981" TYPE="STUDY">Assetto 1981</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1977" TYPE="STUDY">Pavan-Langston 1977</LINK>) and that acyclovir was better than idoxuridine (<LINK REF="STD-Babushkin-1993" TYPE="STUDY">Babushkin 1993</LINK>; <LINK REF="STD-Inocencio-1982" TYPE="STUDY">Inocencio 1982</LINK>) or vidarabine (<LINK REF="STD-McGill-1981" TYPE="STUDY">McGill 1981</LINK>; <LINK REF="STD-Mohan-1987" TYPE="STUDY">Mohan 1987</LINK>).</P>
<P>Analysis of a network of antiviral treatment comparisons indicated that trifluridine, acyclovir, and brivudine had no significant differences in treatment (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>), a finding supported by one-week results (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>) and by their relative rates of healing (<LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>). Based on two trials restricted to geographic epithelial keratitis (<LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>), the two-week healing outcome was better with trifluridine compared to vidarabine but was not significantly different between acyclovir and vidarabine.</P>
<P>Ganciclovir was possibly as or more effective as acyclovir in included studies and in excluded studies (<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>; <LINK REF="STD-Jing-2010" TYPE="STUDY">Jing 2010</LINK>; <LINK REF="STD-Wang-2009" TYPE="STUDY">Wang 2009</LINK>), but interpretation was limited by heterogeneity among the studies. Foscarnet seemed as effective as trifluridine, acyclovir, and ganciclovir but needs further study. The effect of two topical antivirals was examined in only one study. Oral acyclovir may be an alternative to topical antiviral therapy, but few studies examined an oral antiviral or combined oral and topical antivirals in comparison to topical antiviral monotherapy (<LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>). The dosage, formulation, and frequency of administration of antiviral therapy were evaluated in few studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Interferon therapy</HEADING>
<P>Interferon at a concentration of 1 million IU/ml or higher was more effective than control in included studies and an excluded study (<LINK REF="STD-Shiota-1988" TYPE="STUDY">Shiota 1988</LINK>). Used either alone or in combination with debridement (<LINK REF="REF-Cantell-1995" TYPE="REFERENCE">Cantell 1995</LINK>; <LINK REF="REF-Sundmacher-1982" TYPE="REFERENCE">Sundmacher 1982</LINK>; <LINK REF="REF-Sundmacher-1984b" TYPE="REFERENCE">Sundmacher 1984b</LINK>) interferon was as effective as a nucleoside antiviral agent. Excluded studies (<LINK REF="STD-Jin-1992" TYPE="STUDY">Jin 1992</LINK>; <LINK REF="STD-Scialdone-1986" TYPE="STUDY">Scialdone 1986</LINK>; <LINK REF="STD-Tamburi-1990" TYPE="STUDY">Tamburi 1990</LINK>) had insufficient outcome data to adequately determine relative effectiveness between interferon and nucleoside antivirals. A topical interferon inducer did not compare favourably with a topical antiviral agent in a single included study (<LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>) but had encouraging clinical activity in excluded studies (<LINK REF="STD-Galin-1976" TYPE="STUDY">Galin 1976</LINK>; <LINK REF="STD-Kasparov-1972" TYPE="STUDY">Kasparov 1972</LINK>; <LINK REF="STD-Kasparov-1974" TYPE="STUDY">Kasparov 1974</LINK>; <LINK REF="STD-Kasparov-1991" TYPE="STUDY">Kasparov 1991</LINK>; <LINK REF="STD-Lin-2009" TYPE="STUDY">Lin 2009</LINK>). Interferon-&#945; and interferon-&#946; did not differ in included studies or among excluded studies (<LINK REF="STD-Kuyama-1979" TYPE="STUDY">Kuyama 1979</LINK>; <LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>).</P>
<P>The combination of interferon and a nucleoside antiviral agent offers the prospect of faster healing than antiviral therapy alone (<LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>). The possible advantage of combining interferon and an antiviral agent was supported by observational experience (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>) and by several excluded studies (<LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>; <LINK REF="STD-Gu-2005" TYPE="STUDY">Gu 2005</LINK>; <LINK REF="STD-Huang-2009" TYPE="STUDY">Huang 2009</LINK>; <LINK REF="STD-Lin-2013b" TYPE="STUDY">Lin 2013b</LINK>; <LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>; <LINK REF="STD-Tamburi-1990" TYPE="STUDY">Tamburi 1990</LINK>; <LINK REF="STD-Wan-2014" TYPE="STUDY">Wan 2014</LINK>; <LINK REF="STD-Weng-2014" TYPE="STUDY">Weng 2014</LINK>; <LINK REF="STD-Zhao-2001" TYPE="STUDY">Zhao 2001</LINK>; <LINK REF="STD-Zhou-2008" TYPE="STUDY">Zhou 2008</LINK>), but evidence is limited by heterogeneity among included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Debridement</HEADING>
<P>Trials of physicochemical debridement were relatively few and inconsistent. The comparison of debridement to topical antiviral therapy was limited by heterogeneity among included studies and by different findings among excluded studies (<LINK REF="STD-Patterson-1967c" TYPE="STUDY">Patterson 1967c</LINK>; <LINK REF="STD-Tarakji-1978" TYPE="STUDY">Tarakji 1978</LINK>; <LINK REF="STD-Whitcher-1976" TYPE="STUDY">Whitcher 1976</LINK>). Various methods of curettage, cauterisation, and chemoablation were used to remove the corneal epithelium and likely produced variously sized corneal epithelial defects. Thermomechanical scraping, cryotherapy, and chemical abrasion could leave a large denuded area of the corneal surface while wiping and swabbing aim to selectively remove loosened, infected epithelial cells along the dendrite (<LINK REF="REF-Wilhelmus-1989" TYPE="REFERENCE">Wilhelmus 1989</LINK>). Potential shortcomings of debridement included damage to Bowman's layer (<LINK REF="REF-Coster-1977b" TYPE="REFERENCE">Coster 1977b</LINK>) and exacerbation of corneal inflammation and opacification (<LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>).</P>
<P>Epithelial keratitis occurred soon after debridement in some debridement-treated eyes. Presumably, post-debridement viral shedding (<LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>; <LINK REF="STD-Sundmacher-1976b" TYPE="STUDY">Sundmacher 1976b</LINK>) or infection of remaining cells of the ocular surface can lead to recrudescent epithelial keratitis (<LINK REF="REF-Coster-1977b" TYPE="REFERENCE">Coster 1977b</LINK>). While a relapsing episode could be treated by repeating debridement, recrudescent keratitis is preventable by using an antiviral agent for several days after debridement (<LINK REF="REF-Coster-1977b" TYPE="REFERENCE">Coster 1977b</LINK>). However, any healing advantage that might be gained by following debridement with an antiviral agent or interferon was uncertain because of study heterogeneity (<LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>). Excluded studies were also difficult to interpret: some inferred that the combination of debridement and an antiviral agent healed more quickly than antiviral treatment alone (<LINK REF="STD-Koev-2007" TYPE="STUDY">Koev 2007</LINK>; <LINK REF="STD-Mathur-1984" TYPE="STUDY">Mathur 1984</LINK>) while others found little difference in average healing times (<LINK REF="STD-Fellinger-1980" TYPE="STUDY">Fellinger 1980</LINK>; <LINK REF="STD-Guo-2003" TYPE="STUDY">Guo 2003</LINK>; <LINK REF="STD-Shimomura-1987" TYPE="STUDY">Shimomura 1987</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Ancillary agents</HEADING>
<P>Trials that evaluated the addition of a lubricant, growth factors, or a nonsteroidal anti-inflammatory drug to topical antiviral therapy were few in number and did not provide convincing evidence of effectiveness. The role of an immunomodulator such as inosine pranobex was uncertain in included studies and in an excluded study (<LINK REF="STD-Prost-1986" TYPE="STUDY">Prost 1986</LINK>). Studies did not examine justifications for using cycloplegic or antibacterial eye drops. Secondary microbial infection during herpetic epithelial keratitis (<LINK REF="REF-Boisjoly-1983" TYPE="REFERENCE">Boisjoly 1983</LINK>; <LINK REF="REF-Wilhelmus-1982" TYPE="REFERENCE">Wilhelmus 1982</LINK>) was not reported in any included study.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-04 16:38:18 +0000" MODIFIED_BY="[Empty name]">
<P>This systematic review aimed to synthesise the relative effectiveness among available interventions that can be used in the treatment of HSV epithelial keratitis. The literature was systematically searched for all relevant comparative clinical trials using electronic databases, handsearching, and personal contact.</P>
<SUBSECTION>
<HEADING LEVEL="3">Participant characteristics and potential effect modifiers</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Age, gender and ethnicity</HEADING>
<P>The incidence of HSV keratitis rises with advancing age (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>). Participants in studies included in this systematic review averaged 43 years of age, but few studies described the shape of the age distribution. Males outnumbered females in 91% of studies, and studies enrolled, on average, 50% more men than women. While some cohort investigations have suggested that men might be more likely to be diagnosed and treated for HSV epithelial keratitis (<LINK REF="REF-Gold-1965" TYPE="REFERENCE">Gold 1965</LINK>; <LINK REF="STD-Gundersen-1936" TYPE="STUDY">Gundersen 1936</LINK>; <LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>; <LINK REF="REF-Liesegang-1989a" TYPE="REFERENCE">Liesegang 1989a</LINK>; <LINK REF="REF-Wilhelmus-1981b" TYPE="REFERENCE">Wilhelmus 1981b</LINK>), population-based studies show that men and women have similar rates of ocular herpes (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>; <LINK REF="REF-Stanzel-2014" TYPE="REFERENCE">Stanzel 2014</LINK>). Selective enrolment according to age or gender could reflect under-representation of children, the elderly, and women in clinical drug trials (<LINK REF="REF-Van-Spall-2007" TYPE="REFERENCE">Van Spall 2007</LINK>). Women of childbearing potential have often been systematically deemed ineligible for topical ophthalmic antiviral trials because of an unproven concern about antiviral teratogenicity during pregnancy (<LINK REF="REF-Ahrens-2013" TYPE="REFERENCE">Ahrens 2013</LINK>; <LINK REF="REF-Chung-2004" TYPE="REFERENCE">Chung 2004</LINK>; <LINK REF="REF-Itoi-1975" TYPE="REFERENCE">Itoi 1975</LINK>; <LINK REF="REF-Pasternak-2010" TYPE="REFERENCE">Pasternak 2010</LINK>). Among studies that examined the effect of patient characteristics on outcome, neither age nor gender influenced the rate of corneal healing during antiviral therapy for HSV epithelial keratitis (<LINK REF="STD-de-Koning-1982" TYPE="STUDY">de Koning 1982</LINK>; <LINK REF="STD-de-Koning-1983" TYPE="STUDY">de Koning 1983</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>). Observational studies have suggested that some ethnic groups may be susceptible to recurrent HSV epithelial keratitis (<LINK REF="REF-McDonald-2015" TYPE="REFERENCE">McDonald 2015</LINK>; <LINK REF="REF-Wilhelmus-1996a" TYPE="REFERENCE">Wilhelmus 1996a</LINK>), but ethnicity was not significantly associated with recurrence in a cohort followed for 18 months (<LINK REF="REF-HEDS-Group-2001" TYPE="REFERENCE">HEDS Group 2001</LINK>). Insufficient information was available to examine age, gender, or ethnicity as possible effect modifiers in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Immune status</HEADING>
<P>Medical conditions may modulate viral eradication and epithelial regeneration during HSV infection. Poorly controlled diabetes (<LINK REF="REF-Kaiserman-2005" TYPE="REFERENCE">Kaiserman 2005</LINK>), atopy (<LINK REF="REF-Rezende-2006" TYPE="REFERENCE">Rezende 2006</LINK>), and immunosuppression (<LINK REF="REF-Field-1995" TYPE="REFERENCE">Field 1995</LINK>; <LINK REF="REF-Oshry-1998" TYPE="REFERENCE">Oshry 1998</LINK>) might slow resolution of HSV epithelial keratitis. Health status was not examined as a possible effect modifier in studies included in this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Previous herpetic eye disease</HEADING>
<P>Neither the number of previous episodes nor the duration of symptoms prior to initiating antiviral treatment affected healing rates in most studies that evaluated these factors (<LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-H_x00f8_vding-1989" TYPE="STUDY">Høvding 1989</LINK>; <LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-Sugar-1980" TYPE="STUDY">Sugar 1980</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>). Neither the prior use of antiviral agents (<LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>) nor the recent use of corticosteroids (<LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-Sugar-1980" TYPE="STUDY">Sugar 1980</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>) affected relative treatment response.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration between onset and treatment</HEADING>
<P>One study found that the interval between the start of symptoms and the beginning of antiviral treatment correlated with healing time: patients who received earlier treatment healed faster (<LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Pattern of epithelial keratitis</HEADING>
<P>Approximately 90% of eyes enrolled in studies included in this systematic review had dendritic epithelial keratitis. Geographic epithelial keratitis was much less prevalent. In epidemiological studies geographic epithelial keratitis accounts for 5% to 15% of HSV epithelial keratitis (<LINK REF="REF-Labetoulle-2005" TYPE="REFERENCE">Labetoulle 2005</LINK>; <LINK REF="REF-Liesegang-1989a" TYPE="REFERENCE">Liesegang 1989a</LINK>; <LINK REF="REF-Pramod-1999" TYPE="REFERENCE">Pramod 1999</LINK>), although a slightly higher frequency was evident in some studies enrolling both dendritic and geographic epithelial keratitis.</P>
<P>Corneal epithelial wound healing follows a distribution function (<LINK REF="REF-Callaghan-2006" TYPE="REFERENCE">Callaghan 2006</LINK>) similar to the logistic healing curve of HSV epithelial keratitis (<LINK REF="REF-Wilhelmus-2000" TYPE="REFERENCE">Wilhelmus 2000</LINK>). The rate of healing depends on the area of the corneal epithelial defect (<LINK REF="REF-Chung-1998" TYPE="REFERENCE">Chung 1998</LINK>). Larger HSV epithelial keratitis re-epithelialises at a greater rate than smaller lesions (<LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Sugar-1980" TYPE="STUDY">Sugar 1980</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>). Even so, geographic epithelial keratitis resolves more slowly than dendritic epithelial keratitis (<LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>) and, on average, takes longer to heal (<LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK>). Investigators have stated that eyes with geographic epithelial keratitis "constitute the most difficult therapeutic challenge for antiviral drugs" (<LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>), "respond least well to conventional treatment" (<LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>), and "frequently require more prolonged therapy than simple dendritic ulcers" (<LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>). On the other hand, one study found that the relative effect between antivirals was not necessarily affected by lesion size (<LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>). It is unclear whether geographic epithelial keratitis offers a more stringent test of antiviral effectiveness.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Corneal stromal inflammation</HEADING>
<P>Corneal characteristics of HSV epithelial keratitis that may be associated with slow healing include a peripheral corneal location (<LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>) and the presence of stromal inflammation (<LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Daniel-1972" TYPE="STUDY">Daniel 1972</LINK>; <LINK REF="STD-Klauber-1982" TYPE="STUDY">Klauber 1982</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>). While inflammatory cells may slow corneal epithelial wound healing (<LINK REF="REF-Wagoner-1984" TYPE="REFERENCE">Wagoner 1984</LINK>), studies have not demonstrated that stromal keratitis impacts the rate of re-epithelialisation (<LINK REF="STD-H_x00f8_vding-1989" TYPE="STUDY">Høvding 1989</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>). Insufficient data were available to undertake metaregression of these and other potential effect modifiers.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Virology and antiviral susceptibility</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Viral infection</HEADING>
<P>Laboratory methods can detect herpes simplex virus in specimens from the ocular surface (<LINK REF="REF-Satpathy-2011" TYPE="REFERENCE">Satpathy 2011</LINK>). One quarter of studies included in this review undertook viral isolation, including five studies that required viral confirmation before randomisation. The overall sensitivity of HSV recovery from the ocular surface was 68% at trial entry. One study reported that viral culture positivity did not affect healing (<LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>). Antiviral therapy usually eliminates HSV from the ocular surface within the first few days of therapy (<LINK REF="STD-Sundmacher-1984a" TYPE="STUDY">Sundmacher 1984a</LINK>; <LINK REF="STD-Sundmacher-1985" TYPE="STUDY">Sundmacher 1985</LINK>), although HSV could sometimes be recovered up to ten days after beginning antiviral therapy (<LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>). HSV strains may differ in pathogenicity (<LINK REF="REF-Brandt-2005" TYPE="REFERENCE">Brandt 2005</LINK>), but how virulence genes might impact the healing rate of herpetic epithelial keratitis remains to be determined.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Antiviral resistance</HEADING>
<P>Genetic mutations of HSV affecting thymidine kinase or DNA polymerase can impart resistance to antiviral agents (<LINK REF="REF-Duan-2009" TYPE="REFERENCE">Duan 2009</LINK>). HSV strains that are not readily susceptible to acyclovir can emerge among immunocompromised persons and during antiviral treatment of otherwise healthy individuals (<LINK REF="REF-Burrel-2013" TYPE="REFERENCE">Burrel 2013</LINK>; <LINK REF="REF-van-Velzen-2013" TYPE="REFERENCE">van Velzen 2013</LINK>; <LINK REF="REF-Zhang-2007" TYPE="REFERENCE">Zhang 2007</LINK>). Mutant HSV strains may recur more frequently and heal more slowly (<LINK REF="REF-Pan-2014" TYPE="REFERENCE">Pan 2014</LINK>) but usually respond to an alternative antiviral (<LINK REF="REF-Hlinomazov_x00e1_-2012" TYPE="REFERENCE">Hlinomazová 2012</LINK>; <LINK REF="REF-Turner-2013" TYPE="REFERENCE">Turner 2013</LINK>; <LINK REF="REF-Yao-1996" TYPE="REFERENCE">Yao 1996</LINK>), a combination of nucleoside antivirals, or co-administration of an antiviral with interferon (<LINK REF="REF-Minkovitz-1995" TYPE="REFERENCE">Minkovitz 1995</LINK>). Susceptibility testing could be considered for treatment-unresponsive infection due to HSV (<LINK REF="REF-Choong-2010" TYPE="REFERENCE">Choong 2010</LINK>).</P>
<P>In this review, the 14-day outcome with topical acyclovir declined during a 25-year period while the response rate with topical ganciclovir remained stable over 15 years. Although the emergence of acyclovir resistance is a potential reason for this observed longitudinal trend, studies did not do susceptibility testing. Dissimilarities in defining cure in diverse studies might be a more likely explanation for this ebb in reported responses to topical acyclovir.</P>
</SUBSECTION>
</SUBSECTION>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-03 22:34:55 +0000" MODIFIED_BY="[Empty name]">
<P>This systematic review endeavoured to encapsulate a pragmatic and quantitative digest of clinical research. Many trials in this review were inconclusive because of inadequate sample size. In addition, trials concluding a similarity between treatments were not designed to demonstrate equivalence (<LINK REF="REF-Musch-2006" TYPE="REFERENCE">Musch 2006</LINK>). Systematic pooling of studies and network analysis endeavoured to improve precision through an objective appraisal of clinical evidence.</P>
<P>Data were extracted from journal articles and other sources to estimate relative effect measures of corneal healing for different interventions. Healing curves (<LINK REF="STD-Graupner-1968" TYPE="STUDY">Graupner 1968</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>) and survival analysis (<LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>) are recommended for reporting treatment trials of HSV epithelial keratitis, but these analytical methods were unevenly applied. Nearly a third of otherwise eligible studies were not included in this review because of incompletely reported data. The estimation of cumulative risk and the use of hazard functions that consider variable follow-up durations need to be more widely implemented in clinical trials of ophthalmic interventions (<LINK REF="REF-Hosmer-2009" TYPE="REFERENCE">Hosmer 2009</LINK>; <LINK REF="REF-Jewell-2009" TYPE="REFERENCE">Jewell 2009</LINK>).</P>
<P>Publication of studies included in this review peaked during the 1980s (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>), an era of antiviral discovery and investigation (<LINK REF="REF-Gordon-2000" TYPE="REFERENCE">Gordon 2000</LINK>). After a brief lull, the number of published studies began to rise again after 2005 with the advent of antiviral trials undertaken in China. In comparison, the number of excluded studies that had remained fairly stable throughout the late 20<SUP>th</SUP> century also increased during the early 21<SUP>st</SUP> century, largely driven by studies of traditional Chinese medicines. The inclusion of studies that lack adherence to proper study design, random allocation and analysis would dampen the quality of the cumulative evidence (<LINK REF="REF-Panagiotou-2013" TYPE="REFERENCE">Panagiotou 2013</LINK>; <LINK REF="REF-Wu-2009" TYPE="REFERENCE">Wu 2009</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-04 14:47:15 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Internal and external validity</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Attention to detail in study design and reporting</HEADING>
<P>Methodological rigour varied among studies. Nearly a quarter of studies did not clarify the method of random sequence generation, and authenticating randomisation was problematic for brief reports (<LINK REF="REF-Wu-2009" TYPE="REFERENCE">Wu 2009</LINK>). Why the number of study eyes sometimes exceeded the number of participants was unclear; presumably, persons with bilateral keratitis or participants experiencing a recurrence were re-enrolled into some studies. Half of the included studies lacked masking of both patients and trialists. Withdrawals were infrequent during the initial two weeks of observation and therapy, even among studies that had a risk of attrition bias. For studies did not specify censoring times, extrapolation of data from healing curves could have misinterpreted the number of healed eyes. Sensitivity analyses that omitted studies with a higher risk of bias left few trials for each treatment comparison.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Issues of consistency</HEADING>
<P>Heterogeneity of trial results limited the interpretation of some treatment comparisons. Some trials of the ganciclovir trials enrolled patients with disciform or stromal keratitis and did not stratify outcome by type of corneal disease. Diverse treatment dosages and formulations of antivirals and interferons and varied physical and chemical methods of removing corneal epithelium tempered the comparability of studies. Pooling different antiviral agents in the interferon-antiviral and debridement-antiviral comparisons did not take into consideration potential differences in antiviral effectiveness. The use of a cycloplegic or antibiotic could have affected therapeutic effects since atropine and neomycin are capable of inhibiting HSV (<LINK REF="REF-Alarc_x00f3_n-1984" TYPE="REFERENCE">Alarcón 1984</LINK>; <LINK REF="REF-Langeland-1987" TYPE="REFERENCE">Langeland 1987</LINK>).</P>
<P>The asymmetric geometry of the network of treatment comparisons was a web of open and closed loops. To contend with multiple treatment comparisons this systematic review integrated direct head-to-head comparisons of antivirals with indirect comparisons. As noted in the Cochrane Handbook, "indirect comparisons are not randomized comparisons, and cannot be interpreted as such" (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Blending direct and indirect risk ratios offers increased precision but is liable to confounding and bias (<LINK REF="REF-Mills-2012" TYPE="REFERENCE">Mills 2012</LINK>). The validity of network analysis depends on homogeneity among studies and consistency between direct and indirect results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Possible shortcomings in selecting and reviewing studies</HEADING>
<P>Eighty-six of 143 excluded studies were not appropriate for this review due to use of an alternative intervention or problematic design. The remaining 57 studies were excluded because data on cumulative healing proportions at one or two weeks of study treatment were not reported. The exclusion of adequately designed studies because relevant outcome information was not available in the published report could dampen the robustness of the review (<LINK REF="REF-Felton-1992" TYPE="REFERENCE">Felton 1992</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety</HEADING>
<P>Topically applied antivirals and other medications that delay epithelial regeneration (<LINK REF="REF-Lass-1984" TYPE="REFERENCE">Lass 1984</LINK>) could impact the assessment of relative treatment effects. Thus, while safety was an auxiliary concern, the evaluation of effectiveness could be affected by side effects. Less than half of the studies included in this review reported the incidence of drug-related ocular allergy or toxicity. The relative safety of antivirals, interferon, and other interventions summarised in this review is likely to be inexact. Ophthalmic studies and case reports have described adverse reactions at the ocular surface due to antivirals (<LINK REF="REF-Chen-1989" TYPE="REFERENCE">Chen 1989</LINK>; <LINK REF="REF-Falcon-1981" TYPE="REFERENCE">Falcon 1981</LINK>; <LINK REF="REF-Naito-1987" TYPE="REFERENCE">Naito 1987</LINK>) and interferon (<LINK REF="REF-Aldave-2007" TYPE="REFERENCE">Aldave 2007</LINK>) that were more serious than those detected in treatment trials. Postmarketing surveillance and pharmacovigilance are needed to define the prevalence of common adverse reactions and to detect uncommon complications such as lacrimal punctal stenosis, conjunctival cicatrisation, corneal dysplasia, and anterior segment ischæmia.</P>
</SUBSECTION>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-01-03 23:28:42 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Medical therapy</HEADING>
<P>Literature reviews have deduced that currently available topical ophthalmic antiviral agents are effective for HSV epithelial keratitis (<LINK REF="REF-AAO-2013" TYPE="REFERENCE">AAO 2013</LINK>; <LINK REF="REF-Barker-2008" TYPE="REFERENCE">Barker 2008</LINK>; <LINK REF="REF-Behrens_x002d_Baumann-2010" TYPE="REFERENCE">Behrens-Baumann 2010</LINK>; <LINK REF="REF-Hergeldzhieva-2012" TYPE="REFERENCE">Hergeldzhieva 2012</LINK>; <LINK REF="REF-Labetoulle-2012" TYPE="REFERENCE">Labetoulle 2012</LINK>; <LINK REF="REF-Wei-2008" TYPE="REFERENCE">Wei 2008</LINK>). A systematic review of 28 randomised, double-masked, controlled, English-language clinical trials (including two trials that were subsets of larger trials) found that either trifluridine or acyclovir is effective for the treatment of HSV epithelial keratitis and that the combination of an antiviral with interferon might offer additional benefit (<LINK REF="REF-Guess-2007" TYPE="REFERENCE">Guess 2007</LINK>). While literature reviews have considered ganciclovir gel to be similar in efficacy to acyclovir ointment (<LINK REF="REF-Kaufman-2012" TYPE="REFERENCE">Kaufman 2012</LINK>; <LINK REF="REF-Sahin-2012" TYPE="REFERENCE">Sahin 2012</LINK>), a systematic review of 14 randomized trials that compared topical ophthalmic acyclovir and ganciclovir in the treatment of HSV epithelial keratitis concluded that despite heterogeneity (I<SUP>2</SUP>=55%) ganciclovir improves the cure rate (RR, 1.22; 95% CI, 1.10, 1.36), has a lower risk of adverse reactions (RR, 0.12; 95% CI, 0.03 to 0.46), and reduces the risk of recurrence during the ensuing year (0.22; 92% CI, 0.11-0.45) (<LINK REF="REF-Li-2014d" TYPE="REFERENCE">Li 2014d</LINK>). An evidence-based guideline from the American Academy of Ophthalmology and Ocualr Microbiology and Immunology Group concluded that topical trifluridine, acyclovir, and ganciclovir are effective, that debridement is an alternative treatment, that combining debridement with a topical antiviral agent confers "limited or no benefit," and that oral antiviral agents such as acyclovir, valacyclovir, and famciclovir "appear to be as effective as topical antiviral agents" (<LINK REF="REF-White-2014" TYPE="REFERENCE">White 2014</LINK>). The therapeutic effect of oral acyclovir for treating herpetic epithelial keratitis is consistent with its efficacy for treating labial or genital herpes (<LINK REF="REF-Cernik-2008" TYPE="REFERENCE">Cernik 2008</LINK>). and an oral antiviral might be preferred to topical antivirals when treating herpetic keratitis in children (<LINK REF="REF-Revere-2013" TYPE="REFERENCE">Revere 2013</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complementary and alternative medicine</HEADING>
<P>This systematic review excluded clinical studies of ethnomedicinal products and alternative practices. A review of traditional herbal medicines in the treatment of herpetic keratitis found variable study quality and inconsistent results among 29 comparative trials of botanical and herbal preparations (<LINK REF="REF-Ma-2006b" TYPE="REFERENCE">Ma 2006b</LINK>). Rather than reporting the proportion of eyes healed at each follow-up visit, the outcome was often based on clinical scoring of symptoms and signs, measurements of the length of residual dendrites, or visual acuity. Systematic evaluation is needed to assess how herbal and botanical products and other alternative or complementary interventions such as acupuncture compare to or might integrate with antiviral chemotherapy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Prevention</HEADING>
<P>This review did not systematically evaluate whether interventions for treating HSV epithelial keratitis influenced subsequent inflammatory episodes or future recurrences. Limited evidence exists that short-term antiviral therapy for dendritic epithelial keratitis can forestall consequent HSV stromal keratitis (<LINK REF="REF-Maudgal-1979" TYPE="REFERENCE">Maudgal 1979</LINK>; <LINK REF="REF-Wilhelmus-1981b" TYPE="REFERENCE">Wilhelmus 1981b</LINK>). The evidence that a topical antiviral might also affect future episodes of epithelial keratitis is conflicting. Several studies included in this systematic review found no differential effect between interventions on later recurrences (<LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>; <LINK REF="STD-McGill-1981" TYPE="STUDY">McGill 1981</LINK>; <LINK REF="STD-Patterson-1963a" TYPE="STUDY">Patterson 1963a</LINK>; <LINK REF="STD-Power-1991" TYPE="STUDY">Power 1991</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>; <LINK REF="REF-Yamagami-1998" TYPE="REFERENCE">Yamagami 1998</LINK>). On the other hand, several included studies comparing ganciclovir and acyclovir observed that topical ganciclovir reduced the risk of ocular recurrence during the year after completing treatment (<LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Lin-2014" TYPE="STUDY">Lin 2014</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Liu-2014a" TYPE="STUDY">Liu 2014a</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Yang-2008" TYPE="STUDY">Yang 2008</LINK>; <LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>). Whether a short-term intervention for HSV epithelial keratitis affects future recurrences deserves to be critically evaluated.</P>
<P>The prevention of recurrent ocular herpes is feasible through chronic suppressive antiviral prophylaxis (<LINK REF="REF-Jones-1977" TYPE="REFERENCE">Jones 1977</LINK>) and by drugs that inhibit viral reactivation (<LINK REF="REF-Kaufman-2002" TYPE="REFERENCE">Kaufman 2002</LINK>; <LINK REF="REF-Luzi-1983" TYPE="REFERENCE">Luzi 1983</LINK>). Prolonged use of a topical antiviral (<LINK REF="REF-Wilhelmus-1983" TYPE="REFERENCE">Wilhelmus 1983</LINK>; <LINK REF="REF-Romano-1988" TYPE="REFERENCE">Romano 1988</LINK>) or oral antiviral (<LINK REF="REF-HEDS-Group-2000b" TYPE="REFERENCE">HEDS Group 2000b</LINK>; <LINK REF="REF-Uchoa-2003" TYPE="REFERENCE">Uchoa 2003</LINK>; <LINK REF="REF-Wu-2002" TYPE="REFERENCE">Wu 2002</LINK>; <LINK REF="REF-Young-2010" TYPE="REFERENCE">Young 2010</LINK>) can deter recurrent herpetic eye disease. This issue is examined in another systematic review (<LINK REF="REF-de-la-Parra-2013" TYPE="REFERENCE">de la Parra 2013</LINK>). Though costly (<LINK REF="REF-Lairson-2003" TYPE="REFERENCE">Lairson 2003</LINK>), prolonged antiviral use may be helpful for previously infected people who have an increased risk of recurrence, such as with increased sunlight exposure (<LINK REF="REF-Ludema-2014b" TYPE="REFERENCE">Ludema 2014b</LINK>), topical corticosteroid use (<LINK REF="REF-Wilhelmus-1996a" TYPE="REFERENCE">Wilhelmus 1996a</LINK>), or ocular surgery (<LINK REF="REF-Bhatt-2009" TYPE="REFERENCE">Bhatt 2009</LINK>). A safe and effective vaccine is awaited (<LINK REF="REF-Chentoufi-2012" TYPE="REFERENCE">Chentoufi 2012</LINK>).</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-03 23:44:15 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-03 23:29:07 +0000" MODIFIED_BY="[Empty name]">
<P>Ophthalmic formulations of trifluridine, acyclovir, ganciclovir, brivudine, and foscarnet are effective in the treatment of HSV epithelial keratitis. The combination of an antiviral with interferon might be considered for clinically recalcitrant dendritic keratitis. Wiping debridement may be an option to avoid chemotherapeutic drugs, but the relative value of debridement accompanied by an antiviral agent is unclear.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-03 23:44:15 +0000" MODIFIED_BY="[Empty name]">
<P>The design and reporting of future clinical trials of HSV epithelial keratitis should follow guidelines for Enhancing the Quality and Transparency of Health Research (<A HREF="http://www.equator-network.org">EQUATOR</A>), including the Consolidated Standards of Reporting Trials (<A HREF="http://www.consort-statement.org">CONSORT</A>). Studies should specify the eligibility and healing criteria, methods of randomisation and allocation concealment, means of masking outcome evaluation, and rationale for the numbers of enrolled eyes and participants. Since dendritic epithelial keratitis heals relatively rapidly with currently available treatment, trialists may consider estimating sample size based on a non-inferiority comparison. The time to corneal re-epithelialisation is a key measure of therapeutic efficacy and days by which healing or censoring occur during the initial weeks of therapy should be given in graphs or tables. The effects of characteristics that might modify healing would be a useful supplementary analysis. Virological evaluation will have increasing relevance if optimal therapy is affected by the emergence of viral strains with enhanced resistance or virulence. Adverse events should be recorded, and a comprehensive evaluation of the safety of antivirals and other interventions should extend to data sources beyond clinical trials. Additional research is needed to clarify the roles of topical ganciclovir, topical foscarnet, oral antiviral treatment, concurrent use of an antiviral with interferon, and corneal epithelial debridement. However, future clinical trials should avoid unnecessarily randomising patients without contributing new information or addressing reasons for heterogeneity among previous studies. The potential value of integrative and alternative therapy with herbal medicines remains to be systematically reviewed.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-01-03 23:44:52 +0000" MODIFIED_BY="[Empty name]">
<P>The United States Cochrane Center and the Cochrane Eyes and Vision Group editorial teams developed and executed electronic searches and provided translations. Peer reviewers of previous and current version of this review included Rainer Sundmacher, John Dart, Jayne Tierney, Christopher J Rapuano, David B Glasser, Prashant Garg, and Barbara Hawkins. An initial version of this work was published by the American Ophthalmological Society (<LINK REF="REF-Wilhelmus-2000" TYPE="REFERENCE">Wilhelmus 2000</LINK>).</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-25 11:52:38 +0100" MODIFIED_BY="[Empty name]">
<P>None known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-05-01 14:37:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>KRW developed the protocol, selected studies, extracted data, and wrote the review.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-11-06 08:15:49 +0000" MODIFIED_BY="[Empty name]">
<P>This updated review uses 14 days, rather than seven days, as the primary treatment outcome time and estimates risk ratios and hazard ratios instead of odds ratios.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-09-25 11:53:03 +0100" MODIFIED_BY="[Empty name]">
<P>Issue 12, 2010: the original title of 'Therapeutic interventions for herpes simplex virus epithelial keratitis' was changed.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-04 20:54:38 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2014-12-27 19:42:25 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-12-27 19:42:25 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abe-1987" MODIFIED="2014-12-07 14:37:00 +0000" MODIFIED_BY="Anupa Shah" NAME="Abe 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-12-07 14:37:00 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abe T, Hara S</AU>
<TI>Use of acyclovir in herpetic ocular infections</TI>
<TO>&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#24615;&#8203;&#30524;&#8203;&#24863;&#8203;&#26579;&#8203;&#30151;&#8203;&#12392;&#8203;&#26704;&#8203;&#27810;&#8203;&#22411;&#8203;&#12406;&#8203;&#12393;&#8203;&#12358;&#8203;&#33180;&#8203;&#28814;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427; &#8203;a&#8203;c&#8203;y&#8203;c&#8203;l&#8203;o&#8203;v&#8203;i&#8203;r &#8203;&#12398;&#8203;&#20351;&#8203;&#29992;&#8203;&#32076;&#8203;&#39443;&#8203;</TO>
<SO>Japanese Journal of Clinical Ophthalmology [Rinsho Ganka]</SO>
<YR>1987</YR>
<VL>41</VL>
<NO>1</NO>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Altinisik-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Altinisik 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Altinisik C</AU>
<TI>Treatment of herpetic keratitis with IDU, acyclovir and debridement + acyclovir and comparing of their results</TI>
<TO>Herpetik keratitlerin IDU, acyclovir ve debritman + acyclovir ile tedavileri ve sonuçlarinin karsilastirilmasi</TO>
<SO>Türk Oftalmoloji Gazetesi</SO>
<YR>1987</YR>
<VL>17</VL>
<PG>39-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Austin-1974" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Austin 1974" YEAR="1974">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Austin DJ, Walker WM</AU>
<TI>Idoxuridine and iodization in the treatment of simple dendritic ulceration</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1974</YR>
<VL>94</VL>
<PG>553</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bartholomew-1977" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Bartholomew 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bartholomew RS, Clarke M, Phillips CI</AU>
<TI>"Dye/light". Dye-induced photosensitization of herpes virus. A clinical trial on humans</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>508-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Behrens_x002d_Baumann-1992" NAME="Behrens-Baumann 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Behrens-Baumann W</AU>
<TI>Phosphonoformate (foscarnet, PFA) versus trifluorthymidine in the treatment of keratitis dendritica in the human. A double-blind, randomized, preliminary trial</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1992</YR>
<VL>70</VL>
<PG>690-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blake-1977" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Blake 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blake J, Browne M</AU>
<TI>Treatment of herpetic keratitis</TI>
<SO>Documenta Ophthalmologica</SO>
<YR>1977</YR>
<VL>44</VL>
<PG>23-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burns-1963" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Burns 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns RP</AU>
<TI>A double-blind study of IDU in human herpes simplex keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1963</YR>
<VL>70</VL>
<PG>381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2001" MODIFIED="2014-12-07 17:03:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Cao 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-12-07 17:03:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao K</AU>
<TI>Clinical research on treatment of herpes simplex keratitis with foscarnet sodium eye drops</TI>
<TO>&#33190;&#30002;&#37240;&#38048;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Ophthalmology in China [Yanke]</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>6</NO>
<PG>343-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carmassi-1993" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Carmassi 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carmassi L, Prantera M, Bergamini F</AU>
<TI>Use of acyclovir and interferon in the treatment of herpetic keratitis</TI>
<TO>L'uso del'acyclovir e dell'interferone nel trattamento della cheratite herpetica</TO>
<SO>Annali di Ottalmologia e Clinica Oculistica</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cellini-1994" NAME="Cellini 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cellini M, Baldi A, Caramazza N, De Felice GP, Gazzaniga A</AU>
<TI>Epidermal growth factor in the topical treatment of herpetic corneal ulcers</TI>
<SO>Ophthalmologica</SO>
<YR>1994</YR>
<VL>208</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2008" MODIFIED="2013-11-04 19:21:21 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chen 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-04 19:21:21 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen J, Jin M, Gao ZY</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in the treatment of viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Chinese Journal of Practical Ophthalmology [Zhongguo Shiyong Yanke Zazhi]</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>3</NO>
<PG>248-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1981" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Colin 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-05-25 23:01:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin C, Chastel C</AU>
<TI>Human herpes infections and their treatment</TI>
<TO>L'infection herpétique humaine et ses traitements</TO>
<SO>Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale et de Santé Publique</SO>
<YR>1981</YR>
<VL>3-4</VL>
<PG>111-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Tournoux A, Chastel C, Renard G</AU>
<TI>Superficial herpes simplex keratitis. Double-blind comparative trial of acyclovir and idoxuridine</TI>
<TO>Kératite herpétique superficielle. Traitement comparatif en double insu par acyclovir et idoxuridine</TO>
<SO>La Nouvelle Presse Médicale</SO>
<YR>1981</YR>
<VL>10</VL>
<PG>2969-70, 2975</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1982" MODIFIED="2014-09-25 12:36:08 +0100" MODIFIED_BY="[Empty name]" NAME="Colin 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-09-25 12:36:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Bonisset JF, Renard G</AU>
<TI>Superficial herpetic keratitis: comparative treatment with trifluorothymidine or the combination isoprinosine-trifluorothymidine</TI>
<TO>Kératite herpétique superficielle: traitement comparatif par trifluorothymidine ou l'association isoprinosine-trifluorothymidine</TO>
<SO>Bulletin des Sociétes d'Ophtalmologie de France</SO>
<YR>1982</YR>
<VL>82</VL>
<NO>6-7</NO>
<PG>779-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1983" MODIFIED="2014-12-01 14:51:50 +0000" MODIFIED_BY="Anupa Shah" NAME="Colin 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-12-01 14:51:50 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Chastel C, Renard G, Cantell K</AU>
<TI>Combination therapy for dendritic keratitis with human leukocyte interferon and acyclovir</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1983</YR>
<VL>95</VL>
<PG>346-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-25 23:02:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Chastel C, Renard G, Cantell K</AU>
<TI>Interferon: major therapeutic contributions in ocular herpes</TI>
<TO>L'interféron: apport thérapeutique majeur dans l'herpès oculaire</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1983</YR>
<VL>83</VL>
<PG>435-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Chastel C, Renard G, Cantell K</AU>
<TI>Ocular herpes: synergistic antiviral activity of acyclovir and human leukocyte interferon</TI>
<TO>Herpès oculaire: activité antivirale synergique de l'acyclovir et de l'interféron leucocytaire humain</TO>
<SO>La Nouvelle Presse Médicale</SO>
<YR>1982</YR>
<VL>11</VL>
<PG>2783</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Colin J, Chastel C, Renard G</AU>
<TI>Human leukocyte interferon and aciclovir versus albumin placebo and aciclovir in the treatment of dendritic keratitis</TI>
<SO>Acta XXIV International Congress of Ophthalmology</SO>
<YR>1982</YR>
<VL>1</VL>
<PG>225-6</PG>
<ED>Henkind P</ED>
<PB>JB Lippincott Company</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1984" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Colin 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J</AU>
<TI>Superficial herpetic keratitis: comparative double-blind treatment with iododeoxycytidine and acyclovir</TI>
<TO>Kératite herpétique superficielle: traitement comparatif en double-insu par iododesoxycytidine et acyclovir</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1984</YR>
<VL>84</VL>
<PG>1283-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1987" MODIFIED="2010-09-14 18:21:40 +0100" MODIFIED_BY="[Empty name]" NAME="Colin 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-09-14 18:21:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Chastel C, Kaufman HE, Kissling GE</AU>
<TI>Combination therapy for dendritic keratitis with acyclovir and vidarabine</TI>
<SO>Journal of Ocular Pharmacology</SO>
<YR>1987</YR>
<VL>3</VL>
<PG>39-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1997a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Colin 1997a" YEAR="1997">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Hoh HB, Easty DL, Herbort CP, Resnikoff S, Rigal D, et al</AU>
<TI>Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis</TI>
<SO>Cornea</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-1997b" MODIFIED="2010-02-23 20:37:29 +0000" MODIFIED_BY="[Empty name]" NAME="Colin 1997b" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colin J, Hoh HB, Easty DL, Herbort CP, Resnikoff S, Rigal D, et al</AU>
<TI>Ganciclovir ophthalmic gel (Virgan; 0.15%) in the treatment of herpes simplex keratitis</TI>
<SO>Cornea</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-02-23 20:37:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoh HB, Hurley C, Claoué C, Viswalingham M, Easty DL, Goldschmidt P, et al</AU>
<TI>Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>80</VL>
<PG>140-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-2007a" MODIFIED="2009-03-10 17:33:19 +0000" MODIFIED_BY="[Empty name]" NAME="Colin 2007a" YEAR="2007">
<REFERENCE MODIFIED="2009-03-10 17:33:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Colin J</AU>
<TI>Ganciclovir ophthalmic gel 0.15%: a valuable tool for treating ocular herpes</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2007</YR>
<VL>1</VL>
<PG>441-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colin-2007b" MODIFIED="2014-12-06 20:49:30 +0000" MODIFIED_BY="Anupa Shah" NAME="Colin 2007b" YEAR="2007">
<REFERENCE MODIFIED="2014-12-06 20:49:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Colin J, Resnikoff S, Adrien JLM</AU>
<TI>Comparative efficacy of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis</TI>
<SO>Annual Meeting of the American Academy of Ophthalmology</SO>
<YR>1992</YR>
<PG>125</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-10 17:33:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colin J</AU>
<TI>Ganciclovir ophthalmic gel 0.15%: a valuable tool for treating ocular herpes</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2007</YR>
<VL>1</VL>
<PG>441-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-05-25 23:05:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Dart JKG</AU>
<TI>Randomised, parallel comparative multicentre study of LCM 1316 (ganciclovir) suspension <I>versus</I> acyclovir ointment 3% in herpes simplex keratitis (N0141164542)</TI>
<SO>National Research Register, Department of Health, Great Britain. Unpublished clinical trial sponsored by Chauvin Pharmaceuticals, 2000-2001</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoh HB, Hurley C, Claoué C, Viswalingham M, Easty DL, Goldschmidt P, et al</AU>
<TI>Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>80</VL>
<PG>140-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-27 20:51:27 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurley C, Hillery M, Hoh HB, Claoué E, Easty DL, Kenna P, et al</AU>
<TI>Randomised trial of ganciclovir 0.15% gel and acyclovir 3% ointment in the treatment of herpes simplex dendritic keratitis: a multicentre study [abstract]</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1995</YR>
<VL>164</VL>
<PG>332 (abstract 294)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-11-27 20:42:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hurley C, Hillery M, O'Doherty D, Collum LMT</AU>
<TI>Acyclovir vs ganciclovir in the treatment of herpes simplex keratitis</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1994</YR>
<VL>163</VL>
<PG>309</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collum-1980" MODIFIED="2014-09-25 12:38:00 +0100" MODIFIED_BY="[Empty name]" NAME="Collum 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collum L, Logan P</AU>
<TI>Acyclovir in herpes simplex keratitis [abstract]</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1981</YR>
<VL>150</VL>
<PG>225</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, Benedict Smith A, Hillary IB</AU>
<TI>Randomised double-blind trial of acyclovir and idoxuridine in dendritic corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1980</YR>
<VL>64</VL>
<PG>766-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Collum LMT, Benedict-Smith A, Hillary IB</AU>
<TI>Acyclovir in dendritic corneal ulceration</TI>
<SO>The Cornea in Health and Disease. VIth Congress of the European Society of Ophthalmology</SO>
<YR>1980</YR>
<PG>765-71</PG>
<ED>Trevor-Roper PD</ED>
<PB>Royal Society of Medicine</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 12:38:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, Logan P, Hillary IB, Ravenscroft T</AU>
<TI>Acyclovir in herpes keratitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73 Suppl 1A</VL>
<PG>290-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collum-1985" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Collum 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, Logan P, McAuliffe-Curtin D, Hung SO, Patterson A, Rees PJ</AU>
<TI>Randomised double-blind trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex amoeboid corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1985</YR>
<VL>69</VL>
<PG>847-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, Logan P</AU>
<TI>Acyclovir in complicated herpetic keratitis [abstract]</TI>
<SO>Irish Journal of Medical Science</SO>
<YR>1982</YR>
<VL>151</VL>
<PG>291-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collum-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Collum 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, Akhtar J, McGettrick P</AU>
<TI>Oral acyclovir in herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1985</YR>
<VL>104</VL>
<PG>629-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Collum LMT, MacGettrick P, Akhtar J, Rees PJ</AU>
<TI>Oral acyclovir (Zovirax) in herpetic keratitis</TI>
<SO>Herpetic Eye Diseases</SO>
<YR>1985</YR>
<PG>233-40</PG>
<ED>Maudgal PC, Missotten L</ED>
<PB>Dr W Junk Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Collum LMT, McGettrick P, Akhtar J, Lavin J, Rees PJ</AU>
<TI>Oral acyclovir (Zovirax) in herpes simplex dendritic corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1986</YR>
<VL>70</VL>
<PG>435-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coster-1976" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Coster 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, McKinnon JR, McGill JI, Jones BR, Fraunfelder FT</AU>
<TI>Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>133 Suppl</VL>
<PG>A173-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Jones BR, McGill JI, McKinnon JR, Holt-Wilson AD, Williams HP</AU>
<TI>Preliminary experience with adenine arabinoside in comparison with idoxuridine and trifluorothymidine in the management of herpetic keratitis</TI>
<SO>Adenine-Arabinoside: An Antiviral Agent</SO>
<YR>1975</YR>
<PG>411-6</PG>
<ED>Pavan-Langston D, Buchanan RA, Alford CA Jr</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGill JI, Coster D, Fraunfelder T, Holt-Wilson AD, Williams H, Jones BR</AU>
<TI>Adenine arabinoside in the management of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1975</YR>
<VL>95</VL>
<PG>246-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>McKinnon JR, McGill JI, Jones BR</AU>
<TI>A coded clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of ulcerative herpetic keratitis</TI>
<SO>Adenine-Arabinoside: An Antiviral Agent</SO>
<YR>1975</YR>
<PG>401-10</PG>
<ED>Pavan-Langston D, Buchanan RA, Alford CA Jr</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coster-1977a" MODIFIED="2014-09-25 12:39:16 +0100" MODIFIED_BY="[Empty name]" NAME="Coster 1977a" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, Falcon MG, Cantell K, Jones BR</AU>
<TI>Clinical experience of human leucocyte interferon in the management of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>327-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 12:39:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR, Coster DJ, Falcon MG, Cantell K</AU>
<TI>Clinical trials of topical interferon therapy of ulcerative viral keratitis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>133 Suppl</VL>
<PG>A169-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-01 11:56:18 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR, Coster DJ, Falcon MG, Cantell K</AU>
<TI>Topical therapy of ulcerative herpetic keratitis with human interferon</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>2</VL>
<PG>128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coster-1979" MODIFIED="2010-11-06 09:04:36 +0000" MODIFIED_BY="[Empty name]" NAME="Coster 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, Jones BR, McGill JI</AU>
<TI>Treatment of amoeboid herpetic ulcers with adenine arabinoside or trifluorothymidine</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1979</YR>
<VL>63</VL>
<PG>418-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-06 09:04:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, McKinnon JR, McGill JI, Jones BR, Fraunfelder FT</AU>
<TI>Clinical evaluation of adenine arabinoside and trifluorothymidine in the treatment of corneal ulcers caused by herpes simplex virus</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>133 Suppl</VL>
<PG>A173-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coster-1980" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Coster 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, Wilhelmus KR, Michaud R, Jones BR</AU>
<TI>A comparison of acyclovir and idoxuridine as treatment for ulcerative herpetic keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1980</YR>
<VL>64</VL>
<PG>763-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Jones BR, Coster DJ, Michaud R, Wilhelmus KR</AU>
<TI>Acyclovir (Zovirax) in the management of herpetic keratitis</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>295-301</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jones BR, Coster DJ, Wilhelmus KR, Michaud R</AU>
<TI>Acyclovir (Zovirax) an effective antiviral for herpetic keratitis</TI>
<SO>The Cornea in Health and Disease. VIth Congress of the European Society of Ophthalmology</SO>
<YR>1980</YR>
<PG>773-9</PG>
<ED>Trevor-Roper P</ED>
<PB>Royal Society of Medicine</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2009a" MODIFIED="2014-12-07 15:17:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Dai 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-12-07 15:17:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai X, Huang HH, Hu XJ, Liu Q, Liu ZR</AU>
<TI>Use of ganciclovir for herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#22312;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20013;&#30340;&#24212;&#29992;</TO>
<SO>Strait Pharmaceutical Journal [Haixia Yaoxue]</SO>
<YR>2009</YR>
<VL>21</VL>
<NO>10</NO>
<PG>145</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dai-2009b" MODIFIED="2014-12-07 15:18:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Dai 2009b" YEAR="2009">
<REFERENCE MODIFIED="2014-12-07 15:18:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dai ZX, Zhang H, Lin MY, Liang XY</AU>
<TI>Clinical observation of treatment of epithelial herpes simplex virus keratitis by ganciclovir ophthalmic gel</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Asia-Pacific Traditional Medicine [Yatai Chuantong Yiyao]</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>7</NO>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1972" NAME="Daniel 1972" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel R, Karseras A</AU>
<TI>Assessment of possible potentiating action of ultraviolet light on 5 iodo-2' deoxyuridine in superficial herpetic keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1972</YR>
<VL>56</VL>
<PG>604-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-1964" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Davidson 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson SI, Jameson Evans P</AU>
<TI>IDU and the treatment of herpes simplex keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1964</YR>
<VL>48</VL>
<PG>678-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Koning-1982" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="de Koning 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Koning EWJ, van Bijsterveld OP, Cantell K</AU>
<TI>Combination interferon-trifluorothymidine in the treatment of herpetic keratitis</TI>
<TO>La combinaison interféron-trifluorothymidine dans le traitement des kératites herpétiques</TO>
<SO>Bulletins et Mémoires de la Société Française d'Ophtalmologie</SO>
<YR>1982</YR>
<VL>94</VL>
<PG>130-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>de Koning EWJ, van Bijsterveld OP, Cantell K</AU>
<TI>Combination therapy for dendritic keratitis with human leucocyte interferon and trifluorothymidine</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>66</VL>
<PG>509-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>de Koning EWJ, van Bijsterveld OP, Cantell K</AU>
<TI>Human leukocyte interferon and trifluorothymidine versus albumin placebo and trifluorothymidine in the treatment of dendritic keratitis</TI>
<SO>The Biology of the Interferon System</SO>
<YR>1981</YR>
<PG>351-4</PG>
<ED>De Maeyer E, Galasso G, Schellekens H</ED>
<PB>Elsevier/North-Holland Biomed Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Koning-1983" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="de Koning 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Koning EWJ, van Bijsterveld OP, Cantell K</AU>
<TI>Combination therapy for dendritic keratitis with acyclovir and &#945;-interferon</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1983</YR>
<VL>101</VL>
<PG>1866-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denis-1983" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Denis 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denis J, Thenault-Giono S, Ray-Cohen M-L, Tournoux A, Pouliquen Y</AU>
<TI>Double-blind treatment of ocular herpes simplex: Vira-A and acyclovir</TI>
<TO>Traitement de l'herpès oculaire en double insu: Vira-A et acyclovir</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1983</YR>
<VL>83</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fu-2012" MODIFIED="2014-12-07 15:19:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Fu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 15:19:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fu JY</AU>
<TI>Clinical research of ganciclovir ophthalmic gel in combination with interferon treatment for herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Strait Pharmaceutical Journal [Haixia Yaoxue]</SO>
<YR>2012</YR>
<VL>19</VL>
<NO>6</NO>
<PG>174-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fulhorst-1972" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Fulhorst 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fulhorst HW, Richards AB, Bowbyes J, Jones BR</AU>
<TI>Cryotherapy of epithelial herpes simplex keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1972</YR>
<VL>73</VL>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gen_x00e9_e-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Genée 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genée E, Maith J</AU>
<TI>Comparison of the effectiveness of acyclovir and vidarabine in superficial herpes keratitis</TI>
<TO>Wirksamkeitsvergleich von Aciclovir und Vidarabin bei oberflächlichen Herpeskeratitiden</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1987</YR>
<VL>191</VL>
<PG>30-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graupner-1966" MODIFIED="2010-11-01 11:57:38 +0000" MODIFIED_BY=" Iris Gordon" NAME="Graupner 1966" YEAR="1966">
<REFERENCE MODIFIED="2010-11-01 11:57:38 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graupner K, Müller F</AU>
<TI>On the treatment of dendritic keratitis with para-fluorophenylalanine (Preliminary report)</TI>
<TO>Zur Behandlung der Keratitis dendritica mit para-Fluorphenylalanin (Vorlaufige Mitteilung)</TO>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1966</YR>
<VL>171</VL>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graupner-1968" MODIFIED="2010-11-01 11:57:46 +0000" MODIFIED_BY=" Iris Gordon" NAME="Graupner 1968" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graupner K, Klein S, Müller F</AU>
<TI>Treatment of dendritic keratitis</TI>
<TO>Die Behandlung der Keratitis dendritica</TO>
<SO>Advances in Ophthalmology</SO>
<YR>1969</YR>
<VL>21</VL>
<PG>113-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graupner K, Klein S, Müller F</AU>
<TI>Treatment of dendritic keratitis</TI>
<TO>Die Behandlung der Keratitis dendritica</TO>
<SO>Bibliotheca Ophthalmologica</SO>
<YR>1969</YR>
<VL>80</VL>
<PG>113-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-01 11:57:46 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Graupner K, Müller F</AU>
<TI>On the treatment of dendritic keratitis with para-fluorophenylalanine</TI>
<TO>Zur Behandlung der Keratitis dendritica mit para-Fluorophenylalanin</TO>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1968</YR>
<VL>174</VL>
<PG>231-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Graupner-1969" MODIFIED="2010-11-01 11:58:07 +0000" MODIFIED_BY=" Iris Gordon" NAME="Graupner 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-11-01 11:58:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graupner K, Klein S, Müller F</AU>
<TI>Studies on the effectiveness of non-specific and virostatic treatment of dendritic keratitis with special reference to the combination of 5-iodo-2-deoxyuridine and para-fluorophenylalanine</TI>
<TO>Untersuchungen über die Wirksamkeit unspezifischer und virostatischer Behandlung der Keratitis dendritica unter besonderer Berucksichtigung der Kombination von 5-Jod-2-deoxyuridin und para-Flurophenylalanin</TO>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1969</YR>
<VL>177</VL>
<PG>89-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guerra-1979" MODIFIED="2014-12-07 15:20:58 +0000" MODIFIED_BY="Anupa Shah" NAME="Guerra 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerra R, Frezzotti R, Bonanni R, Dianzani F, Rita G</AU>
<TI>A preliminary study on treatment of human herpes simplex keratitis with an interferon inducer</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1970</YR>
<VL>173</VL>
<PG>823-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 15:20:58 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerra R, Frezzotti R, Bonanni R, Rita G, Dianzani F</AU>
<TI>Possibilities of treatment of human herpetic keratitis with an inducer of the interferon system</TI>
<TO>Possibilita di trattamento della cheratite erpetica umana con un induttore del sistema interferone</TO>
<SO>Atti dell Accademia Dei Fisiocritici in Siena</SO>
<YR>1968</YR>
<VL>17</VL>
<PG>1513-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Guerra R, Frezzotti R, Caporossi A, Speri A, Russi M, Bargigli V</AU>
<TI>Clinical appraisal of the therapeutic effectiveness of an interferon inducer in human herpetic keratitis</TI>
<TO>Una sperimentazione clinica sull'efficacia terapeutica di un induttore di interferone nella cheratite erpetica umana</TO>
<SO>Minerva Oftalmologica</SO>
<YR>1979</YR>
<VL>21</VL>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerra R, Galin MA, Frezzotti R</AU>
<TI>Interferon and viral infections of man</TI>
<SO>Texas Reports on Biology and Medicine</SO>
<YR>1981-1982</YR>
<VL>41</VL>
<PG>555-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guerra R, Galin MA, Frezzotti R</AU>
<TI>Use of interferon in eye infections of man</TI>
<SO>Texas Reports on Biology and Medicine</SO>
<YR>1977</YR>
<VL>35</VL>
<PG>497-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2010" MODIFIED="2014-12-01 17:11:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Han 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-01 17:11:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han K</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in combination with interferon treatment of herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>World Health Digest [Zhongguo Qi Kan Wang]</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>7</NO>
<PG>148-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2014" MODIFIED="2014-12-07 15:22:42 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Han 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 15:22:42 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han P</AU>
<TI>Ganciclovir in combination with Beifushu (recombinant-bFGF) in treatment of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#32852;&#21512;&#36125;&#22797;&#33298;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Journal of Otolaryngology and Ophthalmology of Shandong University [Shandong Daxue Er Bi Hou Yan Xuebao]</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>3</NO>
<PG>73-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hart-1965" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Hart 1965" YEAR="1965">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brightman VJF, Hart DRL, Porter GTJ, Readshaw GG, Tully MJ</AU>
<TI>A controlled study of the effectiveness of IDU in the treatment of human herpes simplex keratitis</TI>
<SO>Transactions of the Asia-Pacific Academy of Ophthalmology</SO>
<YR>1965</YR>
<VL>2</VL>
<PG>152-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hart DRL, Brightman VJF, Readshaw GG, Porter GTJ, Tully MJ</AU>
<TI>Treatment of human herpes simplex keratitis with idoxuridine. A sequential double-blind controlled study</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1965</YR>
<VL>73</VL>
<PG>623-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haut-1983" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Haut 1983" YEAR="1983">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haut J, Debrat G, Moulin F, Monin C, Sarnikovski C</AU>
<TI>Double-blind clinical trial of isoprinosine and placebo in herpetic keratitis</TI>
<TO>Essai clinique en double insue de l'isoprinosine contre placebo dans la kératite herpétique</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1983</YR>
<VL>83</VL>
<PG>617-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-HEDS-Group-1997" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="HEDS Group 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herpetic Eye Disease Study Group</AU>
<TI>A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1997</YR>
<VL>115</VL>
<PG>703-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoang_x002d_Xuan-1984" MODIFIED="2013-09-27 16:35:22 +0100" MODIFIED_BY="Anupa Shah" NAME="Hoang-Xuan 1984" YEAR="1984">
<REFERENCE MODIFIED="2013-09-27 16:35:22 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoang-Xuan T, Denis J, Renard G, Pouliquen Y</AU>
<TI>Comparative study of the effect of trifluorothymidine and acyclovir in herpetic anterior segmentitis</TI>
<TO>Étude comparative de l'action de la TFT et de l'aciclovir sur la segmentite antérieure herpétique</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1983</YR>
<VL>83</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hoang-Xuan T, Frot P, Denis J, Pouliquen Y</AU>
<TI>Acyclovir and trifluorothymidine in herpetic kerato-uveitis. A comparative clinical study. Indications for corticoid therapy</TI>
<TO>Aciclovir et trifluorothymidine dans la kérato-uvéite herpétique. Une étude comparative en clinique humaine. Indications de la corticothérapie</TO>
<SO>Journal Français d'Ophtalmologie</SO>
<YR>1984</YR>
<VL>7</VL>
<PG>125-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2008a" MODIFIED="2014-12-07 15:24:11 +0000" MODIFIED_BY=" Iris Gordon" NAME="Huang 2008a" YEAR="2008">
<REFERENCE MODIFIED="2014-12-07 15:23:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao N, Huang T</AU>
<TI>Ganciclovir ophthalmic gel for herpes simplex keratitis and tear film stability</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#23545;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#35282;&#33180;&#19978;&#30382;&#21450;&#27882;&#33180;&#31283;&#23450;&#24615;&#30340;&#24433;&#21709;</TO>
<SO>Recent Advances in Ophthalmology [Yanke Xin Jinzhan]</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>10</NO>
<PG>775-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 15:24:11 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huang T, Gao N, Wang YJ</AU>
<TI>Observation of efficacy of ganciclovir gel in treatment of epithelial herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Recent Advances in Ophthalmology [Yanke Xin Jinzhan]</SO>
<YR>2008</YR>
<VL>29</VL>
<NO>4</NO>
<PG>297-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hung-1984" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Hung 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hung SO, Patterson A, Clark DI, Rees PJ</AU>
<TI>Oral acyclovir in the management of dendritic herpetic corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1984</YR>
<VL>68</VL>
<PG>398-400</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-H_x00f8_vding-1989" MODIFIED="2010-06-14 22:27:18 +0100" MODIFIED_BY="[Empty name]" NAME="Høvding 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-06-14 22:27:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Høvding G</AU>
<TI>A comparison between acyclovir and trifluorothymidine ophthalmic ointment in the treatment of epithelial dendritic keratitis. A double blind, randomized parallel group trial</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1989</YR>
<VL>67</VL>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-1984" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Jackson 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson WB, Breslin CW, Lorenzetti DWC, Michaud R, Dubé I</AU>
<TI>Treatment of herpes simplex keratitis: comparison of acyclovir and vidarabine</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>1984</YR>
<VL>19</VL>
<PG>107-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-1982" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Jensen 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jensen KB, Nissen SH, Jessen F</AU>
<TI>Acyclovir in the treatment of herpetic keratitis</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1982</YR>
<VL>60</VL>
<PG>557-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jepson-1964" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Jepson 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jepson CN</AU>
<TI>Treatment of herpes simplex of the cornea with IDU. A double-blind study</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1964</YR>
<VL>57</VL>
<PG>213-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kato-1979" MODIFIED="2014-12-07 14:38:05 +0000" MODIFIED_BY="[Empty name]" NAME="Kato 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-12-07 14:38:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kato F, Ohno S, Matsuda H</AU>
<TI>Treatment of epithelial herpes simplex keratitis with simple debridement</TI>
<TO>&#35282;&#33180;&#21336;&#32020; &#30274;&#36942;&#36802;&#12395;&#12424;&#12427;&#19978;&#30382;&#24615;&#35282;&#12504;&#12523;&#12506;&#12473;&#12504;&#12523;&#12506;&#12473;&#12398;&#27835;&#27835;&#30274;&#12398;&#35430;&#12415;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1979</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1241-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitano-1983" MODIFIED="2014-12-07 20:20:34 +0000" MODIFIED_BY="[Empty name]" NAME="Kitano 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-12-07 14:54:39 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kitano S, Yamanishi M, Matsuda H, Hyoudo T, Aoki K</AU>
<TI>Clinical results of topical human fibroblast interferon for herpetic keratitis: comparison with IDU eyedrops</TI>
<TO>&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#24615;&#8203;&#35282;&#8203;&#33180;&#8203;&#28814;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427;&#8203;&#12498;&#8203;&#12488;&#8203;&#32218;&#8203;&#32173;&#8203;&#33469;&#8203;&#32048;&#8203;&#32990;&#8203;&#12452;&#8203;&#12531;&#8203;&#12479;&#8203;&#12540;&#8203;&#12501;&#8203;&#12455;&#8203;&#12525;&#8203;&#12531;&#8203;&#28857;&#8203;&#30524;&#8203;&#12398;&#8203;&#33256;&#8203;&#24202;&#8203;&#25104;&#8203;&#32318;&#8203;&#65293;&#8203;I&#8203;D&#8203;U&#8203;&#28857;&#8203;&#30524;&#8203;&#21092;&#8203;&#12392;&#8203;&#12398;&#8203;&#27604;&#8203;&#36611;&#8203;&#35430;&#8203;&#39443;&#8203;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>11</NO>
<PG>1777-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 20:20:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitano S</AU>
<TI>Clinical trials of interferon in ophthalmology</TI>
<TO>&#30524;&#8203;&#31185;&#8203;&#12395;&#8203;&#12362;&#8203;&#12369;&#8203;&#12427;&#8203;&#12452;&#8203;&#12531;&#8203;&#12479;&#8203;&#12540;&#8203;&#12501;&#8203;&#12455;&#8203;&#12525;&#8203;&#12531;&#8203;&#12398;&#8203;&#33256;&#8203;&#24202;&#8203;</TO>
<SO>Cancer and Chemotherapy [Gan To Kagaku Ryoho]</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>2</NO>
<PG>212-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 14:39:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitano S</AU>
<TI>Clinical trials of interferon in ophthalmology</TI>
<TO>&#30524;&#8203;&#31185;&#8203;&#12395;&#8203;&#12362;&#8203;&#12369;&#8203;&#12427;&#8203;&#12452;&#8203;&#12531;&#8203;&#12479;&#8203;&#12540;&#8203;&#12501;&#8203;&#12455;&#8203;&#12525;&#8203;&#12531;&#8203;&#12398;&#8203;&#33256;&#8203;&#24202;&#8203;</TO>
<SO>Japanese Journal of Cancer and Chemotherapy [Gan To Kagaku Ryoho]</SO>
<YR>1984</YR>
<VL>11</VL>
<NO>2</NO>
<PG>212-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitano-1985" MODIFIED="2014-12-07 15:30:45 +0000" MODIFIED_BY="[Empty name]" NAME="Kitano 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-12-07 14:39:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitano S, Yamanishi M, Shudo M, Uchida Y, Kaneko M, Tanaka N, et al</AU>
<TI>A double-blind comparative study of acyclovir (ACV) and IDU ophthalmic ointment in the treatment of herpes simplex keratitis</TI>
<TO>&#12450;&#8203;&#12471;&#8203;&#12463;&#8203;&#12525;&#8203;&#12499;&#8203;&#12523;&#8203;(&#8203;A&#8203;C&#8203;V&#8203;)&#8203;&#12392;&#8203;I&#8203;D&#8203;U&#8203;&#30524;&#8203;&#36575;&#8203;&#12371;&#8203;&#12358;&#8203;&#12392;&#8203;&#12398;&#8203;&#21336;&#8203;&#32020;&#8203;&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#24615;&#8203;&#35282;&#8203;&#33180;&#8203;&#28814;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427;&#8203;&#27835;&#8203;&#30274;&#8203;&#21177;&#8203;&#26524;&#8203;&#12398;&#8203;&#20108;&#8203;&#37325;&#8203;&#30450;&#8203;&#26908;&#8203;&#27861;&#8203;&#12395;&#8203;&#12424;&#8203;&#12427;&#8203;&#27604;&#8203;&#36611;&#8203;&#26908;&#8203;&#35342;&#8203;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1983</YR>
<VL>77</VL>
<NO>8</NO>
<PG>1273-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 15:30:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kitano S</AU>
<TI>Efficacy of acyclovir in dendritic keratitis: a double-blind comparative study with IDU</TI>
<TO>&#27193;&#8203;&#26525;&#8203;&#29366;&#8203;&#35282;&#8203;&#33180;&#8203;&#28814;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427;&#8203;A&#8203;c&#8203;y&#8203;c&#8203;l&#8203;o&#8203;v&#8203;i&#8203;r&#8203;&#12398;&#8203;&#21177;&#8203;&#26524;&#8203; &#8203; &#8203;&#20108;&#8203;&#37325;&#8203;&#30450;&#8203;&#26908;&#8203;&#27861;&#8203;&#12395;&#8203;&#12424;&#8203;&#12427;&#8203;I&#8203;D&#8203;U&#8203;&#12392;&#8203;&#12398;&#8203;&#27604;&#8203;&#36611;&#8203;</TO>
<SO>Therapeutic Research [Serapyuttiku Risachi]</SO>
<YR>1985</YR>
<VL>2</VL>
<NO>4</NO>
<PG>643-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klauber-1982" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Klauber 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klauber A, Ottovay E</AU>
<TI>Acyclovir and idoxuridine treatment of herpes simplex keratitis&#8212;a double blind clinical study</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1982</YR>
<VL>60</VL>
<PG>838-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-1987" MODIFIED="2010-06-14 23:27:10 +0100" MODIFIED_BY="[Empty name]" NAME="Kumar 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar S, Singh TP, Satsangi SK, Bist HK</AU>
<TI>Comparative study of acyclovir and 5 I.D.U. in the management of viral corneal ulcer</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>139-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laibson-1964" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Laibson 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibson PR, Leopold IH</AU>
<TI>An evaluation of double-blind IDU therapy in 100 cases of herpetic keratitis</TI>
<SO>Transactions of the American Academy of Ophthalmology and Otolaryngology</SO>
<YR>1964</YR>
<VL>68</VL>
<PG>22-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laibson-1977" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Laibson 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibson PR, Arentsen JJ, Mazzanti WD, Eiferman RA</AU>
<TI>Double controlled comparison of IDU and trifluorothymidine in thirty-three patients with superficial herpetic keratitis</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1977</YR>
<VL>75</VL>
<PG>316-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Lau-1982" MODIFIED="2014-08-26 14:59:24 +0100" MODIFIED_BY="[Empty name]" NAME="La Lau 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-08-26 14:19:59 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Lau C, Oosterhuis JA, Van Rij G, Benardel de Lavalette JGC, Craandijk A, Lamers WR, et al</AU>
<TI>Double-blind study of aciclovir and trifluorothymidine ointment in the treatment of dendritic or geographic herpes simplex</TI>
<TO>Dubbelblind onderzoek van aciclovir- en trifluorthymidinezalf bij de behandeling van herpes simplex dendritica of geografica</TO>
<SO>Nederlands Tijdschrift voor Geneeskunde</SO>
<YR>1980</YR>
<VL>124</VL>
<PG>2204</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:22:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Lau C, Oosterhuis JA, Versteeg J, van Rij G, Renardel de Lavalette JGC, Craandijk A, et al</AU>
<TI>Aciclovir and trifluorothymidine in herpetic keratitis. Preliminary report of a multicentered trial</TI>
<SO>Documenta Ophthalmologica</SO>
<YR>1981</YR>
<VL>50</VL>
<PG>287-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:57:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>La Lau C, Oosterhuis JA, Versteeg J, van Rij G, Renardel de Lavalette JGC, Craandijk A, et al</AU>
<TI>Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>66</VL>
<NO>8</NO>
<PG>506-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:59:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Lau C, Oosterhuis JA, Versteeg J, van Rij G, Renardel de Lavalette JGC, Craandijk A, et al</AU>
<TI>Multicenter trial of acyclovir and trifluorothymidine in herpetic keratitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73</VL>
<NO>1</NO>
<PG>305-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:23:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>La Lau C, Oosterhuis JA, van Rij G, Renardel de Lavalette JGC, Craandijk A, Lamers WR, et al</AU>
<TI>Double-blind study of aciclovir and trifluorothymidine ointment in the treatment of dendritic or geographic herpes simplex</TI>
<SO>Ophthalmologica</SO>
<YR>1980</YR>
<VL>181</VL>
<PG>293</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2008" MODIFIED="2014-12-07 15:32:53 +0000" MODIFIED_BY=" Iris Gordon" NAME="Li 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-07 15:32:53 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li Y, Yan JF, Zhang Q, Huang DL, Liu Y</AU>
<TI>Treatment of relapsing herpes simplex keratitis with ganciclovir ophthalmic gel</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#22797;&#21457;&#24615;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Medical Journal of the Chinese People's Armed Police Forces [Wujing Yixue]</SO>
<YR>2008</YR>
<VL>19</VL>
<NO>3</NO>
<PG>232-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2009" MODIFIED="2014-12-03 15:38:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-03 15:38:12 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li GX, Sun AP</AU>
<TI>Interferon combined with antiviral drug for herpes simplex viral keratitis</TI>
<TO>&#24178;&#25200;&#32032;&#32852;&#21512;&#25239;&#30149;&#27602;&#33647;&#29289;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Recent Advances in Ophthalmology [Yanke Xinjinzhan]</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>9</NO>
<PG>703-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2013a" MODIFIED="2014-12-07 15:35:47 +0000" MODIFIED_BY="[Empty name]" NAME="Li 2013a" YEAR="2013">
<REFERENCE MODIFIED="2014-12-07 15:35:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li JP, Zhou PH, Guo XY</AU>
<TI>Observation on the effect of ganciclovir ophthalmic gel in the treatment of herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#22312;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20013;&#24212;&#29992;&#30340;&#25928;&#26524;&#35266;&#23519;</TO>
<SO>Clinical Medicine and Engineering [Linchuang Yixue Gongcheng]</SO>
<YR>2013</YR>
<VL>20</VL>
<NO>3</NO>
<PG>306-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2013b" MODIFIED="2014-12-07 17:04:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2013b" YEAR="2013">
<REFERENCE MODIFIED="2014-12-07 17:04:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li L, Zhou H, Wang P</AU>
<TI>Clinical effects of the combination of recombinant human interferon and ganciclovir in the treatment of herpes simplex keratitis</TI>
<TO>&#37325;&#32452;&#20154;&#24178;&#25200;&#32032;&#32852;&#21512;&#26356;&#26132;&#27931;&#38886;&#27835;&#30103;&#21333;&#32431;&#30116;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#25928;&#26524;&#35266;&#23519;</TO>
<SO>China Medical Herald [Zhongguo Yiyao Daobao]</SO>
<YR>2013</YR>
<VL>10</VL>
<NO>10</NO>
<PG>77-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2011" MODIFIED="2014-12-06 22:04:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Lin 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-06 22:04:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin TF, Xue SY, Zhuo WY, Shi CC</AU>
<TI>Efficacy of ganciclovir ophthalmic gel and acyclovir eye drops in the treatment of herpes simplex viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#21644;&#38463;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#30129;&#24615;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>China Pharmaceuticals [Zhongguo Yaoye]</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>13</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2014" MODIFIED="2014-12-07 15:37:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Lin 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 15:37:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin HB, Zhuo X, He AQ</AU>
<TI>Efficacy of treatment with ganciclovir and acyclovir for herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#19982;&#38463;&#26132;&#27931;&#38886;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Hainan Medical Journal [Hainan Yixue]</SO>
<YR>2014</YR>
<VL>25</VL>
<NO>1</NO>
<PG>96-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Liu-2009a" MODIFIED="2014-12-07 15:42:36 +0000" MODIFIED_BY=" Iris Gordon" NAME="Liu 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-12-07 15:42:36 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Wang LQ</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in the treatment of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Chinese Journal of Drug Application and Monitoring [Zhongguo Yaowu Yingyong Yu Jiance]</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>1</NO>
<PG>1-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2010" MODIFIED="2014-12-07 15:38:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-07 15:38:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YZ</AU>
<TI>Clinical efficacy of ganciclovir gel in the treatment of herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Medical Forum [Yiyao Luntan Zazhi]</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>15</NO>
<PG>161-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2011" MODIFIED="2014-12-07 15:39:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-07 15:39:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J</AU>
<TI>Effect of sodium hyaluronate eye drops on epithelial healing of herpes simplex virus keratitis</TI>
<TO>&#36879;&#26126;&#36136;&#37240;&#38048;&#28404;&#30524;&#28082;&#23545;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#35282;&#33180;&#28814;&#19978;&#30382;&#24840;&#21512;&#30340;&#24433;&#21709;</TO>
<SO>Journal of Hauihai Medicine [Huaihai Yiyao]</SO>
<YR>2011</YR>
<VL>29</VL>
<NO>6</NO>
<PG>522-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012a" MODIFIED="2014-12-01 16:16:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2012a" YEAR="2012">
<REFERENCE MODIFIED="2014-12-01 16:16:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu LJ</AU>
<TI>Clinical efficacy of ganciclovir ophthalmic gel for herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#20957;&#33014;&#23545;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Health Care and Nutrition [Zhongguo Bao Jian Ying Yang]</SO>
<YR>2012</YR>
<VL>22</VL>
<NO>8</NO>
<PG>2819-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2012b" MODIFIED="2014-12-04 14:55:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2012b" YEAR="2012">
<REFERENCE MODIFIED="2014-12-04 14:55:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu L, Zhong RY, Yu L</AU>
<TI>The efficacy and safety of ganciclovir ophthalmic gel and acyclovir eye drops in the treatment of herpes simplex viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#21644;&#38463;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#30129;&#24615;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#21450;&#23433;&#20840;&#24615;</TO>
<SO>Chinese Community Doctors [Zhongguo Shequ Yishi]</SO>
<YR>2012</YR>
<VL>9</VL>
<NO>20</NO>
<PG>175-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2014a" MODIFIED="2014-12-07 20:23:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2014a" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 20:23:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu J, Jin ZT, Sun L</AU>
<TI>Curative effect of ganciclovir ophthalmic gel on herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Pharmacoepidemiology [Zhongguo Difangbing Xue Zazhi]</SO>
<YR>2014</YR>
<VL>23</VL>
<NO>2</NO>
<PG>80-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luntz-1963" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Luntz 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luntz MH, MacCallum FO</AU>
<TI>Treatment of herpes keratitis</TI>
<SO>Lancet</SO>
<YR>1963</YR>
<VL>1</VL>
<PG>830-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Luntz MH, MacCallum FO</AU>
<TI>Treatment of herpes simplex keratitis with 5-iodo-2'-deoxyuridine</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1963</YR>
<VL>47</VL>
<PG>449-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacKenzie-1964" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="MacKenzie 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacKenzie AD</AU>
<TI>A comparison of IDU solution, IDU ointment, and carbolization in the treatment of dendritic corneal ulcer</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1964</YR>
<VL>48</VL>
<PG>274-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maichuk-1980" MODIFIED="2013-08-13 19:04:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Maichuk 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-08-13 19:04:06 +0100" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maichuk YF</AU>
<TI>Interferon and interferon inducers in the treatment of herpesvirus and adenovirus eye diseases</TI>
<SO>Revue Internationale du Trachome et de Pathologie Oculaire Tropicale et Subtropicale</SO>
<YR>1980</YR>
<VL>57</VL>
<NO>2-3</NO>
<PG>61-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maichuk-1988" MODIFIED="2013-08-13 19:00:59 +0100" MODIFIED_BY="Anupa Shah" NAME="Maichuk 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-08-13 19:00:59 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maichuk YF, Kazachenko MA</AU>
<TI>Acyclovir and acyclovir in combination with interferon in the treatment of ophthalmic herpes</TI>
<TO>&#1040;&#1094;&#1080;&#1082;&#1083;&#1086;&#1074;&#1080;&#1088; &#1080; &#1072;&#1094;&#1080;&#1082;&#1083;&#1086;&#1074;&#1080;&#1088; &#1074; c&#1086;&#1095;e&#1090;&#1072;&#1085;&#1080;&#1080; &#1089; &#1080;&#1085;&#1090;&#1077;&#1088;&#1092;&#1077;&#1088;&#1086;&#1085;&#1086;&#1084; &#1074; &#1083;&#1077;&#1095;&#1077;&#1085;&#1080;&#1080; &#1075;&#1083;&#1072;&#1079;&#1085;&#1086;&#1081; &#1086;&#1092;&#1090;&#1072;&#1083;&#1100;&#1084;&#1086;&#1075;&#1077;&#1088;&#1087;&#1077;&#1089;&#1072;</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1988</YR>
<VL>43</VL>
<NO>7</NO>
<PG>402-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markham-1977" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Markham 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Markham RHC, Carter C, Scobie MA, Metcalf C, Easty DL</AU>
<TI>Double-blind clinical trial of adenine arabinoside and idoxuridine in herpetic corneal ulcers</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>333-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Markham RHC, Easty DL, Carter C, Scobie MA, Metcalf C</AU>
<TI>The effect of adenine arabinoside in ulcerative herpetic keratitis</TI>
<SO>Immunology and Immunopathology of the Eye</SO>
<YR>1979</YR>
<PG>269-75</PG>
<ED>Silverstein AM, O'Connor AM</ED>
<PB>Masson</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matth_x00e4_us-1970" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Matthäus 1970" YEAR="1970">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matthäus W, Klein S, Graupner K, Dietze H</AU>
<TI>Comparative studies on the effect of cryotherapy and iodization in combination with unspecific and virostatic after-treatment in dendritic keratitis</TI>
<TO>Vergleichende Untersuchungen über die Wirksamkeit der Kalteapplikation und der Jod-Abrasio in Kombination mit unspezifischer und virostatischer Nachlehandlung bei der Keratitis dendritica</TO>
<SO>Ophthalmologica</SO>
<YR>1970</YR>
<VL>161</VL>
<PG>484-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCulley-1982" NAME="McCulley 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCulley JP, Binder PS, Kaufman HE, O'Day DM, Poirier RH</AU>
<TI>A double-blind, multicenter clinical trial of acyclovir vs idoxuridine for treatment of epithelial herpes simplex keratitis</TI>
<SO>Ophthalmology</SO>
<YR>1982</YR>
<VL>89</VL>
<PG>1195-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGill-1974" NAME="McGill 1974" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGill J, Holt-Wilson AD, McKinnon JR, Williams HP, Jones BR</AU>
<TI>Some aspects of the clinical use of trifluorothymidine in the treatment of herpetic ulceration of the cornea</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1974</YR>
<VL>94</VL>
<PG>342-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meurs-1985" MODIFIED="2014-09-25 12:44:40 +0100" MODIFIED_BY="[Empty name]" NAME="Meurs 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Meurs PJ, van Bijsterveld OP</AU>
<TI>Acyclovir and recombinant human alpha 2 arg interferon treatment for dendritic keratitis</TI>
<SO>Herpetic Eye Diseases</SO>
<YR>1985</YR>
<PG>367-76</PG>
<ED>Maudgal PC, Missotten L</ED>
<PB>Dr W Junk Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meurs PJ, van Bijsterveld OP</AU>
<TI>Berofor® alpha 2 (r-HUIFN-alpha 2 arg) and acyclovir in the treatment of dendritic keratitis</TI>
<TO>Berofor® alpha 2 (r-Hu IFN-alpha 2 arg) und Aciclovir in der Behandlung der Herpes-Keratitis-dendritica</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1985</YR>
<VL>187</VL>
<PG>40-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 12:44:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meurs PJ, van Bijsterveld OP</AU>
<TI>Combination therapy of recombinant human alpha 2 interferon and acyclovir in the treatment of herpes simplex keratitis</TI>
<SO>Antiviral Research</SO>
<YR>1985</YR>
<VL>5 Suppl 1</VL>
<PG>225-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meurs PJ, van Bijsterveld OP</AU>
<TI>Combination therapy of recombinant human interferon and acyclovir in the treatment of herpetic keratitis</TI>
<TO>La combinaison interféron récombinante humain et acyclovir dans le traitement des kératites herpétiques</TO>
<SO>Bulletins et Mémoires de la Société Française d'Ophtalmologie</SO>
<YR>1986</YR>
<VL>97</VL>
<PG>434-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norn-1973" NAME="Norn 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norn MS</AU>
<TI>Oxyphenbutazonum (Tanderil®) as an adjuvant in treatment of dendritic keratitis. Double-blind trial using fluorescein-rose bengal vital staining</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1973</YR>
<VL>51</VL>
<PG>591-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Day-1975" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="O'Day 1975" YEAR="1975">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Day DM, Jones BR, Poirier R, Pilley S, Chisholm I, Steele A, et al</AU>
<TI>Proflavine photodynamic viral inactivation in herpes simplex keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1975</YR>
<VL>79</VL>
<PG>941-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Panda-1995" NAME="Panda 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panda A, Das GK, Khokhar S, Rao V</AU>
<TI>Efficacy of four antiviral agents in the treatment of uncomplicated herpetic keratitis</TI>
<SO>Canadian Journal of Ophthalmology</SO>
<YR>1995</YR>
<VL>30</VL>
<PG>256-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parlato-1985" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Parlato 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parlato CJ, Cohen EJ, Sakauye CM, Dreizen NG, Galentine PG, Laibson PR</AU>
<TI>Role of debridement and trifluridine trifluorothymidine in herpes simplex dendritic keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1985</YR>
<VL>103</VL>
<PG>673-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1963a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Patterson 1963a" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Fox AD, Davies G, Maguire C, Holmes Sellers PJ, Wright P, et al</AU>
<TI>Controlled studies of IDU in the treatment of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1963</YR>
<VL>83</VL>
<PG>583-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1963b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Patterson 1963b" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Fox AD, Davies G, Maguire C, Holmes Sellers PJ, Wright P, et al</AU>
<TI>Controlled studies of IDU in the treatment of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1963</YR>
<VL>83</VL>
<PG>583-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1963c" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Patterson 1963c" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Fox AD, Davies G, Maguire C, Holmes Sellers PJ, Wright P, et al</AU>
<TI>Controlled studies of IDU in the treatment of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1963</YR>
<VL>83</VL>
<PG>583-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1967a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Patterson 1967a" YEAR="1967">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Jones BR</AU>
<TI>The management of ocular herpes</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1967</YR>
<VL>87</VL>
<PG>59-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1967b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Patterson 1967b" YEAR="1967">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR</AU>
<TI>Prospects in treating viral disease of the eye</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1967</YR>
<VL>87</VL>
<PG>537-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Jones BR</AU>
<TI>The management of ocular herpes</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1967</YR>
<VL>87</VL>
<PG>59-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavan_x002d_Langston-1976" MODIFIED="2014-09-25 12:47:58 +0100" MODIFIED_BY="[Empty name]" NAME="Pavan-Langston 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-08-26 14:29:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan RA</AU>
<TI>Advances in antiviral chemotherapy</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1979</YR>
<VL>120</VL>
<NO>1</NO>
<PG>7-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-25 12:47:58 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chin GN</AU>
<TI>Treatment of herpes simplex keratitis with a new antiviral agent--vidarabine (Vira-A)</TI>
<SO>Journal of the Kentucky Medical Association</SO>
<YR>1977</YR>
<VL>75</VL>
<NO>7</NO>
<PG>322-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chin GN</AU>
<TI>Treatment of herpes simplex keratitis with idoxuridine and vidarabine: a double-blind study</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1978</YR>
<VL>10</VL>
<PG>1171-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Dresner AJ, Seamans ML</AU>
<TI>Evidence of the safety and efficacy of adenine arabinoside in the treatment of herpes simplex epithelial keratitis</TI>
<SO>Adenine-Arabinoside: An Antiviral Agent</SO>
<YR>1975</YR>
<PG>381-92</PG>
<ED>Pavan-Langston R, Buchanan RA, Alford CA, Jr</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Hyndiuk RA, Schultz RO, Hull DS</AU>
<TI>Herpetic keratitis&#8212;clinical evaluation of adenine arabinoside and idoxuridine</TI>
<SO>Adenine-Arabinoside: An Antiviral Agent</SO>
<YR>1975</YR>
<PG>331-5</PG>
<ED>Pavan-Langston D, Buchanan RA, Alford CA Jr</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Keeney RE, Buchanan RA</AU>
<TI>Clinical application of adenine arabinoside</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1975</YR>
<VL>255</VL>
<PG>185-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibson PR, Hyndiuk R, Krachmer JH, Schultz RO</AU>
<TI>Ara-A and IDU therapy of human superficial herpetic keratitis</TI>
<SO>Investigative Ophthalmology</SO>
<YR>1975</YR>
<VL>14</VL>
<PG>762-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Laibson PR, Krachmer JH</AU>
<TI>Controlled comparison of adenine arabinoside and idoxuridine therapy of human superficial dendritic keratitis</TI>
<SO>Adenine-Arabinoside: An Antiviral Agent</SO>
<YR>1975</YR>
<PG>323-30</PG>
<ED>Pavan-Langston D, Buchanan D, Alford CA Jr</ED>
<PB>Raven Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D, Buchanan R</AU>
<TI>Vidarabine therapy of simple and IDU-complicated herpetic keratitis</TI>
<SO>Transactions of the American Academy of Ophthalmology and Otolaryngology</SO>
<YR>1976</YR>
<VL>81</VL>
<PG>813-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D</AU>
<TI>Clinical evaluation of adenine arabinoside and idoxuridine in the treatment of ocular herpes simplex</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1975</YR>
<VL>80</VL>
<PG>495-502</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D</AU>
<TI>Use of vidarabine in ophthalmology: a review</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1977</YR>
<VL>9</VL>
<PG>835-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavan_x002d_Langston-1981" MODIFIED="2014-09-25 12:49:09 +0100" MODIFIED_BY="[Empty name]" NAME="Pavan-Langston 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-09-25 12:49:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibson PR, Pavan-Langston D, Yeakley WR, Lass J</AU>
<TI>Acyclovir and vidarabine for the treatment of herpes simplex keratitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73 Suppl 1A</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D, Lass J, Hettinger M, Udell I</AU>
<TI>Acyclovir and vidarabine in the treatment of ulcerative herpes simplex keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>92</VL>
<PG>829-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Power-1991" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Power 1991" YEAR="1991">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Power WJ, Benedict-Smith A, Hillery M, Brady K, Collum LMT</AU>
<TI>Brivudine and trifluorothymidine (TFT) in dendritic corneal ulceration: a double blind controlled study</TI>
<SO>Current Eye Research</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>183-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Power WJ, Benedict-Smith A, Hillery M, Brady K, Collum LMT</AU>
<TI>Randomised double-blind trial of brivudine and trifluorothymidine (TFT) in dendritic corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1991</YR>
<VL>75</VL>
<PG>649-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramirez-2002" MODIFIED="2014-12-27 19:42:25 +0000" MODIFIED_BY="[Empty name]" NAME="Ramirez 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-12-27 19:42:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramirez JB, Baca O, Velasco R, Viggiano D, Erazo J</AU>
<TI>Topical treatment for epithelial herpetic keratitis: ganciclovir gel versus aciclovir ointment</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2002</YR>
<VL>43</VL>
<PG>abstract 3072</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Richter-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Richter 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Richter S, Matthes H</AU>
<TI>Results of treating herpetic keratitis with bromovinyl-deoxyuridine</TI>
<TO>Ergebnisse der Therapie herpetischer Hornhauterkrankungen mit (E)-5-(2-Bromvinyl)-2'-Desoxyuridin</TO>
<SO>Folia Ophthalmologica</SO>
<YR>1986</YR>
<VL>11</VL>
<PG>95-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serifoglu-1987" MODIFIED="2014-12-07 15:45:05 +0000" MODIFIED_BY="[Empty name]" NAME="Serifoglu 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-12-07 15:45:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#350;erifo&#287;lu A, Karakurt A</AU>
<TI>Clinical evaluation of acyclovir and idoxuridine with debridement in the treatment of superficial herpetic keratitis</TI>
<TO>Vüzeysel herpetik keratitlerin tedavisinde idoxuridine ve acyclovirin debridmanla beraber kullanilmasiyla alinan sonuçlar</TO>
<SO>Türk Oftalmoloji Gazetesi</SO>
<YR>1987</YR>
<VL>17</VL>
<PG>380-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2014" MODIFIED="2014-12-13 19:40:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Shen 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-13 19:03:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shen AJ, Chen XJ, Wang BZ</AU>
<TI>Efficacy of combination therapy with corneal debridement for herpes simplex epithelial keratitis</TI>
<TO>&#35282;&#33180;&#28165;&#21019;&#32852;&#21512;&#33647;&#29289;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Practical Medicine [Zhongguo Shiyong Yiyao]</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>6</NO>
<PG>157-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-13 19:40:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="OTHER">
<AU>Xiao F, Zheng L, Lai Y</AU>
<TI>Efficacy of combination therapy with corneal debridement for herpes simplex epithelial keratitis</TI>
<TO>&#35282;&#33180;&#28165;&#21019;&#32852;&#21512;&#33647;&#29289;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Medical Tribune [Zhongguo Yixue Luntan Bao]</SO>
<YR>2014</YR>
<VL>http://gp.cmt.com.cn/detail/555817.html</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Srinivas-1993" NAME="Srinivas 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Srinivas C</AU>
<TI>Combination therapy of acyclovir and idurine in herpetic keratitis</TI>
<SO>Afro-Asian Journal of Ophthalmology</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>336-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Struck-1989" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Struck 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Struck HG, Schäfer K</AU>
<TI>Investigations on the topical treatment of herpes simplex virus infection of the eye</TI>
<TO>Untersuchungen zur lokalen Herpestherapie im Augenbereich</TO>
<SO>Folia Ophthalmologica</SO>
<YR>1989</YR>
<VL>14</VL>
<PG>335-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sugar-1980" MODIFIED="2013-11-08 16:19:17 +0000" MODIFIED_BY="Anupa Shah" NAME="Sugar 1980" YEAR="1980">
<REFERENCE MODIFIED="2013-11-08 16:19:17 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sugar J, Stark W, Binder PS, Meyer R, Chandler JW, Waring GO III, et al</AU>
<TI>Trifluorothymidine treatment of herpes simplex epithelial keratitis and comparison with idoxuridine</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1980</YR>
<VL>12</VL>
<PG>611-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2013a" MODIFIED="2014-12-04 15:25:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sun 2013a" YEAR="2013">
<REFERENCE MODIFIED="2014-12-03 15:46:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun CX</AU>
<TI>Efficacy of ganciclovir ophthalmic gel in treatment of herpes simplex viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#30129;&#24615;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>China Practical Medicine [Zhongguo Shiyong Yiyao]</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>14</NO>
<PG>164-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1976a" MODIFIED="2014-09-25 12:50:08 +0100" MODIFIED_BY="[Empty name]" NAME="Sundmacher 1976a" YEAR="1976">
<REFERENCE MODIFIED="2014-09-25 12:50:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Neumann-Haefelin D, Manthey KF, Müller O</AU>
<TI>Interferon in treatment of dendritic keratitis in humans: a preliminary report</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1976</YR>
<VL>133 Suppl A</VL>
<PG>A160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:37:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Neumann-Haefelin D, Manthey KF</AU>
<TI>Human-interferon therapy in dendritic keratitis</TI>
<TO>Humaninterferon-therapie der keratitis dendritica</TO>
<SO>Deutsche Ophthalmologische Gesellschaft</SO>
<YR>1977</YR>
<VL>74</VL>
<PG>615-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1976b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1976b" YEAR="1976">
<REFERENCE MODIFIED="2010-02-09 17:36:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Neumann-Haefelin D, Cantell K</AU>
<TI>Interferon treatment of dendritic keratitis</TI>
<SO>Lancet</SO>
<YR>1976</YR>
<VL>1</VL>
<PG>1406-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Neumann-Haefelin D, Cantell K</AU>
<TI>Successful treatment of dendritic keratitis with human leukocyte interferon. A controlled clinical study</TI>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1976</YR>
<VL>201</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1978a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1978a" YEAR="1978">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Cantell K, Haug P, Neumann Haefelin D</AU>
<TI>Role of debridement and interferon in the treatment of dendritic keratitis</TI>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1978</YR>
<VL>207</VL>
<PG>77-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1978b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1978b" YEAR="1978">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Cantell K, Skoda R, Hallermann C, Neumann Haefelin D</AU>
<TI>Human leukocyte and fibroblast interferon in a combination therapy of dendritic keratitis</TI>
<SO>Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie</SO>
<YR>1978</YR>
<VL>208</VL>
<PG>229-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1981a" MODIFIED="2014-08-26 14:43:22 +0100" MODIFIED_BY="[Empty name]" NAME="Sundmacher 1981a" YEAR="1981">
<REFERENCE MODIFIED="2014-04-26 18:37:30 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Sundmacher R, Cantell K, Neumann-Haefelin D</AU>
<TI>Evaluation of interferon in ocular viral diseases</TI>
<SO>The Biology of the Interferon System</SO>
<YR>1981</YR>
<PG>343-50</PG>
<ED>De Maeyer E, Galasso G, Schellekens H</ED>
<PB>Elsevier/North-Holland Biomed Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:43:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sundmacher R, Neumann-Haefelin D, Cantell K</AU>
<TI>The clinical value of interferon in ocular viral disease</TI>
<SO>Interferon: Properties, Mode of Action, Production, Clinical Application</SO>
<YR>1982</YR>
<VL>11</VL>
<PG>191-6</PG>
<EN>Contributions to Oncology</EN>
<ED>Munk K, Kirchner H</ED>
<PB>Karger</PB>
<CY>Basel</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1981b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1981b" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Cantell K, Neumann-Haefelin D</AU>
<TI>Combination therapy of dendritic keratitis with trifluorothymidine and interferon</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>2</VL>
<PG>687</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sundmacher R, Cantell K, Neumann-Haefelin D</AU>
<TI>Evaluation of interferon in ocular viral diseases</TI>
<SO>The Biology of the Interferon System</SO>
<YR>1981</YR>
<PG>343-50</PG>
<ED>De Maeyer E, Galasso G, Schellekens H</ED>
<PB>Elsevier/ North-Holland Biomed Press</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Sundmacher R, Neumann-Haefelin D, Cantell K</AU>
<TI>Therapy and prophylaxis of dendritic keratitis with topical human interferon</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>401-7</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1984a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1984a" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Cantell K, Mattes A</AU>
<TI>Combination therapy for dendritic keratitis. High-titer alpha-interferon and trifluridine</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1984</YR>
<VL>102</VL>
<PG>554-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1985" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Sundmacher R, Neumann-Haefelin D, Mattes A, Merk W, Adolf G, Cantell K</AU>
<TI>Human leukocyte interferon plus trifluorothymidin versus recombinant alpha 2 arg interferon plus trifluorothymidin for therapy of dendritic keratitis. A controlled clinical study</TI>
<SO>Herpetic Eye Diseases</SO>
<YR>1985</YR>
<PG>359-66</PG>
<ED>Maudgal PC, Missotten L</ED>
<PB>Dr W Junk Publishers</PB>
<CY>Dordrecht</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sundmacher-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Mattes A, Neumann-Haefelin D, Adolf G, Kruss B</AU>
<TI>The potency of interferon-alpha 2 and interferon-gamma in a combination therapy of dendritic keratitis. A controlled clinical study</TI>
<SO>Current Eye Research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>273-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanaka-1988a" MODIFIED="2014-08-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" NAME="Tanaka 1988a" YEAR="1988">
<REFERENCE MODIFIED="2014-08-26 14:45:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka N, Kitano S, Uchida Y, Hosaka A, Matsuda H, Kamada K, et al</AU>
<TI>Clinical results of Ro22-8181 ophthalmic solution for herpes simplex keratitis: a comparison test of 10<SUP>3</SUP> IU/ml and 10<SUP>7</SUP> IU/ml</TI>
<TO>&#21336;&#32020;&#12504;&#12523;&#12506;&#12473;&#24615;&#35282;&#33180;&#28814;&#12395;&#23550;&#12377;&#12427;Ro22&#8208;8181&#28857;&#30524;&#28082;&#12398;&#33256;&#24202;&#25104;&#32318;:10<SUP>3</SUP>IU/ml&#12392;10<SUP>7</SUP>IU/ml&#12398;&#27604;&#36611;&#35430;&#39443;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>4</NO>
<PG>699-705</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tanaka-1988b" MODIFIED="2014-08-26 14:44:25 +0100" MODIFIED_BY="[Empty name]" NAME="Tanaka 1988b" YEAR="1988">
<REFERENCE MODIFIED="2014-08-26 14:44:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tanaka N, Kitano S, Uchida Y, Akio H, Matsuda H, Matsuyama S, et al</AU>
<TI>Effect of eye drop solution of recombinant human leukocyte interferon-&#945; on herpes simplex keratitis: double-blind comparative study with IDU eye drop</TI>
<TO>&#21336;&#32020;&#12504;&#12523;&#12506;&#12473;&#24615;&#35282;&#33180;&#28814;&#12395;&#23550;&#12377;&#12427;&#32068;&#25563;&#12360;&#22411;&#12498;&#12488;&#30333;&#34880;&#29699;&#12452;&#12531;&#12479;&#12540;&#12501;&#12455;&#12525;&#12531;A&#28857;&#30524;&#28082;&#12398;&#21177;&#26524;: IDU&#28857;&#30524;&#21092;&#12392;&#12398;&#20108;&#37325;&#30450;&#26908;&#27604;&#36611;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1988</YR>
<VL>82</VL>
<NO>5</NO>
<PG>908-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Travers-1978" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Travers 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Travers JP, Patterson A</AU>
<TI>A controlled trial of adenine arabinoside and trifluorothymidine in herpetic keratitis</TI>
<SO>Journal of International Medical Research</SO>
<YR>1978</YR>
<VL>6</VL>
<PG>102-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchida-1981" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Uchida 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Uchida Y, Kaneko M, Yamanishi R, Kobayashi S</AU>
<TI>Effect of human fibroblast interferon on dendritic keratitis</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>409-13</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamazaki S</AU>
<TI>Further studies on clinical trials of interferon in Japan</TI>
<SO>Japanese Journal of Medical Science and Biology</SO>
<YR>1984</YR>
<VL>37</VL>
<PG>209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uchida-1982" MODIFIED="2014-12-07 15:46:47 +0000" MODIFIED_BY="[Empty name]" NAME="Uchida 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-02-09 17:54:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Uchida Y, Kaneko M, Yamanishi R, Kobayashi S</AU>
<TI>Effect of human fibroblast interferon on dendritic keratitis</TI>
<SO>Herptische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>409-13</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-12-07 15:46:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Uchida Y</AU>
<TI>Therapeutic effect of human fibroblast interferon on herpes simplex keratitis</TI>
<TO>&#12452;&#8203;&#12531;&#8203;&#12479;&#8203;&#12540;&#8203;&#12501;&#8203;&#12455;&#8203;&#12525;&#8203;&#12531;&#8203;&#28857;&#8203;&#30524;&#8203;&#12395;&#8203;&#12424;&#8203;&#12427;&#8203;&#21336;&#8203;&#32020;&#8203;&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#35282;&#8203;&#33180;&#8203;&#28814;&#8203;&#12398;&#8203;&#27835;&#8203;&#30274;&#8203;</TO>
<SO>Folia Ophthalmologica Japonica [Nippon Ganka Kiyo]</SO>
<YR>1982</YR>
<VL>33</VL>
<NO>8</NO>
<PG>1661-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Uchida Y</AU>
<TI>Therapeutic effect of human fibroblast interferon on herpes simplex keratitis</TI>
<SO>Herpesvirus: Clinical, Pharmacological and Basic Aspects</SO>
<YR>1982</YR>
<PG>302-7</PG>
<ED>Shiota H, Cheng Y-C, Prusoff WH</ED>
<PB>Excerpta Medica</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Bijsterveld-1980" MODIFIED="2014-08-26 14:49:00 +0100" MODIFIED_BY="[Empty name]" NAME="van Bijsterveld 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>van Bijsterveld OP, Post H</AU>
<TI>Trifluorothymidine and adenine arabinoside in the treatment of dendritic keratitis</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>380-3</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-08-26 14:49:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Bijsterveld OP, Post H</AU>
<TI>Trifluorothymidine versus adenine arabinoside in the treatment of herpes simplex keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1980</YR>
<VL>64</VL>
<NO>1</NO>
<PG>33-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Bijsterveld-1989" MODIFIED="2014-08-26 14:51:35 +0100" MODIFIED_BY="[Empty name]" NAME="van Bijsterveld 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-08-26 14:51:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>van Bijsterveld OP, Meurs PJ, de Clerq E, Maudgal PC</AU>
<TI>Brivudine and interferon treatment in ulcerative herpetic keratitis: a double masked study</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1989</YR>
<VL>73</VL>
<NO>8</NO>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Bijsterveld OP, Meurs PJ</AU>
<TI>Herpetic keratitis</TI>
<TO>Keratitis herpetica</TO>
<SO>Tijdschrift voor Therapie Geneesmiddel en Onderzoek</SO>
<YR>1985</YR>
<VL>10</VL>
<PG>641-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vannini-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Vannini 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vannini A, Cembrano S, Assetto V, Giannitelli A</AU>
<TI>Interferon-beta treatment of herpes simplex keratitis</TI>
<SO>Ophthalmologica</SO>
<YR>1986</YR>
<VL>192</VL>
<PG>6-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2004" MODIFIED="2014-12-07 15:48:28 +0000" MODIFIED_BY="[Empty name]" NAME="Wang 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-12-07 15:48:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang J, Ni N, Yang Z, Han F</AU>
<TI>Two ways of using acyclovir in treatment of herpes simplex virus keratitis</TI>
<TO>&#38463;&#26132;&#27931;&#38886;&#27835;&#30103;&#22522;&#26412;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20004;&#31181;&#29992;&#33647;&#36884;&#24452;&#30340;&#27604;&#36739;</TO>
<SO>International Journal of Ophthalmology [Guoji Yanke Zazhi]</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>2</NO>
<PG>349-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2014a" MODIFIED="2014-12-05 22:11:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wang 2014a" YEAR="2014">
<REFERENCE MODIFIED="2014-12-05 22:11:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang Y</AU>
<TI>Observation on curative effect of ganciclovir ophthalmic gel and aciclovir eye drops in the treatment of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#21644;&#38463;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Beihua University (Natural Science) [Beihua Daxue Xuebao (Zirankexueban)]</SO>
<YR>2014</YR>
<VL>15</VL>
<NO>5</NO>
<PG>633-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wellings-1972" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Wellings 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wellings PC, Awdry PN, Bors FH, Jones BR, Brown DC, Kaufman HE</AU>
<TI>Clinical evaluation of trifluorothymidine in the treatment of herpes simplex corneal ulcers</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1972</YR>
<VL>73</VL>
<PG>932-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilhelmus-1981a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Wilhelmus 1981a" YEAR="1981">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Coster DJ, Jones BR</AU>
<TI>Acyclovir and debridement in the treatment of ulcerative herpetic keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>91</VL>
<PG>323-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2009a" MODIFIED="2014-12-06 22:04:47 +0000" MODIFIED_BY=" Iris Gordon" NAME="Xu 2009a" YEAR="2009">
<REFERENCE MODIFIED="2014-12-06 22:04:47 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu JJ</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in treatment of viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>China Pharmaceuticals [Zhongguo Yaoye]</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>7</NO>
<PG>42-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamazaki-1984a" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Yamazaki 1984a" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamazaki S</AU>
<TI>Further studies on clinical trials of interferon in Japan</TI>
<SO>Japanese Journal of Medical Science and Biology</SO>
<YR>1984</YR>
<VL>37</VL>
<PG>209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamazaki-1984b" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Yamazaki 1984b" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamazaki S</AU>
<TI>Further studies on clinical trials of interferon in Japan</TI>
<SO>Japanese Journal of Medical Science and Biology</SO>
<YR>1984</YR>
<VL>37</VL>
<PG>209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamazaki-1984c" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Yamazaki 1984c" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamazaki S</AU>
<TI>Further studies on clinical trials of interferon in Japan</TI>
<SO>Japanese Journal of Medical Science and Biology</SO>
<YR>1984</YR>
<VL>37</VL>
<PG>209-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2000" MODIFIED="2014-12-07 17:04:07 +0000" MODIFIED_BY=" Iris Gordon" NAME="Yang 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-12-07 17:04:07 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang BL, Jin XY, Wu ZJ, Sun XQ</AU>
<TI>A clinical investigation of ganciclovir in the treatment of 137 cases of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#28404;&#30524;&#21058;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#35282;&#33180;&#28814;137&#20363;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Ophthalmology in China [Yanke]</SO>
<YR>2000</YR>
<VL>9</VL>
<NO>5</NO>
<PG>297-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2008" MODIFIED="2014-12-07 15:50:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yang 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-07 15:50:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang X, Wang BW, Ye QY, Liang XD</AU>
<TI>Ganciclovir ophthalmic gel in the treatment of 32 patients with herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;32&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Guangdong Medical College [Guangdong Yixueyuan Xuebao]</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>6</NO>
<PG>628-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yeakley-1981" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Yeakley 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laibson PR, Pavan-Langston D, Yeakley WR, Lass J</AU>
<TI>Acyclovir and vidarabine for the treatment of herpes simplex keratitis</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yeakley WR, Laibson PR, Michelson MA, Arentsen JJ</AU>
<TI>A double-controlled evaluation of acyclovir and vidarabine for the treatment of herpes simplex epithelial keratitis</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1981</YR>
<VL>79</VL>
<PG>168-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1982" MODIFIED="2014-09-25 12:52:21 +0100" MODIFIED_BY="[Empty name]" NAME="Young 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-09-25 12:52:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young B, Patterson A, Ravenscroft T</AU>
<TI>Double-blind clinical trial of acyclovir and adenine arabinoside in herpetic corneal ulceration</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73 Suppl 1A</VL>
<PG>311-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Young BJ, Patterson A, Ravenscroft T</AU>
<TI>A randomised double-blind clinical trial of acyclovir (Zovirax) and adenine arabinoside in herpes simplex corneal ulceration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>66</VL>
<PG>361-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2012a" MODIFIED="2014-12-07 15:11:19 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yu 2012a" YEAR="">
<REFERENCE MODIFIED="2014-12-07 15:11:19 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu J, Zhang MC</AU>
<TI>Clinical investigation of foscarnet sodium eye drops for the treatment of epithelial herpes simplex keratitis</TI>
<TO>&#33190;&#30002;&#37240;&#38048;&#28404;&#30524;&#28082;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>International Eye Science [Guoji Yanke Zazhi]</SO>
<YR>2012</YR>
<VL>12</VL>
<NO>5</NO>
<PG>899-901</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2014" MODIFIED="2014-12-01 20:04:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhang 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-01 20:04:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang DY</AU>
<TI>Comparison of ganciclovir ophthalmic gel and acyclovir eye drops in the treatment of herpes simplex virus keratitis</TI>
<TO>&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#24212;&#29992;&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#21644;&#38463;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#27835;&#30103;&#30340;&#27604;&#36739;</TO>
<SO>Chinese Journal of Modern Drug Application [Zhong Guo Xian Dai Yao Wu Ying Yong]</SO>
<YR>2014</YR>
<VL>8</VL>
<NO>12</NO>
<PG>126-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2006" MODIFIED="2014-12-07 15:51:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhao 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-12-07 15:51:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao L, Liu X, Wang SG, Huang FY</AU>
<TI>Comparative efficacy of treatment of viral keratitis with ganciclovir ophthalmic gel and acyclovir eye drops</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#22312;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20013;&#30340;&#24212;&#29992;</TO>
<SO>Recent Advances in Ophthalmology [Yanke Xin Jinzhan]</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>1</NO>
<PG>809</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhen-2012" MODIFIED="2014-12-07 15:52:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhen 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 15:52:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhen YJ</AU>
<TI>Effect comparison of two drugs on herpes simplex keratitis</TI>
<TO>&#20004;&#31181;&#33647;&#29289;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>Journal of Hainan Medical University [Hainan Yixue]</SO>
<YR>2012</YR>
<VL>18</VL>
<NO>7</NO>
<PG>945-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2010" MODIFIED="2014-12-01 16:24:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zheng 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-01 16:24:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng W, Cui YX</AU>
<TI>Clinical efficacy of ganciclovir ophthalmic gel for herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#20957;&#33014;&#23545;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese Journal of Hospital Pharmacy [Zhongguo Yiyuan Yaoxue Zazhi]</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>8</NO>
<PG>707-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-2012" MODIFIED="2014-12-07 15:01:40 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 15:01:40 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhu Y</AU>
<TI>Efficacy analysis of ganciclovir ophthalmic gel in combination with interferon treatment of herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Guide of China Medicine [Zhongguo Yiyao Xuekan]</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>17</NO>
<PG>214-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-12-13 16:58:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Abboud-1967" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Abboud 1967" YEAR="1967">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abboud I</AU>
<TI>Evaluation of I.D.U. in the treatment of dendritic ulcer</TI>
<SO>Bulletin of the Ophthalmological Society of Egypt</SO>
<YR>1967</YR>
<VL>60</VL>
<PG>245-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akberova-2000" MODIFIED="2014-08-26 15:02:25 +0100" MODIFIED_BY="[Empty name]" NAME="Akberova 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-08-26 15:02:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akberova SI, Musaev-Galbinur PI</AU>
<TI>The new interferon inducer Aktipol in the treatment of herpetic keratitis</TI>
<TO>&#1053;&#1086;&#1074;&#1099;&#1081; &#1080;&#1085;&#1076;&#1091;&#1082;&#1090;&#1086;&#1088; &#1080;&#1085;&#1090;&#1077;&#1088;&#1092;&#1077;&#1088;&#1086;&#1085;&#1072; &#1040;&#1082;&#1090;&#1080;&#1087;&#1086;&#1083; &#1074; &#1083;&#1077;&#1095;&#1077;&#1085;&#1080;&#1080; &#1075;&#1077;&#1088;&#1087;&#1077;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1086;&#1075;&#1086; &#1082;&#1077;&#1088;&#1072;&#1090;&#1080;&#1090;&#1072;</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>2000</YR>
<VL>116</VL>
<NO>2</NO>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Assetto-1981" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Assetto 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Assetto V, Lega M, Vinci V</AU>
<TI>Evaluation of the clinical effectiveness of methods of treating herpetic keratitis</TI>
<TO>Valutazione dell'efficacia clinica della terapia della cheratite erpetica</TO>
<SO>Minerva Oftalmologica</SO>
<YR>1981</YR>
<VL>23</VL>
<PG>301-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Babushkin-1993" MODIFIED="2014-08-26 15:03:23 +0100" MODIFIED_BY="[Empty name]" NAME="Babushkin 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-08-26 15:03:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Babushkin AE, Mal'khanov VB</AU>
<TI>The results of using Virolex (acyclovir) in patients with herpetic keratitis</TI>
<TO>&#1056;&#1077;&#1079;&#1091;&#1083;&#1100;&#1090;&#1072;&#1090;&#1099; &#1087;&#1088;&#1080;&#1084;&#1077;&#1085;&#1077;&#1085;&#1080;&#1103; &#1074;&#1080;&#1088;&#1086;&#1083;&#1077;&#1082;&#1089;&#1072; (&#1072;&#1094;&#1080;&#1082;&#1083;&#1086;&#1074;&#1080;&#1088;&#1072;) &#1091; &#1087;&#1072;&#1094;&#1080;&#1077;&#1085;&#1090;&#1086;&#1074; &#1075;&#1077;&#1088;&#1087;&#1077;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1080;&#1084; &#1082;&#1077;&#1088;&#1072;&#1090;&#1080;&#1090;&#1086;&#1084;</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>1993</YR>
<VL>109</VL>
<NO>5</NO>
<PG>26-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchetti-1964" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Bianchetti 1964" YEAR="1964">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bianchetti M, Witmer R</AU>
<TI>Herpes simplex keratitis</TI>
<TO>Ein jahr erfahrung mit Iododeoxyuridine</TO>
<SO>Ophthalmologica</SO>
<YR>1964</YR>
<VL>147</VL>
<PG>251-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butikova-1990" MODIFIED="2013-08-11 22:31:08 +0100" MODIFIED_BY="[Empty name]" NAME="Butikova 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-08-11 22:31:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butikova VA, Soldatenkova NA, Ostrovskaya OV, Vlasova MA, Nefedova OA</AU>
<TI>The usage of an immunoglobulin in a complex treatment of ophthalmoherpes</TI>
<TO>Primenenie imunoglobulina v kompleksnom lechenii oftal'mogerpesa</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1990</YR>
<VL>3</VL>
<PG>162-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2012" MODIFIED="2014-12-07 15:04:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Cao 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 15:04:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao SX, Zhang J</AU>
<TI>The clinical research of yin qiao jing fang decoction on epithelial herpes simplex keratitis of the wind-heat in liver meridian system</TI>
<TO>&#38134;&#32728;&#33606;&#38450;&#27748;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#32925;&#32463;&#39118;&#28909;&#35777;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>China Foreign Medical Treatment [Zhongwai Yiliao]</SO>
<YR>2012</YR>
<VL>14</VL>
<NO>16</NO>
<PG>109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cao-2013" MODIFIED="2014-12-06 21:00:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Cao 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-06 21:00:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cao BY, Zhang R</AU>
<TI>Clinical observation on combination of traditional Chinese and western medicine in treatment of herpes simplex virus keratitis</TI>
<TO>&#20013;&#35199;&#33647;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Liaoning Journal of Traditional Chinese Medicine [Liaoning Zhongyi Zazhi]</SO>
<YR>2013</YR>
<VL>40</VL>
<NO>5</NO>
<PG>966-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2000" MODIFIED="2014-12-06 21:04:29 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-12-06 21:04:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen F</AU>
<TI>Treatment of herpes simplex viral conjunctivitis by traditional Chinese medicine combined with Western medicine: a clinical observation of 86 cases</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;86&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>New Journal of Traditional Chinese Medicine [Xin Zhong Yi]</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>7</NO>
<PG>23-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2014-12-07 15:57:41 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-07 15:57:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen XD, Tang LS</AU>
<TI>Effect evaluation of aciclovir eye drops combined with recombinant human interferon-&#945;-2b eye drops in treatment of herpes simplex keratitis</TI>
<TO>&#27491;&#22823;&#25463;&#26222;&#32852;&#21512;&#37325;&#32452;&#20154;&#24178;&#25200;&#32032;a-2b&#27835;&#30103;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Food and Drug [Shipin Yu Yaopin]</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>5</NO>
<PG>17-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2009" MODIFIED="2014-12-06 21:08:52 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chen 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-06 21:08:52 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen JX, Li H, Zhang DX</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis in 100 cases</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;100&#20363;</TO>
<SO>Gansu Journal of Traditional Chinese Medicine [Gansu Zhong Yi]</SO>
<YR>2009</YR>
<VL>22</VL>
<NO>9</NO>
<PG>38-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corina-1998" MODIFIED="2010-03-22 18:42:45 +0000" MODIFIED_BY="[Empty name]" NAME="Corina 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-03-22 18:42:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corina P</AU>
<TI>Acyclovir treatment&#8212;its effect on visual acuity and the rate of recurrences in herpetic keratitis</TI>
<TO>Tratamentul cu acyclovir&#8212;efectul asupra acuitatii vizuale si a ratei recurentelor in keratita herpetica</TO>
<SO>Oftalmologia</SO>
<YR>1998</YR>
<VL>42</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corina-1999" NAME="Corina 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corina P, Dimitris S, Emanuil T, Nora R</AU>
<TI>Treatment with acyclovir combined with a new Romanian product from plants</TI>
<TO>Tratamentul cu acyclovir asociat cu un nou produs romanesc din plante</TO>
<SO>Oftalmologia</SO>
<YR>1999</YR>
<VL>46</VL>
<PG>55-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deng-2003" MODIFIED="2014-12-06 21:06:03 +0000" MODIFIED_BY=" Iris Gordon" NAME="Deng 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-12-06 21:06:03 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deng Z, Han J</AU>
<TI>Combination of Chinese and western medicine treatment for herpes simplex keratitis: clinical observation of 53 cases</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#27602;&#24615;&#35282;&#33180;&#28814;53&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>New Journal of Traditional Chinese Medicine [Xin Zhong Yi]</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>3</NO>
<PG>51-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-2008" MODIFIED="2014-12-06 21:16:05 +0000" MODIFIED_BY="[Empty name]" NAME="Du 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-06 21:16:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Du C, Yu QZ</AU>
<TI>Combination of Chinese and western medicine treatment of herpes simplex virus keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Zhejiang University of Traditional Chinese Medicine [Zhe Jiang Zhong Yi Yao Da Xue Xue Bao]</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>4</NO>
<PG>475-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dundarov-1998" MODIFIED="2010-11-06 09:09:40 +0000" MODIFIED_BY="[Empty name]" NAME="Dundarov 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-11-06 09:09:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dundarov S, Petrunova S, Panova N, Petrova A</AU>
<TI>Treatment of viral eye diseases with pandavir and alphaferon</TI>
<SO>Problems in Infectious and Parasitic Diseases</SO>
<YR>1998</YR>
<VL>25</VL>
<PG>30-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Elze-1979" NAME="Elze 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Elze KL</AU>
<TI>Ten years of clinical experience with ethyldeoxyuridine</TI>
<SO>Advances in Ophthalmology</SO>
<YR>1979</YR>
<VL>38</VL>
<PG>134-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fellinger-1980" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Fellinger 1980" YEAR="1980">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fellinger C, Bartl G</AU>
<TI>Clinical experience with different methods of treating herpes corneæ</TI>
<TO>Klinische Erfahrungen über die Therapie des herpes corneæ mit verschiedenen Behandlungsmethoden</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1980</YR>
<VL>176</VL>
<PG>239-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2004" MODIFIED="2014-12-06 21:18:32 +0000" MODIFIED_BY="[Empty name]" NAME="Feng 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-12-06 21:18:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng Z, Jin H</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis: clinical observation of 52 cases</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;52&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Ningxia Medical College [Ningxia Yike Daxue Xuebao]</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>6</NO>
<PG>467-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galin-1976" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Galin 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galin MA, Chowchuvech E, Kronenberg B</AU>
<TI>Therapeutic use of inducers of interferon on herpes simplex keratitis in humans</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1976</YR>
<VL>8</VL>
<PG>72-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gao-2006" MODIFIED="2014-12-06 21:19:33 +0000" MODIFIED_BY=" Iris Gordon" NAME="Gao 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-12-06 21:19:33 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao Y</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis: clinical analysis of 86 cases</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;86&#20363;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Journal of Shanxi Medical College for Continuing Education [Shanxi Zhigong Yixueyuan Xuebao]</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>32-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gilkes-1963" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Gilkes 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gilkes MJ</AU>
<TI>Further experiences in the therapy of herpetiform and other keratitis with 5-iodo, deoxyuridine (IDU) in hospital practice</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1963</YR>
<VL>83</VL>
<PG>593-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gong-2013" MODIFIED="2014-12-06 21:20:21 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gong 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-06 21:20:21 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gong J</AU>
<TI>Clinical efficacy of integrative medicine in 55 cases of herpes simplex keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;55&#20363;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Modern Diagnosis and Treatment [Xiandai Zhenduan Yu Zhiliao]</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>18</NO>
<PG>4124-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gu-2005" MODIFIED="2014-12-06 21:22:00 +0000" MODIFIED_BY=" Iris Gordon" NAME="Gu 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-12-06 21:22:00 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gu J, Lin Y, Qiu P, Huang G, Wu C</AU>
<TI>The treatment of herpes simplex keratitis with interferon-&#945;-2b and acyclovir</TI>
<TO>&#945;-&#24178;&#25200;&#32032;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Chinese Journal of Primary Medicine and Pharmacy [Zhongguo Ji Ceng Yi Yao]</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>10</NO>
<PG>1395-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gulinuer-2011" MODIFIED="2013-11-04 19:22:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gulinuer 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-11-04 19:22:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gulinuer T, Liu XQ</AU>
<TI>Retrospective analysis of the effects of ganciclovir and acyclovir in the treatment of patients with herpes simplex keratitis in our hospital</TI>
<TO>&#22238;&#39038;&#24615;&#20998;&#26512;&#26412;&#38498;&#29992;&#26356;&#26132;&#27931;&#38886;&#19982;&#38463;&#26132;&#27931;&#38886;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;</TO>
<SO>Chinese Journal of Clinical Pharmacology [Zhongguo Linchuang Yaolixue Zazhi]</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>6</NO>
<PG>425-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gundersen-1936" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Gundersen 1936" YEAR="1936">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gundersen T</AU>
<TI>Herpes corneæ. With special reference to its treatment with strong solution of iodine</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1936</YR>
<VL>15</VL>
<PG>225-49</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guo-2003" MODIFIED="2014-12-06 22:07:30 +0000" MODIFIED_BY="[Empty name]" NAME="Guo 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-12-06 22:07:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guo XW</AU>
<TI>The treatment of herpes simplex keratitis with antivirus drugs combined with deep freezing method</TI>
<TO>&#25239;&#30149;&#27602;&#33647;&#29289;&#32852;&#21512;&#20302;&#28201;&#20919;&#20923;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>West China Medical Journal [Huaxi Yixue]</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>4</NO>
<PG>462-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hao-2008" MODIFIED="2014-12-06 21:23:08 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hao 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-06 21:23:08 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hao Z</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis: clinical observation</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Hebei Journal of Traditional Chinese Medicine [He Bei Zhong Yi]</SO>
<YR>2008</YR>
<VL>30</VL>
<NO>11</NO>
<PG>1197-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-He-2014" MODIFIED="2014-11-29 21:22:16 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="He 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-11-29 21:22:16 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>He GJ</AU>
<TI>Efficacy of autologous serum treatment of herpes simplex virus keratitis</TI>
<TO>&#33258;&#20307;&#34880;&#28165;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Anhui Medical and Pharmaceutical Journal [Anhui Yiyao]</SO>
<YR>2014</YR>
<VL>18</VL>
<NO>4</NO>
<PG>755-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Herbort-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Herbort 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herbort CP, Buechi ER, Matter M</AU>
<TI>Blunt spatula debridement and trifluorothymidine in epithelial herpetic keratitis</TI>
<SO>Current Eye Research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>225-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hilsdorf-1969" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Hilsdorf 1969" YEAR="1969">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hilsdorf C, Forudastan E</AU>
<TI>Therapeutic results of keratitis herpetica simplex with cryotherapy</TI>
<TO>Behandlungsergebnisse der Keratitis herpetica simplex mit Kälte</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1969</YR>
<VL>154</VL>
<PG>627-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horode_x0148_scy-1979" MODIFIED="2010-06-17 17:06:20 +0100" MODIFIED_BY="[Empty name]" NAME="Horode&#328;scy 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-06-17 17:06:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horode&#328;scy A, Horode&#328;scy J</AU>
<TI>Treatment of corneal herpes with cytarabine</TI>
<TO>Leczenie cytarbinq zapale&#324; herpetycznych rogówki</TO>
<SO>Klinika Oczna</SO>
<YR>1979</YR>
<VL>81</VL>
<PG>217-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2013" MODIFIED="2014-12-01 22:15:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Hu 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-01 22:15:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu B, Dai J, Lei MS, Huang HY</AU>
<TI>Clinical study of Tujia Minority medicine on herpes simplex keratitis</TI>
<TO>&#22303;&#23478;&#33647;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Guiding Journal of Traditional Chinese Medicine and Pharmacy [Zhong Yi Yao Dao Bao]</SO>
<YR>2013</YR>
<VL>19</VL>
<NO>4</NO>
<PG>13-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2007" MODIFIED="2014-12-07 15:59:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Huang 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-07 15:59:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Z</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in the treatment of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Sichuan Medical Journal [Sichuan Yixue]</SO>
<YR>2007</YR>
<VL>28</VL>
<NO>2</NO>
<PG>221-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2008b" MODIFIED="2014-12-06 21:25:10 +0000" MODIFIED_BY=" Iris Gordon" NAME="Huang 2008b" YEAR="2008">
<REFERENCE MODIFIED="2014-12-06 21:25:10 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang CL, Chen ZG, Yu JF</AU>
<TI>Observation on herpes simplex keratitis treated by traditional Chinese medicine and Western medicine combined in clinic</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Liaoning Journal of Traditional Chinese Medicine [Liao Ning Zhong Yi Zazhi]</SO>
<YR>2008</YR>
<VL>36</VL>
<NO>8</NO>
<PG>1212-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2009" MODIFIED="2014-12-06 22:08:11 +0000" MODIFIED_BY=" Iris Gordon" NAME="Huang 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-06 22:08:11 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang ZW, Wu ZF, Huang ZC</AU>
<TI>The clinical effect of acyclovir combined with interferon on herpes simplex keratitis</TI>
<TO>&#26080;&#29615;&#40479;&#33527;-&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Tropical Medicine [Zhongguo Hedai Yixue]</SO>
<YR>2009</YR>
<VL>15</VL>
<NO>4</NO>
<PG>686, 695</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2013" MODIFIED="2014-12-07 15:05:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Huang 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-07 15:05:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang XY</AU>
<TI>Curative effect and preventive reoccurrence function of liver detoxification soup [qing gan jie yu tang] combined with ganciclovir ophthalmic gel on herpes simplex keratitis</TI>
<TO>&#28165;&#32925;&#35299;&#27602;&#27748;&#32852;&#21512;&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#21450;&#39044;&#38450;&#22797;&#21457;&#20316;&#29992;</TO>
<SO>China Modern Doctor [Zhongguo Xiandai Yisheng]</SO>
<YR>2013</YR>
<VL>51</VL>
<NO>25</NO>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Inocencio-1982" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Inocencio 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Inocencio FP, Valenton MJ, Dy-Liacco JU, Batungbakal RT, Chua NG</AU>
<TI>Acycloguanosine and idoxuridine in herpes simplex keratitis</TI>
<SO>Philippine Journal of Ophthalmology</SO>
<YR>1982</YR>
<VL>14</VL>
<PG>39-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2011" MODIFIED="2014-12-07 15:06:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Jiang 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-07 15:06:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang M, Jiang J, Zhang Y</AU>
<TI>Efficacy of Tobradex adjuvant therapy for herpes simplex keratitis</TI>
<TO>&#20856;&#24517;&#27530;&#36741;&#21161;&#27835;&#30103;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Medical Herald [Zhongguo Yiyao Daobao]</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>1</NO>
<PG>80-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-1992" MODIFIED="2013-11-04 19:08:41 +0000" MODIFIED_BY="Anupa Shah" NAME="Jin 1992" YEAR="1992">
<REFERENCE MODIFIED="2013-11-04 19:08:41 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin XY</AU>
<TI>A clinical investigation of rHuIFN alpha-1 in the treatment of herpes simplex virus keratitis</TI>
<TO>&#22522;&#22240;&#24037;&#31243;&#24178;&#25200;&#32032;&#945;&#8212;1&#27835;&#30103;&#21333;&#30129;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Chinese Journal of Ophthalmology [Zhonghua Yanke Zazhi]</SO>
<YR>1992</YR>
<VL>28</VL>
<NO>3</NO>
<PG>134-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jing-2010" MODIFIED="2014-12-07 16:00:34 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Jing 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-07 16:00:34 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jing GL, Jing SY, Zhou YZ</AU>
<TI>Clinical observation of ganciclovir ophthalmic gel in treatment of herpes simplex keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Henan Medical Research [Henan Yixue Yanjiu]</SO>
<YR>2010</YR>
<VL>19</VL>
<NO>1</NO>
<PG>74-5, 80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1979" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Jones 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR, Coster DJ, Fison PN, Thompson GM, Cobo LM, Falcon MG</AU>
<TI>Efficacy of acycloguanosine (Wellcome 248U) against herpes-simplex corneal ulcers</TI>
<SO>Lancet</SO>
<YR>1979</YR>
<VL>1</VL>
<PG>243-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasparov-1972" MODIFIED="2013-08-12 17:34:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kasparov 1972" YEAR="1972">
<REFERENCE MODIFIED="2013-08-12 17:34:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasparov AA</AU>
<TI>Significance of interferon inductors in the contemporary antiviral therapy of herpetic eye diseases</TI>
<TO>&#1047;&#1085;&#1072;&#1095;&#1077;&#1085;&#1080;&#1077; &#1080;&#1085;&#1076;&#1091;&#1082;&#1090;&#1086;&#1088;&#1086;&#1074; &#1080;&#1085;&#1090;&#1077;&#1088;&#1092;&#1077;&#1088;&#1086;&#1085;&#1072; &#1074; &#1089;&#1086;&#1074;&#1088;&#1077;&#1084;&#1077;&#1085;&#1085;&#1086;&#1081; &#1087;&#1088;&#1086;&#1090;&#1080;&#1074;&#1086;&#1074;&#1080;&#1088;&#1091;&#1089;&#1085;&#1086;&#1081; &#1090;&#1077;&#1088;&#1072;&#1087;&#1080;&#1080; &#1075;&#1077;&#1088;&#1087;&#1077;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1080;&#1086;&#1081; &#1073;&#1086;&#1083;&#1077;&#1079;&#1085;&#1080; &#1075;&#1083;&#1072;&#1079;</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>1972</YR>
<VL>2</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasparov-1974" MODIFIED="2013-08-12 17:44:26 +0100" MODIFIED_BY="Anupa Shah" NAME="Kasparov 1974" YEAR="1974">
<REFERENCE MODIFIED="2013-08-12 17:44:26 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasparov AA, Fadeeva LL, Avetisov SE</AU>
<TI>Experience with combined use of polyribonucleotide complex and iododesoxyuridine in treatment of herpetic keratitis</TI>
<TO>&#1054;&#1087;&#1099;&#1090; &#1082;&#1086;&#1084;&#1073;&#1080;&#1085;&#1080;&#1088;&#1086;&#1074;&#1072;&#1085;&#1086;&#1075;&#1086; &#1080;&#1089;&#1087;&#1086;&#1083;&#1100;&#1079;&#1086;&#1074;&#1072;&#1085;&#1080;&#1103; &#1087;&#1086;&#1083;&#1080;&#1088;&#1080;&#1073;&#1086;&#1085;&#1091;&#1082;&#1083;&#1077;&#1086;&#1090;&#1080;&#1076;&#1085;&#1086;&#1075;&#1086; &#1082;&#1086;&#1084;&#1087;&#1083;&#1077;&#1082;&#1089;&#1072; &#1080; 5-&#1081;&#1086;&#1076;-2-&#1076;&#1077;&#1079;&#1086;&#1082;&#1089;&#1080;&#1091;&#1088;&#1080;&#1076;&#1080;&#1085;&#1072; &#1074; &#1083;&#1077;&#1095;&#1077;&#1085;&#1080;&#1080; &#1075;&#1077;&#1088;&#1087;&#1077;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1086;&#1075;&#1086; &#1082;&#1077;&#1088;&#1072;&#1090;&#1080;&#1090;&#1072;</TO>
<SO>Antibiotiki</SO>
<YR>1974</YR>
<VL>19</VL>
<PG>458-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasparov-1990" NAME="Kasparov 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasparov AA, Oganesiants VA, Riabokon' BV, Gorbovitskaia GE</AU>
<TI>Microdiathermocoagulation in the treatment of herpetic keratitis</TI>
<TO>Mikrodiatermokoaguliatsiia v lechenii gerpeticheskogo keratita</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>1990</YR>
<VL>106</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasparov-1991" MODIFIED="2013-08-12 17:55:44 +0100" MODIFIED_BY="Anupa Shah" NAME="Kasparov 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-08-12 17:55:44 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasparov AA, Pereverzina OK, Gorbovitskaya GE</AU>
<TI>A new combination in medicamentous treatment (poludan + aciclovir) of different forms of ophthalmoherpes</TI>
<TO>&#1053;&#1086;&#1074;&#1086;&#1077; &#1074; &#1082;&#1086;&#1084;&#1073;&#1080;&#1085;&#1080;&#1088;&#1086;&#1074;&#1072;&#1085;&#1085;&#1086;&#1081; &#1084;&#1077;&#1076;&#1080;&#1082;&#1072;&#1084;&#1077;&#1085;&#1090;&#1086;&#1079;&#1085;&#1086;&#1081; &#1090;&#1077;&#1088;&#1072;&#1087;&#1080;&#1080; (&#1055;&#1086;&#1083;&#1091;&#1076;&#1072;&#1085; + &#1072;&#1094;&#1080;&#1082;&#1083;&#1086;&#1074;&#1080;&#1088;) &#1088;&#1072;&#1079;&#1083;&#1080;&#1095;&#1085;&#1099;&#1093; &#1087;&#1088;&#1086;&#1090;&#1103;&#1074;&#1083;&#1077;&#1085;&#1080;&#1081; o&#1092;&#1090;&#1072;&#1083;&#1100;&#1084;&#1086;&#1075;&#1077;&#1088;&#1087;&#1077;&#1089;&#1072;</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1991</YR>
<VL>46</VL>
<PG>196-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koev-2007" MODIFIED="2010-10-31 19:04:54 +0000" MODIFIED_BY=" Iris Gordon" NAME="Koev 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-31 19:04:54 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Koev K, Tanev V, Avramov L, Borisova E</AU>
<TI>Clinical investigation of combined therapy influence over keratitis herpetica dendritica with He-Ne laser, pandavir and acyclovir</TI>
<SO>Proceedings of SPIE, the International Society for Optical Engineering. 14th International School on Quantum Electronics: Laser Physics and Applications</SO>
<YR>2007</YR>
<VL>6604</VL>
<PG>66042E-1-5</PG>
<ED>Atanasov PA, Dreischuh TN, Gateva SV, Kovachev LM</ED>
<PB>Society of Photo-Optical Instrumentation Engineers</PB>
<CY>Bellingham, Washington</CY>
<IDENTIFIERS MODIFIED="2010-10-31 19:04:54 +0000" MODIFIED_BY=" Iris Gordon"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolomiets-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Kolomiets 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolomiets AG, Chekina AY, Birach TV, Kolomiets ND, Votiakov VI</AU>
<TI>Clinical studies of the therapeutic efficacy of antiherpes immunoglobulin in ophthalmoherpes</TI>
<TO>Klinicheskoe izuchenie teraperticheskoi effektivnosti protirogerpeticheskoga imunoglobulina pri oftal'mogerpene</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1986</YR>
<VL>2</VL>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuyama-1979" MODIFIED="2010-11-06 09:12:13 +0000" MODIFIED_BY="[Empty name]" NAME="Kuyama 1979" YEAR="1979">
<REFERENCE MODIFIED="2010-11-06 09:12:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuyama H, Imanishi J, Itoi M</AU>
<TI>Comparative evaluation of human leukocyte and fibroblast interferon in the treatment of herpetic keratitis</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>1979</YR>
<VL>18 Suppl</VL>
<PG>57-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leopold-1965" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Leopold 1965" YEAR="1965">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leopold IH</AU>
<TI>Clinical experience with nucleosides in herpes simplex eye infections in man and animals</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1965</YR>
<VL>130</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-1998" MODIFIED="2014-12-06 21:34:06 +0000" MODIFIED_BY="[Empty name]" NAME="Li 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-12-06 21:34:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li SF, Wu X, Zhuge P, Zhang ZQ</AU>
<TI>Clinical observations on treating herpes simplex virus keratitis with Ban Lan Gen injection: report of 31 cases</TI>
<TO>&#26495;&#34013;&#26681;&#27880;&#23556;&#28082;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;&#65288;&#38468;31&#20363;&#25253;&#21578;)</TO>
<SO>Journal of Hebei Medical University [He Bei Yike Daxue Xuebao]</SO>
<YR>1998</YR>
<VL>19</VL>
<NO>4</NO>
<PG>215-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2012" MODIFIED="2014-12-07 16:02:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 16:02:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li LJ, Yuan RJ</AU>
<TI>Clinical analysis on increased and decreased dosage of yin qiao san in treating herpes simplex viral keratitis</TI>
<TO>&#38134;&#32728;&#25955;&#21152;&#20943;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Journal of Hebei North University (Natural Science Edition) [Hebei Beifang Xueyuan Xuebao (Ziran Kexueban)]</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>3</NO>
<PG>83-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2013c" MODIFIED="2014-12-07 15:02:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2013c" YEAR="2013">
<REFERENCE MODIFIED="2014-12-07 15:02:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li HY</AU>
<TI>Traditional Chinese medicine combined with acyclovir treatment of herpes simplex keratitis</TI>
<TO>&#20013;&#33647;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Guide of China Medicine [Zhongguo Yiyao Xuekan]</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>13</NO>
<PG>448-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014a" MODIFIED="2014-11-29 22:24:40 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2014a" YEAR="2014">
<REFERENCE MODIFIED="2014-11-29 21:05:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li SM, He RX</AU>
<TI>Observation of integrative effect of combined traditional Chinese and Western medicine in the treatment of 92 patients with recurrent herpes simplex keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#22797;&#21457;&#24615;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;92&#20363;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Nei Mongol Journal of Traditional Chinese Medicine [Nei Mung-gu Zhong Yi Yao]</SO>
<YR>2014</YR>
<VL>33</VL>
<NO>3</NO>
<PG>67-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014b" MODIFIED="2014-11-29 22:30:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2014b" YEAR="2014">
<REFERENCE MODIFIED="2014-11-29 22:30:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li CJ, Zhang CH, Ding LL, Yu JL</AU>
<TI>Clinical experience with traditional Chinese medicine for herpes simplex keratitis</TI>
<TO>&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#36827;&#34892;&#20013;&#21307;&#36776;&#35777;&#27835;&#30103;&#20020;&#24202;&#20307;&#20250;</TO>
<SO>Medicine and Health Care [Yi Yao Yu Bao Jian]</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>1</NO>
<PG>134</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Li-2014c" MODIFIED="2014-12-05 23:20:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2014c" YEAR="2014">
<REFERENCE MODIFIED="2014-12-05 23:20:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Li XH, Jubo L, Lu X, Hong Y</AU>
<TI>Eye drops of basic fibroblast growth factor for herpes simplex keratitis</TI>
<TO>&#30897;&#24615;&#25104;&#32420;&#32500;&#32454;&#32990;&#29983;&#38271;&#22240;&#23376;&#28404;&#30524;&#28082;&#22312;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20013;&#30340;&#24212;&#29992;</TO>
<SO>International Medicine and Health Guidance News [Guoji Yiyao Weisheng Daobao]</SO>
<YR>2014</YR>
<VL>20</VL>
<NO>10</NO>
<PG>1392-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2009" MODIFIED="2014-12-06 22:09:44 +0000" MODIFIED_BY=" Iris Gordon" NAME="Lin 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-06 22:09:44 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YY</AU>
<TI>Effect of acyclovir combined with polyinosinic-polycytidylic acid injection on herpes simplex keratitis</TI>
<TO>&#26080;&#29615;&#40479;&#33527;&#32852;&#21512;&#32858;&#32908;&#32990;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>China Tropical Medicine [Zhongguo Hedai Yixue]</SO>
<YR>2009</YR>
<VL>9</VL>
<NO>4</NO>
<PG>681, 769</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2013a" MODIFIED="2014-08-26 15:21:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2013a" YEAR="2013">
<REFERENCE MODIFIED="2014-08-26 15:21:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin T, Gong L, Sun XH, Zhao NQ, Chen W, Yuan HP, et al</AU>
<TI>Effectiveness and safety of 0.15% ganciclovir in situ ophthalmic gel for herpes simplex keratitis&#65293;a multicenter, randomized, investigator-masked, parallel group study in Chinese patients</TI>
<SO>Drug Design, Development and Therapy</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>361-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2013b" MODIFIED="2014-12-06 21:30:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Lin 2013b" YEAR="2013">
<REFERENCE MODIFIED="2014-12-06 21:30:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin X</AU>
<TI>Efficacy of the treatment of herpes simplex virus keratitis with ganciclovir ophthalmic solution in combination with interferon</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#28404;&#30524;&#28082;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Modern Diagnosis and Treatment [Xiandai Zhenduan Yu Zhiliao]</SO>
<YR>2013</YR>
<VL>23</VL>
<NO>10</NO>
<PG>2324</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2014-12-07 16:04:04 +0000" MODIFIED_BY=" Iris Gordon" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-12-07 16:04:04 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu T, Shi HW, Xie CZ</AU>
<TI>Subconjunctival interferon injection on 36 patients with herpes simplex keratitis</TI>
<TO>&#29699;&#32467;&#33180;&#19979;&#27880;&#23556;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;36&#20363;</TO>
<SO>International Journal of Ophthalmology [Guoji Yanke Zazhi]</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>2</NO>
<PG>118-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2007" MODIFIED="2014-12-07 16:06:48 +0000" MODIFIED_BY=" Iris Gordon" NAME="Liu 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-07 16:06:48 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu ZW, Li XC, Wen SZ</AU>
<TI>Evaluation of the therapeutic effects of basic fibroblast growth factor (bFGF) on herpes simplex keratitis</TI>
<TO>&#26080;&#29615;&#40479;&#33527;&#28404;&#30524;&#28082;&#32852;&#21512;&#30897;&#24615;&#25104;&#32420;&#32500;&#32454;&#32990;&#29983;&#38271;&#22240;&#23376;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Clinical Ophthalmology [Linchuang Yanke Zazhi]</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>2</NO>
<PG>155-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2009b" MODIFIED="2014-12-06 21:34:19 +0000" MODIFIED_BY=" Iris Gordon" NAME="Liu 2009b" YEAR="2009">
<REFERENCE MODIFIED="2014-12-06 21:34:19 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis: clinical observation</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Hebei Journal of Traditional Chinese Medicine [He Bei Zhong Yi]</SO>
<YR>2009</YR>
<VL>31</VL>
<NO>6</NO>
<PG>896-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-08-13 21:40:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Liu YH</AU>
<TI>Clinical study of qiang huo sheng feng decoction combined with acyclovir treatment on herpes simplex keratitis</TI>
<TO>&#32652;&#27963;&#32988;&#39118;&#27748;&#21152;&#20943;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Fujian Medical University</SO>
<YR>2008</YR>
<VL>Master's Thesis</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2014b" MODIFIED="2014-12-05 21:51:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Liu 2014b" YEAR="2014">
<REFERENCE MODIFIED="2014-12-05 21:51:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu YH, Dong XH</AU>
<TI>Curative effect observation of combination therapy of aciclovir joint muscle cell [polyinosinic acid] on herpes simplex keratitis</TI>
<TO>&#38463;&#26132;&#27931;&#38886;&#32852;&#21512;&#32858;&#32908;&#32990;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Heilongjiang Medical Journal [Heilonghang Yixue]</SO>
<YR>2014</YR>
<VL>38</VL>
<NO>4</NO>
<PG>430-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Long-2011" MODIFIED="2014-12-07 16:08:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Long 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-07 16:08:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Long KL</AU>
<TI>Effect of different treatments on tear EGF, Ig, and complement C3 of viral keratitis patients</TI>
<TO>&#19981;&#21516;&#27835;&#30103;&#26041;&#26696;&#23545;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#27882;&#28082;EGF&#12289;Ig&#21644;&#34917;&#20307;C3 &#30340;&#24433;&#21709;&#30740;&#31350;</TO>
<SO>Modern Preventive Medicine [Xiandai Yufang Yixue]</SO>
<YR>2011</YR>
<VL>20</VL>
<NO>15</NO>
<PG>3120-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-1982" MODIFIED="2013-11-04 19:08:56 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 1982" YEAR="1982">
<REFERENCE MODIFIED="2013-11-04 19:08:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma ZX</AU>
<TI>Clinical investigation of anti-herpes simplex virus agents</TI>
<TO>&#25239;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#33647;&#30137;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Chinese Journal of Ophthalmology [Zhonghua Yanke Zazhi]</SO>
<YR>1982</YR>
<VL>18</VL>
<NO>2</NO>
<PG>92-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2006a" MODIFIED="2014-12-07 16:09:55 +0000" MODIFIED_BY=" Iris Gordon" NAME="Ma 2006a" YEAR="2006">
<REFERENCE MODIFIED="2014-12-07 16:09:55 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma YD</AU>
<TI>Combination of Chinese and Western medicine treatment of herpes simplex virus keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Liaoning Journal of Traditional Chinese Medicine [Liaoning Zhongyi Zazhi]</SO>
<YR>2006</YR>
<VL>33</VL>
<NO>9</NO>
<PG>1158</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2010" MODIFIED="2014-12-07 16:10:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Ma 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-07 16:10:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma XL, Zhi Z, Liu J, Qi BY, Qu J</AU>
<TI>Efficacy of traditional Chinese medicine for herpes simplex virus keratitis and its anti-retroviral role</TI>
<TO>&#20013;&#33647;&#20869;&#26381;&#22806;&#34224;&#23545;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#21450;&#25239;&#22797;&#21457;&#20316;&#29992;&#30340;&#30740;&#31350;</TO>
<SO>Chinese Journal of Difficult and Complicated Cases [Yinanbing Zazhi]</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>8</NO>
<PG>613-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2011" MODIFIED="2014-12-07 16:12:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Ma 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-07 16:12:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma HX, Bao ZS, Xu CX, Sun L</AU>
<TI>Efficacy of curcuma oil eye gel in the treatment of herpes simplex virus keratitis</TI>
<TO>&#33706;&#26415;&#27833;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Practical Medicine [Zhongguo Shiyong Yiyao]</SO>
<YR>2011</YR>
<VL>6</VL>
<NO>15</NO>
<PG>188-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ma-2013" MODIFIED="2014-12-07 15:08:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Ma 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-12-07 15:08:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ma JP</AU>
<TI>Differential treatment of 29 cases of herpes simplex keratitis</TI>
<TO>&#36776;&#35777;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;29&#20363;</TO>
<SO>Chinese Medicine Modern Distance Education of China [Zhongguo Zhongyiyao Xiandai Yuancheng Jiaoyu]</SO>
<YR>2013</YR>
<VL>11</VL>
<NO>22</NO>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maichuk-1990" MODIFIED="2013-08-13 19:01:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Maichuk 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-08-13 19:01:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maichuk YF, Kazachenko MA, Dyadina UV</AU>
<TI>Rengazyl (pyroprophene) in treatment of inflammatory eye diseases</TI>
<TO>Rengazil (piprofen) v lechenii vospalitel'nykh zabolevanii glaz</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1990</YR>
<VL>45</VL>
<PG>290-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mal_x0027_khanov-1991" MODIFIED="2014-08-26 15:28:38 +0100" MODIFIED_BY="[Empty name]" NAME="Mal'khanov 1991" YEAR="1991">
<REFERENCE MODIFIED="2014-08-26 15:28:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mal'khanov VB, Gripas' IA, Nasibullina GKh, Belousova MA</AU>
<TI>Use of T-activin and thymalin in the treatment of ophthalmic herpes</TI>
<TO>&#1055;&#1088;&#1080;&#1084;&#1077;&#1085;&#1077;&#1085;&#1080;&#1077; &#1058;&#1072;&#1082;&#1090;&#1080;&#1074;&#1080;&#1085;&#1072; &#1080; &#1090;&#1080;&#1084;&#1072;&#1083;&#1080;&#1085;&#1072; &#1087;&#1088;&#1080; &#1083;&#1077;&#1095;&#1077;&#1085;&#1080;&#1080; &#1086;&#1092;&#1090;&#1072;&#1083;&#1100;&#1084;&#1086;&#1075;&#1077;&#1088;&#1087;&#1077;&#1089;&#1072;</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>1991</YR>
<VL>107</VL>
<NO>5</NO>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marquardt-1971" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Marquardt 1971" YEAR="1971">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marquardt R, Roth HW</AU>
<TI>Susceptibility of corneal herpes to treatment</TI>
<TO>Über die therapeutische Beeinflußbarkeit der Herpes corneæ</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1971</YR>
<VL>158</VL>
<PG>517-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martenet-1979" NAME="Martenet 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martenet AC</AU>
<TI>Experiences with iododeoxycytidine in the treatment of ocular herpes simplex infections</TI>
<SO>Advances in Ophthalmology</SO>
<YR>1979</YR>
<VL>38</VL>
<PG>105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matalia-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Matalia 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matalia PD</AU>
<TI>Herpetic keratitis newer modality of better approach: study of 440 cases/460 eyes</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>94-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathur-1984" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Mathur 1984" YEAR="1984">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathur AG, Elhence A</AU>
<TI>Cryotherapy, immunotherapy and wiping in herpes keratitis</TI>
<SO>Indian Journal of Ophthalmology</SO>
<YR>1984</YR>
<VL>32</VL>
<PG>382-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-McGill-1981" MODIFIED="2014-09-26 12:13:25 +0100" MODIFIED_BY="[Empty name]" NAME="McGill 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-03-04 22:21:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>McGill J, Tormey P, Walker CB</AU>
<TI>Comparative trial of acyclovir and adenine arabinoside in the treatment of herpes simplex corneal ulcers</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>65</VL>
<PG>610-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-26 12:13:25 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGill J, Tormey P</AU>
<TI>Use of acyclovir in herpetic ocular infection</TI>
<SO>American Journal of Medicine</SO>
<YR>1982</YR>
<VL>73 Suppl 1A</VL>
<PG>286-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tormey P, McGill J, Walker C</AU>
<TI>Use of acyclovir in herpes simplex corneal ulcers</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1981</YR>
<VL>101</VL>
<PG>6-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Mohan-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Mohan 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohan M, Gupta SK, Vajpayee RB, Kalra VK</AU>
<TI>Acyclovir and adenine arabinoside in the treatment of herpes simplex keratitis: a prospective controlled clinical trial</TI>
<SO>Medical Science Research</SO>
<YR>1987</YR>
<VL>15</VL>
<PG>1173</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morimoto-1986" MODIFIED="2014-12-07 16:13:17 +0000" MODIFIED_BY="Anupa Shah" NAME="Morimoto 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-12-07 16:13:17 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morimoto K, Yagi J, Miyamoto Y, Yasumoto K, Nishida T, Otori T</AU>
<TI>Zovirax for epithelial herpetic keratitis</TI>
<TO>&#19978;&#30382;&#22411;&#35282;&#33180;&#12504;&#12523;&#12506;&#12473;&#12395;&#23550;&#12377;&#12427;&#12478;&#12499;&#12521;&#12483;&#12463;&#12473;&#12398;&#27835;&#30274;&#21177;&#26524;&#12395;&#12388;&#12356;&#12390;</TO>
<SO>Folia Ophthalmologica Japonica [Nippon Ganka Kiyo]</SO>
<YR>1986</YR>
<VL>37</VL>
<NO>4</NO>
<PG>602-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patterson-1967c" MODIFIED="2010-02-09 17:41:10 +0000" MODIFIED_BY="[Empty name]" NAME="Patterson 1967c" YEAR="1967">
<REFERENCE MODIFIED="2010-02-09 17:41:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patterson A, Jones BR</AU>
<TI>The management of ocular herpes</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1967</YR>
<VL>87</VL>
<PG>59-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Pavan_x002d_Langston-1972" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Pavan-Langston 1972" YEAR="1972">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D, Dohlman CH</AU>
<TI>A double blind clinical study of adenine arabinoside therapy of viral keratoconjunctivitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1972</YR>
<VL>74</VL>
<PG>81-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Pavan_x002d_Langston-1977" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Pavan-Langston 1977" YEAR="1977">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D, Foster CS</AU>
<TI>Trifluorothymidine and idoxuridine therapy of ocular herpes</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1977</YR>
<VL>84</VL>
<PG>818-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D</AU>
<TI>Current trends in therapy of ocular herpes simplex: experimental and clinical studies</TI>
<SO>Advances in Ophthalmology</SO>
<YR>1979</YR>
<VL>38</VL>
<PG>82-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pietruschka-1968" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Pietruschka 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pietruschka G</AU>
<TI>On the epidemiology and therapy of herpes corneæ</TI>
<TO>Zur Epidemiologie und Therapie des Herpes corneæ</TO>
<SO>Das Deutsche Gesundheitswesen</SO>
<YR>1968</YR>
<VL>23</VL>
<PG>1249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pint_x00e9_r-1973" MODIFIED="2010-06-17 17:13:16 +0100" MODIFIED_BY="[Empty name]" NAME="Pintér 1973" YEAR="1973">
<REFERENCE MODIFIED="2010-06-17 17:13:16 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pintér L, Biró A, Berencsi G</AU>
<TI>Treatment of corneal herpes with a photosensitising dye</TI>
<TO>Die Behandlung des Herpes corneæ mit einem photosensibilisierenden Farbstoff</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1973</YR>
<VL>163</VL>
<PG>600-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Pivetti_x002d_Pezzi-1985" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Pivetti-Pezzi 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pivetti-Pezzi P, De Liso P, Tamburi S, Luzi G, Sirianni MC, Palmisano L, et al</AU>
<TI>Thymic factor therapy for herpetic keratitis</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1985</YR>
<VL>17</VL>
<PG>327-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prost-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Prost 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prost M, Gerkowicz K, Kozak U</AU>
<TI>Clinical investigations on the therapeutic effectiveness of isoprinosine in herpetic keratitis</TI>
<TO>Badania kliniczne uad skutecznoscia terapeutyczna preparatu isoprinosine w opryszczkocoym zapaleniu rogowki</TO>
<SO>Klinika Oczna</SO>
<YR>1986</YR>
<VL>88</VL>
<PG>276-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rykun-1988" MODIFIED="2013-08-13 18:37:27 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Rykun 1988" YEAR="1988">
<REFERENCE MODIFIED="2013-08-13 18:37:27 +0100" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rykun VS, Maichuk YF</AU>
<TI>Clinico-experimental substantiation of the use of tocopherol in the treatment of ocular herpes simplex</TI>
<TO>&#1050;&#1083;&#1080;&#1085;&#1080;&#1082;&#1086;-&#1101;&#1082;&#1089;&#1087;&#1077;&#1088;&#1080;&#1084;&#1077;&#1085;&#1090;&#1072;&#1083;&#1100;&#1085;&#1086;&#1077; &#1086;&#1073;&#1086;&#1089;&#1085;&#1086;&#1074;&#1072;&#1085;&#1080;&#1077; &#1087;&#1088;&#1080;&#1084;&#1077;&#1085;&#1077;&#1085;&#1080;&#1103; &#1090;&#1086;&#1082;&#1086;&#1092;&#1077;&#1088;&#1086;&#1083;&#1072; &#1074; &#1083;&#1077;&#1095;&#1077;&#1085;&#1080;&#1080; &#1086;&#1092;&#1090;&#1072;&#1083;&#1100;&#1084;&#1086;&#1075;&#1077;&#1088;&#1087;&#1077;&#1089;&#1072;</TO>
<SO>Vestnik Oftalmologii</SO>
<YR>1988</YR>
<VL>104</VL>
<NO>4</NO>
<PG>65-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salcedo-Hernandez-2007" MODIFIED="2010-02-22 22:34:52 +0000" MODIFIED_BY="[Empty name]" NAME="Salcedo Hernandez 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-02-22 22:34:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Salcedo Hernandez CI, Velasco R, Baca O, Babayan A, Salas F</AU>
<TI>Autologous serum vs topical acyclovir in the treatment of epithelial herpetic keratitis</TI>
<SO>ARVO Annual Meeting</SO>
<YR>2007</YR>
<PG>withdrawn abstract 381</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scialdone-1986" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Scialdone 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scialdone D, Chisci C, Volpe C</AU>
<TI>Valuation of efficacy of beta interferon in the treatment of herpes simplex virus (HSV) keratoconjunctivitis</TI>
<TO>Valutazione dell'efficacia del beta interferone nella terapia delle cheratocongiuntiviti da virus herpes simplex (HSV)</TO>
<SO>Annali di Ottalmologia e Clinica Oculistica</SO>
<YR>1986</YR>
<VL>112</VL>
<PG>1101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellitti-1982" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Sellitti 1982" YEAR="1982">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sellitti G, Mastroberti A, Scarpa M, Santamarina M</AU>
<TI>Methisoprinol eye drops in herpetic dendritic keratitis</TI>
<TO>Il metisoprinolo in collirio nella cheratite erpetica dendritica</TO>
<SO>Annali di Ottalmologia e Clinica Oculistica</SO>
<YR>1982</YR>
<VL>108</VL>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shimomura-1987" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Shimomura 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shimomura Y, Ohashi Y, Maeda N, Matsuda M, Hamano T, Manabe R</AU>
<TI>Herpetic keratitis therapy to reduce recurrence</TI>
<SO>Current Eye Research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>105-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiota-1979" MODIFIED="2014-12-07 14:47:27 +0000" MODIFIED_BY="Anupa Shah" NAME="Shiota 1979" YEAR="1979">
<REFERENCE MODIFIED="2014-12-07 14:47:27 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiota H, Inoue S, Imai M, Yamane S, Ogawa T</AU>
<TI>Clinical evaluation of trifluorothymidine and adenine arabinoside against ulcerative herpetic keratitis</TI>
<TO>Trifluorothymidine&#12362;&#12424;&#12403; adenine arabinoside &#12395;&#12424;&#12427;&#35282;&#33180;&#12504;&#12523;&#12506;&#12473;&#12398;&#27835;&#8203;&#30274;&#25104;&#32318;&#8203;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1979</YR>
<VL>33</VL>
<NO>2</NO>
<PG>145-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiota-1988" MODIFIED="2014-12-07 14:48:06 +0000" MODIFIED_BY="Anupa Shah" NAME="Shiota 1988" YEAR="1988">
<REFERENCE MODIFIED="2014-12-07 14:48:06 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shiota H, Naito T, Kusujima K, Katan T, Mimura Y</AU>
<TI>Topical interferon in the treatment of herpetic keratitis</TI>
<TO>&#35282;&#8203;&#33180;&#8203;&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#12398;&#8203;&#27835;&#8203;&#30274;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427;&#8203;&#12452;&#8203;&#12531;&#8203;&#12479;&#8203;&#12540;&#8203;&#12501;&#8203;&#12455;&#8203;&#12525;&#8203;&#12531;&#8203;&#12398;&#8203;&#24540;&#8203;&#29992;&#8203;</TO>
<SO>Japanese Journal of Clinical Ophthalmology [Rinsho Ganka]</SO>
<YR>1988</YR>
<VL>42</VL>
<NO>5</NO>
<PG>542-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sozen-2006" MODIFIED="2010-10-31 19:11:17 +0000" MODIFIED_BY=" Iris Gordon" NAME="Sozen 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-31 19:11:17 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sozen E, Avunduk AM, Akyol N</AU>
<TI>Comparison of efficacy of oral valacyclovir and topical acyclovir in the treatment of herpes simplex keratitis: a randomized clinical trial</TI>
<SO>Chemotherapy</SO>
<YR>2006</YR>
<VL>52</VL>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stambuk-1995" MODIFIED="2010-11-06 09:14:18 +0000" MODIFIED_BY="[Empty name]" NAME="Stambuk 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-11-06 09:14:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stambuk M, Stambuk V, Pesic MC</AU>
<TI>Effect of adjuvant immunotherapy with thymic extract thymex-L in herpetic keratitis</TI>
<SO>International Journal of Thymology</SO>
<YR>1995</YR>
<VL>3</VL>
<PG>252-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-2010" MODIFIED="2014-12-07 16:16:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Su 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-07 16:16:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su YY, He YZ, Wen TS</AU>
<TI>Clinical observation about ganciclovir ophthalmic gel combined interferon in the treatment of herpes simplex viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>China Modern Medicine [Zhongguo Dangdai Yiyao]</SO>
<YR>2010</YR>
<VL>3</VL>
<NO>10</NO>
<PG>53-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2012" MODIFIED="2014-12-07 16:18:22 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sun 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 16:18:22 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun H</AU>
<TI>Efficacies of yanhuning combined with acyclovir and single use of acyclovir in treatment of herpes simplex virus keratitis: a comparative study</TI>
<TO>&#28814;&#29733;&#23425;&#32852;&#21512;&#38463;&#26132;&#27931;&#38886;&#19982;&#21333;&#29420;&#37319;&#29992;&#38463;&#26132;&#27931;&#38886;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>Chinese Journal of Nosocomiology [Zhonghua Yiyuanganranxue Zazhi]</SO>
<YR>2012</YR>
<VL>17</VL>
<NO>23</NO>
<PG>5376-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sun-2014" MODIFIED="2014-12-13 16:43:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sun 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-13 16:43:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sun L,, Zhang YQ, Zhong YH, Gao RH</AU>
<TI>Clinical observation of corneal scarring after herpes simplex virus keratitis with large doses of vitamin C treatment</TI>
<TO>&#22823;&#21058;&#37327;&#32500;&#29983;&#32032;C&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#21518;&#35282;&#33180;&#30242;&#30165;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Guide of China Medicine</SO>
<YR>2014</YR>
<VL>12</VL>
<NO>5</NO>
<PG>145-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Tamburi-1990" MODIFIED="2010-03-04 22:26:20 +0000" MODIFIED_BY="[Empty name]" NAME="Tamburi 1990" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tamburi S, Palombaro P, Micozzi I, Florio FR, Abdulaziz MA</AU>
<TI>Alpha interferon therapy for superficial herpetic keratitis</TI>
<TO>L'interferon alfa naturale nel trattamento della cheratite erpetica superficiale</TO>
<SO>Atti del LXX Congresso della Societa del Ottalmologia Italiano, Roma</SO>
<YR>1990</YR>
<PG>369-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarakji-1978" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Tarakji 1978" YEAR="1978">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarakji MS, Matta CS, Shammas HF</AU>
<TI>Cryotherapy of herpes simplex keratitis</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1978</YR>
<VL>10</VL>
<PG>1557-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tommila-1963" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Tommila 1963" YEAR="1963">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tommila V</AU>
<TI>Treatment of dendritic keratitis with interferon</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1963</YR>
<VL>41</VL>
<PG>478-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Topciu-1992" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Topciu 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Topciu V, Chercot&#259; G, Mih&#259;ilescu R, Dressler S</AU>
<TI>Immunologic and antiviral therapy in herpetic keratitis</TI>
<SO>Roumanian Archives of Microbiology and Immunology</SO>
<YR>1992</YR>
<VL>51</VL>
<PG>233-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wan-2014" MODIFIED="2014-12-07 15:10:49 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wan 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 15:10:49 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wan JL, Kang B</AU>
<TI>Treatment of epithelial herpes simplex viral keratitis by recombinant human interferon &#945;-2b eye drops</TI>
<TO>&#37325;&#32452;&#20154;&#24178;&#25200;&#32032; &#945;-2b &#28404;&#30524;&#28082;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>International Eye Science [Guoji Yanke Zazhi]</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>2</NO>
<PG>276-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2009" MODIFIED="2014-12-07 16:17:29 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wang 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-12-07 16:17:29 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SL, Xu M</AU>
<TI>Ganciclovir ophthalmic gel and acyclovir eye drops: comparative efficacy in treatment of viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#19982;&#38463;&#26132;&#27931;&#38886;&#30524;&#28082;&#27835;&#30103;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#27604;&#36739;</TO>
<SO>China Modern Medicine [Zhongguo Dangdai Yiyao]</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>17</NO>
<PG>53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2010a" MODIFIED="2014-12-06 21:31:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wang 2010a" YEAR="2010">
<REFERENCE MODIFIED="2014-12-06 21:31:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang QL</AU>
<TI>Clinical observation of integrated traditional Chinese and western medical therapy on herpes simplex keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Hebei Journal of Traditional Chinese Medicine [He Bei Zhong Yi]</SO>
<YR>2010</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1388-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2010b" MODIFIED="2014-12-06 21:35:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wang 2010b" YEAR="2010">
<REFERENCE MODIFIED="2014-12-06 21:35:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZP</AU>
<TI>Clinical experience in herpes simplex viral keratitis treated with integrated Chinese and western medicine</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#20307;&#20250;</TO>
<SO>World Journal of Integrated Traditional and Western Medicine [Shijie Zhongxiyi Jiehe Zazhi]</SO>
<YR>2010</YR>
<VL>5</VL>
<NO>9</NO>
<PG>780-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2011" MODIFIED="2014-12-06 21:37:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wang 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-06 21:37:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang ZY, Wang F</AU>
<TI>Clinical analysis of herpes simplex keratitis treated by Chinese herbs</TI>
<TO>&#20013;&#33647;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Journal of Practical Traditional Chinese Medicine [Shiyong Zhongyiyiao Zazhi]</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>5</NO>
<PG>294-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2014b" MODIFIED="2014-12-06 21:38:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wang 2014b" YEAR="2014">
<REFERENCE MODIFIED="2014-12-06 21:38:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang YZ, Xu Y, Wang LQ, Xin YF, Yang XS, Gu GX</AU>
<TI>Clinical study of yiqi jiedu granules combined with wester medicine for 107 cases of herpes simplex keratitis</TI>
<TO>&#30410;&#27668;&#35299;&#27602;&#20914;&#21058;&#32852;&#21512;&#35199;&#33647;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;107&#20363;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Journal of Traditional Chinese Medicine [Zhongyi Zazhi]</SO>
<YR>2014</YR>
<VL>55</VL>
<NO>2</NO>
<PG>133-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wei-2012" MODIFIED="2014-12-07 16:19:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wei 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 16:19:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wei XH, Li L, Su JL, Cui GD, Wang XM, Wang XJ</AU>
<TI>Polyinosinic acid combined with ganciclovir gel in treating herpes simplex keratitis</TI>
<TO>&#32858;&#32908;&#32990;&#32852;&#21512;&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Medical Journal of Trauma and Disability [Shangcan Yixue Zazhi]</SO>
<YR>2012</YR>
<VL>20</VL>
<NO>9</NO>
<PG>27-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wen-2011" MODIFIED="2014-12-06 21:39:30 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wen 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-06 21:39:30 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wen HL</AU>
<TI>Observation of the curative effect on herpes simplex keratitis treated by the combination of Chinese traditional medicine and western medicine</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Chinese and Foreign Women Health [Zhong Wai Fu Er Jian Kang]</SO>
<YR>2011</YR>
<VL>2</VL>
<NO>9</NO>
<PG>4-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weng-2014" MODIFIED="2014-12-07 20:36:38 +0000" MODIFIED_BY="[Empty name]" NAME="Weng 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 20:36:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weng CY, Hong B</AU>
<TI>Recombinant human interferon combined with acyclovir in the treatment of herpes simplex virus keratitis and the prevention of recurrence</TI>
<TO>&#37325;&#32452;&#20154;&#24178;&#25200;&#32032;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#25928;&#26524;&#21450;&#39044;&#38450;&#22797;&#21457;&#20316;&#29992;</TO>
<SO>Chinese Remedies and Clinics [Zhongguo Yaowu Yu Linchuang]</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>1</NO>
<PG>76-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whitcher-1976" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Whitcher 1976" YEAR="1976">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whitcher JP, Dawson CR, Hoshiwara I, Daghfous T, Messadi M, Triki F, et al</AU>
<TI>Herpes simplex keratitis in a developing country. Natural history and treatment of epithelial ulcers in Tunisia</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1976</YR>
<VL>94</VL>
<PG>587-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xiao-1998" MODIFIED="2014-12-07 16:24:58 +0000" MODIFIED_BY=" Iris Gordon" NAME="Xiao 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-12-07 16:24:58 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xiao AY, Li Y, Li JY, Zhang XH, Shen XF</AU>
<TI>Clinical study of curing herpes simplex keratitis with human recombinant IL-2</TI>
<TO>hrIL-2&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Chinese Ophthalmic Research [Yanke Yan Jiu]</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>1</NO>
<PG>46-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xie-2005" MODIFIED="2014-12-06 22:13:01 +0000" MODIFIED_BY=" Iris Gordon" NAME="Xie 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-12-06 22:13:01 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xie W, Jiang S, Xie Y, Xie K</AU>
<TI>Clinical study of frost-snow eye drops in the treatment of herpes simplex keratitis</TI>
<TO>&#20912;&#38684;&#38634;&#30524;&#33647;&#27700;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>China Journal of Modern Medicine [Zhongguo Xiandai Yixue Zazhi]</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>15</NO>
<PG>2344-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2009b" MODIFIED="2014-12-07 16:25:51 +0000" MODIFIED_BY=" Iris Gordon" NAME="Xu 2009b" YEAR="">
<REFERENCE MODIFIED="2014-12-07 16:25:51 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu JJ</AU>
<TI>Clinical study on treating herpes simplex keratitis with recombinant human interleukin 2</TI>
<TO>&#37325;&#32452;&#30333;&#32454;&#32990;&#20171;&#32032;&#8545;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Modern Preventive Medicine [Xiandai Yufang Yixue]</SO>
<YR>2009</YR>
<VL>36</VL>
<NO>6</NO>
<PG>1182-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2012" MODIFIED="2014-12-13 16:58:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Xu 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-13 16:58:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu GY</AU>
<TI>
<I>Houttuynia cordata</I> as a treatment method for herpes simplex keratitis</TI>
<TO>&#40060;&#33125;&#33609;&#27835;&#30103;&#21333;&#32431;&#30105;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Guide of China Medicine [Zhongguo Yiyao Xuekan]</SO>
<YR>2012</YR>
<VL>10</VL>
<NO>24</NO>
<PG>15,17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamamoto-1984" MODIFIED="2014-12-07 14:48:37 +0000" MODIFIED_BY="[Empty name]" NAME="Yamamoto 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-12-07 14:48:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamamoto K, Fujiwara H, Kohno M, Kurimoto R, Hanafusa M</AU>
<TI>Effectiveness of topical zinc sulfate for herpes simplex keratitis</TI>
<TO>&#21336;&#8203;&#32020;&#8203;&#12504;&#8203;&#12523;&#8203;&#12506;&#8203;&#12473;&#8203;&#24615;&#8203;&#35282;&#8203;&#33180;&#8203;&#28814;&#8203;&#12395;&#8203;&#23550;&#8203;&#12377;&#8203;&#12427;&#8203;&#30827;&#8203;&#37240;&#8203;&#20124;&#8203;&#37467;&#8203;&#28857;&#8203;&#30524;&#8203;&#12398;&#8203;&#26377;&#8203;&#21177;&#8203;&#24615;&#8203;</TO>
<SO>Japanese Journal of Clinical Ophthalmology [Rinsho Ganka]</SO>
<YR>1984</YR>
<VL>38</VL>
<NO>7</NO>
<PG>743-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2012" MODIFIED="2014-12-06 21:45:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yang 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-12-06 21:45:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang XB</AU>
<TI>Compound Chinese medicine eye drops contrasted with acyclovir eye drops in the treatment of herpes simplex keratitis</TI>
<TO>&#22797;&#26041;&#20013;&#33647;&#28404;&#30524;&#28082;&#19982;&#26080;&#29615;&#40479;&#33527;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#25928;&#26524;&#23545;&#27604;</TO>
<SO>Lishizhen Medicine and Materia Medica Research [Zhizhen Guoyi Guoyao]</SO>
<YR>2012</YR>
<VL>23</VL>
<NO>8</NO>
<PG>2067-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yi-2011" MODIFIED="2014-12-07 16:29:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yi 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-07 16:29:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yi YM, Yi JL, Wang HZ, Luo JY, Gong JM, Li RJ, Wang HY</AU>
<TI>Curative effect of qinggan xiehuo combined with acupuncture in the treatment of herpes simplex virus keratitis</TI>
<TO>&#28165;&#32925;&#27899;&#28779;&#27861;&#32852;&#21512;&#38024;&#21050;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;</TO>
<SO>Practical Clinical Medicine [Shiyong Linchuang Yixue]</SO>
<YR>2011</YR>
<VL>12</VL>
<NO>9</NO>
<PG>77-8,82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-1999" MODIFIED="2014-12-06 21:46:31 +0000" MODIFIED_BY="[Empty name]" NAME="Yu 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-12-06 21:46:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu XL, Zeng QH, Li X, Wang MF</AU>
<TI>A clinical study on the efficacy of miedulin eye drops in the treatment of herpes simplex keratitis</TI>
<TO>&#28781;&#27602;&#28789;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Journal of Traditional Chinese Ophthalmology [Zhongguo Zhongyi Yanke Zazhi]</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>1</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2012b" MODIFIED="2014-12-07 16:30:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yu 2012b" YEAR="2012">
<REFERENCE MODIFIED="2014-12-07 16:30:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu J, Zhang MC, Xiang QY</AU>
<TI>Clinical observation of epithelial herpes simplex keratitis treated by live attenuated measles vaccine</TI>
<TO>&#40635;&#30137;&#20943;&#27602;&#27963;&#30123;&#33495;&#27835;&#30103;&#19978;&#30382;&#22411;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Journal of Xinxiang Medical College [Xinxiang Yixueyuan Xuebao]</SO>
<YR>2012</YR>
<VL>29</VL>
<NO>6</NO>
<PG>454-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yu-2014" MODIFIED="2014-11-29 20:51:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yu 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-11-29 20:51:22 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yu AZ</AU>
<TI>Clinical efficacy of Chinese herbs combined with acyclovir in treatment of herpes simplex keratitis</TI>
<TO>&#20013;&#33647;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Journal of Guiyang College of Traditional Chinese Medicine [Guiyang Zhongyi Xueyuan Xuebao]</SO>
<YR>2014</YR>
<VL>36</VL>
<NO>2</NO>
<PG>79-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yuan-2011" MODIFIED="2014-12-06 21:47:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yuan 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-06 21:47:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yuan HY</AU>
<TI>Effects of ganciclovir ophthalmic gel combined with interferon in the treatment of herpes simplex viral keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#30524;&#29992;&#20957;&#33014;&#32852;&#21512;&#24178;&#25200;&#32032;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;&#20998;&#26512;&#19982;&#35780;&#20215;</TO>
<SO>Chinese Journal of Clinical Rational Drug Use [Linchuang Heli Yongyao Zazhi]</SO>
<YR>2011</YR>
<VL>18</VL>
<NO>4</NO>
<PG>43-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zagaigora-1971" MODIFIED="2014-08-26 15:45:21 +0100" MODIFIED_BY="[Empty name]" NAME="Zagaigora 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-08-26 15:45:21 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zagaigora EP</AU>
<TI>Comparative effectiveness of gamma-globulin, deoxyribonuclease and Kerecid in herpetic keratitis</TI>
<TO>&#1057;&#1088;&#1072;&#1074;&#1085;&#1077;&#1085;&#1080;&#1077; &#1101;&#1092;&#1092;&#1077;&#1082;&#1090;&#1080;&#1074;&#1085;&#1086;&#1089;&#1090;&#1080; &#1075;&#1072;&#1084;&#1084;&#1072;-&#1075;&#1083;&#1086;&#1073;&#1091;&#1083;&#1080;&#1085;&#1072;, &#1076;&#1077;&#1079;&#1086;&#1082;&#1089;&#1080;&#1088;&#1080;&#1073;&#1086;&#1085;&#1091;&#1082;&#1083;&#1077;&#1072;&#1079;&#1099; &#1080; Ke&#1088;e&#1094;&#1080;&#1076;&#1072; &#1074; &#1075;&#1077;&#1088;&#1087;&#1077;&#1090;&#1080;&#1095;&#1077;&#1089;&#1082;&#1080;x &#1082;&#1077;&#1088;&#1072;&#1090;&#1080;&#1090;&#1072;x</TO>
<SO>Oftalmologicheskii Zhurnal</SO>
<YR>1971</YR>
<VL>26</VL>
<NO>1</NO>
<PG>29-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zaj_x00e1_cz-1968" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Zajácz 1968" YEAR="1968">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zajácz M, Kovács M</AU>
<TI>Superficial herpetic keratitis (statistical assessment of 146 cases)</TI>
<TO>Felületes herpes-keratitis (146 eset statisztikai értékelése)</TO>
<SO>Szemészet</SO>
<YR>1968</YR>
<VL>105</VL>
<PG>294-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhai-2007" MODIFIED="2014-12-06 21:49:11 +0000" MODIFIED_BY="[Empty name]" NAME="Zhai 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-06 21:49:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhai N, Chen Y</AU>
<TI>Integrated traditional Chinese and Western medicine in the treatment of 58 cases of herpes simplex virus keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;58&#20363;</TO>
<SO>Journal of Shaanxi College of Traditional Chinese Medicine [Shaanxi Zhong Yixue Yuan Xuebao]</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>4</NO>
<PG>34-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhan-2011" MODIFIED="2014-12-06 21:52:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhan 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-12-06 21:52:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhan YH, Xiao YQ, Wu ZL</AU>
<TI>Traditional Chinese medicine compared with conventional western medicine, each in the treatment of 50 cases of herpes simplex keratitis</TI>
<TO>&#28040;&#32755;&#26041;&#37197;&#21512;&#24120;&#35268;&#35199;&#33647;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;50&#20363;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Guiding Journal of Traditional Chinese Medicine and Pharmacy [Zhongyiyao Daobao]</SO>
<YR>2011</YR>
<VL>8</VL>
<NO>3</NO>
<PG>50-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1992" MODIFIED="2014-12-07 16:31:33 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhang 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-12-07 16:31:33 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang MD, Luan XH, Meng W, Zhao XZ</AU>
<TI>Clinical and immunologic evaluation of combination therapy for herpes simplex keratitis with antiviral drugs and immunopotentiating agent</TI>
<TO>&#25239;&#30149;&#27602;&#33647;&#32852;&#21512;&#20813;&#30123;&#22686;&#24378;&#21058;&#27835;&#30103;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#19982;&#20813;&#30123;&#23398;&#35780;&#20215;</TO>
<SO>Chinese Ophthalmic Research [Yanke Yan Jiu]</SO>
<YR>1992</YR>
<VL>19</VL>
<NO>2</NO>
<PG>38-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1995" MODIFIED="2014-12-07 16:32:28 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-12-07 16:32:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Li X, Li X, Liang Q, Xiang Y</AU>
<TI>Clinical observations on herpes simplex keratitis treated with qing gan xie huo decoction</TI>
<TO>&#28165;&#32925;&#27899;&#28779;&#27748;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Bulletin of Hunan Medical University [Hunan Yike Daxue Xuebao]</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>5</NO>
<PG>439-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-1997" MODIFIED="2014-12-07 16:33:10 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-12-07 16:33:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang H, Song HW, Guo RX, Sun NX</AU>
<TI>Detection of subtribe of T-lymphocyte before and after traditional Chinese medicine treatment in simple herpetic keratitis with applied OKT-McAb</TI>
<TO>&#24212;&#29992;OKT&#21333;&#20811;&#38534;&#25239;&#20307;&#26816;&#27979;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20013;&#33647;&#27835;&#30103;&#21069;&#21518;&#22806;&#21608;&#34880;T&#32454;&#32990;&#20122;&#32676;</TO>
<SO>Journal of Xi'an Medical University [Xi'an Yike Daxue Xuebao]</SO>
<YR>1997</YR>
<VL>18</VL>
<NO>4</NO>
<PG>433-5, 452</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2003" MODIFIED="2013-11-04 19:16:46 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhang 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-11-04 19:16:46 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang XF, Li WH, Zhang JM, Yao J, Yang J, Sheng W</AU>
<TI>The comparison of interferon-&#945;-1b and interferon-&#945;-2b on the treatment of herpes simplex virus keratitis</TI>
<TO>&#945;1b&#12289;&#945;2b&#22411;&#24178;&#25200;&#32032;&#28404;&#30524;&#21058;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#23545;&#27604;&#30740;&#31350;</TO>
<SO>Chinese Journal of Practical Ophthalmology [Zhongguo Shiyong Erke Zazhi]</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>828-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2008" MODIFIED="2014-12-07 16:33:52 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhang 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-07 16:33:52 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang P</AU>
<TI>Integrated treatment of Chinese and Western medicine of 100 patients with herpes simplex virus keratitis</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;100&#20363;</TO>
<SO>Chinese Archives of Traditional Chinese Medicine [Zhonghua Zhongyiyao Xuekan]</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1595-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2010" MODIFIED="2014-12-07 16:36:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhang 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-12-07 16:36:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YY, Chen GY</AU>
<TI>Effect of combined treatment of traditional Chinese medicine and western medicine on recurrent herpes simplex keratitis</TI>
<TO>&#22797;&#21457;&#24615;&#21333;&#32431;&#30165;&#33678;&#24615;&#35282;&#33180;&#28814;&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#30340;&#30103;&#25928;&#20998;&#26512;</TO>
<SO>Journal of Jinggangshan University (Natural Science) [Jinggangshan Daxue Xuebao (Ziranban)]</SO>
<YR>2010</YR>
<VL>6</VL>
<NO>1</NO>
<PG>106-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2001" MODIFIED="2014-12-07 16:07:33 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-12-07 16:07:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao X, Feng Y, Ding Y, Guo Y, Tang Y, Feng D</AU>
<TI>Clinical observation of the effect of acyclovir with interferon and diclofenac on treatment of herpes simplex keratitis</TI>
<TO>&#26080;&#29615;&#40479;&#33527;&#32852;&#21512;&#24178;&#25200;&#32032;&#12289;&#21452;&#27695;&#33452;&#37240;&#38048;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Journal of Clinical Ophthalmology [Linchuang Yanke Zazhi]</SO>
<YR>2001</YR>
<VL>9</VL>
<NO>5</NO>
<PG>400-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2007" MODIFIED="2014-12-06 21:54:04 +0000" MODIFIED_BY="[Empty name]" NAME="Zhao 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-06 21:54:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao Y, Wu L, Liang Q</AU>
<TI>Clinical observation of herpes simplex keratitis during treatment with yinhuang eye drop</TI>
<TO>&#38134;&#40644;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Journal of Traditional Chinese Ophthalmology [Zhongguo Zhongyi Yanke Zazhi]</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>8</NO>
<PG>187-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2010" MODIFIED="2013-11-04 19:27:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhao 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-11-04 19:27:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao AX, Sun MQ, Sun HY</AU>
<TI>Chinese medicine combined with eyebrow injection in the treatment of 54 cases of recurrent herpes simplex keratitis</TI>
<TO>&#20013;&#33647;&#32467;&#21512;&#30473;&#24339;&#27880;&#23556;&#27835;&#30103;&#22797;&#21457;&#24615;&#21333;&#30129;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;54 &#20363;</TO>
<SO>Chinese Journal of Experimental Traditional Medical Formulae [Zhongguo Shiyan Fangjixue Zazhi]</SO>
<YR>2010</YR>
<VL>16</VL>
<NO>8</NO>
<PG>206-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhao-2013" MODIFIED="2014-11-30 00:11:10 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhao 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-11-30 00:11:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhao SQ, Zhao L, Sun ZX</AU>
<TI>Randomized controlled research of herpes simplex keratitis treated with modified yupingfeng powder</TI>
<TO>&#29577;&#23631;&#39118;&#25955;&#21152;&#21619;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#38543;&#26426;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>World Journal of Integrated Traditional and Western Medicine [Shijie Zhongxiyi Jiehe Zazhi]</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>8</NO>
<PG>812-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2008" MODIFIED="2014-12-06 21:56:05 +0000" MODIFIED_BY="[Empty name]" NAME="Zheng 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-12-06 21:56:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng LM, Cai HY, Lin RS</AU>
<TI>Therapeutic effect of Chinese medicine combined with iontophoresis of <I>Radix astragali</I> for herpes simplex keratitis</TI>
<TO>&#35266;&#23519;&#20013;&#33647;&#37197;&#21512;&#30005;&#31163;&#23376;&#23548;&#20837;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#30103;&#25928;</TO>
<SO>Journal of Guangzhou University of Traditional Chinese Medicine [Guangzhou Zhong Yiyao Daxue Xuebao]</SO>
<YR>2008</YR>
<VL>25</VL>
<NO>4</NO>
<PG>289-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zheng-2014" MODIFIED="2014-12-07 16:39:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zheng 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-12-07 16:39:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zheng HY</AU>
<TI>Effects observation on treating 45 cases of herpes simplex in the integrative medicine</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;45&#20363;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>Clinical Journal of Chinese Medicine [Zhongyi Linchuang Yanjiu]</SO>
<YR>2014</YR>
<VL>6</VL>
<NO>7</NO>
<PG>100-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhi-2001" MODIFIED="2013-11-04 19:19:28 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhi 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-11-04 19:19:28 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhi S, Yang F, Liang C, Sun X</AU>
<TI>Clinical study of curing herpes simplex keratitis with recombinant lL-2</TI>
<TO>rIL-2&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Chinese Journal of Practical Ophthalmology [Zhongguo Shiyong Yanke Zazhi]</SO>
<YR>2001</YR>
<VL>19</VL>
<NO>8</NO>
<PG>604-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhong-2003" MODIFIED="2014-12-07 16:40:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Zhong 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-12-07 16:40:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhong LY, Wang XM, Lai J, Liu YQ</AU>
<TI>Ultrasonic nebulization of reduqing eye drop in clinical treatment of herpes simplex keratitis</TI>
<TO>&#28909;&#27602;&#28165;&#30524;&#33647;&#27700;&#38654;&#21270;&#27835;&#30103;&#21333;&#30129;&#24615;&#35282;&#33180;&#28814;&#20020;&#24202;&#30740;&#31350;</TO>
<SO>Bulletin of the Academy of Military Medical Sciences [Junshi Yixue Kexueyuan Yuankan]</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2007" MODIFIED="2014-12-06 21:58:52 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhou 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-12-06 21:58:52 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou LS, Wu DL</AU>
<TI>Clinical observation on the treatment of 38 cases of herpes simplex virus keratitis with atomization of traditional Chinese medicine and acyclovir</TI>
<TO>&#20013;&#33647;&#38654;&#21270;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;38&#20363;&#20020;&#24202;&#35266;&#23519;</TO>
<SO>Guiding Journal of Traditional Chinese Medicine and Pharmacy [Zhong Yi Yao Dao Bao]</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>11</NO>
<PG>44-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2008" MODIFIED="2013-11-04 19:20:18 +0000" MODIFIED_BY=" Iris Gordon" NAME="Zhou 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-11-04 19:20:18 +0000" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Q, Chen K, Fang L, Yu J, Yue X</AU>
<TI>Interferon combined with acyclovir for herpes simplex keratitis</TI>
<TO>&#24178;&#25200;&#32032;&#32852;&#21512;&#26080;&#29615;&#40479;&#33527;&#28404;&#30524;&#28082;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;</TO>
<SO>Chinese Journal of General Practice [Zhongguo Quanke Yixue]</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>10</NO>
<PG>1009-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zirm-1981" MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" NAME="Zirm 1981" YEAR="1981">
<REFERENCE MODIFIED="2010-11-03 11:27:54 +0000" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="BOOK_SECTION">
<AU>Zirm M, Söser M, Ogriseg M</AU>
<TI>Dendritic keratitis&#8212;a comparison of different therapy forms with special emphasis on antibody-therapy</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>365-72</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-08-26 15:52:14 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ajanta-Pharma-2013" MODIFIED="2013-08-15 18:03:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Ajanta Pharma 2013" YEAR="2013">
<REFERENCE MODIFIED="2013-08-15 18:03:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Singh S</AU>
<TI>A clinical trial in patients with herpes keratitis: clinical trial is to study efficacy, safety and tolerability of ganciclovir ophthalmic gel 0.15% vs acyclovir ophthalmic ointment 3% in patients with herpes keratitis</TI>
<SO>Ajanta Pharma Ltd (protocol APL/CT/09/031)</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2013-08-15 18:03:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<IDENTIFIER MODIFIED="2013-08-15 18:03:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" TYPE="OTHER" VALUE="CTRI/2010/091/000198"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bausch-_x0026_-Lomb-2003" MODIFIED="2014-08-26 15:52:14 +0100" MODIFIED_BY="[Empty name]" NAME="Bausch &amp; Lomb 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-08-26 15:52:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Anonymous</AU>
<TI>Safety and efficacy of cidofovir topical ophthalmic solution in the treatment of unilateral epithelial keratitis due to HSV: comparative study between cidofovir (0.3% and 0.5%) vs Viroptic 1%</TI>
<SO>Unpublished clinical trial sponsored by Bausch and Lomb and Gilead Sciences</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-04 20:54:38 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-04 20:54:38 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AAO-2013" MODIFIED="2014-08-26 15:59:43 +0100" MODIFIED_BY="[Empty name]" NAME="AAO 2013" TYPE="OTHER">
<AU>American Academy of Ophthalmology</AU>
<TI>Herpes simplex virus epithelial keratitis&#65293;2013</TI>
<SO>one.aao.org/clinical-questions/herpes-simplex-virus-epithelial-keratitis</SO>
<YR>(accessed 21 August 2013)</YR>
<IDENTIFIERS MODIFIED="2014-08-26 15:55:16 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Adhin-2012" MODIFIED="2013-08-08 15:37:11 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Adhin 2012" TYPE="JOURNAL_ARTICLE">
<AU>Adhin MR, Grunberg MG, Labadie-Bracho M, Pawiroredjo J</AU>
<TI>Incidence of alpha-herpes virus induced ocular disease in Suriname</TI>
<SO>Journal of Medical Virology</SO>
<YR>2012</YR>
<VL>84</VL>
<NO>12</NO>
<PG>1937-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ahrens-2013" MODIFIED="2014-12-27 20:08:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Ahrens 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ahrens KA, Anderka MT, Feldkamp ML, Canfield MA, Mitchell AA, Werler MM, et al</AU>
<TI>Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007</TI>
<SO>Pediatric and Perinatal Epidemiology</SO>
<YR>2013</YR>
<VL>27</VL>
<NO>4</NO>
<PG>340-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alarc_x00f3_n-1984" MODIFIED="2014-08-26 16:01:16 +0100" MODIFIED_BY="[Empty name]" NAME="Alarcón 1984" TYPE="JOURNAL_ARTICLE">
<AU>Alarcón B, González ME, Carrasco L</AU>
<TI>Antiherpesvirus action of atropine</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>1984</YR>
<VL>26</VL>
<NO>5</NO>
<PG>702-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aldave-2007" MODIFIED="2014-08-26 16:02:02 +0100" MODIFIED_BY="[Empty name]" NAME="Aldave 2007" TYPE="JOURNAL_ARTICLE">
<AU>Aldave AJ, Nguyen A</AU>
<TI>Ocular surface toxicity associated with topical interferon &#945;-2b</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2007</YR>
<VL>91</VL>
<NO>8</NO>
<PG>1087-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alm-2008" MODIFIED="2010-11-06 09:16:17 +0000" MODIFIED_BY="[Empty name]" NAME="Alm 2008" TYPE="JOURNAL_ARTICLE">
<AU>Alm A, Grierson I, Shields MB</AU>
<TI>Side effects associated with prostaglandin analog therapy</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2008</YR>
<VL>53 Suppl 1</VL>
<PG>93-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ambr_x00f3_sio-2001" MODIFIED="2014-08-26 16:03:40 +0100" MODIFIED_BY="[Empty name]" NAME="Ambrósio 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ambrósio Jr R, Moro F, Fonseca VC, Noleto S, Cvintal T</AU>
<TI>Herpetic keratitis after penetrating keratoplasty for cases not related to herpes simplex infection</TI>
<TO>Ceratite herpética em transplante de córnea por causas não ligadas ao Herpes</TO>
<SO>Revista Brasileira de Oftalmologia</SO>
<YR>2001</YR>
<VL>60</VL>
<NO>11</NO>
<PG>828-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ashaye-2008" MODIFIED="2014-08-26 16:04:39 +0100" MODIFIED_BY="[Empty name]" NAME="Ashaye 2008" TYPE="JOURNAL_ARTICLE">
<AU>Ashaye A, Aimola A</AU>
<TI>Keratitis in children as seen in a tertiary hospital in Africa</TI>
<SO>Journal of the National Medical Association</SO>
<YR>2008</YR>
<VL>100</VL>
<NO>4</NO>
<PG>386-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barker-2008" MODIFIED="2010-06-24 18:08:47 +0100" MODIFIED_BY="[Empty name]" NAME="Barker 2008" TYPE="OTHER">
<AU>Barker NH</AU>
<TI>Ocular herpes simplex</TI>
<SO>BMJ Clinical Evidence</SO>
<YR>2008</YR>
<VL>0707</VL>
<IDENTIFIERS MODIFIED="2010-06-24 18:08:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-24 18:08:47 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="www.clinicalevidence.bmj.com"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1985" MODIFIED="2010-05-25 17:24:28 +0100" MODIFIED_BY="[Empty name]" NAME="Bauer 1985" TYPE="JOURNAL_ARTICLE">
<AU>Bauer DJ</AU>
<TI>A history of the discovery and clinical application of antiviral drugs</TI>
<SO>British Medical Bulletin</SO>
<YR>1985</YR>
<VL>41</VL>
<PG>309-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Behrens_x002d_Baumann-2010" MODIFIED="2010-09-07 23:10:45 +0100" MODIFIED_BY="[Empty name]" NAME="Behrens-Baumann 2010" TYPE="JOURNAL_ARTICLE">
<AU>Behrens-Baumann W</AU>
<TI>Herpes simplex keratitis. A short overview of current therapy</TI>
<TO>Herpes-simplex-Keratitis. Ein kurzer Überblick zur aktuellen Therapie</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>2010</YR>
<VL>227</VL>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhatt-2009" MODIFIED="2010-02-18 15:49:00 +0000" MODIFIED_BY="[Empty name]" NAME="Bhatt 2009" TYPE="COCHRANE_PROTOCOL">
<AU>Bhatt UK, Abdul Karim MN, Prydal JI</AU>
<TI>Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-02-18 15:49:00 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-02-18 15:49:00 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD007824"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bierly-1994" MODIFIED="2010-11-06 09:17:17 +0000" MODIFIED_BY="[Empty name]" NAME="Bierly 1994" TYPE="JOURNAL_ARTICLE">
<AU>Bierly JR, Ostler HB</AU>
<TI>Varicella dendritic keratitis</TI>
<SO>Journal of Pediatric Ophthalmology and Strabismus</SO>
<YR>1994</YR>
<VL>31</VL>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boisjoly-1983" MODIFIED="2010-09-13 21:17:35 +0100" MODIFIED_BY="[Empty name]" NAME="Boisjoly 1983" TYPE="JOURNAL_ARTICLE">
<AU>Boisjoly HM, Pavan-Langston D, Kenyon KR, Backer AS</AU>
<TI>Superinfections in herpes simplex keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1983</YR>
<VL>96</VL>
<PG>354-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borderie-2004" MODIFIED="2010-10-31 19:20:19 +0000" MODIFIED_BY=" Iris Gordon" NAME="Borderie 2004" TYPE="JOURNAL_ARTICLE">
<AU>Borderie VM, Méritet JF, Chaumeil C, Rozenberg F, Baudrimont M, Touzeau O, et al</AU>
<TI>Culture-proven herpetic keratitis after penetrating keratoplasty in patients with no previous history of herpes disease</TI>
<SO>Cornea</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>118-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Borkar-2014" MODIFIED="2014-08-26 16:07:12 +0100" MODIFIED_BY="[Empty name]" NAME="Borkar 2014" TYPE="JOURNAL_ARTICLE">
<AU>Borkar DS, Gonzales JA, Tham VM, Esterberg E, Vinoya AC, Parker JV, et al</AU>
<TI>Association between atopy and herpetic eye disease: results from the Pacific Ocular Inflammation Study</TI>
<SO>JAMA Ophthalmology</SO>
<YR>2014</YR>
<VL>132</VL>
<NO>3</NO>
<PG>326-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boto_x002d_de_x002d_los_x002d_Bueis-2013" MODIFIED="2014-11-29 17:21:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Boto-de-los-Bueis 2013" TYPE="JOURNAL_ARTICLE">
<AU>Boto-de-los-Bueis A, Romero Gómez MP, del Hierro Zarzuelo A, Sanchez EG, Mediero S, Noval S</AU>
<TI>Recurrent ocular surface inflammation associated with human herpesvirus 6 infection</TI>
<SO>Eye &amp; Contact Lens</SO>
<YR>2014</YR>
<VL>40</VL>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brandt-2005" MODIFIED="2010-09-13 21:38:51 +0100" MODIFIED_BY="[Empty name]" NAME="Brandt 2005" TYPE="JOURNAL_ARTICLE">
<AU>Brandt CR</AU>
<TI>The role of viral and host genes in corneal infection with herpes simplex virus type 1</TI>
<SO>Experimental Eye Research</SO>
<YR>2005</YR>
<VL>80</VL>
<PG>607-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1997" MODIFIED="2008-11-06 19:30:52 +0000" MODIFIED_BY="Anupa Shah" NAME="Bucher 1997" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Guyatt GH, Griffith LE, Walter SD</AU>
<TI>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1997</YR>
<VL>50</VL>
<PG>683-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burrel-2013" MODIFIED="2014-08-26 16:08:12 +0100" MODIFIED_BY="[Empty name]" NAME="Burrel 2013" TYPE="JOURNAL_ARTICLE">
<AU>Burrel S, Boutolleau D, Azar G, Doan S, Deback C, Cochereau I, et al</AU>
<TI>Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2013</YR>
<VL>58</VL>
<NO>1</NO>
<PG>321-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Callaghan-2006" MODIFIED="2010-06-10 00:39:51 +0100" MODIFIED_BY="[Empty name]" NAME="Callaghan 2006" TYPE="JOURNAL_ARTICLE">
<AU>Callaghan T, Khain E, Sander LM, Ziff RM</AU>
<TI>A stochastic model for wound healing</TI>
<SO>Journal of Statistical Physics</SO>
<YR>2006</YR>
<VL>122</VL>
<PG>909-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campoli_x002d_Richards-1986" MODIFIED="2014-08-26 16:09:38 +0100" MODIFIED_BY="[Empty name]" NAME="Campoli-Richards 1986" TYPE="JOURNAL_ARTICLE">
<AU>Campoli-Richards DM, Sorkin EM, Heel RC</AU>
<TI>Insoine pranobex: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy</TI>
<SO>Drugs</SO>
<YR>1986</YR>
<VL>32</VL>
<NO>5</NO>
<PG>383-424</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cantell-1995" MODIFIED="2009-03-10 18:02:50 +0000" MODIFIED_BY="[Empty name]" NAME="Cantell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Cantell K</AU>
<TI>Development of antiviral therapy with alpha interferons: promises, false hopes, and accomplishments</TI>
<SO>Annals of Medicine</SO>
<YR>1995</YR>
<VL>27</VL>
<PG>23-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carmine-1982" MODIFIED="2008-11-06 19:30:58 +0000" MODIFIED_BY="Anupa Shah" NAME="Carmine 1982" TYPE="JOURNAL_ARTICLE">
<AU>Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS</AU>
<TI>Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections</TI>
<SO>Drugs</SO>
<YR>1982</YR>
<VL>23</VL>
<PG>329-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cernik-2008" MODIFIED="2010-09-13 23:04:28 +0100" MODIFIED_BY="[Empty name]" NAME="Cernik 2008" TYPE="JOURNAL_ARTICLE">
<AU>Cernik C, Gallina K, Brodell RT</AU>
<TI>The treatment of herpes simplex infections: an evidence-based review</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2008</YR>
<VL>168</VL>
<PG>1137-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaimani-2013" MODIFIED="2014-08-26 16:10:21 +0100" MODIFIED_BY="[Empty name]" NAME="Chaimani 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chaimani A, Higgins JPT, Mavridis D, Spyridonos P, Salanti G</AU>
<TI>Graphical tools for network meta-analysis in STATA</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>10</NO>
<PG>e76654</PG>
<IDENTIFIERS MODIFIED="2014-08-26 16:10:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chanzy-2002" MODIFIED="2010-06-01 23:08:49 +0100" MODIFIED_BY="[Empty name]" NAME="Chanzy 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chanzy B, Braig S, Morand P</AU>
<TI>Debates and updates regarding the virologic diagnosis of herpes</TI>
<TO>Débats et actualités dans le diagnostic virologique de l'herpès</TO>
<SO>Pathologie Biologie</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>419-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chen-1989" MODIFIED="2014-12-07 16:43:02 +0000" MODIFIED_BY=" Iris Gordon" NAME="Chen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Chen CW</AU>
<TI>Adverse side effects caused by topically applied antiviral agents in herpetic keratitis</TI>
<TO>&#25239;&#30149;&#27602;&#34277;&#29289;&#23565;&#21934;&#32020;&#30129;&#30137;&#35282;&#33180;&#28814;&#27835;&#30274;&#20043;&#21103;&#20316;&#29992;</TO>
<SO>Kaohsiung Journal of Medical Sciences [Gaoxiong Yixue Kexue Zazhi]</SO>
<YR>1989</YR>
<VL>5</VL>
<NO>8</NO>
<PG>416-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chentoufi-2012" MODIFIED="2014-08-26 16:11:21 +0100" MODIFIED_BY="[Empty name]" NAME="Chentoufi 2012" TYPE="JOURNAL_ARTICLE">
<AU>Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, BenMohamed L</AU>
<TI>Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown</TI>
<SO>Clinical and Developmental Immunology</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>187585</PG>
<IDENTIFIERS MODIFIED="2014-08-26 16:11:21 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Chodosh-1995" MODIFIED="2010-02-15 15:32:32 +0000" MODIFIED_BY="[Empty name]" NAME="Chodosh 1995" TYPE="JOURNAL_ARTICLE">
<AU>Chodosh J, Miller D, Stroop WG, Pflugfelder SC</AU>
<TI>Adenovirus epithelial keratitis</TI>
<SO>Cornea</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>167-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Choong-2010" MODIFIED="2010-06-08 20:19:38 +0100" MODIFIED_BY="[Empty name]" NAME="Choong 2010" TYPE="JOURNAL_ARTICLE">
<AU>Choong K, Walker NJ, Apel AJG, Whitby M</AU>
<TI>Aciclovir-resistant herpes keratitis</TI>
<SO>Clinical and Experimental Ophthalmology</SO>
<YR>2010</YR>
<VL>38</VL>
<PG>309-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chou-2014" MODIFIED="2014-10-28 15:46:29 +0000" MODIFIED_BY="[Empty name]" NAME="Chou 2014" TYPE="JOURNAL_ARTICLE">
<AU>Chou TY, Hong B</AU>
<TI>Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications</TI>
<SO>Therapeutics and Clinical Risk Management</SO>
<YR>2014</YR>
<VL>10</VL>
<PG>665-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chung-1998" MODIFIED="2010-06-09 22:44:36 +0100" MODIFIED_BY="[Empty name]" NAME="Chung 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chung JH</AU>
<TI>Correlation between epithelial healing rate and initial wound size in contact lens-induced central epithelial abrasion</TI>
<SO>Ophthalmologica</SO>
<YR>1998</YR>
<VL>212</VL>
<PG>46-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chung-2004" MODIFIED="2010-03-22 18:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Chung 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chung CY, Kwok AKH, Chung KL</AU>
<TI>Use of ophthalmic medications during pregnancy</TI>
<SO>Hong Kong Medical Journal</SO>
<YR>2004</YR>
<VL>10</VL>
<PG>191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coster-1977b" MODIFIED="2008-11-06 19:31:04 +0000" MODIFIED_BY="Anupa Shah" NAME="Coster 1977b" TYPE="JOURNAL_ARTICLE">
<AU>Coster DJ, Jones BR, Falcon MG</AU>
<TI>Role of debridement in the treatment of herpetic keratitis</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>314-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Croxtall-2011" MODIFIED="2013-11-26 22:12:54 +0000" MODIFIED_BY="[Empty name]" NAME="Croxtall 2011" TYPE="JOURNAL_ARTICLE">
<AU>Croxtall JD</AU>
<TI>Ganciclovir ophthalmic gel 0.15%: in acute herpetic keratitis (dendritic ulcers)</TI>
<SO>Drugs</SO>
<YR>2011</YR>
<VL>71</VL>
<NO>5</NO>
<PG>603-10</PG>
<IDENTIFIERS MODIFIED="2013-11-26 22:12:54 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dantas-1997" MODIFIED="2014-08-26 16:26:12 +0100" MODIFIED_BY="[Empty name]" NAME="Dantas 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dantas PEC, Dantas MCN, Holzchuchk N</AU>
<TI>Recurrence of corneal herpetic disease after argon laser treatment</TI>
<TO>Recorrência de doença herpética corneal após tratamento para neovascularizaçäo de córnea com argon laser</TO>
<SO>Arquivos Brasileiros de Oftalmologia</SO>
<YR>1997</YR>
<VL>60</VL>
<NO>1</NO>
<PG>103-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Darougar-1985" MODIFIED="2014-08-26 16:27:10 +0100" MODIFIED_BY="[Empty name]" NAME="Darougar 1985" TYPE="JOURNAL_ARTICLE">
<AU>Darougar S, Wishart MS, Viswalingam ND</AU>
<TI>Epidemiological and clinical features of primary herpes simplex virus ocular infection</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1985</YR>
<VL>69</VL>
<NO>1</NO>
<PG>2-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Clerq-2005" MODIFIED="2010-06-01 15:29:04 +0100" MODIFIED_BY="[Empty name]" NAME="De Clerq 2005" TYPE="JOURNAL_ARTICLE">
<AU>De Clerq E</AU>
<TI>(E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)</TI>
<SO>Medical Research Reviews</SO>
<YR>2005</YR>
<VL>25</VL>
<PG>1-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-la-Parra-2013" MODIFIED="2013-08-08 16:34:36 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="de la Parra 2013" TYPE="COCHRANE_PROTOCOL">
<AU>de la Parra-Colin P, Garza-Leon M, Ortiz-Nieva G, Barrientos-Gutierrez T, Lindsley K</AU>
<TI>Oral antivirals for preventing recurrence of herpes simplex virus keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2013-08-08 16:34:36 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<IDENTIFIER MODIFIED="2013-08-08 16:34:27 +0100" MODIFIED_BY="Kirk R. Wilhelmus" TYPE="DOI" VALUE="10.1002/14651858.CD010556"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2002" MODIFIED="2010-06-11 23:21:23 +0100" MODIFIED_BY="[Empty name]" NAME="Deeks 2002" TYPE="JOURNAL_ARTICLE">
<AU>Deeks JJ</AU>
<TI>Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1575-600</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-2011" MODIFIED="2014-12-07 16:44:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Di 2011" TYPE="JOURNAL_ARTICLE">
<AU>Di Y, Zhang Y</AU>
<TI>Diagnosis and treatment of herpetic keratitis after laser-assisted sub-epithelial keratomileusis</TI>
<TO>LASEK &#26415;&#21518;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#35786;&#26029;&#21450;&#27835;&#30103;</TO>
<SO>Recent Advances in Ophthalmology [Yanke Xin Jinzhan]</SO>
<YR>2011</YR>
<VL>22</VL>
<NO>10</NO>
<PG>948-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Du-2010" MODIFIED="2013-11-04 19:13:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Du 2010" TYPE="JOURNAL_ARTICLE">
<AU>Du ZN, Yang YY, Zhu QW</AU>
<TI>Six cases of cataract surgery complicated by herpes simplex keratitis</TI>
<TO>&#30333;&#20869;&#38556;&#26415;&#21518;&#24182;&#21457;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;6&#20363;</TO>
<SO>Chinese Journal of Ophthalmology and Otorhinolaryngology [Zhongguo Yan Er Bi Houke Zazhi]</SO>
<YR>2010</YR>
<VL>10</VL>
<NO>4</NO>
<PG>238</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Duan-2009" MODIFIED="2010-10-31 19:23:16 +0000" MODIFIED_BY=" Iris Gordon" NAME="Duan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Duan R, de Vries RD, van Dun JM, van Leonen FB, Osterhaus ADME, Remeijer L, et al</AU>
<TI>Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2009</YR>
<VL>200</VL>
<PG>1402-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elbadawy-2012" MODIFIED="2014-12-27 20:35:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Elbadawy 2012" TYPE="JOURNAL_ARTICLE">
<AU>Elbadawy HM, Gailledrat M, Desseaux C, Ponzin D, Ferrari S</AU>
<TI>Targeting herpetic keratitis by gene therapy</TI>
<SO>Journal of Ophthalmology</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>594869</PG>
<IDENTIFIERS MODIFIED="2014-12-27 20:35:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<IDENTIFIER MODIFIED="2014-12-27 20:35:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus" TYPE="DOI" VALUE="dx.doi.org/10.1155/2012/594869"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Emmert-1885" MODIFIED="2014-12-26 22:29:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Emmert 1885" TYPE="JOURNAL_ARTICLE">
<AU>Emmert E</AU>
<TI>Keratitis dendritica exulcdrans mycotica: an undescribed form of ulcerative keratitis</TI>
<TO>Keratitis dendritica exulcerans mycotica: Eine noch nicht beschriebene Form ulcerirender Hornhautentzündung</TO>
<SO>Zentralblatt für praktische Augenheilkunde</SO>
<YR>1885</YR>
<VL>9</VL>
<PG>302-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Epstein-1989" MODIFIED="2010-06-03 15:56:59 +0100" MODIFIED_BY="[Empty name]" NAME="Epstein 1989" TYPE="BOOK_SECTION">
<AU>Epstein RJ, Wilhelmus KR</AU>
<TI>Dendritic keratitis&#8212;will wiping it off wipe it out?</TI>
<SO>Ophthalmic Clinical Debates</SO>
<YR>1989</YR>
<PG>85-99</PG>
<ED>Deutsch TA</ED>
<PB>Year Book Medical Publishers</PB>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Falcon-1981" MODIFIED="2010-06-17 17:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="Falcon 1981" TYPE="BOOK_SECTION">
<AU>Falcon MG, Jones BR, Williams HP, Wilhelmus K, Coster DJ</AU>
<TI>Adverse reactions in the eye from topical therapy with idoxuridine, adenine arabinoside and trifluorothymidine</TI>
<SO>Herpetische Augenerkrankungen</SO>
<YR>1981</YR>
<PG>263-8</PG>
<ED>Sundmacher R</ED>
<PB>JF Bergmann Verlag</PB>
<CY>München</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farhatullah-2004" MODIFIED="2014-08-27 15:00:19 +0100" MODIFIED_BY=" Iris Gordon" NAME="Farhatullah 2004" TYPE="JOURNAL_ARTICLE">
<AU>Farhatullah S, Kaza S, Athmanathan S, Garg P, Reddy SB, Sharma S</AU>
<TI>Diagnosis of herpes simplex virus-1 keratitis using Giemsa stain, immunofluorescence assay, and polymerase chain reaction assay on corneal scrapings</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>88</VL>
<NO>1</NO>
<PG>142-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farooq-2012" MODIFIED="2014-08-27 15:04:23 +0100" MODIFIED_BY=" Iris Gordon" NAME="Farooq 2012" TYPE="JOURNAL_ARTICLE">
<AU>Farooq AV, Shukla D</AU>
<TI>Herpes simplex epithelial and stromal keratitis: an epidemiologic update</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>5</NO>
<PG>448-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felton-1992" MODIFIED="2014-08-27 15:05:38 +0100" MODIFIED_BY=" Iris Gordon" NAME="Felton 1992" TYPE="JOURNAL_ARTICLE">
<AU>Felton DT</AU>
<TI>Bias in meta-analytic research</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<NO>8</NO>
<PG>885-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Field-1995" MODIFIED="2013-08-08 17:07:55 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Field 1995" TYPE="JOURNAL_ARTICLE">
<AU>Field AJ, Gottsch JD</AU>
<TI>Persisting epithelial herpes simplex keratitis while on cyclosporin-A ointment</TI>
<SO>Australian and New Zealand Journal of Ophthalmology</SO>
<YR>1995</YR>
<VL>23</VL>
<NO>4</NO>
<PG>333-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Friedenwald-1900" MODIFIED="2010-05-25 17:03:42 +0100" MODIFIED_BY="[Empty name]" NAME="Friedenwald 1900" TYPE="JOURNAL_ARTICLE">
<AU>Friedenwald H</AU>
<TI>On the treatment of dendritic keratitis and of marginal ulcer of the cornea with tincture of iodine</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1900</YR>
<VL>9</VL>
<PG>129-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Medina-2011" MODIFIED="2015-01-04 15:58:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Garcia-Medina 2011" TYPE="JOURNAL_ARTICLE">
<AU>Garcia-Medina JJ, del-Rio-Vellosillo M, Garcia-Medina M</AU>
<TI>Herpetic blepharitis and inhaled budesonide</TI>
<SO>Ophthalmology</SO>
<YR>2011</YR>
<VL>118</VL>
<NO>12</NO>
<PG>2520.e5-7</PG>
<IDENTIFIERS MODIFIED="2015-01-04 15:58:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<IDENTIFIER MODIFIED="2015-01-04 15:58:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" TYPE="DOI" VALUE="10.1016/j.ophtha.2011.07.054"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Glenny-2005" MODIFIED="2010-10-31 19:24:29 +0000" MODIFIED_BY=" Iris Gordon" NAME="Glenny 2005" TYPE="JOURNAL_ARTICLE">
<AU>Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al</AU>
<TI>Indirect comparisons of competing interventions</TI>
<SO>Health Technology Assessment</SO>
<YR>2005</YR>
<VL>9</VL>
<PG>1-134</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gold-1965" MODIFIED="2013-08-08 17:21:52 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gold 1965" TYPE="JOURNAL_ARTICLE">
<AU>Gold JA, Stewart RC, McKee J</AU>
<TI>The epidemiology and chemotherapy of herpes simplex keratitis and herpes simplex skin infections</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1965</YR>
<VL>130</VL>
<NO>1</NO>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldschmidt-2006" MODIFIED="2014-08-27 15:08:29 +0100" MODIFIED_BY=" Iris Gordon" NAME="Goldschmidt 2006" TYPE="JOURNAL_ARTICLE">
<AU>Goldschmidt P, Rostane H, Saint-Jean C, Batellier L, Alouch C, Zito E, et al</AU>
<TI>Effects of topical anaesthetics and fluorescein on the real-time PCR used for the diagnosis of <I>Herpesviruses</I> and <I>Acanthamoeba</I> keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>90</VL>
<NO>11</NO>
<PG>1354-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gordon-2000" NAME="Gordon 2000" TYPE="JOURNAL_ARTICLE">
<AU>Gordon YJ</AU>
<TI>The evolution of antiviral therapy for external ocular viral infections over twenty-five years</TI>
<SO>Cornea</SO>
<YR>2000</YR>
<VL>19</VL>
<PG>673-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gr_x00fc_ter-1920" MODIFIED="2010-06-01 15:25:44 +0100" MODIFIED_BY="[Empty name]" NAME="Grüter 1920" TYPE="JOURNAL_ARTICLE">
<AU>Grüter W</AU>
<TI>Experimental and clinical studies on so-called corneal herpes</TI>
<TO>Experimentelle und klinische Untersuchungen über den sogenannten Herpes corneæ</TO>
<SO>Berichte über die Versammlung der Deutschen Ophthalmologischen Gesellschaft</SO>
<YR>1920</YR>
<VL>42</VL>
<PG>162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gu-2014" MODIFIED="2014-12-07 16:46:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gu 2014" TYPE="JOURNAL_ARTICLE">
<AU>Gu ZS, Lu SL</AU>
<TI>Observation on diagnosis and treatment of new-onset herpes simplex virus keratitis after cataract surgery</TI>
<TO>&#30333;&#20869;&#38556;&#26415;&#21518;&#21021;&#21457;&#24615;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#35786;&#30103;&#35266;&#23519;</TO>
<SO>Journal of Shanghai Jiaotong University (Medical Science) [Shanghai Jiaotong Daxue Xuebao (Yixue Ban)]</SO>
<YR>2014</YR>
<VL>34</VL>
<NO>5</NO>
<PG>677-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guess-2007" MODIFIED="2009-03-10 18:50:11 +0000" MODIFIED_BY="[Empty name]" NAME="Guess 2007" TYPE="JOURNAL_ARTICLE">
<AU>Guess S, Stone DU, Chodosh J</AU>
<TI>Evidence-based treatment of herpes simplex virus keratitis: a systematic review</TI>
<SO>The Ocular Surface</SO>
<YR>2007</YR>
<VL>5</VL>
<PG>240-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guess-2010" MODIFIED="2013-11-26 19:55:37 +0000" MODIFIED_BY="[Empty name]" NAME="Guess 2010" TYPE="JOURNAL_ARTICLE">
<AU>Guess SM, Butt AL, Neely SB, Wild RC, Chou AF, Chodosh J</AU>
<TI>Dissemination of knowledge from randomized clinical trials for herpes simplex virus keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2010</YR>
<VL>128</VL>
<NO>12</NO>
<PG>1624-5</PG>
<IDENTIFIERS MODIFIED="2013-11-26 19:55:37 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gulkilik-2007" MODIFIED="2013-08-08 18:05:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gulkilik 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gulkilik G, Demirci G, Ozdamar AM, Muftuoglu GT</AU>
<TI>A case of herpetic keratitis after intravitreal triamcinolone injection</TI>
<SO>Cornea</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>8</NO>
<PG>1000-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f3_mez-Garc_x00ed_a-2004" MODIFIED="2013-08-08 17:33:56 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Gómez García 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gómez García S, Piñero Bustamente AM, Gutiérrez Sánchez E, Piñero Bustamente A</AU>
<TI>Herpes simplex keratitis following laser in situ keratomileusis</TI>
<TO>Queratitis por herpes simplex tras laser in situ keratomileusis</TO>
<SO>Archivos de la Sociedad Española de Oftalmología</SO>
<YR>2004</YR>
<VL>79</VL>
<NO>3</NO>
<PG>139-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamoudi-2013" MODIFIED="2013-11-26 19:59:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Hamoudi 2013" TYPE="JOURNAL_ARTICLE">
<AU>Hamoudi H</AU>
<TI>Picture of the month: Epithelial herpes simplex virus keratitis</TI>
<TO>Månedens billede</TO>
<SO>Ugeskrift for Læger</SO>
<YR>2013</YR>
<VL>175</VL>
<PG>744</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamroush-2014" MODIFIED="2014-08-27 15:21:03 +0100" MODIFIED_BY=" Iris Gordon" NAME="Hamroush 2014" TYPE="JOURNAL_ARTICLE">
<AU>Hamroush A, Welch J</AU>
<TI>Herpes simplex epithelial keratitis associated with daily disposable contact lens wear</TI>
<SO>Contact Lens and Anterior Eye</SO>
<YR>2014</YR>
<VL>37</VL>
<NO>3</NO>
<PG>228-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-Grut-1886" MODIFIED="2014-12-26 22:10:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Hansen Grut 1886" TYPE="CONFERENCE_PROC">
<AU>Hansen Grut E</AU>
<TI>Two typical forms of keratitis</TI>
<TO>Sur deux formes typiques de kératite</TO>
<SO>Compte-Rendu: Congrès Périodique International des Sciences Médicales. 8me Session, Copenhague, 1884</SO>
<YR>1886</YR>
<VL>3</VL>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2008" MODIFIED="2014-08-27 15:23:13 +0100" MODIFIED_BY=" Iris Gordon" NAME="Harris 2008" TYPE="JOURNAL_ARTICLE">
<AU>Harris RJ, Bradburn MJ, Deeks JJ, Harbord RM, Altman DG, Sterne JAC</AU>
<TI>Metan: fixed- and random-effects meta-analysis</TI>
<SO>The Stata Journal</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>1</NO>
<PG>3-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hashizume-2009" MODIFIED="2010-02-15 15:53:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hashizume 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hashizume K, Nabeshima T, Fujiwara T, Machida S, Kurosaka D</AU>
<TI>A case of herpetic epithelial keratitis after triamcinolone acetonide subtenon injection</TI>
<SO>Cornea</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>463-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hassan-2009" MODIFIED="2013-11-26 22:13:10 +0000" MODIFIED_BY="[Empty name]" NAME="Hassan 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hassan M, Patel DK, Subrayan V</AU>
<TI>Primary herpes virus keratitis after penetrating keratoplasty</TI>
<SO>Annals of Ophthalmology</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>3-4</NO>
<PG>203-5</PG>
<IDENTIFIERS MODIFIED="2013-11-26 22:13:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hayashi-2008" MODIFIED="2014-08-27 15:25:41 +0100" MODIFIED_BY=" Iris Gordon" NAME="Hayashi 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hayashi T, Ishioka M, Ito N, Kato Y, Nakagawa H, Hatano H, et al</AU>
<TI>Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>2</NO>
<PG>457-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HEDS-Group-2000a" NAME="HEDS Group 2000a" TYPE="JOURNAL_ARTICLE">
<AU>Herpetic Eye Disease Study Group</AU>
<TI>Psychological stress and other potential triggers for recurrences of herpes simplex virus eye infections</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>1617-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HEDS-Group-2000b" NAME="HEDS Group 2000b" TYPE="JOURNAL_ARTICLE">
<AU>Herpetic Eye Disease Study Group</AU>
<TI>Oral acyclovir for herpes simplex virus eye disease: effect on prevention of epithelial keratitis and stromal keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2000</YR>
<VL>118</VL>
<PG>1030-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HEDS-Group-2001" NAME="HEDS Group 2001" TYPE="JOURNAL_ARTICLE">
<AU>Herpetic Eye Disease Study Group</AU>
<TI>Predictors of recurrent herpes simplex virus keratitis</TI>
<SO>Cornea</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>123-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hergeldzhieva-2012" MODIFIED="2014-09-26 12:27:05 +0100" MODIFIED_BY="[Empty name]" NAME="Hergeldzhieva 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hergeldzhieva T</AU>
<TI>Treatment: medical therapy</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2012</YR>
<VL>90</VL>
<NO>Suppl 249</NO>
<PG>0</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2010-06-01 16:30:15 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-03 22:58:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions, version 5.1.0 [updated March 2011]</SO>
<YR>2011. Available from www.cochrane-handbook.org</YR>
<PB>The Cochrane Collaboration</PB>
<IDENTIFIERS MODIFIED="2015-01-03 22:57:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus"/>
</REFERENCE>
<REFERENCE ID="REF-Hlinomazov_x00e1_-2012" MODIFIED="2013-11-26 22:13:45 +0000" MODIFIED_BY="[Empty name]" NAME="Hlinomazová 2012" TYPE="JOURNAL_ARTICLE">
<AU>Hlinomazová Z, Loukotová V, Horá&#269;ková M, &#352;erý O</AU>
<TI>The treatment of HSV1 ocular infections using quantitative real-time PCR results</TI>
<SO>Acta Ophthalmologica</SO>
<YR>2012</YR>
<VL>90</VL>
<NO>5</NO>
<PG>456-60</PG>
<IDENTIFIERS MODIFIED="2013-11-26 22:13:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Hodge-1997" MODIFIED="2010-10-31 19:28:26 +0000" MODIFIED_BY=" Iris Gordon" NAME="Hodge 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hodge WG, Margolis TP</AU>
<TI>Herpes simplex virus keratitis among patients who are positive or negative for human immunodeficiency virus: an epidemiologic study</TI>
<SO>Ophthalmology</SO>
<YR>1997</YR>
<VL>104</VL>
<PG>120-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horner-1871" MODIFIED="2014-04-27 20:03:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Horner 1871" TYPE="JOURNAL_ARTICLE">
<AU>Horner F</AU>
<TI>On corneal herpes</TI>
<TO>Ueber Herpes cornealis</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1871</YR>
<VL>9</VL>
<PG>321-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hosmer-2009" MODIFIED="2010-09-15 15:51:54 +0100" MODIFIED_BY="[Empty name]" NAME="Hosmer 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hosmer DW, Lemeshow S</AU>
<TI>Survival analysis: applications to ophthalmic research</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2009</YR>
<VL>147</VL>
<PG>957-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hou-2004" MODIFIED="2013-08-08 17:57:25 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Hou 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hou YC, Chen CC, Wang IJ, Hu FR</AU>
<TI>Recurrent herpetic keratouveitis following YAG laser peripheral iridotomy</TI>
<SO>Cornea</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>6</NO>
<PG>641-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hu-2010" MODIFIED="2010-06-17 17:22:55 +0100" MODIFIED_BY="[Empty name]" NAME="Hu 2010" TYPE="JOURNAL_ARTICLE">
<AU>Hu AY, Strauss EC, Holland GN, Chan MF, Yu F, Margolis TP</AU>
<TI>Late varicella-zoster virus dendriform keratitis in patients with histories of herpes zoster ophthalmicus</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2010</YR>
<VL>149</VL>
<PG>214-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inoue-2014" MODIFIED="2014-11-28 20:47:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Inoue 2014" TYPE="JOURNAL_ARTICLE">
<AU>Inoue H, Suzuki T, Joko T, Inoue T, Ohashi Y</AU>
<TI>A case of herpetic keratitis after subconjunctival triamcinolone acetonide injection</TI>
<SO>Case Reports in Ophthalmology</SO>
<YR>2014</YR>
<VL>5</VL>
<NO>3</NO>
<PG>277-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Itoi-1975" MODIFIED="2010-03-22 18:49:00 +0000" MODIFIED_BY="[Empty name]" NAME="Itoi 1975" TYPE="JOURNAL_ARTICLE">
<AU>Itoi M, Gefter JW, Kaneko N, Ishii Y, Ramer RM, Gasset AR</AU>
<TI>Teratogenicities of ophthalmic drugs. I. Antiviral ophthalmic drugs</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1975</YR>
<VL>93</VL>
<PG>46-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jewell-2009" MODIFIED="2010-09-15 15:50:14 +0100" MODIFIED_BY="[Empty name]" NAME="Jewell 2009" TYPE="JOURNAL_ARTICLE">
<AU>Jewell NP</AU>
<TI>Risk comparisons</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2009</YR>
<VL>148</VL>
<PG>484-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jezegabel-1967" MODIFIED="2013-08-08 18:20:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Jezegabel 1967" TYPE="JOURNAL_ARTICLE">
<AU>Jezegabel C, Rossazza C, Delplace MP</AU>
<TI>Recurrence of herpes on a lamellar keratoplasty</TI>
<TO>Les récidives d'herpes sur kératoplastie lamellaire</TO>
<SO>Bulletin des Sociétés d'Ophtalmologie de France</SO>
<YR>1967</YR>
<VL>67</VL>
<NO>9</NO>
<PG>759-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1967" MODIFIED="2010-06-22 22:04:07 +0100" MODIFIED_BY="[Empty name]" NAME="Jones 1967" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR</AU>
<TI>Prospects in treating viral disease of the eye</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1967</YR>
<VL>87</VL>
<PG>537-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1977" NAME="Jones 1977" TYPE="JOURNAL_ARTICLE">
<AU>Jones BR, Coster DJ, Falcon MG</AU>
<TI>Prospects of prevention of recurrent herpetic eye disease</TI>
<SO>Transactions of the Ophthalmological Society of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>350-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Joseph-2005" MODIFIED="2015-01-04 15:25:49 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Joseph 2005" TYPE="JOURNAL_ARTICLE">
<AU>Joseph MA, Kaufman HE, Insler M</AU>
<TI>Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders</TI>
<SO>Cornea</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>4</NO>
<PG>417-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaiserman-2005" MODIFIED="2010-10-31 19:29:36 +0000" MODIFIED_BY=" Iris Gordon" NAME="Kaiserman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kaiserman I, Kaiserman N, Nakar S, Vinker S</AU>
<TI>Herpetic eye disease in diabetic patients</TI>
<SO>Ophthalmology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>2184-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaiserman-2006" MODIFIED="2009-03-10 18:09:50 +0000" MODIFIED_BY="[Empty name]" NAME="Kaiserman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Kaiserman I, Kaiserman N, Elhayany A, Vinker S</AU>
<TI>Increased risk for herpetic eye disease in patients with allergic conjunctivitis</TI>
<SO>Current Eye Research</SO>
<YR>2006</YR>
<VL>31</VL>
<PG>721-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaneko-2008" MODIFIED="2010-06-01 15:12:15 +0100" MODIFIED_BY="[Empty name]" NAME="Kaneko 2008" TYPE="JOURNAL_ARTICLE">
<AU>Kaneko H, Kawana T, Ishioka K, Ohno S, Aoki K, Suzutani T</AU>
<TI>Evaluation of mixed infections cases with both herpes simplex virus types 1 and 2</TI>
<SO>Journal of Medical Virology</SO>
<YR>2008</YR>
<VL>80</VL>
<PG>883-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kastner-1984" MODIFIED="2010-06-17 17:23:52 +0100" MODIFIED_BY="[Empty name]" NAME="Kastner 1984" TYPE="JOURNAL_ARTICLE">
<AU>Kastner JK, Weiss SM, Kulikowski CA, Dawson CR</AU>
<TI>Therapy selection in an expert medical consultation system for ocular herpes simplex</TI>
<SO>Computers in Biology and Medicine</SO>
<YR>1984</YR>
<VL>14</VL>
<PG>285-301</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:14 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-1962" MODIFIED="2009-03-10 18:10:18 +0000" MODIFIED_BY="[Empty name]" NAME="Kaufman 1962" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman HE</AU>
<TI>Clinical cure of herpes simplex keratitis by 5-iodo-2'-deoxyuridine</TI>
<SO>Proceedings of the Society for Experimental Biology and Medicine</SO>
<YR>1962</YR>
<VL>109</VL>
<PG>251-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-1972" MODIFIED="2014-05-14 16:30:39 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Kaufman 1972" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman HE</AU>
<TI>The natural history and diagnosis of herpes cornea</TI>
<SO>Israel Journal of Medical Sciences</SO>
<YR>1972</YR>
<VL>8</VL>
<PG>1212-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-2002" NAME="Kaufman 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman HE</AU>
<TI>Can we prevent recurrences of herpes infections without antiviral drugs?</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2002</YR>
<VL>43</VL>
<PG>1325-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaufman-2012" MODIFIED="2014-08-27 15:34:45 +0100" MODIFIED_BY=" Iris Gordon" NAME="Kaufman 2012" TYPE="JOURNAL_ARTICLE">
<AU>Kaufman HE, Haw WH</AU>
<TI>Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis</TI>
<SO>Current Eye Research</SO>
<YR>2012</YR>
<VL>37</VL>
<NO>7</NO>
<PG>654-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khalili-2009" MODIFIED="2010-02-15 15:55:59 +0000" MODIFIED_BY="[Empty name]" NAME="Khalili 2009" TYPE="JOURNAL_ARTICLE">
<AU>Khalili MR, Mehdizadeh M, Mehryar M</AU>
<TI>Herpetic epithelial keratitis after intravitreal injection of bevacizumab (Avastin)</TI>
<SO>Cornea</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>360-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kip-2001" MODIFIED="2014-08-27 15:36:33 +0100" MODIFIED_BY=" Iris Gordon" NAME="Kip 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kip KE, Cohen F, Cole SR, Wilhelmus KR, Patrick DL, Blair RC, et al</AU>
<TI>Recall bias in a prospective cohort study of acute time-varying exposures: example from the Herpetic Eye Disease Study</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2001</YR>
<VL>54</VL>
<NO>5</NO>
<PG>482-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kipp-1880" MODIFIED="2014-12-26 21:46:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Kipp 1880" TYPE="JOURNAL_ARTICLE">
<AU>Kipp CJ</AU>
<TI>On keratitis from malarial fever</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1880</YR>
<VL>3</VL>
<PG>91-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kipp-1890" MODIFIED="2010-05-25 16:55:45 +0100" MODIFIED_BY="[Empty name]" NAME="Kipp 1890" TYPE="JOURNAL_ARTICLE">
<AU>Kipp CJ</AU>
<TI>Further observations on malarial keratitis</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>1890</YR>
<VL>5</VL>
<PG>331-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knickelbein-2009" MODIFIED="2010-05-25 23:26:16 +0100" MODIFIED_BY="[Empty name]" NAME="Knickelbein 2009" TYPE="JOURNAL_ARTICLE">
<AU>Knickelbein JE, Hendricks RL, Charukamnoetkanok P</AU>
<TI>Management of herpes simplex virus stromal keratitis: an evidence-based review</TI>
<SO>Survey of Ophthalmology</SO>
<YR>2009</YR>
<VL>54</VL>
<PG>226-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kowalski-1993" MODIFIED="2014-08-27 15:37:50 +0100" MODIFIED_BY=" Iris Gordon" NAME="Kowalski 1993" TYPE="JOURNAL_ARTICLE">
<AU>Kowalski RP, Gordon YJ, Romanowski EG, Araullo-Cruz T, Kinchington PR</AU>
<TI>A comparison of enzyme immunoassay and polymerase chain reaction with the clinical examination for diagnosing ocular herpetic disease</TI>
<SO>Ophthalmology</SO>
<YR>1993</YR>
<VL>100</VL>
<NO>4</NO>
<PG>530-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kremer-1991" MODIFIED="2013-08-08 18:41:55 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Kremer 1991" TYPE="JOURNAL_ARTICLE">
<AU>Kremer I, Wagner A, Shmuel D, Yussim A, Shapira Z</AU>
<TI>Herpes simplex keratitis in renal transplant patients</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1991</YR>
<VL>75</VL>
<NO>2</NO>
<PG>94-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kymionis-2007" MODIFIED="2014-08-27 15:40:10 +0100" MODIFIED_BY=" Iris Gordon" NAME="Kymionis 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kymionis GD, Portaliou DM, Bouzoukis DI, Suh LH, Pallikaris AI, Markomanolakis M, et al</AU>
<TI>Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus</TI>
<SO>Journal of Cataract and Refractive Surgery</SO>
<YR>2007</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1982-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labetoulle-2005" MODIFIED="2010-03-02 16:11:39 +0000" MODIFIED_BY="[Empty name]" NAME="Labetoulle 2005" TYPE="JOURNAL_ARTICLE">
<AU>Labetoulle M, Auquier P, Conrad H, Crochard A, Daniloski M, Bouée S, et al</AU>
<TI>Incidence of herpes simplex virus keratitis in France</TI>
<SO>Ophthalmology</SO>
<YR>2005</YR>
<VL>112</VL>
<PG>888-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Labetoulle-2012" MODIFIED="2014-08-27 15:41:15 +0100" MODIFIED_BY=" Iris Gordon" NAME="Labetoulle 2012" TYPE="JOURNAL_ARTICLE">
<AU>Labetoulle M, Colin J</AU>
<TI>Current concepts in the treatment of herpetic keratitis</TI>
<TO>Aspects actuels du traitement des kératites herpétiques</TO>
<SO>Journal Français d'Ophtalmologie</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>4</NO>
<PG>292-307</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lairson-2003" MODIFIED="2010-06-01 22:47:44 +0100" MODIFIED_BY="[Empty name]" NAME="Lairson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Lairsen DR, Begley CE, Reynolds TF, Wilhelmus KR</AU>
<TI>Prevention of herpes simplex virus eye disease: a cost-effectiveness analysis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2003</YR>
<VL>121</VL>
<PG>108-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Langeland-1987" MODIFIED="2014-08-27 15:43:24 +0100" MODIFIED_BY=" Iris Gordon" NAME="Langeland 1987" TYPE="JOURNAL_ARTICLE">
<AU>Langeland N, Holmsen H, Lillehaug JR, Haarr L</AU>
<TI>Evidence that neomycin inhibits binding of herpes simplex virus type 1 to the cellular receptor</TI>
<SO>Journal of Virology</SO>
<YR>1987</YR>
<VL>61</VL>
<NO>11</NO>
<PG>3388-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larra_x00f1_aga-Fragoso-2015" MODIFIED="2014-11-29 16:23:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Larrañaga Fragoso 2015" TYPE="JOURNAL_ARTICLE">
<AU>Larrañaga Fragoso P, Boto de Los Bueis A, Bravo Ljubetic L, del Hierro Zarzuelo A, Romero Gómez MP, Mora Rillo M</AU>
<TI>Herpes simplex keratitis in rheumatoid arthritis patients</TI>
<SO>Ocular Immunology and Inflammation</SO>
<YR>2015</YR>
<VL>23</VL>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lass-1984" MODIFIED="2010-06-10 00:41:39 +0100" MODIFIED_BY="[Empty name]" NAME="Lass 1984" TYPE="JOURNAL_ARTICLE">
<AU>Lass JH, Langston RH, Foster CS, Pavan-Langston D</AU>
<TI>Antiviral medications and corneal wound healing</TI>
<SO>Antiviral Research</SO>
<YR>1984</YR>
<VL>4</VL>
<PG>143-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2014d" MODIFIED="2014-12-05 23:17:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Li 2014d" TYPE="JOURNAL_ARTICLE">
<AU>Li JY, Li SQ</AU>
<TI>Systematic reviews of ganciclovir versus acyclovir for herpes simplex virus keratitis</TI>
<TO>&#26356;&#26132;&#27931;&#38886;&#23545;&#27604;&#38463;&#26132;&#27931;&#38886;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#31995;&#32479;&#35780;&#20215;</TO>
<SO>International Eye Science [Guoji Yanke Zazhi]</SO>
<YR>2014</YR>
<VL>14</VL>
<NO>9</NO>
<PG>1590-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liesegang-1989a" MODIFIED="2008-11-06 19:31:34 +0000" MODIFIED_BY="Anupa Shah" NAME="Liesegang 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Liesegang TJ</AU>
<TI>Epidemiology of ocular herpes simplex. Natural history in Rochester, Minn, 1950 through 1982</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1989</YR>
<VL>107</VL>
<PG>1160-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liesegang-1989b" MODIFIED="2014-08-27 15:45:13 +0100" MODIFIED_BY=" Iris Gordon" NAME="Liesegang 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Liesegang TJ, Melton LJ III, Daly PJ, Ilstrup DM</AU>
<TI>Epidemiology of ocular herpes simplex. Incidence in Rochester, Minn, 1950 through 1982</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1989</YR>
<VL>107</VL>
<NO>8</NO>
<PG>1155-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liesegang-2001" MODIFIED="2010-03-11 15:17:10 +0000" MODIFIED_BY="[Empty name]" NAME="Liesegang 2001" TYPE="JOURNAL_ARTICLE">
<AU>Liesegang TJ</AU>
<TI>Herpes simplex virus epidemiology and ocular importance</TI>
<SO>Cornea</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>1-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lingua-1985" MODIFIED="2013-08-08 19:46:34 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Lingua 1985" TYPE="JOURNAL_ARTICLE">
<AU>Lingua RW</AU>
<TI>Sequelae of botulinum toxin injection</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1985</YR>
<VL>100</VL>
<NO>2</NO>
<PG>305-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2006" MODIFIED="2014-08-27 15:47:46 +0100" MODIFIED_BY=" Iris Gordon" NAME="Lu 2006" TYPE="JOURNAL_ARTICLE">
<AU>Lu CK, Chen KH, Lee SM, Hsu WM, Lai JY, Li YS</AU>
<TI>Herpes simplex keratitis following excimer laser application</TI>
<SO>Journal of Refractive Surgery</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>5</NO>
<PG>509-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2011" MODIFIED="2014-12-07 16:49:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Lu 2011" TYPE="JOURNAL_ARTICLE">
<AU>Lu JY</AU>
<TI>Observation on diagnosis and treatment of herpes simplex keratitis after phacoemulsification surgery</TI>
<TO>&#36229;&#22768;&#20083;&#21270;&#30333;&#20869;&#38556;&#21560;&#38500;&#26415;&#21518;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#35786;&#30103;&#35266;&#23519;</TO>
<SO>Journal of Clinical and Experimental Medicine [Linchuang He Shiyan Yixue Zazhi]</SO>
<YR>2011</YR>
<VL>10</VL>
<NO>9</NO>
<PG>666-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ludema-2014a" MODIFIED="2014-08-27 15:49:52 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ludema 2014a" TYPE="JOURNAL_ARTICLE">
<AU>Ludema C, Cole SR, Poole C, Smith JS, Schoenbach VJ, Wilhelmus KR</AU>
<TI>Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2014</YR>
<VL>179</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ludema-2014b" MODIFIED="2014-08-27 15:52:58 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ludema 2014b" TYPE="JOURNAL_ARTICLE">
<AU>Ludema C, Cole SR, Hudgens MG, Poole C, Smith JS, Schoenbach VJ, et al</AU>
<TI>Prophylactic oral acyclovir and multiple herpes simplex virus recurrences</TI>
<SO>PLOS One</SO>
<YR>2014</YR>
<VL>9</VL>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luzi-1983" NAME="Luzi 1983" TYPE="JOURNAL_ARTICLE">
<AU>Luzi G, Voci MC, Bonomo R, Aiuti F, Pivetti-Pezzi P, Aziz M</AU>
<TI>Levamisole therapy: clinical and immunological evaluation in herpetic keratitis</TI>
<SO>International Journal of Immunopharmacology</SO>
<YR>1983</YR>
<VL>5</VL>
<PG>197-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ma-2006b" MODIFIED="2014-12-07 15:12:27 +0000" MODIFIED_BY="[Empty name]" NAME="Ma 2006b" TYPE="JOURNAL_ARTICLE">
<AU>Ma YD</AU>
<TI>Analysis of the integration of Chinese and western medical treatment of herpes simplex keratitis using evidence-based medicine</TI>
<TO>&#20013;&#35199;&#21307;&#32467;&#21512;&#27835;&#30103;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#30340;&#24490;&#35777;&#21307;&#23398;&#20998;&#26512;</TO>
<SO>Journal of Traditional Chinese Ophthalmology [Zhongguo Zhongyi Yanke Zazhi]</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>2</NO>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maudgal-1979" MODIFIED="2009-03-10 18:11:21 +0000" MODIFIED_BY="[Empty name]" NAME="Maudgal 1979" TYPE="JOURNAL_ARTICLE">
<AU>Maudgal PC, Van Deuren H, Missotten L</AU>
<TI>Therapeutic effect of corneal replicas in herpetic keratitis</TI>
<SO>Bulletin de la Société Belge d'Ophtalmologie</SO>
<YR>1979</YR>
<VL>185</VL>
<PG>39-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McAllum-2003" MODIFIED="2010-03-19 22:44:42 +0000" MODIFIED_BY="[Empty name]" NAME="McAllum 2003" TYPE="JOURNAL_ARTICLE">
<AU>McAllum PJ, McGhee CNJ</AU>
<TI>Prescribing trends in infectious keratitis: a survey of New Zealand ophthalmologists</TI>
<SO>Clinical &amp; Experimental Ophthalmology</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>496-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2015" MODIFIED="2015-01-04 16:35:49 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="McDonald 2015" TYPE="JOURNAL_ARTICLE">
<AU>McDonald EM, Patel DV, McGhee CN</AU>
<TI>A prospective study of the clinical characteristics of patients with herpes simplex and varicella zoster keratitis, presenting to a New Zealand emergency eye clinic</TI>
<SO>Cornea</SO>
<YR>2015</YR>
<VL>34</VL>
<PG>in press</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Michiels-2005" MODIFIED="2010-09-14 18:39:53 +0100" MODIFIED_BY="[Empty name]" NAME="Michiels 2005" TYPE="JOURNAL_ARTICLE">
<AU>Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP</AU>
<TI>Meta-analysis when only the median survival times are known: a comparison with individual patient data results</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2005</YR>
<VL>21</VL>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mills-2012" MODIFIED="2014-08-27 16:02:11 +0100" MODIFIED_BY=" Iris Gordon" NAME="Mills 2012" TYPE="JOURNAL_ARTICLE">
<AU>Mills EJ, Ioannidis JPA, Thorlund K, Schünemann HJ, Puhan MA, Guyatt GH</AU>
<TI>How to use an article reporting a multiple treatment comparison meta-analysis</TI>
<SO>JAMA</SO>
<YR>2012</YR>
<VL>308</VL>
<NO>12</NO>
<PG>1246-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minkovitz-1995" MODIFIED="2014-08-27 16:03:00 +0100" MODIFIED_BY=" Iris Gordon" NAME="Minkovitz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Minkovitz JB, Pepose JS</AU>
<TI>Topical interferon alpha-2a treatment of herpes simplex keratitis resistant to multiple antiviral medications in an immunosuppressed patient</TI>
<SO>Cornea</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>3</NO>
<PG>326-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miyajima-2003" MODIFIED="2014-12-07 14:51:42 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Miyajima 2003" TYPE="JOURNAL_ARTICLE">
<AU>Miyajima S, Sano Y, Sotozono C, Yokoi N, Ishino Y, Kinoshita S</AU>
<TI>Herpes simplex after ophthalmic surgery</TI>
<TO>&#30524;&#31185;&#25163;&#34899;&#24460;&#12395;&#30330;&#30151;&#12375;&#12383;&#35282;&#33180;&#12504;&#12523;&#12506;&#12473;</TO>
<SO>Japanese Journal of Ophthalmology [Nihon Ganka Gakkai Zasshi]</SO>
<YR>2003</YR>
<VL>107</VL>
<NO>9</NO>
<PG>538-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mortensen-1979" MODIFIED="2010-06-01 17:11:03 +0100" MODIFIED_BY="[Empty name]" NAME="Mortensen 1979" TYPE="JOURNAL_ARTICLE">
<AU>Mortensen KK, Sjølie AK</AU>
<TI>Keratitis dendritica. An epidemiological investigation</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1979</YR>
<VL>57</VL>
<PG>750-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mucci-2009" MODIFIED="2014-09-26 12:35:31 +0100" MODIFIED_BY="[Empty name]" NAME="Mucci 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mucci JJ, Utz VM, Galor A, Feuer W, Jeng BH</AU>
<TI>Recurrence rates of herpes simplex virus keratitis in contact lens and non-contact lens wearers</TI>
<SO>Eye and Contact Lens</SO>
<YR>2009</YR>
<VL>35</VL>
<PG>185-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Musch-2006" MODIFIED="2010-05-25 19:49:54 +0100" MODIFIED_BY="[Empty name]" NAME="Musch 2006" TYPE="JOURNAL_ARTICLE">
<AU>Musch DC, Gillespie BW</AU>
<TI>The state of being noninferior</TI>
<SO>Ophthalmology</SO>
<YR>2006</YR>
<VL>113</VL>
<PG>1-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nagy-2003" MODIFIED="2014-08-27 16:04:57 +0100" MODIFIED_BY=" Iris Gordon" NAME="Nagy 2003" TYPE="JOURNAL_ARTICLE">
<AU>Nagy ZZ, Keleman E, Kovács A</AU>
<TI>Herpes simplex keratitis after photorefractive keratectomy</TI>
<SO>Journal of Cataract and Refractive Surgery</SO>
<YR>2003</YR>
<VL>29</VL>
<NO>1</NO>
<PG>222-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naito-1987" MODIFIED="2010-06-10 00:17:22 +0100" MODIFIED_BY="[Empty name]" NAME="Naito 1987" TYPE="JOURNAL_ARTICLE">
<AU>Naito T, Shiota H, Mimura Y</AU>
<TI>Side effects in the treatment of herpetic keratitis</TI>
<SO>Current Eye Research</SO>
<YR>1987</YR>
<VL>6</VL>
<PG>237-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nataneli-2013" MODIFIED="2014-08-27 16:07:08 +0100" MODIFIED_BY=" Iris Gordon" NAME="Nataneli 2013" TYPE="JOURNAL_ARTICLE">
<AU>Nataneli N, Chai JSM, Donnenfeld ED, Perry HD</AU>
<TI>Recurrent herpes simplex keratitis adjacent to femtosecond laser arcuate keratotomies</TI>
<SO>JAMA Ophthalmology</SO>
<YR>2013</YR>
<VL>131</VL>
<NO>10</NO>
<PG>1372</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Neumann_x002d_Haefelin-1978" MODIFIED="2009-03-10 18:10:54 +0000" MODIFIED_BY="[Empty name]" NAME="Neumann-Haefelin 1978" TYPE="JOURNAL_ARTICLE">
<AU>Neumann-Haefelin D, Sundmacher R, Wochnik G, Bablok B</AU>
<TI>Herpes simplex virus types 1 and 2 in ocular disease</TI>
<SO>Acta Ophthalmologica</SO>
<YR>1978</YR>
<VL>96</VL>
<PG>64-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ng-1998" MODIFIED="2014-08-27 16:09:35 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ng 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ng P, McCluskey P, McCaughan G, Glanville A, MacDonald P, Keogh A</AU>
<TI>Ocular complications of heart, lung, and liver transplantation</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>82</VL>
<NO>4</NO>
<PG>423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Okuno-2011" MODIFIED="2014-08-27 16:11:16 +0100" MODIFIED_BY=" Iris Gordon" NAME="Okuno 2011" TYPE="JOURNAL_ARTICLE">
<AU>Okuno T, Hooper LC, Ursea R, Smith J, Nussenblatt R, Hooks JJ, et al</AU>
<TI>Role of human herpes virus 6 in corneal inflammation alone or with human herpesviruses</TI>
<SO>Cornea</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>2</NO>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oshry-1998" MODIFIED="2014-08-27 16:12:48 +0100" MODIFIED_BY=" Iris Gordon" NAME="Oshry 1998" TYPE="JOURNAL_ARTICLE">
<AU>Oshry T, Lifshitz T</AU>
<TI>Intravenous acyclovir treatment for extensive herpetic keratitis in a liver transplant patient</TI>
<SO>International Ophthalmology</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>5</NO>
<PG>265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pan-2014" MODIFIED="2014-08-27 16:14:25 +0100" MODIFIED_BY=" Iris Gordon" NAME="Pan 2014" TYPE="JOURNAL_ARTICLE">
<AU>Pan D, Kaye SB, Hopkins M, Kirwan R, Hart IJ, Coen DM</AU>
<TI>Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2014</YR>
<VL>209</VL>
<NO>3</NO>
<PG>345-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Panagiotou-2013" MODIFIED="2014-05-15 03:41:55 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Panagiotou 2013" TYPE="JOURNAL_ARTICLE">
<AU>Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JP</AU>
<TI>Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment</TI>
<SO>BMJ</SO>
<YR>2013</YR>
<VL>346</VL>
<PG>f707</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parmar-1998" MODIFIED="2010-06-10 22:54:02 +0100" MODIFIED_BY="[Empty name]" NAME="Parmar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MKB, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2815-34</PG>
<IDENTIFIERS MODIFIED="2010-06-10 22:54:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-10 22:54:02 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Addendum: Freels S. Statistics in Medicine 2004;23:1817."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pasternak-2010" MODIFIED="2010-11-10 15:49:09 +0000" MODIFIED_BY="[Empty name]" NAME="Pasternak 2010" TYPE="JOURNAL_ARTICLE">
<AU>Pasternak B, Hviid A</AU>
<TI>Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects</TI>
<SO>JAMA</SO>
<YR>2010</YR>
<VL>304</VL>
<NO>8</NO>
<PG>859-66</PG>
<IDENTIFIERS MODIFIED="2010-11-10 15:46:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Patel-2009" MODIFIED="2010-05-25 23:27:39 +0100" MODIFIED_BY="[Empty name]" NAME="Patel 2009" TYPE="JOURNAL_ARTICLE">
<AU>Patel NN, Teng CC, Sperber LT, Dodick JM</AU>
<TI>New-onset herpes simplex virus keratitis after cataract surgery</TI>
<SO>Cornea</SO>
<YR>2009</YR>
<VL>28</VL>
<PG>108-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pavan_x002d_Langston-1973" MODIFIED="2010-09-14 14:57:05 +0100" MODIFIED_BY="[Empty name]" NAME="Pavan-Langston 1973" TYPE="JOURNAL_ARTICLE">
<AU>Pavan-Langston D, McCulley JP</AU>
<TI>Herpes zoster dendritic keratitis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1973</YR>
<VL>89</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pflugfelder-1990" MODIFIED="2010-02-15 15:33:30 +0000" MODIFIED_BY="[Empty name]" NAME="Pflugfelder 1990" TYPE="JOURNAL_ARTICLE">
<AU>Pflugfelder SC, Huang A, Crouse C</AU>
<TI>Epstein-Barr virus keratitis after a chemical facial peel</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1990</YR>
<VL>110</VL>
<PG>571-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pollard-1982" MODIFIED="2014-08-27 16:19:43 +0100" MODIFIED_BY=" Iris Gordon" NAME="Pollard 1982" TYPE="JOURNAL_ARTICLE">
<AU>Pollard RB</AU>
<TI>Interferons and interferon inducers: development of clinical usefulness and therapeutic promise</TI>
<SO>Drugs</SO>
<YR>1982</YR>
<VL>23</VL>
<NO>1-2</NO>
<PG>37-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prabriputaloong-2006" MODIFIED="2009-03-10 18:40:01 +0000" MODIFIED_BY="[Empty name]" NAME="Prabriputaloong 2006" TYPE="JOURNAL_ARTICLE">
<AU>Prabriputaloong T, Margolis TOP, Lietman TM, Wong IG, Mather R, Gritz DC</AU>
<TI>Atopic disease and herpes simplex eye disease: a population based case-control study</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>142</VL>
<PG>745-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pramod-1999" MODIFIED="2014-12-07 14:53:20 +0000" MODIFIED_BY="[Empty name]" NAME="Pramod 1999" TYPE="JOURNAL_ARTICLE">
<AU>Pramod NP, Rajendran P, Kannan KA, Thyagarajan SP</AU>
<TI>Herpes simplex keratitis in South India: clinico-virological correlation</TI>
<SO>Japanese Journal of Ophthalmology [Nihon Ganka Gakkai Zasshi]</SO>
<YR>1999</YR>
<VL>43</VL>
<PG>303-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prasher-2009" MODIFIED="2014-08-27 16:20:36 +0100" MODIFIED_BY=" Iris Gordon" NAME="Prasher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Prasher P, Muftuoglu O</AU>
<TI>Herpetic keratitis after descemet stripping automated endothelial keratoplasty for failed graft</TI>
<SO>Eye and Contact Lens</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>1</NO>
<PG>41-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rao-2009" MODIFIED="2014-08-27 16:21:27 +0100" MODIFIED_BY=" Iris Gordon" NAME="Rao 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rao A, Tandon R, Sharma N, Sihota R, Gupta V, Dada T</AU>
<TI>Herpetic keratitis and keratouveitis after mitomycin-C use in glaucoma filtering surgery: a short case series</TI>
<SO>European Journal of Ophthalmology</SO>
<YR>2009</YR>
<VL>19</VL>
<NO>6</NO>
<PG>1088-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Remeijer-1997" MODIFIED="2009-03-10 18:12:53 +0000" MODIFIED_BY="[Empty name]" NAME="Remeijer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Remeijer L, Doornenbal P, Geerards AJ, Rijneveld WA, Beekhuis WH</AU>
<TI>Newly acquired herpes simplex virus keratitis after penetrating keratoplasty</TI>
<SO>Ophthalmology</SO>
<YR>1997</YR>
<VL>104</VL>
<PG>648-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Remeijer-2002" MODIFIED="2014-12-27 19:53:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Remeijer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Remeijer L, Maertzdorf J, Buitenwerf J, Osterhaus ADME, Verjans GMGM</AU>
<TI>Corneal herpes simplex virus type 1 superinfection in patients with recrudescent herpetic keratitis</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>2002</YR>
<VL>43</VL>
<NO>2</NO>
<PG>358-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revere-2013" MODIFIED="2014-08-27 16:24:20 +0100" MODIFIED_BY=" Iris Gordon" NAME="Revere 2013" TYPE="JOURNAL_ARTICLE">
<AU>Revere K, Davidson SL</AU>
<TI>Update on management of herpes keratitis in children</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>2013</YR>
<VL>24</VL>
<NO>4</NO>
<PG>343-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rezende-2004" MODIFIED="2010-02-15 16:25:04 +0000" MODIFIED_BY="[Empty name]" NAME="Rezende 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rezende RA, Uchoa UB, Raber IM, Rapuano CJ, Laibson PR, Cohen EJ</AU>
<TI>New onset of herpes simplex virus epithelial keratitis after penetrating keratoplasty</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2004</YR>
<VL>137</VL>
<PG>415-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rezende-2006" MODIFIED="2010-05-25 22:30:00 +0100" MODIFIED_BY="[Empty name]" NAME="Rezende 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rezende RA, Hammersmith K, Bisol T, Lima AL, Webster GF, Freitas JF, et al</AU>
<TI>Comparative study of ocular herpes simplex virus in patients with and without self-reported atopy</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>141</VL>
<PG>1120-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ribaric-1976" MODIFIED="2014-08-27 16:26:11 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ribaric 1976" TYPE="JOURNAL_ARTICLE">
<AU>Ribari&#263; V</AU>
<TI>The incidence of herpetic keratitis among population</TI>
<SO>Ophthalmologica</SO>
<YR>1976</YR>
<VL>173</VL>
<NO>1</NO>
<PG>19-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richards-1983" MODIFIED="2008-11-06 19:33:28 +0000" MODIFIED_BY="Anupa Shah" NAME="Richards 1983" TYPE="JOURNAL_ARTICLE">
<AU>Richards DM, Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS</AU>
<TI>Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy</TI>
<SO>Drugs</SO>
<YR>1983</YR>
<VL>26</VL>
<PG>378-438</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:28 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Roat-1987" MODIFIED="2010-03-25 16:35:21 +0000" MODIFIED_BY="[Empty name]" NAME="Roat 1987" TYPE="JOURNAL_ARTICLE">
<AU>Roat MI, Romanowski E, Araullo-Cruz T, Gordon YJ</AU>
<TI>The antiviral effects of rose bengal and fluorescein</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1987</YR>
<VL>105</VL>
<PG>1415-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robert-2005" MODIFIED="2010-02-15 16:13:37 +0000" MODIFIED_BY="[Empty name]" NAME="Robert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Robert PY, Adenis JP, Pleyer U</AU>
<TI>How "safe" is corneal transplantation? A contribution on the risk of HSV-transmission due to corneal transplantation</TI>
<TO>Wie "sicher" ist das Hornhauttransplantat? Ein Beitrag zum Risiko der HSV-Transmission durch Hornhauttransplantation</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>2005</YR>
<VL>222</VL>
<PG>870-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romano-1988" MODIFIED="2010-11-01 13:06:09 +0000" MODIFIED_BY=" Iris Gordon" NAME="Romano 1988" TYPE="JOURNAL_ARTICLE">
<AU>Romano A, Sadan Y</AU>
<TI>Ten years of experience with human fibroblast interferon in treatment of viral ophthalmic infections</TI>
<SO>Metabolic, Pediatric, and Systemic Ophthalmology</SO>
<YR>1988</YR>
<VL>11</VL>
<PG>43-6</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:37 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Ruiz-2007" MODIFIED="2014-08-27 16:27:55 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ruiz 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ruiz L, Rodriguez I, Baez R, Aldana R</AU>
<TI>Stability of an extemporaneously prepared recombinant human interferon alfa-2b eye drop formulation</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>16</NO>
<PG>1716-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sahin-2012" MODIFIED="2013-08-13 21:03:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sahin 2012" TYPE="JOURNAL_ARTICLE">
<AU>Sahin A, Hamrah P</AU>
<TI>Acute herpetic keratitis: what is the role for ganciclovir ophthalmic gel?</TI>
<SO>Ophthalmology and Eye Diseases</SO>
<YR>2012</YR>
<VL>4</VL>
<PG>23-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Santos-1983" MODIFIED="2014-08-27 16:31:36 +0100" MODIFIED_BY=" Iris Gordon" NAME="Santos 1983" TYPE="JOURNAL_ARTICLE">
<AU>Santos CR</AU>
<TI>Herpetic corneal ulcer following radial keratotomy</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1983</YR>
<VL>15</VL>
<NO>1</NO>
<PG>82-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Satpathy-2011" MODIFIED="2011-05-26 08:42:21 +0100" MODIFIED_BY="Anupa Shah" NAME="Satpathy 2011" TYPE="JOURNAL_ARTICLE">
<AU>Satpathy G, Mishra AK, Tandon R, Sharma MK, Sharma A, Nayak N, et al</AU>
<TI>Evaluation of tear samples for herpes simplex virus 1 (HSV) detection in suspected cases of viral keratitis using PCR assay and conventional laboratory diagnostic tools</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2011</YR>
<VL>95</VL>
<NO>3</NO>
<PG>415-8</PG>
<IDENTIFIERS MODIFIED="2011-05-26 08:42:21 +0100" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Seitzman-2006" MODIFIED="2010-06-01 23:30:00 +0100" MODIFIED_BY="[Empty name]" NAME="Seitzman 2006" TYPE="JOURNAL_ARTICLE">
<AU>Seitzman GD, Cevallos V, Margolis TP</AU>
<TI>Rose bengal and lissamine green inhibit detection of herpes simplex virus by PCR</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2006</YR>
<VL>141</VL>
<PG>756-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shtein-2007" MODIFIED="2013-08-08 17:59:12 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Shtein 2007" TYPE="JOURNAL_ARTICLE">
<AU>Shtein RM, Stahl RM, Saxe SJ, Mian SI</AU>
<TI>Herpes simplex keratitis after intravitreal triamcinolone acetonide</TI>
<SO>Cornea</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>5</NO>
<PG>641-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siddique-2011" MODIFIED="2014-08-27 16:38:13 +0100" MODIFIED_BY=" Iris Gordon" NAME="Siddique 2011" TYPE="JOURNAL_ARTICLE">
<AU>Siddique SS, Gonzalez-Gonzalez LA, Amorese L, Shaikh M, Foster CS</AU>
<TI>Herpes keratitis in a patient undergoing treatment with topical mitomycin C</TI>
<SO>Cornea</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>4</NO>
<PG>466-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Smith-2002" MODIFIED="2014-09-26 12:36:35 +0100" MODIFIED_BY="[Empty name]" NAME="Smith 2002" TYPE="JOURNAL_ARTICLE">
<AU>Smith JS, Robinson NJ</AU>
<TI>Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2002</YR>
<VL>186 Suppl 1</VL>
<PG>S3-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2003" MODIFIED="2011-05-26 08:42:38 +0100" MODIFIED_BY="Anupa Shah" NAME="Song 2003" TYPE="JOURNAL_ARTICLE">
<AU>Song F, Altman DG, Glenny AM, Deeks JJ</AU>
<TI>Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>2003</YR>
<VL>326</VL>
<NO>7387</NO>
<PG>472</PG>
<IDENTIFIERS MODIFIED="2011-05-26 08:42:38 +0100" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Song-2009" MODIFIED="2010-10-31 19:36:47 +0000" MODIFIED_BY=" Iris Gordon" NAME="Song 2009" TYPE="JOURNAL_ARTICLE">
<AU>Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG</AU>
<TI>Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b1147</PG>
<IDENTIFIERS MODIFIED="2010-10-31 19:36:47 +0000" MODIFIED_BY=" Iris Gordon"/>
</REFERENCE>
<REFERENCE ID="REF-Souza-2003" MODIFIED="2010-05-25 23:31:29 +0100" MODIFIED_BY="[Empty name]" NAME="Souza 2003" TYPE="JOURNAL_ARTICLE">
<AU>Souza PMF, Holland EJ, Huang AJW</AU>
<TI>Bilateral herpetic keratoconjunctivitis</TI>
<SO>Ophthalmology</SO>
<YR>2003</YR>
<VL>110</VL>
<PG>493-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stan-2000" MODIFIED="2010-03-11 15:20:00 +0000" MODIFIED_BY="[Empty name]" NAME="Stan 2000" TYPE="JOURNAL_ARTICLE">
<AU>Stan C, Bedeoan S, Stan R</AU>
<TI>The influence of meteorological factors for frequency of herpes simplex keratitis</TI>
<TO>Influenta factorilor meteorologici asupra frecventei de aparitie a cheratitei herpetice</TO>
<SO>Oftalmologia</SO>
<YR>2000</YR>
<VL>50</VL>
<PG>32-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stanzel-2014" MODIFIED="2014-11-28 21:04:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Stanzel 2014" TYPE="JOURNAL_ARTICLE">
<AU>Stanzel TP, Diaz JD, Mather R, Wong IG, Margolis TP, Gritz DC</AU>
<TI>The epidemiology of herpes simplex virus eye disease in northern California</TI>
<SO>Ophthalmic Epidemiology</SO>
<YR>2014</YR>
<VL>21</VL>
<NO>6</NO>
<PG>370-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sun-2013b" MODIFIED="2014-12-07 17:03:32 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sun 2013b" TYPE="JOURNAL_ARTICLE">
<AU>Sun L, Chen W</AU>
<TI>Clinical characteristics and treatment of herpes simplex keratitis after phacoemulsification</TI>
<TO>&#30333;&#20869;&#38556;&#36229;&#22768;&#20083;&#21270;&#21560;&#38500;&#26415;&#21518;&#24182;&#21457;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;&#30340;&#29305;&#28857;&#21450;&#27835;&#30103;</TO>
<SO>Ophthalmology in China [Yanke]</SO>
<YR>2013</YR>
<VL>22</VL>
<NO>3</NO>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1977" MODIFIED="2014-08-27 16:40:05 +0100" MODIFIED_BY=" Iris Gordon" NAME="Sundmacher 1977" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R, Mackensen G</AU>
<TI>Herpes therapy and prophylaxis. II. Results of a survey of practicing ophthalmologists</TI>
<TO>Herpestherapie und-prophylaxe. II. Das Ergebnis einer Umfrage bei niedergelassenen Augenarzten</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1977</YR>
<VL>171</VL>
<NO>1</NO>
<PG>90-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1978c" MODIFIED="2015-01-04 15:41:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Sundmacher 1978c" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R</AU>
<TI>Trifluorothymidin-prophylaxis of dendritic keratitis in steroid-treated herpetic keratouveitis</TI>
<TO>Trifluorthymidinprophylaxe bei der Steroidtherapie herpetischer Keratouveitiden</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1978</YR>
<VL>173</VL>
<NO>4</NO>
<PG>516-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1982" NAME="Sundmacher 1982" TYPE="BOOK_SECTION">
<AU>Sundmacher R</AU>
<TI>Interferon in ocular viral diseases</TI>
<SO>Interferon</SO>
<YR>1982</YR>
<PG>177-200</PG>
<ED>Gresser I</ED>
<PB>Academic Press</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1983" MODIFIED="2008-11-06 19:33:44 +0000" MODIFIED_BY="Anupa Shah" NAME="Sundmacher 1983" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R</AU>
<TI>Use of nucleoside analogues in the treatment of herpes simplex virus eye diseases</TI>
<SO>Metabolic, Pediatric, and Systemic Ophthalmology</SO>
<YR>1983</YR>
<VL>7</VL>
<PG>89-94</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:44 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1984b" MODIFIED="2009-03-10 18:13:38 +0000" MODIFIED_BY="[Empty name]" NAME="Sundmacher 1984b" TYPE="BOOK_SECTION">
<AU>Sundmacher R</AU>
<TI>The role of interferon in prophylaxis and treatment of dendritic keratitis</TI>
<SO>Herpes Simplex Infections of the Eye</SO>
<YR>1984</YR>
<PG>129-46</PG>
<ED>Blodi F</ED>
<PB>Churchill Livingstone</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-1986" MODIFIED="2010-02-15 16:32:19 +0000" MODIFIED_BY="[Empty name]" NAME="Sundmacher 1986" TYPE="JOURNAL_ARTICLE">
<AU>Sundmacher R</AU>
<TI>Dendritic keratitis following corneal foreign body</TI>
<TO>Keratitis dendritica nach Hornhautfremdkorper</TO>
<SO>Klinische Monatsblätter für Augenheilkunde</SO>
<YR>1986</YR>
<VL>188</VL>
<PG>307-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sundmacher-2009" MODIFIED="2010-06-24 17:58:46 +0100" MODIFIED_BY="[Empty name]" NAME="Sundmacher 2009" TYPE="BOOK">
<AU>Sundmacher R</AU>
<SO>Color Atlas of Herpetic Eye Disease: A Practical Guide to Clinical Management</SO>
<YR>2009:13-9</YR>
<PB>Springer</PB>
<CY>Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tabbara-2010" MODIFIED="2010-09-15 15:21:38 +0100" MODIFIED_BY="[Empty name]" NAME="Tabbara 2010" TYPE="JOURNAL_ARTICLE">
<AU>Tabbara KF, Al Balushi N</AU>
<TI>Topical ganciclovir in the treatment of acute herpetic keratitis</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2010</YR>
<VL>4</VL>
<PG>905-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tabery-2010" MODIFIED="2010-06-24 17:59:10 +0100" MODIFIED_BY="[Empty name]" NAME="Tabery 2010" TYPE="BOOK">
<AU>Tabery HM</AU>
<SO>Herpes Simplex Virus Epithelial Keratitis: In Vivo Morphology in the Human Cornea</SO>
<YR>2010:1-24</YR>
<PB>Springer</PB>
<CY>Heidelberg</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thygeson-1976" MODIFIED="2014-08-27 16:41:23 +0100" MODIFIED_BY=" Iris Gordon" NAME="Thygeson 1976" TYPE="JOURNAL_ARTICLE">
<AU>Thygeson P</AU>
<TI>Historical observations on herpetic keratitis</TI>
<SO>Survey of Ophthalmology</SO>
<YR>1976</YR>
<VL>21</VL>
<NO>2</NO>
<PG>82-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tierney-2007" MODIFIED="2009-03-10 19:07:29 +0000" MODIFIED_BY="[Empty name]" NAME="Tierney 2007" TYPE="JOURNAL_ARTICLE">
<AU>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR</AU>
<TI>Practical methods for incorporating summary time-to-event data into meta-analysis</TI>
<SO>Trials</SO>
<YR>2007</YR>
<VL>8</VL>
<PG>16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2006" MODIFIED="2010-06-09 23:06:36 +0100" MODIFIED_BY="[Empty name]" NAME="Turner 2006" TYPE="COCHRANE_REVIEW">
<AU>Turner A, Rabiu M</AU>
<TI>Patching for corneal abrasion</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2010-06-09 23:06:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-06-09 23:06:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004764.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Turner-2013" MODIFIED="2013-11-30 15:38:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Turner 2013" TYPE="JOURNAL_ARTICLE">
<AU>Turner LD, Beckingsale P</AU>
<TI>Acyclovir-resistant herpetic keratitis in a solid-organ transplant recipient on systemic immunosuppression</TI>
<SO>Clinical Ophthalmology</SO>
<YR>2013</YR>
<VL>7</VL>
<PG>229-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uchio-1994" MODIFIED="2014-12-07 14:53:42 +0000" MODIFIED_BY=" Iris Gordon" NAME="Uchio 1994" TYPE="JOURNAL_ARTICLE">
<AU>Uchio E, Hatano H, Mitsui K, Sugita M, Okada K, Goto K, et al</AU>
<TI>A retrospective study of herpes simplex keratitis over the last 30 years</TI>
<SO>Japanese Journal of Ophthalmology [Nihon Ganka Gakkai Zasshi]</SO>
<YR>1994</YR>
<VL>38</VL>
<PG>196-201</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uchoa-2003" MODIFIED="2010-10-31 19:39:08 +0000" MODIFIED_BY=" Iris Gordon" NAME="Uchoa 2003" TYPE="JOURNAL_ARTICLE">
<AU>Uchoa UB, Rezende RA, Carrasco MA, Rapuano CJ, Laibson PR, Cohen EJ</AU>
<TI>Long-term acyclovir use to prevent recurrent ocular herpes simplex virus infection</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2003</YR>
<VL>121</VL>
<PG>1702-4</PG>
<IDENTIFIERS MODIFIED="2010-05-25 23:37:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Ukety-1991" MODIFIED="2011-05-04 18:56:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ukety 1991" TYPE="JOURNAL_ARTICLE">
<AU>Ukety TO, Maertens K</AU>
<TI>Ocular ulcerative herpes following measles in Kinshasa, Zaire</TI>
<SO>Current Eye Research</SO>
<YR>1991</YR>
<VL>10</VL>
<NO>Suppl</NO>
<PG>131-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Spall-2007" MODIFIED="2010-11-01 11:42:53 +0000" MODIFIED_BY=" Iris Gordon" NAME="Van Spall 2007" TYPE="JOURNAL_ARTICLE">
<AU>Van Spall HGC, Toren A, Kiss A, Fowler RA</AU>
<TI>Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling view</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>297</VL>
<PG>1233-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Velzen-2013" MODIFIED="2014-08-27 16:47:16 +0100" MODIFIED_BY=" Iris Gordon" NAME="van Velzen 2013" TYPE="JOURNAL_ARTICLE">
<AU>van Velzen M, van de Vijver DA, van Loenen FB, Osterhaus AD, Remeijer L, Verjans GM.</AU>
<TI>Acyclovir prophylaxis predisposes to antiviral resistant recurrent herpetic keratitis</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2013</YR>
<VL>208</VL>
<NO>9</NO>
<PG>1359-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhoeff-1909" MODIFIED="2010-11-01 11:42:45 +0000" MODIFIED_BY=" Iris Gordon" NAME="Verhoeff 1909" TYPE="JOURNAL_ARTICLE">
<AU>Verhoeff FH</AU>
<TI>Neuropathic keratitis and some allied conditions, with special reference to treatment</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1909</YR>
<VL>53</VL>
<PG>191-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villegas-2008" MODIFIED="2010-11-10 15:28:23 +0000" MODIFIED_BY="[Empty name]" NAME="Villegas 2008" TYPE="JOURNAL_ARTICLE">
<AU>Villegas VM, Diaz L, Izquierdo NJ</AU>
<TI>Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report</TI>
<SO>Puerto Rico Health Sciences Journal</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>4</NO>
<PG>348-9</PG>
<IDENTIFIERS MODIFIED="2010-11-10 15:26:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Wagoner-1984" MODIFIED="2010-06-09 22:46:28 +0100" MODIFIED_BY="[Empty name]" NAME="Wagoner 1984" TYPE="JOURNAL_ARTICLE">
<AU>Wagoner MD, Kenyon KR, Gipson IK, Hanninen LA, Seng WL</AU>
<TI>Polymorphonuclear neutrophils delay corneal epithelial wound healing in vitro</TI>
<SO>Investigative Ophthalmology &amp; Visual Science</SO>
<YR>1984</YR>
<VL>25</VL>
<PG>1217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagstaff-1994" MODIFIED="2008-11-06 19:33:50 +0000" MODIFIED_BY="Anupa Shah" NAME="Wagstaff 1994" TYPE="JOURNAL_ARTICLE">
<AU>Wagstaff AJ, Faulds D, and Goa KL</AU>
<TI>Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy</TI>
<SO>Drugs</SO>
<YR>1994</YR>
<VL>47</VL>
<PG>153-205</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:50 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Webre-2012" MODIFIED="2014-08-27 16:54:00 +0100" MODIFIED_BY=" Iris Gordon" NAME="Webre 2012" TYPE="JOURNAL_ARTICLE">
<AU>Webre JM, Hill JM, Nolan NM, Clement C, McFerrin HE, Bhattacharjee PS, et al</AU>
<TI>Rabbit and mouse models of HSV-1 latency, reactivation, and recurrent eye diseases</TI>
<SO>Journal of Biomedicine and Biotechnology</SO>
<YR>2012</YR>
<VL>2012</VL>
<PG>Article ID 612316</PG>
<IDENTIFIERS MODIFIED="2013-11-26 22:14:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus"/>
</REFERENCE>
<REFERENCE ID="REF-Wei-2008" MODIFIED="2014-12-07 16:04:13 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wei 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wei X, Chen XM, Liu XY, Deng YP</AU>
<TI>Evaluation of the effectiveness of the common drugs for herpes simplex keratitis by using the evidence-based medicine method</TI>
<TO>&#20851;&#20110;&#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;&#33647;&#29289;&#27835;&#30103;&#30340;&#24490;&#35777;&#35777;&#25454;</TO>
<SO>International Journal of Ophthalmology [Guoji Yanke Zazhi]</SO>
<YR>2008</YR>
<VL>8</VL>
<NO>10</NO>
<PG>2084-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weinberg-1977" MODIFIED="2014-08-27 16:57:35 +0100" MODIFIED_BY=" Iris Gordon" NAME="Weinberg 1977" TYPE="JOURNAL_ARTICLE">
<AU>Weinberg RJ, Oh JO</AU>
<TI>The effect of a topical anesthetic on the recovery of herpes simplex virus</TI>
<SO>Annals of Ophthalmology</SO>
<YR>1977</YR>
<VL>9</VL>
<NO>8</NO>
<PG>977-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wells-2009" MODIFIED="2010-09-08 16:45:36 +0100" MODIFIED_BY="[Empty name]" NAME="Wells 2009" TYPE="COMPUTER_PROGRAM">
<AU>Wells GA, Sultan SA, Chen L, Khan M, Coyle D</AU>
<TI>Indirect treatment comparison</TI>
<YR>2009</YR>
<EN>1.0</EN>
<PB>Canadian Agency for Drugs and Technologies in Health</PB>
<CY>Ottawa</CY>
<IDENTIFIERS MODIFIED="2010-09-08 16:45:36 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-09-08 16:45:36 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="www.cadth.ca/media/pdf/H0462_itc_tr_e.pdf"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wheeler-1959" MODIFIED="2010-06-24 16:19:18 +0100" MODIFIED_BY="[Empty name]" NAME="Wheeler 1959" TYPE="JOURNAL_ARTICLE">
<AU>Wheeler CE, Canby CM</AU>
<TI>Effect of temperature on the growth curves of herpes simplex virus in tissue cultures</TI>
<SO>Journal of Immunology</SO>
<YR>1959</YR>
<VL>83</VL>
<PG>392-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2012" MODIFIED="2014-08-27 16:59:41 +0100" MODIFIED_BY=" Iris Gordon" NAME="White 2012" TYPE="JOURNAL_ARTICLE">
<AU>White IR, Barrett JK, Jackson D, Higgins JPT</AU>
<TI>Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression</TI>
<SO>Research Synthesis Methods</SO>
<YR>2012</YR>
<VL>3</VL>
<NO>2</NO>
<PG>111-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2014" MODIFIED="2014-12-10 16:52:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="White 2014" TYPE="OTHER">
<AU>White ML, Chodosh J</AU>
<TI>Herpes simplex virus keratitis: a treatment guideline - 2014</TI>
<SO>ONE Network [The Ophthalmic News &amp; Education Network]</SO>
<YR>2014</YR>
<VL>American Academy of Ophthalmology</VL>
<NO>http://one.aao.org/clinical-statement/herpes-simplex-virus-keratitis-treatment-guideline</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitley-1980" MODIFIED="2008-11-06 19:33:56 +0000" MODIFIED_BY="Anupa Shah" NAME="Whitley 1980" TYPE="JOURNAL_ARTICLE">
<AU>Whitley R, Alford C, Hess F, Buchanan R</AU>
<TI>Vidarabine: a preliminary review of its pharmacological properties and therapeutic use</TI>
<SO>Drugs</SO>
<YR>1980</YR>
<VL>20</VL>
<PG>267-82</PG>
<IDENTIFIERS MODIFIED="2008-11-06 19:33:56 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1981b" MODIFIED="2008-11-06 19:31:57 +0000" MODIFIED_BY="Anupa Shah" NAME="Wilhelmus 1981b" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Coster DJ, Donovan HC, Falcon MG, Jones BR</AU>
<TI>Prognostic indicators of herpetic keratitis. Analysis of a five-year observation period after corneal ulceration</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1981</YR>
<VL>99</VL>
<PG>1578-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1981c" MODIFIED="2010-02-23 20:20:55 +0000" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 1981c" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Falcon MG, Jones BR</AU>
<TI>Bilateral herpetic keratitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1981</YR>
<VL>65</VL>
<PG>385-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1982" MODIFIED="2010-09-13 21:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 1982" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR</AU>
<TI>Suppurative corneal ulceration following herpetic keratitis</TI>
<SO>Documenta Ophthalmologica</SO>
<YR>1982</YR>
<VL>53</VL>
<PG>17-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1983" NAME="Wilhelmus 1983" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Jones DB</AU>
<TI>What's new: acyclovir for treatment of ocular viral infections</TI>
<SO>Texas Medicine</SO>
<YR>1983</YR>
<VL>70</VL>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1989" MODIFIED="2013-09-25 21:10:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wilhelmus 1989" TYPE="BOOK_SECTION">
<AU>Wilhelmus KR</AU>
<TI>Dendritic keratitis: will wiping it off wipe it out?</TI>
<SO>Ophthalmic Clinical Debates</SO>
<YR>1989</YR>
<PG>94-9</PG>
<ED>Deutsch TA</ED>
<PB>Year Book Medical Publishers</PB>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1996a" MODIFIED="2010-10-31 19:43:01 +0000" MODIFIED_BY=" Iris Gordon" NAME="Wilhelmus 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Dawson CR, Barron BA, Bacchetti P, Gee L, Jones DB, et al</AU>
<TI>Risk factors for herpes simplex virus epithelial keratitis recurring during treatment of stromal keratitis or iridocyclitis</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>80</VL>
<PG>969-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-1996b" MODIFIED="2010-06-03 15:24:06 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR, Font RL, Lehmann RP, Cernoch PL</AU>
<TI>Cytomegalovirus keratitis in acquired immunodeficiency syndrome</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1996</YR>
<VL>114</VL>
<PG>869-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2000" MODIFIED="2009-03-10 19:05:53 +0000" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR</AU>
<TI>The treatment of herpes simplex virus epithelial keratitis</TI>
<SO>Transactions of the American Ophthalmological Society</SO>
<YR>2000</YR>
<VL>98</VL>
<PG>505-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2007a" MODIFIED="2009-03-10 18:54:41 +0000" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2007a" TYPE="JOURNAL_ARTICLE">
<AU>Wilhelmus KR</AU>
<TI>Redundant publication of clinical trials on herpetic keratitis</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2007</YR>
<VL>144</VL>
<PG>222-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2008a" MODIFIED="2009-08-25 18:13:00 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2008a" TYPE="BOOK_SECTION">
<AU>Wilhelmus KR</AU>
<TI>The epidemiology of ocular infections</TI>
<SO>Duane's Foundations of Clinical Ophthalmology</SO>
<YR>2008</YR>
<ED>Jaeger EA, Tasman W</ED>
<PB>Lippincott-Raven</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-1977" MODIFIED="2010-06-09 23:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="Williams 1977" TYPE="JOURNAL_ARTICLE">
<AU>Williams HP, Falcon MG, Jones BR</AU>
<TI>Corticosteroids in the management of herpetic eye disease</TI>
<SO>Transactions of the Ophthalmological Societies of the United Kingdom</SO>
<YR>1977</YR>
<VL>97</VL>
<PG>341-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-1936" MODIFIED="2015-01-04 20:54:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Wood 1936" TYPE="BOOK">
<AU>Wood CA</AU>
<SO>Memorandum Book of a Tenth-Century Oculist for the Use of Modern Ophthalmologists: A Translation of the Tadhkirat of Ali ibn Isa of Baghdad (cir. 940-1010 A.D.), the Most Complete Practical and Original of All the Early Textbooks on the Eye and its Diseases</SO>
<YR>1936:154</YR>
<PB>Northwestern University</PB>
<CY>Chicago</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2002" MODIFIED="2014-12-11 17:44:07 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2002" TYPE="JOURNAL_ARTICLE">
<AU>Wu X, Chen X</AU>
<TI>Acyclovir for the treatment and prevention of recurrent infectious herpes simplex keratitis</TI>
<SO>Chinese Medical Journal [Zhonghua Yixue Zazhi]</SO>
<YR>2002</YR>
<VL>115</VL>
<PG>1569-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wu-2009" MODIFIED="2010-03-22 18:24:59 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wu T, Li Y, Bian Z, Liu G, Moher D</AU>
<TI>Randomized trials published in some Chinese journals: how many are randomized?</TI>
<SO>Trials</SO>
<YR>2009</YR>
<VL>10</VL>
<PG>46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yamagami-1998" MODIFIED="2013-08-30 18:56:03 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yamagami 1998" TYPE="JOURNAL_ARTICLE">
<AU>Yamagami H, Takamura E</AU>
<TI>The effect of acyclovir ointment on herpes simplex keratitis</TI>
<TO>&#35282;&#33180;&#12504;&#12523;&#12506;&#12473;&#12398;&#36605;&#30151;&#21270;&#12395;&#23550;&#12377;&#12427;&#12450;&#12471;&#12463;&#21475;&#12499;&#12523;&#38480;&#36575;&#33167;&#12398;&#21177;&#26524;</TO>
<SO>Japanese Review of Clinical Ophthalmology [Ganka Rinsho Iho]</SO>
<YR>1998</YR>
<VL>92</VL>
<NO>8</NO>
<PG>170-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2011" MODIFIED="2014-12-07 16:50:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yang 2011" TYPE="JOURNAL_ARTICLE">
<AU>Yang YY</AU>
<TI>Seven cases of cataract surgery complicated by herpes simplex virus keratitis</TI>
<TO>&#30333;&#20869;&#38556;&#26415;&#21518;&#24182;&#21457;&#21333;&#32431;&#30129;&#30137;&#30149;&#27602;&#24615;&#35282;&#33180;&#28814;7 &#20363;</TO>
<SO>Journal of Practical Medicine [Shiyong Yixue Zazhi]</SO>
<YR>2011</YR>
<VL>27</VL>
<NO>3</NO>
<PG>551-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yao-1996" MODIFIED="2013-11-30 15:44:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NAME="Yao 1996" TYPE="JOURNAL_ARTICLE">
<AU>Yao YF, Inoue Y, Kase T, Uchihori Y, Mori Y, Ohashi Y</AU>
<TI>Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1996</YR>
<VL>234</VL>
<NO>Suppl 1</NO>
<PG>S126-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoon-2010" MODIFIED="2014-08-27 17:02:20 +0100" MODIFIED_BY=" Iris Gordon" NAME="Yoon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Yoon KC, Im SK, Park HY</AU>
<TI>Recurrent herpes simplex keratitis after verteporfin photodynamic therapy for corneal neovascularization</TI>
<SO>Cornea</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>4</NO>
<PG>465-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yorston-1992" MODIFIED="2014-08-27 17:05:00 +0100" MODIFIED_BY=" Iris Gordon" NAME="Yorston 1992" TYPE="JOURNAL_ARTICLE">
<AU>Yorston D, Foster A</AU>
<TI>Herpetic keratitis in Tanzania: association with malaria</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>1992</YR>
<VL>76</VL>
<NO>10</NO>
<PG>582-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2010" MODIFIED="2010-11-10 15:26:09 +0000" MODIFIED_BY="[Empty name]" NAME="Young 2010" TYPE="JOURNAL_ARTICLE">
<AU>Young RC, Hodge DO, Liesegang TJ, Baratz KH</AU>
<TI>Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2010</YR>
<VL>128</VL>
<NO>9</NO>
<PG>1178-83</PG>
<IDENTIFIERS MODIFIED="2010-11-09 20:18:43 +0000" MODIFIED_BY="Anupa Shah"/>
</REFERENCE>
<REFERENCE ID="REF-Yuksel-2011" MODIFIED="2014-08-27 17:09:00 +0100" MODIFIED_BY=" Iris Gordon" NAME="Yuksel 2011" TYPE="JOURNAL_ARTICLE">
<AU>Yuksel N, Bilgihan K, Hondur AM</AU>
<TI>Herpetic keratitis after corneal collagen cross-linking with riboflavin and ultraviolet-A for progressive keratoconus</TI>
<SO>International Ophthalmology</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>6</NO>
<PG>513-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhang-2007" MODIFIED="2010-09-13 22:54:50 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" TYPE="JOURNAL_ARTICLE">
<AU>Zhang W, Suzuki T, Shiraishi A, Shimamura I, Inoue Y, Ohashi Y</AU>
<TI>Dendritic keratitis caused by an acyclovir-resistant herpes simplex virus with frameshift mutation</TI>
<SO>Cornea</SO>
<YR>2007</YR>
<VL>26</VL>
<PG>105-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ziahosseini-2009" MODIFIED="2014-08-27 17:11:06 +0100" MODIFIED_BY=" Iris Gordon" NAME="Ziahosseini 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ziahosseini K, Ikram K</AU>
<TI>Current clinical practice of consultant ophthalmologists in treating herpetic eye disease in the United Kingdom</TI>
<SO>Eye</SO>
<YR>2009</YR>
<VL>23</VL>
<NO>4</NO>
<PG>993-4</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-09-08 21:54:38 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Wilhelmus-2001" MODIFIED="2009-08-25 18:14:57 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2001" TYPE="COCHRANE_REVIEW">
<AU>Wilhelmus KR</AU>
<TI>Interventions for herpes simplex virus epithelial keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-08-25 18:14:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-25 17:59:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2003" MODIFIED="2010-11-06 09:27:13 +0000" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2003" TYPE="COCHRANE_REVIEW">
<AU>Wilhelmus KR</AU>
<TI>Interventions for herpes simplex virus epithelial keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-08-25 18:15:02 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-25 18:09:21 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002898"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2007" MODIFIED="2009-08-25 18:10:55 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2007" TYPE="COCHRANE_REVIEW">
<AU>Wilhelmus KR</AU>
<TI>Therapeutic interventions for herpes simplex virus epithelial keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-08-25 18:10:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-25 18:10:55 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002898.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2008" MODIFIED="2009-08-25 18:19:45 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2008" TYPE="COCHRANE_REVIEW">
<AU>Wilhelmus KR</AU>
<TI>Therapeutic interventions for herpes simplex virus epithelial keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2009-08-25 18:14:17 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-25 18:14:17 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002898.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilhelmus-2010" MODIFIED="2014-09-08 21:54:37 +0100" MODIFIED_BY="[Empty name]" NAME="Wilhelmus 2010" TYPE="COCHRANE_REVIEW">
<AU>Wilhelmus KR</AU>
<TI>Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2014-09-08 21:54:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-09-08 21:54:33 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002898.pub4"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2013-08-30 19:16:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-09 10:56:13 +0000" MODIFIED_BY="Anupa Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-12-27 15:49:58 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-03-18 23:00:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abe-1987">
<CHAR_METHODS MODIFIED="2010-03-18 22:52:50 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-18 23:00:46 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Japan<BR/>Number enrolled: 27<BR/>Average age (range): 35 (2-77)<BR/>Sex: 17 males, 10 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-18 23:00:00 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=9): idoxuridine solution<BR/>Treatment two (n=18): acyclovir 3% ointment 3 to 5 times per day (one patient received intravenous acyclovir 5 mg/kg every 8 hours)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-18 22:57:41 +0000" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: antibiotic solution 3 to 5 times per day<BR/>Report language: Japanese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:38:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Altinisik-1987">
<CHAR_METHODS MODIFIED="2010-02-10 01:33:38 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-11 17:56:13 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Turkey<BR/>Number enrolled: 27<BR/>Average age (range): 38 (4-73)<BR/>Sex: 16 males, 11 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-26 14:27:16 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=9): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=10): acyclovir 3% ointment 5 times per day<BR/>Treatment three (n=8): acyclovir 3% ointment 5 times per day + wiping débridement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 17:42:57 +0000" MODIFIED_BY="[Empty name]">
<P>Epithelial healing (resolution of 'punktat epitelial defektler')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:38:37 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: Turkish<BR/>Study date: 1985-1986<BR/>Financial support: not given<BR/>Adverse reactions: One case of punctate epithelial erosions observed in the idoxuridine group, and none in the acyclovir group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:31:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Austin-1974">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:06 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 41<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 22:31:35 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=16): iodinisation<BR/>Treatment two (n=25): idoxuridine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'When no corneal staining remained'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-25 22:31:41 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: mydriatic, antibiotic (iodinisation group), pad<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 17:36:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bartholomew-1977">
<CHAR_METHODS MODIFIED="2010-05-25 22:14:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva and cornea): performed but results not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:05:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 21<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:24:38 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=6): photodynamic inactivation (neutral red 1% solution x 2 then blue light for 15 minutes)<BR/>Treatment two (n=7): carbolization<BR/>Treatment three (n=8): idoxuridine ointment 6 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'When the ulcerated area no longer stained with fluorescein (scattered superficial punctate erosions were ignored)'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 17:36:43 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: chloramphenicol ointment, corneal scraping<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: private foundation</P>
<P>Adverse reactions (Quote): "none of our patients experienced any adverse reactions."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-10 18:13:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:07 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 19 positive of 20 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-10 18:13:56 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Number enrolled: 20<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one: (n=10): trifluridine 1% solution 5 times per day<BR/>Treatment two (n=10): foscarnet 3% solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:00:46 +0000" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining with 'closure of the corneal epithelium'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:15:42 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: scopolamine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "No punctate keratitis or allergic reactions were observed."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:16:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blake-1977">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:08 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:01:05 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Ireland<BR/>Number enrolled: 30<BR/>Average age (range): 45 (7-75)<BR/>Sex: 16 males, 14 females<BR/>Inclusion criteria: dendritic (23) or geographic (7) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=13): idoxuridine ointment 0.5% 4 times daily<BR/>Treatment two (n=17): vidarabine ointment 3% 4 times daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:01:18 +0000" MODIFIED_BY="[Empty name]">
<P>'Complete re-epithelialisation'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:16:41 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Two patients in the Ara-A group developed mild punctate keratitis...in both cases the condition cleared spontaneously on discontinuing medication."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burns-1963">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:08 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: several (42 sites in entire study)<BR/>Quote: "The signs and symptoms of this infection are clear cut and pathognomonic, thus no confirmatory laboratory tests will be necessary to establish the diagnosis."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 38<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: acute epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=15): distilled water hourly day, 2-hourly night<BR/>Treatment one (n=23): idoxuridine solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:01:39 +0000" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining with 'healing of the ulcer'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: 1962-1963<BR/>Financial support: pharmaceutical industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-14 17:16:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Cao-2001">
<CHAR_METHODS MODIFIED="2013-08-14 17:04:59 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-14 17:16:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 104 dendritic epithelial keratitis (123 total cases of epithelial or disciform keratitis + 41 others with open allocation of study treatments)<BR/>Average age (range): 39 (18-65)<BR/>Sex (imputed from total, for dendritic sample): 75 males, 29 females<BR/>Inclusion criteria: dendritic (104) epithelial keratitis, geographic epithelial keratitis (11), disciform keratitis (8) in trial; and in open allocation, dendritic (14), geographic (9), and disciform (18) cases, for total population of 164</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-14 17:09:28 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=52): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=52): foscarnet 3% solution 6 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-14 17:04:42 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-14 17:09:47 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1%<BR/>Report language: Chinese<BR/>Study date: 1999-2000<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:48:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carmassi-1993">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:10 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (cornea): 10 positive of 15 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Number enrolled: 15<BR/>Average age (range): 44 (25-71)<BR/>Sex: 7 males, 8 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=5): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=5): interferon solution 8 times per day (total of 200,000 units)<BR/>Treatment three (n=5): acyclovir 3% ointment 5 times per day and interferon solution 8 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:02:10 +0000" MODIFIED_BY="[Empty name]">
<P>'Corneal reepithelialization and negativity of the fluorescein test' ('riepitelizzazione corneale e negativizzazione del test alla fluoresceina')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:48:37 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: Italian<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions: Two cases of "cheratite puntata" occurred in the acyclovir group, and one case occurred in the acyclovir-interferon group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 18:33:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cellini-1994">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:14 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Number enrolled: 40<BR/>Average age (range): 43 (19-70)<BR/>Sex: 24 males, 16 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=20): acyclovir 3% ointment 4 times per day<BR/>Treatment two (n=20): acyclovir 3% ointment 4 times per day and murine epidermal growth factor 10 mg/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Negativity of the fluorescein staining test'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 18:33:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry</P>
<P>Adverse reactions (Quote): "The tolerability of EGF was always good, and there have not been signs of interaction or incompatibility between EGF and the antiviral agent."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-22 19:47:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2008">
<CHAR_METHODS MODIFIED="2010-05-18 19:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-22 19:47:36 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 40<BR/>Average age (range): 44<BR/>Sex: 23 males, 17 females<BR/>Inclusion criteria: dendritic (9) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-18 19:01:43 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=20): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=20): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 19:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 19:00:14 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:50:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1981">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:07:12 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 52<BR/>Average age (range): 49 (8-84)<BR/>Sex: 31 males, 21 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:07:17 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=27): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=25): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-23 20:28:05 +0000" MODIFIED_BY="[Empty name]">
<P>'The absence of epithelial ulceration after instillation of fluorescein' ('l'absence d'ulcération epithéliale après instillation de fluorescéine')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:50:06 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: French<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: Two cases of "kératite ponctuée" occurred in the idoxuridine group, and one case in the acyclovir group</P>
<P>[Presumed typographical error in publication's table of 11 males, instead of 17 males, randomised to idoxuridine]</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 18:37:39 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Colin-1982">
<CHAR_METHODS MODIFIED="2014-04-22 20:38:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: not given ("traitement comparatif")<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-11 18:51:47 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: France<BR/>Number enrolled: 24<BR/>Average age (range): 55<BR/>Sex: 13 males, 11 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-11 18:55:34 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=12): trifluridine solution 5 times per day<BR/>Treatment two (n=12): trifluridine solution 5 times per day + oral isoprinosine 50 mg/kg/day (one tablet per 10 kg body weight per day) for 5 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-11 19:08:57 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Florescein staining: 'l'absence d'ulcération épithéliale après instillation de fluorescéine'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 18:37:39 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% 2 times per day<BR/>Report language: French<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quotes): one patient treated with trifluridine had not healed by day 12 when he still had a 2-mm epithelial defect and "kératite ponctuée diffuse et conjonctivite folliculaire." "Tolerance: en dehors de cette observation il n'a pas été noté de signes to toxicité dus à la TFT. Cependant 9 patients ont signalé une sensation de brûlure oculaire lors de l'installation des gouttes. Aucune manifestation générale n'a été signalée pendant cet essai chez les patients recevant de l'Isoprinosine." </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:51:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1983">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva and cornea): inclusion criterion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:14:44 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 45<BR/>Average age (range): not given<BR/>Sex: 36 males, 9 females<BR/>Inclusion criteria: dendritic epithelial keratitis (culture-confirmed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=21): acyclovir 3% ointment 5 times per day and albumin once per day<BR/>Treatment two (n=24): acyclovir 3% ointment 5 times per day and human leukocyte interferon 30 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'The absence of fluorescein staining in the area of the previous corneal ulceration'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:51:22 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions: "Diffuse superficial punctate epitheliopathy was noted in five patients" including three in the acyclovir-placebo group and two in the acyclovir-interferon group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:51:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1984">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: France<BR/>Number enrolled: 32<BR/>Average age (range): 48 (7-79)<BR/>Sex: 20 males, 12 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=17): iododeoxycytidine 1% ointment 5 times per day<BR/>Treatment two (n=15): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:04:18 +0000" MODIFIED_BY="[Empty name]">
<P>'The absence of epithelial ulceration after the instillation of fluorescein, using the biomicroscope' ('l'absence d'ulcération après instillation de fluorescéïne')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:51:59 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: French<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions: One case of kératite ponctuée" was observed in the iododeoxycytidine group and one case in the acyclovir group. Another case of "allergie oculo-palpébrale" occurred in the acyclovir group</P>
<P>[Day 15 healing data of iododeoxycytidine group used for day 14 data table in this systematic review]</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 19:29:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1987">
<CHAR_METHODS MODIFIED="2010-05-25 22:15:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 24 positive of 32 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-25 19:29:33 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 32<BR/>Average age (range): 49 (8-77)<BR/>Sex: 19 males, 13 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-25 19:26:25 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=16): acyclovir 3% ointment 4 times per day and placebo ointment 3 times per day<BR/>Treatment two (n=16): acyclovir 3% ointment 4 times per day and vidarabine 3% ointment 3 time per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'The absence of fluorescein staining in the area of previous corneal ulceration'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency<BR/>Adverse reactions (Quote): "Diffuse superficial punctate epitheliopathy was noted in four patients (two in each group)...and resolved after the treatment was discontinued."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-06 20:11:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1997a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: three<BR/>HSV isolation (conjunctiva): 35 positive of 59 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Mali and Tunisia<BR/>Number enrolled: 67<BR/>Average age (range): 41<BR/>Sex: 37 males, 30 females<BR/>Inclusion criteria: dendritic (51) or geographic (16) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=22): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=23): ganciclovir 0.15% gel 5 times per day<BR/>Treatment three (n=22): ganciclovir 0.05% gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Absence of fluorescein staining at ulcer site'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-06 20:11:31 +0000" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1990-1992<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (from <LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK>, Table 3): "Toxic superficial punctate keratitis related to treatment at Day 14" was observed in two cases in the acyclovir group, three cases in the ganciclovir 0.15% group, and no cases in the ganciclovir 0.05% group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:25:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-1997b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: four<BR/>HSV isolation (conjunctiva): 7 positive of 35 tested (Quote: "Because of problems of refrigeration during transportation, percentages of positive conjunctival swabs were very low.")</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:15:34 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France, Switzerland, and Great Britain<BR/>Number enrolled: 37<BR/>Average age (range): 48<BR/>Sex: 26 males, 11 females<BR/>Inclusion criteria: dendritic (36) or geographic (1) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=18): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=19): ganciclovir 0.15% gel 5 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Absence of fluorescein staining at ulcer site'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:25:27 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1990-1992<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote from Colin, 2007, Study B): "There were no cases of superficial punctate keratitis that were found to be toxic."<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:26:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-2007a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: multiple</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Pakistan<BR/>Number enrolled: 109<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=38): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=36): ganciclovir 0.15% gel 5 times per day<BR/>Treatment three (n=35): ganciclovir 0.05% gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Lack of fluorescein staining'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:26:48 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote): "The number of superficial punctate keratitis cases that appeared or were exacerbated while receiving treatment was similar across the treatment groups."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:27:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Colin-2007b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: 28</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Country: 28 European centres<BR/>Number enrolled: 164<BR/>Average age (range): 45<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (138) or geographic (26) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=80): acyclovir 3% ointment 5 times per day (n=67 dendrites)<BR/>Treatment two (n=84): ganciclovir 0.15% gel 5 times per day (n=71 dendrites)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'When there was no fluorescein uptake'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:27:33 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1992-1994<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "The frequency of toxic superficial punctate keratitis was reduced by half in the GCV0.15% group compared with the ACV group."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:55:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collum-1980">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 19 positive of 54 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-22 19:02:08 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Ireland<BR/>Number enrolled: 60, including 8 idoxuridine-treated censored patients (7 who were not improved or worse at day 4 and one who defaulted)<BR/>Average age (range): 41 (4-79)<BR/>Sex: 44 males, 16 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=30): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=30): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'No fluorescein uptake'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:55:14 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: homatropine, pad<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: Six cases of "superficial punctate keratopathy" were observed in the idoxuridine group, and no cases in the acyclovir group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 17:02:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collum-1985">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: two</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Ireland and UK <BR/>Number enrolled: 51<BR/>Average age (range): 55 (range not given)<BR/>Sex: 29 males, 22 females<BR/>Inclusion criteria: geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=26): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=25): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 17:02:44 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>'No further staining of the ulcer area'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:30:48 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: pad "as appropriate"<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote): "The only adverse reaction noted was superficial punctate epitheliopathy in two patients receiving acyclovir and five patients receiving Ara-A."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:32:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collum-1986">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Ireland<BR/>Number enrolled: 56<BR/>Average age (range): 47 (range not given)<BR/>Sex: 45 males, 11 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=29): acyclovir 3% ointment 5 times per day and oral placebo 5 times per day<BR/>Treatment two (n=27): placebo ointment 5 times per day and oral acyclovir 400 mg 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'When there was no further staining with fluorescein, though slight irregularity or cystic change in the epithelium might still exist'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:32:09 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "In four patients receiving acyclovir ointment large punctate epithelial defects were noted...one other patient receiving acyclovir ointment had a minor degree of superficial punctate epitheliopathy."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:56:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coster-1976">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:21 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:06:05 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 102<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (87) or geographic (15) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=48): vidarabine 3.3% ointment 5 times per day<BR/>Treatment two (n=54): trifluridine 1% solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Absence of staining with fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 12:56:44 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "The only indication of toxicity observed was punctate epithelial staining with Bengal rose. This effect was considered to be due to drug toxicity if it affected areas of the cornea remote from the original lesion. Such a staining pattern was seen in nine patients, of whom eight had been treated with ara-A and one with F<SUB>3</SUB>T</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:06:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coster-1977a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:06:10 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 78<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Control (n=22): minimal wiping débridement and placebo solution once per day<BR/>Treatment one (n=26): minimal wiping débridement and human leukocyte interferon 11 million units/ml once per day<BR/>Treatment two (n=30): minimal wiping débridement and human leukocyte interferon 33 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-28 18:53:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coster-1979">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-25 22:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 30<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-28 18:53:41 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n = 17): vidarabine 3.3% ointment 5 times per day<BR/>Treatment two (n = 13): trifluridine 1% solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'The absence of staining with fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-28 18:47:06 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "The only manifestation of antiviral toxicity observed was punctate staining of the corneal epithelium with Bengal rose. This occurred in 3 patients treated with Ara-A and 4 treated with F<SUB>3</SUB>T."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:36:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coster-1980">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:06:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 59<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (54) or geographic (5) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=30): idoxuridine 1% ointment 5 times per day<BR/>Treatment two (n=29): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'No epithelial defect was demonstrable with rose-Bengal and fluorescein staining'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:36:21 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote); "There were no untoward reactions that necessitated withdrawal of therapy."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 16:44:30 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Dai-2009a">
<CHAR_METHODS MODIFIED="2013-11-07 16:30:19 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 16:33:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 58 patients (71 eyes)<BR/>Average age (range): 38 (15-66)<BR/>Sex: 40 males, 18 females<BR/>Inclusion criteria: dendritic (59) or geographic (12) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 16:35:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=30 patients, 36 eyes): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=28 patients, 35 eyes): ganciclovir 0.15% gel 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 16:43:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#35282;&#33180;&#33639;&#20809;&#32034;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 16:44:30 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% for iridocyclitis<BR/>Report language: Chinese<BR/>Study date: 2008<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 16:53:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Dai-2009b">
<CHAR_METHODS MODIFIED="2013-11-07 16:44:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 16:48:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 79<BR/>Average age (range): 32 (11-57)<BR/>Sex: 45 males, 34 females<BR/>Inclusion criteria: dendritic (51) or geographic (28) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 16:48:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=39): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=40): ganciclovir 0.15% gel 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 16:53:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#32032;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 16:49:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 0.3% 4 times per day<BR/>Report language: Chinese<BR/>Study date: 2007-2008<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 17:35:22 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Daniel-1972">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: alternate patients<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:06:30 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 54<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-22 19:02:59 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=25): idoxuridine ointment 5 times per day<BR/>Treatment two (n=29): idoxuridine ointment 5 times per day and ultraviolet (2536 Å) light for 2-4 minutes once or twice</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-25 22:16:01 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 17:35:22 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: mydriatic, pad<BR/>Report language: English<BR/>Study date: 1970-1971<BR/>Financial support: not given</P>
<P>Adverse reactions (Quote): "Considerable pain resulted from the phototherapy, because of the resulting photochemical keratitis....In some patients pain prevented the further exposure that was necessary to achieve a confluent corneal stain."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:37:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-1964">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised with table<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (cornea): 51 positive of 75 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:06:36 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 75<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: not given</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 22:31:49 +0100" MODIFIED_BY="[Empty name]">
<P>Control (n=25): gamma-globulin 1% solution hourly during day, 2-hourly during night<BR/>Treatment one (n=25): débridement (with orange stick) and iodinisation (with alcohol solution of iodine and potassium iodide on soaked cotton wool)<BR/>Treatment two (n=25): idoxuridine 0.1% solution hourly during day, 2-hourly during night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'The absence of staining with two per cent fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:37:52 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: pad, atropine (débridement group), chloramphenicol ointment (débridement group)<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "There were no allergic reactions to the drops, nor were there any complaints of burning or irritation. Some areas of punctate stain were noted after healing with IDU or gamma globulin drops, but there were no more frequent than after iodization."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Koning-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 58 positive of 61 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands<BR/>Number enrolled: 53<BR/>Average age (range): not given<BR/>Sex: 33 males, 20 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=28): trifluridine 1% solution 5 times per day and albumin solution<BR/>Treatment two (n=25): trifluridine 1% solution 5 times per day and human leukocyte interferon 10 million units/ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'No staining with fluorescein' and 'closure of the epithelial wound without any epithelial edema or cystic change in the area of the previous dendrite'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-14 22:21:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Koning-1983">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 55 positive of 59 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 22:21:02 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Netherlands<BR/>Number enrolled: 51 (actually 59, but 8 patients dropped from description and analysis)<BR/>Average age (range): not given<BR/>Sex: 30 males, 21 females<BR/>Inclusion criteria: dendritic (42) or geographic (9) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=26): acyclovir 3% ointment 5 times per day and albumin solution every morning<BR/>Treatment two (n=25): acyclovir 3% ointment 5 times per day and human leukocyte interferon 30 million units/ml every morning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'No staining with fluorescein' and 'absence of epithelial edema and cystic changes'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:43:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Denis-1983">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-12 15:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 23<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=9): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=14): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:06:39 +0000" MODIFIED_BY="[Empty name]">
<P>Ulcer healing ('cicatrisation de l'ulcère')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: mydriatic, antibiotic (rarely)<BR/>Report language: French<BR/>Study date: 1980-1981<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "La tolérance locale à l'acyclovir et à l'Ara A est bonne, identique pour les deux substances. Chacune d'elle a occasionné dans cette étude: 5 kératites ponctuées superficielles qui n'ont pas empêché la poursuite du traitement et one disparu spontanément dès l'arrêt; et, chez 3 malades, une douleur modérée à chaque application de pommade."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-11 21:11:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Fu-2012">
<CHAR_METHODS MODIFIED="2013-08-11 19:58:46 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised <BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-11 21:10:57 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 78<BR/>Average age (range): 34 (18-75)<BR/>Sex: 48 males, 30 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-11 20:01:46 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=38): ganciclovir 0.15% gel 4 times per day<BR/>Treatment two (n=40): ganciclovir 0.15% gel 4 times per day + subconjunctival interferon (0.5 ml of 1 million units/ml every other day for 14 days)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-11 20:03:06 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-11 21:11:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: 2010-2011<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-09-25 18:43:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fulhorst-1972">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:07:26 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 90<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (74) or geographic (16) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-09-25 18:43:43 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=26): idoxuridine ointment 5 times per day<BR/>Treatment two (n=18): cryotherapy (multiple applications at -70° to -80° C) and idoxuridine ointment 5 times per day<BR/>Treatment three (n=18): cryotherapy (multiple applications at -70° to -80° C) and placebo ointment 5 times per day<BR/>Treatment four (n=13): carbolization (débridement with orange stick followed by touching epithelial edge with phenol) and idoxuridine ointment 5 times per day<BR/>Treatment five (n=15): carbolization (débridement with orange stick followed by touching epithelial edge with phenol) and placebo ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:07:15 +0000" MODIFIED_BY="[Empty name]">
<P>'When the lesion no longer stained with rose Bengal'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: scopolamine, chloramphenicol ointment, patching for 48 hours<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gen_x00e9_e-1987">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 28<BR/>Average age (range): not given<BR/>Sex: 21 males, 7 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=14): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=14): vidarabine 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: German<BR/>Study date: 1981-1984<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 15:22:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graupner-1966">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double (partial)<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 32<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-22 19:03:37 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=12): idoxuridine 0.1% solution every 2 hours<BR/>Treatment two (n=20): <I>para</I>-fluorophenylalanine 0.1% solution every 2 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 15:22:30 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein ('Der Behandlungserfolg wurde an Hand der Anfärbbarkeit der Cornea beurteilt')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine<BR/>Report language: German<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 15:24:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graupner-1968">
<CHAR_METHODS MODIFIED="2014-04-22 20:49:21 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 53<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-22 19:03:43 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=27): idoxuridine 0.1% ointment 5 times per day<BR/>Treatment two (n=26): <I>para</I>-fluorophenylalanine 0.1% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 15:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein ('vollständige Epithelisation der Hornhaut')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine<BR/>Report language: German<BR/>Study date: note given<BR/>Financial support: pharmaceutical industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-09 19:26:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Graupner-1969">
<CHAR_METHODS MODIFIED="2014-04-22 20:57:31 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation methods: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 33<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-09 19:26:36 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=18): iodinization /débridement plus idoxuridine 0.1% ointment every 4 hours<BR/>Treatment two (n=15): iodinization /débridement plus <I>para</I>-fluorophenylalanine 0.1% ointment every 4 hours</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 15:22:40 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein ('Anfärbbharkeit der Hornhaut mit Fluorescein beurteilt')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine<BR/>Report language: German<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-13 18:50:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guerra-1979">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: single<BR/>Number of centres: one<BR/>HSV isolation (cornea): 11 positive of 20 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:09:13 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Italy<BR/>Number enrolled: 20<BR/>Average age (range): 46 (9-76)<BR/>Sex: 13 males, 7 females<BR/>Inclusion criteria: dendritic (18) or geographic (2) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-13 18:50:08 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=10): polyinosinic-polycytidylic 1000 &#956;g/ml hourly<BR/>Treatment two (n=10): idoxuridine 0.2% solution hourly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:09:31 +0000" MODIFIED_BY="[Empty name]">
<P>Healing ('cicatrizzato')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine<BR/>Report language: Italian<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-04 17:51:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Han-2010">
<CHAR_METHODS MODIFIED="2014-12-04 15:29:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 15:31:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 40<BR/>Average age (range): not give<BR/>Sex: not given<BR/>Inclusion criteria: epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 15:31:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=19): acyclovir solution<BR/>Treatment two (n=21): ganciclovir gel</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-04 15:29:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:51:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
<P>Recurrence rate: in one year, 2 episodes in acyclovir group and 1 episode in ganciclovir group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:51:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Han-2014">
<CHAR_METHODS MODIFIED="2014-12-04 15:34:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 15:46:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 96<BR/>Average age (range): 40 (22-58)<BR/>Sex: 58 males, 38 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis (possibly also stromal keratitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 15:48:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=48): acyclovir solution hourly and recombinant fibroblast growth factor gel every 2 hours<BR/>Treatment two (n=48): ganciclovir gel hourly and recombinant fibroblast growth factor every 2 hours (apparent typographical error stating 46 patients enrolled in this treatment arm)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:51:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#30154;&#24840;: &#30524;&#37096;&#30140;&#30171;&#12289;&#30031;&#20809;&#12289;&#27969;&#27882;&#31561;&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;&#65292;&#35282;&#33180;&#28291;&#30113;&#24840;&#21512;&#65292;&#33639;&#20809;&#32032;&#38048;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 15:48:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: January 2012 - December 2012<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 23:40:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hart-1965">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 25 positive of 32 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Australia<BR/>Number enrolled: 32<BR/>Average age (range): 48 (14-80)<BR/>Sex: only given for healed patients (20 males, 6 females)<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=13): neomycin 0.3% solution hourly day, 2-hourly night<BR/>Treatment one (n=19): idoxuridine 0.1% solution hourly day, 2-hourly night<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-25 23:40:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Quote: "the criterion of epithelial healing being the absence of discrete fluorescein staining of the cornea...in the assessment of epithelial healing, when such staining was no greater on the ulcer region than elsewhere, the ulcer would be deemed healed, but when punctate stains were confined to the ulcer region, it would be deemed not healed."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 23:30:52 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: mydriatic ("reserved for those patients in whom iritis was diagnosed"), pad<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 18:39:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haut-1983">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:22 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:09:55 +0000" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 26<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (15) or geographic (11) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=12): oral placebo<BR/>Treatment one (n=14): oral isoprinosine 500 mg 6 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:10:15 +0000" MODIFIED_BY="[Empty name]">
<P>Healing ('amélioration')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 18:39:50 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine, antibiotic<BR/>Report language: French<BR/>Study date: not given<BR/>Financial support: not given</P>
<P>Adverse reactions (Quote): "Nous n'avons remarqué aucun signe secondaire important ni constant, et le produit a été bien toleré par tous les malades."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-HEDS-Group-1997">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by permuted blocks<BR/>Masking: double<BR/>Number of centres: 60</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: USA<BR/>Number enrolled: 287<BR/>Average age (range): 48 (range not given)<BR/>Sex: 179 males, 108 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=134): trifluridine 1% solution 8 times per day and oral placebo 5 times per day<BR/>Treatment two (n=153): trifluridine 1% solution 8 times per day and oral acyclovir 400 mg 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1992-1995<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 21:03:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<CHAR_METHODS MODIFIED="2014-04-22 21:03:50 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (cornea and conjunctiva): results not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-03 17:51:50 +0100" MODIFIED_BY="[Empty name]">
<P>Country: France<BR/>Number enrolled: 29<BR/>Average age (range): not given<BR/>Sex: only given for total group with herpetic keratitis (28 males, 9 females)<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis (n=29), or keratouveitis (n=8)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=11): trifluridine 1% solution 6 times per day<BR/>Treatment two (n=18): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:11:47 +0000" MODIFIED_BY="[Empty name]">
<P>No fluorescein staining ('lorsque la coloration épithéliale par la fluorescéine à l'examen biomicroscopique de la cornée a disparu')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:46:47 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: cycloplegic, antibiotic, timolol<BR/>Report language: French<BR/>Study date: 1980-1982<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Effets secondaires...sont limités à de simples kératites ponctuées superficielles: 8 dans le groupe ACV et 3 dans le groupe TFT, et à une conjonctivite folliculaire dans le groupe ACV."<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-22 19:48:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2008a">
<CHAR_METHODS MODIFIED="2010-05-18 19:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-22 19:48:07 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 45<BR/>Average age (range): 32<BR/>Sex: 31 males, 14 females<BR/>Inclusion criteria: dendritic (29) or geographic (16) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-18 19:21:05 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=15): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=16): ganciclovir 0.15% gel 4 times per day<BR/>Treatment three (n=14): ganciclovir 0.1% solution 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 19:13:45 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:47:31 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "No obviously adverse drug reaction was found in all of three agents."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:48:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hung-1984">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:08:05 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 29<BR/>Average age (range): 56 (range not given)<BR/>Sex: 23 males, 6 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=14): minimal wiping débridement and oral placebo 5 times per day<BR/>Treatment two (n=15): minimal wiping débridement and oral acyclovir 400 mg 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Ulcer stained with rose-Bengal to assess healing'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:48:06 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote): "No adverse reaction was found in the acyclovir treated group."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:48:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-H_x00f8_vding-1989">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Norway<BR/>Number enrolled: 50<BR/>Average age (range): 46 (range not given)<BR/>Sex: 27 males, 23 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=25): trifluridine 2% ointment 5 times per day<BR/>Treatment two (n=25): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Disappearance of epithelial ulceration(s) staining with fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:48:52 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Apart from a slight epithelial punctate keratopathy in a few patients in both treatment groups, no drug adverse effects were observed."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 16:41:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jackson-1984">
<CHAR_METHODS MODIFIED="2014-04-22 21:31:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: three<BR/>HSV isolation (conjunctiva): 14 positive of 29 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:12:11 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Canada<BR/>Number enrolled: 66<BR/>Average age (range): 45 (12-80)<BR/>Sex: 39 males, 27 females<BR/>Inclusion criteria: dendritic (59) or geographic (7) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=34): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=32): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 16:41:36 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Using fluorescein and rose bengal staining 'treatment failure was defined as follows: ulceration worse or unchanged by day 7, healing incomplete by day 15 or recurrence between days 15 and 21'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:50:14 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote):<BR/> "Lid swelling with burning were each reported by one patient treated with vidarabine. Four patients treated with acyclovir and two treated with vidarabine were thought to exhibit drug-related punctate epithelial keratitis."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 16:36:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jensen-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Number enrolled: 43<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-26 14:25:33 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=20): acyclovir 3% ointment 6 times per day<BR/>Treatment two (n=23): acyclovir 3% ointment 6 times per day and wiping débridement</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 16:36:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>'No epithelial defect was demonstrated after staining' with fluorescein and rose bengal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: cycloplegic, chloramphenicol ointment<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: "Superificial punctate keratitis" was observed in four cases in the acyclovir group and in three cases in the acyclovir-débridement group. Six patients "complained of stinging after application of acyclovir ointment." "No other side effects were observed, and no patients were withdrawn due to side effects."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:10:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jepson-1964">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double<BR/>Number of centres: one<BR/>Quote: "No viral identification studies were done. We considered the acute initial or recurrent dendritic figure to be definitely of herpetic etiology."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 24<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=12): distilled water with thimerosal hourly day, 2-hourly night<BR/>Treatment one (n=12): idoxuridine 0.1% solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Absence of fluorescein staining pattern'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: scopolamine<BR/>Report language: English<BR/>Study date: 1962-1963<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 17:37:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kato-1979">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 27<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=10): minimal wiping débridement<BR/>Treatment two (n=17): idoxuridine</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Fluorescein staining'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 17:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: pad (débridement group)<BR/>Report language: Japanese<BR/>Study date: not given<BR/>Financial support: not given</P>
<P>Adverse reactions (Quote): "No adverse reactions were observed in eyes treated with debridement." </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-01 21:10:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitano-1983">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single (partial)<BR/>Number of centres: 21</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 55<BR/>Average age (range): not given<BR/>Sex: 34 males, 21 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:10:48 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=25): idoxuridine every 1 or 2 hours<BR/>Treatment two (n=30): interferon-&#946; 20,000 IU/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none <BR/>Report language: Japanese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 13:14:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kitano-1985">
<CHAR_METHODS MODIFIED="2010-09-13 22:15:26 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: several</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 109 (excluding 5 withdrawals)<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-16 23:00:23 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=55, excluding 3 drop outs): idoxuridine 0.25% ointment 5 times per day<BR/>Treatment two: (n=54, excluding 2 drop outs): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 13:14:06 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: Japanese<BR/>Study date: August 1981 - May 1982<BR/>Financial support: not given<BR/>Adverse reactions: "Multiple erosion" (Table 6) occurred in seven of 56 eyes treated with idoxuridine and in 12 of 54 eyes treated with acyclovir</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 15:00:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Klauber-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-01 15:00:44 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Denmark<BR/>Number enrolled: 38<BR/>Average age (range): 51 (range not given)<BR/>Sex: 25 males, 13 females<BR/>Inclusion criteria: "typical dendritic corneal ulcerations"</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:30:45 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=20): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=18): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 15:00:40 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>'Fluorescein and Rose-Bengal'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 21:14:01 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: scopolamine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Punctate staining with Rose-Bengal was the only adverse reaction in 6 patients. A transient staining was localised at the inferior cornea and adjacent conjunctiva in 1 patient treated with ACV, corresponding to the application of the ointment. In the other 5 patients (1 treated with ACV and 4 with IDU) the staining was temporarily localised around the previous ulcer and disappeared with the discontinuation of the ointment."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kumar-1987">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: India<BR/>Number enrolled: 36<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=17): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=19): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Fluorescein staining'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:57:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-La-Lau-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: four</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Netherlands<BR/>Number enrolled: 59<BR/>Average age (range): not given<BR/>Sex: 34 males, 25 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-12 15:15:37 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=28): trifluridine 2% ointment 5 times per day<BR/>Treatment two (n=31): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "The most frequently observed side effect was superficial punctate keratopathy, showing fluorescein staining outside the area of the herpetic lesions. This occurred in about 70&amp; of patients in both groups...In both groups a few patients complained of a stinging sensation after application of the ointment, but extensive conjunctival hyperaemia was seen in only 3 patients receiving TFT."<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:58:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laibson-1964">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 18 positive of 21 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:24 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 100<BR/>Average age (range): 45 (range not given)<BR/>Sex: 72 males, 28 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis, without or with stromal keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-06-07 20:58:23 +0100" MODIFIED_BY="[Empty name]">
<P>Control one (n=53): distilled water with thimerosal 0.002% hourly day, 2-hourly night<BR/>Treatment one (n=47): idoxuridine 0.1% solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1962-1963<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 20:59:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laibson-1977">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:29 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 33<BR/>Average age (range): not given<BR/>Sex: 25 males, 8 females<BR/>Inclusion criteria: dendritic (30) or geographic (3) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=17): idoxuridine solution hourly day, 2-hourly night<BR/>Treatment two (n=16): trifluridine solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 20:59:07 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions: One patient in the idoxuridine group "developed a drug toxicity."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-22 19:49:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-2008">
<CHAR_METHODS MODIFIED="2010-05-18 18:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-22 19:49:29 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 58<BR/>Average age (range): 38 (10-65)<BR/>Sex: 22 males, 36 females<BR/>Inclusion criteria: dendritic (48) or geographic (10) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-18 18:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=28): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=30): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 18:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 18:30:56 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:50:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2009">
<CHAR_METHODS MODIFIED="2014-12-04 15:52:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 15:59:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 79<BR/>Average age (range): 44 (11-66)<BR/>Sex: 35 males, 44 females<BR/>Inclusion criteria: dendritic (32) or geographic (29) epithelial keratitis or disciform keratitis (18)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 15:56:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=34): acyclovir 0.1% solution 6 to 8 times per day<BR/>Treatment two (n=45): acyclovir 0.1% solution 6 to 8 times per day and subconjunctival interferon 100,000 units every 1 to 2 days for 6 to 8 injections and intramuscular interferon (1 million units for adults and 1 million units/square meter for children) every 1 to 2 days for 6 to 8 injections</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:50:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840;&#25110;&#22522;&#26412;&#27835;&#24840;: &#33258;&#35273;&#30151;&#29366;&#28040;&#22833;, &#20805;&#34880;&#19982;&#21050;&#28608;&#30151;&#29366;&#28040;&#36864;, &#35282;&#33180;&#28291;&#30113;&#24840;&#21512;, &#33639;&#20809;&#32032;&#26579;&#33394;&#36716;&#38452;&#25110;&#27531;&#30041;&#26497;&#23569;&#19978;&#30382;&#30528;&#33394;&#28857;, &#35282;&#33180;&#23454;&#36136;&#28024;&#28070;&#21560;&#25910;, &#27700;&#32959;&#21644;&#21518;&#24377;&#21147;&#23618;&#30385;&#35126;&#28040;&#22833;, &#35282;&#33180;&#20809;&#20999;&#38754;&#21402;&#24230;&#24674;&#22797;&#27491;&#24120;&#25110;&#21464;&#34180;, KP &#28040;&#22833;&#25110;&#26497;&#23569;, Tyndall&#24449;&#36716;&#38452;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 16:01:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% (if iridocyclitis)<BR/>Report language: Chinese<BR/>Study date: November 2005 - January 2008<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-26 15:11:23 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2013a">
<CHAR_METHODS MODIFIED="2013-11-07 16:55:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-26 15:11:23 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 87<BR/>Average age (range): 35 (19-56)<BR/>Sex: 49 males, 38 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 17:01:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=42): acyclovir 0.1% solution 6 times per day + recombinant interferon &#945;-2b 6 times per day + oral acyclovir 200 mg 6 times per day + subconjunctival ribavirin 0.2 ml every other day<BR/>Treatment two (n=45): ganciclovir 0.15% gel 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 17:03:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#32032;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 17:04:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1%<BR/>Report language: Chinese<BR/>Study date: 2010-2012<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-20 18:42:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2013b">
<CHAR_METHODS MODIFIED="2014-04-19 21:24:13 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-20 18:42:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 85<BR/>Average age (range): 38, median (16-67)<BR/>Sex: 52 males, 33 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-19 21:33:52 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=46): ganciclovir 0.15% gel 4-6 times per day<BR/>Treatment two (n=39): ganciclovir 0.15% gel 4-6 times per day + recombinant human interferon &#945;-1b 10 gm/mL 4-6 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-19 21:29:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#32032;&#38048;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-19 21:38:56 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: 2008-2010<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:51:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Lin-2011">
<CHAR_METHODS MODIFIED="2014-12-04 16:03:34 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:14:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 68<BR/>Average age (range): 36 (17-72)<BR/>Sex: 39 males, 29 females<BR/>Inclusion criteria: epithelial keratitis (59, including 6 with stromal keratitis) or stromal keratitis (9)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:05:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=34): acyclovir 0.1% solution 10 times per day<BR/>Treatment two (n=34): ganciclovir 0.15% gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:51:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840;&#25110;&#22522;&#26412;&#27835;&#24840;: &#33258;&#35273;&#30151;&#29366;&#28040;&#22833;, &#20805;&#34880;&#19982;&#21050;&#28608;&#30151;&#29366;&#28040;&#36864;, &#35282;&#33180;&#28291;&#30113;&#24840;&#21512;, &#33639;&#20809;&#32032;&#26579;&#33394;&#36716;&#38452;&#25110;&#27531;&#30041;&#26497;&#23569;&#19978;&#30382;&#30528;&#33394;&#28857;, &#35282;&#33180;&#23454;&#36136;&#28024;&#28070;&#21560;&#25910;, &#27700;&#32959;&#21644;&#21518;&#24377;&#21147;&#23618;&#30385;&#35126;&#28040;&#22833;, &#35282;&#33180;&#20809;&#20999;&#38754;&#21402;&#24230;&#24674;&#22797;&#27491;&#24120;&#25110;&#21464;&#34180;, KP &#28040;&#22833;&#25110;&#26497;&#23569;, Tyndall&#24449;&#36716;&#38452;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:52:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 0.3% 3 times per day<BR/>Report language: Chinese<BR/>Study date: January 2006 - September 2009<BR/>Financial support: not given</P>
<P>Recurrence rate: in one year, 8 episodes in acyclovir group and 2 episodes in ganciclovir group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:51:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Lin-2014">
<CHAR_METHODS MODIFIED="2014-12-04 16:19:34 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:19:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 112<BR/>Average age (range): 44 (17-72)<BR/>Sex: 59 males, 53 females<BR/>Inclusion criteria: dendritic (60) or geographic (52) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:19:22 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=56): acyclovir 0.1% solution 8 times per day<BR/>Treatment two (n=56): ganciclovir 0.15% gel 8 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:51:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840;&#65306;&#33639;&#20809;&#32032;&#26579;&#33394;&#38452;&#24615;&#65292;&#27969;&#27882;&#12289;&#30031;&#20809;&#12289;&#30140;&#30171;&#12289;&#31561;&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;&#65292;&#35282;&#33180;&#28291;&#30113;&#20462;&#22797;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:52:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: mydriatic if uveitis, oral indomethacin, oral 'antiviral', oral anti-glaucoma drug(s) if increased intraocular pressure<BR/>Report language: Chinese<BR/>Study date: February 2011 - February 2013<BR/>Financial support: not given</P>
<P>Adverse reactions: 7 occurrences in acyclovir group and 2 occurrences in ganciclovir group</P>
<P>Recurrence rate: in one year, 12 episodes in acyclovir group and 3 episodes in ganciclovir group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-18 18:34:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2009a">
<CHAR_METHODS MODIFIED="2010-05-18 18:05:52 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-18 18:20:28 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 36 eyes (29 patients)<BR/>Average age (range): 40<BR/>Sex: 17 males, 12 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-18 18:34:30 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=13 eyes, 11 patients): acyclovir 0.3% solution 6 times per day<BR/>Treatment two (n=23 eyes, 18 patients): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 18:05:09 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 18:24:18 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-12 20:52:03 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2010">
<CHAR_METHODS MODIFIED="2013-08-12 20:37:34 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-12 20:42:02 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 67 eyes (50 patients)<BR/>Average age (range): 30 (16-68<BR/>Sex: 30 males, 20 females (based on estimation of GCV group's eye data)<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-12 20:51:47 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=28 eyes, 20 patients): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=39 eyes, 30 patients): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-12 20:37:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-12 20:52:03 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 0.3% 4 times per day<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-12 16:22:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2011">
<CHAR_METHODS MODIFIED="2013-08-12 16:19:42 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-12 16:21:23 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 26<BR/>Average age (range): not given (21-53)<BR/>Sex: 14 males, 12 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-12 16:22:25 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=12): ganciclovir 0.15% gel 4 times per day + ofloxacin 0.3% 4 times per day<BR/>Treatment two (n=14): ganciclovir 0.15% gel 4 times per day + sodium hyaluronate 0.1% 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-12 16:18:33 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-12 16:22:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:52:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2012a">
<CHAR_METHODS MODIFIED="2014-12-04 16:24:56 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:26:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 80<BR/>Average age (range): not given (17-46)<BR/>Sex: 48 males, 32 females<BR/>Inclusion criteria: dendritic (38) or geographic (21) epithelial keratitis or disciform keratitis (21)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:29:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=40): acyclovir 0.1% solution 6 times per day and intravenous ribavirin 500 mg/day<BR/>Treatment two (n=40): ganciclovir 0.15% gel 4 times per day and intramuscular interferon every other day and oral vitamin C 200 mg 3 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:52:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining, with disappearance of signs of corneal inflammation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:53:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: oral indomethacin<BR/>Report language: Chinese<BR/>Study date: January 2010 - January 2012<BR/>Financial support: not given</P>
<P>Recurrence rate: in one year, 7 episodes in acyclovir group and 1 episode in ganciclovir group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:52:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2012b">
<CHAR_METHODS MODIFIED="2014-12-04 16:36:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:38:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 76<BR/>Average age (range): 35 (21-67)<BR/>Sex: 35 males, 41 females<BR/>Inclusion criteria: epithelial keratitis (51, including 15 with stromal keratitis) or stromal keratitis (25)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:39:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=38): acyclovir 0.1% solution 8 times per day<BR/>Treatment two (n=38): ganciclovir 0.15% gel 5 times per day (presumed typographic error of 0.5% gel)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:52:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840;: &#24739;&#32773;&#19981;&#23384;&#22312;&#30524;&#37096;&#21050;&#28608;&#30151;&#29366;, &#21516;&#26102;&#20854;&#30524;&#37096;&#20805;&#34880;&#24773;&#20917;&#28040;&#36864;, &#23545;&#20854;&#36827;&#34892;&#33639;&#20809;&#32032;&#26579;&#33394;, &#21576;&#38452;&#24615;, &#24739;&#32773;&#35282;&#33180;&#22522;&#36136;&#30340;&#27700;&#32959;&#21450;&#28024;&#28070;&#24773;&#20917;&#28040;&#22833;, &#35282;&#33180;&#21518;&#27785;&#30528;&#29289;&#20943;&#36864;&#31561;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:54:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 0.3% 3 times per day<BR/>Report language: Chinese<BR/>Study date: October 2009 - June 2011<BR/>Financial support: not given</P>
<P>Recurrence rate: in six months, 10 episodes in acyclovir group and 2 episodes in ganciclovir group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:48:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2014a">
<CHAR_METHODS MODIFIED="2014-12-04 16:43:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:45:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 64<BR/>Average age (range): 38 (not given)<BR/>Sex: 38 males, 28 females<BR/>Inclusion criteria: dendritic (34) or geographic (19) epithelial keratitis or disciform keratitis (11)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:46:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=32): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=32): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:48:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#30154;&#24840;: &#27835;&#30103;&#21518;&#30524;&#37096;&#21050;&#28608;, &#20805;&#34880;&#30151;&#29366;&#23436;&#20840;&#28040;&#22833;, &#35282;&#33180;&#28291;&#30113;&#23436;&#20840;&#20462;&#22797;, &#31361;&#20809;&#32032;&#26579;&#33394;&#36716;&#38452;, &#35282;&#33180;&#21518;&#27785;&#30528;&#29289;&#28040;&#22833;&#25110;&#21576;&#33394;&#32032;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:56:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 0.3% 4 times per day<BR/>Report language: Chinese<BR/>Study date: January 2007 - July 2011<BR/>Financial support: not given</P>
<P>Adverse reactions: 5 occurrences in acyclovir group and 3 occurrences in ganciclovir group</P>
<P>Recurrence rate: in one year, 6 episodes in acyclovir group and 2 episodes in ganciclovir group; in two years, 10 episodes in acyclovir group and 4 episodes in ganciclovir group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:10:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luntz-1963">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:23 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: alternate patients<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (cornea): results not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 22<BR/>Average age (range): 49 (20-83)<BR/>Sex: 15 males, 7 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-09 18:13:06 +0000" MODIFIED_BY="[Empty name]">
<P>Control (n=11): neomycin 1% ointment 2 times daily<BR/>Treatment one (n=11): idoxuridine 0.1% solution hourly</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine, pad, small scraping<BR/>Report language: English<BR/>Study date: 1962<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 13:20:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MacKenzie-1964">
<CHAR_METHODS MODIFIED="2014-04-22 21:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 80<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-26 13:20:33 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=27): carbolisation "followed by local chemotherapy"<BR/>Treatment two (n=25): idoxuridine 0.1% solution hourly day, 2-hourly night<BR/>Treatment three (n=28): idoxuridine 0.5% ointment 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'The disappearance of staining with 2 per cent fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 13:20:25 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: mydriatic<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions: One case of "S.P.K." was observed in the idoxuridine 0.1% solution group, four cases in the idoxuridine 0.5% ointment group, and three in the carbolisation group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-17 20:30:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Maichuk-1980">
<CHAR_METHODS MODIFIED="2013-08-13 19:11:02 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 19:11:22 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Russia<BR/>Number enrolled: 39<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 19:20:42 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=20): human leukocyte interferon 500-700 units/mL 5-6 times per day<BR/>Treatment two (n=19): human leukocyte interferon 500-700 units/mL + methacil (methyluracil) 3 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-17 20:30:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Quote: "corneal epithelialization"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 19:18:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:18:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maichuk-1988">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:14:27 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Russia<BR/>Number enrolled: 138<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (76) or geographic (62) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-25 22:18:35 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=63): idoxuridine 0.1% solution<BR/>Treatment two (n=39): acyclovir 3% ointment<BR/>Treatment three (n=36): acyclovir 3% ointment and leukocyte interferon 10,000 units/ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-12 15:16:37 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: variable, including corticosteroid<BR/>Report language: Russian<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:03:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Markham-1977">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 64<BR/>Average age (range): 51 (18-87)<BR/>Sex: 44 males, 20 females<BR/>Inclusion criteria: dendritic (60) or geographic (4) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=20): placebo ointment 4 times per day<BR/>Treatment one (n=21): idoxuridine 0.5% ointment 4 times per day<BR/>Treatment two (n=23): vidarabine 3% ointment 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:03:41 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: homatropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency<BR/>Adverse reactions (Quote): "No patient had to be removed from the trial because of drug toxicity. In the group receiving Ara-A, two patients developed punctate epithelial keratitis over the lower cornea and away from the ulcer area; two others developed a mild follicular reaction chiefly on the lower tarsal plate and fornix; a further patient developed an allergic skin rash, but this might equally have been due to homatropine. In the group receiving IDU, one patient developed a punctate epithelial keratitis, and three others a mild follicular reaction....All reactions were short-lived."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-09 19:27:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matth_x00e4_us-1970">
<CHAR_METHODS MODIFIED="2014-04-22 17:44:24 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised ("wurden zufällig...zugeordnet")<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 120<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-09 19:27:14 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=33): iodinisation plus panthenol ointment<BR/>Treatment two (n=27): iodinisation plus <I>para</I>-fluorophenylalanine 0.1% ointment<BR/>Treatment three (n=26): cryotherapy plus panthenol ointment<BR/>Treatment four (n=34): cryotherapy plus <I>para</I>-fluorophenylalanine 0.1% ointment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining ('Anfärbbarkeit der Hornhaut mit Fluoreszein beurteilt')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: atropine<BR/>Report language: German<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:06:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McCulley-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: double<BR/>Number of centres: five</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:03 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 64<BR/>Average age (range): 46 (15-80)<BR/>Sex: 43 males, 21 females<BR/>Inclusion criteria: dendritic (52) or geographic (12) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=34): idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=30): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:06:14 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Few adverse reactions were encountered in either treatment group....The most frequently encountered adverse reaction was superficial punctate keratopathy, which was found in 11% (<I>sic</I>) of patients receiving ACV and 42.4% (<I>sic</I>) of those receiving IDU...and was mild to moderate, not severe."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-25 22:11:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGill-1974">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:09 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 20<BR/>Average age (range): 48 (21-79)<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (15) or geographic (5) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=9): trifluridine 1% aqueous solution 5 times per day<BR/>Treatment two (n=11): trifluridine 1% viscous solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 16:28:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meurs-1985">
<CHAR_METHODS MODIFIED="2014-04-22 17:52:23 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea and conjunctiva): eligibility criterion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-13 22:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Netherlands<BR/>Number enrolled: 93<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis (culture-confirmed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:11:18 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=45): acyclovir ointment 5 times per day and albumin solution every morning<BR/>Treatment two (n=24): acyclovir ointment 5 times per day and recombinant human interferon-&#945;-2 30 million units/ml every morning<BR/>Treatment three (n=24): acyclovir ointment 5 times per day and recombinant human interferon-&#945;-2 rod every morning</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 16:28:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Partial healing ('no staining of the epithelium of the cornea with fluorescein') and complete healing ('absence of the epidelial oedema and microcystic changes')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 18:46:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Norn-1973">
<CHAR_METHODS MODIFIED="2014-04-22 21:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double<BR/>Number of centres: one<BR/>Quote: "Virus culture was not performed."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Denmark<BR/>Number enrolled: 29<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=14): idoxuridine 1% solution hourly and idoxuridine 2% ointment at bedtime and placebo ointment 6 times per day<BR/>Treatment two (n=15): idoxuridine 1% solution hourly and idoxuridine 2% ointment at bedtime and oxyphenbutazone 10% ointment 6 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-25 18:46:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1990-1993<BR/>Financial support: not given</P>
<P>Adverse reactions (Quote): "No instances were observed of allergy caused by Tanderil or ointment base."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 17:53:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Day-1975">
<CHAR_METHODS MODIFIED="2014-04-22 17:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one<BR/>Quote: "Viral isolation was not attempted routinely."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:26 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 17<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=9): idoxuridine 0.5 % ointment 5 times per day<BR/>Treatment two (n=8): proflavine hemisulphate 0.1% solution with fluorescent light exposure daily for 3 or more days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:07:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Panda-1995">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: India<BR/>Number enrolled: 80<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis (first episode)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-01 15:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=20): idoxuridine 1% ointment 5 times per day<BR/>Treatment two (n=20): trifluridine 2% ointment 5 times per day<BR/>Treatment three (n=20): acyclovir 3% ointment 5 times per day<BR/>Treatment four (n=20): brivudine 1% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>"Fluorescein staining and reduced corneal sensitivity"</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:07:37 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: 1988-1993<BR/>Financial support: not given<BR/>Adverse reactions: Follicular conjunctivitis occurred in one case in the idoxuridine group. Epithelial keratopathy was observed in four cases: three in the idoxuridine group and one in the trifluridine group.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-14 22:24:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parlato-1985">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:24 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: single (partial)<BR/>Number of centres: one<BR/>HSV isolation (cornea or conjunctiva): 11 positive of 22 tested, including 10 of 13 corneal specimens and 1 of 9 conjunctival specimens</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 22:24:30 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 34 (actually 39, but 5 dropped from description and analysis)<BR/>Average age (range): 46 (15-80)<BR/>Sex: 25 males, 9 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=8): minimal wiping débridement<BR/>Treatment two (n=14): trifluridine 1% solution 9 times per day<BR/>Treatment three (n=12): minimal wiping débridement and trifluridine 1% solution 9 times per day (beginning on second day)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 16:25:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>'The lesions were stained with fluorescein.' 'The disappearance of dendritic staining, despite the occasional persistence of fine superficial punctate keratitis'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: cycloplegic, patch (débridement group)<BR/>Report language: English<BR/>Study date: 1981-1984<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote): "Adverse reactions to treatment were minimal. One patient developed superficial punctate keratitis that resolved when treatment was stopped. Mechanical débridement was not associated with notable discomfort in any patients."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:15:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1963a">
<CHAR_METHODS MODIFIED="2014-04-22 18:03:59 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised (personal communication) "in a double-blind controlled trial"<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:40 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 23<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=13): 199 tissue-culture medium hourly day, 2-hourly night<BR/>Treatment one (n=10): idoxuridine 0.1% solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 18:15:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% twice daily, hot bathings three times daily, pad<BR/>Report language: English<BR/>Study date: 1962<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:17:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1963b">
<CHAR_METHODS MODIFIED="2014-04-22 18:17:12 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:47 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 32<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-22 18:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>Control (n=15): phenyl mercuric nitrate 0.004% solution hourly day, 2-hourly night<BR/>Treatment one (n=17): idoxuridine 0.1% solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 18:14:10 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine, heat, pad<BR/>Report language: English<BR/>Study date: 1962<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:18:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1963c">
<CHAR_METHODS MODIFIED="2014-04-22 18:17:33 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:50 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 30<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=14): placebo hourly day, 2-hourly night<BR/>Treatment one (n=16): idoxuridine 0.1% solution hourly day, 2-hourly night</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 18:18:02 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine, heat, pad<BR/>Report language: English<BR/>Study date: 1962<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 17:56:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1967a">
<CHAR_METHODS MODIFIED="2014-04-22 17:56:36 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:52 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 77<BR/>Average age (range): 33 (1-66)<BR/>Sex: 54 males, 23 females<BR/>Inclusion criteria: dendritic (74) or geographic (3) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=39): carbolization<BR/>Treatment one (n=38): idoxuridine ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 17:58:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1967b">
<CHAR_METHODS MODIFIED="2014-04-22 17:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 28<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis with disciform keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Control (n=11): carbolization<BR/>Treatment one (n=17): idoxuridine ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 13:29:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: several</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:16:01 +0000" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 169<BR/>Average age (range): 47 (2-85)<BR/>Sex: 115 males, 54 females<BR/>Inclusion criteria: dendritic (133) or geographic (36) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=82): idoxuridine ointment 5 times per day<BR/>Treatment two (n=87): vidarabine ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-26 13:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: There were six cases of "drug-related adverse experiences" but no case of superficial keratopathy in the idoxuridine group. There were ten cases of "drug-related adverse experiences" including one case of "marked superficial punctate keratitis" in the vidarabine group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:13:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: two<BR/>HSV isolation (conjunctiva): 3 positive of 81 tested before treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 41<BR/>Average age (range): not given (16-82)<BR/>Sex: 23 males, 18 females<BR/>Inclusion criteria: dendritic (36) or geographic (5) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=21): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=20): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry and governmental agency<BR/>Adverse reactions (Quote): "Adverse reactions for vidarabine included two instances of superficial punctate keratitis and one instance of severe pain (possibly related but lasting only one day). In the acyclovir-treated group, one patient reported itching and discontinued the drug within one week of entering the study...[but] there was no objective sign of allergic reaction. Approximately 25% of patients in both groups had superficial punctate keratitis...not believed to be drug-related."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:16:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Power-1991">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Ireland<BR/>Number enrolled: 60<BR/>Average age (range): 45 (9-72)<BR/>Sex: 43 males, 17 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-01 15:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=30): trifluridine 1% solution 5 times per day<BR/>Treatment two (n=30): brivudine 0.1% solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:16:32 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Side effects were seen infrequently. Stinging on initial application of the drops was noted by three patients in the BVDU group and in five who were treated with TFT....One patient in the TFT group developed a punctate epitheliopathy...There was no evidence of epithelial toxicity in any of the patients treated with BVDU."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:19:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Ramirez-2002">
<CHAR_METHODS MODIFIED="2014-04-22 18:19:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: not given<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 19:59:38 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Mexico<BR/>Number enrolled: 19<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 20:01:57 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=9): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=10): ganciclovir 0.15% gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 20:02:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 20:02:22 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 21:50:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Richter-1986">
<CHAR_METHODS MODIFIED="2014-04-22 21:50:39 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 57<BR/>Average age (range): not given (11-71)<BR/>Sex: 34 males, 23 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-01 15:10:06 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=32): brivudine solution<BR/>Treatment two (n=25): brivudine solution and epithelial abrasion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:17:54 +0000" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining ('den fluoreszeinnegativen Schluß der Dendriticafigur')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: cycloplegic, antibiotic<BR/>Report language: German<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 21:56:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Serifoglu-1987">
<CHAR_METHODS MODIFIED="2014-04-22 21:56:17 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:18:07 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Turkey<BR/>Number enrolled: 25<BR/>Average age (range): 36 (4-78)<BR/>Sex: 17 males, 8 females<BR/>Inclusion criteria: dendritic (21) or geographic (4) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=12): minimal wiping débridement and idoxuridine 0.5% ointment 5 times per day<BR/>Treatment two (n=13): minimal wiping débridement and acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: Turkish<BR/>Study date: 1985-1986<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-13 19:18:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Shen-2014">
<CHAR_METHODS MODIFIED="2014-12-13 16:14:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-13 16:22:56 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 86<BR/>Average age (range): not given (8-72)<BR/>Sex: 40 males, 38 females (78 patients; 86 eyes)<BR/>Inclusion criteria: punctate or dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-13 19:17:04 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=43): ganciclovir gel 4 times per day + bovine fibroblast growth factor solution 4 times per day + oral acyclovir<BR/>Treatment two (n=43): debridement with sterile needle + ganciclovir gel 4 times per day + bovine fibroblast growth factor solution 4 times per day + oral acyclovir</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-13 16:22:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840; : &#35282;&#33180;&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;, &#28291;&#30113;&#24840;&#21512;, &#33639;&#20809;&#32032;&#26579;&#33394;(-), &#22522;&#36136;&#27700;&#32959;&#28040;&#22833;, KP(-), &#37096;&#20998;&#36951;&#30041;&#35282;&#33180;&#20113;&#32755;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-13 19:18:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin eye drops 4 times per day; atropine 1% if uveitis; gatifloxacin ointment following debridement<BR/>Report language: Chinese<BR/>Study date: January 2009 - June 2013<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 19:17:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Srinivas-1993">
<CHAR_METHODS MODIFIED="2014-04-22 19:17:48 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: India<BR/>Number enrolled: 40<BR/>Average age (range): not given<BR/>Sex: 18 males, 14 females, 8 children<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=20): idoxuridine solution 5 times per day<BR/>Treatment two (n=20): idoxuridine solution 5 times per day and oral acyclovir 200 mg 3 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: cycloplegic<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:44:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Struck-1989">
<CHAR_METHODS MODIFIED="2014-04-22 18:44:57 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 109<BR/>Average age (range): not given (1-89)<BR/>Inclusion criteria: dendritic epithelial keratitis without or with stromal keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Control (n=34): débridement, débridement with iodinisation, cryoapplication, or other<BR/>Treatment one (n=28): idoxuridine 0.1% solution 5 times per day<BR/>Treatment two (n=16): trifluridine 1% solution 5 times per day<BR/>Treatment three (n=31): brivudine 0.1% solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal straining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-03 18:32:23 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: German<BR/>Study date: 1981-1985<BR/>Financial support: not given<BR/>Adverse reactions (superficial keratopathy): none reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-13 15:57:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sugar-1980">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: six</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:12:21 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 61<BR/>Average age (range): 46 (range not given)<BR/>Sex: 43 males, 18 females<BR/>Inclusion criteria: dendritic (44) or geographic (17) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=27): idoxuridine 0.1% solution 19 times per day<BR/>Treatment two (n=34): trifluridine 1% solution 9 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:57:00 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: "One patient taking IDU developed follicular conjunctivitis." "No patients developed allergic reactions to F<SUB>3</SUB>T."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:52:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Sun-2013a">
<CHAR_METHODS MODIFIED="2014-12-04 16:54:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 16:57:12 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 75<BR/>Average age (range): 30 (17-63)<BR/>Sex: 51 males, 25 females (no explanation for total of 76 instead of 75)<BR/>Inclusion criteria: dendritic (51) or geographic (25) epithelial keratitis (no explanation for total of 76 instead of 75)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 16:57:21 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=37): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=38): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:52:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 16:58:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: ofloxacin 4 times per day<BR/>Report language: Chinese<BR/>Study date: September 2010 - January 2013<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-14 22:25:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1976a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single (partial)<BR/>Number of centres: one<BR/>HSV isolation (cornea and conjunctiva): 55 positive of 73 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 22:25:14 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Germany<BR/>Number enrolled: 55 (actually 73, but only 55 were culture-positive)<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=17): thermomechanical débridement and placebo solution 3 times per day<BR/>Treatment two (n=22): thermomechanical débridement and human leukocyte interferon 62,500 units/ml 3 times per day<BR/>Treatment three (n=16): human leukocyte interferon 62,500 units/ml 3 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:19:18 +0000" MODIFIED_BY="[Empty name]">
<P>'Fluorescein-negative healing of the corneal epithelium, which was defined as complete closure of all erosions except for some single dye-positive micropunctations'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: scopolamine, lubricating ointment, pad<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1976b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 40 positive of 51 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 40<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=18): thermomechanical débridement and human albumin 2 times per day<BR/>Treatment two (n=22): thermomechanical débridement and human leukocyte interferon 3 million units/ml 2 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: homatropine, lubricating ointment, pad<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1978a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one<BR/>HSV isolation (cornea): 42 positive of 42 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 42<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=18): thermomechanical débridement plus human leukocyte interferon 6 million units/ml once per day<BR/>Treatment two (n=24): minimal wiping débridement plus human leukocyte interferon 6 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: homatropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-14 22:26:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1978b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 38 positive of 53 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 22:26:10 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Germany<BR/>Number enrolled: 38 (actually 53, but only 38 were culture-positive)<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=18): thermomechanical débridement plus human leukocyte interferon 1 million units/ml once per day<BR/>Treatment two (n=20): thermomechanical débridement plus human fibroblast interferon 1 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: homatropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-13 22:05:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1981a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): eligibility criterion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-13 22:05:57 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Number enrolled: 51<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis (culture-confirmed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=24): trifluridine 1% solution 5 times per day plus human leukocyte interferon 10 million units/ml once per day<BR/>Treatment two (n=27): trifluridine 1% solution 5 times per day plus human leukocyte interferon 30 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-13 22:06:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1981b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): eligibility criterion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-13 22:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Number enrolled: 70<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis (culture-confirmed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=20): trifluridine 1% solution 5 times per day and albumin solution once per day<BR/>Treatment two (n=24): trifluridine 1% solution 5 times per day and human leukocyte interferon 1 million units/ml once per day<BR/>Treatment three (n=26): trifluridine 1% solution 5 times per day and human leukocyte interferon 30 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-09-13 22:06:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1984a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): eligibility criterion</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-09-13 22:06:29 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany<BR/>Number enrolled: 36<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (29) or geographic (7) epithelial keratitis (culture-confirmed)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=17): trifluridine 1% solution 5 times per day plus human leukocyte interferon 30 million units/ml once per day<BR/>Treatment two (n=19): trifluridine 1% solution 5 times per day plus human leukocyte interferon 100 million units/ml once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-01 21:12:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1985">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 32 positive of 42 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Germany<BR/>Number enrolled: 32<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:12:20 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=17): trifluridine 1% solution 5 times per day plus human interferon-&#945; 30 million units/ml once per day<BR/>Treatment two (n=15): trifluridine 1% solution 5 times per day plus recombinant interferon-&#945;-2 23 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-02-09 18:20:14 +0000" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining 'except for minor punctate stainings'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-14 22:27:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sundmacher-1987">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 45 positive of 75 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-14 22:27:42 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Germany<BR/>Number enrolled: 45 (actually 75, but only 45 were culture-positive and compliant)<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=16): trifluridine 1% solution 5 times per day plus recombinant interferon-&#945; 30 million units/ml once per day<BR/>Treatment two (n=14): trifluridine 1% solution 5 times per day plus recombinant interferon-&#947; 30 million units/ml once per day<BR/>Treatment three (n=8): trifluridine 1% solution 5 times per day plus recombinant interferon-&#945; 0.3 million units/ml once per day and interferon-&#947; 0.3 million units/ml once per day<BR/>Treatment four (n=7): trifluridine 1% solution 5 times per day plus recombinant interferon-&#945; 1.5 million units/ml once per day and interferon-&#947; 1.5 million units/ml once per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 21:23:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Tanaka-1988a">
<CHAR_METHODS MODIFIED="2013-11-26 20:29:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: 18</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-26 20:36:31 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Japan<BR/>Number enrolled: 36<BR/>Average age (range): 47 (not given)<BR/>Sex: 19 males, 17 females<BR/>Inclusion criteria: dendritic (33) or geographic (3) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 21:23:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=16): recombinant interferon-&#945;-2a (Ro22-8181) 1000 IU/ml 4 times per day<BR/>Treatment two (n=20): recombinant interferon-&#945;-2a (Ro22-8181) 10 million IU/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-26 20:28:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-26 20:45:32 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine, micronomicin<BR/>Report language: Japanese<BR/>Study date: 1983<BR/>Financial support: not given (study medicines were provided by pharmaceutical firm)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-26 20:33:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Tanaka-1988b">
<CHAR_METHODS MODIFIED="2013-08-30 19:19:25 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: single (partial "double blind method")<BR/>Number of centres: 31</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-30 19:23:47 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Japan<BR/>Number enrolled: 137<BR/>Average age (range): not given<BR/>Sex: 75 males, 62 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-26 20:33:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=71): idoxuridine solution every 1 or 2 hours<BR/>Treatment two (n=30): recombinant interferon-&#945; (Ro22-8181) 10 million IU/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-30 19:18:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-30 19:18:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Japanese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-22 18:49:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Travers-1978">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:12:28 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 100<BR/>Average age (range): 50 (range not given)<BR/>Sex: 52 males, 48 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=50): vidarabine ointment 5 times per day<BR/>Treatment two (n=50): trifluridine solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-22 18:49:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: "mydriatics and antiglaucoma therapy was given when necessary"<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchida-1981">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by code<BR/>Masking: double<BR/>Number of centres: eight</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 54<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]">
<P>Control (n=17): minimal wiping débridement and human albumin 4 times per day<BR/>Treatment one (n=17): minimal wiping débridement and idoxuridine solution hourly day, 2-hourly night<BR/>Treatment two (n=20): minimal wiping débridement and fibroblast interferon 1 million units/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Disappearance of gross staining areas with fluorescein'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: gentamicin solution<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Uchida-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): 41 positive (by culture or immunofluorescent antigen) of 44 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 68 (5 others disqualified)<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=32): human fibroblast interferon 1000 units/ml 4 times per day<BR/>Treatment two (n=36): human fibroblast interferon 1 million units/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: none<BR/>Report language: Japanese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-04-25 19:50:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Bijsterveld-1980">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-25 19:50:18 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: Netherlands<BR/>Number enrolled: 56<BR/>Average age (range): 46 (range not given)<BR/>Sex: 36 males, 20 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=28): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=28): trifluridine 2% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining; 'no epithelial edema and cystic changes were present in the epithelium covering the site of the original ulcer'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:19:44 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: scopolamine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "In 5 out of 17 patients that received the virostatic treatment longer than 14 days a very mild diffuse epithelial staining was observed with Bengal rose. Four of these patients received ara-A and 1 received treatment with TFT."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:20:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Bijsterveld-1989">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (cornea): results not reported</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-02-09 18:20:43 +0000" MODIFIED_BY="[Empty name]">
<P>Country: Netherlands<BR/>Number enrolled: 41<BR/>Average age (range): 39 (7-81)<BR/>Sex: 22 males, 19 females<BR/>Inclusion criteria: dendritic (33) or geographic (8) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-22 19:11:15 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=22): brivudine 1% ointment 5 times per day and albumin rod daily<BR/>Treatment two (n=19): brivudine 1% ointment 5 times per day and recombinant interferon-&#945;-2 rod (1.5 million units) daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Wound closure'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:20:23 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "In the present investigation no toxic effects, including drug allergy, were observed."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:21:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vannini-1986">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 13 positive of 20 tested, including 11 HSV-1 and 2 HSV-2</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Italy<BR/>Number enrolled: 20<BR/>Average age (range): 41 (18-76)<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-01 21:14:26 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=10): idoxuridine solution 7 times per day<BR/>Treatment two (n=10): interferon-&#946; 1 million units/ml 7 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:21:46 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions: Seven cases in the idoxuridine group developed "superficial punctate keratitis [that] was evident in the days subsequent to the disappearance of dendritis (<I>sic</I>), which must be interpreted as a toxic effect of IDU on the corneal epithelium."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 19:32:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2004">
<CHAR_METHODS MODIFIED="2010-03-02 19:27:29 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-03-02 19:30:30 +0000" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 60<BR/>Average age (range): 36 (7-65)<BR/>Sex: 32 males, 28 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 19:31:14 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=30): topical acyclovir 0.1% solution 5 to 8 times per day<BR/>Treatment two (n=30): oral acyclovir 200 mg 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-02 19:32:00 +0000" MODIFIED_BY="[Empty name]">
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-03-02 19:32:29 +0000" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:48:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wang-2014a">
<CHAR_METHODS MODIFIED="2014-12-05 22:41:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-05 22:42:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 104<BR/>Average age (range): 38 (18-71)<BR/>Sex: 76 males, 28 females<BR/>Inclusion criteria: epithelial keratitis (shallow, deep, combined)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-05 22:43:46 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=52): topical acyclovir solution 8 times per day<BR/>Treatment two (n=52): topical ganciclovir gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:45:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#27835;&#24840;:&#24739;&#32773;&#24739;&#30524;&#30340;&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;,&#20805;&#34880;&#28040;&#36864;, &#35282;&#33180;&#22522;&#36136;&#26080;&#27700;&#32959;&#21644;&#28024;&#28070;, &#21518;&#24377;&#21147;&#23618;&#35126;&#30385;&#28040;&#36864;, &#35282;&#33180;&#21518;&#27785;&#30528;&#29289;&#21560;&#25910;, &#28291;&#30113;&#24840;&#21512;&#33391;&#22909;, &#33639;&#20809;&#33394;&#26579;&#33394;&#21576;&#38452;&#24615;, &#25151;&#27700;&#38378;&#36745;&#21576;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-05 22:48:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: December 2011 to December 2013<BR/>Financial support: not given</P>
<P>Adverse reactions: 11 occurrences of pain or discomfort in acyclovir group and 3 occurrences of pain or discomfort in ganciclovir group</P>
<P>Recurrence rate: in one year, 11 episodes in acyclovir group and 3 episodes in ganciclovir group</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:23:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wellings-1972">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: double<BR/>Number of centres: two</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:12:46 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain and United States<BR/>Number enrolled: 78<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic (69) or geographic (9) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=38): idoxuridine 0.1% solution 5 times per day<BR/>Treatment two (n=40): trifluridine 1% solution 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein and rose-Bengal staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:23:01 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: governmental agency<BR/>Adverse reactions: "No symptoms or signs were observed in either center during the two-week period of administration of either drug that could be ascribed to side effect of toxicity from, or allergy to either preparation."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:25:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wilhelmus-1981a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by table<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:12:49 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 50<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=25): minimal wiping débridement and acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=25): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>'Disappearance of specific Bengal-rose staining of the precise site of the healing dendritic ulceration'</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:25:28 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: private foundation<BR/>Adverse reactions (Quote): "Whether debridement was performed or not, the only adverse symptom related to topical acyclovir was a mild transient stinging sensation immediately after application of the antiviral ointment in nine (18%) patients. We found mild punctate epithelial staining with Bengal rose of the inferior bulbar conjunctiva and corneoscleral limbus remote from the original lesion in eight (16%) patients...[that] disappeared within three days after discontinuation of the antiviral medication."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-13 15:56:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2009a">
<CHAR_METHODS MODIFIED="2010-05-18 17:11:47 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 15:56:29 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 36<BR/>Average age (range): 45 (10-68)<BR/>Sex: 19 males, 17 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 15:56:27 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=18): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=18): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 15:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:56:22 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-18 15:52:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamazaki-1984a">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 40<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-18 15:52:13 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=21): minimal wiping débridement and idoxuridine 0.1% solution<BR/>Treatment two (n=19): minimal wiping débridement and fibroblast interferon 20,000 units/ml</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamazaki-1984b">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:26 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 74<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=41): albumin solution 4 times per day<BR/>Treatment two (n=33): human leukocyte interferon 20 million units/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-03-02 16:30:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamazaki-1984c">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: single<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Country: Japan<BR/>Number enrolled: 36<BR/>Average age (range): not given<BR/>Sex: not given<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-02 16:30:02 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=16): recombinant interferon-&#945; 1000 units/ml 4 times per day<BR/>Treatment two (n=20): recombinant interferon-&#945; 10 million units/ml 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Nonstudy interventions: not given<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-22 19:46:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2000">
<CHAR_METHODS MODIFIED="2010-05-18 17:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>Allocation method: not given<BR/>Masking: double<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-22 19:46:37 +0100" MODIFIED_BY="[Empty name]">
<P>Country: China<BR/>Number enrolled: 137<BR/>Average age (range): 33 (1-65)<BR/>Sex: 93 males, 44 females<BR/>Inclusion criteria: dendritic (55) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-18 17:53:01 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=70): acyclovir 0.1% solution<BR/>Treatment two (n=67): ganciclovir 0.1% solution</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-18 17:44:46 +0100" MODIFIED_BY="[Empty name]">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-05-18 17:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: not given<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: governmental agency</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 17:11:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Yang-2008">
<CHAR_METHODS MODIFIED="2013-11-07 17:05:31 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 17:07:40 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 62<BR/>Average age (range): 40 (20-73)<BR/>Sex: 27 males, 35 females<BR/>Inclusion criteria: dendritic (49) or geographic (13) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 17:07:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=30): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=32): ganciclovir 0.15% gel 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 17:11:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#32032;&#38048;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 17:10:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% for iridocyclitis; oral indomethacin 25 mg 3 times per day<BR/>Report language: Chinese<BR/>Study date: 2010-2012<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-07 21:27:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yeakley-1981">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised by code<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 13 positive of 40 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:13:02 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States<BR/>Number enrolled: 40<BR/>Average age (range): 49 (7-81)<BR/>Sex: 27 males, 13 females<BR/>Inclusion criteria: dendritic (38) or geographic (2) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=21): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=19): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:27:10 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: none<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: not given<BR/>Adverse reactions (Quote): "Diffuse superficial punctate epitheliopathy was noted in one patient on acyclovir...and resolved within two days after the drug was discontinued. No other adverse effects were noted in either drug treatment group during the course of therapy."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-01 15:50:06 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Young-1982">
<CHAR_METHODS MODIFIED="2010-02-15 17:33:27 +0000" MODIFIED_BY="[Empty name]">
<P>Allocation method: randomised<BR/>Masking: double<BR/>Number of centres: one<BR/>HSV isolation (conjunctiva): 35 positive of 93 tested</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-25 22:13:06 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Great Britain<BR/>Number enrolled: 93<BR/>Average age (range): 51 (range not given)<BR/>Sex: 62 males, 31 females<BR/>Inclusion criteria: dendritic (85) or geographic (8) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Treatment one (n=45): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=48): acyclovir 3% ointment 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-01 15:50:06 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Rose Bengal</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-07 21:28:56 +0100" MODIFIED_BY="[Empty name]">
<P>Nonstudy interventions: atropine<BR/>Report language: English<BR/>Study date: not given<BR/>Financial support: pharmaceutical industry<BR/>Adverse reactions (Quote): "Two patients developed adverse symptoms during therapy possibly due to their antiviral therapy. One patient on acyclovir experienced an allergic response; this could also have been caused by the atropine drops being administered concurrently. One patient on ara-A complained of grittiness after application of the ointment. No other adverse effect was seen in this group of patients."<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-13 15:59:33 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Yu-2012a">
<CHAR_METHODS MODIFIED="2013-08-13 15:53:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 15:58:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 60<BR/>Average age (range): 39 (17-60)<BR/>Sex: 32 males, 28 females<BR/>Inclusion criteria: dendritic (36) or geographic (24) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 15:59:33 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=30): ganciclovir 0.1% solution 8 times per day<BR/>Treatment two (n=30): foscarnet 3% solution 6 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 15:59:05 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 15:59:11 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: 2008-2009<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:52:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhang-2014">
<CHAR_METHODS MODIFIED="2014-12-04 17:04:40 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 17:05:55 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 84<BR/>Average age (range): 39 (22-60)<BR/>Sex: 46 males, 38 females<BR/>Inclusion criteria: dendritic (55) or geographic (29) epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 17:06:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=42): acyclovir 0.1% solution every 2 hours<BR/>Treatment two (n=42): ganciclovir 0.15% gel 5 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:52:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#24739;&#32773;&#30340;&#30524;&#37096;&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;, &#35282;&#33180;&#20805;&#34880;&#28040;&#36864;, &#28291;&#30113;&#24471;&#21040;&#20462;&#22797;, &#24182;&#19988;&#33639;&#20809;&#32032;&#26579;&#33394;&#36716;&#20026;&#38452;&#24615;, &#28024;&#28070;&#21644;&#27700;&#32959;&#28040;&#22833;, &#35282;&#33180;&#21518;&#30340;&#27785;&#30528;&#29289;&#21576;&#29616;&#33394;&#32032;&#24615;&#25110;&#32773;&#28040;&#22833;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:06:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: January 2012 - June 2013<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-05 22:53:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhao-2006">
<CHAR_METHODS MODIFIED="2014-12-04 17:09:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 17:10:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 124<BR/>Average age (range): 37 (12-64)<BR/>Sex: 81 males, 43 females<BR/>Inclusion criteria: epithelial keratitis (106) or stromal keratitis (18)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 17:11:00 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=62): acyclovir solution every 1-2 hours<BR/>Treatment two (n=62): ganciclovir gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-05 22:53:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#21050;&#28608;&#30151;&#29366;&#28040;&#22833;, &#30693;&#35273;&#24674;&#22797;, &#28291;&#30113;&#38754;&#24840;&#21512;, &#22522;&#36136;&#23618;&#27700;&#32959;&#28040;&#22833;, &#33639;&#20809;&#32032;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:12:16 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% and "antibiotic eye drop"<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-11-07 17:19:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhen-2012">
<CHAR_METHODS MODIFIED="2013-11-07 17:12:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-11-07 17:15:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 128<BR/>Average age (range): not given (15-65)<BR/>Sex: 55 males, 73 females<BR/>Inclusion criteria: dendritic or geographic epithelial keratitis (some eyes may have had disciform stromal keratitis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-11-07 17:16:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=64): acyclovir 0.1% solution 8 times per day<BR/>Treatment two (n=64): ganciclovir 0.15% gel 4 times per day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-11-07 17:19:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining ('&#33639;&#20809;&#32032;&#26579;&#33394;&#38452;&#24615;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-07 17:18:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: atropine 1% for iridocyclitis; dexamethasone 0.05% for keratouveitis<BR/>Report language: Chinese<BR/>Study date: 2009-2012<BR/>Financial support: university</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-12-04 17:25:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zheng-2010">
<CHAR_METHODS MODIFIED="2014-12-04 17:14:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-12-04 17:22:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 210 (not including 38 cases of stromal keratitis)<BR/>Average age (range): not given (18-65)<BR/>Sex: 185 males, 62 females (gender distribution for epithelial keratitis patients not reported separately)<BR/>Inclusion criteria: dendritic (178) or geographic (31) epithelial keratitis (38 cases, including 35 disciform keratitis and 3 necrotizing keratitis, are being excluded from this analysis)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-12-04 17:20:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one (n=104): ganciclovir 0.1% solution 6 times per day<BR/>Treatment two (n=105): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-12-04 17:25:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Healing ('&#27835;&#24840;: &#21050;&#28608;&#30151;&#29366;&#28040;&#22833;, &#30693;&#35273;&#24674;&#22797;, &#28291;&#30113;&#38754;&#24840;&#21512;')</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-12-04 17:22:12 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: mydriatic and subconjunctival dexamethasone 3 mg for stromal keratitis<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-26 12:39:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhu-2012">
<CHAR_METHODS MODIFIED="2013-08-13 17:17:28 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Allocation method: randomised<BR/>Masking: none<BR/>Number of centres: one</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 17:18:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: China<BR/>Number enrolled: 74 eyes (68 participants)<BR/>Average age (range): not given (16-67)<BR/>Sex: 32 males, 36 females<BR/>Inclusion criteria: dendritic epithelial keratitis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-26 12:39:59 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment one (n=38): ganciclovir 0.15% gel 4 times per day<BR/>Treatment two (n=36): ganciclovir 0.15% gel 4 times per day + interferon 1 million units/ml (0.5 ml) subconjunctival injection every other day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-13 17:17:28 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Fluorescein staining</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 17:17:29 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Nonstudy interventions: none<BR/>Report language: Chinese<BR/>Study date: not given<BR/>Financial support: not given</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-12-13 17:04:31 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:05:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abboud-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:05:49 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=39): idoxuridine 0.1% solution<BR/>Treatment two (n=24, subset of treatment one following failure to heal within one week using idoxuridine): iodine cauterisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-09 19:22:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akberova-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-09 19:22:39 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=118): <I>para</I>-aminobenzoic acid 0.007% (Aktipal), an interferon inducer, 4 to 6 times per day<BR/>Treatment two (n=34): idoxuridine solution 8 to 10 times per day<BR/>Treatment three (n=41): acyclovir ointment 5 times per day<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:06:48 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Assetto-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:06:48 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=8): wiping debridement<BR/>Treatment two (n=8): idoxuridine 0.1% solution 5 times per day<BR/>Treatment three (n=8): cytarabine solution 5 times per day<BR/>Treatment four (n=8): idoxuridine 0.1% solution and oral isoprinosine 3 times per day<BR/>Treatment five (n=8): cytarabine solution and oral isoprinosine 3 times per day<BR/>Treatment six (n=8): trifluridine 1% solution 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 19:52:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Babushkin-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 19:52:11 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=60): idoxuridine 0.1% solution<BR/>Treatment two (n=24): acyclovir 3% ointment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:17:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bianchetti-1964">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:17:05 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=31): idoxuridine 0.1% solution (Stoxil or Dispersa)<BR/>Treatment two (n=33): idoxuridine ointment or gel (Dispersa or Chauvin-Blache)<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:17:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Butikova-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:17:13 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Control (n=10): historical controls<BR/>Treatment one (n=18): antiherpetic immunoglobulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-09 22:20:38 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Cao-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-09 22:20:38 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=30): ganciclovir 0.15% gel<BR/>Treatment two (n=30): ganciclovir 0.15% gel and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:42:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Cao-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:42:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=28): acyclovir 0.1% solution 4 times daily and oral antiviral (plus dexamethsone and tobramycin for stromal keratitis)<BR/>Treatment two (n=30): acyclovir 0.1% solution 4 times daily and oral antiviral and oral botanical extract twice daily (plus dexamethonse and tobramycin for stromal keratitis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:46:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:46:32 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=80): antiviral solution<BR/>Treatment two (n=86): antiviral solution and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 15:01:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 15:01:40 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=43): acyclovir 0.1% solution<BR/>Treatment two (n=69): acyclovir 0.1% solution and recombinant interferon-&#945;-2b and intravenous acyclovir<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:46:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:46:52 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=54): antiviral<BR/>Treatment two (n=46): antiviral and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 19:54:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corina-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 19:54:18 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome not based on epithelial healing</P>
<P>Treatment one (n=65): idoxuridine<BR/>Treatment two (n=76): acyclovir ointment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Corina-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:09 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=26): acyclovir ointment<BR/>Treatment two (n=26): acyclovir ointment with botanical extract<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deng-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:20 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=53): acyclovir 0.1% solution<BR/>Treatment two (n=53): acyclovir 0.1% solution and subconjunctival ribavirin and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Du-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:27 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=71): antiviral<BR/>Treatment two (n=78): antiviral and traditional Chinese medicine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:18:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dundarov-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:18:09 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Control (n=19): "symptomatic medicines"<BR/>Treatment one (n=55): pandavir (nigericin 0.001%) 2 times on first day then 10 to 12 times per day<BR/>Treatment two (n=52): pandavir (nigericin 0.001%) with interferon-&#945; 10,000 to 50,000 IU/ml 2 times on first day then 10 to 12 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:19:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Elze-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:19:57 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=97): ethyldeoxyuridine 0.15% solution topically and 0.5% subconjunctivally daily<BR/>Treatment two (n=71): ethyldeoxyuridine 2% solution topically and 0.5% subconjunctivally and 0.3% gel, with initial iodinisation debridement<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:20:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fellinger-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:20:27 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=13): idoxuridine 0.1% solution and 0.5% ointment<BR/>Treatment two (n=16): trifluridine 1% solution and 2% ointment<BR/>Treatment three (n=13): iodinisation debridement and idoxuridine<BR/>Treatment four (n=18): iodinisation debridement and trifluridine<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:36 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=52): acyclovir 0.1% solution<BR/>Treatment two (n=52): acyclovir 0.1% solution and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:22:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galin-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:22:03 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): idoxuridine 0.5% solution<BR/>Treatment two (n=19): polyinosinic-polycytidylic acid 0.1% solution<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gao-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:46 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=42): antiviral therapy<BR/>Treatment two (n=44): antiviral therapy and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:22:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gilkes-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:22:29 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=77): historical controls treated by "carbolization or iodization" debridement<BR/>Treatment two (n=82): idoxuridine 0.1% solution hourly or 0.5% ointment 2-hourly<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:22:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Gong-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:22:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=55): antiviral<BR/>Treatment two (n=55): antiviral and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 20:54:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gu-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 20:54:01 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): acyclovir 0.1% solution 4 to 6 times per day<BR/>Treatment two (n=19): acyclovir 0.1% solution 4 to 6 times per day and recombinant interferon-&#945;-2b 3 to 4 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-11 21:27:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Gulinuer-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-11 21:27:26 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Non-concurrent/non-randomised treatment allocation</P>
<P>Treatment one (n=37): acyclovir 0.1% solution 6 times per day<BR/>Treatment two (n=48): ganciclovir 0.15% gel 4 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:24:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gundersen-1936">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:24:20 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Control (n=53): historical controls using "various mydriatics and antiseptics"<BR/>Treatment one (n=97): focal iodinisation debridement<BR/>Treatment two (n=45): entire corneal iodinisation debridement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-23 16:37:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-23 16:37:25 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one: (n=34): "conventional antiviral therapy"<BR/>Treatment two (n=35): cryotherapy and "conventional antiviral therapy"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:47:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hao-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:47:55 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=60): antiviral<BR/>Treatment two (n=68): antiviral and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:08:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-He-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:08:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=34): antiviral<BR/>Treatment two (n=34): autologous serum</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:24:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Herbort-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:24:43 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=20): scraping debridement with trifluridine 1% solution 8 times daily for one day then 5 times daily<BR/>Treatment two (n=11): trifluridine 1% solution 8 times daily for one day then 5 times daily<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:25:08 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hilsdorf-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:25:08 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): iodinisation debridement with idoxuridine ointment<BR/>Treatment two (n=20): cryotherapy with idoxuridine ointment<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:23:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Horode_x0148_scy-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:23:32 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=17): idoxuridine 0.1% solution<BR/>Treatment two (n=17): cytarabine 0.1% solution<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:20:06 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Hu-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:20:06 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=30): ganciclovir<BR/>Treatment two (n=40): ganciclovir and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-11-07 15:38:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Huang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-11-07 15:38:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=62): acyclovir 0.1% solution<BR/>Treatment two (n=62): ganciclovir 0.15% gel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:48:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2008b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:48:22 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=33): antiviral<BR/>Treatment two (n=33): antiviral and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 21:15:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 21:15:06 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=36): acyclovir 0.1% solution<BR/>Treatment two (n=29): acyclovir 0.1% solution and recombinant interferon-&#945; solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:34:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Huang-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:34:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=34): ganciclovir 0.15% gel 4 times daily<BR/>Treatment two (n=34): ganciclovir 0.15% gel 4 times daily and oral botanical extract (qinggan jiedu)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-18 17:48:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Inocencio-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-18 17:48:49 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=9): idoxuridine 0.5% ointment 5 times daily<BR/>Treatment two (n=14): acyclovir 3% ointment 5 times daily<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-11 21:58:40 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Jiang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-11 21:58:40 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Varied eligibility criteria (both shallow and deep forms)</P>
<P>Treatment one (n=22, shallow type): acyclovir 0.1% solution + basic fibroblast growth factor<BR/>Treatment two (n=23, shallow type): acyclovir 0.1% solution + tobramycin-dexamethasone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 21:15:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jin-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 21:15:16 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=41): acyclovir 0.1% solution<BR/>Treatment two (n=59): recombinant human interferon-&#945; 1 million IU/ml</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-11 22:24:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Jing-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-11 22:24:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=22): acyclovir 0.1% solution 5 times daily<BR/>Treatment two (n=24): ganciclovir 0.15% gel 5 times daily</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:26:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:26:26 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome not based on epithelial healing</P>
<P>Treatment one (n=12): wiping debridement and placebo ointment 5 times per day<BR/>Treatment two (n=13): wiping debridement and acyclovir 3% ointment 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:26:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasparov-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:26:36 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=16): idoxuridine<BR/>Treatment two (n=43): polyadenylic:polyuridylic acid solution<BR/>Treatment three (n=167): various immunomodulators such as mebavin (IBC)<BR/>Treatment four (n=33): immunomodulator(s) with debridement by either diathermy or cryotherapy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:27:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasparov-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:27:03 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Control (n=30): "nonspecific drugs, such as antibiotics, sulphanyl amides, vitamins"<BR/>Treatment one (n=28): idoxuridine 0.1% solution<BR/>Treatment two (n=27): polyadenylic-polyuridylic acid solution<BR/>Treatment three (n=15): idoxuridine 0.1% solution and polyadenylic-polyuridylic acid solution<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:27:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasparov-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:27:15 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=46): idoxuridine<BR/>Treatment two (n=80): thermal debridement and polyadenylic-polyuridylic acid solution in soft contact lens</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:27:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasparov-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:27:36 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=45): acyclovir 3% ointment<BR/>Treatment two (n=65): polyadenylic-polyuridylic acid solution<BR/>Treatment three (n=40): acyclovir 3% ointment and polyadenylic-polyuridylic acid solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:27:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koev-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:27:55 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=25): acyclovir ointment<BR/>Treatment two (n=24): acyclovir ointment and pandavir<BR/>Treatment three (n=26): acyclovir ointment and pandavir and laser debridement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:25:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kolomiets-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:25:04 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=10): non-specific immunoglobulin<BR/>Treatment two (n=14): antiherpetic immunoglobulin<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 21:15:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuyama-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 21:15:48 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=not stated): interferon-&#945; 1 million IU/ml<BR/>Treatment two (n=not stated): interferon-&#946; 1 million IU/ml</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 23:54:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Leopold-1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 23:54:34 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=5): idoxuridine solution<BR/>Treatment two (n=5): cytarabine solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:49:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Li-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:49:19 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=30): acyclovir 0.1% solution and botanical extract (Ban Lan Gen) by subconjunctival and intramuscular injection<BR/>Treatment two (n=31): acyclovir 0.1% solution and ribavirin by subconjunctival injection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-09 22:23:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-09 22:23:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=39): acyclovir 0.1% solution<BR/>Treatment two (n=41): acyclovir 0.1% solution and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:22:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2013c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:22:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=85): acyclovir<BR/>Treatment two (n=90): acyclovir and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:07:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2014a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:07:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=44): antiviral<BR/>Treatment two (n=48): antiviral and botanical extract and oral transfer factor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:09:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2014b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:09:38 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=40): antiviral<BR/>Treatment two (n=40): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-05 23:22:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Li-2014c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-05 23:22:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=21): ganciclovir gel and acyclovir solution</P>
<P>Treatment two (n=21): ganciclovir gel and basic fibroblast growth factor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-13 18:49:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-13 18:49:10 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=27): acyclovir<BR/>Treatment two (n=22): acyclovir and polyinosinic-polycytidylic acid injection</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:30:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2013a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:30:14 +0100" MODIFIED_BY="[Empty name]">
<P>Outcome not based on epithelial healing (total score of symptoms and signs)</P>
<P>Treatment one (n=114): ganciclovir 0.15% gel<BR/>Treatment two (n=116): ganciclovir 0.15% in situ gel</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:31:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2013b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:31:54 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided (unclear time until outcome assessment)</P>
<P>Treatment one (n=33): ganciclovir 0.1% solution 4 times daily + levofloxacin solution 4 times daily<BR/>Treatment two (n=33): ganciclovir 0.1% solution 4 times daily + levofloxacin solution 4 times daily + subconjunctival interferon one million units/ml (0.3 ml) every other day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 22:11:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 22:11:09 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=21): topical antiviral<BR/>Treatment two (n=21): topical antiviral and subconjunctival interferon</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 20:37:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 20:37:58 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=50): acyclovir 0.1% solution<BR/>Treatment two (n=46): acyclovir 0.1% solution and fibroblast growth factor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:48:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:48:37 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=48): acyclovir<BR/>Treatment two (n=48): acyclovir and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-05 21:56:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Liu-2014b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-05 21:56:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=not given): acyclovir solution</P>
<P>Treatment two (n=not given): periocular injection of polyinosinic acid 0.5 mg every other day</P>
<P>Treatment three (n=not given): acyclovir solution and periocular polyinosinic acid 0.5 mg every other day</P>
<P>(Total enrolled=38 patients, 60 eyes)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-12 19:22:12 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Long-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-12 19:22:12 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Varied eligibility criteria (25 eyes with HSV keratitis and 19 eyes with herpes zoster keratitis)</P>
<P>Treatment one (n=13, HSV keratitis): acyclovir 0.1% solution 6-8 times per day<BR/>Treatment two (n=12, HSV keratitis): acyclovir 0.1% solution 6-8 times per day + interferon eye drops 4 times per day + subconjunctival (1 mL) interferon one million units/mL every 1-2 days (6-8 injections)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:25:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:25:57 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=29): idoxuridine 0.1% solution<BR/>Treatment two (n=8): vidarabine 0.5% solution<BR/>Treatment three (n=8): acyclovir 0.1% solution<BR/>Treatment four (n=11): foscarnet 1% to 5% solution<BR/>Treatment five (n=58): cyclocytidine 0.05% solution<BR/>Treatment six (n=14): cyclocytidine 0.1% solution<BR/>Treatment seven (n=6): cytarabine 0.025% solution<BR/>Treatment eight (n=4): cyclocytidine monophosphate 0.5% solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:48:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ma-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:48:03 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=60): acyclovir 0.1% solution 4 times per day<BR/>Treatment two (n=60): acyclovir 0.1% solution 4 times per day and botanical extract 4 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 15:06:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Ma-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 15:06:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=42): acyclovir solution<BR/>Treatment two (n=40): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 14:38:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Ma-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 14:38:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=34): acyclovir solution<BR/>Treatment two (n=34): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:11:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Ma-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:11:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=29): antiviral<BR/>Treatment two (n=29): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:22:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Maichuk-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:22:34 +0000" MODIFIED_BY="[Empty name]">
<P>Varied eligibility criteria</P>
<P>Treatment one (n=28): oral pirprofen<BR/>Treatment two (n=24): intramuscular pirprofen<BR/>Treatment three (n=29): oral indomethacin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 16:30:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mal_x0027_khanov-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 16:30:54 +0000" MODIFIED_BY="[Empty name]">
<P>Varied eligibility criteria</P>
<P>Treatment one (n=15): thymalin (thymic peptide)<BR/>Treatment two (n=12): tactivin (thymic peptide)<BR/>Treatment three (n=48): pirogenal (bacterial lipopolysaccharide)<BR/>Treatment four (n=20): gamma-globulin<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:40:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marquardt-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:40:19 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=87): thermocauterisation debridement<BR/>Treatment two (n=75): scraping debridement<BR/>Treatment three (n=64): idoxuridine<BR/>Treatment four (n=64): unspecified treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:26:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martenet-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:26:27 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=8): idoxuridine 0.1% solution hourly during day and 0.25% ointment at night<BR/>Treatment two (n=1): iododeoxycytidine 0.15% solution hourly during day and 1% ointment at night</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:26:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matalia-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:26:37 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=102, eyes with epithelial keratitis): idoxuridine<BR/>Treatment two (n=104, eyes with epithelial keratitis): vidarabine<BR/>Treatment three (n=22, eyes with epithelial keratitis): trifluridine<BR/>Treatment four (n=100, eyes with epithelial keratitis): acyclovir<BR/>Treatment five (n=36, eyes with epithelial keratitis): vidarabine and idoxuridine<BR/>Treatment six (n=52, eyes with epithelial keratitis): vidarabine and acyclovir<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathur-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=50): iodinisation debridement<BR/>Treatment two (n=20): cryotherapy debridement<BR/>Treatment three (n=24): cryotherapy debridement and topical autologous serum<BR/>Treatment four (n=30): wiping debridement<BR/>Treatment five (n=30): wiping debridement and idoxuridine 0.1% solution 3 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:41:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGill-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:41:30 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=29): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=28): acyclovir 3% ointment 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:23:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohan-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:23:42 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=19): vidarabine 3% ointment 5 times per day<BR/>Treatment two (n=21): acyclovir 3 ointment 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:27:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morimoto-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:27:17 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=22): idoxuridine ointment<BR/>Treatment two (n=15): acyclovir 3% ointment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:43:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Patterson-1967c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:43:05 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Inclusion criteria: 24 eyes with corticosteroid-enhanced epithelial keratitis: 22 eyes with geographic "amoeboid" epithelial keratitis and two eyes with "multiple linear ulcers"; "a severe stromal keratitis was often present."</P>
<P>Treatment one (n=9): cauterisation, debridement<BR/>Treatment two (n=15): idoxuridine ointment 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:25:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavan_x002d_Langston-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:25:15 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=14): idoxuridine 0.5% ointment 3 to 5 times per day<BR/>Treatment two (n=15): vidarabine 3.3% ointment 3 to 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:25:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pavan_x002d_Langston-1977">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:25:45 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=17): idoxuridine 0.1% solution 19 times per day<BR/>Treatment two (n=23): trifluridine 1% solution 9 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-09 19:23:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pietruschka-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-09 19:23:50 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=30): <I>para</I>-fluorophenylalanine 0.1% solution hourly<BR/>Treatment two (n=28): idoxuridine 0.1% solution hourly<BR/>Treatment three (n=40): <I>para</I>-fluorophenylalanine 0.1 % solution and idoxuridine 0.1% solution hourly, alternating</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:44:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pint_x00e9_r-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:44:02 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=16): photoinactivation with acridine orange<BR/>Treatment two (n=6): idoxuridine with or without oral moroxydine<BR/>Treatment three (n=2): idoxuridine and thermal debridement<BR/>Treatment four (n=8): iodinisation debridement<BR/>Treatment five (n=2): miscellaneous interventions including autologous blood injection (1)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-25 22:38:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pivetti_x002d_Pezzi-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-25 22:38:45 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=13): intramuscular placebo daily with "local conventional therapy"<BR/>Treatment two (n=11): intramuscular thymic extract daily with "local conventional therapy"</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 22:17:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prost-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 22:17:47 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): cryotherapy and oral placebo<BR/>Treatment two (n=19): cryotherapy and oral isoprinosine</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:44:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rykun-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:44:55 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent, non-randomised treatment allocation</P>
<P>Treatment one (n=38, dendritic type): antiviral (idoxuridine)<BR/>Treatment two (n=22, dendritic type): antiviral + &#945;-tocopherol 10% solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 22:33:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salcedo-Hernandez-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 22:33:03 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=9): diluted autologous serum 4 times per day<BR/>Treatment two (n=8): acyclovir 3% ointment 4 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:28:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scialdone-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:28:08 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=8): idoxuridine solution 6 times per day and oral isoprinosine and intramuscular thymic extract<BR/>Treatment two (n=12): interferon-&#946; solution 6 times per day and oral isoprinosine and intramuscular thymic extract<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 22:18:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sellitti-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 22:18:04 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): isoprinosine solution and oral isoprinosine and cytosine solution every 2 hours<BR/>Treatment two (n=20): oral isoprinosine and cytosine solution every 2 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:46:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shimomura-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:46:35 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=16): wiping debridement and idoxuridine solution every hour<BR/>Treatment two (n=15): idoxuridine solution every hour</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:28:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiota-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:28:22 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=16): vidarabine 3% ointment<BR/>Treatment two (n=9): trifluridine 1% solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 21:17:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiota-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 21:17:35 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=14): interferon-&#946; 100,000 IU/ml<BR/>Treatment two (n=46): interferon-&#946; 1 million IU/ml</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:28:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sozen-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:28:43 +0000" MODIFIED_BY="[Empty name]">
<P>Varied eligibility criteria</P>
<P>Treatment one (n=15): acyclovir 3% ointment 5 times per day<BR/>Treatment two (n=15, of 13 patients): oral valacyclovir 1 g 2 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-01 23:47:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stambuk-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-01 23:47:14 +0000" MODIFIED_BY="[Empty name]">
<P>Outcome not based on epithelial healing</P>
<P>Treatment one (n=8): idoxuridine ointment or acyclovir ointment<BR/>Treatment two (n=12): bovine thymic extract and either idoxuridine ointment or acyclovir ointment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:49:16 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Su-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:49:16 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=40 eyes, 29 patients): ganciclovir 0.15% gel 4 times per day<BR/>Treatment two (n=38 eyes, 30 patients): ganciclovir 0.15% gel 4 times per day + subconjunctival interferon one million units/mL (1 ml) every other day (6-8 injections)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-12 21:37:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Sun-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-12 21:37:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=35): acyclovir solution 4-6 times per day</P>
<P>Treatment two (n=33): acyclovir solution 4-6 times per day + intravenous yan hu ning (dehydroandrographolide succinate) 400 mg in 250 mL saline, repeated every third day for 10 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-13 17:04:31 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Sun-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-13 17:04:31 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=34): acyclovir solution</P>
<P>Treatment two (n=34): acyclovir solution + oral vitamin C</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-05-24 14:29:15 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Tamburi-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-05-24 14:29:15 +0100" MODIFIED_BY="Anupa Shah">
<P>Insufficient data provided</P>
<P>Treatment one (n=8): acyclovir 3% ointment 4 times per day<BR/>Treatment two (n=8): interferon-&#945; 3 million IU/ml 8 times per day<BR/>Treatment three (n=8): acyclovir 3% ointment 4 times per day and interferon-&#945; 3 million IU/ml 8 times per day<BR/>Note: 3 randomised groups were also compared to a historical group treated with idoxuridine (n=8)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:38:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tarakji-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:38:45 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=21): cryotherapy<BR/>Treatment two (n=14): idoxuridine solution hourly and ointment at night</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:50:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tommila-1963">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:50:55 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=17): iodinisation debridement<BR/>Treatment two (n=17): interferon-&#946; solution every 1 to 3 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-02-22 21:41:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Topciu-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-02-22 21:41:00 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=120): idoxuridine and foscarnet<BR/>Treatment two (n=113): idoxuridine and foscarnet and oral moroxydine and percutaneous vaccinia virus antigens and subcutaneous heat-killed <I>Corynebacterium parvum</I>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-19 20:46:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wan-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-19 20:46:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided (average healing time and outcome assessment at 4 weeks)</P>
<P>Treatment one (n=24): ganciclovir 0.15% gel 6 times daily<BR/>Treatment two (n=26): ganciclovir 0.15% gel 6 times daily + recombinant human interferon &#945;-2b solution 6 times daily</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 22:58:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 22:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=39): acyclovir 0.1% solution 10 times per day<BR/>Treatment two (n=39): ganciclovir 0.15% gel 5 times per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 15:52:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wang-2010a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 15:52:41 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=102): ganciclovir gel + intravenous acyclovir<BR/>Treatment two (n=111): ganciclovir gel + intravenous acyclovir + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 17:08:16 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wang-2010b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 17:08:16 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=42): acyclovir 0.1% solution + subconjunctival acyclovir<BR/>Treatment two (n=45): acyclovir 0.1% solution + subconjunctival acyclovir + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 17:13:50 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wang-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 17:13:50 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation<BR/>Treatment one (n=48): acyclovir 0.1% solution<BR/>Treatment two (n=108): acyclovir 0.1% solution + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:10:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wang-2014b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:10:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=106): ganciclovir 0.15% gel<BR/>Treatment two (n=107): ganciclovir 0.15% gel and botanical extract (yiqi jiedu)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-12 22:20:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wei-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-12 22:20:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided</P>
<P>Treatment one (n=24): ganciclovir 0.15% gel 6 times per day<BR/>Treatment two (n=24): ganciclovir 0.15% gel 6 times per day + polyinosinic acid (poly I:C) 0.5 mg subconjunctival injection every 3 days + poly I:C 1.5 mg intramuscular injection every other day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 16:15:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Wen-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 16:15:04 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=41): acyclovir 0.1% solution<BR/>Treatment two (n=40): acyclovir 0.1% solution + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-04-19 20:46:48 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Weng-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-04-19 20:46:48 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Insufficient data provided (outcome assessment at 6 weeks)</P>
<P>Treatment one (n=35): acyclovir 0.1% solution 6-8 times daily + tobramycin 0.3% 3 times daily<BR/>Treatment two (n=35): acyclovir 0.1% solution 6-8 times daily + tobramycin 0.3% 3 times daily + subconjunctival recombinant human interferon &#945;-2b one million U</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:53:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Whitcher-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:53:38 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): wiping debridement<BR/>Treatment two (n=31): idoxuridine solution hourly day and ointment at night</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-05-25 22:39:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xiao-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-05-25 22:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>Varied eligibility criteria</P>
<P>Treatment one (n=10, epithelial type): acyclovir 0.1% solution<BR/>Treatment two (n=20, epithelial type): acyclovir 0.1% solution and recombinant interleukin-2</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:49:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xie-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:49:32 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=34): acyclovir solution<BR/>Treatment two (n=26): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:49:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2009b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:49:50 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=30): acyclovir 0.1% solution<BR/>Treatment two (n=32): acyclovir 0.1% solution and recombinant interleukin-2</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 17:06:08 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Xu-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 17:06:08 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=43): acyclovir 0.1% solution + intravenous acyclovir<BR/>Treatment two (n=67): acyclovir 0.1% solution + intravenous acyclovir + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:29:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamamoto-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:29:54 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=7): zinc sulfate 0.3%<BR/>Treatment two (n=7): zinc sulfate 0.3% and idoxuridine<BR/>Treatment three (n=2): zinc sulfate 0.3% and collagenase</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-11 16:44:46 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Yang-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-11 16:44:46 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=33): acyclovir 0.1% solution<BR/>Treatment two (n=35): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 17:52:13 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Yi-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 17:52:13 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=60): acyclovir 0.1% solution + ganciclovir gel + intravenous acyclovir<BR/>Treatment two (n=67): acyclovir 0.1% solution + botanical extract + acupuncture</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:01 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=51): acyclovir 0.1% solution every 2 hours<BR/>Treatment two (n=53): botanical extract (miedulin 0.8%) every 2 hours</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:55:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yu-2012b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:55:29 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided (outcome based on clinical scores and corneal sensation)</P>
<P>Treatment one (n=30): ganciclovir 0.15% gel 8 times per day<BR/>Treatment two (n=30): ganciclovir 0.15% gel 8 times per day + subconjunctival live attenuated measles vaccine (0.5 ml) every other day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:06:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Yu-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:06:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=46): acyclovir<BR/>Treatment two (n=50): acyclovir and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:55:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yuan-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:55:44 +0100" MODIFIED_BY="[Empty name]">
<P>Varied eligibility criteria (both epithelial and stromal keratitis)</P>
<P>Treatment one (n=35, epithelial type): acyclovir 0.1% solution 4 times per day + interferon 1 million units/mL (0.5 ml) subconjunctival injection every other day<BR/>Treatment two (n=34, epithelial type): ganciclovir 0.15% gel 4 times per day + interferon 1 million units/mL (0.5 ml) subconjunctival injection every other day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-06 08:30:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zagaigora-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-06 08:30:06 +0000" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=41): gamma-globulin<BR/>Treatment two (n=37): desoxyribonuclease<BR/>Treatment three (n=28): idoxuridine 0.1% solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-11-09 19:52:44 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Zaj_x00e1_cz-1968">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-11-09 19:52:44 +0000" MODIFIED_BY="Anupa Shah">
<P>Non-concurrent treatment allocation</P>
<P>Control (n=84): "conservative treatment" with chloramphenicol<BR/>Treatment one (n=20): corneal scraping débridement with chloramphenicol<BR/>Treatment two (n=42): thermocoagulation with chloramphenicol ointment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhai-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:08 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=58): acyclovir 0.1% solution and oral acyclovir<BR/>Treatment two (n=57): acyclovir 0.1% solution and oral acyclovir and intravenous botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 18:05:53 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhan-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 18:05:53 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=50): acyclovir 0.1% solution + oral acyclovir<BR/>Treatment two (n=50): botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 20:28:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 20:28:40 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=20): acyclovir and interferon<BR/>Treatment two (n=21): acyclovir and interferon and transfer factor</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:19 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=20): idoxuridine 0.1% solution every 3 to 4 hours<BR/>Treatment two (n=20): herbal extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:48:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:48:13 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=52): acyclovir 0.1% solution every 2 hours<BR/>Treatment two (n=60): botanical extract one time per day</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-02 21:56:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-02 21:56:02 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=29): interferon-&#945;-1b<BR/>Treatment two (n=17): interferon-&#945;-2b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:29 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=50): acyclovir solution<BR/>Treatment two (n=100): acyclovir solution and oral botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 18:27:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhang-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 18:27:09 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=57): acyclovir 0.1% solution (or ganciclovir gel)<BR/>Treatment two (n=61): acyclovir 0.1% solution (or ganciclovir gel) + botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 16:27:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 16:27:02 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=89): acyclovir 0.1% solution<BR/>Treatment two (n=97): acyclovir 0.1% solution and recombinant interferon-&#945; 10 &#956;g/ml and diclofenac 0.1% solution</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhao-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:38 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=111): acyclovir 0.1% solution<BR/>Treatment two (n=112): topical botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-08-10 18:52:43 +0100" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhao-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-08-10 18:52:43 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=54): botanical extract<BR/>Treatment two (n=52): periocular injection of polyinosinic acid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:29:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zhao-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:29:14 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=48): antiviral<BR/>Treatment two (n=48): antiviral and botanical extract (yu ping feng)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zheng-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:46 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=45): topical antiviral<BR/>Treatment two (n=45): topical antiviral and systemic botanical extracts</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-12-01 22:08:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus" STUDY_ID="STD-Zheng-2014">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-12-01 22:08:57 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=39): acyclovir solution<BR/>Treatment two (n=45): acyclovir solution and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 16:40:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhi-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 16:40:29 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=30): topical acyclovir<BR/>Treatment two (n=38): topical acyclovir and systemic interleukin-2</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:58:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhong-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=30): acyclovir 0.1% solution 6 times per day + intramuscular polyinosinic acid<BR/>Treatment two (n=30): re du qing solution 6 times per day + intramuscular polyinosinic acid</P>
<P>Treatment three (n=50): re du qing nebuliser for 15 minutes 2 times per day + intramuscular polyinosinic acid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-03-04 15:50:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-03-04 15:50:53 +0000" MODIFIED_BY="[Empty name]">
<P>Botanical or herbal preparation</P>
<P>Treatment one (n=34): acyclovir 0.1% solution<BR/>Treatment two (n=38): acyclovir 0.1% solution and botanical extract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-11 14:38:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-11 14:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>Insufficient data provided</P>
<P>Treatment one (n=35): acyclovir<BR/>Treatment two (n=66): acyclovir and recombinant interferon-&#945;-2b</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-26 11:59:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zirm-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-26 11:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Non-concurrent treatment allocation</P>
<P>Treatment one (n=23): iodinisation debridement<BR/>Treatment two (n=14): trifluridine or idoxuridine 3 to 5 times per day<BR/>Treatment three (n=49): scraping debridement and trifluridine or idoxuridine<BR/>Treatment four (n=33): trifluridine and antiherpetic immunoglobulin</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-01-09 10:56:13 +0000" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-01-09 10:56:10 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Ajanta-Pharma-2013">
<CHAR_METHODS MODIFIED="2015-01-09 10:56:10 +0000" MODIFIED_BY="Anupa Shah">
<P>Allocation method: randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-15 18:08:06 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Country: India</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-15 18:08:56 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Treatment one: acyclovir 3% ointment five times per day<BR/>Treatment two: ganciclovir 0.15% gel five times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-15 18:09:37 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Corneal epithelial healing</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-15 18:08:02 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Financial support: pharmaceutical industry</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-01-09 10:56:13 +0000" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Bausch-_x0026_-Lomb-2003">
<CHAR_METHODS MODIFIED="2015-01-09 10:56:13 +0000" MODIFIED_BY="Anupa Shah">
<P>Allocation method: randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-01 15:02:20 +0100" MODIFIED_BY="[Empty name]">
<P>Country: United States</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-02-10 01:30:38 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment one: cidofovir 0.3% solution five times per day<BR/>Treatment two: cidofovir 0.5% solution five times per day<BR/>Treatment three: trifluridine 1.0% solution five times per day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-06 08:31:11 +0000" MODIFIED_BY="[Empty name]">
<P>Corneal epithelial healing and adverse reactions (e.g., punctal occlusion)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-01 15:08:21 +0100" MODIFIED_BY="[Empty name]">
<P>Financial support: pharmaceutical industry</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-12-27 15:49:58 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-12-13 16:24:28 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>Unequal (1:2) treatment assignment, with allocation of treatment based on availability of the intervention and on judgement of the clinician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>Allocation apparently by judgment of the clinician</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:39:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>Insufficient information provided about the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 21:39:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>Quote: "The bottles were numbered consecutively, and active drug and placebo were randomly distributed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process. However, additional study groups had open allocation of study treatments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>Insufficient information ("i pazienti sono stati suddivisi in 3 gruppi di 5 pazienti ciascuno e sottoposti a 3 differenti trattamenti")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:51:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:52:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:52:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 21:57:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>Quote: "The patients were randomly allocated to the various treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process ("étude clinique comparative randomisée")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:55:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:55:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:15:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>Quote: "On a random basis patients were allocated either 3% acyclovir ophthalmic ointment and placebo tablets, or placebo ointment and acyclovir tablets."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:19:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>A preliminary communication (Jones et al, 1976) described treatment allocation in a "randomised manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>The investigators describe a non-random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:40:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>Quote: "The patient's treatment was determined by stratified randomization."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 20:49:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "Alle Patienten, bei denen in unserer Klinik die Diagnose Keratitis dendritica gestellt werden konnte, wurden zufällig einer der beiden Therapiegruppen zugeordnet."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 20:58:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process: "Alle Patienten, bei denen in unserer Klinik die Diagnose Keratitis dendritica gestellt werden konnte, wurden zufällig einer der beiden Therapiegruppen."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:06:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
<P>Quote: "Il trattamento iniziale è stato assegnato su di una base prerandomizzata con la terz'ultima fila della tabella dei numeri casuali."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:08:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>The investigators describe the use of "a computer-generated list of random numbers" in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:33:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:36:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:07:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:07:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>The authors describe this study as a "essai clinique en double insue" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>The authors describe this study as "une étude comparative en clinique humaine" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:10:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>The investigator describes a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 21:33:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>The investigators describe a random component of the sequence generation process (personal communication) in this multicentre "double-blind comparative study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>The authors describe this study as a "double-blind study" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:43 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:13:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>The investigators describe a random component of the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>The authors describe this study as "a double-blind clinical trial" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>The authors describe a random component in the sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:15:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 21:36:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>The investigators describe a random component of the sequence generation process (personal communication) in this "double-blind study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 21:38:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>The investigators describe a random component of the sequence generation process (personal communication) in this "double controlled study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:39:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:44:49 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:57:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process ("&#38543;&#26426;&#36873;&#25321;"); however, no explanation for imbalance in the numbers of eyes assigned to each intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process but do not account for the unequal group sizes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:00:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:05:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:07:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:29:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>Quote: "Alternate patients were put into 'treated' (with I.D.U.) and 'control' (without I.D.U.) groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 21:41:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>Insufficient information on how "the eighty eyes were divided into three groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:22:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 17:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>Quote: "Alle Patienten, bei denen die Diagnose einer Keratitis dendritica...wurden zufällig einer der folgenden 4 Therapiegruppen."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>The investigators describe a random component to the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:24:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:24:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>The author describes this study as "a prospective study, based on double-blind trials" but does not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 17:54:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>The investigators describe an allocation sequence process that aimed "to evaluate photoinactivation in comparison with IDU by random selection," although it is unclear how "these eight eyes were matched to nine randomly selected eyes that received IDU therapy for dendritic ulcers."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:25:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:26:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:27:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>The investigators used a random component in the sequence generation process (personal communication)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>The investigators used a random component in the sequence generation process (personal communication)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>The investigators used a random component in the sequence generation process (personal communication)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
<P>Quote: "the 77 cases of simplex dendritic ulceration were divided randomly into groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:29:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information. No explanation for the imbalance in numbers of participants assigned to each intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:29:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:30:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-22 21:51:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>Insufficient information on how patients "2 Gruppen zugeordnet."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-13 16:24:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>The investigators state that this was a "clinical trial" but do not describe whether a random component was used in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>The authors describe this study "Im Rahmen einer multizentrischen Prüfung" but do not provide information about the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:09:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:35:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:56:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:36:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:40:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>The authors describe this study as "a controlled trial" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>The investigator describes a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:44:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 23:08:05 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:44:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:46:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>The authors describe these studies as "clinical trials" (and reference collaborators whose trial was randomised) but do not provide sufficient information on the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>The authors describe these studies as "clinical trials" (and reference collaborators whose trial was randomised) but do not provide sufficient information on the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>The authors describe these studies as "clinical trials" (and reference collaborators whose trial was randomised) but do not provide sufficient information on the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>The authors describe "a double blind clinical investigation" but do not describe the method of treatment allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:42:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:42:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:41:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:11:46 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:13:37 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:15:56 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>The investigators describe a randomised method of sequence generation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:01:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>The investigators describe "a randomised arrangement" of the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:36:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>Quote: "Treatment with either interferon or placebo was assigned randomly to patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>Insufficient information. The investigators did not describe how the sequence generation process was developed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>The investigators describe a random component in the sequence generation process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-12-13 16:24:19 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>Unconcealed procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>Unconcealed procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:39:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 21:36:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>The drug allocation code was not "broken" unless "treatment was considered a failure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-18 20:50:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>Study medications were distributed from a central location and "dispensed consecutively to ophthalmologists when requested."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:51:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:52:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 21:55:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>Quote: "The coded treatment were randomly allocated by the pharmacist."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>There is no evidence that treatment assignments were not concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>There is no evidence that treatment assignments were not concealed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>Centralized distribution process</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>Centralized distribution scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:11:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>Quote: "The ointments were of similar appearance and packed in identical tubes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:13:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>Quote: "Both drugs were identically packaged and coded."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>There is no evidence that participants or investigators could foresee treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:17:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>Quote: "Each patient received coded treatment, randomly allocated by the pharmacist, who followed a stratification table."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:20:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>According to a preliminary report (Jones et al, 1976), "the coded, randomized allocation of treatment was stratified for size of the ulcer."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:21:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>Quote: "The coded treatments were randomly allocated by the pharmacist within closely matched strata."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:24:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>Quote: "Patients were allocated to strata on the basis of clinical features likely to be significant in prognosis....Within these strata patients were randomly allocated to 1 of 2 treatment groups."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>Quote: "The first four patients who presented were treated with the combined therapy...; thereafter alternate patients were treated" with combined idoxuridine and ultraviolet therapy or with idoxuridine alone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:30:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>Quote: "The patients admitted to the trial were allocated to one of the three groups using randomized sample tables, with which the pharmacist was provided."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:06:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:06:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:56:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>Quote: "Each patient was randomly assigned to receive either oral acyclovir...or oral placebo...identical in appearance and taste."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:33:22 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:36:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:52:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>Quote: Study medications "were supplied by [the manufacturer] in plastic dispensing bottles of identical appearance...[that were] then arranged...in random order."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:07:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-23 21:01:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>Allocation method based on availability of the drug at the time of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:03:05 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>Quote: "Each patient received 2 identical, masked tubes containing either 3% acyclovir or 2% [trifluridine] ophthalmic ointment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 01:18:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>Quote: "Each patient [received] a numbered tube of ointment containing either 3% acyclovir or 3% vidarabine."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>Quote: "The hospital pharmacy coded the two groups" of study medications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>Unconcealed allocation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:13:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>Centralised allocation scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-22 19:04:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>Quote: "The Burroughs Wellcome Foundation, Copenhagen supplied the coded 3% acyclovir eye ointment and the coded 0.5% idoxuridine eye ointment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 01:21:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>Quote: "[Idoxuridine] and acyclovir were in form of ointments, these were wrapped in similar paper and were labelled with different numbers randomly distributed. The master list was kept with the person who was dispensing the drug and was not connected with the study."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:23:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>Quote: "We used 3% acyclovir and 2% trifluorothymidine ointment, both specially prepared for this trial and packed in identical tubes."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:25:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>Quote: "All patients...were given a plain brown bottle sealed at the neck with a label on it bearing code numbers. The sealed code was held by the supplier (SKF) and was not known to the investigators. The bottles...were used in sequence."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:16:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:43:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:44:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:57:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:04:50 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>Possible open enrolment since treatment plans were complex, involving different topical and systemic medications for each study arm</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:05:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:07:36 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>Allocation based on non-random alternation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:20:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>Apparent open allocation scheme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>Open allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:35 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>Open allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:32:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>Quote: "The drugs were issued according to a fully randomized code, so that neither the patient nor the observer was at any time aware of which therapy had been allocated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:22:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:39:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>Quote: "Acyclovir ophthalmic ointment, 3%, and IDU ophthalmic ointment, 0.5%, were assigned to patients by a predesignated random code test."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:24:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 01:23:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>Quote: "Each tube was provided with a code number (1-30). The code was broken after the recording of the results."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:25:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>The investigators apparently used an open allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:25:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:00:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>Quote: "Patients were placed by random number selections in three treatment categories."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:27:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:29:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:10:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>Quote: "Drugs were identified for patient and investigator by number only; the code was not broken until the end of the study, or until a patient was removed."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:30:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>Quote: "Drugs were packaged in a sequential order by random code number designation and were also dispensed sequentially," according to an ancillary, subsequent report (Laibson et al 1982)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:32:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>Quote: "Treatment consisted of either BVDU 0.1% or TFT 1.0% ophthalmic drops, which were packaged in identical bottles and prescribed five times daily."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>The investigators apparently used an open allocation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-13 16:24:19 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>Quote: "The first twenty cases were treated with Acyclovir...along with IDU drops....The second 20 cases received the IDU eye drops." It is unclear whether this statement means an unconcealed (i.e., open) allocation process or whether the authors are merely summarizing the number of participants (20 per group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>Investigators enrolling participants could possibly have foreseen treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:41:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>Quote: "An administrative assistant dispensed medication in the double-masked protocol on a random basis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:09:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>"Group 1 received uncoded interferon, and groups 2 and 3 were treated with coded interferon or mock interferon, respectively," using sequentially numbered drug containers of similar appearance</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:35:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>Centralised allocation of coded vials, although "one vial could be used for more than one patient."</P>
<P>Quote: "After the treatment of 51 cases, the coded results were mailed from Freiburg to Helskinki and the code from Helsinki to Freiburg on the same day."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:57:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:36:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>Use of coded eyedropper vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>Use of coded eyedropper vials</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>Quote: "&#945;-interferon was prepared and bottled in identical calibrated dispensing systems and then coded" by a central facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>Centralised allocation facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>Coded eyedropper vials dispensed from centralized facility</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:40:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:16:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>Quote: "the code was kept by National Institute of Health, Tokyo, and was broken after the results had been evaluated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:22:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>Quote: "Samples to be tested were coded....The code was kept by National Institute of Health Tokyo, and broken after the result had been evaluated."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:42 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>Investigators enrolling participants could possibly have foreseen open treatment assignments</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:44:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 23:08:04 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:31:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>Quote: "Each patient received randomly allocated coded treatment by the pharmacist, according to prearranged tables held in the pharmacy....The two preparations were indistinguishable other than by the code."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>Central allocation of treatment assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:46:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:36:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>Quote: "The drugs were packaged in sequential order by random code number designation and were dispensed sequentially."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:38:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>Quote: "The ophthalmic ointments were provided in identical tubes bearing a trial number, and the entire study was carried out in a double-blind manner."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:41:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:11:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:13:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:15:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:01:24 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 16:24:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>Quote: "Each patient received a coded treatment sequentially allocated by the central dispensing unit....The ointment tubes were identical in design."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-12-13 16:24:29 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:38:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>Study personnel not masked</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:38:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>No masking, although outcome may not have been influenced by lack of masking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:39:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:45:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>No masking was likely because of disparate interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:46:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:46:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-10 01:09:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>Study treatment medications "were supplied in identical brown bottles, labelled only with a code number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:48:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>Double-masked trial design described but no details of masking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:48:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:49:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:49:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>No masking was undertaken, and outcome assessment could have been influenced by the lack of a masked assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:50:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>Double-masked ("en double insu") trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:51:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>Double-masked ("en double insu") trial design described in the preliminary report</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:52:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>Double-masked ("en double insu") trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 21:56:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>Quote: "All patients were examined by one ophthalmologist (JC), who did not know whether the patient was receiving vidarabine or placebo."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 21:58:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>Quote: "Double-blind conditions were not possible because of the obviously different formulations of the two antiviral agents."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:53:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>No masking performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:54:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>Single-blind ("en simple insu") trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 22:09:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>Quote: "The trial could not be made double masked owing to the obvious difference in the appearance between the gel and ointment formulations of the two drugs."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:55:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:55:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:56:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:56:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:57:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>Double-masked trial design implied (Note: Another systematic review judged this trial as not double-blind (<LINK REF="REF-Guess-2007" TYPE="REFERENCE">Guess 2007</LINK>))</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:58:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>The different treatment formulations (ointment <I>versus</I> drops) indicate probable lack of masking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 22:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>Quote: "Neither the patient nor the ophthalmologist knew which treatment was being used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:59:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:59:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 22:27:41 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>Quote: "A double-blind controlled trial was not possible as it was obvious to any observer which patients had received ultraviolet therapy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:00:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>Quote: "The usual precautions of a double-blind clinical trial were followed, e.g. the observer was unaware of the type of drop being administered." While the nature of the interventions (chemical débridement and topical antiviral agent) would not permit a double-masked design, it is unclear whether lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:02:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>Double-masked ("en double insu") trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:03:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>No masking was likely because one treatment group received subconjunctival injections</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:03:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>While the trial is described as "double-blind," the trial design is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:04:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>Double-masked trial design ("Doppelblindstudie") described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:04:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:05:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:06:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>Single-masked study design</P>
<P>Quote: "I due farmaci erano stati preparati della Cattedra di Virologia dell'Università di Siena in contenitori etichettati A e B, l'identità del contenuto dei quali era sconosciuta ai ricercatori clinici."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 22:57:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>Quote: "Patients and clinic personnel were masked to the oral medication treatment assignments; the data analysts and the data and safety monitoring committee were not."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 17:33:46 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 17:36:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 22:52:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>Quote: "The investigators were unaware of the nature of the drops being used to treat a particular patient until after assessment of the results had been made on the seventh day of treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:07:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>Double-masked ("en double-insu") trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:09:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>Insufficient information to permit judgment of whether lack of masking influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:09:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>The investigators describe a double-masked design, but different formulations (ointment, gel, and solution) of study medications were used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:09:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:10:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:11:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>Whether the lack of masking influenced outcome assessment could not be determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-08 23:10:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>Quote: "Neither the physician nor the patient knew whether the active substance or placebo was being used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:12:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>No masking was undertaken, and outcome assessment could have been influenced by the lack of a masked assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:13:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>Incomplete masking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:14:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:14:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:15:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:15:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:16:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:16:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:17:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>No masking was undertaken, and outcome assessment could have been influenced by the lack of a masked assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 17:39:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:17:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:18:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 17:44:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 17:58:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>Incomplete masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:18:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>No masking was undertaken, and outcome assessment could have been influenced by the lack of a masked assessor</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:19:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:19:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:00:47 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:05:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:08:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>Incomplete masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:19:56 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:20:49 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>Lack of masking may have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:21:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:21:36 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:22:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:23:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:23:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:24:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:24:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:25:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:25:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:26:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>Quote: "Healing was determined in a masked fashion by one of two investigators (E.J.C. and P.R.L.) who did not participate in other aspects of patient care in the study...including débridement, patching, and dispensing of medication." (Note: Another systematic review judged this trial as not double-blind (<LINK REF="REF-Guess-2007" TYPE="REFERENCE">Guess 2007</LINK>). While participants were aware of the choice of intervention, this review classifies the study's blinding status as adequate)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:27:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>Double-masked trial design described ("in accordance with the design of a double-blind trial the observer was at no time conversant with the type of medication being administered"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:28:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:28:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:28:53 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:29:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:30:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:30:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:31:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:31:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>Unmasked study design could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:31:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>Unmasked study design could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:32:21 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>Lack of apparent masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-13 16:24:29 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:32:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:33:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>Lack of apparent masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:34:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>Quote: "During the double-masked study the ophthalmologist who examined the patient was not aware of the drug or dosage schedules being used." [Note: Another systematic review judged this trial as not double-blind (<LINK REF="REF-Guess-2007" TYPE="REFERENCE">Guess 2007</LINK>)]</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:11:16 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>Incomplete masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>"Group 1 was treated with human leukocyte interferon...[while] groups 2 and 2 were studied on a double-blind basis." However, the same investigators who performed débridement performed the outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:35:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-09 15:57:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>The outcome assessor differed from the treating investigator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:36:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:37:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:37:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:38:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:38:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:39:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:39:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>Uncertain masking despite double-blind method</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-08-30 19:31:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>Incomplete masking despite "double blind method."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:41:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:41:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:42:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:43:44 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:44:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>Single-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-05 23:08:08 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-02-09 16:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>Quote: "In no case during the trial was any observer, or any patient, aware of the identity of the antiviral drug being used."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:45:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:46:33 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:45:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:44:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:44:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:43:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:43:07 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:42:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:42:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:41:27 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:11:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:13:39 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>Incomplete masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:40:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-12-04 18:15:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>Incomplete masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 12:40:15 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>Lack of masking could have influenced outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:01:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:02:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:42:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-09-26 13:43:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>Double-masked trial design described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-12-13 16:24:41 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:38:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:38:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:39:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>Treatment failures (area of corneal staining increased from one visit to the next) included 5 in idoxuridine treatment group and 2 in iodinisation group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>No missing primary outcome data, although times to treatment failure (2 in idoxuridine group, 1 in carbolization group, and 2 in 'dye light' group) were not provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:46:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>No missing primary outcome data, although times to treatment failure (1 in trifluridine group and 1 in foscarnet group) were not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:46:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>No missing primary outcome data within 14 days of treatment onset</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:47:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>Insufficient reporting of attrition</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:48:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>Primary outcome data available for dendritic epithelial keratitis but not for other strata (e.g., geographic epithelial keratitis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:48:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:49:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:49:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:50:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>No missing primary outcome data, although results of treatment failure ("échecs") not described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:50:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:52:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:52:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-10 01:34:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>Quote: "Eight case-report forms from seven of the 67 patients included were found to be faulty during on-site audits and were excluded from the efficacy analysis. Therefore, only 59 patients were assessed fro the efficacy (per protocol analysis)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:03:15 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>Quote: "Two patients were found to have been misdiagnosed (one in each treatment group): they were excluded from efficacy analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:54:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:54:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:11:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>Seven patients treated with idoxuridine were "withdrawn" and 1 "defaulted."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-04-26 17:36:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>Quote: "Three patients were withdrawn from the study owing to failure of treatment."</P>
<P>Quote: "Three patients randomly allocated to acyclovir treatment failed to return after their initial assessment and were excluded from the analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:16:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>Quote: "Of the 60 patients who entered the study three receiving the oral medication failed to come for follow-up, and one was lost from the local therapy group."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-22 18:41:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>Of 107 patients "who consented to the study...five patients were subsequently withdraw&#8212;four because of failure to attend the clinic for assessment and one because of an error dispensing."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>Quote: "All the ulcers healed within 48 hours."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:22:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>Quote: "In 6 patients the ulcers failed to heal."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 22:25:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>Quote: "One patient treated with acyclovir failed to present regularly for follow-up [and]...is not included in the analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:59:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:59:40 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:00:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>Three censored patients underwent débridement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:00:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>Outcomes were reported only for virologically confirmed cases</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:02:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:03:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>No missing primary outcome data, although survival data of healing were not tabulated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:03:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:04:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>Of 30 enrolled patients, 2 were excluded&#8212;1 for incorrect enrolment (recent vidarabine treatment) and 1 for non-compliance. Note that there is an apparent typographical error in the table (13 instead of 14 patients in one treatment arm)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:05:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:05:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>No missing primary outcome dat</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:06:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:06:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 17:35:56 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 17:37:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:07:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>Two patients "were admitted to the trial but were subsequently discarded"&#8212;1 for loss to follow up and 1 for worsened corneal disease</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:07:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>Insufficient information. The time to healing was not adequately provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:09:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:09:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 23:01:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>Quote: "Two patients were excluded from the analysis because no clinical assessment was made on day 6,7, or 8."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:10:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>No missing primary outcome data during 14 days of follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:10:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:11:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:12:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:12:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:13:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:14:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:14:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:15:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:15:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 23:25:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>Quote: "Cautery was necessary in 5 cases because of failure to respond."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:16:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:17:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 17:39:44 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Healing outcome presumed to be measured on day 14</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:17:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>Healing outcome presumed to be measured on day 15</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 17:47:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>Healing outcome reported at 3 weeks instead of 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 17:58:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:18:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:19:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:19:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:01:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>Healing outcome reported for combined cured and improved criteria</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:05:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>Healing outcome reported at 3 weeks instead of 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:07:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>Healing outcome reported at 3 weeks instead of 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:19:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:20:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:21:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 23:33:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>Quote: "Of the original 69 patients four failed to attend for sufficient follow-up examinations, and one received incorrect treatment, leaving 64 patients in the trial."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:22:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:23:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:23:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:24:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:24:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-08 23:49:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>Idoxuridine-treated eyes "healed in approximately seven days," but "one of the nine eyes was a failure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:26:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>No missing primary outcome data. Thirteen patients were classified as "treatment failures" by the pre-specified definition of being "not healed after 14 days of therapy</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 15:03:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>Quote: "Thirty-nine patients with a clinical diagnosis of herpes simplex dendritic keratitis were enrolled in the study...[and]...thirty-four (87%) completed the study." Patients assigned to the minimal-wiping débridement group were considered a treatment failure and received trifluridine "if new dendrites were noted at any follow-up before healing occurred."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:27:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:28:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:28:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:28:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:29:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:30:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:30:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 15:32:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>Quote: "One patient in the BVDU group was lost to follow-up and was not included in the analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:31:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:31:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:32:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-13 16:24:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:32:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>Insufficient reporting of attrition or delayed healing</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:33:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>No missing primary outcome data within first 14 days of treatment and follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:34:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:09:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>Healing outcome reported at 3 weeks instead of 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 15:50:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>Quote: "Fifty-five (75%) of 73 patients in the study yielded isolated herpes simplex virus before treatment, and further discussion will be confined to the results in these patients."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 15:54:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>Quote: "Only those 40 cases...in which the diagnosis was virologically confirmed and the virologic follow-up was without technical failures were accepted for final evaluation."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 15:57:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>No missing primary outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:36:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>Of 53 enrolled patients, "these were reduced to 38 persons with virologically proven herpes simplex virus disease" for analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:37:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>Only "virologically proven dendritic keratitis" cases were reported and analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 16:04:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>Quote: "For final evaluation, only the results of those patients were used who had delivered positive virus cultures before initiation of therapy."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 16:08:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>Quote: "The only patients accepted for final evaluation were those in whom a virus culture from the cul-de-sac before the initiation of therapy had yielded herpes simplex virus."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:39:01 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>Only virologically confirmed participants were analysed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 16:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>Quote: "Of 75 patients who entered the study 30 had to be excluded because all virus cultures turned out negative or because of noncompliance."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:39:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>Three patients withdrew from the study, and after the study was completed a judgment committee that reviewed eligibility forms and photographs decided to exclude 11 patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:40:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:41:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:41:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-22 19:10:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>Quote: "Out of 73 patients subjected to the double blind test, 5 were excluded from the final evaluation; three patients did not follow the medication schedule, and two were considered to have dendrites with coexisting metaherpetic alteration before treatment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:43:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:44:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-05 23:08:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>Healing outcome reported at 3 weeks instead of 2 weeks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-18 15:52:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>Quote: "Patients whose ulcers failed to heal were taken out of the trial and treated by débridement or if slow healing had been taking place under the coded antiviral therapy, this was continued for a further short period."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:45:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:46:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:45:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:44:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:44:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:43:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:43:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 16:37:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>Quote: "All patients used the medication as directed, and no patient was lost to follow-up prior to complete corneal re-epithelialization."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:42:06 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:11:59 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:14:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>Uncertain time when healing outcome reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:40:52 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-12-04 18:17:34 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 12:40:16 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>Incomplete primary outcome data (outcome day unclear)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:01:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>Quote: "Eight patients were excluded from the study"&#8212;two for failure to comply with the examination protocol, 3 for negative herpes simplex virus isolation, 2 for stromal keratitis, and 1 for metaherpes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:02:09 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>Quote: Of 59 patients who were enrolled and treated, "eight patients were excluded form the trial, two because they did not follow the instructions and four because all herpes simplex virus isolations were negative" and two treatment failures of geographic epithelial keratitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-09 16:24:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>Quote: "Seven out of 63 treated ulcers failed to heal within 23 days, which was our arbitrary limit. These cases were excluded from the analysis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-09-26 13:43:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>No missing primary outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-12-27 15:49:58 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:48:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:39:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>The method of performing paired comparison that "was made prospectively and at random" is unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:47:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>The time to "healing of the ulcer" was not clearly described</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:51:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported. The trial was limited to "virologically identified dendritic keratitis."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>The pre-specified primary outcomes was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>Outcome data are provided for both the intention-to-treat analysis and the per protocol analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:57:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:57:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:14 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>Outcomes reported for 58 patients rather than for 71 eyes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:05:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:05:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:49:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:08:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:36:04 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:37:54 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:07:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:08:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:36 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:10:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately assessed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:13:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:15:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:15:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:16:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>Quote: "Patients who developed signs of toxicity to the drug were also construed as treatment failures." Thus, the investigators did not distinguish between effectiveness outcomes and withdrawals for other reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:48:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:48:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:58:18 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:48:33 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:48:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:49:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:20:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:20:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:39 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:33:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>Quote: "No patient had to be removed from the trial because of drug toxicity."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:25:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:26:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:26:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:27:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:29:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:30:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-13 16:24:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:11:02 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:35:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:36:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>"Thirty-eight patients...were selected for the study," but the report gives results for 36, 19 in one treatment group and 17 in the other treatment group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:40:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:50:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:44:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:49:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:46:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:46:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:51:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:51:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:12:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:49:58 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:46:34 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported, but the report did not stratify outcomes for participants treated with topical corticosteroid for stromal keratouveitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:20:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>Vague description of assessing healing</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:01:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:51:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>The pre-specified primary outcome was adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-12-27 15:45:05 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Abe-1987">
<DESCRIPTION>
<P>The study interventions may not have occurred concurrently</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:38:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Altinisik-1987">
<DESCRIPTION>
<P>Insufficient information to determine if patients were treated concurrently or sequentially during 9 months of study enrolment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:39:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Austin-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bartholomew-1977">
<DESCRIPTION>
<P>Insufficient information</P>
<P>Quote: "none of our patients experienced any adverse reactions."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-10 01:09:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Behrens_x002d_Baumann-1992">
<DESCRIPTION>
<P>The trial was apparently stopped early when "no significant difference between [treatment groups was found]...after 10 paired analyses."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:46:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Blake-1977">
<DESCRIPTION>
<P>While "patients with disciform keratitis...were excluded" the table of patient characteristics lists one patient with "stromal" keratitis. In addition, a baseline imbalance of treatment groups occurred with respect to patient age</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-25 17:25:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burns-1963">
<DESCRIPTION>
<P>Quote: "The physician was instructed that, if after a week of therapy, he was dissatisfied with the patient's results, he could telephone this report, and the code would be broken."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cao-2001">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:48:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Carmassi-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:26 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cellini-1994">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:49:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:50:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:51:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:51:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1983">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:52:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1984">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:52:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1997a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 22:04:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Colin-1997b">
<DESCRIPTION>
<P>Quote: "There was a longer duration of disease before presentation" in the acyclovir group compared to the ganciclovir group that "occurred entirely by accident despite the randomization procedure."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:54:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Colin-2007b">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:55:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1980">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:55:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1985">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Collum-1986">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:56:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1976">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:57:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1977a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1979">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:58:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coster-1980">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:59:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dai-2009b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Daniel-1972">
<DESCRIPTION>
<P>This study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:00:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Davidson-1964">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Denis-1983">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:03:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fulhorst-1972">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:04:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gen_x00e9_e-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:05:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Graupner-1966">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:05:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1968">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:06:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Graupner-1969">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:06:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guerra-1979">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:08:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-HEDS-Group-1997">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:36:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:38:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Han-2014">
<DESCRIPTION>
<P>Some patients had concomitant stromal keratitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:07:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hart-1965">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:08:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Haut-1983">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hoang_x002d_Xuan-1984">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2008a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:09:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hung-1984">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:10:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-H_x00f8_vding-1989">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jackson-1984">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:11:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Jensen-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Jepson-1964">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:12:50 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kato-1979">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:13:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1983">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kitano-1985">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:14:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Klauber-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:15:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kumar-1987">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:15:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-La-Lau-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1964">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laibson-1977">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:46:11 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Li-2009">
<DESCRIPTION>
<P>Among 79 eyes, the investigators enrolled 23% of eyes having disciform keratitis and did not separately report outcomes for epithelial keratitis (61) and stromal keratitis (18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:17:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Li-2013b">
<DESCRIPTION>
<P>The investigators enrolled more eyes (85) than patients (68), making it difficult to determine the primary unit of analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:46:17 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Lin-2011">
<DESCRIPTION>
<P>Among 68 eyes, the investigators enrolled 13% of eyes having stromal keratitis and did not separately report outcomes for epithelial keratitis (59) and stromal keratitis (9)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 17:59:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Lin-2014">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:18:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2010">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:19:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu-2011">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:03:42 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012a">
<DESCRIPTION>
<P>Among 80 eyes, the investigators enrolled 26% of eyes having disciform keratitis and did not separately report outcomes for epithelial keratitis (59) and stromal keratitis (21)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:07:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2012b">
<DESCRIPTION>
<P>Among 76 eyes, the investigators enrolled 33% of eyes having stromal keratitis without epithelial keratitis and did not separately report outcomes for epithelial keratitis (36), combined epithelial and stromal keratitis (15), and stromal keratitis (25)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:09:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Liu-2014a">
<DESCRIPTION>
<P>Among 64 eyes, the investigators enrolled 17% of eyes having disciform keratitis and did not separately report outcomes for epithelial keratitis (53) and disciform keratitis (11)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-08 23:30:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Luntz-1963">
<DESCRIPTION>
<P>Quote: "Three 'treated' cases were given topical cortisone drops."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:20:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-MacKenzie-1964">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maichuk-1980">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:21:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Maichuk-1988">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:22:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Markham-1977">
<DESCRIPTION>
<P>No other sources of bias were found</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:22:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Matth_x00e4_us-1970">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-McCulley-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:23:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-McGill-1974">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:24:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Meurs-1985">
<DESCRIPTION>
<P>Study limited to virologically confirmed participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:24:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Norn-1973">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-25 17:55:32 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Day-1975">
<DESCRIPTION>
<P>The investigators "suspended the study because several of the patients [treated with proflavine photoinactivation]...had mild adverse reactions." These consisted "of a generalized epithelial keratitis and an anterior uveitis, possibly of phototoxic origin."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:26:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Panda-1995">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:26:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parlato-1985">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:27:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:28:38 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1963c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-04-26 16:10:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Patterson-1967a">
<DESCRIPTION>
<P>Quote: "Those cases treated with IDU which did not show progression to healing at 5 days were classed as failures and cauterized; ulcers treated initially with cauterization which showed dendritic figures in the next few days were classed as failures and either cauterized again or treated with IDU."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:29:32 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Patterson-1967b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:30:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1976">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:30:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pavan_x002d_Langston-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Power-1991">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramirez-2002">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:31:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Richter-1986">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:32:25 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Serifoglu-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-13 16:24:20 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Shen-2014">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Srinivas-1993">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:33:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Struck-1989">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sugar-1980">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:10:56 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Sun-2013a">
<DESCRIPTION>
<P>75 eyes were allocated to two treatment groups but demographic information (gender and type of epithelial keratitis) were given for 76 eyes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:34:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:35:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sundmacher-1976b">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-02-09 15:57:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sundmacher-1978a">
<DESCRIPTION>
<P>Fifteen of 42 patients underwent additional débridement.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:36:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1978b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981a">
<DESCRIPTION>
<P>Study limited to virologically confirmed participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:37:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1981b">
<DESCRIPTION>
<P>Study limited to virologically confirmed participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:38:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1984a">
<DESCRIPTION>
<P>Study limited to virologically confirmed participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1985">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:39:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Sundmacher-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:40:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tanaka-1988a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:40:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tanaka-1988b">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Travers-1978">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:41:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Uchida-1981">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Uchida-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vannini-1986">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:44:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wang-2004">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-05 23:13:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Wang-2014a">
<DESCRIPTION>
<P>Among 104 eyes, the investigators enrolled 41 eyes with shallow keratitis, 35 eyes with deep keratitis, and 28 eyes with mixed type.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wellings-1972">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:45:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wilhelmus-1981a">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:46:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Xu-2009a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:45:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984b">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:44:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamazaki-1984c">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2000">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:43:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yang-2008">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:42:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yeakley-1981">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:42:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Young-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:41:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yu-2012a">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:12:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="YES" STUDY_ID="STD-Zhang-2014">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:15:35 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="NO" STUDY_ID="STD-Zhao-2006">
<DESCRIPTION>
<P>Among 124 eyes, the investigators enrolled 15% of eyes having stromal keratitis and did not separately report outcomes for epithelial keratitis (106) and disciform keratitis (18)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-27 15:45:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhen-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-12-04 18:19:46 +0000" MODIFIED_BY="Kirk R. Wilhelmus" RESULT="UNKNOWN" STUDY_ID="STD-Zheng-2010">
<DESCRIPTION>
<P>Among 247 eyes, outcome data for 209 eyes having epithelial keratitis were extracted while ignoring 38 eyes with corticosteroid-treated disciform or stromal keratitis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 12:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhu-2012">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:01:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1982">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:02:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Koning-1983">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:42:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1980">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-09-26 13:43:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Bijsterveld-1989">
<DESCRIPTION>
<P>The study appears to be free of other sources of bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-12-27 16:18:53 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-12-26 21:09:36 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-09-27 14:42:47 +0100" MODIFIED_BY="[Empty name]">Network analysis of antiviral agents and combination interventions</TITLE>
<TABLE COLS="6" ROWS="24">
<TR>
<TH COLSPAN="6">
<P>Network analysis of antiviral agents and combination interventions</P>
</TH>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> relative corneal epithelial healing at two weeks following trial enrolment</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Comparison</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Pooling method</B>
<SUP>1</SUP>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Risk ratio (95% CI)<SUP>2</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No. trials (no. participants) of direct comparisons</B>
<BR/>
</P>
</TH>
<TH ALIGN="CENTER">
<P>No. indirect network <B>intermed</B>iates studied</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>
<B>Inactive control</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.74 (1.03-2.91)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2 (63)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD>
<P>
<B>Inactive control</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.81 (1.09-3.01)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (43)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.13 (1.02-1.25)</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (243)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.30 (1.18-1.43)</P>
</TD>
<TD ALIGN="CENTER">
<P>5 (256)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.17 (1.03-1.32)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (188)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Acyclovir</B>
</P>
</TD>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.23 (1.14-1.34)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>11 (606)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.11 (1.03-1.19)</P>
</TD>
<TD ALIGN="CENTER">
<P>7 (342)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>0.96 (0.90-1.04)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (178)</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Brivudine</B>
</P>
</TD>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.34 (1.18-1.51)</P>
</TD>
<TD ALIGN="CENTER">
<P>2 (99)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.01 (0.92-1.12)</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (147)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.04 (0.95-1.15)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (40)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ganciclovir</B>
</P>
</TD>
<TD>
<P>
<B>Acyclovir</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.34 (1.20-1.51)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>28 (2062)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Foscarnet</B>
</P>
</TD>
<TD>
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.09 (0.92-1.29)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (20)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>1.15 (1.01-1.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (104)</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ganciclovir</B>
</P>
</TD>
<TD>
<P>Combined</P>
</TD>
<TD ALIGN="CENTER">
<P>0.92 (0.75-1.13)</P>
</TD>
<TD ALIGN="CENTER">
<P>1 (60)</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Interferon</B>
</P>
</TD>
<TD>
<P>
<B>Inactive control</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1.32 (1.06-1.64)</P>
</TD>
<TD ALIGN="CENTER">
<P>2 (110)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Antiviral</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22 (0.91-1.62)</P>
</TD>
<TD ALIGN="CENTER">
<P>4 (222)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interferon + antiviral</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>
<B>Antiviral</B>
<SUP>4</SUP>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1.06 (0.99-1.13)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>12 (718)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Antiviral</B>
<SUP>5</SUP>
</P>
</TD>
<TD>
<P>
<B>Debridement</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>0.98 (0.72-1.32)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>7 (317)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Debridement + Antiviral</B>
<SUP>6</SUP>
</P>
</TD>
<TD>
<P>
<B>Debridement</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1.25 (0.78-2.00)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>3 (99)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Debridement + Antiviral</B>
<SUP>7</SUP>
</P>
</TD>
<TD>
<P>
<B>Antiviral</B>
<SUP>7</SUP>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1.05 (0.94-1.17)<SUP>8</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>7 (334)</P>
</TD>
<TD ALIGN="CENTER">
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Combined method uses direct and indirect risk ratios in a multiple treatment meta-analysis; direct method is the risk ratio of the direct meta-analysis.<BR/>
<SUP>2</SUP> Adjusted RRs of antiviral comparisons are taken from <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK> for combined direct and indirect estimates in network meta-analysis. Corresponding direct RRs for antiviral comparisons are tabulated in <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK> and are supplemented with HRs in <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>. Direct RRs of interferon comparisons are taken from <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; and <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>. Direct RRs of debridement comparisons are taken from <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>; <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>; and <LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>. Direct comparisons that are restricted to studies of randomized, double-masked trials are tabulated in <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>.<BR/>
<SUP>3</SUP> Idoxuridine or acyclovir<BR/>
<SUP>4</SUP> Trifluridine, acyclovir, brivudine, or ganciclovir<BR/>
<SUP>5</SUP> Idoxuridine, trifluridine, acyclovir, or brivudine<BR/>
<SUP>6</SUP> Trifluridine or interferon<BR/>
<SUP>7</SUP> Idoxuridine, trifluridine, brivudine, or ganciclovir</P>
<P>
<SUP>8</SUP> I<SUP>2</SUP> &gt; 50% of direct comparison suggests diversity among studies</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-12-13 17:34:48 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-09-27 14:32:34 +0100" MODIFIED_BY="[Empty name]">Relative healing outcomes with topical antiviral therapy</TITLE>
<TABLE COLS="7" ROWS="67">
<TR>
<TH COLSPAN="7">
<P>Relative healing outcomes with topical antiviral therapy</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> corneal epithelial healing at 7 and 14 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Treatment comparisons</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative healing percentages* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative risk**</P>
<P>(95% Cl)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No. of participants<BR/>(no. studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed healing</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding healing</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Treatment A</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Treatment B</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Idoxuridine (B) versus inactive control (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Different substances used as inactive control; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>25%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>52% (31%-88%)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.09 (1.24-3.51)</P>
</TD>
<TD ALIGN="CENTER">
<P>392 (10)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>50%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>65% (22%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.31 (0.45-3.84)</P>
</TD>
<TD ALIGN="CENTER">
<P>63 (2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Vidarabine (B) versus inactive control (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Direct analysis limited to one study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>25%</P>
</TD>
<TD ALIGN="CENTER">
<P>54% (20%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.17 (0.81-5.87)</P>
</TD>
<TD ALIGN="CENTER">
<P>23 (1)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>50%</P>
</TD>
<TD ALIGN="CENTER">
<P>98% (55%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.96 (1.10-3.49)</P>
</TD>
<TD ALIGN="CENTER">
<P>23 (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Vidarabine (B) versus idoxuridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Combined direct and indirect comparisons indicate vidarabine more effective than idoxuridine; neither antiviral commercially marketed</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>50%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>55% (43%-71%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.10 (0.85-1.42)</P>
</TD>
<TD ALIGN="CENTER">
<P>243 (3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>75%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>78% (69%-89%)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.04 (0.92-1.18)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>243 (3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Trifluridine (B) versus idoxuridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Indirect comparison shows similar results</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>50%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>100% (87%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.52 (1.74-3.63)</P>
</TD>
<TD ALIGN="CENTER">
<P>223 (4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>75%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>100% (89%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.38 (1.19-1.60)</P>
</TD>
<TD ALIGN="CENTER">
<P>256 (5)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Acyclovir (B) versus idoxuridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Indirect comparison shows similar results; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>50%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>99% (68%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.98 (1.35-2.90)</P>
</TD>
<TD ALIGN="CENTER">
<P>468 (9)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>75%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>92% (81%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22 (1.08-1.38)</P>
</TD>
<TD ALIGN="CENTER">
<P>606 (11)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Brivudine (B) versus idoxuridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Few studies, with slow healing of idoxuridine-treated eyes, but indirect analysis yields similar relative effect at 14 days</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>50%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>100% (100%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>7.94 (2.80-22.53)</P>
</TD>
<TD ALIGN="CENTER">
<P>99 (2)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>75%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>100% (79%-100%)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.38 (1.05-1.81)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>99 (2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Trifluridine (B) versus vidarabine (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Results partly influenced by one study restricted to geographic epithelial keratitis; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>65%</P>
</TD>
<TD ALIGN="CENTER">
<P>70% (61%-80%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.08 (0.94-1.23)</P>
</TD>
<TD ALIGN="CENTER">
<P>288 (4)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>82%</P>
</TD>
<TD ALIGN="CENTER">
<P>92% (69%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.12 (0.84-1.49)</P>
</TD>
<TD ALIGN="CENTER">
<P>188 (3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Acyclovir (B) versus vidarabine (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Indirect analysis also favours acyclovir but one study restricted to geographic epithelial keratitis does not</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>58%</P>
</TD>
<TD ALIGN="CENTER">
<P>71% (61%-84%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.23 (1.05-1.44)</P>
</TD>
<TD ALIGN="CENTER">
<P>314 (6)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>84%</P>
</TD>
<TD ALIGN="CENTER">
<P>92% (84%-99%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.09 (1.00-1.18)</P>
</TD>
<TD ALIGN="CENTER">
<P>342 (7)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>
<B>Acyclovir (B) versus trifluridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Studies differ in trifluridine formulation, in solution and as ointment</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>71%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>70% (58%-85%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.99 (0.82-1.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>178 (4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4" ROWSPAN="1">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>90%</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="1" VALIGN="MIDDLE">
<P>89% (81%-98%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.99 (0.90-1.09)</P>
</TD>
<TD ALIGN="CENTER">
<P>178 (4)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4">
<P>
<B>Brivudine (B) versus trifluridine (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Heterogeneity among studies at 7-day outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>61%</P>
</TD>
<TD ALIGN="CENTER">
<P>57% (43%-74%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.93 (0.71-1.21)</P>
</TD>
<TD ALIGN="CENTER">
<P>147 (3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>88%</P>
</TD>
<TD ALIGN="CENTER">
<P>88% (77%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00 (0.88-1.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>147 (3)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4">
<P>
<B>Brivudine (B) versus acyclovir (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Direct analysis limited to one study, but indirect analysis yields similar relative effect</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>80%</P>
</TD>
<TD ALIGN="CENTER">
<P>95% (74%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.19 (0.93-1.51)</P>
</TD>
<TD ALIGN="CENTER">
<P>40 (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>95%</P>
</TD>
<TD ALIGN="CENTER">
<P>100% (87%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.05 (0.92-1.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>40 (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4">
<P>
<B>Ganciclovir (B) versus acyclovir (A)</B>
</P>
</TD>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1,2,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="MIDDLE">
<P>Slow healing in some studies results in unusually low assumed healing rate with acyclovir; substantial heterogeneity among studies; random-effects model used to estimate relative risk</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>43%</P>
</TD>
<TD ALIGN="CENTER">
<P>49% (41%-58%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.14 (0.96-1.35)</P>
</TD>
<TD ALIGN="CENTER">
<P>551 (7)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>55%</P>
</TD>
<TD ALIGN="CENTER">
<P>76% (67%-86%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.38 (1.22-1.57)</P>
</TD>
<TD ALIGN="CENTER">
<P>2062 (28)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Foscarnet (B) versus trifluridine (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Direct analysis limited to one study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>90%</P>
</TD>
<TD ALIGN="CENTER">
<P>90% (68%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00 (0.75-1.34)</P>
</TD>
<TD ALIGN="CENTER">
<P>20 (1)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Foscarnet (B) versus acyclovir (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Direct analysis limited to one study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>75%</P>
</TD>
<TD ALIGN="CENTER">
<P>86% (71%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.15 (0.95-1.40)</P>
</TD>
<TD ALIGN="CENTER">
<P>104 (1)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Foscarnet (B) versus ganciclovir (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>4</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Direct analysis limited to one study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>83%</P>
</TD>
<TD ALIGN="CENTER">
<P>80% (63%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.96 (0.76-1.22)</P>
</TD>
<TD ALIGN="CENTER">
<P>60 (1)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>90%</P>
</TD>
<TD ALIGN="CENTER">
<P>86% (72%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.96 (0.80-1.16)</P>
</TD>
<TD ALIGN="CENTER">
<P>60 (1)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The <B>assumed risk</B> for inactive control is chosen to be 25% at 7 days and 50% at 14 days. The <B>assumed risk</B> for idoxuridine, based on observational studies and trials using idoxuridine as a control, is chosen to be 50% at 7 days and 75% at 14 days. For other comparisons, the basis for each <B>assumed risk</B> is the mean baseline risk estimated as the overall healing percentage, at 7 and 14 days respectively, among all included studies for participants who received treatment A. Each <B>corresponding risk</B> (and its 95% confidence interval, with an upper bound of 100%) is based on the assumed risk and the <B>risk ratio</B> directly comparing treatment B to treatment A.</P>
<P>**The <B>relative risk</B> is the pooled risk ratio. Pooling was based on fixed-effects models except for heterogenous comparisons in which a random-effects model was used.<BR/>
<BR/>CI: confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Some studies had a potential risk of bias<BR/>
<SUP>2</SUP> Pooling was limited by inconsistent results for either the 7-day or 14-day outcome<BR/>
<SUP>3</SUP> Analysis based only on indirect comparison<BR/>
<SUP>4</SUP> Few studies<BR/>
<SUP>5</SUP> Possible publication bias (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2014-09-25 12:00:16 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-09-27 14:35:03 +0100" MODIFIED_BY="Kirk R. Wilhelmus">Relative healing rates with antiviral agents and combination interventions</TITLE>
<TABLE COLS="4" ROWS="14">
<TR>
<TD COLSPAN="4">
<P>Relative healing rates with antiviral agents and combination interventions</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> rate of corneal epithelial healing following trial enrolment</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>Comparison</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Hazard ratio (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>No. of participants</B>
<BR/>
<B>(no. studies)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD>
<P>
<B>Inactive control</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.62 (1.00-2.65)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>95 (3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD>
<P>
<B>Inactive control</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2.47 (1.14-5.33)</P>
</TD>
<TD ALIGN="CENTER">
<P>43 (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.36 (0.81-2.28)</P>
</TD>
<TD ALIGN="CENTER">
<P>74 (2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2.29 (1.37-3.83)</P>
</TD>
<TD ALIGN="CENTER">
<P>78 (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.31 (0.96-1.79)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>188 (3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Acyclovir</B>
</P>
</TD>
<TD>
<P>
<B>Idoxuridine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2.15 (1.70-2.72)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>355 (8)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vidarabine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.13 (0.86-1.47)</P>
</TD>
<TD ALIGN="CENTER">
<P>259 (5)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.92 (0.65-1.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>140 (3)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine</B>
</P>
</TD>
<TD>
<P>
<B>Trifluridine</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.60 (0.35-1.02)</P>
</TD>
<TD ALIGN="CENTER">
<P>60 (1)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interferon + antiviral</B>
<SUP>2</SUP>
</P>
</TD>
<TD>
<P>
<B>Antiviral</B>
<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>2.84 (2.13-3.79)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>229 (5)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Debridement</B> <B>+</B> <B>antiviral</B>
<SUP>3</SUP>
</P>
</TD>
<TD>
<P>
<B>Antiviral</B>
<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.76 (1.32-2.35)<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>248 (6)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> I<SUP>2 </SUP>&gt; 50%<BR/>
<SUP>2</SUP> Trifluridine or acyclovir<BR/>
<SUP>3</SUP> Idoxuridine, trifluridine, or acyclovir</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2014-12-27 16:18:53 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2014-09-25 12:02:10 +0100" MODIFIED_BY="[Empty name]">Relative healing outcomes with combined topical or topical and oral antiviral therapy</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TH COLSPAN="7">
<P>Relative healing outcomes with combined topical and/or oral antiviral therapy</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> corneal epithelial healing at 7 and 14 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Treatment comparisons</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Illustrative comparative healing percentages* (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Relative risk</B>** <B>(95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>No. of participants</B>
<BR/>
<B>(no. studies)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Assumed healing</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Corresponding healing</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment A</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment B</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Topical acyclovir/vidarabine (B) versus topical acyclovir (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate</P>
</TD>
<TD ROWSPAN="4">
<P>Analysis limited to one study</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>62%</P>
</TD>
<TD ALIGN="CENTER">
<P>93% (63%-100%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.50 (1.01-2.24)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>32 (1)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>100%</P>
</TD>
<TD ALIGN="CENTER">
<P>100% (89%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00 (0.89-1.12)</P>
</TD>
<TD ALIGN="CENTER">
<P>32 (1)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Oral antiviral (B) versus topical antiviral (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Only oral and topical acyclovir studied in comparative treatment trials; substantial heterogeneity between 2 trials at 7-day outcome</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>52%</P>
</TD>
<TD ALIGN="CENTER">
<P>79% (59%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.51 (1.13-2.02)</P>
</TD>
<TD ALIGN="CENTER">
<P>116 (2)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>97%</P>
</TD>
<TD ALIGN="CENTER">
<P>89% (77%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.92 (0.79-1.07)</P>
</TD>
<TD ALIGN="CENTER">
<P>56 (1)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Oral antiviral + topical antiviral (B) versus topical antiviral (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Oral acyclovir was studied with topical trifluridine and with topical idoxuridine; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>63%</P>
</TD>
<TD ALIGN="CENTER">
<P>71% (60%-84%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.13 (0.95-1.33)</P>
</TD>
<TD ALIGN="CENTER">
<P>287 (1)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>84%</P>
</TD>
<TD ALIGN="CENTER">
<P>100% (57%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.36 (0.68-2.74)</P>
</TD>
<TD ALIGN="CENTER">
<P>327 (2)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the overall 7-day or 14-day healing percentage among included studies for participants who received treatment A of both treatment comparisons (oral versus topical and oral/topical versus topical). The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk and the <B>risk ratio</B> comparing treatment B to treatment A (and its 95% CI), with upper limits bounded at 100%.</P>
<P>**The <B>relative risk</B> is the pooled risk ratio.<BR/>
<BR/>CI: confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Inconsistent and insufficient studies</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2014-12-11 14:49:23 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-09-27 14:35:27 +0100" MODIFIED_BY="[Empty name]">Relative healing outcomes with topical interferon</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TH COLSPAN="7">
<P>Relative healing outcomes with topical interferon</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> corneal epithelial healing at 7 and 14 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Treatment comparisons</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Illustrative comparative healing percentages* (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Relative risk** (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>No. of participants</B>
<BR/>
<B>(no. studies)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Assumed healing</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Corresponding healing</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment A</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment B</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Interferon (B) versus inactive control (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8861;&#8861;&#8861;</P>
<P>very low<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>One study used debridement</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>25%</P>
</TD>
<TD ALIGN="CENTER">
<P>37% (27%-52%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.48 (1.07-2.06)</P>
</TD>
<TD ALIGN="CENTER">
<P>178 (3)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>50%</P>
</TD>
<TD ALIGN="CENTER">
<P>66% (53%-82%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.32 (1.06-1.64)</P>
</TD>
<TD ALIGN="CENTER">
<P>110 (2)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Interferon (B) versus antiviral (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Different antiviral agents used as comparative treatment; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>55%</P>
</TD>
<TD ALIGN="CENTER">
<P>57% (45%-70%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.99 (0.81-1.21)</P>
</TD>
<TD ALIGN="CENTER">
<P>85 (3)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>69%</P>
</TD>
<TD ALIGN="CENTER">
<P>84% (63%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22 (0.91-1.62)</P>
</TD>
<TD ALIGN="CENTER">
<P>222 (4)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Interferon + antiviral (B) versus antiviral (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Heterogeneity among trials at 7 and 14 days; slow healing with antiviral monotherapy in some trials; smaller relative effect size in sensitivity analyses</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>44%</P>
</TD>
<TD ALIGN="CENTER">
<P>83% (72%-96%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.64 (1.35-2.55)</P>
</TD>
<TD ALIGN="CENTER">
<P>475 (9)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>86%</P>
</TD>
<TD ALIGN="CENTER">
<P>95% (90%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.06 (0.99-1.13)</P>
</TD>
<TD ALIGN="CENTER">
<P>718 (12)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The <B>assumed risk</B> for inactive control is chosen to be 25% at 7 days and 50% at 14 days. The basis for the <B>assumed risk</B> of antiviral therapy is the overall 7-day or 14-day healing percentage among included studies for participants who received treatment A. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk and the <B>risk ratio</B> comparing treatment B to treatment A (and its 95% CI), with upper limits bounded at 100%.</P>
<P>**The <B>relative risk</B> is the pooled risk ratio.<BR/>
<BR/>CI: confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Inconsistent results among studies using different interferon dosages<BR/>
<SUP>2</SUP> Different antiviral agents and different types and routes of interferon administration among studies</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2014-12-13 17:21:56 +0000" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2014-09-25 12:05:06 +0100" MODIFIED_BY="[Empty name]">Relative healing outcomes with corneal debridement</TITLE>
<TABLE COLS="7" ROWS="19">
<TR>
<TH COLSPAN="7">
<P>Relative healing outcomes with corneal debridement</P>
</TH>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Study population: </B>trial participants with dendritic or geographic epithelial keratitis</P>
<P>
<B>Outcomes:</B> corneal epithelial healing at 7 and 14 days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Treatment comparisons</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>
<B>Illustrative comparative healing percentages* (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Relative risk** (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>No. of participants</B>
<BR/>
<B>(studies)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Quality of the evidence</B>
<BR/>
<B>(GRADE)</B>
</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>
<B>Comments</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Assumed healing</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Corresponding healing</B>
</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment A</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment B</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Antiviral (B) versus debridement (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8861;&#8861;</P>
<P>low<SUP>1,2</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Debridement limited by recrudescent epithelial keratitis during healing stage; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>61%</P>
</TD>
<TD ALIGN="CENTER">
<P>57% (45%-73%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.94 (0.74-1.20)</P>
</TD>
<TD ALIGN="CENTER">
<P>372 (7)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>72%</P>
</TD>
<TD ALIGN="CENTER">
<P>71% (52%-95%)</P>
</TD>
<TD ALIGN="CENTER">
<P>0.98 (0.72-1.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>317 (7)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Debridement + antiviral or interferon (B) versus debridement (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Debridement limited by recrudescent epithelial keratitis during healing stage; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>71%</P>
</TD>
<TD ALIGN="CENTER">
<P>80% (67%-97%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.13 (0.94-1.36)</P>
</TD>
<TD ALIGN="CENTER">
<P>347 (8)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>81%</P>
</TD>
<TD ALIGN="CENTER">
<P>100% (63%-100%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.25 (0.78-2.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>99 (3)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4">
<P>
<B>Debridement + antiviral (B) versus antiviral (A)</B>
</P>
</TD>
<TD COLSPAN="4">
<P>
<B>7 days</B>
</P>
</TD>
<TD ROWSPAN="4">
<P>&#8853;&#8853;&#8853;&#8861;</P>
<P>moderate<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="4">
<P>Different antiviral agents and different interferon dosages; random-effects model used</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>53%</P>
</TD>
<TD ALIGN="CENTER">
<P>68% (57%-81%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.28 (1.07-1.53)</P>
</TD>
<TD ALIGN="CENTER">
<P>305 (7)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="4">
<P>
<B>14 days</B>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>75%</P>
</TD>
<TD ALIGN="CENTER">
<P>79% (70%-88%)</P>
</TD>
<TD ALIGN="CENTER">
<P>1.05 (0.94-1.17)</P>
</TD>
<TD ALIGN="CENTER">
<P>334 (7)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the overall 7-day or 14-day healing percentage among included studies for participants who received treatment A. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk and the <B>risk ratio</B> comparing treatment B to treatment A (and its 95% CI), with upper limits bounded at 100%.</P>
<P>**The <B>relative risk</B> is the pooled risk ratio.<BR/>
<BR/>CI: confidence interval.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Inconsistent results among studies using different physicochemical methods of corneal epithelial debridement<BR/>
<SUP>2</SUP> Disparate relative effect found in sensitivity analysis</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2014-12-13 19:06:25 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-12-13 18:08:32 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-04-26 17:30:26 +0100" MODIFIED_BY="[Empty name]">Overview of trial and participant characteristics among included studies</TITLE>
<TABLE COLS="3" ROWS="9">
<TR>
<TH ALIGN="CENTER">
<P>Study characteristics</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Categories</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No. (%) trials</B>
<BR/>
<B>(n=137)</B>
</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No. centres</P>
</TD>
<TD>
<P>One<BR/>Two or more</P>
</TD>
<TD ALIGN="CENTER">
<P>118 (86%)<BR/>19 (14%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No. eyes per study</P>
</TD>
<TD>
<P>&lt; 50</P>
<P>50 to 100<BR/>&gt; 100</P>
</TD>
<TD ALIGN="CENTER">
<P>62 (45%)</P>
<P>58 (42%)</P>
<P>17 (12%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Average age of participants</P>
</TD>
<TD>
<P>&lt; 40 years<BR/>40 to 50 years<BR/>&gt; 50 years<BR/>Not stated</P>
</TD>
<TD ALIGN="CENTER">
<P>24 (18%)<BR/>36 (26%)<BR/>6 (4%)<BR/>71 (52%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Gender of participants</P>
</TD>
<TD>
<P>Males exceed females<BR/>Females exceed males<BR/>Not stated</P>
</TD>
<TD ALIGN="CENTER">
<P>71 (52%)<BR/>7 (5%)<BR/>59 (43%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Type of epithelial keratitis</P>
</TD>
<TD>
<P>Dendritic<BR/>Dendritic or geographic<BR/>Geographic<BR/>Not specified</P>
</TD>
<TD ALIGN="CENTER">
<P>74 (54%)<BR/>59 (43%)<BR/>2 (1%)<BR/>2 (1%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>No. of intervention groups<SUP>1</SUP>
</P>
</TD>
<TD>
<P>Two<BR/>Three<BR/>Four<BR/>Five</P>
</TD>
<TD ALIGN="CENTER">
<P>116 (85%)<BR/>16 (12%)<BR/>4 (3%)<BR/>1 (1%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Cycloplegic or mydriatic eye drops</P>
</TD>
<TD>
<P>Yes<BR/>None, variable, or not stated</P>
</TD>
<TD ALIGN="CENTER">
<P>51 (37%)<BR/>86 (63%)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Antibacterial eye drops</P>
</TD>
<TD>
<P>Yes<BR/>None or not stated</P>
</TD>
<TD ALIGN="CENTER">
<P>19 (14%)<BR/>118 (86%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Of 142 excluded studies, 121 had two intervention groups, ten had three groups, six had four groups, two had five groups, two had six groups, and one had eight groups.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2014-12-06 18:50:22 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-04-28 21:47:57 +0100" MODIFIED_BY="[Empty name]">Outcomes reported in studies excluded due to insufficient healing data</TITLE>
<TABLE COLS="3" ROWS="63">
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Study</B>
</P>
<P>
<B>(n=57)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment group (no. eyes)<SUP>1</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Mean healing time ± SD, days; or P value<SUP>2</SUP>
</B>
</P>
</TH>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Antiviral agents</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Babushkin-1993" TYPE="STUDY">Babushkin 1993</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (60)<BR/>Acyclovir (24)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS<BR/>5.9 ± 1.2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Huang-2007" TYPE="STUDY">Huang 2007</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (62)</P>
<P>Ganciclovir (62)</P>
</TD>
<TD ALIGN="CENTER">
<P>12</P>
<P>9.6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Inocencio-1982" TYPE="STUDY">Inocencio 1982</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (9)<BR/>Acyclovir (14)</P>
</TD>
<TD ALIGN="CENTER">
<P>10.4<BR/>7.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jing-2010" TYPE="STUDY">Jing 2010</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (22)</P>
<P>Ganciclovir (24)</P>
</TD>
<TD ALIGN="CENTER">
<P>P = 0.005</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Leopold-1965" TYPE="STUDY">Leopold 1965</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (5)<BR/>Cytarabine (5)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS<BR/>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-McGill-1981" TYPE="STUDY">McGill 1981</LINK>
</P>
</TD>
<TD>
<P>Vidarabine (29)<BR/>Acyclovir (28)</P>
</TD>
<TD ALIGN="CENTER">
<P>6.2 ± 1.8<BR/>4.5 ± 2.7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mohan-1987" TYPE="STUDY">Mohan 1987</LINK>
</P>
</TD>
<TD>
<P>Vidarabine (19)<BR/>Acyclovir (21)</P>
</TD>
<TD ALIGN="CENTER">
<P>8.3 ± 0.9<BR/>6.5 ± 0.6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pavan_x002d_Langston-1972" TYPE="STUDY">Pavan-Langston 1972</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (14)<BR/>Vidarabine (15)</P>
</TD>
<TD ALIGN="CENTER">
<P>3.0 - 4.5<BR/>3.5 - 4.5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pavan_x002d_Langston-1977" TYPE="STUDY">Pavan-Langston 1977</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (17)<BR/>Trifluridine (23)</P>
</TD>
<TD ALIGN="CENTER">
<P>5.3<BR/>5.5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pietruschka-1968" TYPE="STUDY">Pietruschka 1968</LINK>
</P>
</TD>
<TD>
<P>Fluorophenylalanine (30)<BR/>Idoxuridine (28)<BR/>Fluorophenylalanine, idoxuridine (40)</P>
</TD>
<TD ALIGN="CENTER">
<P>15<BR/>18<BR/>22</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wang-2009" TYPE="STUDY">Wang 2009</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (39)<BR/>Ganciclovir (39)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Debridement</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Assetto-1981" TYPE="STUDY">Assetto 1981</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Debridement (8)<BR/>Idoxuridine (16)<BR/>Cytarabine (16)<BR/>Trifluridine (8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3 - 19<BR/>10 - 18<BR/>13 - 21<BR/>6 - 13</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fellinger-1980" TYPE="STUDY">Fellinger 1980</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (13)<BR/>Trifluridine (16)<BR/>Debridement, idoxuridine (13)<BR/>Debridement, trifluridine (18)</P>
</TD>
<TD ALIGN="CENTER">
<P>8.1 ± 2.5<BR/>5.5 ± 2.5<BR/>13.4 ± 9<BR/>6.8 ± 4.2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Guo-2003" TYPE="STUDY">Guo 2003</LINK>
</P>
</TD>
<TD>
<P>Antiviral (34)<BR/>Cryotherapy, antiviral (35)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS<BR/>NS<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hilsdorf-1969" TYPE="STUDY">Hilsdorf 1969</LINK>
</P>
</TD>
<TD>
<P>Iodinisation, idoxuridine (20)<BR/>Cryotherapy, idoxuridine (20)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>4.3<BR/>14.0 </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Koev-2007" TYPE="STUDY">Koev 2007</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (25)<BR/>Acyclovir, pandavir (24)<BR/>Debridement, acyclovir, pandavir (26)</P>
</TD>
<TD ALIGN="CENTER">
<P>9.3 ± 1.2<BR/>8.2 ± 1.1<BR/>6.2 ± 1.3</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mathur-1984" TYPE="STUDY">Mathur 1984</LINK>
</P>
</TD>
<TD>
<P>Iodinisation (50)<BR/>Cryotherapy (20)<BR/>Cryotherapy, autologous serum (24)<BR/>Debridement (30)<BR/>Debridement, idoxuridine (30)</P>
</TD>
<TD ALIGN="CENTER">
<P>11<BR/>9<BR/>7<BR/>9<BR/>6</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Patterson-1967c" TYPE="STUDY">Patterson 1967c</LINK>
</P>
</TD>
<TD>
<P>Debridement (9)<BR/>Idoxuridine (15)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shimomura-1987" TYPE="STUDY">Shimomura 1987</LINK>
</P>
</TD>
<TD>
<P>Debridement, idoxuridine (16)<BR/>Idoxuridine (15)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &gt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tarakji-1978" TYPE="STUDY">Tarakji 1978</LINK>
</P>
</TD>
<TD>
<P>Cryotherapy (21)<BR/>Idoxuridine (14)</P>
</TD>
<TD ALIGN="CENTER">
<P>2.4<BR/>6.2</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Whitcher-1976" TYPE="STUDY">Whitcher 1976</LINK>
</P>
</TD>
<TD>
<P>Debridement (20)<BR/>Idoxuridine (31)</P>
</TD>
<TD ALIGN="CENTER">
<P>5<BR/>13</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Interferon and interferon/antiviral combinations</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Chen-2007" TYPE="STUDY">Chen 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (43)<BR/>Acyclovir, interferon (69)<BR/>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>P &lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Gu-2005" TYPE="STUDY">Gu 2005</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (20)<BR/>Acyclovir, interferon (19)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Huang-2009" TYPE="STUDY">Huang 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (36)<BR/>Acyclovir, interferon (29)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>39.6<BR/>30.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Jin-1992" TYPE="STUDY">Jin 1992</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (41)<BR/>Interferon (59)</P>
</TD>
<TD ALIGN="CENTER">
<P>8.2 - 9.6<BR/>9.9 - 12.4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kuyama-1979" TYPE="STUDY">Kuyama 1979</LINK>
</P>
</TD>
<TD>
<P>Interferon-&#945; (NS)<BR/>Interferon-&#946; (NS)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS<BR/>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lin-2013b" TYPE="STUDY">Lin 2013b</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir (33)</P>
<P>Ganciclovir, interferon (33)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Liu-2003" TYPE="STUDY">Liu 2003</LINK>
</P>
</TD>
<TD>
<P>Antiviral (21)<BR/>Antiviral/interferon (21)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS<BR/>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Scialdone-1986" TYPE="STUDY">Scialdone 1986</LINK>
</P>
</TD>
<TD>
<P>Idoxuridine (8)<BR/>Interferon (12)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>10 - 14<BR/>7 - 10<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shiota-1988" TYPE="STUDY">Shiota 1988</LINK>
</P>
</TD>
<TD>
<P>Interferon 100,000 IU/ml (14)<BR/>Interferon 1 million IU/ml (46)</P>
</TD>
<TD ALIGN="CENTER">
<P>4.4 ± 3.8<BR/>4.2 ± 4.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Su-2010" TYPE="STUDY">Su 2010</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir (40)</P>
<P>Ganciclovir, interferon (38)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tamburi-1990" TYPE="STUDY">Tamburi 1990</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (8)<BR/>Interferon (8)<BR/>Acyclovir, interferon (8)</P>
</TD>
<TD ALIGN="CENTER">
<P>5.2<BR/>9.0<BR/>5.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wan-2014" TYPE="STUDY">Wan 2014</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir (24)</P>
<P>Ganciclovir, interferon (26)</P>
</TD>
<TD ALIGN="CENTER">
<P>6.5 ± 2.1<BR/>4.2 ± 1.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Weng-2014" TYPE="STUDY">Weng 2014</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (35)</P>
<P>Acyclovir, interferon (35)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhang-2003" TYPE="STUDY">Zhang 2003</LINK>
</P>
</TD>
<TD>
<P>Interferon-&#945;-1b (29)<BR/>Interferon-&#945;-2b (17)</P>
</TD>
<TD ALIGN="CENTER">
<P>12.9 ± 2.1<BR/>9.4 ± 3.0</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhao-2001" TYPE="STUDY">Zhao 2001</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (89)<BR/>Acyclovir, interferon (97)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhou-2008" TYPE="STUDY">Zhou 2008</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (35)<BR/>Acyclovir, interferon (66)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Interferon inducers</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Galin-1976" TYPE="STUDY">Galin 1976</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Idoxuridine (20)<BR/>Poly I:C (19)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>NS<BR/>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kasparov-1972" TYPE="STUDY">Kasparov 1972</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Idoxuridine (16)<BR/>Poly A:U (43)<BR/>Immunomodulators (167)<BR/>Debridement, immunomodulators (33)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P> P &lt; 0.01</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kasparov-1974" TYPE="STUDY">Kasparov 1974</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control (30)<BR/>Idoxuridine (28)<BR/>Poly A:U (27)<BR/>Idoxuridine/poly A:U (15)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>14.1 ± 2.0<BR/>14.5 ± 2.0<BR/>10.2 ± 1.3<BR/>13.8 ± 3.2<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kasparov-1991" TYPE="STUDY">Kasparov 1991</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (45)<BR/>Poly A:U (65)<BR/>Acyclovir, poly A:U (40) </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>13.8 ± 0.8<BR/>14.6 ± 1.2<BR/>9.5 ± 1.1</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lin-2009" TYPE="STUDY">Lin 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (27)<BR/>Acyclovir, poly I:C (22)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Liu-2014b" TYPE="STUDY">Liu 2014b</LINK>
</P>
</TD>
<TD>
<P>Acyclovir (NS)</P>
<P>Poly I:C (NS)</P>
<P>Acyclovir, poly I:C (NS)</P>
</TD>
<TD ALIGN="CENTER">
<P>NS</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Wei-2012" TYPE="STUDY">Wei 2012</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir (24)</P>
<P>Poly I:C (24)</P>
</TD>
<TD ALIGN="CENTER">
<P>22.75 ± 5.09</P>
<P>13.54 ± 4.06</P>
</TD>
</TR>
<TR>
<TD COLSPAN="3">
<P>
<B>Cytokines, growth factors, and immunomodulators</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-He-2014" TYPE="STUDY">He 2014</LINK>
</P>
</TD>
<TD>
<P>Antiviral (34)</P>
<P>Autologous serum (34)</P>
</TD>
<TD ALIGN="CENTER">
<P>P = 0.015</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kolomiets-1986" TYPE="STUDY">Kolomiets 1986</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control (10)<BR/>HSV-immunoglobulin (14)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>28.6<BR/>16.8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Liu-2007" TYPE="STUDY">Liu 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (50)<BR/>Acyclovir, fibroblast growth factor (46)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Li-2014c" TYPE="STUDY">Li 2014c</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir, acyclovir (21)</P>
<P>Ganciclovir, fibroblast growth factor (21)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Pivetti_x002d_Pezzi-1985" TYPE="STUDY">Pivetti-Pezzi 1985</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Placebo (13)<BR/>Thymic extract (11) </P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>23 ± 13<BR/>23 ± 9</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Prost-1986" TYPE="STUDY">Prost 1986</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Cryotherapy (20)<BR/>Cryotherapy, oral inosine pranobex (19)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>6.8 ± 3.9<BR/>6.5 ± 3.8</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Salcedo-Hernandez-2007" TYPE="STUDY">Salcedo Hernandez 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Autologous serum (9)<BR/>Acyclovir (8)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>10<BR/>7</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Sellitti-1982" TYPE="STUDY">Sellitti 1982</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Topical/oral inosine pranobex (20)<BR/>Oral inosine pranobex (20)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>13.3<BR/>25</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Topciu-1992" TYPE="STUDY">Topciu 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Idoxuridine, foscarnet (120)<BR/>Idoxuridine, foscarnet, immunostimulant (113)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>30<BR/>3 - 4</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Xu-2009b" TYPE="STUDY">Xu 2009b</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (30)<BR/>Acyclovir, interleukin-2 (32)<BR/>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11 ± 2.7 - 41 ± 6.7<BR/>9 ± 2.5 - 28 ± 4.5</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yu-2012b" TYPE="STUDY">Yu 2012b</LINK>
</P>
</TD>
<TD>
<P>Ganciclovir (30)</P>
<P>Ganciclovir, measles vaccine (30)</P>
</TD>
<TD ALIGN="CENTER">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhang-1992" TYPE="STUDY">Zhang 1992</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir, interferon (20)<BR/>Acyclovir, interferon, transfer factor (21)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>P &lt; 0.05</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhi-2001" TYPE="STUDY">Zhi 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Acyclovir (30)<BR/>Acyclovir, interleukin-2 (38)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>9 ± 2.5 - 30 ± 4.5<BR/>13 ± 2.7 - 25 ± 3.1</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1 </SUP>Similar treatment groups were combined when possible; interventions are tabulated in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>
<SUP>2</SUP> A range of average healing times indicates that mean estimates were provided for subcategories (e.g., dendritic <I>vs</I>. geographic epithelial keratitis) without summary estimation. For studies not reporting mean healing times, P values are given that either compare the proportion healed in study groups at a time other than 14 days or compare clinical scores of symptoms and signs between study groups.</P>
<P>NS, not stated; SD, standard deviation (when reported)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2014-12-13 19:06:25 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-11-07 15:30:13 +0000" MODIFIED_BY="[Empty name]">Sensitivity analysis omitting potentially biased studies: relative healing at 14 days after omitting trials with incomplete randomisation, concealment, or masking</TITLE>
<TABLE COLS="6" ROWS="14">
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment comparisons<SUP>1</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Studies under investigation<SUP>2</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Risk ratio (95% CI) with studies included</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>I<SUP>2</SUP> (with studies included)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Risk ratio (95% CI) with studies omitted</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>I<SUP>2</SUP> (with studies omitted)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine versus inactive control</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Luntz-1963" TYPE="STUDY">Luntz 1963</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.31 (0.45-3.84)</P>
</TD>
<TD ALIGN="CENTER">
<P>92%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.79 (0.98-3.26)</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.38 (1.19-1.60)</P>
</TD>
<TD ALIGN="CENTER">
<P>32%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.43 (1.23-1.67)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Abe-1987" TYPE="STUDY">Abe 1987</LINK>; <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Maichuk-1988" TYPE="STUDY">Maichuk 1988</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22 (1.08-1.38)</P>
</TD>
<TD ALIGN="CENTER">
<P>63%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.18 (1.03-1.35)</P>
</TD>
<TD ALIGN="CENTER">
<P>66%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.38 (1.05-1.81)</P>
</TD>
<TD ALIGN="CENTER">
<P>30%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.64 (1.15-2.35)</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine versus vidarabine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.12 (0.84-1.49)</P>
</TD>
<TD ALIGN="CENTER">
<P>74%</P>
</TD>
<TD ALIGN="CENTER">
<P>0.99 (0.79-1.25)</P>
</TD>
<TD ALIGN="CENTER">
<P>65%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine versus trifluridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00 (0.88-1.14)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
<TD ALIGN="CENTER">
<P>0.98 (0.89-1.08)</P>
</TD>
<TD ALIGN="CENTER">
<P>36%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ganciclovir versus acyclovir</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-1997b" TYPE="STUDY">Colin 1997b</LINK>; <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>; <LINK REF="STD-Chen-2008" TYPE="STUDY">Chen 2008</LINK>; <LINK REF="STD-Dai-2009a" TYPE="STUDY">Dai 2009a</LINK>; <LINK REF="STD-Dai-2009b" TYPE="STUDY">Dai 2009b</LINK>; <LINK REF="STD-Han-2010" TYPE="STUDY">Han 2010</LINK>; <LINK REF="STD-Han-2014" TYPE="STUDY">Han 2014</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-Li-2008" TYPE="STUDY">Li 2008</LINK>; <LINK REF="STD-Li-2013a" TYPE="STUDY">Li 2013a</LINK>; <LINK REF="STD-Lin-2011" TYPE="STUDY">Lin 2011</LINK>; <LINK REF="STD-Lin-2014" TYPE="STUDY">Lin 2014</LINK>; <LINK REF="STD-Liu-2009a" TYPE="STUDY">Liu 2009a</LINK>; <LINK REF="STD-Liu-2010" TYPE="STUDY">Liu 2010</LINK>; <LINK REF="STD-Liu-2012a" TYPE="STUDY">Liu 2012a</LINK>; <LINK REF="STD-Liu-2012b" TYPE="STUDY">Liu 2012b</LINK>; <LINK REF="STD-Liu-2014a" TYPE="STUDY">Liu 2014a</LINK>; <LINK REF="STD-Ramirez-2002" TYPE="STUDY">Ramirez 2002</LINK>; <LINK REF="STD-Sun-2013a" TYPE="STUDY">Sun 2013a</LINK>; <LINK REF="STD-Wang-2014a" TYPE="STUDY">Wang 2014a</LINK>; <LINK REF="STD-Xu-2009a" TYPE="STUDY">Xu 2009a</LINK>; <LINK REF="STD-Yang-2000" TYPE="STUDY">Yang 2000</LINK>; <LINK REF="STD-Yang-2008" TYPE="STUDY">Yang 2008</LINK>; <LINK REF="STD-Zhang-2014" TYPE="STUDY">Zhang 2014</LINK>; <LINK REF="STD-Zhao-2006" TYPE="STUDY">Zhao 2006</LINK>; <LINK REF="STD-Zhen-2012" TYPE="STUDY">Zhen 2012</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.38 (1.22-1.57)</P>
</TD>
<TD ALIGN="CENTER">
<P>79%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.21 (0.95-1.54)</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Oral + topical antivirals versus topical antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Srinivas-1993" TYPE="STUDY">Srinivas 1993</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.36 (0.68-2.74)</P>
</TD>
<TD ALIGN="CENTER">
<P>90%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.01 (0.93-1.09)</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interferon versus nucleoside antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Kitano-1983" TYPE="STUDY">Kitano 1983</LINK>; <LINK REF="STD-Tanaka-1988b" TYPE="STUDY">Tanaka 1988b</LINK>; <LINK REF="STD-Vannini-1986" TYPE="STUDY">Vannini 1986</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22 (0.91-1.62)</P>
</TD>
<TD ALIGN="CENTER">
<P>67%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.57 (0.77-3.22)</P>
</TD>
<TD ALIGN="CENTER">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interferon + antiviral versus antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Fu-2012" TYPE="STUDY">Fu 2012</LINK>; <LINK REF="STD-Li-2009" TYPE="STUDY">Li 2009</LINK>; <LINK REF="STD-Li-2013b" TYPE="STUDY">Li 2013b</LINK>; <LINK REF="STD-Maichuk-1988" TYPE="STUDY">Maichuk 1988</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.06 (0.99-1.13)</P>
</TD>
<TD ALIGN="CENTER">
<P>67%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.02 (0.98-1.05)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Topical antiviral versus debridement</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Bartholomew-1977" TYPE="STUDY">Bartholomew 1977</LINK>; <LINK REF="STD-Kato-1979" TYPE="STUDY">Kato 1979</LINK>; <LINK REF="STD-MacKenzie-1964" TYPE="STUDY">MacKenzie 1964</LINK>; <LINK REF="STD-O_x0027_Day-1975" TYPE="STUDY">O'Day 1975</LINK>; <LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>; <LINK REF="STD-Struck-1989" TYPE="STUDY">Struck 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.98 (0.72-1.32)</P>
</TD>
<TD ALIGN="CENTER">
<P>79%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.43 (0.44-4.67)</P>
</TD>
<TD ALIGN="CENTER">
<P>87%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Debridement + antiviral or interferon versus debridement</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.25 (0.78-2.00)</P>
</TD>
<TD ALIGN="CENTER">
<P>89%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.54 (0.21-11.5)</P>
</TD>
<TD ALIGN="CENTER">
<P>96%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Debridement + antiviral versus antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Daniel-1972" TYPE="STUDY">Daniel 1972</LINK>; <LINK REF="STD-Richter-1986" TYPE="STUDY">Richter 1986</LINK>; <LINK REF="STD-Shen-2014" TYPE="STUDY">Shen 2014</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>1.05 (0.99-1.17)</P>
</TD>
<TD ALIGN="CENTER">
<P>66%</P>
</TD>
<TD ALIGN="CENTER">
<P>1.01 (0.89-1.15)</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Three comparisons that included a study judged to have a potentially high risk of bias were limited to a single study (<LINK REF="STD-Matth_x00e4_us-1970" TYPE="STUDY">Matthäus 1970</LINK>; <LINK REF="STD-Serifoglu-1987" TYPE="STUDY">Serifoglu 1987</LINK>; <LINK REF="STD-Sundmacher-1976a" TYPE="STUDY">Sundmacher 1976a</LINK>).</P>
<P>
<SUP>2</SUP> Two studies judged to have a potentially high risk of bias did not provide data for the 14-day outcome (<LINK REF="STD-Patterson-1967a" TYPE="STUDY">Patterson 1967a</LINK>; <LINK REF="STD-Travers-1978" TYPE="STUDY">Travers 1978</LINK>).</P>
<P>NA: not applicable (single study available for evaluation)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2014-12-11 14:56:05 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2013-08-19 18:26:30 +0100" MODIFIED_BY="[Empty name]">Sensitivity analysis including only higher-quality studies: relative healing at 14 days using only randomised, double-masked trials</TITLE>
<TABLE COLS="6" ROWS="17">
<TR>
<TH ALIGN="CENTER">
<P>
<B>Treatment comparisons</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Randomised, double-masked studies<SUP>1</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Risk ratio (95% CI) all studies</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>I<SUP>2</SUP> (with all studies)</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Risk ratio (95% CI) - only randomised, double-masked studies</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>I<SUP>2</SUP> (with only randomised, double-masked studies)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>
<B>Idoxuridine versus inactive control</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.31 (0.45-3.84)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>92%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.79 (0.98-3.26)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Vidarabine versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1976" TYPE="STUDY">Pavan-Langston 1976</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.04 (0.92-1.18)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.03 (0.90-1.17)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Sugar-1980" TYPE="STUDY">Sugar 1980</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.38 (1.19-1.60)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.47 (1.23-1.75)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Colin-1981" TYPE="STUDY">Colin 1981</LINK>; <LINK REF="STD-Collum-1980" TYPE="STUDY">Collum 1980</LINK>; <LINK REF="STD-Coster-1980" TYPE="STUDY">Coster 1980</LINK>; <LINK REF="STD-Kitano-1985" TYPE="STUDY">Kitano 1985</LINK>; <LINK REF="STD-Kumar-1987" TYPE="STUDY">Kumar 1987</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.22 (1.08-1.38)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>63%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.17 (1.02-1.34)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>69%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine versus idoxuridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.38 (1.05-1.81)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>30%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.64 (1.15-2.35)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Trifluridine versus vidarabine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.12 (0.84-1.49)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>74%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.07 (0.98-1.17)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir versus vidarabine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Denis-1983" TYPE="STUDY">Denis 1983</LINK>; <LINK REF="STD-Gen_x00e9_e-1987" TYPE="STUDY">Genée 1987</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.09 (1.00-1.18)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.07 (0.98-1.18)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir versus trifluridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-H_x00f8_vding-1989" TYPE="STUDY">Høvding 1989</LINK>; <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.99 (0.90-1.09)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.01 (0.91-1.12)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine versus trifluridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Power-1991" TYPE="STUDY">Power 1991</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.00 (0.88-1.14)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.98 (0.89-1.08)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Brivudine versus acyclovir</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.05 (0.92-1.20)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Ganciclovir versus acyclovir</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Colin-2007a" TYPE="STUDY">Colin 2007a</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.38 (1.22-1.57)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>79%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.21 (0.95-1.54)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Foscarnet versus trifluridine</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Behrens_x002d_Baumann-1992" TYPE="STUDY">Behrens-Baumann 1992</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.00 (0.75-1.34)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Acyclovir, vidarabine versus acyclovir</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Colin-1987" TYPE="STUDY">Colin 1987</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.00 (0.89-1.12)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Oral versus topical antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Collum-1986" TYPE="STUDY">Collum 1986</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0.92 (0.79-1.07)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Oral + topical antivirals versus topical antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-HEDS-Group-1997" TYPE="STUDY">HEDS Group 1997</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.36 (0.68-2.74)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>90%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.01 (0.93-1.09)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Interferon + antiviral versus antiviral</B>
</P>
</TD>
<TD>
<P>
<LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-de-Koning-1982" TYPE="STUDY">de Koning 1982</LINK>; <LINK REF="STD-de-Koning-1983" TYPE="STUDY">de Koning 1983</LINK>; <LINK REF="STD-Meurs-1985" TYPE="STUDY">Meurs 1985</LINK>; <LINK REF="STD-Sundmacher-1987" TYPE="STUDY">Sundmacher 1987</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.06 (0.99-1.13)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>67%</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>1.02 (0.98-1.06)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>0%</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Thirteen of 46 randomised, double-masked trials are not tabulated because two-week outcome data were not provided (<LINK REF="STD-Burns-1963" TYPE="STUDY">Burns 1963</LINK>; <LINK REF="STD-Wang-2004" TYPE="STUDY">Wang 2004</LINK>) or because comparative interventions not listed in this table were studied (<LINK REF="STD-Cellini-1994" TYPE="STUDY">Cellini 1994</LINK>; <LINK REF="STD-Colin-1984" TYPE="STUDY">Colin 1984</LINK>; <LINK REF="STD-Coster-1977a" TYPE="STUDY">Coster 1977a</LINK>; <LINK REF="STD-Guerra-1979" TYPE="STUDY">Guerra 1979</LINK>; <LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>; <LINK REF="STD-Sundmacher-1976b" TYPE="STUDY">Sundmacher 1976b</LINK>; <LINK REF="STD-Sundmacher-1978a" TYPE="STUDY">Sundmacher 1978a</LINK>; <LINK REF="STD-Sundmacher-1984a" TYPE="STUDY">Sundmacher 1984a</LINK>; <LINK REF="STD-Sundmacher-1985" TYPE="STUDY">Sundmacher 1985</LINK>; <LINK REF="STD-Uchida-1981" TYPE="STUDY">Uchida 1981</LINK>; <LINK REF="STD-Uchida-1982" TYPE="STUDY">Uchida 1982</LINK>). </P>
<P>NA: not applicable (single study available for evaluation)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2014-12-13 17:52:03 +0000" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2010-11-06 08:57:49 +0000" MODIFIED_BY="[Empty name]">Combined direct and indirect comparisons: relative healing of HSV epithelial keratitis at 14 days between topical antiviral agents</TITLE>
<TABLE COLS="5" ROWS="45">
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Treatment comparisons</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Type of comparison (intermediate comparator)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>No. trials<SUP>1</SUP>
</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Risk ratio (95% CI)</B>
</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Combined risk ratio (95% CI)<SUP>2</SUP>
</B>
</P>
</TH>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Idoxuridine versus placebo</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>2</P>
</TD>
<TD>
<P>1.31 (0.45-3.84)*</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.74 (1.03-2.91)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (vidarabine)</P>
</TD>
<TD ALIGN="CENTER">
<P>3, 1</P>
</TD>
<TD>
<P>1.89 (1.04-3.40)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Vidarabine versus placebo</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD>
<P>1.96 (1.10-3.49)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.81 (1.09-3.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER">
<P>3, 2</P>
</TD>
<TD>
<P>1.36 (0.46-4.01)*</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Vidarabine versus idoxuridine</B>
</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1.04 (0.92-1.18)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>1.13 (1.02-1.25)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (inactive control)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1, 2</P>
</TD>
<TD VALIGN="TOP">
<P>1.67 (0.55-5.12)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3, 5</P>
</TD>
<TD VALIGN="TOP">
<P>1.23 (0.89-1.70)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7, 11</P>
</TD>
<TD VALIGN="TOP">
<P>1.12 (0.96-1.30)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Trifluridine versus idoxuridine</B>
</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (1.19-1.60)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>1.30 (1.18-1.43)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (vidarabine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.17 (0.85-1.59)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4, 11</P>
</TD>
<TD VALIGN="TOP">
<P>1.23 (1.06-1.44)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (brivudine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3, 2</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (1.02-1.87)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Acyclovir versus idoxuridine</B>
</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11</P>
</TD>
<TD VALIGN="TOP">
<P>1.22 (1.08-1.38)*</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>1.23 (1.14-1.34)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (vidarabine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.13 (0.98-1.32)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4, 5</P>
</TD>
<TD VALIGN="TOP">
<P>1.37 (1.15-1.63)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (brivudine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1, 2</P>
</TD>
<TD VALIGN="TOP">
<P>1.31 (0.97-1.78)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Brivudine versus idoxuridine</B>
</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (1.05-1.81)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.34 (1.18-1.51)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3, 5</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (1.13-1.68)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1, 11</P>
</TD>
<TD VALIGN="TOP">
<P>1.28 (1.07-1.54)*</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Trifluridine versus vidarabine</B>
</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>3</P>
</TD>
<TD VALIGN="TOP">
<P>1.12 (0.84-1.49)*</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.17 (1.03-1.32)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>5, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.33 (1.09-1.61)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4, 7</P>
</TD>
<TD VALIGN="TOP">
<P>1.10 (0.97-1.25)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Acyclovir versus vidarabine</B>
</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7</P>
</TD>
<TD VALIGN="TOP">
<P>1.09 (1.00-1.18)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.11 (1.03-1.19)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.17 (0.99-1.40)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.11 (0.82-1.50)*</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="4" VALIGN="TOP">
<P>
<B>Acyclovir versus trifluridine</B>
</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4</P>
</TD>
<TD VALIGN="TOP">
<P>0.99 (0.90-1.09)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="4" VALIGN="MIDDLE">
<P>0.96 (0.90-1.04) </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>11, 5</P>
</TD>
<TD VALIGN="TOP">
<P>0.90 (0.76-1.06)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (vidarabine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>7, 3</P>
</TD>
<TD VALIGN="TOP">
<P>0.97 (0.72-1.31)*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (brivudine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1, 3</P>
</TD>
<TD VALIGN="TOP">
<P>0.95 (0.79-1.15)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Brivudine versus trifluridine</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>3</P>
</TD>
<TD>
<P>1.00 (0.88-1.14)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.01 (0.92-1.12)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER">
<P>2, 5</P>
</TD>
<TD>
<P>1.00 (0.73-1.36)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 4</P>
</TD>
<TD>
<P>1.04 (0.88-1.22)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Brivudine versus acyclovir</B>
</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>1</P>
</TD>
<TD VALIGN="TOP">
<P>1.05 (0.92-1.20)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.04 (0.95-1.15)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (idoxuridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>2, 11</P>
</TD>
<TD VALIGN="TOP">
<P>1.13 (0.84-1.53)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>4, 3</P>
</TD>
<TD VALIGN="TOP">
<P>1.01 (0.86-1.19)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2" VALIGN="TOP">
<P>
<B>Ganciclovir versus acyclovir</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Direct</P>
</TD>
<TD ALIGN="CENTER" VALIGN="TOP">
<P>28</P>
</TD>
<TD VALIGN="TOP">
<P>1.38 (1.22-1.57)*</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.34 (1.20-1.51)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (foscarnet)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 1</P>
</TD>
<TD>
<P>1.20 (0.92-1.57)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Foscarnet versus trifluridine</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD>
<P>1.00 (0.75-1.34)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>1.09 (0.92-1.29)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 4</P>
</TD>
<TD>
<P>1.14 (0.92-1.41)</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3">
<P>
<B>Foscarnet versus acyclovir</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD>
<P>1.15 (0.95-1.40)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>1.15 (1.01-1.32)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (trifluridine)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 4</P>
</TD>
<TD>
<P>1.01 (0.74-1.37)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (ganciclovir)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 17</P>
</TD>
<TD>
<P>1.27 (0.99-1.63)*</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="2">
<P>
<B>Foscarnet versus ganciclovir</B>
</P>
</TD>
<TD>
<P>Direct</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD>
<P>0.96 (0.80-1.16)</P>
</TD>
<TD ALIGN="CENTER" ROWSPAN="2" VALIGN="MIDDLE">
<P>0.92 (0.75-1.13)</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirect (acyclovir)</P>
</TD>
<TD ALIGN="CENTER">
<P>1, 12</P>
</TD>
<TD>
<P>0.86 (0.62-1.20)*</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Data derive from a network of antiviral treatment trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Comparisons are based on reported outcomes at 14 days in which two antivirals were directly compared in at least one clinical trial. Indirect comparisons are limited to a linked network of trials having a single shared intermediate intervention since multiple intermediates were not considered for indirect adjustment. The number of trials indicate the number of direct comparisons made in either head-to-head trials or the number of trials between the first antiviral and the intermediate antiviral followed by the number of trials between the intermediate antiviral and the second antiviral.</P>
<P>
<SUP>2</SUP> While I<SUP>2 </SUP>&lt; 25% for all combined direct and indirect comparisons estimated by the DerSimonian-Laird random-effects model method, networks that had at least one heterogeneous head-to-head comparison are identified (*).</P>
<P>CI: confidence interval; NA: not applicable (only direct or indirect comparison available)</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2014-05-01 16:49:04 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-11-06 09:01:18 +0000" MODIFIED_BY="[Empty name]">Safety assessment among antiviral treatment studies</TITLE>
<TABLE COLS="4" ROWS="8">
<TR>
<TH ALIGN="CENTER">
<P>
<B>Topical antiviral agent</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No. studies reporting corneal toxicity prevalence</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>No. antiviral-treated participants assessed for corneal toxicity</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>
<B>Median prevalence of punctate epithelial erosions during antiviral use (interquartile range)</B>
</P>
</TH>
</TR>
<TR>
<TD>
<P>Idoxuridine</P>
</TD>
<TD ALIGN="CENTER">
<P>14<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>430</P>
</TD>
<TD ALIGN="CENTER">
<P>10% (5%-20%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Vidarabine</P>
</TD>
<TD ALIGN="CENTER">
<P>12<SUP>2</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>395</P>
</TD>
<TD ALIGN="CENTER">
<P>11% (4%-17%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Trifluridine</P>
</TD>
<TD ALIGN="CENTER">
<P>9<SUP>3</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>220</P>
</TD>
<TD ALIGN="CENTER">
<P>4% (2%-7%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Acyclovir</P>
</TD>
<TD ALIGN="CENTER">
<P>25<SUP>4</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>667</P>
</TD>
<TD ALIGN="CENTER">
<P>10% (0%-17%)</P>
</TD>
</TR>
<TR>
<TD>
<P>Brivudine</P>
</TD>
<TD ALIGN="CENTER">
<P>3<SUP>5</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>72</P>
</TD>
<TD ALIGN="CENTER">
<P>0%</P>
</TD>
</TR>
<TR>
<TD>
<P>Ganciclovir</P>
</TD>
<TD ALIGN="CENTER">
<P>4<SUP>6</SUP>
</P>
</TD>
<TD ALIGN="CENTER">
<P>156</P>
</TD>
<TD ALIGN="CENTER">
<P>4% (0%-11%)</P>
</TD>
</TR>
<TR>
<TD>
<P>All of above</P>
</TD>
<TD ALIGN="CENTER">
<P>40</P>
</TD>
<TD ALIGN="CENTER">
<P>1940</P>
</TD>
<TD ALIGN="CENTER">
<P>8% (0%-17%)</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Included idoxuridine studies: <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-Colin-1981" TYPE="STUDY">Colin 1981</LINK>; <LINK REF="STD-Collum-1980" TYPE="STUDY">Collum 1980</LINK>; <LINK REF="STD-Kitano-1985" TYPE="STUDY">Kitano 1985</LINK>; <LINK REF="STD-Klauber-1982" TYPE="STUDY">Klauber 1982</LINK>; <LINK REF="STD-Laibson-1977" TYPE="STUDY">Laibson 1977</LINK>; <LINK REF="STD-MacKenzie-1964" TYPE="STUDY">MacKenzie 1964</LINK>; <LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1976" TYPE="STUDY">Pavan-Langston 1976</LINK>; <LINK REF="STD-Vannini-1986" TYPE="STUDY">Vannini 1986</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>
</P>
<P>
<SUP>2</SUP> Included vidarabine studies: <LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>; <LINK REF="STD-Denis-1983" TYPE="STUDY">Denis 1983</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1976" TYPE="STUDY">Pavan-Langston 1976</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK>
</P>
<P>
<SUP>3</SUP> Included trifluridine studies: <LINK REF="STD-Behrens_x002d_Baumann-1992" TYPE="STUDY">Behrens-Baumann 1992</LINK>; <LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>; <LINK REF="STD-Hoang_x002d_Xuan-1984" TYPE="STUDY">Hoang-Xuan 1984</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Parlato-1985" TYPE="STUDY">Parlato 1985</LINK>; <LINK REF="STD-Power-1991" TYPE="STUDY">Power 1991</LINK>; <LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK> (omitting <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK> because of imprecise assessment)</P>
<P>
<SUP>4</SUP> Included acyclovir studies: <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Carmassi-1993" TYPE="STUDY">Carmassi 1993</LINK>; <LINK REF="STD-Colin-1981" TYPE="STUDY">Colin 1981</LINK>; <LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-Colin-1984" TYPE="STUDY">Colin 1984</LINK>; <LINK REF="STD-Colin-1987" TYPE="STUDY">Colin 1987</LINK>; <LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-1997b" TYPE="STUDY">Colin 1997b</LINK>; <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>; <LINK REF="STD-Collum-1980" TYPE="STUDY">Collum 1980</LINK>; <LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Collum-1986" TYPE="STUDY">Collum 1986</LINK>; <LINK REF="STD-Denis-1983" TYPE="STUDY">Denis 1983</LINK>; <LINK REF="STD-Hoang_x002d_Xuan-1984" TYPE="STUDY">Hoang-Xuan 1984</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Jensen-1982" TYPE="STUDY">Jensen 1982</LINK>; <LINK REF="STD-Kitano-1985" TYPE="STUDY">Kitano 1985</LINK>; <LINK REF="STD-Klauber-1982" TYPE="STUDY">Klauber 1982</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Pavan_x002d_Langston-1981" TYPE="STUDY">Pavan-Langston 1981</LINK>; <LINK REF="STD-Wilhelmus-1981a" TYPE="STUDY">Wilhelmus 1981a</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK> (omitting <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK> because of imprecise assessment)</P>
<P>
<SUP>5</SUP> Included brivudine studies: <LINK REF="STD-Panda-1995" TYPE="STUDY">Panda 1995</LINK>; <LINK REF="STD-Power-1991" TYPE="STUDY">Power 1991</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>
</P>
<P>
<SUP>6</SUP> Included ganciclovir studies: <LINK REF="STD-Colin-1997a" TYPE="STUDY">Colin 1997a</LINK>; <LINK REF="STD-Colin-1997b" TYPE="STUDY">Colin 1997b</LINK>; <LINK REF="STD-Colin-2007b" TYPE="STUDY">Colin 2007b</LINK>; <LINK REF="STD-Huang-2008a" TYPE="STUDY">Huang 2008a</LINK>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-09 11:00:20 +0000" MODIFIED_BY="Anupa Shah">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-09 10:51:00 +0000" MODIFIED_BY="Anupa Shah" NO="1">
<NAME>Topical antiviral agents</NAME>
<DICH_OUTCOME CHI2="92.44788907882602" CI_END="3.0515329570437872" CI_START="1.1995480407453418" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9132329653995914" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="71" I2="88.10140489998554" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.4845180647677764" LOG_CI_START="0.07901764572845528" LOG_EFFECT_SIZE="0.2817678552481159" METHOD="MH" MODIFIED="2013-08-21 17:21:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.10702591327572E-15" P_Q="0.4431871692413889" P_Z="0.006453188558429471" Q="0.5880168310521143" RANDOM="YES" SCALE="30.0" SORT_BY="EFFECT_SIZE" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.5656478355630955" TOTALS="SUB" TOTAL_1="233" TOTAL_2="222" WEIGHT="200.0" Z="2.7238188783911">
<NAME>Idoxuridine <I>versus</I> inactive control: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Idoxuridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Idoxuridine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="37.501190073312436" CI_END="3.506967223615661" CI_START="1.2443328681762613" DF="9" EFFECT_SIZE="2.0889793163078028" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="52" I2="76.00076162274964" ID="CMP-001.01.01" LOG_CI_END="0.5449317069509712" LOG_CI_START="0.09493657285851403" LOG_EFFECT_SIZE="0.31993413990474256" MODIFIED="2013-08-21 17:21:00 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.1414189379065363E-5" P_Z="0.005320492026873478" STUDIES="10" TAU2="0.43913865984241307" TOTAL_1="201" TOTAL_2="191" WEIGHT="100.0" Z="2.7869607652657744">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.2587142893192786" CI_START="0.6435137877381638" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.09992716247203741" LOG_CI_START="-0.19144214359338768" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2013-08-21 17:21:00 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.17115177268415682" STUDY_ID="STD-Luntz-1963" TOTAL_1="11" TOTAL_2="11" VAR="0.029292929292929287" WEIGHT="14.915735207299326"/>
<DICH_DATA CI_END="3.301852527389963" CI_START="0.27470320704330037" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5187576722062951" LOG_CI_START="-0.5611362703461714" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2010-05-25 23:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.6343350474165466" STUDY_ID="STD-Markham-1977" TOTAL_1="21" TOTAL_2="20" VAR="0.4023809523809524" WEIGHT="8.302838632384281"/>
<DICH_DATA CI_END="3.027071320549603" CI_START="0.7432926950632548" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.48102265344955175" LOG_CI_START="-0.12884013533818925" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-05-25 23:48:46 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.35823642100341124" STUDY_ID="STD-Davidson-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.1283333333333333" WEIGHT="12.312504635120064"/>
<DICH_DATA CI_END="2.6108766429832766" CI_START="0.9458079000930638" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="7" LOG_CI_END="0.41678635304192385" LOG_CI_START="-0.024197062753987433" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2010-05-25 23:48:52 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.2590358413416319" STUDY_ID="STD-Jepson-1964" TOTAL_1="12" TOTAL_2="12" VAR="0.06709956709956709" WEIGHT="13.801805502684761"/>
<DICH_DATA CI_END="3.8609304457677585" CI_START="1.3174193461925237" EFFECT_SIZE="2.25531914893617" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="13" LOG_CI_END="0.5866919779277678" LOG_CI_START="0.11972403673033753" LOG_EFFECT_SIZE="0.3532080073290528" MODIFIED="2010-05-25 23:48:52 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.2742992801879594" STUDY_ID="STD-Laibson-1964" TOTAL_1="47" TOTAL_2="53" VAR="0.07524009511163265" WEIGHT="13.583378938155043"/>
<DICH_DATA CI_END="6.220247867281874" CI_START="1.0867734122875052" EFFECT_SIZE="2.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.7938076910007773" LOG_CI_START="0.03613900494085858" LOG_EFFECT_SIZE="0.414973347970818" MODIFIED="2010-05-25 23:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.4450583367120799" STUDY_ID="STD-Patterson-1963a" TOTAL_1="10" TOTAL_2="13" VAR="0.1980769230769231" WEIGHT="10.964894352186093"/>
<DICH_DATA CI_END="11.750262697293131" CI_START="0.7330005449398671" EFFECT_SIZE="2.9347826086956523" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.070047576114946" LOG_CI_START="-0.13489570248808178" LOG_EFFECT_SIZE="0.46757593681343207" MODIFIED="2010-05-25 23:47:48 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.7077896464168428" STUDY_ID="STD-Burns-1963" TOTAL_1="23" TOTAL_2="15" VAR="0.5009661835748793" WEIGHT="7.432151419281453"/>
<DICH_DATA CI_END="17.624308189178073" CI_START="1.3015579349565916" EFFECT_SIZE="4.7894736842105265" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.2461120785417787" LOG_CI_START="0.11446350419475061" LOG_EFFECT_SIZE="0.6802877913682647" MODIFIED="2010-05-25 23:48:41 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.6647359743222313" STUDY_ID="STD-Hart-1965" TOTAL_1="19" TOTAL_2="13" VAR="0.4418739155581261" WEIGHT="7.9306490524277296"/>
<DICH_DATA CI_END="21.40264334226768" CI_START="1.5368942092753568" EFFECT_SIZE="5.735294117647059" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="2" LOG_CI_END="1.330467414380326" LOG_CI_START="0.18664397426019994" LOG_EFFECT_SIZE="0.7585556943202629" MODIFIED="2010-05-25 23:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.6718875507439065" STUDY_ID="STD-Patterson-1963b" TOTAL_1="17" TOTAL_2="15" VAR="0.4514328808446455" WEIGHT="7.8455252914177604"/>
<DICH_DATA CI_END="315.8624609039237" CI_START="1.303894137638399" EFFECT_SIZE="20.294117647058822" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="2.4994980146641854" LOG_CI_START="0.11524233272581486" LOG_EFFECT_SIZE="1.307370173695" MODIFIED="2010-05-25 23:48:32 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="1.4005235898265689" STUDY_ID="STD-Patterson-1963c" TOTAL_1="16" TOTAL_2="14" VAR="1.9614663256606992" WEIGHT="2.9105169690434853"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.979849780148246" CI_END="3.8417918400856528" CI_START="0.44592921220996606" DF="1" EFFECT_SIZE="1.3088801353539106" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" I2="91.65264992172861" ID="CMP-001.01.02" LOG_CI_END="0.5845338297731355" LOG_CI_START="-0.3507340766837204" LOG_EFFECT_SIZE="0.11689987654470756" MODIFIED="2013-08-21 17:21:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.377919250132424E-4" P_Z="0.6241658132560566" STUDIES="2" TAU2="0.55609642908256" TOTAL_1="32" TOTAL_2="31" WEIGHT="100.0" Z="0.48995490221148674">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1815689975317274" CI_START="0.8463322938304735" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0724590872653571" LOG_CI_START="-0.07245908726535714" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-21 17:21:07 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.08512565307587489" STUDY_ID="STD-Luntz-1963" TOTAL_1="11" TOTAL_2="11" VAR="0.007246376811594207" WEIGHT="53.5765217376753"/>
<DICH_DATA CI_END="3.257253194494667" CI_START="0.9789768617292863" EFFECT_SIZE="1.7857142857142858" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5128515186809308" LOG_CI_START="-0.00922757269333158" LOG_EFFECT_SIZE="0.2518119729937996" MODIFIED="2010-05-25 23:48:59 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.30667184260642355" STUDY_ID="STD-Markham-1977" TOTAL_1="21" TOTAL_2="20" VAR="0.09404761904761903" WEIGHT="46.4234782623247"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="7.779373173913043" CI_END="2.651143340338447" CI_START="0.9950214381910375" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.6241750088442293" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="21" I2="74.29098777898072" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.42343320952679114" LOG_CI_START="-0.002167562080636861" LOG_EFFECT_SIZE="0.21063282372307712" MODIFIED="2013-08-21 18:15:33 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.020451788515229552" P_Q="1.0" P_Z="0.052379689882883274" Q="0.0" SCALE="15.0" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="51" TOTAL_2="44" WEIGHT="100.0" Z="1.94">
<NAME>Idoxuridine <I>versus</I> inactive control: healing rate</NAME>
<GROUP_LABEL_1>Idoxuridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Idoxuridine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.631639918161123" CI_START="0.3401442135449904" EFFECT_SIZE="0.7449784404608818" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.21262432181362506" LOG_CI_START="-0.46833691275825967" LOG_EFFECT_SIZE="-0.12785629547231733" MODIFIED="2013-08-21 18:15:33 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="-1.84" SE="0.4" STUDY_ID="STD-Luntz-1963" TOTAL_1="11" TOTAL_2="11" VAR="6.25" WEIGHT="39.0625"/>
<IPD_DATA CI_END="11.501552109091019" CI_START="1.620148817581776" EFFECT_SIZE="4.316737894510043" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="2" LOG_CI_END="1.0607564513909336" LOG_CI_START="0.2095549081760778" LOG_EFFECT_SIZE="0.6351556797835057" MODIFIED="2010-06-10 23:23:18 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="5.85" SE="0.5" STUDY_ID="STD-Hart-1965" TOTAL_1="19" TOTAL_2="13" VAR="4.0" WEIGHT="25.0"/>
<IPD_DATA CI_END="4.347214941231266" CI_START="0.8477346790928031" EFFECT_SIZE="1.919709577814344" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.6382111137318807" LOG_CI_START="-0.07174005037981315" LOG_EFFECT_SIZE="0.2832355316760338" MODIFIED="2010-06-14 23:06:41 +0100" MODIFIED_BY="[Empty name]" ORDER="223" O_E="3.75" SE="0.41702882811414954" STUDY_ID="STD-Markham-1977" TOTAL_1="21" TOTAL_2="20" VAR="5.75" WEIGHT="35.9375"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="0.03374486389727304" CI_END="3.3807407659499873" CI_START="1.2177160195419545" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="2.028985507246377" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.5290118704895844" LOG_CI_START="0.08554601939238096" LOG_EFFECT_SIZE="0.30727894494098273" METHOD="MH" MODIFIED="2013-08-19 18:22:35 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8542506258944556" P_Q="0.8573544008077219" P_Z="0.006604978432053273" Q="0.032307536305861376" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="46" TOTAL_2="40" WEIGHT="200.00000000000003" Z="2.716130966123855">
<NAME>Vidarabine <I>versus</I> inactive control: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Vidarabine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vidarabine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.866222276659645" CI_START="0.8056118056433318" DF="0" EFFECT_SIZE="2.1739130434782608" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.7683585147812267" LOG_CI_START="-0.09387417814437507" LOG_EFFECT_SIZE="0.3372421683184259" MODIFIED="2013-08-17 15:42:22 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1252294858225749" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.00000000000001" Z="1.533188220292507">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="5.866222276659645" CI_START="0.8056118056433318" EFFECT_SIZE="2.1739130434782608" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.7683585147812267" LOG_CI_START="-0.09387417814437507" LOG_EFFECT_SIZE="0.3372421683184259" MODIFIED="2010-03-11 16:53:30 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.5064797519451639" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="20" VAR="0.2565217391304348" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.488707573043341" CI_START="1.0972479737964054" DF="0" EFFECT_SIZE="1.9565217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.542664567976028" LOG_CI_START="0.040304787539473544" LOG_EFFECT_SIZE="0.29148467775775083" MODIFIED="2013-08-17 15:42:21 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.022938138472010757" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.00000000000001" Z="2.2744634132692365">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="3.488707573043341" CI_START="1.0972479737964054" EFFECT_SIZE="1.9565217391304348" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.542664567976028" LOG_CI_START="0.040304787539473544" LOG_EFFECT_SIZE="0.29148467775775083" MODIFIED="2010-03-11 16:53:30 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.2950886217494506" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="20" VAR="0.08707729468599033" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.0" CI_END="5.329028032906859" CI_START="1.1412066407554282" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="2.4660742446092625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.7266480048167682" LOG_CI_START="0.057364290180137695" LOG_EFFECT_SIZE="0.392006147498453" MODIFIED="2010-06-14 23:17:13 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.021679260139718683" Q="0.0" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="20" WEIGHT="100.0" Z="2.2959409111945943">
<NAME>Vidarabine <I>versus</I> inactive control: healing rate</NAME>
<GROUP_LABEL_1>Vidarabine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vidarabine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="5.329028032906859" CI_START="1.1412066407554284" EFFECT_SIZE="2.4660742446092625" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.7266480048167682" LOG_CI_START="0.057364290180137785" LOG_EFFECT_SIZE="0.392006147498453" MODIFIED="2010-06-14 23:11:13 +0100" MODIFIED_BY="[Empty name]" ORDER="224" O_E="5.84" SE="0.3931405669853757" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="20" VAR="6.47" WEIGHT="100.0"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="4.21794032733384" CI_END="1.2024883784283915" CI_START="0.9391577582882951" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0626976474296606" ESTIMABLE="YES" EVENTS_1="170" EVENTS_2="146" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.08008088778282568" LOG_CI_START="-0.02726144948111204" LOG_EFFECT_SIZE="0.026409719150856804" METHOD="MH" MODIFIED="2013-08-17 15:42:21 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.5184836965465659" P_Q="0.7226535176379767" P_Z="0.33483027633695495" Q="0.12596449117082165" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="254" TOTAL_2="232" WEIGHT="200.0" Z="0.9644302461986148">
<NAME>Vidarabine <I>versus</I> idoxuridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Vidarabine</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vidarabine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.6282883602121867" CI_END="1.4209240038915092" CI_START="0.8478505845840072" DF="2" EFFECT_SIZE="1.0976024997005356" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="54" I2="44.87758961134397" ID="CMP-001.05.01" LOG_CI_END="0.15257085092314004" LOG_CI_START="-0.07168067605472439" LOG_EFFECT_SIZE="0.040445087434207834" MODIFIED="2013-08-17 15:42:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16297739718274917" P_Z="0.4795775679830768" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="116" WEIGHT="100.0" Z="0.7069821623149579">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.2585560584149085" CI_START="0.7058568520271166" EFFECT_SIZE="0.9425287356321839" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.09987256459478765" LOG_CI_START="-0.15128336506459136" LOG_EFFECT_SIZE="-0.025705400234901855" ORDER="1" O_E="0.0" SE="0.14753023632382184" STUDY_ID="STD-Pavan_x002d_Langston-1976" TOTAL_1="87" TOTAL_2="82" VAR="0.021765170629762725" WEIGHT="80.48842027999297"/>
<DICH_DATA CI_END="2.7786863801192525" CI_START="0.7073464838695482" EFFECT_SIZE="1.4019607843137254" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.4438395323586182" LOG_CI_START="-0.15036780095232974" LOG_EFFECT_SIZE="0.14673586570314423" MODIFIED="2010-05-25 23:50:05 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.3490403289605886" STUDY_ID="STD-Blake-1977" TOTAL_1="17" TOTAL_2="13" VAR="0.12182915124091592" WEIGHT="12.081673535236144"/>
<DICH_DATA CI_END="6.187909229907813" CI_START="0.842013394812603" EFFECT_SIZE="2.282608695652174" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.7915439344327454" LOG_CI_START="-0.0746809996560175" LOG_EFFECT_SIZE="0.358431467388364" MODIFIED="2010-05-25 23:50:05 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.5088248141663172" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="21" VAR="0.2589026915113872" WEIGHT="7.429906184770891"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5367018692452181" CI_END="1.1782920712457736" CI_START="0.9218845406876572" DF="2" EFFECT_SIZE="1.0422328170309734" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="92" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.07125295531365199" LOG_CI_START="-0.03532346775564137" LOG_EFFECT_SIZE="0.017964743779005327" MODIFIED="2013-08-17 15:42:20 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.764639411304279" P_Z="0.508771874259565" STUDIES="3" TAU2="0.0" TOTAL_1="127" TOTAL_2="116" WEIGHT="99.99999999999999" Z="0.6607512202853266">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1654358674458183" CI_START="0.8802706202943313" EFFECT_SIZE="1.0128667009778693" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="67" LOG_CI_END="0.06648837980363961" LOG_CI_START="-0.055383792812559174" LOG_EFFECT_SIZE="0.005552293495540223" ORDER="1" O_E="0.0" SE="0.07158831747173917" STUDY_ID="STD-Pavan_x002d_Langston-1976" TOTAL_1="87" TOTAL_2="82" VAR="0.005124887198434517" WEIGHT="71.85845501538633"/>
<DICH_DATA CI_END="1.6190558416104472" CI_START="0.8126612503543608" EFFECT_SIZE="1.1470588235294117" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.20926182792882128" LOG_CI_START="-0.09009044796033322" LOG_EFFECT_SIZE="0.05958568998424405" MODIFIED="2010-05-25 23:50:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.17584100867495345" STUDY_ID="STD-Blake-1977" TOTAL_1="17" TOTAL_2="13" VAR="0.030920060331825053" WEIGHT="11.805875293601243"/>
<DICH_DATA CI_END="1.5482598289396408" CI_START="0.7753567351951092" EFFECT_SIZE="1.0956521739130434" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="15" LOG_CI_END="0.18984384575617655" LOG_CI_START="-0.11049843622827411" LOG_EFFECT_SIZE="0.039672704763951176" MODIFIED="2010-05-25 23:50:10 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.17642254315593964" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="21" VAR="0.031124913733609386" WEIGHT="16.335669691012416"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.1493547694699348" CI_END="2.2842307221859652" CI_START="0.8142151071822088" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="1.3637650685853264" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.358739968361705" LOG_CI_START="-0.0892608438566402" LOG_EFFECT_SIZE="0.13473956225253245" MODIFIED="2010-06-14 23:21:01 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.6991528804972336" P_Q="1.0" P_Z="0.23841915498374" Q="0.0" SCALE="15.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="34" WEIGHT="100.0" Z="1.1789473684210525">
<NAME>Vidarabine <I>versus</I> idoxuridine: healing rate</NAME>
<GROUP_LABEL_1>Vidarabine</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Vidarabine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.6312984544731837" CI_START="0.5641609449050458" EFFECT_SIZE="1.2183906690396056" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.42017011063972315" LOG_CI_START="-0.2485969819865866" LOG_EFFECT_SIZE="0.08578656432656827" MODIFIED="2010-06-14 23:19:25 +0100" MODIFIED_BY="[Empty name]" ORDER="225" O_E="1.28" SE="0.3928371006591931" STUDY_ID="STD-Blake-1977" TOTAL_1="17" TOTAL_2="13" VAR="6.48" WEIGHT="44.875346260387815"/>
<IPD_DATA CI_END="2.994271208265887" CI_START="0.7462603348577657" EFFECT_SIZE="1.4948263559810107" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="14" LOG_CI_END="0.47629113432332065" LOG_CI_START="-0.12710964133578145" LOG_EFFECT_SIZE="0.17459074649376957" MODIFIED="2010-06-14 23:19:33 +0100" MODIFIED_BY="[Empty name]" ORDER="226" O_E="3.2" SE="0.3544406025041679" STUDY_ID="STD-Markham-1977" TOTAL_1="23" TOTAL_2="21" VAR="7.96" WEIGHT="55.124653739612185"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="1.7574657794076862" CI_END="1.128780501131414" CI_START="0.8413594224543793" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.974530712963779" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="82" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.05260949868731615" LOG_CI_START="-0.07501843720742479" LOG_EFFECT_SIZE="-0.011204469260054308" METHOD="MH" MODIFIED="2014-10-14 16:34:15 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.8815820041464099" P_Q="0.7011333862586671" P_Z="0.7307478699108765" Q="1.418802207158877" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="122" TOTAL_2="114" WEIGHT="400.0" Z="0.3441308685537942">
<NAME>
<I>para</I>-Fluorophenylalanine <I>versus</I> idoxuridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Idoxuridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluorophenylalanine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Fluoro-&#934;-alanine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.16184160508063505" CI_END="1.538991755850167" CI_START="0.590115155806703" DF="1" EFFECT_SIZE="0.9529860228716646" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.18723629338679365" LOG_CI_START="-0.2290632313215227" LOG_EFFECT_SIZE="-0.020913468967364506" MODIFIED="2014-10-14 16:33:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6874668428958188" P_Z="0.8438871544750464" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="39" WEIGHT="100.0" Z="0.19692381823664218">
<NAME>Healing at 7 days: without debridement</NAME>
<DICH_DATA CI_END="1.6396573399619208" CI_START="0.44807769260379904" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.21475309749126945" LOG_CI_START="-0.3486466767524959" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2010-03-18 21:00:14 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.33094381626464864" STUDY_ID="STD-Graupner-1966" TOTAL_1="20" TOTAL_2="12" VAR="0.10952380952380951" WEIGHT="47.14104193138501"/>
<DICH_DATA CI_END="2.0736470232041677" CI_START="0.5200510765798388" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.3167348326118632" LOG_CI_START="-0.2839540002355244" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2010-03-18 21:00:21 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.35284759387223336" STUDY_ID="STD-Graupner-1968" TOTAL_1="26" TOTAL_2="27" VAR="0.12450142450142451" WEIGHT="52.858958068614996"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.07954888573208546" CI_END="1.135475853877456" CI_START="0.7508125664719971" DF="1" EFFECT_SIZE="0.9233252623083131" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.055177903294390325" LOG_CI_START="-0.1244684671325065" LOG_EFFECT_SIZE="-0.03464528191905807" MODIFIED="2014-10-14 16:34:02 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7779096891977628" P_Z="0.4496680467962654" STUDIES="2" TAU2="0.0" TOTAL_1="46" TOTAL_2="39" WEIGHT="100.0" Z="0.7559685690752368">
<NAME>Healing at 14 days: without debridement</NAME>
<DICH_DATA CI_END="1.3416572179962398" CI_START="0.6869116698648305" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.1276415714600928" LOG_CI_START="-0.16309910538095593" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2010-03-18 21:00:59 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.17078251276599332" STUDY_ID="STD-Graupner-1966" TOTAL_1="20" TOTAL_2="12" VAR="0.029166666666666674" WEIGHT="35.647027172450905"/>
<DICH_DATA CI_END="1.1744344594690042" CI_START="0.694314709456572" EFFECT_SIZE="0.903010033444816" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="23" LOG_CI_END="0.06982878553664194" LOG_CI_START="-0.1584436338675266" LOG_EFFECT_SIZE="-0.04430742416544236" MODIFIED="2010-03-18 21:01:10 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.13408834912470852" STUDY_ID="STD-Graupner-1968" TOTAL_1="26" TOTAL_2="27" VAR="0.01797968537098972" WEIGHT="64.3529728275491"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4337034717778105" CI_START="0.8749368503966362" DF="0" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" I2="0.0" ID="CMP-001.07.03" LOG_CI_END="0.15645933690546296" LOG_CI_START="-0.05802329156509971" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2014-10-14 16:34:05 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.36837652800244036" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="100.0" Z="0.8995185531966908">
<NAME>Healing at 7 days: with debridement</NAME>
<DICH_DATA CI_END="1.4337034717778108" CI_START="0.8749368503966362" EFFECT_SIZE="1.12" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.15645933690546304" LOG_CI_START="-0.05802329156509971" LOG_EFFECT_SIZE="0.04921802267018165" MODIFIED="2010-03-18 21:01:19 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.12598815766974247" STUDY_ID="STD-Graupner-1969" TOTAL_1="15" TOTAL_2="18" VAR="0.015873015873015886" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1779752930905705" CI_START="0.8290572835169849" DF="0" EFFECT_SIZE="0.9882352941176471" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" I2="0.0" ID="CMP-001.07.04" LOG_CI_END="0.07113618163363301" LOG_CI_START="-0.08141546093845511" LOG_EFFECT_SIZE="-0.005139639652411056" MODIFIED="2014-10-14 16:34:15 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8949314040258729" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="18" WEIGHT="100.0" Z="0.1320668652581621">
<NAME>Healing at 14 days: with debridement</NAME>
<DICH_DATA CI_END="1.1779752930905703" CI_START="0.829057283516985" EFFECT_SIZE="0.9882352941176471" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="17" LOG_CI_END="0.07113618163363294" LOG_CI_START="-0.08141546093845506" LOG_EFFECT_SIZE="-0.005139639652411056" MODIFIED="2010-03-18 21:01:29 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.089609589989654" STUDY_ID="STD-Graupner-1969" TOTAL_1="15" TOTAL_2="18" VAR="0.008029878618113898" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.488637124678515" CI_END="1.930370122839298" CI_START="1.4299321836843526" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.661414567490796" ESTIMABLE="YES" EVENTS_1="178" EVENTS_2="107" I2="48.34923217838607" I2_Q="88.6161775839311" ID="CMP-001.08" LOG_CI_END="0.2856405871920468" LOG_CI_START="0.15531544099648664" LOG_EFFECT_SIZE="0.2204780140942667" METHOD="MH" MODIFIED="2013-08-17 15:42:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.05031229890280009" P_Q="0.0030382029836827362" P_Z="3.3217633781528585E-11" Q="8.784395640153745" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="236" TOTAL_2="243" WEIGHT="200.0" Z="6.631551617202768">
<NAME>Trifluridine <I>versus</I> idoxuridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Trifluridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Trifluridine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.0833718884862105" CI_END="3.632156735229919" CI_START="1.7439056498310723" DF="3" EFFECT_SIZE="2.516771473860795" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="25" I2="57.64728935273889" ID="CMP-001.08.01" LOG_CI_END="0.5601645809770174" LOG_CI_START="0.24152298468705102" LOG_EFFECT_SIZE="0.4008437828320342" MODIFIED="2013-08-17 15:42:20 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.06928746882153047" P_Z="8.173478363077094E-7" STUDIES="4" TAU2="0.0" TOTAL_1="110" TOTAL_2="113" WEIGHT="100.0" Z="4.931179023234895">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="3.426380524679973" CI_START="1.310753146331847" EFFECT_SIZE="2.1192307692307693" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" LOG_CI_END="0.5348355928944496" LOG_CI_START="0.11752090886748462" LOG_EFFECT_SIZE="0.3261782508809671" ORDER="1" O_E="0.0" SE="0.245132711138441" STUDY_ID="STD-Wellings-1972" TOTAL_1="40" TOTAL_2="38" VAR="0.060090046070082365" WEIGHT="51.18767223869781"/>
<DICH_DATA CI_END="2.681690904347147" CI_START="0.7432174907049172" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.4284087189770331" LOG_CI_START="-0.12888407831036888" LOG_EFFECT_SIZE="0.14976232033333212" ORDER="2" O_E="0.0" SE="0.3273565477704573" STUDY_ID="STD-Sugar-1980" TOTAL_1="34" TOTAL_2="27" VAR="0.10716230936819171" WEIGHT="38.516625504200476"/>
<DICH_DATA CI_END="12.12315055910787" CI_START="1.010463405553999" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="1.0836154987599118" LOG_CI_START="0.004520589940639576" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2010-05-25 23:55:04 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.6338656910463875" STUDY_ID="STD-Struck-1989" TOTAL_1="16" TOTAL_2="28" VAR="0.4017857142857143" WEIGHT="8.376164548150548"/>
<DICH_DATA CI_END="485.1332616818927" CI_START="1.9808990145683694" EFFECT_SIZE="31.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="0" LOG_CI_END="2.685861051722935" LOG_CI_START="0.29686233594561046" LOG_EFFECT_SIZE="1.4913616938342726" MODIFIED="2010-05-25 23:55:04 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="1.4033096713819666" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.9692780337941629" WEIGHT="1.9195377089511676"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.1885424156622575" CI_END="1.603932332787735" CI_START="1.194772367761045" DF="4" EFFECT_SIZE="1.3843171713784737" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="82" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.20518604217957342" LOG_CI_START="0.07728516985134781" LOG_EFFECT_SIZE="0.14123560601546062" MODIFIED="2013-08-17 15:42:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7011274816007738" P_Z="1.5005121266685685E-5" STUDIES="5" TAU2="0.0" TOTAL_1="126" TOTAL_2="130" WEIGHT="100.00000000000001" Z="4.328613184351248">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="2.0049852354770197" CI_START="1.164887024661087" EFFECT_SIZE="1.5282608695652173" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="23" LOG_CI_END="0.30211117886419736" LOG_CI_START="0.06628380781230235" LOG_EFFECT_SIZE="0.18419749333824986" ORDER="1" O_E="0.0" SE="0.13852616512019683" STUDY_ID="STD-Wellings-1972" TOTAL_1="40" TOTAL_2="38" VAR="0.019189498422908034" WEIGHT="29.338299823650022"/>
<DICH_DATA CI_END="1.7110174816803236" CI_START="0.978797997308811" EFFECT_SIZE="1.2941176470588236" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="13" LOG_CI_END="0.233254446804989" LOG_CI_START="-0.009306927917124319" LOG_EFFECT_SIZE="0.11197375944393233" MODIFIED="2010-03-18 16:36:00 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.14248175220993886" STUDY_ID="STD-Laibson-1977" TOTAL_1="16" TOTAL_2="17" VAR="0.02030104971281442" WEIGHT="16.310090221837235"/>
<DICH_DATA CI_END="1.7751854182613245" CI_START="0.9867871185658628" EFFECT_SIZE="1.3235294117647058" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.2492437218542738" LOG_CI_START="-0.0057765283880967045" LOG_EFFECT_SIZE="0.12173359673308855" ORDER="3" O_E="0.0" SE="0.14980015736296637" STUDY_ID="STD-Sugar-1980" TOTAL_1="34" TOTAL_2="27" VAR="0.02244008714596949" WEIGHT="24.955329301171727"/>
<DICH_DATA CI_END="1.7977820827239193" CI_START="0.66542495555826" EFFECT_SIZE="1.09375" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.2547370477942241" LOG_CI_START="-0.17690091573348476" LOG_EFFECT_SIZE="0.03891806603036966" MODIFIED="2010-05-25 23:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.253546276418555" STUDY_ID="STD-Struck-1989" TOTAL_1="16" TOTAL_2="28" VAR="0.0642857142857143" WEIGHT="14.472015090875583"/>
<DICH_DATA CI_END="2.2961368445440336" CI_START="1.091809684776115" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.36099776746258483" LOG_CI_START="0.03814694234782348" LOG_EFFECT_SIZE="0.1995723549052041" MODIFIED="2010-05-25 23:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.18964417280976953" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.03596491228070173" WEIGHT="14.924265562465445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.0" CI_END="3.826262131198863" CI_START="1.3701780831603447" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="2.2896856798685437" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="23" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.582774719542176" LOG_CI_START="0.13677701643205187" LOG_EFFECT_SIZE="0.359775867987114" MODIFIED="2010-06-14 23:24:06 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.0015662834668443743" Q="0.0" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="38" WEIGHT="100.0" Z="3.1621137904706558">
<NAME>Trifluridine <I>versus</I> idoxuridine: healing rate</NAME>
<GROUP_LABEL_1>Trifluridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Trifluridine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="3.826262131198863" CI_START="1.3701780831603447" EFFECT_SIZE="2.2896856798685437" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="23" LOG_CI_END="0.582774719542176" LOG_CI_START="0.13677701643205187" LOG_EFFECT_SIZE="0.359775867987114" MODIFIED="2010-06-14 23:22:32 +0100" MODIFIED_BY="[Empty name]" ORDER="227" O_E="12.07" SE="0.26198125853112303" STUDY_ID="STD-Wellings-1972" TOTAL_1="40" TOTAL_2="38" VAR="14.57" WEIGHT="100.0"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="119.77281116484994" CI_END="1.2331583037943663" CI_START="1.0467158610305056" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1361189883735938" ESTIMABLE="YES" EVENTS_1="471" EVENTS_2="351" I2="82.46680544961364" I2_Q="79.16181195973095" ID="CMP-001.10" LOG_CI_END="0.09101883170629878" LOG_CI_START="0.01982880514210739" LOG_EFFECT_SIZE="0.05542381842420313" METHOD="MH" MODIFIED="2015-01-09 10:51:00 +0000" MODIFIED_BY="Anupa Shah" NO="10" P_CHI2="1.4432899320127035E-15" P_Q="0.0024120854288770532" P_Z="0.0022747730496146547" Q="14.396645208319494" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.08553095045235012" TOTALS="SUB" TOTAL_1="556" TOTAL_2="582" WEIGHT="400.0" Z="3.051795124677362">
<NAME>Acyclovir <I>versus</I> idoxuridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.36147938916296" CI_END="2.9034801952278118" CI_START="1.3480368477219158" DF="8" EFFECT_SIZE="1.978382746032201" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="91" I2="72.75341649524402" ID="CMP-001.10.01" LOG_CI_END="0.4629188680367751" LOG_CI_START="0.12970176352243465" LOG_EFFECT_SIZE="0.29631031577960487" MODIFIED="2015-01-09 10:50:38 +0000" MODIFIED_BY="Anupa Shah" NO="1" P_CHI2="2.7395178197131553E-4" P_Z="4.907397483197213E-4" STUDIES="9" TAU2="0.19447180423017132" TOTAL_1="234" TOTAL_2="234" WEIGHT="100.0" Z="3.485760720609841">
<NAME>Healing at 7 days: acyclovir <I>versus</I> idoxuridine</NAME>
<DICH_DATA CI_END="9.917414139789937" CI_START="2.3555647451872894" EFFECT_SIZE="4.833333333333333" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.9963984492493534" LOG_CI_START="0.3720950457812714" LOG_EFFECT_SIZE="0.6842467475153124" MODIFIED="2010-03-13 15:45:32 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.3667189095488391" STUDY_ID="STD-Collum-1980" TOTAL_1="30" TOTAL_2="30" VAR="0.13448275862068965" WEIGHT="11.646457918091608"/>
<DICH_DATA CI_END="1.6226602002990782" CI_START="0.9346744204249392" EFFECT_SIZE="1.2315270935960592" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.21022758416045376" LOG_CI_START="-0.029339642642804326" LOG_EFFECT_SIZE="0.09044397075882471" MODIFIED="2010-03-13 15:45:34 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.14072297490113203" STUDY_ID="STD-Coster-1980" TOTAL_1="29" TOTAL_2="30" VAR="0.019802955665024637" WEIGHT="17.879639557550465"/>
<DICH_DATA CI_END="3.092395724945027" CI_START="1.1253154417094815" EFFECT_SIZE="1.8654545454545455" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.4902950642123997" LOG_CI_START="0.051274278350707594" LOG_EFFECT_SIZE="0.27078467128155365" MODIFIED="2010-03-13 15:45:35 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.25788298280309674" STUDY_ID="STD-Colin-1981" TOTAL_1="25" TOTAL_2="27" VAR="0.06650363281942229" WEIGHT="14.68013816364922"/>
<DICH_DATA CI_END="4.6805172124397885" CI_START="1.0550696388453455" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6702938466846698" LOG_CI_START="0.023281125764642783" LOG_EFFECT_SIZE="0.3467874862246563" MODIFIED="2010-03-13 15:45:37 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.38005847503304596" STUDY_ID="STD-Klauber-1982" TOTAL_1="18" TOTAL_2="20" VAR="0.14444444444444443" WEIGHT="11.304136311519727"/>
<DICH_DATA CI_END="1.8167307378732436" CI_START="0.7877473522617789" EFFECT_SIZE="1.1962962962962962" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="18" LOG_CI_END="0.25929056422530444" LOG_CI_START="-0.1036130478810734" LOG_EFFECT_SIZE="0.07783875817211554" MODIFIED="2010-03-13 15:45:39 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.2131713781531383" STUDY_ID="STD-McCulley-1982" TOTAL_1="30" TOTAL_2="34" VAR="0.04544203646370829" WEIGHT="15.968880586990286"/>
<DICH_DATA CI_END="2.159247215431043" CI_START="1.1371264928003257" EFFECT_SIZE="1.566951566951567" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="26" LOG_CI_END="0.33430236820322545" LOG_CI_START="0.0558087778536141" LOG_EFFECT_SIZE="0.19505557302841978" MODIFIED="2010-03-13 15:45:41 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.16358851353686713" STUDY_ID="STD-Kitano-1985" TOTAL_1="54" TOTAL_2="55" VAR="0.02676120176120176" WEIGHT="17.317287065909905"/>
<DICH_DATA CI_END="9.85719642624147" CI_START="0.7672059755111896" EFFECT_SIZE="2.75" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.9937534109100272" LOG_CI_START="-0.11508802324950194" LOG_EFFECT_SIZE="0.43933269383026263" MODIFIED="2010-03-13 15:45:43 +0000" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.6513389472789296" STUDY_ID="STD-Abe-1987" TOTAL_1="18" TOTAL_2="9" VAR="0.42424242424242425" WEIGHT="6.192124403967001"/>
<DICH_DATA CI_END="31.59889895988302" CI_START="0.6408451138031354" EFFECT_SIZE="4.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.4996719502140399" LOG_CI_START="-0.19324692266335236" LOG_EFFECT_SIZE="0.6532125137753437" MODIFIED="2010-03-13 15:45:43 +0000" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.9944289260117531" STUDY_ID="STD-Altinisik-1987" TOTAL_1="10" TOTAL_2="9" VAR="0.9888888888888887" WEIGHT="3.2375213199863433"/>
<DICH_DATA CI_END="515.0232665063925" CI_START="2.114467580051519" EFFECT_SIZE="33.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="0" LOG_CI_END="2.711826849016137" LOG_CI_START="0.3252010307396384" LOG_EFFECT_SIZE="1.5185139398778875" ORDER="9" O_E="0.0" SE="1.401915819643949" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.9653679653679654" WEIGHT="1.7738146723354413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="27.27991792371515" CI_END="1.3800232569420936" CI_START="1.081281332154737" DF="10" EFFECT_SIZE="1.2215536769503277" ESTIMABLE="YES" EVENTS_1="270" EVENTS_2="235" I2="63.34299821589002" ID="CMP-001.10.02" LOG_CI_END="0.13988640544218447" LOG_CI_START="0.0339387051524145" LOG_EFFECT_SIZE="0.08691255529729944" MODIFIED="2015-01-09 10:50:45 +0000" MODIFIED_BY="Anupa Shah" NO="2" P_CHI2="0.0023514696667765733" P_Z="0.0013014845646653315" STUDIES="11" TAU2="0.023391739778642458" TOTAL_1="292" TOTAL_2="314" WEIGHT="99.99999999999997" Z="3.2156522080451606">
<NAME>Healing at 14 days: acyclovir <I>versus</I> idoxuridine</NAME>
<DICH_DATA CI_END="1.8003331173080268" CI_START="1.1178148848974299" EFFECT_SIZE="1.4186046511627908" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.25535287044973465" LOG_CI_START="0.048369888412626384" LOG_EFFECT_SIZE="0.15186137943118053" MODIFIED="2010-03-13 15:44:25 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.1215828282308827" STUDY_ID="STD-Collum-1980" TOTAL_1="30" TOTAL_2="30" VAR="0.014782384120620329" WEIGHT="10.145867677068955"/>
<DICH_DATA CI_END="1.0851543091281615" CI_START="0.8548433682237291" EFFECT_SIZE="0.9631391200951248" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.03549149932540257" LOG_CI_START="-0.06811345316392745" LOG_EFFECT_SIZE="-0.016310976919262442" MODIFIED="2010-03-13 15:44:27 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.06085806194501844" STUDY_ID="STD-Coster-1980" TOTAL_1="29" TOTAL_2="30" VAR="0.003703703703703702" WEIGHT="14.29427091762881"/>
<DICH_DATA CI_END="1.3981943056055344" CI_START="0.9117804842150472" EFFECT_SIZE="1.1290909090909091" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.1455675290552333" LOG_CI_START="-0.04010970769056052" LOG_EFFECT_SIZE="0.052728910682336365" MODIFIED="2010-03-13 15:44:29 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.10906772798162451" STUDY_ID="STD-Colin-1981" TOTAL_1="25" TOTAL_2="27" VAR="0.011895769287073636" WEIGHT="10.975827425185136"/>
<DICH_DATA CI_END="2.099503220704683" CI_START="0.9187946589724942" EFFECT_SIZE="1.3888888888888888" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.32211654519601074" LOG_CI_START="-0.03678153805854765" LOG_EFFECT_SIZE="0.14266750356873154" MODIFIED="2013-08-18 20:37:28 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.21081851067789195" STUDY_ID="STD-Klauber-1982" TOTAL_1="18" TOTAL_2="20" VAR="0.04444444444444444" WEIGHT="5.709484019564614"/>
<DICH_DATA CI_END="1.2081455558670955" CI_START="0.7900964045819329" EFFECT_SIZE="0.9770114942528736" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.08211926069385209" LOG_CI_START="-0.10231991450250363" LOG_EFFECT_SIZE="-0.010100326904325779" MODIFIED="2010-03-13 15:44:33 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.1083404844989811" STUDY_ID="STD-McCulley-1982" TOTAL_1="30" TOTAL_2="34" VAR="0.011737660581473963" WEIGHT="11.025226898255893"/>
<DICH_DATA CI_END="1.3879978039195602" CI_START="1.010536903175047" EFFECT_SIZE="1.1843238587424634" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="43" LOG_CI_END="0.14238877898168098" LOG_CI_START="0.0045521778737343185" LOG_EFFECT_SIZE="0.07347047842770761" MODIFIED="2010-03-16 18:32:37 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.08096590179298738" STUDY_ID="STD-Kitano-1985" TOTAL_1="54" TOTAL_2="55" VAR="0.006555477253151677" WEIGHT="12.933075195560237"/>
<DICH_DATA CI_END="3.116301616217032" CI_START="1.0057068102138618" EFFECT_SIZE="1.770334928229665" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="5" LOG_CI_END="0.4936394849181952" LOG_CI_START="0.0024713909936867856" LOG_EFFECT_SIZE="0.24805543795594098" MODIFIED="2013-08-18 20:37:27 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.288514569692533" STUDY_ID="STD-Abe-1987" TOTAL_1="18" TOTAL_2="9" VAR="0.08324065692486746" WEIGHT="3.6321945463428484"/>
<DICH_DATA CI_END="2.2393040311340586" CI_START="0.8138689408231115" EFFECT_SIZE="1.35" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.35011306190415215" LOG_CI_START="-0.08944552491413992" LOG_EFFECT_SIZE="0.13033376849500614" MODIFIED="2013-08-18 20:37:26 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.25819888974716115" STUDY_ID="STD-Altinisik-1987" TOTAL_1="10" TOTAL_2="9" VAR="0.06666666666666668" WEIGHT="4.300649157112969"/>
<DICH_DATA CI_END="1.7128516474096052" CI_START="0.9866587118363903" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.23371974971306653" LOG_CI_START="-0.005833045099392968" LOG_EFFECT_SIZE="0.11394335230683679" ORDER="9" O_E="0.0" SE="0.14071449747829745" STUDY_ID="STD-Kumar-1987" TOTAL_1="19" TOTAL_2="17" VAR="0.01980056980056978" WEIGHT="8.967096539712749"/>
<DICH_DATA CI_END="1.6044212094215835" CI_START="1.0775381816288194" EFFECT_SIZE="1.3148479427549196" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="43" LOG_CI_END="0.20531839444266525" LOG_CI_START="0.03243266795287803" LOG_EFFECT_SIZE="0.11887553119777163" MODIFIED="2013-08-18 20:37:25 +0100" MODIFIED_BY="[Empty name]" ORDER="10" O_E="0.0" SE="0.1015539315382493" STUDY_ID="STD-Maichuk-1988" TOTAL_1="39" TOTAL_2="63" VAR="0.010313201010875427" WEIGHT="11.491182025467545"/>
<DICH_DATA CI_END="2.2961368445440336" CI_START="1.091809684776115" EFFECT_SIZE="1.5833333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="12" LOG_CI_END="0.36099776746258483" LOG_CI_START="0.03814694234782348" LOG_EFFECT_SIZE="0.1995723549052041" ORDER="11" O_E="0.0" SE="0.18964417280976953" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.03596491228070173" WEIGHT="6.525125598100236"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.628940083480143" CI_START="0.7634044066107768" DF="0" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-001.10.03" LOG_CI_END="0.41978068815639114" LOG_CI_START="-0.11724533749509293" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2015-01-09 10:50:54 +0000" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="1.0" P_Z="0.26952719986077855" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="1.1041520578579096">
<NAME>Healing at 7 days: acyclovir <I>versus</I> iododeoxycytidine</NAME>
<DICH_DATA CI_END="2.628940083480143" CI_START="0.7634044066107768" EFFECT_SIZE="1.4166666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.41978068815639114" LOG_CI_START="-0.11724533749509293" LOG_EFFECT_SIZE="0.15126767533064914" MODIFIED="2010-02-19 23:56:34 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.31545174578938157" STUDY_ID="STD-Colin-1984" TOTAL_1="15" TOTAL_2="17" VAR="0.09950980392156862" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1248546846945364" CI_START="0.8890037207531017" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" I2="0.0" ID="CMP-001.10.04" LOG_CI_END="0.05109642137043974" LOG_CI_START="-0.05109642137043975" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-09 10:51:00 +0000" MODIFIED_BY="Anupa Shah" NO="4" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="17" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 14 days: acyclovir <I>versus</I> iododeoxycytidine</NAME>
<DICH_DATA CI_END="1.1248546846945364" CI_START="0.8890037207531017" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.05109642137043974" LOG_CI_START="-0.05109642137043975" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-19 23:56:44 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.06002858168872262" STUDY_ID="STD-Colin-1984" TOTAL_1="15" TOTAL_2="17" VAR="0.0036034306195596444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="16.906967709827057" CI_END="2.7189697516056164" CI_START="1.7013644595992723" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="2.150804152429332" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="136" I2="58.59695174119663" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="0.4344043761112811" LOG_CI_START="0.2307973564334223" LOG_EFFECT_SIZE="0.33260086627235175" MODIFIED="2010-06-14 23:32:49 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.01800603592932326" P_Q="1.0" P_Z="1.5198252527329712E-10" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="179" TOTAL_2="176" WEIGHT="100.00000000000001" Z="6.403371751642229">
<NAME>Acyclovir <I>versus</I> idoxuridine: healing rate</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="10.83720496508737" CI_START="3.07628539368592" EFFECT_SIZE="5.773935862345443" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="1.0349172872982313" LOG_CI_START="0.48802662344196435" LOG_EFFECT_SIZE="0.7614719553700979" MODIFIED="2010-06-14 23:30:35 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="16.99" SE="0.3212462831016178" STUDY_ID="STD-Collum-1980" TOTAL_1="30" TOTAL_2="30" VAR="9.69" WEIGHT="13.860678014590189"/>
<IPD_DATA CI_END="2.760633864165632" CI_START="0.9465011829567205" EFFECT_SIZE="1.6164600886329217" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.4410088110881499" LOG_CI_START="-0.023878838909635068" LOG_EFFECT_SIZE="0.20856498608925741" MODIFIED="2010-06-14 23:30:39 +0100" MODIFIED_BY="[Empty name]" ORDER="229" O_E="6.44" SE="0.2730773068396801" STUDY_ID="STD-Coster-1980" TOTAL_1="29" TOTAL_2="30" VAR="13.41" WEIGHT="19.181805178086112"/>
<IPD_DATA CI_END="3.760071788297015" CI_START="1.103252391920197" EFFECT_SIZE="2.0367395990234822" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.5751961366733086" LOG_CI_START="0.042674877697853913" LOG_EFFECT_SIZE="0.30893550718558127" MODIFIED="2010-06-14 23:30:41 +0100" MODIFIED_BY="[Empty name]" ORDER="230" O_E="7.27" SE="0.3128056235449272" STUDY_ID="STD-Colin-1981" TOTAL_1="25" TOTAL_2="27" VAR="10.22" WEIGHT="14.618795594335577"/>
<IPD_DATA CI_END="5.389487027613374" CI_START="1.152778571988635" EFFECT_SIZE="2.4925659789549037" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.731547430923526" LOG_CI_START="0.06174589515362139" LOG_EFFECT_SIZE="0.39664666303857365" MODIFIED="2010-06-14 23:30:43 +0100" MODIFIED_BY="[Empty name]" ORDER="231" O_E="5.9" SE="0.39344473768231686" STUDY_ID="STD-Klauber-1982" TOTAL_1="18" TOTAL_2="20" VAR="6.46" WEIGHT="9.240452009726793"/>
<IPD_DATA CI_END="1.9161557192960368" CI_START="0.6532768602338854" EFFECT_SIZE="1.1188298315744523" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="29" LOG_CI_END="0.28243079977539254" LOG_CI_START="-0.1849027247134716" LOG_EFFECT_SIZE="0.048764037530960466" MODIFIED="2010-06-14 23:30:45 +0100" MODIFIED_BY="[Empty name]" ORDER="232" O_E="1.49" SE="0.2745140256230141" STUDY_ID="STD-McCulley-1982" TOTAL_1="30" TOTAL_2="34" VAR="13.27" WEIGHT="18.981547704191104"/>
<IPD_DATA CI_END="5.982610657301103" CI_START="1.114272567382196" EFFECT_SIZE="2.581909939707229" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.7768907402835189" LOG_CI_START="0.046991438621179445" LOG_EFFECT_SIZE="0.41194108945234914" MODIFIED="2010-06-14 23:30:47 +0100" MODIFIED_BY="[Empty name]" ORDER="233" O_E="5.16" SE="0.4287464628562721" STUDY_ID="STD-Abe-1987" TOTAL_1="18" TOTAL_2="9" VAR="5.44" WEIGHT="7.781433271348878"/>
<IPD_DATA CI_END="7.898124384556846" CI_START="1.0461082147248633" EFFECT_SIZE="2.874420428469654" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.8975239689929922" LOG_CI_START="0.019576612472917275" LOG_EFFECT_SIZE="0.4585502907329547" MODIFIED="2010-06-14 23:30:51 +0100" MODIFIED_BY="[Empty name]" ORDER="234" O_E="3.97" SE="0.5157106231293968" STUDY_ID="STD-Altinisik-1987" TOTAL_1="10" TOTAL_2="9" VAR="3.76" WEIGHT="5.378343584608783"/>
<IPD_DATA CI_END="4.633113235895678" CI_START="1.124008710511361" EFFECT_SIZE="2.282029718021266" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.6658729147344904" LOG_CI_START="0.05076967681343435" LOG_EFFECT_SIZE="0.3583212957739623" MODIFIED="2010-06-14 23:30:55 +0100" MODIFIED_BY="[Empty name]" ORDER="235" O_E="6.32" SE="0.36131468676496203" STUDY_ID="STD-Kumar-1987" TOTAL_1="19" TOTAL_2="17" VAR="7.66" WEIGHT="10.956944643112575"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="14.40290637809074" CI_END="2.835541861704601" CI_START="1.5640283515385933" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="2.1059125964010286" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="31" I2="79.17087064758327" I2_Q="90.12210031495681" ID="CMP-001.12" LOG_CI_END="0.4526360632506935" LOG_CI_START="0.19424462136140222" LOG_EFFECT_SIZE="0.32344034230604785" METHOD="MH" MODIFIED="2013-11-02 21:42:20 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.002405008116301288" P_Q="0.0014638309762058377" P_Z="9.259677590293773E-7" Q="10.123609591967918" RANDOM="NO" SCALE="30.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="102" TOTAL_2="96" WEIGHT="200.0" Z="4.906752463874333">
<NAME>Brivudine <I>versus</I> idoxuridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Brivudine</GROUP_LABEL_1>
<GROUP_LABEL_2>Idoxuridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Idoxuridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Brivudine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8677023421531427" CI_END="22.530442465796607" CI_START="2.7962879249933135" DF="1" EFFECT_SIZE="7.937354988399072" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="3" I2="74.14485625997521" ID="CMP-001.12.01" LOG_CI_END="1.352769720732575" LOG_CI_START="0.4465818873160869" LOG_EFFECT_SIZE="0.8996758040243309" MODIFIED="2013-08-17 15:42:18 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04922391778109547" P_Z="9.95202146142782E-5" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="48" WEIGHT="100.0" Z="3.891758658912316">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="9.84429652570367" CI_START="0.9208003563959327" EFFECT_SIZE="3.010752688172043" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.993184686861048" LOG_CI_START="-0.035834521284479864" LOG_EFFECT_SIZE="0.4786750827882841" MODIFIED="2010-06-01 17:16:04 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.604450976591914" STUDY_ID="STD-Struck-1989" TOTAL_1="31" TOTAL_2="28" VAR="0.36536098310291865" WEIGHT="86.31090487238978"/>
<DICH_DATA CI_END="604.7049456133243" CI_START="2.5152762699126257" EFFECT_SIZE="39.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="0" LOG_CI_END="2.7815435205222525" LOG_CI_START="0.4005856935307457" LOG_EFFECT_SIZE="1.591064607026499" MODIFIED="2010-06-01 17:16:04 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="1.3985864135061359" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="1.956043956043956" WEIGHT="13.689095127610209"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4375542051627206" CI_END="1.8093020502037844" CI_START="1.0514936002828907" DF="1" EFFECT_SIZE="1.379300375831165" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="28" I2="30.43740567077905" ID="CMP-001.12.02" LOG_CI_END="0.2575110753100459" LOG_CI_START="0.021806633779083307" LOG_EFFECT_SIZE="0.13965885454456464" MODIFIED="2013-08-17 15:42:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23053580038232802" P_Z="0.020199392828551467" STUDIES="2" TAU2="0.0" TOTAL_1="51" TOTAL_2="48" WEIGHT="100.0" Z="2.3226233943793337">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.772737531285524" CI_START="0.7927693657535066" EFFECT_SIZE="1.185483870967742" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.2486444394066442" LOG_CI_START="-0.10085314023476208" LOG_EFFECT_SIZE="0.07389564958594105" MODIFIED="2010-06-01 17:16:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.205296608322283" STUDY_ID="STD-Struck-1989" TOTAL_1="31" TOTAL_2="28" VAR="0.04214669738863287" WEIGHT="57.35761780861521"/>
<DICH_DATA CI_END="2.348214986431359" CI_START="1.1453806468067271" EFFECT_SIZE="1.64" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.37073785541486687" LOG_CI_START="0.05894984068052884" LOG_EFFECT_SIZE="0.21484384804769785" MODIFIED="2010-06-01 17:16:08 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.18314582323051437" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.03354239256678282" WEIGHT="42.64238219138479"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.670615925442966" CI_END="1.2558991447061216" CI_START="0.9965452674206196" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.118731580413501" ESTIMABLE="YES" EVENTS_1="205" EVENTS_2="183" I2="45.469228826815964" I2_Q="37.36221720233384" ID="CMP-001.13" LOG_CI_END="0.0989547646748429" LOG_CI_START="-0.0015029689710492572" LOG_EFFECT_SIZE="0.04872589785189686" METHOD="MH" MODIFIED="2013-08-18 20:38:29 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.06587563993854062" P_Q="0.18788079148474135" P_Z="0.057260486686757046" Q="4.789441557487213" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.01449216829697232" TOTALS="SUB" TOTAL_1="266" TOTAL_2="270" WEIGHT="400.0" Z="1.9013171298634115">
<NAME>Trifluridine <I>versus</I> vidarabine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Trifluridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Vidarabine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vidarabine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Trifluridine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.7989055199891877" CI_END="1.2280762098633158" CI_START="0.944527890150894" DF="3" EFFECT_SIZE="1.0770107852044493" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="93" I2="0.0" ID="CMP-001.13.01" LOG_CI_END="0.08922531834922748" LOG_CI_START="-0.024785213644952703" LOG_EFFECT_SIZE="0.032220052352137415" MODIFIED="2010-06-14 22:48:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6151732792236975" P_Z="0.2679504265294871" STUDIES="4" TAU2="0.0" TOTAL_1="145" TOTAL_2="143" WEIGHT="100.0" Z="1.1077948867637581">
<NAME>Healing at 7 days: all groups</NAME>
<DICH_DATA CI_END="1.2679685953383313" CI_START="0.8416275065966272" EFFECT_SIZE="1.033033033033033" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="37" LOG_CI_END="0.10310849720488653" LOG_CI_START="-0.07488007907446603" LOG_EFFECT_SIZE="0.014114209065210255" MODIFIED="2010-02-15 14:50:37 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.10455137076415379" STUDY_ID="STD-Coster-1976" TOTAL_1="54" TOTAL_2="48" VAR="0.01093098912866355" WEIGHT="41.03039387194792"/>
<DICH_DATA CI_END="1.3497540149091893" CI_START="0.9430213188837864" EFFECT_SIZE="1.1282051282051282" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="39" LOG_CI_END="0.1302546279753327" LOG_CI_START="-0.025478489055956302" LOG_EFFECT_SIZE="0.05238806945968822" ORDER="2" O_E="0.0" SE="0.09147840383554125" STUDY_ID="STD-Travers-1978" TOTAL_1="50" TOTAL_2="50" VAR="0.008368298368298367" WEIGHT="53.595458672710556"/>
<DICH_DATA CI_END="3.1251499228199897" CI_START="0.5471926831767979" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.494870856589416" LOG_CI_START="-0.2618597184465417" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2010-02-18 16:27:20 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.44450728565288067" STUDY_ID="STD-Coster-1979" TOTAL_1="13" TOTAL_2="17" VAR="0.19758672699849167" WEIGHT="2.269903430114869"/>
<DICH_DATA CI_END="1.5319481188339124" CI_START="0.34526340241686393" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="11" LOG_CI_END="0.18524405766886112" LOG_CI_START="-0.461849454001424" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2010-06-14 22:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.3801059319196683" STUDY_ID="STD-van-Bijsterveld-1980" TOTAL_1="28" TOTAL_2="28" VAR="0.1444805194805195" WEIGHT="3.104244025226658"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.596685442617352" CI_END="1.4948073555203285" CI_START="0.835358630488122" DF="2" EFFECT_SIZE="1.1174525606713839" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="76" I2="73.672728519467" ID="CMP-001.13.02" LOG_CI_END="0.17458522622204115" LOG_CI_START="-0.07812703612811525" LOG_EFFECT_SIZE="0.04822909504696293" MODIFIED="2013-08-18 20:38:29 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.022407900531644653" P_Z="0.45439857081834945" STUDIES="3" TAU2="0.04525934976247969" TOTAL_1="95" TOTAL_2="93" WEIGHT="100.0" Z="0.74810211756191">
<NAME>Healing at 14 days: all groups</NAME>
<DICH_DATA CI_END="1.1748622587873971" CI_START="0.9757855635309594" EFFECT_SIZE="1.0707070707070707" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="44" LOG_CI_END="0.06998695277362807" LOG_CI_START="-0.01064561143918742" LOG_EFFECT_SIZE="0.02967067066722033" MODIFIED="2010-02-15 14:51:14 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.04736396735623788" STUDY_ID="STD-Coster-1976" TOTAL_1="54" TOTAL_2="48" VAR="0.0022433454037227678" WEIGHT="46.388420412892124"/>
<DICH_DATA CI_END="3.326035659891317" CI_START="1.1568225748428689" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5219269011706331" LOG_CI_START="0.06326675508360369" LOG_EFFECT_SIZE="0.2925968281271184" MODIFIED="2013-08-18 20:38:29 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.2694192402158608" STUDY_ID="STD-Coster-1979" TOTAL_1="13" TOTAL_2="17" VAR="0.07258672699849168" WEIGHT="18.69875565382457"/>
<DICH_DATA CI_END="1.1369847607921821" CI_START="0.6733819365059553" EFFECT_SIZE="0.875" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.05575464380100054" LOG_CI_START="-0.17173853775637404" LOG_EFFECT_SIZE="-0.057991946977686754" MODIFIED="2013-08-18 20:38:29 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.13363062095621217" STUDY_ID="STD-van-Bijsterveld-1980" TOTAL_1="28" TOTAL_2="28" VAR="0.01785714285714285" WEIGHT="34.91282393328331"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.1251499228199897" CI_START="0.5471926831767979" DF="0" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" I2="0.0" ID="CMP-001.13.03" LOG_CI_END="0.494870856589416" LOG_CI_START="-0.2618597184465417" LOG_EFFECT_SIZE="0.11650556907143717" MODIFIED="2010-03-13 15:54:49 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.5461703740046491" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="100.0" Z="0.6035086381107573">
<NAME>Healing at 7 days: geographic epithelial keratitis</NAME>
<DICH_DATA CI_END="3.1251499228199897" CI_START="0.5471926831767979" EFFECT_SIZE="1.3076923076923077" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.494870856589416" LOG_CI_START="-0.2618597184465417" LOG_EFFECT_SIZE="0.11650556907143717" ORDER="65153" O_E="0.0" SE="0.44450728565288067" STUDY_ID="STD-Coster-1979" TOTAL_1="13" TOTAL_2="17" VAR="0.19758672699849167" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.326035659891317" CI_START="1.1568225748428689" DF="0" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" I2="0.0" ID="CMP-001.13.04" LOG_CI_END="0.5219269011706331" LOG_CI_START="0.06326675508360369" LOG_EFFECT_SIZE="0.2925968281271184" MODIFIED="2010-03-13 15:54:58 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.0123957996127543" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="17" WEIGHT="100.0" Z="2.5006717937555116">
<NAME>Healing at 14 days: geographic epithelial keratitis</NAME>
<DICH_DATA CI_END="3.326035659891317" CI_START="1.1568225748428689" EFFECT_SIZE="1.9615384615384615" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.5219269011706331" LOG_CI_START="0.06326675508360369" LOG_EFFECT_SIZE="0.2925968281271184" ORDER="65154" O_E="0.0" SE="0.2694192402158608" STUDY_ID="STD-Coster-1979" TOTAL_1="13" TOTAL_2="17" VAR="0.07258672699849168" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="4.630951026272224" CI_END="1.7861789027563693" CI_START="0.9612852451586442" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="1.3103539309794718" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="76" I2="56.81232669804457" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.25192495544207905" LOG_CI_START="-0.017147723656259273" LOG_EFFECT_SIZE="0.11738861589290989" MODIFIED="2010-06-14 23:36:05 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.09871940072875829" P_Q="1.0" P_Z="0.08723794886976087" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="95" TOTAL_2="93" WEIGHT="100.0" Z="1.7101510277156229">
<NAME>Trifluridine <I>versus</I> vidarabine: healing rate</NAME>
<GROUP_LABEL_1>Trifluridine</GROUP_LABEL_1>
<GROUP_LABEL_2>Vidarabine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vidarabine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Trifluridine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.092669617147236" CI_START="0.9418738183702328" EFFECT_SIZE="1.4039340165726595" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="44" LOG_CI_END="0.32070066896191146" LOG_CI_START="-0.026007275186001096" LOG_EFFECT_SIZE="0.1473466968879552" MODIFIED="2010-06-14 23:35:21 +0100" MODIFIED_BY="[Empty name]" ORDER="236" O_E="8.18" SE="0.2036579626244864" STUDY_ID="STD-Coster-1976" TOTAL_1="54" TOTAL_2="48" VAR="24.11" WEIGHT="60.22982762927804"/>
<IPD_DATA CI_END="6.5758810192371975" CI_START="1.0719530101608639" EFFECT_SIZE="2.655001968555015" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.8179539466919384" LOG_CI_START="0.030175748159808096" LOG_EFFECT_SIZE="0.4240648474258733" MODIFIED="2010-06-14 23:35:24 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="4.56" SE="0.46274481338274753" STUDY_ID="STD-Coster-1979" TOTAL_1="13" TOTAL_2="17" VAR="4.67" WEIGHT="11.6662503122658"/>
<IPD_DATA CI_END="1.5123756515890876" CI_START="0.4700035519101011" EFFECT_SIZE="0.8431025608247342" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="24" LOG_CI_END="0.17965967684599737" LOG_CI_START="-0.32789886000230734" LOG_EFFECT_SIZE="-0.074119591578155" MODIFIED="2010-06-14 23:35:26 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="-1.92" SE="0.29814239699997197" STUDY_ID="STD-van-Bijsterveld-1980" TOTAL_1="28" TOTAL_2="28" VAR="11.25" WEIGHT="28.10392205845616"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="29.92377888055802" CI_END="1.230656182967485" CI_START="1.0544013380476756" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1391248948195105" ESTIMABLE="YES" EVENTS_1="303" EVENTS_2="266" I2="53.214465138639184" I2_Q="57.65650123895561" ID="CMP-001.15" LOG_CI_END="0.09013673798732881" LOG_CI_START="0.02300594837508003" LOG_EFFECT_SIZE="0.05657134318120438" METHOD="MH" MODIFIED="2010-06-14 23:36:05 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.00781846589543611" P_Q="0.06924009364410155" P_Z="9.554165113947552E-4" Q="7.084912885753247" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="380" TOTAL_2="378" WEIGHT="400.0" Z="3.303336541478287">
<NAME>Acyclovir <I>versus</I> vidarabine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Vidarabine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vidarabine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="22.346510215515462" CI_END="1.4433644312384417" CI_START="1.0546536046837616" DF="5" EFFECT_SIZE="1.233794756139752" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="91" I2="77.62514168083194" ID="CMP-001.15.01" LOG_CI_END="0.15937599879519984" LOG_CI_START="0.023109841361766328" LOG_EFFECT_SIZE="0.09124292007848311" MODIFIED="2010-06-14 22:59:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="4.498456264302453E-4" P_Z="0.008671059513803356" STUDIES="6" TAU2="0.0" TOTAL_1="158" TOTAL_2="156" WEIGHT="100.0" Z="2.624757908587155">
<NAME>Healing at 7 days: all groups</NAME>
<DICH_DATA CI_END="1.0982695700395315" CI_START="0.7252830013047966" EFFECT_SIZE="0.8925" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.04070895068942317" LOG_CI_START="-0.1394925011209616" LOG_EFFECT_SIZE="-0.049391775215769214" ORDER="1" O_E="0.0" SE="0.10585122480499264" STUDY_ID="STD-Pavan_x002d_Langston-1981" TOTAL_1="20" TOTAL_2="21" VAR="0.011204481792717089" WEIGHT="21.51215782860716"/>
<DICH_DATA CI_END="1.2169191911795363" CI_START="0.8036376745759519" EFFECT_SIZE="0.9889196675900277" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.08526174011172763" LOG_CI_START="-0.09493971169865713" LOG_EFFECT_SIZE="-0.0048389857934647285" ORDER="2" O_E="0.0" SE="0.10585122480499264" STUDY_ID="STD-Yeakley-1981" TOTAL_1="19" TOTAL_2="21" VAR="0.011204481792717089" WEIGHT="19.900090501325913"/>
<DICH_DATA CI_END="3.17428879830438" CI_START="1.1880536166098952" EFFECT_SIZE="1.9419642857142858" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.5016464365348524" LOG_CI_START="0.07483604070609677" LOG_EFFECT_SIZE="0.28824123862047457" MODIFIED="2009-08-12 16:38:37 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.25071053925534426" STUDY_ID="STD-Young-1982" TOTAL_1="48" TOTAL_2="45" VAR="0.06285577449370552" WEIGHT="15.932875604671628"/>
<DICH_DATA CI_END="1.2064997902302566" CI_START="0.34253243097835817" EFFECT_SIZE="0.6428571428571429" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.08152725073560449" LOG_CI_START="-0.4652983032134308" LOG_EFFECT_SIZE="-0.1918855262389131" MODIFIED="2010-06-14 22:59:25 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.3212080372198105" STUDY_ID="STD-Denis-1983" TOTAL_1="14" TOTAL_2="9" VAR="0.10317460317460317" WEIGHT="9.395201103841694"/>
<DICH_DATA CI_END="1.7980114254440178" CI_START="0.9624397171349509" EFFECT_SIZE="1.3154761904761905" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="21" LOG_CI_END="0.25479244712553295" LOG_CI_START="-0.01662646320703728" LOG_EFFECT_SIZE="0.11908299195924785" ORDER="5" O_E="0.0" SE="0.1594328114746263" STUDY_ID="STD-Jackson-1984" TOTAL_1="32" TOTAL_2="34" VAR="0.025418821374703728" WEIGHT="22.450870170219112"/>
<DICH_DATA CI_END="2.9370506751571384" CI_START="0.9427470977673403" EFFECT_SIZE="1.664" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.46791143979867833" LOG_CI_START="-0.0256047958892681" LOG_EFFECT_SIZE="0.2211533219547051" MODIFIED="2010-02-18 16:28:59 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.2898938797878657" STUDY_ID="STD-Collum-1985" TOTAL_1="25" TOTAL_2="26" VAR="0.08403846153846153" WEIGHT="10.808804791334483"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.994572961506829" CI_END="1.1775102507282496" CI_START="1.0029356916326653" DF="6" EFFECT_SIZE="1.086723082352947" ESTIMABLE="YES" EVENTS_1="157" EVENTS_2="143" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.0709646965358269" LOG_CI_START="0.001273086894343642" LOG_EFFECT_SIZE="0.036118891715085276" MODIFIED="2010-06-14 22:59:37 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5445094328022075" P_Z="0.04219710391943792" STUDIES="7" TAU2="0.0" TOTAL_1="172" TOTAL_2="170" WEIGHT="100.0" Z="2.031571010836038">
<NAME>Healing at 14 days: all groups</NAME>
<DICH_DATA CI_END="1.246264897974312" CI_START="0.8846433866443736" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.09561036295009365" LOG_CI_START="-0.05323176481021744" LOG_EFFECT_SIZE="0.021189299069938092" ORDER="1" O_E="0.0" SE="0.08743060262682179" STUDY_ID="STD-Pavan_x002d_Langston-1981" TOTAL_1="20" TOTAL_2="21" VAR="0.007644110275689217" WEIGHT="12.92331513952209"/>
<DICH_DATA CI_END="1.195239321585051" CI_START="0.915992670496134" EFFECT_SIZE="1.0463414634146342" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.07745487234489949" LOG_CI_START="-0.038108001414921926" LOG_EFFECT_SIZE="0.01967343546498877" ORDER="2" O_E="0.0" SE="0.06788220409197003" STUDY_ID="STD-Yeakley-1981" TOTAL_1="19" TOTAL_2="21" VAR="0.004607993632383872" WEIGHT="13.611586935799899"/>
<DICH_DATA CI_END="1.3516101010563815" CI_START="1.0050862675425265" EFFECT_SIZE="1.1655405405405406" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="37" LOG_CI_END="0.13085142874998482" LOG_CI_START="0.0022033392786862845" LOG_EFFECT_SIZE="0.06652738401433556" MODIFIED="2009-08-12 16:38:58 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.07556852457375413" STUDY_ID="STD-Young-1982" TOTAL_1="48" TOTAL_2="45" VAR="0.005710601906254081" WEIGHT="26.627733876611224"/>
<DICH_DATA CI_END="1.7427015636955774" CI_START="0.8178931129251414" EFFECT_SIZE="1.1938775510204083" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.24122302088089487" LOG_CI_START="-0.08730344877356126" LOG_EFFECT_SIZE="0.07695978605366682" MODIFIED="2010-06-14 22:59:37 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.19297807450727983" STUDY_ID="STD-Denis-1983" TOTAL_1="14" TOTAL_2="9" VAR="0.03724053724053725" WEIGHT="5.941176227757411"/>
<DICH_DATA CI_END="1.2598921910125478" CI_START="0.9567652022477209" EFFECT_SIZE="1.0979166666666667" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" LOG_CI_END="0.10033338412429055" LOG_CI_START="-0.019194628450371756" LOG_EFFECT_SIZE="0.04056937783695939" MODIFIED="2010-03-18 16:38:15 +0000" MODIFIED_BY="[Empty name]" ORDER="5" O_E="0.0" SE="0.07021134625956124" STUDY_ID="STD-Jackson-1984" TOTAL_1="32" TOTAL_2="34" VAR="0.004929633143580005" WEIGHT="20.281566343364812"/>
<DICH_DATA CI_END="1.142092051897903" CI_START="0.6339649065839585" EFFECT_SIZE="0.850909090909091" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.057701109181439385" LOG_CI_START="-0.19793478202167897" LOG_EFFECT_SIZE="-0.07011683642011979" MODIFIED="2010-02-18 16:29:39 +0000" MODIFIED_BY="[Empty name]" ORDER="6" O_E="0.0" SE="0.15016178791078155" STUDY_ID="STD-Collum-1985" TOTAL_1="25" TOTAL_2="26" VAR="0.022548562548562544" WEIGHT="15.037190732519257"/>
<DICH_DATA CI_END="2.335428123572061" CI_START="0.8095410776796976" EFFECT_SIZE="1.375" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.36836650574224244" LOG_CI_START="-0.09176110940967948" LOG_EFFECT_SIZE="0.13830269816628146" MODIFIED="2010-02-18 16:29:26 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.2702812388086677" STUDY_ID="STD-Gen_x00e9_e-1987" TOTAL_1="14" TOTAL_2="14" VAR="0.07305194805194806" WEIGHT="5.577430744425324"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4667036281283115E-31" CI_END="2.9370506751571375" CI_START="0.9427470977673402" DF="0" EFFECT_SIZE="1.6639999999999997" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" I2="100.0" ID="CMP-001.15.03" LOG_CI_END="0.46791143979867816" LOG_CI_START="-0.025604795889268152" LOG_EFFECT_SIZE="0.22115332195470505" MODIFIED="2010-03-13 15:55:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.07898792339851944" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.7565887999141254">
<NAME>Healing at 7 days: geographic epithelial keratitis</NAME>
<DICH_DATA CI_END="2.9370506751571384" CI_START="0.9427470977673403" EFFECT_SIZE="1.664" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.46791143979867833" LOG_CI_START="-0.0256047958892681" LOG_EFFECT_SIZE="0.2211533219547051" ORDER="65166" O_E="0.0" SE="0.2898938797878657" STUDY_ID="STD-Collum-1985" TOTAL_1="25" TOTAL_2="26" VAR="0.08403846153846153" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.142092051897903" CI_START="0.6339649065839585" DF="0" EFFECT_SIZE="0.850909090909091" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" I2="0.0" ID="CMP-001.15.04" LOG_CI_END="0.057701109181439385" LOG_CI_START="-0.19793478202167897" LOG_EFFECT_SIZE="-0.07011683642011979" MODIFIED="2010-03-13 15:55:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.2822970521808623" STUDIES="1" TAU2="0.0" TOTAL_1="25" TOTAL_2="26" WEIGHT="100.0" Z="1.0751735481785492">
<NAME>Healing at 14 days: geographic epithelial keratitis</NAME>
<DICH_DATA CI_END="1.142092051897903" CI_START="0.6339649065839585" EFFECT_SIZE="0.850909090909091" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.057701109181439385" LOG_CI_START="-0.19793478202167897" LOG_EFFECT_SIZE="-0.07011683642011979" MODIFIED="2009-08-12 16:41:49 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.15016178791078155" STUDY_ID="STD-Collum-1985" TOTAL_1="25" TOTAL_2="26" VAR="0.022548562548562544" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.8977831025958717" CI_END="1.4653574781508087" CI_START="0.8647504708761997" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="1.1256858217250816" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="112" I2="0.0" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="0.16594358499717266" LOG_CI_START="-0.06310919283036355" LOG_EFFECT_SIZE="0.05141719608340451" MODIFIED="2010-06-14 23:40:50 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.9248786817922355" P_Q="1.0" P_Z="0.37889417997380725" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="130" TOTAL_2="129" WEIGHT="99.99999999999999" Z="0.8799356503363199">
<NAME>Acyclovir <I>versus</I> vidarabine: healing rate</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Vidarabine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Vidarabine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.163450875660485" CI_START="0.6204636047246782" EFFECT_SIZE="1.1585950668620448" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.3351470383506472" LOG_CI_START="-0.20728368834867456" LOG_EFFECT_SIZE="0.0639316750009863" MODIFIED="2010-06-14 23:39:36 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="1.45" SE="0.31862649393858306" STUDY_ID="STD-Yeakley-1981" TOTAL_1="19" TOTAL_2="21" VAR="9.85" WEIGHT="17.83128167994207"/>
<IPD_DATA CI_END="1.6615413352772985" CI_START="0.6283432007907377" EFFECT_SIZE="1.021772088508124" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="32" LOG_CI_END="0.22051114998399787" LOG_CI_START="-0.2018030799943193" LOG_EFFECT_SIZE="0.009354034994839224" MODIFIED="2010-06-14 23:39:39 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.35" SE="0.2480694691784169" STUDY_ID="STD-Young-1982" TOTAL_1="40" TOTAL_2="39" VAR="16.25" WEIGHT="29.417089065894277"/>
<IPD_DATA CI_END="2.232967482094266" CI_START="0.34164823900319613" EFFECT_SIZE="0.8734354057449851" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.34888239864248494" LOG_CI_START="-0.46642081346951175" LOG_EFFECT_SIZE="-0.05876920741351345" MODIFIED="2010-06-14 23:39:42 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="-0.59" SE="0.47891314261057566" STUDY_ID="STD-Denis-1983" TOTAL_1="14" TOTAL_2="9" VAR="4.36" WEIGHT="7.892831281679943"/>
<IPD_DATA CI_END="2.221228730002557" CI_START="0.8072995219400921" EFFECT_SIZE="1.3391030176392937" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" LOG_CI_END="0.3465932821248955" LOG_CI_START="-0.09296530469339646" LOG_EFFECT_SIZE="0.12681398871574953" MODIFIED="2010-06-14 23:39:45 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="4.38" SE="0.2581988897471611" STUDY_ID="STD-Jackson-1984" TOTAL_1="32" TOTAL_2="34" VAR="15.0" WEIGHT="27.154236060825486"/>
<IPD_DATA CI_END="2.062387696668282" CI_START="0.5888461357907973" EFFECT_SIZE="1.1020113546082912" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="22" LOG_CI_END="0.31437030920007064" LOG_CI_START="-0.22999817058900948" LOG_EFFECT_SIZE="0.04218606930553064" MODIFIED="2010-06-14 23:39:47 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.95" SE="0.31976473969553965" STUDY_ID="STD-Collum-1985" TOTAL_1="25" TOTAL_2="26" VAR="9.78" WEIGHT="17.704561911658217"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="4.929911307932145" CI_END="1.095730516208987" CI_START="0.8998027830308595" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9929458031215433" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="136" I2="0.0" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="0.0397037569640035" LOG_CI_START="-0.04585266792409045" LOG_EFFECT_SIZE="-0.003074455480043483" METHOD="MH" MODIFIED="2013-08-17 15:42:16 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.6685163996905077" P_Q="0.9967041323283562" P_Z="0.8879790094620884" Q="1.7063254968823302E-5" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="188" TOTAL_2="168" WEIGHT="200.0" Z="0.14086194042910702">
<NAME>Acyclovir <I>versus</I> trifluridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Trifluridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.015401707077952" CI_END="1.1964864177176415" CI_START="0.8244373286318045" DF="3" EFFECT_SIZE="0.9931908507267724" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="60" I2="25.287674338736842" ID="CMP-001.17.01" LOG_CI_END="0.07790777295049224" LOG_CI_START="-0.08384235258934136" LOG_EFFECT_SIZE="-0.002967289819424538" MODIFIED="2013-08-17 15:42:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2598059016439299" P_Z="0.9426729865230017" STUDIES="4" TAU2="0.0" TOTAL_1="94" TOTAL_2="84" WEIGHT="100.0" Z="0.0719106851800523">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.6303080419708498" CI_START="0.8170218401727957" EFFECT_SIZE="1.1541218637992832" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="18" LOG_CI_END="0.2122696708386692" LOG_CI_START="-0.08776633399420253" LOG_EFFECT_SIZE="0.062251668422233356" MODIFIED="2009-08-12 16:36:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.17624263444100585" STUDY_ID="STD-La-Lau-1982" TOTAL_1="31" TOTAL_2="28" VAR="0.031061466194706025" WEIGHT="29.982490759011704"/>
<DICH_DATA CI_END="1.0481071749933293" CI_START="0.356315459939327" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.020405694029718056" LOG_CI_START="-0.44816533391988006" LOG_EFFECT_SIZE="-0.21387981994508098" MODIFIED="2009-08-12 16:35:47 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.27524094128159016" STUDY_ID="STD-Hoang_x002d_Xuan-1984" TOTAL_1="18" TOTAL_2="11" VAR="0.07575757575757575" WEIGHT="17.70934659959423"/>
<DICH_DATA CI_END="1.4129859384780423" CI_START="0.7077211264233256" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.15013783992939383" LOG_CI_START="-0.15013783992939383" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.17638342073763932" STUDY_ID="STD-H_x00f8_vding-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.031111111111111096" WEIGHT="28.53172507712404"/>
<DICH_DATA CI_END="1.490730242218044" CI_START="0.7632351887387008" EFFECT_SIZE="1.0666666666666667" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.17339906202076785" LOG_CI_START="-0.11734161482028072" LOG_EFFECT_SIZE="0.028028723600243534" ORDER="4" O_E="0.0" SE="0.17078251276599324" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.029166666666666646" WEIGHT="23.776437564270033"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9123114225965727" CI_END="1.0937439651714342" CI_START="0.9010844099784044" DF="3" EFFECT_SIZE="0.9927515477318292" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="76" I2="0.0" ID="CMP-001.17.02" LOG_CI_END="0.038915669778963186" LOG_CI_START="-0.04523452414772859" LOG_EFFECT_SIZE="-0.003159427184382722" MODIFIED="2013-08-17 15:42:16 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8224559411570105" P_Z="0.882994622623716" STUDIES="4" TAU2="0.0" TOTAL_1="94" TOTAL_2="84" WEIGHT="100.0" Z="0.14717407540525607">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.3205742952969093" CI_START="0.851337358797424" EFFECT_SIZE="1.0603085553997196" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.12076283956779783" LOG_CI_START="-0.0698983082691158" LOG_EFFECT_SIZE="0.025432265649341007" MODIFIED="2009-08-12 16:36:58 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.11199530202730607" STUDY_ID="STD-La-Lau-1982" TOTAL_1="31" TOTAL_2="28" VAR="0.012542947676187507" WEIGHT="30.370060293610052"/>
<DICH_DATA CI_END="1.2111444915715512" CI_START="0.6937882173641016" EFFECT_SIZE="0.9166666666666666" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.08319595829487249" LOG_CI_START="-0.1587730800736721" LOG_EFFECT_SIZE="-0.0377885608893998" MODIFIED="2010-03-18 16:38:41 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.14213381090374036" STUDY_ID="STD-Hoang_x002d_Xuan-1984" TOTAL_1="18" TOTAL_2="11" VAR="0.02020202020202022" WEIGHT="15.598493026944853"/>
<DICH_DATA CI_END="1.1029903338460918" CI_START="0.8326480745985659" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.04257170647854228" LOG_CI_START="-0.07953851786656857" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2009-08-12 16:37:12 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.07172815023567715" STUDY_ID="STD-H_x00f8_vding-1989" TOTAL_1="25" TOTAL_2="25" VAR="0.005144927536231872" WEIGHT="30.15708651876005"/>
<DICH_DATA CI_END="1.1527965029661043" CI_START="0.8674557889679884" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="19" LOG_CI_END="0.06175265036593677" LOG_CI_START="-0.061752650365936815" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0725476250110011" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.005263157894736831" WEIGHT="23.87436016068504"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="2.4638323392449606" CI_END="1.319886489602102" CI_START="0.6466977089510575" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.9238872057243424" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="59" I2="18.82564539221454" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="0.12053658343376175" LOG_CI_START="-0.18929867762049724" LOG_EFFECT_SIZE="-0.034381047093367714" MODIFIED="2010-06-14 23:44:33 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.29173311248052713" P_Q="1.0" P_Z="0.6635790865262357" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="74" TOTAL_2="66" WEIGHT="100.0" Z="0.4349770508655926">
<NAME>Acyclovir <I>versus</I> trifluridine: healing rate</NAME>
<GROUP_LABEL_1>Acyclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Trifluridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Acyclovir</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.1476006059935706" CI_START="0.708350966134017" EFFECT_SIZE="1.2333916507442175" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.3319535178371243" LOG_CI_START="-0.1497515094165446" LOG_EFFECT_SIZE="0.0911010042102898" MODIFIED="2010-06-14 23:42:33 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="2.62" SE="0.2829559174871464" STUDY_ID="STD-La-Lau-1982" TOTAL_1="31" TOTAL_2="28" VAR="12.49" WEIGHT="41.37131500496854"/>
<IPD_DATA CI_END="1.2750181933425908" CI_START="0.256656335737957" EFFECT_SIZE="0.5720502578467553" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" LOG_CI_END="0.10551638179893269" LOG_CI_START="-0.5906480104132674" LOG_EFFECT_SIZE="-0.2425658143071674" MODIFIED="2010-06-14 23:43:10 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="-3.34" SE="0.4089304100547653" STUDY_ID="STD-Hoang_x002d_Xuan-1984" TOTAL_1="18" TOTAL_2="13" VAR="5.98" WEIGHT="19.807883405101027"/>
<IPD_DATA CI_END="1.5372884615904288" CI_START="0.48919061466096614" EFFECT_SIZE="0.8671949535350357" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="24" LOG_CI_END="0.18675536751439703" LOG_CI_START="-0.3105218836881906" LOG_EFFECT_SIZE="-0.06188325808689681" MODIFIED="2010-06-14 23:43:32 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="-1.67" SE="0.292103118918493" STUDY_ID="STD-H_x00f8_vding-1989" TOTAL_1="25" TOTAL_2="25" VAR="11.72" WEIGHT="38.82080158993044"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="7.594603432699099" CI_END="1.1060709233119779" CI_START="0.8525013409227994" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9710442550569875" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="98" I2="34.163777683609545" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="0.04378297562643834" LOG_CI_START="-0.06930492922119555" LOG_EFFECT_SIZE="-0.012760976797378615" METHOD="MH" MODIFIED="2013-08-17 15:42:14 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.18003862904380574" P_Q="0.6016592692345455" P_Z="0.6582508299876269" Q="0.2725006666317833" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="162" TOTAL_2="132" WEIGHT="200.0" Z="0.4423294421116277">
<NAME>Brivudine <I>versus</I> trifluridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Brivudine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Trifluridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Brivudine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.575685684311632" CI_END="1.209836178951334" CI_START="0.7085828685329738" DF="2" EFFECT_SIZE="0.9258883248730965" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="40" I2="69.5849209342285" ID="CMP-001.19.01" LOG_CI_END="0.08272656751138191" LOG_CI_START="-0.14960935184977303" LOG_EFFECT_SIZE="-0.03344139216919554" MODIFIED="2013-08-17 15:42:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.037334377099261795" P_Z="0.5726065411775081" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="66" WEIGHT="100.0" Z="0.5642168841109602">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.938791244426797" CI_START="0.3816656078101959" EFFECT_SIZE="0.8602150537634409" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.28753104978307464" LOG_CI_START="-0.4183169729070577" LOG_EFFECT_SIZE="-0.06539296156199152" MODIFIED="2010-05-26 14:01:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.41461862253224663" STUDY_ID="STD-Struck-1989" TOTAL_1="31" TOTAL_2="16" VAR="0.17190860215053763" WEIGHT="18.883248730964468"/>
<DICH_DATA CI_END="1.11853513169328" CI_START="0.4185331609679849" EFFECT_SIZE="0.6842105263157895" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.048649629256001206" LOG_CI_START="-0.3782701265479856" LOG_EFFECT_SIZE="-0.16481024864599217" MODIFIED="2010-05-26 14:01:28 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.25077477784613567" STUDY_ID="STD-Power-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.0628879892037787" WEIGHT="45.32994923857868"/>
<DICH_DATA CI_END="1.6630666889436485" CI_START="0.9647505148837777" EFFECT_SIZE="1.2666666666666666" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="15" LOG_CI_END="0.22090966476944232" LOG_CI_START="-0.015584980975146913" LOG_EFFECT_SIZE="0.1026623418971477" MODIFIED="2010-05-26 14:01:26 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.1389181255777484" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.01929824561403508" WEIGHT="35.78680203045685"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.7043541504340776" CI_END="1.1359779777170735" CI_START="0.8833374095758707" DF="2" EFFECT_SIZE="1.0017244352474566" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="58" I2="0.0" ID="CMP-001.19.02" LOG_CI_END="0.05536991214202512" LOG_CI_START="-0.05387337668599841" LOG_EFFECT_SIZE="7.482677280133376E-4" MODIFIED="2013-08-17 15:42:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.42648573392900646" P_Z="0.9785795683499325" STUDIES="3" TAU2="0.0" TOTAL_1="81" TOTAL_2="66" WEIGHT="100.0" Z="0.026849755503214806">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.7009115366842487" CI_START="0.6906745291433234" EFFECT_SIZE="1.0838709677419356" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.23068172682306787" LOG_CI_START="-0.160726559711925" LOG_EFFECT_SIZE="0.03497758355557141" MODIFIED="2010-05-26 14:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.22991516501292078" STUDY_ID="STD-Struck-1989" TOTAL_1="31" TOTAL_2="16" VAR="0.05286098310291859" WEIGHT="21.38299706846008"/>
<DICH_DATA CI_END="1.0672452075062233" CI_START="0.8122081054934676" EFFECT_SIZE="0.9310344827586207" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.028264213269120993" LOG_CI_START="-0.09033268074905858" LOG_EFFECT_SIZE="-0.03103423373996879" MODIFIED="2010-05-26 14:01:37 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.06966440261037213" STUDY_ID="STD-Power-1991" TOTAL_1="30" TOTAL_2="30" VAR="0.004853128991060024" WEIGHT="47.00810484566304"/>
<DICH_DATA CI_END="1.2045981471474054" CI_START="0.917479371826193" EFFECT_SIZE="1.0512820512820513" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.08084219082503445" LOG_CI_START="-0.03740369143856187" LOG_EFFECT_SIZE="0.021719249693236305" MODIFIED="2010-05-26 14:01:35 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="31.608898085876874"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="0.0" CI_END="1.0230099720563302" CI_START="0.3500443764908252" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.5984136427358208" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.009879867131446082" LOG_CI_START="-0.4558768949542466" LOG_EFFECT_SIZE="-0.22299851391140033" MODIFIED="2013-11-02 21:45:10 +0000" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="1.0" P_Q="1.0" P_Z="0.06054379702172239" Q="0.0" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="1.8768124972145193">
<NAME>Brivudine <I>versus</I> trifluridine: healing rate</NAME>
<GROUP_LABEL_1>Brivudine</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Trifluridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Brivudine</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="1.0230099720563302" CI_START="0.3500443764908252" EFFECT_SIZE="0.5984136427358208" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="29" LOG_CI_END="0.009879867131446082" LOG_CI_START="-0.4558768949542466" LOG_EFFECT_SIZE="-0.22299851391140033" MODIFIED="2010-06-14 23:45:53 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="-6.86" SE="0.2735878275822914" STUDY_ID="STD-Power-1991" TOTAL_1="30" TOTAL_2="30" VAR="13.36" WEIGHT="100.0"/>
</IPD_OUTCOME>
<DICH_OUTCOME CHI2="0.9476535298066637" CI_END="1.2718884693998325" CI_START="0.9733935294909515" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1126760563380282" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="0.10444903014269774" LOG_CI_START="-0.011711544999965406" LOG_EFFECT_SIZE="0.04636874257136617" METHOD="MH" MODIFIED="2013-11-02 21:44:34 +0000" MODIFIED_BY="[Empty name]" NO="21" P_CHI2="0.33031746447668386" P_Q="0.38841988388925097" P_Z="0.11764180027916536" Q="0.7438829807864569" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="1.5647488889697887">
<NAME>Brivudine <I>versus</I> acyclovir: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Brivudine</GROUP_LABEL_1>
<GROUP_LABEL_2>Acyclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Brivudine</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.511263979936922" CI_START="0.9330972409326251" DF="0" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" I2="0.0" ID="CMP-001.21.01" LOG_CI_END="0.17934033132549052" LOG_CI_START="-0.030073094731682102" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2013-08-17 15:42:09 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.16240229667056647" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="1.3970374932685137">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.5112639799369219" CI_START="0.9330972409326251" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.17934033132549043" LOG_CI_START="-0.030073094731682102" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2009-09-01 15:57:08 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.12301048307916042" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.015131578947368413" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2045981471474054" CI_START="0.9174793718261931" DF="0" EFFECT_SIZE="1.0512820512820513" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" ID="CMP-001.21.02" LOG_CI_END="0.08084219082503445" LOG_CI_START="-0.037403691438561815" LOG_EFFECT_SIZE="0.021719249693236305" MODIFIED="2013-08-17 15:42:07 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.47152052755815765" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.00000000000001" Z="0.7200072654552178">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.2045981471474054" CI_START="0.917479371826193" EFFECT_SIZE="1.0512820512820513" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.08084219082503445" LOG_CI_START="-0.03740369143856187" LOG_EFFECT_SIZE="0.021719249693236305" MODIFIED="2009-09-01 15:57:21 +0100" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.0694582165681937" STUDY_ID="STD-Panda-1995" TOTAL_1="20" TOTAL_2="20" VAR="0.004824443848834098" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="124.32731252615052" CI_END="1.4263892517075203" CI_START="1.1679668340458544" CI_STUDY="95" CI_TOTAL="95" DF="34" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2907266706913079" ESTIMABLE="YES" EVENTS_1="918" EVENTS_2="679" I2="72.65283121691498" I2_Q="70.34129844875372" ID="CMP-001.22" LOG_CI_END="0.15423805763385673" LOG_CI_START="0.0674305105885572" LOG_EFFECT_SIZE="0.11083428411120697" METHOD="MH" MODIFIED="2014-12-06 19:19:13 +0000" MODIFIED_BY="[Empty name]" NO="22" P_CHI2="3.1982194670376884E-12" P_Q="0.06632569821329626" P_Z="5.58933176748548E-7" Q="3.371691772386371" RANDOM="YES" SCALE="15.0" SORT_BY="USER" STUDIES="28" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.05466531482948624" TOTALS="SUB" TOTAL_1="1326" TOTAL_2="1287" WEIGHT="200.0" Z="5.004892143695436">
<NAME>Ganciclovir <I>versus</I> acyclovir: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Ganciclovir</GROUP_LABEL_1>
<GROUP_LABEL_2>Acyclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Ganciclovir</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="6.234465739313512" CI_END="1.3453088578610415" CI_START="0.9605980924290217" DF="6" EFFECT_SIZE="1.1367942305400667" ESTIMABLE="YES" EVENTS_1="139" EVENTS_2="118" I2="3.7607992267085475" ID="CMP-001.22.01" LOG_CI_END="0.12882200171098057" LOG_CI_START="-0.017458280125093567" LOG_EFFECT_SIZE="0.05568186079294349" MODIFIED="2014-12-06 16:59:55 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3974445213401938" P_Z="0.135665630250566" STUDIES="7" TAU2="0.002196321860135804" TOTAL_1="279" TOTAL_2="272" WEIGHT="100.0" Z="1.4921278572410923">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.9674689949160435" CI_START="0.5626873644006095" EFFECT_SIZE="1.0521739130434782" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.29390789709566534" LOG_CI_START="-0.24973283716998865" LOG_EFFECT_SIZE="0.022087529962838366" MODIFIED="2010-06-03 17:40:47 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="0.31933725837268073" STUDY_ID="STD-Colin-1997a" TOTAL_1="23" TOTAL_2="22" VAR="0.10197628458498025" WEIGHT="7.087502911766803"/>
<DICH_DATA CI_END="1.9305127556681412" CI_START="0.5704205173003676" EFFECT_SIZE="1.0493827160493827" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.2856726755264938" LOG_CI_START="-0.2438048618552079" LOG_EFFECT_SIZE="0.020933906835642984" MODIFIED="2013-08-13 19:49:10 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.3110177264140918" STUDY_ID="STD-Colin-1997b" TOTAL_1="18" TOTAL_2="17" VAR="0.09673202614379085" WEIGHT="7.463216220660955"/>
<DICH_DATA CI_END="1.510224391395948" CI_START="0.5906243560385713" EFFECT_SIZE="0.9444444444444444" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="19" LOG_CI_END="0.17904148021032867" LOG_CI_START="-0.22868864766039304" LOG_EFFECT_SIZE="-0.024823583725032152" MODIFIED="2010-06-08 20:46:09 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="0.23950269540794555" STUDY_ID="STD-Colin-2007a" TOTAL_1="36" TOTAL_2="38" VAR="0.05736154110767114" WEIGHT="12.396745193916486"/>
<DICH_DATA CI_END="1.3307064540185856" CI_START="0.7161217584292855" EFFECT_SIZE="0.9761904761904762" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="40" LOG_CI_END="0.12408226324316322" LOG_CI_START="-0.14501313059949317" LOG_EFFECT_SIZE="-0.01046543367816498" MODIFIED="2010-06-08 20:45:34 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.1580679663868588" STUDY_ID="STD-Colin-2007b" TOTAL_1="84" TOTAL_2="80" VAR="0.024985481997677122" WEIGHT="27.16242289762088"/>
<DICH_DATA CI_END="43.64847115170351" CI_START="0.7184673179274937" EFFECT_SIZE="5.6" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.6399690365408568" LOG_CI_START="-0.14359298252845593" LOG_EFFECT_SIZE="0.7481880270062004" MODIFIED="2010-06-08 20:47:53 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.0476731587756973" STUDY_ID="STD-Li-2008" TOTAL_1="30" TOTAL_2="28" VAR="1.0976190476190475" WEIGHT="0.6713159972075404"/>
<DICH_DATA CI_END="3.8164611407234745" CI_START="0.8756910898328862" EFFECT_SIZE="1.828125" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.5816608447458399" LOG_CI_START="-0.05764906922129098" LOG_EFFECT_SIZE="0.26200588776227446" MODIFIED="2014-12-06 16:08:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="291" O_E="0.0" SE="0.3755338080994054" STUDY_ID="STD-Dai-2009b" TOTAL_1="40" TOTAL_2="39" VAR="0.14102564102564102" WEIGHT="5.155100772462736"/>
<DICH_DATA CI_END="1.614921984654938" CI_START="0.980063645044227" EFFECT_SIZE="1.2580645161290323" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.20815154682052991" LOG_CI_START="-0.00874572043607689" LOG_EFFECT_SIZE="0.09970291319222653" MODIFIED="2014-12-06 16:59:55 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="559" O_E="0.0" SE="0.1274065284453195" STUDY_ID="STD-Han-2014" TOTAL_1="48" TOTAL_2="48" VAR="0.016232423490488004" WEIGHT="40.0636960063646">
<FOOTNOTE>Some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="127.21484028620807" CI_END="1.565815352828056" CI_START="1.22148872264299" DF="27" EFFECT_SIZE="1.3829771492041092" ESTIMABLE="YES" EVENTS_1="779" EVENTS_2="561" I2="78.77606107962296" ID="CMP-001.22.02" LOG_CI_END="0.19474054700932955" LOG_CI_START="0.08688946171753681" LOG_EFFECT_SIZE="0.14081500436343317" MODIFIED="2014-12-06 19:19:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="5.773159728050814E-15" P_Z="3.087498144902353E-7" STUDIES="28" TAU2="0.06701665423105753" TOTAL_1="1047" TOTAL_2="1015" WEIGHT="100.0" Z="5.118026142963297">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.5599268812860538" CI_START="0.8270898364950693" EFFECT_SIZE="1.1358695652173914" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.19310424207355836" LOG_CI_START="-0.08244731587052327" LOG_EFFECT_SIZE="0.05532846310151756" MODIFIED="2014-12-06 18:01:43 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.16186034913856373" STUDY_ID="STD-Colin-1997a" TOTAL_1="23" TOTAL_2="22" VAR="0.026198772623257746" WEIGHT="4.305627465723905"/>
<DICH_DATA CI_END="1.7089839574358132" CI_START="0.8155204814469021" EFFECT_SIZE="1.1805555555555556" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.232737985933257" LOG_CI_START="-0.08856512736720844" LOG_EFFECT_SIZE="0.07208642928302428" MODIFIED="2014-12-06 18:01:44 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.18873503922875512" STUDY_ID="STD-Colin-1997b" TOTAL_1="18" TOTAL_2="17" VAR="0.03562091503267974" WEIGHT="3.9103702959079936"/>
<DICH_DATA CI_END="1.0871531751722328" CI_START="0.8510020852096213" EFFECT_SIZE="0.9618573797678275" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="63" LOG_CI_END="0.03629073860831349" LOG_CI_START="-0.07006937576274157" LOG_EFFECT_SIZE="-0.016889318577214048" MODIFIED="2014-12-06 18:01:45 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.062476457672615004" STUDY_ID="STD-Yang-2000" TOTAL_1="67" TOTAL_2="70" VAR="0.0039033077633180546" WEIGHT="5.659209210023931">
<FOOTNOTE>Data reported for 21 days of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.941860456902704" CI_START="0.567754493419421" EFFECT_SIZE="1.05" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.28821801806706054" LOG_CI_START="-0.24583941992718436" LOG_EFFECT_SIZE="0.021189299069938092" MODIFIED="2014-12-06 18:01:45 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="217" O_E="0.0" SE="0.3137079827047734" STUDY_ID="STD-Ramirez-2002" TOTAL_1="10" TOTAL_2="9" VAR="0.09841269841269842" WEIGHT="2.426116621258907"/>
<DICH_DATA CI_END="1.3668876545190238" CI_START="1.0250168530678943" EFFECT_SIZE="1.183673469387755" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="49" LOG_CI_END="0.1357328210583238" LOG_CI_START="0.010731006010523458" LOG_EFFECT_SIZE="0.07323191353442361" MODIFIED="2014-12-06 18:01:46 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="219" O_E="0.0" SE="0.0734266849280418" STUDY_ID="STD-Zhao-2006" TOTAL_1="62" TOTAL_2="62" VAR="0.00539147805952192" WEIGHT="5.54289814412648">
<FOOTNOTE>Data reported for uncertain days of treatment; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.543218767240416" CI_START="0.951766807517246" EFFECT_SIZE="1.2119341563786008" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="27" LOG_CI_END="0.18842749616731685" LOG_CI_START="-0.0214694451177004" LOG_EFFECT_SIZE="0.08347902552480825" MODIFIED="2014-12-06 16:52:50 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.1232945023174354" STUDY_ID="STD-Colin-2007a" TOTAL_1="36" TOTAL_2="38" VAR="0.015201534301704081" WEIGHT="4.881534235374093"/>
<DICH_DATA CI_END="1.074075712734168" CI_START="0.844474432951393" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="71" LOG_CI_END="0.031034896320428374" LOG_CI_START="-0.07341349446030454" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2014-12-06 18:01:47 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.061353501772475366" STUDY_ID="STD-Colin-2007b" TOTAL_1="84" TOTAL_2="80" VAR="0.003764252179745138" WEIGHT="5.670327245651982"/>
<DICH_DATA CI_END="2.335809423945988" CI_START="1.0452078088954804" EFFECT_SIZE="1.5625" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" LOG_CI_END="0.36843740628927196" LOG_CI_START="0.01920264574295373" LOG_EFFECT_SIZE="0.19382002601611284" MODIFIED="2014-12-06 18:01:47 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="221" O_E="0.0" SE="0.20514222708485283" STUDY_ID="STD-Yang-2008" TOTAL_1="32" TOTAL_2="30" VAR="0.04208333333333333" WEIGHT="3.6787437932221576"/>
<DICH_DATA CI_END="5.554870876468864" CI_START="1.0369277932994063" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="5" LOG_CI_END="0.7446739681753893" LOG_CI_START="0.01574851524782258" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2014-12-06 18:01:48 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.42817441928883765" STUDY_ID="STD-Chen-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.18333333333333335" WEIGHT="1.6031592651463131"/>
<DICH_DATA CI_END="1.1791450348924664" CI_START="0.745375864708749" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.07156722662144056" LOG_CI_START="-0.1276246738219276" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2014-12-06 18:01:50 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.11700630833624392" STUDY_ID="STD-Huang-2008a" TOTAL_1="16" TOTAL_2="15" VAR="0.013690476190476183" WEIGHT="4.972929900950014">
<FOOTNOTE>Data reported for 21 days of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.085894296115963" CI_START="1.261877932201414" EFFECT_SIZE="2.533333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="7" LOG_CI_END="0.7063673296716593" LOG_CI_START="0.10101734545059861" LOG_EFFECT_SIZE="0.4036923375611289" MODIFIED="2014-12-06 18:01:50 +0000" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.35558557726220036" STUDY_ID="STD-Li-2008" TOTAL_1="30" TOTAL_2="28" VAR="0.12644110275689224" WEIGHT="2.0746177787955906"/>
<DICH_DATA CI_END="2.4910872204129197" CI_START="1.0368597864016846" EFFECT_SIZE="1.6071428571428572" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.3963889337512388" LOG_CI_START="0.015720031115010163" LOG_EFFECT_SIZE="0.20605448243312446" MODIFIED="2014-12-06 18:01:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="268" O_E="0.0" SE="0.22360679774997896" STUDY_ID="STD-Dai-2009a" TOTAL_1="28" TOTAL_2="30" VAR="0.049999999999999996" WEIGHT="3.4298613708491628"/>
<DICH_DATA CI_END="2.0651297694069872" CI_START="1.0688659722383265" EFFECT_SIZE="1.4857142857142858" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="0.31494734721111733" LOG_CI_START="0.02892325135792976" LOG_EFFECT_SIZE="0.17193529928452353" MODIFIED="2014-12-06 18:01:51 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="292" O_E="0.0" SE="0.16801196974627128" STUDY_ID="STD-Dai-2009b" TOTAL_1="40" TOTAL_2="39" VAR="0.028228021978021975" WEIGHT="4.213893291128197"/>
<DICH_DATA CI_END="25.17887042241532" CI_START="0.4567697035902564" EFFECT_SIZE="3.391304347826087" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.4010362428363499" LOG_CI_START="-0.34030270949057495" LOG_EFFECT_SIZE="0.5303667666728875" MODIFIED="2014-12-06 19:17:36 +0000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="1.0228711203636676" STUDY_ID="STD-Liu-2009a" TOTAL_1="23" TOTAL_2="13" VAR="1.0462653288740247" WEIGHT="0.3605114500943416">
<FOOTNOTE>Data reported for 21 days of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.050730517147299" CI_START="0.9582772202096577" EFFECT_SIZE="2.2" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.7033541972515988" LOG_CI_START="-0.01850883560718628" LOG_EFFECT_SIZE="0.3424226808222063" MODIFIED="2014-12-06 19:18:03 +0000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.4240259187808922" STUDY_ID="STD-Xu-2009a" TOTAL_1="18" TOTAL_2="18" VAR="0.1797979797979798" WEIGHT="1.6261227932128985"/>
<DICH_DATA CI_END="1.7810352885941991" CI_START="0.8811592276223361" EFFECT_SIZE="1.2527472527472527" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.2506725244547687" LOG_CI_START="-0.05494560642401073" LOG_EFFECT_SIZE="0.09786345901537899" MODIFIED="2014-12-06 19:18:03 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="295" O_E="0.0" SE="0.17952160291234157" STUDY_ID="STD-Han-2010" TOTAL_1="21" TOTAL_2="19" VAR="0.032228005912216445" WEIGHT="4.044055383067558"/>
<DICH_DATA CI_END="3.7988408815401904" CI_START="1.0529527623642536" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.5796511030529313" LOG_CI_START="0.02240888827503109" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-12-06 19:18:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="296" O_E="0.0" SE="0.32732683535398854" STUDY_ID="STD-Liu-2010" TOTAL_1="30" TOTAL_2="20" VAR="0.10714285714285714" WEIGHT="2.304501769251238">
<FOOTNOTE>Data used from day 15</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.4630635304962" CI_START="1.0424296199621688" EFFECT_SIZE="1.9" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.5394604588295215" LOG_CI_START="0.018046743076136365" LOG_EFFECT_SIZE="0.2787536009528289" MODIFIED="2014-12-06 19:18:28 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="297" O_E="0.0" SE="0.3062809976730579" STUDY_ID="STD-Lin-2011" TOTAL_1="34" TOTAL_2="34" VAR="0.0938080495356037" WEIGHT="2.495579924558313">
<FOOTNOTE>Data reported for 21 days of treatment; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2963555415356742" CI_START="0.9635743498401292" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="34" LOG_CI_END="0.1127241285027121" LOG_CI_START="-0.016114769353601982" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2014-12-06 19:18:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="298" O_E="0.0" SE="0.07568060636362897" STUDY_ID="STD-Liu-2012a" TOTAL_1="40" TOTAL_2="40" VAR="0.005727554179566559" WEIGHT="5.51729011645278">
<FOOTNOTE>Events include both cured and improved outcomes; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.152696126297783" CI_START="0.7675186537122034" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.49868211314185223" LOG_CI_START="-0.11491106066402589" LOG_EFFECT_SIZE="0.19188552623891317" MODIFIED="2014-12-06 19:18:23 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="299" O_E="0.0" SE="0.36042766762876866" STUDY_ID="STD-Liu-2012b" TOTAL_1="38" TOTAL_2="38" VAR="0.1299081035923141" WEIGHT="2.0380926528958967">
<FOOTNOTE>Data reported for 21 days of treatment; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.957847033714529" CI_START="1.6192064263352615" EFFECT_SIZE="2.8333333333333335" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="12" LOG_CI_END="0.6952931231904718" LOG_CI_START="0.20930221879878894" LOG_EFFECT_SIZE="0.4522976709946303" MODIFIED="2014-12-06 19:18:53 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="300" O_E="0.0" SE="0.2854734629334497" STUDY_ID="STD-Zhen-2012" TOTAL_1="64" TOTAL_2="64" VAR="0.08149509803921567" WEIGHT="2.7024858030272787"/>
<DICH_DATA CI_END="1.7152558484601959" CI_START="0.8226504611303901" EFFECT_SIZE="1.187878787878788" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.23432890880279802" LOG_CI_START="-0.0847846545176584" LOG_EFFECT_SIZE="0.07477212714256981" MODIFIED="2014-12-06 19:19:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="301" O_E="0.0" SE="0.1874488867320506" STUDY_ID="STD-Li-2013a" TOTAL_1="45" TOTAL_2="42" VAR="0.03513708513708513" WEIGHT="3.9288909498136437">
<FOOTNOTE>Acyclovir group also treated with topical interferon-&#945;, oral acyclovir, and subconjunctival ribavirin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.8249369578810715" CI_START="0.9322341190101936" EFFECT_SIZE="1.6228070175438596" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.45100876042098903" LOG_CI_START="-0.03047500628790655" LOG_EFFECT_SIZE="0.21026687706654118" MODIFIED="2014-12-06 19:19:13 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="302" O_E="0.0" SE="0.2828259479478891" STUDY_ID="STD-Sun-2013a" TOTAL_1="38" TOTAL_2="37" VAR="0.0799905168326221" WEIGHT="2.7301450615580034">
<FOOTNOTE>Data reported for 21 days of treatment</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3222740115134186" CI_START="1.0001709089678943" EFFECT_SIZE="1.15" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="40" LOG_CI_END="0.12132146222768025" LOG_CI_START="7.421847954304537E-5" LOG_EFFECT_SIZE="0.06069784035361165" MODIFIED="2014-12-06 19:19:10 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="557" O_E="0.0" SE="0.07122123116119199" STUDY_ID="STD-Han-2014" TOTAL_1="48" TOTAL_2="48" VAR="0.005072463768115945" WEIGHT="5.567427001918918">
<FOOTNOTE>Both treatment groups also used topical recombinant fibroblast growth factor gel; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3088929837512846" CI_START="1.4032698885575614" EFFECT_SIZE="1.8" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="30" LOG_CI_END="0.36340380401143385" LOG_CI_START="0.14714120619517837" LOG_EFFECT_SIZE="0.25527250510330607" MODIFIED="2014-12-06 19:19:09 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="558" O_E="0.0" SE="0.1270337204743927" STUDY_ID="STD-Lin-2014" TOTAL_1="56" TOTAL_2="56" VAR="0.016137566137566138" WEIGHT="4.826584872228062"/>
<DICH_DATA CI_END="4.291957819743943" CI_START="0.9319756083340629" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="7" LOG_CI_END="0.6326554451805709" LOG_CI_START="-0.030595453852608628" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2014-12-06 19:19:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="560" O_E="0.0" SE="0.3895968612369898" STUDY_ID="STD-Liu-2014a" TOTAL_1="32" TOTAL_2="32" VAR="0.15178571428571427" WEIGHT="1.8343078496536147">
<FOOTNOTE>Data reported for 21 days of treatment; some eyes had disciform keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.701705618965065" CI_START="1.878515749046517" EFFECT_SIZE="3.272727272727273" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="11" LOG_CI_END="0.7560047907778235" LOG_CI_START="0.273814840440301" LOG_EFFECT_SIZE="0.5149098156090622" MODIFIED="2014-12-06 19:19:04 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="561" O_E="0.0" SE="0.2832407637070099" STUDY_ID="STD-Wang-2014a" TOTAL_1="52" TOTAL_2="52" VAR="0.08022533022533022" WEIGHT="2.7257911768500738">
<FOOTNOTE>Data reported for 21 days of treatment; some eyes had stromal keratitis</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.7171524512487335" CI_START="1.0726110738475623" EFFECT_SIZE="1.3571428571428572" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="28" LOG_CI_END="0.2348088541573895" LOG_CI_START="0.030442276391792446" LOG_EFFECT_SIZE="0.13262556527459096" MODIFIED="2014-12-06 19:19:01 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="562" O_E="0.0" SE="0.12004593941038699" STUDY_ID="STD-Zhang-2014" TOTAL_1="42" TOTAL_2="42" VAR="0.014411027568922305" WEIGHT="4.92892457725865"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3393362831748017" CI_START="0.7466384750135873" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="0.1268896342120762" LOG_CI_START="-0.12688963421207616" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-08-14 17:19:38 +0100" MODIFIED_BY="[Empty name]" NO="23" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>Foscarnet <I>versus</I> trifluridine: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Foscarent</GROUP_LABEL_1>
<GROUP_LABEL_2>Trifluridine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Trifluridine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Foscarnet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3393362831748017" CI_START="0.7466384750135873" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" I2="0.0" ID="CMP-001.23.01" LOG_CI_END="0.1268896342120762" LOG_CI_START="-0.12688963421207616" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-06-24 18:10:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.3393362831748015" CI_START="0.7466384750135874" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.1268896342120761" LOG_CI_START="-0.1268896342120761" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.1490711984999859" STUDY_ID="STD-Behrens_x002d_Baumann-1992" TOTAL_1="10" TOTAL_2="10" VAR="0.0222222222222222" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3953477671184844" CI_START="0.9541427435648815" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="0.14468246174417762" LOG_CI_START="-0.020386648246488705" LOG_EFFECT_SIZE="0.062147906748844434" METHOD="MH" MODIFIED="2013-08-20 19:07:40 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="24" P_CHI2="1.0" P_Q="1.0" P_Z="0.13998730103531704" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.00000000000001" Z="1.4758383194672389">
<NAME>Foscarnet <I>versus</I> acyclovir: 14-day healing</NAME>
<GROUP_LABEL_1>Foscarnet</GROUP_LABEL_1>
<GROUP_LABEL_2>Acyclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Acyclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Foscarnet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3953477671184844" CI_START="0.9541427435648815" DF="0" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" I2="0.0" ID="CMP-001.24.01" LOG_CI_END="0.14468246174417762" LOG_CI_START="-0.020386648246488705" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2013-08-14 17:25:43 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="1" P_CHI2="1.0" P_Z="0.13998730103531704" STUDIES="1" TAU2="0.0" TOTAL_1="52" TOTAL_2="52" WEIGHT="100.00000000000001" Z="1.4758383194672389">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.3953477671184842" CI_START="0.9541427435648815" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.14468246174417757" LOG_CI_START="-0.020386648246488705" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2013-08-14 17:25:43 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="269" O_E="0.0" SE="0.09696241231378991" STUDY_ID="STD-Cao-2001" TOTAL_1="52" TOTAL_2="52" VAR="0.009401709401709396" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.1907904691366354E-4" CI_END="1.1169909502641497" CI_START="0.8277204151019392" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9615384615384616" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="52" I2="0.0" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="0.048049654524504645" LOG_CI_START="-0.08211633312206534" LOG_EFFECT_SIZE="-0.017033339298780342" METHOD="MH" MODIFIED="2013-08-20 19:07:49 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="25" P_CHI2="0.9836673108280141" P_Q="0.9840736064764278" P_Z="0.6079818931417411" Q="3.984854387771701E-4" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="60" TOTAL_2="60" WEIGHT="200.0" Z="0.5129562978111808">
<NAME>Foscarnet <I>versus</I> ganciclovir: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Foscarnet</GROUP_LABEL_1>
<GROUP_LABEL_2>Ganciclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Ganciclovir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Foscarnet</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2204548160305106" CI_START="0.7551283242074244" DF="0" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="0.08652170549686848" LOG_CI_START="-0.12197923941773169" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2013-08-13 16:12:12 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="1" P_CHI2="1.0" P_Z="0.7389001491667817" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.3333101895243871">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.2204548160305106" CI_START="0.7551283242074244" EFFECT_SIZE="0.96" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="25" LOG_CI_END="0.08652170549686848" LOG_CI_START="-0.12197923941773169" LOG_EFFECT_SIZE="-0.017728766960431602" MODIFIED="2013-08-13 16:12:12 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="264" O_E="0.0" SE="0.1224744871391589" STUDY_ID="STD-Yu-2012a" TOTAL_1="30" TOTAL_2="30" VAR="0.015" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1577212458149542" CI_START="0.80096799759916" DF="0" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="0.06360400327942735" LOG_CI_START="-0.09638483565576604" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2013-08-13 16:12:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="2" P_CHI2="1.0" P_Z="0.6879888601928265" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="100.0" Z="0.40158583103971346">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1577212458149542" CI_START="0.80096799759916" EFFECT_SIZE="0.9629629629629629" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="27" LOG_CI_END="0.06360400327942735" LOG_CI_START="-0.09638483565576604" LOG_EFFECT_SIZE="-0.01639041618816937" MODIFIED="2013-08-13 16:12:32 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="263" O_E="0.0" SE="0.09397823594805785" STUDY_ID="STD-Yu-2012a" TOTAL_1="30" TOTAL_2="30" VAR="0.008831908831908833" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.67855111918867" CI_END="1.4263660838241603" CI_START="0.9906000739854903" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1886792452830188" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="89.66787499817609" I2_Q="72.48710980366344" ID="CMP-001.26" LOG_CI_END="0.15423100362275696" LOG_CI_START="-0.004101643917171669" LOG_EFFECT_SIZE="0.07506467985279265" METHOD="MH" MODIFIED="2013-08-14 17:21:18 +0100" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.001864338156113643" P_Q="0.056588355275453694" P_Z="0.06310977142114457" Q="3.6346599461700815" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="32" TOTAL_2="32" WEIGHT="200.0" Z="1.8584173423286061">
<NAME>Acyclovir/vidarabine <I>versus</I> acyclovir: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Acyclovir/Vidarabine</GROUP_LABEL_1>
<GROUP_LABEL_2>Acyclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dual Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.237907060582956" CI_START="1.0054036825880937" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" I2="0.0" ID="CMP-001.26.01" LOG_CI_END="0.34984204648451467" LOG_CI_START="0.0023404716268477714" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-02-15 18:37:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.046992782619490754" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="1.986365246734842">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="2.2379070605829563" CI_START="1.0054036825880937" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.3498420464845148" LOG_CI_START="0.0023404716268477714" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-02-15 18:37:04 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.20412414523193156" STUDY_ID="STD-Colin-1987" TOTAL_1="16" TOTAL_2="16" VAR="0.041666666666666685" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1241484443214562" CI_START="0.8895622326850321" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-001.26.02" LOG_CI_END="0.05082366380683236" LOG_CI_START="-0.05082366380683233" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 18:37:04 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1241484443214562" CI_START="0.889562232685032" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.05082366380683236" LOG_CI_START="-0.050823663806832384" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 18:37:04 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.059708143402653256" STUDY_ID="STD-Colin-1987" TOTAL_1="16" TOTAL_2="16" VAR="0.0035650623885918054" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0138662006693667E-4" CI_END="2.3943821814283637" CI_START="0.9683406320070133" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5226876090750436" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.3791934719009074" LOG_CI_START="-0.013971844573252375" LOG_EFFECT_SIZE="0.18261081366382753" METHOD="MH" MODIFIED="2013-08-14 17:21:12 +0100" MODIFIED_BY="[Empty name]" NO="27" P_CHI2="0.991966162459486" P_Q="0.992604940825277" P_Z="0.06865821921792341" Q="8.590444184720087E-5" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="22" WEIGHT="200.0" Z="1.820662214960052">
<NAME>Trifluridine (aqueous) <I>versus</I> trifluridine (viscous)</NAME>
<GROUP_LABEL_1>Aqueous</GROUP_LABEL_1>
<GROUP_LABEL_2>Viscous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Viscous TFT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Aqueous TFT</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.0545053070299675" CI_START="0.5756818061687033" DF="0" EFFECT_SIZE="1.5277777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.607937873212249" LOG_CI_START="-0.23981749575833586" LOG_EFFECT_SIZE="0.18406018872695656" NO="1" P_CHI2="1.0" P_Z="0.3947281714254788" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="0.8510741520411353">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="4.0545053070299675" CI_START="0.5756818061687033" EFFECT_SIZE="1.5277777777777777" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.607937873212249" LOG_CI_START="-0.23981749575833586" LOG_EFFECT_SIZE="0.18406018872695656" ORDER="1" O_E="0.0" SE="0.49797570019007753" STUDY_ID="STD-McGill-1974" TOTAL_1="9" TOTAL_2="11" VAR="0.247979797979798" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.409600502980372" CI_START="0.9588311411548621" DF="0" EFFECT_SIZE="1.52" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.38194504517531164" LOG_CI_START="-0.01825786928576653" LOG_EFFECT_SIZE="0.18184358794477254" NO="2" P_CHI2="1.0" P_Z="0.074891073251305" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="1.781130872928506">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="2.4096005029803718" CI_START="0.9588311411548622" EFFECT_SIZE="1.52" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.3819450451753115" LOG_CI_START="-0.01825786928576648" LOG_EFFECT_SIZE="0.18184358794477254" ORDER="1" O_E="0.0" SE="0.2350811729908136" STUDY_ID="STD-McGill-1974" TOTAL_1="9" TOTAL_2="11" VAR="0.055263157894736833" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2071282894959376" CI_END="1.1364811297442168" CI_START="0.9701586955553712" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0500319282554906" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="162" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.05556222904823488" LOG_CI_START="-0.013157219376246502" LOG_EFFECT_SIZE="0.021202504835994177" METHOD="MH" MODIFIED="2014-12-06 16:08:16 +0000" MODIFIED_BY="[Empty name]" NO="28" P_CHI2="0.9949935047905758" P_Q="0.7451944041535143" P_Z="0.22649251903298773" Q="0.1056135780455936" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="203" TOTAL_2="197" WEIGHT="200.0" Z="1.2094435218365496">
<NAME>Ganciclovir 0.15% gel <I>versus</I> ganciclovir 0.05% gel or 0.1% solution</NAME>
<GROUP_LABEL_1>Ganciclovir 0.15%</GROUP_LABEL_1>
<GROUP_LABEL_2>Ganciclovir 0.05%-0.1%</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours GCV 0.05%-0.1%</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GCV 0.15%</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7382666923839791" CI_START="0.5263483684280391" DF="0" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" I2="0.0" ID="CMP-001.28.01" LOG_CI_END="0.24011640855985047" LOG_CI_START="-0.27872671895062373" LOG_EFFECT_SIZE="-0.01930515519538663" MODIFIED="2014-12-06 16:08:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.8840374488237297" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="22" WEIGHT="100.0" Z="0.1458529828870105">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.7382666923839791" CI_START="0.5263483684280391" EFFECT_SIZE="0.9565217391304348" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.24011640855985047" LOG_CI_START="-0.27872671895062373" LOG_EFFECT_SIZE="-0.01930515519538663" MODIFIED="2014-12-06 15:48:07 +0000" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="0.30477102141455503" STUDY_ID="STD-Colin-1997a" TOTAL_1="23" TOTAL_2="22" VAR="0.09288537549407115" WEIGHT="100.0">
<FOOTNOTE>Ganciclovir 0.15% gel compared with ganciclovir 0.05% gel</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.09854462692068834" CI_END="1.1376682023514268" CI_START="0.9818720252255919" DF="3" EFFECT_SIZE="1.0569032982622175" ESTIMABLE="YES" EVENTS_1="164" EVENTS_2="151" I2="0.0" ID="CMP-001.28.02" LOG_CI_END="0.05601561979305244" LOG_CI_START="-0.007945113394505147" LOG_EFFECT_SIZE="0.024035253199273632" MODIFIED="2014-12-06 15:48:02 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9920115006325155" P_Z="0.14074133441078626" STUDIES="4" TAU2="0.0" TOTAL_1="180" TOTAL_2="175" WEIGHT="100.00000000000001" Z="1.4730359794887886">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.4346402746276723" CI_START="0.7966288495739496" EFFECT_SIZE="1.0690537084398977" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.15674301861083872" LOG_CI_START="-0.09874396985250196" LOG_EFFECT_SIZE="0.028999524379168376" MODIFIED="2014-12-06 15:47:39 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.15007432170435572" STUDY_ID="STD-Colin-1997a" TOTAL_1="23" TOTAL_2="22" VAR="0.02252230203502245" WEIGHT="11.356398815742342">
<FOOTNOTE>Ganciclovir 0.15% gel compared with ganciclovir 0.05% gel</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3296515000078126" CI_START="0.8713659482327881" EFFECT_SIZE="1.0763888888888888" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="28" LOG_CI_END="0.12373782784200826" LOG_CI_START="-0.05979941569192463" LOG_EFFECT_SIZE="0.031969206075041806" MODIFIED="2014-12-06 15:48:02 +0000" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="0.10781068537584017" STUDY_ID="STD-Colin-2007a" TOTAL_1="36" TOTAL_2="35" VAR="0.011623143881208397" WEIGHT="18.55575268477622">
<FOOTNOTE>Ganciclovir 0.15% gel compared with ganciclovir 0.05% gel</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3546128862669409" CI_START="0.7692977861123692" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="12" LOG_CI_END="0.13181520268035687" LOG_CI_START="-0.1139055173745041" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2014-12-06 15:47:04 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="277" O_E="0.0" SE="0.14433756729740646" STUDY_ID="STD-Huang-2008a" TOTAL_1="16" TOTAL_2="14" VAR="0.020833333333333343" WEIGHT="8.36481549599436">
<FOOTNOTE>Ganciclovir 0.15% gel compared with ganciclovir 0.1% solution</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1367716394238612" CI_START="0.9766954018733603" EFFECT_SIZE="1.0536980749746707" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="94" LOG_CI_END="0.055673230124056325" LOG_CI_START="-0.010240856865769091" LOG_EFFECT_SIZE="0.022716186629143622" MODIFIED="2014-12-06 15:45:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="289" O_E="0.0" SE="0.0387182609778162" STUDY_ID="STD-Zheng-2010" TOTAL_1="105" TOTAL_2="104" VAR="0.001499103733146285" WEIGHT="61.72303300348709">
<FOOTNOTE>Ganciclovir 0.15% gel compared with ganciclovir 0.1% solution</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-08-18 18:58:28 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Oral antiviral agents</NAME>
<DICH_OUTCOME CHI2="26.340525257823142" CI_END="1.4774745702469074" CI_START="1.028700999328836" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2328339575530585" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="59" I2="92.40713698597943" I2_Q="88.63783476967859" ID="CMP-002.01" LOG_CI_END="0.1695200146994951" LOG_CI_START="0.012289161729025111" LOG_EFFECT_SIZE="0.0909045882142601" METHOD="MH" MODIFIED="2010-05-26 15:19:23 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.906478113378185E-6" P_Q="0.0030104463932110193" P_Z="0.023430236958832524" Q="8.801139393144636" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="84" TOTAL_2="88" WEIGHT="200.0" Z="2.2663455112446256">
<NAME>Oral antiviral <I>versus</I> topical antiviral</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Topical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Topical Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Oral Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.038904964097632" CI_END="2.0231043763452217" CI_START="1.1297492802922047" DF="1" EFFECT_SIZE="1.511820330969267" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="31" I2="92.87693732127009" ID="CMP-002.01.01" LOG_CI_END="0.30601828954362353" LOG_CI_START="0.05298207333563711" LOG_EFFECT_SIZE="0.17950018143963037" MODIFIED="2010-05-26 14:03:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.790681254302262E-4" P_Z="0.005423525089504009" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="59" WEIGHT="100.0" Z="2.780739422303901">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.2767446023019238" CI_START="0.6739478268703964" EFFECT_SIZE="0.9276094276094277" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.10610403046300376" LOG_CI_START="-0.17137372272182066" LOG_EFFECT_SIZE="-0.03263484612940847" MODIFIED="2010-05-26 14:03:57 +0100" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.16299180575779626" STUDY_ID="STD-Collum-1986" TOTAL_1="27" TOTAL_2="29" VAR="0.026566328744187184" WEIGHT="70.2127659574468">
<FOOTNOTE>Oral acyclovir <I>vs</I>. topical acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.0794968533078615" CI_START="1.6430129308793289" EFFECT_SIZE="2.888888888888889" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="9" LOG_CI_END="0.7058206956197444" LOG_CI_START="0.21564098144324176" LOG_EFFECT_SIZE="0.4607308385314931" MODIFIED="2010-05-26 14:03:57 +0100" MODIFIED_BY="[Empty name]" ORDER="65200" O_E="0.0" SE="0.2879339905359958" STUDY_ID="STD-Wang-2004" TOTAL_1="30" TOTAL_2="30" VAR="0.08290598290598292" WEIGHT="29.78723404255319">
<FOOTNOTE>Oral acyclovir <I>vs</I>. topical acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.6615962149108197E-30" CI_END="1.0696800474636627" CI_START="0.7923571717563129" DF="0" EFFECT_SIZE="0.9206349206349205" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" I2="100.0" ID="CMP-002.01.02" LOG_CI_END="0.029253895068224352" LOG_CI_START="-0.10107900684951332" LOG_EFFECT_SIZE="-0.0359125558906445" MODIFIED="2010-03-13 17:07:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.28009061403520785" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="29" WEIGHT="100.0" Z="1.080115843394194">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.069680047463663" CI_START="0.7923571717563129" EFFECT_SIZE="0.9206349206349206" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.029253895068224442" LOG_CI_START="-0.10107900684951332" LOG_EFFECT_SIZE="-0.035912555890644446" MODIFIED="2010-03-13 17:07:17 +0000" MODIFIED_BY="[Empty name]" ORDER="65201" O_E="0.0" SE="0.07655819174474861" STUDY_ID="STD-Collum-1986" TOTAL_1="27" TOTAL_2="29" VAR="0.005861156723225694" WEIGHT="100.0">
<FOOTNOTE>Oral acyclovir <I>vs</I>. topical acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.550943907655647" CI_END="1.336710568326329" CI_START="0.9678802545587358" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.13744264257282" ESTIMABLE="YES" EVENTS_1="266" EVENTS_2="214" I2="82.68539769572895" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.12603738169261766" LOG_CI_START="-0.014178369965613039" LOG_EFFECT_SIZE="0.05592950586350231" METHOD="MH" MODIFIED="2013-08-18 18:58:28 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0031027452630357777" P_Q="0.6063695114581817" P_Z="0.11791440903856208" Q="0.2654956430130927" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.036358412818407584" TOTALS="SUB" TOTAL_1="326" TOTAL_2="288" WEIGHT="200.0" Z="1.563587769122822">
<NAME>Oral/topical antivirals <I>versus</I> topical antiviral</NAME>
<GROUP_LABEL_1>Oral/topical</GROUP_LABEL_1>
<GROUP_LABEL_2>Topical alone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Single Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Dual Antivirals</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.329262836649687" CI_START="0.9539043098177322" DF="0" EFFECT_SIZE="1.1260504201680672" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="84" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.12361086297471109" LOG_CI_START="-0.020495189030157394" LOG_EFFECT_SIZE="0.051557836972276866" MODIFIED="2010-03-13 17:08:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.1607778578243631" STUDIES="1" TAU2="0.0" TOTAL_1="153" TOTAL_2="134" WEIGHT="100.0" Z="1.4024602323160773">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.329262836649687" CI_START="0.9539043098177322" EFFECT_SIZE="1.1260504201680672" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="84" LOG_CI_END="0.12361086297471109" LOG_CI_START="-0.020495189030157394" LOG_EFFECT_SIZE="0.051557836972276866" MODIFIED="2010-03-13 17:08:49 +0000" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="0.08464860828412173" STUDY_ID="STD-HEDS-Group-1997" TOTAL_1="153" TOTAL_2="134" VAR="0.007165386884438682" WEIGHT="100.0">
<FOOTNOTE>Oral acyclovir + topical trifluridine <I>vs</I>. topical trifluridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.20190985254879" CI_END="2.7378490645294784" CI_START="0.6758635286862347" DF="1" EFFECT_SIZE="1.3602986178641805" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="130" I2="90.19791377836802" ID="CMP-002.02.02" LOG_CI_END="0.4374095021439135" LOG_CI_START="-0.17014098855824153" LOG_EFFECT_SIZE="0.13363425679283597" MODIFIED="2010-03-18 16:40:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.001402964912437299" P_Z="0.38857147659676206" STUDIES="2" TAU2="0.23171128446339506" TOTAL_1="173" TOTAL_2="154" WEIGHT="100.0" Z="0.8622109089634109">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="3.009979465696806" CI_START="1.2663845141340624" EFFECT_SIZE="1.9523809523809523" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.47856353281477815" LOG_CI_START="0.10256559115685425" LOG_EFFECT_SIZE="0.2905645619858162" MODIFIED="2010-03-18 16:40:13 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.22086305214969307" STUDY_ID="STD-Srinivas-1993" TOTAL_1="20" TOTAL_2="20" VAR="0.04878048780487804" WEIGHT="45.40668843732531">
<FOOTNOTE>Oral acyclovir + topical idoxuridine <I>vs</I>. topical idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0888230785570991" CI_START="0.9316764077344514" EFFECT_SIZE="1.00718954248366" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="120" LOG_CI_END="0.03695731754408039" LOG_CI_START="-0.030734901742439424" LOG_EFFECT_SIZE="0.003111207900820499" MODIFIED="2010-03-13 17:08:56 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.039762744690791336" STUDY_ID="STD-HEDS-Group-1997" TOTAL_1="153" TOTAL_2="134" VAR="0.0015810758653450547" WEIGHT="54.59331156267469">
<FOOTNOTE>Oral acyclovir + topical trifluridine <I>vs</I>. topical trifluridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-01-09 10:49:50 +0000" MODIFIED_BY="Anupa Shah" NO="3">
<NAME>Interferon</NAME>
<DICH_OUTCOME CHI2="5.2272271554347745" CI_END="1.6981724754426564" CI_START="1.1482595016414412" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.396403480500173" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="72" I2="23.477593740283893" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.22998179740911087" LOG_CI_START="0.060040047813778905" LOG_EFFECT_SIZE="0.14501092261144488" METHOD="MH" MODIFIED="2014-10-14 16:34:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2647670603406709" P_Q="0.5663051941392699" P_Z="8.23223485622911E-4" Q="0.32890420278793736" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="142" TOTAL_2="146" WEIGHT="200.0" Z="3.3448659480102707">
<NAME>Interferon <I>versus</I> inactive control, without or with debridement</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.4058416300985717" CI_END="2.057692195178826" CI_START="1.0652879628812584" DF="2" EFFECT_SIZE="1.4805521695768495" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="34" I2="41.27736350612063" ID="CMP-003.01.01" LOG_CI_END="0.3133804103034268" LOG_CI_START="0.027467019780329754" LOG_EFFECT_SIZE="0.17042371504187828" MODIFIED="2010-03-19 22:59:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.18215097761307708" P_Z="0.019463003676353837" STUDIES="3" TAU2="0.0" TOTAL_1="89" TOTAL_2="89" WEIGHT="100.0" Z="2.3365421464344815">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="2.5967208212917408" CI_START="0.8147593156689001" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.4144252602608324" LOG_CI_START="-0.08897066526543289" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2010-03-19 22:57:50 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.2956972585041476" STUDY_ID="STD-Uchida-1981" TOTAL_1="36" TOTAL_2="32" VAR="0.08743686868686869" WEIGHT="34.792382339438646">
<FOOTNOTE>Interferon-&#946;/débridement <I>vs</I>. débridement/albumin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8467041734257443" CI_START="0.6507694819706697" EFFECT_SIZE="1.0962566844919786" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.2663973306656725" LOG_CI_START="-0.18657282162716185" LOG_EFFECT_SIZE="0.03991225451925531" MODIFIED="2010-03-19 22:58:18 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.2660769096952271" STUDY_ID="STD-Yamazaki-1984b" TOTAL_1="33" TOTAL_2="41" VAR="0.07079692187296205" WEIGHT="45.29278601845842">
<FOOTNOTE>Interferon-&#945; <I>vs</I>. albumin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.593737517382849" CI_START="1.2538809581966701" EFFECT_SIZE="2.4" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="6" LOG_CI_END="0.6621661763163542" LOG_CI_START="0.0982563071068578" LOG_EFFECT_SIZE="0.38021124171160603" MODIFIED="2010-03-19 22:59:08 +0000" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.33124344857252985" STUDY_ID="STD-Yamazaki-1984c" TOTAL_1="20" TOTAL_2="16" VAR="0.10972222222222222" WEIGHT="19.914831642102932">
<FOOTNOTE>Interferon-&#945; (low dose) <I>vs</I>. interferon-&#945; (high dose)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.38312514784092" CI_END="1.6379179326179367" CI_START="1.0628094619245354" DF="1" EFFECT_SIZE="1.319391782846254" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="38" I2="27.699962540554225" ID="CMP-003.01.02" LOG_CI_END="0.2142921377760111" LOG_CI_START="0.026455412169668204" LOG_EFFECT_SIZE="0.12037377497283965" MODIFIED="2010-03-19 22:59:32 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.23956973434555073" P_Z="0.012002976161331622" STUDIES="2" TAU2="0.0" TOTAL_1="53" TOTAL_2="57" WEIGHT="100.0" Z="2.5120568181574803">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.5590509786128046" CI_START="0.9206424228078665" EFFECT_SIZE="1.198051948051948" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" LOG_CI_END="0.19286031619478414" LOG_CI_START="-0.035909016877551936" LOG_EFFECT_SIZE="0.0784756496586161" MODIFIED="2010-03-19 22:59:32 +0000" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.13438023867315246" STUDY_ID="STD-Yamazaki-1984b" TOTAL_1="33" TOTAL_2="41" VAR="0.018058048545853418" WEIGHT="68.27276439363006">
<FOOTNOTE>Interferon-&#945; <I>vs</I>. albumin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.3109769809584546" CI_START="1.080918021548206" EFFECT_SIZE="1.5804988662131518" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" LOG_CI_END="0.363795619606106" LOG_CI_START="0.03379275765423578" LOG_EFFECT_SIZE="0.19879418863017087" MODIFIED="2010-03-19 22:59:25 +0000" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="0.19384531465104063" STUDY_ID="STD-Yamazaki-1984c" TOTAL_1="20" TOTAL_2="16" VAR="0.03757600601216095" WEIGHT="31.72723560636995">
<FOOTNOTE>Interferon-&#945; (low dose) <I>vs</I>. interferon-&#945; (high dose)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.522958983437217" CI_END="1.4109373418410993" CI_START="1.0641973798067363" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2253635469764796" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="68" I2="78.40517811664593" I2_Q="49.83743489161581" ID="CMP-003.02" LOG_CI_END="0.14950772764741854" LOG_CI_START="0.027022185300151835" LOG_EFFECT_SIZE="0.08826495647378517" METHOD="MH" MODIFIED="2015-01-09 10:49:50 +0000" MODIFIED_BY="Anupa Shah" NO="2" P_CHI2="9.749951504592902E-4" P_Q="0.11256013855040603" P_Z="0.004731602927391583" Q="5.980555407240486" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="132" TOTAL_2="104" WEIGHT="400.0" Z="2.8247600895645606">
<NAME>Interferon dosages</NAME>
<GROUP_LABEL_1>HIgher IFN Dose</GROUP_LABEL_1>
<GROUP_LABEL_2>Lower IFN Dose</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Lower IFN Dose</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Higher IFN Dose</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3482726175751754" CI_END="2.860106485831748" CI_START="1.147409709876158" DF="1" EFFECT_SIZE="1.811550151975684" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" I2="25.831023565659322" ID="CMP-003.02.01" LOG_CI_END="0.45638220283121517" LOG_CI_START="0.059718520749309174" LOG_EFFECT_SIZE="0.2580503617902622" MODIFIED="2015-01-09 10:49:14 +0000" MODIFIED_BY="Anupa Shah" NO="1" P_CHI2="0.24558048820907719" P_Z="0.010768674834776264" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="48" WEIGHT="100.0" Z="2.5501170797986483">
<NAME>Healing at 7 days: interferon 1000 IU/ml <I>versus</I> interferon 1-10 million IU/ml</NAME>
<DICH_DATA CI_END="2.5967208212917408" CI_START="0.8147593156689001" EFFECT_SIZE="1.4545454545454546" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="11" LOG_CI_END="0.4144252602608324" LOG_CI_START="-0.08897066526543289" LOG_EFFECT_SIZE="0.16272729749769976" MODIFIED="2010-03-17 14:43:25 +0000" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.2956972585041476" STUDY_ID="STD-Uchida-1982" TOTAL_1="36" TOTAL_2="32" VAR="0.08743686868686869" WEIGHT="67.70516717325228"/>
<DICH_DATA CI_END="5.469012366822125" CI_START="1.198315081486659" EFFECT_SIZE="2.56" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.7379089054255685" LOG_CI_START="0.07857102519813061" LOG_EFFECT_SIZE="0.4082399653118496" MODIFIED="2013-11-26 20:50:12 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="285" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Tanaka-1988a" TOTAL_1="20" TOTAL_2="16" VAR="0.15000000000000002" WEIGHT="32.29483282674772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1673932070708082" CI_START="0.9351396164012594" DF="0" EFFECT_SIZE="1.0448328267477203" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.06721716187096555" LOG_CI_START="-0.029123544094276112" LOG_EFFECT_SIZE="0.01904680888834473" MODIFIED="2015-01-09 10:49:27 +0000" MODIFIED_BY="Anupa Shah" NO="2" P_CHI2="1.0" P_Z="0.43835149307204146" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.774979985200473">
<NAME>Healing at 7 days: trifluridine + interferon 10 million IU/ml <I>versus</I> trifluridine + interferon 30 million IU/ml</NAME>
<DICH_DATA CI_END="1.1673932070708082" CI_START="0.9351396164012595" EFFECT_SIZE="1.0448328267477203" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.06721716187096555" LOG_CI_START="-0.02912354409427606" LOG_EFFECT_SIZE="0.01904680888834473" MODIFIED="2010-03-17 14:43:37 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.056591007578168664" STUDY_ID="STD-Sundmacher-1981a" TOTAL_1="27" TOTAL_2="24" VAR="0.003202542138712343" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3750907572962576" CI_START="0.9047278033362955" DF="0" EFFECT_SIZE="1.1153846153846154" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.13833136296061008" LOG_CI_START="-0.04348206310433386" LOG_EFFECT_SIZE="0.047424649928138135" MODIFIED="2015-01-09 10:49:35 +0000" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="1.0" P_Z="0.3065521754186191" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="15" WEIGHT="100.00000000000001" Z="1.0224834089575845">
<NAME>Healing at 7 days: trifluridine + interferon 0.3 or 1.5 million IU/ml <I>versus</I> trifluridine + interferon 30 million IU/ml</NAME>
<DICH_DATA CI_END="1.3750907572962576" CI_START="0.9047278033362957" EFFECT_SIZE="1.1153846153846154" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="13" LOG_CI_END="0.13833136296061008" LOG_CI_START="-0.04348206310433381" LOG_EFFECT_SIZE="0.047424649928138135" MODIFIED="2010-03-17 14:43:53 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.10679810646152195" STUDY_ID="STD-Sundmacher-1987" TOTAL_1="30" TOTAL_2="15" VAR="0.011405835543766576" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1803264133311873" CI_START="0.8584076115231565" DF="0" EFFECT_SIZE="1.006578947368421" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="0.0" ID="CMP-003.02.04" LOG_CI_END="0.07200212586994548" LOG_CI_START="-0.06630644012429303" LOG_EFFECT_SIZE="0.0028478428728262407" MODIFIED="2015-01-09 10:49:50 +0000" MODIFIED_BY="Anupa Shah" NO="4" P_CHI2="1.0" P_Z="0.9356699701028361" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="100.0" Z="0.08071328661741789">
<NAME>Healing at 7 days: trifluridine + interferon 30 million IU/ml <I>versus</I> trifluridine + interferon 100 million IU/ml</NAME>
<DICH_DATA CI_END="1.1803264133311873" CI_START="0.8584076115231565" EFFECT_SIZE="1.006578947368421" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.07200212586994548" LOG_CI_START="-0.06630644012429303" LOG_EFFECT_SIZE="0.0028478428728262407" MODIFIED="2010-03-17 14:44:02 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.08124313630345907" STUDY_ID="STD-Sundmacher-1984a" TOTAL_1="19" TOTAL_2="17" VAR="0.006600447196422429" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1728474455331534E-30" CI_END="1.093604306290006" CI_START="0.8140283891719511" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9435173299101414" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="100.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.03886021168623345" LOG_CI_START="-0.08936044886297237" LOG_EFFECT_SIZE="-0.02525011858836948" METHOD="MH" MODIFIED="2014-10-14 16:34:59 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.44015002046449603" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.7719399171177653">
<NAME>Interferon-&#945; with debridement <I>versus</I> interferon-&#946; with debridement</NAME>
<GROUP_LABEL_1>Deb/IFN-&#945;</GROUP_LABEL_1>
<GROUP_LABEL_2>Deb/IFN-&#946;</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN-&#946;</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFN-&#945;</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1728474455331534E-30" CI_END="1.093604306290006" CI_START="0.8140283891719511" DF="0" EFFECT_SIZE="0.9435173299101414" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" I2="100.0" ID="CMP-003.03.01" LOG_CI_END="0.03886021168623345" LOG_CI_START="-0.08936044886297237" LOG_EFFECT_SIZE="-0.02525011858836948" MODIFIED="2010-03-02 16:51:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.44015002046449603" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="20" WEIGHT="100.0" Z="0.7719399171177653">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.093604306290006" CI_START="0.8140283891719508" EFFECT_SIZE="0.9435173299101413" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.03886021168623345" LOG_CI_START="-0.08936044886297255" LOG_EFFECT_SIZE="-0.02525011858836953" MODIFIED="2010-02-15 19:04:48 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.07531745070910967" STUDY_ID="STD-Sundmacher-1978b" TOTAL_1="18" TOTAL_2="20" VAR="0.005672718381319164" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1248546846945366" CI_START="0.8890037207531016" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.05109642137043983" LOG_CI_START="-0.05109642137043981" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2010-05-26 14:05:40 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Natural interferon-&#945; with trifluridine <I>versus</I> recombinant interferon-&#945; with trifluridine</NAME>
<GROUP_LABEL_1>TFT/IFN natural</GROUP_LABEL_1>
<GROUP_LABEL_2>TFT/IFN recombinant</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours recombinant IFN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours natural IFN</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1248546846945366" CI_START="0.8890037207531016" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" I2="0.0" ID="CMP-003.04.01" LOG_CI_END="0.05109642137043983" LOG_CI_START="-0.05109642137043981" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-02 16:53:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.1248546846945364" CI_START="0.8890037207531017" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.05109642137043974" LOG_CI_START="-0.05109642137043975" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 19:06:35 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.06002858168872262" STUDY_ID="STD-Sundmacher-1985" TOTAL_1="17" TOTAL_2="15" VAR="0.0036034306195596444" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.315424748291623" CI_END="1.2481573529451158" CI_START="0.8972579697090883" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0582623173774093" ESTIMABLE="YES" EVENTS_1="119" EVENTS_2="99" I2="51.52889849903593" I2_Q="23.59877777430268" ID="CMP-003.05" LOG_CI_END="0.09626933951948237" LOG_CI_START="-0.047082675446316086" LOG_EFFECT_SIZE="0.024593332036583135" METHOD="MH" MODIFIED="2014-04-24 02:05:55 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.06677558109024484" P_Q="0.25259774020866854" P_Z="0.5012660658727768" Q="1.3088795844729995" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.023559618416801795" TOTALS="SUB" TOTAL_1="156" TOTAL_2="151" WEIGHT="200.0" Z="0.6724990236522086">
<NAME>Interferon <I>versus</I> nucleoside antiviral</NAME>
<GROUP_LABEL_1>Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral agent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral Agent</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Interferon</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.6214597325702016" CI_END="1.21004158402211" CI_START="0.8091733764092923" DF="1" EFFECT_SIZE="0.9895117150083768" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="0.08280029544125678" LOG_CI_START="-0.09195841491352438" LOG_EFFECT_SIZE="-0.004579059736133812" MODIFIED="2014-04-24 02:05:55 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.4305055619444138" P_Z="0.9181926045432276" STUDIES="3" TAU2="0.0" TOTAL_1="45" TOTAL_2="40" WEIGHT="100.0" Z="0.10271067058872024">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.2048546249298902" CI_START="0.8050154085309635" EFFECT_SIZE="0.9848484848484849" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="22" LOG_CI_END="0.08093464906897718" LOG_CI_START="-0.09419580686700334" LOG_EFFECT_SIZE="-0.006630578899013093" MODIFIED="2014-04-24 02:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.1028724967265332" STUDY_ID="STD-Kitano-1983" TOTAL_1="30" TOTAL_2="25" VAR="0.010582750582750586" WEIGHT="99.57591495880584">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2014-04-24 02:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Vannini-1986" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="0.42408504119416385">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-04-24 02:05:55 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.0" STUDY_ID="STD-Carmassi-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.958812468804357" CI_END="1.6214921925933252" CI_START="0.9104990434320371" DF="3" EFFECT_SIZE="1.2150584719628679" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="77" I2="66.5134189330745" ID="CMP-003.05.02" LOG_CI_END="0.20991486190704903" LOG_CI_START="-0.04072050613749178" LOG_EFFECT_SIZE="0.08459717788477865" MODIFIED="2014-04-24 02:05:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.029843567986786113" P_Z="0.18580320167145445" STUDIES="4" TAU2="0.04736825353893258" TOTAL_1="111" TOTAL_2="111" WEIGHT="100.0" Z="1.3230967611756097">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1550240045005273" CI_START="0.8285492987103182" EFFECT_SIZE="0.9782608695652174" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="23" LOG_CI_END="0.06259101012754764" LOG_CI_START="-0.08168164594000839" LOG_EFFECT_SIZE="-0.009545317906230389" MODIFIED="2014-04-24 02:05:34 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.08474647233524778" STUDY_ID="STD-Kitano-1983" TOTAL_1="30" TOTAL_2="25" VAR="0.0071819645732689175" WEIGHT="39.73410400863102">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.802541548192909" CI_START="1.1336589990550048" EFFECT_SIZE="2.3333333333333335" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.6814711307586891" LOG_CI_START="0.05448243983049971" LOG_EFFECT_SIZE="0.36797678529459443" MODIFIED="2014-04-24 02:05:35 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.36829626069529353" STUDY_ID="STD-Vannini-1986" TOTAL_1="10" TOTAL_2="10" VAR="0.13564213564213562" WEIGHT="11.84361199308319">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4190200098931358" CI_START="0.9229636552481544" EFFECT_SIZE="1.1444229529335912" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="47" LOG_CI_END="0.1519885195765022" LOG_CI_START="-0.03481540042148628" LOG_EFFECT_SIZE="0.05858655957750794" MODIFIED="2014-04-24 02:05:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="280" O_E="0.0" SE="0.1097295473011357" STUDY_ID="STD-Tanaka-1988b" TOTAL_1="66" TOTAL_2="71" VAR="0.012040573550912178" WEIGHT="36.4845452492401">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.2219367376379133" CI_START="0.7664296217412432" EFFECT_SIZE="1.5714285714285714" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.508117008844064" LOG_CI_START="-0.11552771855612749" LOG_EFFECT_SIZE="0.1962946451439682" MODIFIED="2014-04-24 02:05:31 +0100" MODIFIED_BY="[Empty name]" ORDER="281" O_E="0.0" SE="0.3663319999660611" STUDY_ID="STD-Carmassi-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.13419913419913418" WEIGHT="11.937738749045685">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6676585117922782" CI_END="1.0657633046211594" CI_START="0.1501271429652706" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.02766076293539044" LOG_CI_START="-0.8235407802794655" LOG_EFFECT_SIZE="-0.3979400086720376" METHOD="MH" MODIFIED="2010-05-26 14:06:34 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.41386946959167503" P_Q="0.4140690558954907" P_Z="0.06686483681942848" Q="0.6670879180774953" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="20" TOTAL_2="20" WEIGHT="200.0" Z="1.83258146374831">
<NAME>Interferon inducer <I>versus</I> nucleoside antiviral</NAME>
<GROUP_LABEL_1>Interferon inducer</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral agent</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFN Inducer</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.171860056625685" CI_START="0.1401210761225251" DF="0" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="0.5013140178713021" LOG_CI_START="-0.8534965359826647" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-03-13 17:01:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.6104074515192484" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="0.5094919356210585">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="3.171860056625685" CI_START="0.1401210761225251" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5013140178713021" LOG_CI_START="-0.8534965359826647" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-03-13 17:01:46 +0000" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.7958224257542215" STUDY_ID="STD-Guerra-1979" TOTAL_1="10" TOTAL_2="10" VAR="0.6333333333333333" WEIGHT="100.0">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.052895839476776" CI_START="0.07753155630455415" DF="0" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.02238540957299151" LOG_CI_START="-1.110521498273543" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2010-03-13 17:01:54 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.05976692781426374" STUDIES="1" TAU2="0.0" TOTAL_1="10" TOTAL_2="10" WEIGHT="100.0" Z="1.8825090829265763">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.052895839476776" CI_START="0.07753155630455415" EFFECT_SIZE="0.2857142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.02238540957299151" LOG_CI_START="-1.110521498273543" LOG_EFFECT_SIZE="-0.5440680443502757" MODIFIED="2010-03-13 17:01:54 +0000" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Guerra-1979" TOTAL_1="10" TOTAL_2="10" VAR="0.44285714285714284" WEIGHT="100.0">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="269.72202761241243" CI_END="1.1499375384896307" CI_START="1.0163972762359323" CI_STUDY="95" CI_TOTAL="95" DF="20" EFFECT_MEASURE="RR" EFFECT_SIZE="1.081107479375808" ESTIMABLE="YES" EVENTS_1="602" EVENTS_2="378" I2="92.58495860458984" I2_Q="91.16970954777887" ID="CMP-003.07" LOG_CI_END="0.06067425128752841" LOG_CI_START="0.007063492547861857" LOG_EFFECT_SIZE="0.03386887191769511" METHOD="MH" MODIFIED="2014-12-11 14:57:25 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.1102230246251565E-15" P_Q="7.648510807548581E-4" P_Z="0.013270193159590105" Q="11.324655801649907" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.06968383343717265" TOTALS="SUB" TOTAL_1="648" TOTAL_2="545" WEIGHT="200.0" Z="2.476434608136469">
<NAME>Interferon/nucleoside antiviral <I>versus</I> nucleoside antiviral: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Antiviral/Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral/IFN</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="39.597947504600306" CI_END="2.5530890568630062" CI_START="1.346026184703036" DF="8" EFFECT_SIZE="1.8537865903108655" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="94" I2="79.79693265902078" ID="CMP-003.07.01" LOG_CI_END="0.4070659641303793" LOG_CI_START="0.1290535084477111" LOG_EFFECT_SIZE="0.2680597362890452" MODIFIED="2013-08-13 17:22:54 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.806178760279444E-6" P_Z="1.570828128660539E-4" STUDIES="9" TAU2="0.15650205735850906" TOTAL_1="262" TOTAL_2="213" WEIGHT="100.0" Z="3.779596331694766">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.5047679550300659" CI_START="0.9569581776289409" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="16" LOG_CI_END="0.17746953406956914" LOG_CI_START="-0.01910704197431953" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2013-08-13 17:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.11547005383792511" STUDY_ID="STD-Sundmacher-1981b" TOTAL_1="50" TOTAL_2="20" VAR="0.013333333333333322" WEIGHT="15.702742794760997">
<FOOTNOTE>Trifluridine; two interferon groups combined</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="45.20047353794635" CI_START="3.0596493615027605" EFFECT_SIZE="11.76" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.6551429846750947" LOG_CI_START="0.4856716588051446" LOG_EFFECT_SIZE="1.0704073217401198" MODIFIED="2013-08-13 17:21:30 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.6869532457924352" STUDY_ID="STD-de-Koning-1982" TOTAL_1="25" TOTAL_2="28" VAR="0.47190476190476194" WEIGHT="4.243877335081015">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6738863996918634" CI_START="1.020008154730261" EFFECT_SIZE="1.3066666666666666" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.2237259807414399" LOG_CI_START="0.008603643860149718" LOG_EFFECT_SIZE="0.1161648123007948" MODIFIED="2013-08-13 17:21:32 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.12636392555681145" STUDY_ID="STD-Colin-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.015967841682127386" WEIGHT="15.46288060882665">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.012287627609222" CI_START="1.6190842160142749" EFFECT_SIZE="3.12" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.7790397490431996" LOG_CI_START="0.2092694389936861" LOG_EFFECT_SIZE="0.4941545940184428" MODIFIED="2013-08-13 17:21:35 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.3346859005316059" STUDY_ID="STD-de-Koning-1983" TOTAL_1="25" TOTAL_2="26" VAR="0.112014652014652" WEIGHT="9.93190130963339">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.2767939762289915" CI_START="1.484962738065427" EFFECT_SIZE="2.2058823529411766" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="17" LOG_CI_END="0.5154491365915191" LOG_CI_START="0.1717155561073707" LOG_EFFECT_SIZE="0.34358234634944496" MODIFIED="2013-08-13 17:21:37 +0100" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.2019108066850538" STUDY_ID="STD-Meurs-1985" TOTAL_1="48" TOTAL_2="45" VAR="0.04076797385620916" WEIGHT="13.518938690585927">
<FOOTNOTE>Acyclovir; two interferon groups combined</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.933510460076539" CI_START="0.8591805434740052" EFFECT_SIZE="1.288888888888889" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="6" LOG_CI_END="0.28634652590028326" LOG_CI_START="-0.06591556632509606" LOG_EFFECT_SIZE="0.11021547978759363" MODIFIED="2013-08-13 17:21:39 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.20692049669866677" STUDY_ID="STD-Sundmacher-1987" TOTAL_1="30" TOTAL_2="8" VAR="0.04281609195402297" WEIGHT="13.380023177418035">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.8691072945404734" CI_START="1.3860770658890536" EFFECT_SIZE="2.3157894736842106" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.5876107733451171" LOG_CI_START="0.14178737772159988" LOG_EFFECT_SIZE="0.3646990755333585" MODIFIED="2013-08-13 17:21:41 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.2618788694506542" STUDY_ID="STD-van-Bijsterveld-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.06858054226475278" WEIGHT="11.848456797395771">
<FOOTNOTE>Brivudine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="83.6853278467926" CI_START="0.2987381497240339" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.922649321867425" LOG_CI_START="-0.5247093131953876" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2013-08-13 17:21:44 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="1.4375905768565218" STUDY_ID="STD-Carmassi-1993" TOTAL_1="5" TOTAL_2="5" VAR="2.066666666666667" WEIGHT="1.1995857213451633">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.1897415048200606" CI_START="1.1814917915752967" EFFECT_SIZE="1.6084656084656084" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" LOG_CI_END="0.3403928501569159" LOG_CI_START="0.07243070871410325" LOG_EFFECT_SIZE="0.20641177943550956" MODIFIED="2013-08-13 17:22:54 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="291" O_E="0.0" SE="0.15740228831750075" STUDY_ID="STD-Zhu-2012" TOTAL_1="36" TOTAL_2="38" VAR="0.02477548036758563" WEIGHT="14.711593564953043">
<FOOTNOTE>Ganciclovir; interferon administered by subconjunctival injection</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="33.631141523250726" CI_END="1.127566343450559" CI_START="0.9942735359936427" DF="11" EFFECT_SIZE="1.0588245252968074" ESTIMABLE="YES" EVENTS_1="367" EVENTS_2="284" I2="67.29221934856061" ID="CMP-003.07.02" LOG_CI_END="0.052142104205729976" LOG_CI_START="-0.0024941197976680596" LOG_EFFECT_SIZE="0.02482399220403098" MODIFIED="2014-12-11 14:57:25 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="4.154847880353252E-4" P_Z="0.07490902303954874" STUDIES="12" TAU2="0.006862732824504301" TOTAL_1="386" TOTAL_2="332" WEIGHT="100.0" Z="1.781020982320367">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.0748297496817238" CI_START="0.930379904627796" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="20" LOG_CI_END="0.031339678549933" LOG_CI_START="-0.03133967854993298" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-11 14:57:21 +0000" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.03681816462828284" STUDY_ID="STD-Sundmacher-1981b" TOTAL_1="50" TOTAL_2="20" VAR="0.001355577246595338" WEIGHT="12.532971007579537">
<FOOTNOTE>Trifluridine; two interferon groups combined</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2896659419879553" CI_START="0.9646551093060544" EFFECT_SIZE="1.1153846153846154" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.11047723096638948" LOG_CI_START="-0.015627931110113184" LOG_EFFECT_SIZE="0.047424649928138135" MODIFIED="2014-04-19 21:46:41 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.07407479643435741" STUDY_ID="STD-de-Koning-1982" TOTAL_1="25" TOTAL_2="28" VAR="0.005487075466791488" WEIGHT="8.340197630839787">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.088535173573273" CI_START="0.9186657668739877" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.03684246685619331" LOG_CI_START="-0.03684246685619328" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-06 15:07:28 +0000" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.04328289480896029" STUDY_ID="STD-Colin-1983" TOTAL_1="24" TOTAL_2="21" VAR="0.0018734089830435216" WEIGHT="11.790083554207104">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1547487353873038" CI_START="0.9338848650067656" EFFECT_SIZE="1.0384615384615385" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.062487495305147286" LOG_CI_START="-0.02970666292880851" LOG_EFFECT_SIZE="0.016390416188169384" MODIFIED="2014-12-06 15:07:30 +0000" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.054155304915069105" STUDY_ID="STD-de-Koning-1983" TOTAL_1="25" TOTAL_2="26" VAR="0.002932797050444108" WEIGHT="10.514984198640217">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.086637866726959" CI_START="0.9633899765862721" EFFECT_SIZE="1.023159825728044" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="44" LOG_CI_END="0.03608483508388172" LOG_CI_START="-0.016197876535096658" LOG_EFFECT_SIZE="0.009943479274392507" MODIFIED="2014-12-11 14:55:23 +0000" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.030711123608584318" STUDY_ID="STD-Meurs-1985" TOTAL_1="48" TOTAL_2="45" VAR="9.43173113301745E-4" WEIGHT="13.195116963110653">
<FOOTNOTE>Acyclovir; two interferon groups combined</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1790856197277915" CI_START="0.8481148300586213" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="8" LOG_CI_END="0.07154534269069393" LOG_CI_START="-0.0715453426906939" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-06 15:07:34 +0000" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.08405217690334332" STUDY_ID="STD-Sundmacher-1987" TOTAL_1="30" TOTAL_2="8" VAR="0.007064768442190922" WEIGHT="7.395428647254466">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1805375304119552" CI_START="0.8837637937410943" EFFECT_SIZE="1.0214285714285714" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="35" LOG_CI_END="0.07207979826923848" LOG_CI_START="-0.05366379469559102" LOG_EFFECT_SIZE="0.009208001786823752" MODIFIED="2014-12-11 14:57:22 +0000" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.07386240894836463" STUDY_ID="STD-Maichuk-1988" TOTAL_1="36" TOTAL_2="39" VAR="0.005455655455655455" WEIGHT="8.361470633157774">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0973879665090907" CI_START="0.9112547526661038" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="22" LOG_CI_END="0.04036019359711778" LOG_CI_START="-0.04036019359711779" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-06 15:07:39 +0000" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.047415555010254816" STUDY_ID="STD-van-Bijsterveld-1989" TOTAL_1="19" TOTAL_2="22" VAR="0.0022482348569305005" WEIGHT="11.3050386582175">
<FOOTNOTE>Brivudine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.0860393758160356" CI_START="0.5760709962774482" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.48940146307208326" LOG_CI_START="-0.23952398985548332" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2014-12-11 14:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.42817441928883754" STUDY_ID="STD-Carmassi-1993" TOTAL_1="5" TOTAL_2="5" VAR="0.18333333333333324" WEIGHT="0.5415455952012934">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.379335781676819" CI_START="1.0834152379109003" EFFECT_SIZE="1.6055555555555556" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="16" LOG_CI_END="0.37645573579050257" LOG_CI_START="0.034794939515981074" LOG_EFFECT_SIZE="0.2056253376532418" MODIFIED="2014-12-11 14:57:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="298" O_E="0.0" SE="0.2006932429798716" STUDY_ID="STD-Li-2009" TOTAL_1="45" TOTAL_2="34" VAR="0.04027777777777778" WEIGHT="2.184953886507213">
<FOOTNOTE>Acyclovir; interferon administered by subconjunctival and intramuscular injection</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4011702872621687" CI_START="1.0194410507209606" EFFECT_SIZE="1.1951612903225806" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="31" LOG_CI_END="0.1464909192430705" LOG_CI_START="0.008362117719077963" LOG_EFFECT_SIZE="0.07742651848107426" MODIFIED="2014-12-11 14:57:24 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="299" O_E="0.0" SE="0.08113754176378812" STUDY_ID="STD-Fu-2012" TOTAL_1="40" TOTAL_2="38" VAR="0.006583300683470461" WEIGHT="7.660239861168137">
<FOOTNOTE>Ganciclovir; interferon administered by subconjunctival injection</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5164280410718467" CI_START="1.0285177951876454" EFFECT_SIZE="1.248868778280543" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="34" LOG_CI_END="0.18082180659729682" LOG_CI_START="0.012211810162917178" LOG_EFFECT_SIZE="0.09651680838010701" MODIFIED="2014-12-11 14:57:25 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="300" O_E="0.0" SE="0.09904234653849776" STUDY_ID="STD-Li-2013b" TOTAL_1="39" TOTAL_2="46" VAR="0.00980938640785188" WEIGHT="6.1779693641163025">
<FOOTNOTE>Ganciclovir; outcome assessed at 15 days</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="9.644242599451944" CI_END="3.7910902701518103" CI_START="2.1326692223052155" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="2.8434383302849264" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="98" I2="58.52447759632976" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.5787641255928984" LOG_CI_START="0.3289235014562413" LOG_EFFECT_SIZE="0.4538438135245699" MODIFIED="2010-09-16 18:40:20 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.04686633507300719" P_Q="1.0" P_Z="1.0739611555895204E-12" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="100" WEIGHT="100.0" Z="7.120679690808998">
<NAME>Interferon/nucleoside antiviral <I>versus</I> nucleoside antiviral: healing rate</NAME>
<GROUP_LABEL_1>Antiviral/Interferon</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral/IFN</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="2.8154903980476584" CI_START="1.0905077398602248" EFFECT_SIZE="1.7522311692733685" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="20" LOG_CI_END="0.44955405056105235" LOG_CI_START="0.037628752323391815" LOG_EFFECT_SIZE="0.24359140144222205" MODIFIED="2010-09-16 18:40:20 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="9.58" SE="0.24196695924791364" STUDY_ID="STD-Sundmacher-1981b" TOTAL_1="50" TOTAL_2="20" VAR="17.08" WEIGHT="36.786560413525734">
<FOOTNOTE>Trifluridine; two interferon groups combined</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="11.213317878069418" CI_START="2.890318580104921" EFFECT_SIZE="5.692983489138777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="27" LOG_CI_END="1.0497341338205588" LOG_CI_START="0.4609457147137191" LOG_EFFECT_SIZE="0.7553399242671389" MODIFIED="2010-09-16 18:39:12 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="14.54" SE="0.34585723193303736" STUDY_ID="STD-de-Koning-1982" TOTAL_1="25" TOTAL_2="28" VAR="8.36" WEIGHT="18.00559982769761">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="5.156772515519747" CI_START="1.465719359418674" EFFECT_SIZE="2.7492510449421363" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="21" LOG_CI_END="0.7123779734789324" LOG_CI_START="0.1660508241091073" LOG_EFFECT_SIZE="0.43921439879401986" MODIFIED="2010-09-16 18:39:09 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="9.82" SE="0.32091527190284" STUDY_ID="STD-Colin-1983" TOTAL_1="24" TOTAL_2="21" VAR="9.71" WEIGHT="20.91320267068706">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="7.990685756402372" CI_START="2.1851394617416195" EFFECT_SIZE="4.178607755304571" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="26" LOG_CI_END="0.9025840518348585" LOG_CI_START="0.3394791600853825" LOG_EFFECT_SIZE="0.6210316059601205" MODIFIED="2010-09-16 18:39:06 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="13.07" SE="0.33077060082781123" STUDY_ID="STD-de-Koning-1983" TOTAL_1="25" TOTAL_2="26" VAR="9.14" WEIGHT="19.6855481369804">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="7.732337993181007" CI_START="0.5303615577037453" EFFECT_SIZE="2.0250764980008364" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.8883108294958326" LOG_CI_START="-0.27542796251086993" LOG_EFFECT_SIZE="0.30644143349248143" MODIFIED="2010-09-16 18:39:03 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="1.51" SE="0.6835859270246633" STUDY_ID="STD-Carmassi-1993" TOTAL_1="5" TOTAL_2="5" VAR="2.14" WEIGHT="4.6090889511091975">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-01-09 10:48:50 +0000" MODIFIED_BY="Anupa Shah" NO="4">
<NAME>Debridement</NAME>
<DICH_OUTCOME CHI2="0.8485525074923786" CI_END="1.5890470961011256" CI_START="0.9213697967746236" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.21" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.20113676899701702" LOG_CI_START="-0.035566028364116896" LOG_EFFECT_SIZE="0.08278537031645007" METHOD="MH" MODIFIED="2014-10-14 16:32:17 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6542431377053599" P_Q="0.5179203245884889" P_Z="0.17038397309134168" Q="0.41803273387052214" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="103" TOTAL_2="57" WEIGHT="200.0" Z="1.3709710749172208">
<NAME>Debridement <I>versus</I> control</NAME>
<GROUP_LABEL_1>Physical methods</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débridement</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.2617744767776914" CI_END="2.110541926494087" CI_START="0.8236427705024923" DF="1" EFFECT_SIZE="1.3184584178498984" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="15" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.32439398395508856" LOG_CI_START="-0.0842611092238376" LOG_EFFECT_SIZE="0.12006643736562549" MODIFIED="2010-03-19 23:06:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6089037213718972" P_Z="0.2494406547936303" STUDIES="2" TAU2="0.0" TOTAL_1="64" TOTAL_2="41" WEIGHT="99.99999999999999" Z="1.1517090911950276">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="3.027071320549603" CI_START="0.7432926950632548" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.48102265344955175" LOG_CI_START="-0.12884013533818925" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2010-03-19 23:04:36 +0000" MODIFIED_BY="[Empty name]" ORDER="1" O_E="0.0" SE="0.35823642100341124" STUDY_ID="STD-Davidson-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.1283333333333333" WEIGHT="44.62474645030425">
<FOOTNOTE>Débridement <I>vs</I>. gamma-globulin</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.210217647551737" CI_START="0.6216409569637604" EFFECT_SIZE="1.1721611721611722" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" LOG_CI_END="0.3444350422265412" LOG_CI_START="-0.20646037966824127" LOG_EFFECT_SIZE="0.06898733127914997" MODIFIED="2010-03-19 23:06:42 +0000" MODIFIED_BY="[Empty name]" ORDER="65211" O_E="0.0" SE="0.32359869779731376" STUDY_ID="STD-Sundmacher-1976a" TOTAL_1="39" TOTAL_2="16" VAR="0.1047161172161172" WEIGHT="55.375253549695735">
<FOOTNOTE>Débridement/placebo or low-dose interferon-&#945; <I>vs</I>. low-dose interferon-&#945;</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4299177801776655" CI_START="0.8531965073658739" DF="0" EFFECT_SIZE="1.1045364891518739" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.1553110663869418" LOG_CI_START="-0.06895093104121282" LOG_EFFECT_SIZE="0.043180067672864475" MODIFIED="2010-03-19 23:06:50 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.45039629652465174" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="16" WEIGHT="100.0" Z="0.7547545144462511">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.4299177801776655" CI_START="0.8531965073658739" EFFECT_SIZE="1.1045364891518739" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="13" LOG_CI_END="0.1553110663869418" LOG_CI_START="-0.06895093104121282" LOG_EFFECT_SIZE="0.043180067672864475" MODIFIED="2010-03-19 23:06:50 +0000" MODIFIED_BY="[Empty name]" ORDER="65212" O_E="0.0" SE="0.131732607404089" STUDY_ID="STD-Sundmacher-1976a" TOTAL_1="39" TOTAL_2="16" VAR="0.017353479853479847" WEIGHT="100.0">
<FOOTNOTE>Débridement/placebo or low-dose interferon-&#945; <I>vs</I>. low-dose interferon-&#945;</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="37.79384755272053" CI_END="1.1534352586764922" CI_START="0.7915255464628067" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9554964539093692" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="182" I2="65.60286702256062" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.06199322296754002" LOG_CI_START="-0.10153506373430145" LOG_EFFECT_SIZE="-0.019770920383380707" METHOD="MH" MODIFIED="2014-10-14 16:35:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="3.10753949014253E-4" P_Q="0.8442745474356895" P_Z="0.6355514714856616" Q="0.03858432026063531" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.062222287156889516" TOTALS="SUB" TOTAL_1="413" TOTAL_2="276" WEIGHT="200.0" Z="0.47392769378533073">
<NAME>Topical antiviral agent <I>versus</I> debridement</NAME>
<GROUP_LABEL_1>Antiviral agent</GROUP_LABEL_1>
<GROUP_LABEL_2>Physicochemical</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Débridement</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.704999369350253" CI_END="1.1983117692412675" CI_START="0.7391044732759777" DF="6" EFFECT_SIZE="0.9411044517084551" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="98" I2="52.77449588486799" ID="CMP-004.02.01" LOG_CI_END="0.07856982476937316" LOG_CI_START="-0.13129416923655707" LOG_EFFECT_SIZE="-0.02636217223359196" MODIFIED="2010-03-09 23:26:33 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.047967311994926654" P_Z="0.6224339552421223" STUDIES="7" TAU2="0.044589512150287336" TOTAL_1="212" TOTAL_2="160" WEIGHT="99.99999999999999" Z="0.49240374345131405">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.780684380677381" CI_START="0.5615818338450271" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2505869492907612" LOG_CI_START="-0.25058694929076114" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-09 23:26:25 +0000" MODIFIED_BY="[Empty name]" ORDER="223" O_E="0.0" SE="0.29439202887759486" STUDY_ID="STD-Davidson-1964" TOTAL_1="25" TOTAL_2="25" VAR="0.08666666666666664" WEIGHT="11.577940542581349">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1597635292735695" CI_START="0.8045160189295748" EFFECT_SIZE="0.9659442724458205" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" LOG_CI_END="0.06436944750214338" LOG_CI_START="-0.0944653041274635" LOG_EFFECT_SIZE="-0.015047928312660075" MODIFIED="2010-03-09 23:26:25 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.09330031935193203" STUDY_ID="STD-Patterson-1967a" TOTAL_1="38" TOTAL_2="39" VAR="0.008704949591172503" WEIGHT="28.514712120770014">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2919431924646592" CI_START="0.8296292873294597" EFFECT_SIZE="1.035294117647059" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.11124341788389114" LOG_CI_START="-0.08111592501213931" LOG_EFFECT_SIZE="0.015063746435875934" MODIFIED="2010-03-09 23:26:23 +0000" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.11299283021123238" STUDY_ID="STD-Patterson-1967b" TOTAL_1="17" TOTAL_2="11" VAR="0.012767379679144389" WEIGHT="26.49509388877523">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.6889917315908005" CI_START="0.18330876708848645" EFFECT_SIZE="0.3553846153846154" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="25" LOG_CI_END="-0.16178598991535856" LOG_CI_START="-0.7368167635860638" LOG_EFFECT_SIZE="-0.44930137675071125" MODIFIED="2010-03-09 23:26:21 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.33777592290240893" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="26" TOTAL_2="33" VAR="0.11409257409257409" WEIGHT="9.576860691529278">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8660788007350742" CI_START="0.5150740584263471" EFFECT_SIZE="0.9803921568627451" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.27092997917566025" LOG_CI_START="-0.2881303226994954" LOG_EFFECT_SIZE="-0.00860017176191758" MODIFIED="2010-03-09 23:26:33 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="0.32839478871459266" STUDY_ID="STD-Kato-1979" TOTAL_1="17" TOTAL_2="10" VAR="0.10784313725490194" WEIGHT="9.969493019501268">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="4.944755929140809" CI_START="0.7337304339837483" EFFECT_SIZE="1.9047619047619047" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.6941448598880378" LOG_CI_START="-0.13446346669995166" LOG_EFFECT_SIZE="0.2798406965940431" MODIFIED="2010-03-09 23:26:33 +0000" MODIFIED_BY="[Empty name]" ORDER="228" O_E="0.0" SE="0.48672863271515265" STUDY_ID="STD-Parlato-1985" TOTAL_1="14" TOTAL_2="8" VAR="0.23690476190476195" WEIGHT="5.398604427356591">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.211572412203943" CI_START="0.5241569775035759" EFFECT_SIZE="1.0766666666666667" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" LOG_CI_END="0.3447011637850908" LOG_CI_START="-0.2805386285622099" LOG_EFFECT_SIZE="0.03208126761144045" MODIFIED="2010-03-09 23:25:37 +0000" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.3672689490116919" STUDY_ID="STD-Struck-1989" TOTAL_1="75" TOTAL_2="34" VAR="0.13488648090815272" WEIGHT="8.467295309486262">
<FOOTNOTE>Idoxuridine or trifluridine or brivudine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="28.30037825592412" CI_END="1.320904907986367" CI_START="0.7243723032123714" DF="6" EFFECT_SIZE="0.9781753066412023" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="84" I2="78.79886994533715" ID="CMP-004.02.02" LOG_CI_END="0.1208715538573141" LOG_CI_START="-0.14003816353742435" LOG_EFFECT_SIZE="-0.009583304840055132" MODIFIED="2013-11-28 22:11:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.247948687056805E-5" P_Z="0.8855160098701824" STUDIES="7" TAU2="0.12064920154806329" TOTAL_1="201" TOTAL_2="116" WEIGHT="100.0" Z="0.1439803202956918">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="0.7338781755200987" CI_START="0.43994776561997545" EFFECT_SIZE="0.5682148040638607" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="26" LOG_CI_END="-0.13437602740069143" LOG_CI_START="-0.3565988836266358" LOG_EFFECT_SIZE="-0.24548745551366358" MODIFIED="2013-11-28 22:11:15 +0000" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.13053480576799892" STUDY_ID="STD-MacKenzie-1964" TOTAL_1="53" TOTAL_2="27" VAR="0.0170393355168892" WEIGHT="17.059171182562835">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1972675637876868" CI_START="0.698188435592809" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.078191216815187" LOG_CI_START="-0.15602734887592634" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2010-03-09 23:26:52 +0000" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.13758114488755874" STUDY_ID="STD-Austin-1974" TOTAL_1="25" TOTAL_2="16" VAR="0.018928571428571433" WEIGHT="16.828269097407578">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4404611365548352" CI_START="0.7164358400166048" EFFECT_SIZE="1.0158730158730158" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.15850154556855514" LOG_CI_START="-0.1448226965079443" LOG_EFFECT_SIZE="0.006839424530305442" MODIFIED="2013-11-28 22:11:16 +0000" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="0.1781741612749496" STUDY_ID="STD-O_x0027_Day-1975" TOTAL_1="9" TOTAL_2="8" VAR="0.031746031746031744" WEIGHT="15.412898900419117">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.6054279508461604" CI_START="0.5921318359375526" EFFECT_SIZE="0.975" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.20559081986697855" LOG_CI_START="-0.22758158846990498" LOG_EFFECT_SIZE="-0.010995384301463193" MODIFIED="2013-11-28 22:11:17 +0000" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.2544476168950885" STUDY_ID="STD-Bartholomew-1977" TOTAL_1="8" TOTAL_2="13" VAR="0.06474358974358974" WEIGHT="12.66959900276028">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.05664023192764" CI_START="0.5842546215084746" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.02392714257231981" LOG_CI_START="-0.2333978436123458" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2013-11-28 22:11:17 +0000" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.15115397066409747" STUDY_ID="STD-Kato-1979" TOTAL_1="17" TOTAL_2="10" VAR="0.02284752284752284" WEIGHT="16.368682515654143">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.668448623911123" CI_START="1.0900293749051997" EFFECT_SIZE="2.4857142857142858" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="3" LOG_CI_END="0.7534642147544697" LOG_CI_START="0.03743820178221612" LOG_EFFECT_SIZE="0.3954512082683429" MODIFIED="2010-03-09 23:27:20 +0000" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.42059722440582903" STUDY_ID="STD-Parlato-1985" TOTAL_1="14" TOTAL_2="8" VAR="0.17690202517788728" WEIGHT="7.893942664975139">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.358554466050965" CI_START="0.9820396932306164" EFFECT_SIZE="1.5219047619047619" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="14" LOG_CI_END="0.3726459098512814" LOG_CI_START="-0.007870958035212322" LOG_EFFECT_SIZE="0.1823874759080345" MODIFIED="2013-11-28 22:11:18 +0000" MODIFIED_BY="[Empty name]" ORDER="236" O_E="0.0" SE="0.22351749178540053" STUDY_ID="STD-Struck-1989" TOTAL_1="75" TOTAL_2="34" VAR="0.04996006913403659" WEIGHT="13.767436636220912">
<FOOTNOTE>Idoxuridine or trifluridine or brivudine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.31628817103983" CI_END="1.106107349007103" CI_START="0.952805735984539" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0265989610108808" ESTIMABLE="YES" EVENTS_1="175" EVENTS_2="177" I2="47.768023749210535" I2_Q="44.05875423289834" ID="CMP-004.03" LOG_CI_END="0.04379727779963268" LOG_CI_START="-0.020995637021778493" LOG_EFFECT_SIZE="0.011400820388927063" METHOD="MH" MODIFIED="2015-01-09 10:48:50 +0000" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="0.05327950237351464" P_Q="0.07425630847703035" P_Z="0.49035645268675576" Q="14.300718352440942" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="198" TOTAL_2="203" WEIGHT="900.0" Z="0.689742000899237">
<NAME>Different debridement methods</NAME>
<GROUP_LABEL_1>Débride method 1</GROUP_LABEL_1>
<GROUP_LABEL_2>Débride method 2</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Débride Method 2</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débride Method 1</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3102347136392303" CI_START="0.9500278768278028" DF="0" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.36365610528609105" LOG_CI_START="-0.022263650948140937" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2015-01-09 10:46:51 +0000" MODIFIED_BY="Anupa Shah" NO="1" P_CHI2="1.0" P_Z="0.08294932527132648" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="15" WEIGHT="100.0" Z="1.7338239473026618">
<NAME>Healing at 7 days: cryotherapy <I>versus</I> carbolisation</NAME>
<DICH_DATA CI_END="2.3102347136392303" CI_START="0.9500278768278028" EFFECT_SIZE="1.4814814814814814" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.36365610528609105" LOG_CI_START="-0.022263650948140937" LOG_EFFECT_SIZE="0.17069622716897506" MODIFIED="2013-09-27 16:51:19 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="273" O_E="0.0" SE="0.22669117514559073" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="18" TOTAL_2="15" VAR="0.05138888888888889" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.073249229373591" CI_START="0.9931014204087316" DF="0" EFFECT_SIZE="1.4349030470914128" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" I2="0.0" ID="CMP-004.03.02" LOG_CI_END="0.31665151262719893" LOG_CI_START="-0.003006396948048662" LOG_EFFECT_SIZE="0.15682255783957513" MODIFIED="2015-01-09 10:47:09 +0000" MODIFIED_BY="Anupa Shah" NO="2" P_CHI2="1.0" P_Z="0.05446788329688121" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="13" WEIGHT="100.00000000000001" Z="1.9230968865274556">
<NAME>Healing at 7 days: cryotherapy/idoxuridine <I>versus</I> carbolisation/idoxuridine</NAME>
<DICH_DATA CI_END="2.073249229373591" CI_START="0.9931014204087315" EFFECT_SIZE="1.4349030470914128" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="9" LOG_CI_END="0.31665151262719893" LOG_CI_START="-0.0030063969480487104" LOG_EFFECT_SIZE="0.15682255783957513" MODIFIED="2013-09-27 16:51:58 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="271" O_E="0.0" SE="0.18776863841667238" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="18" TOTAL_2="13" VAR="0.03525706157285105" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1332504038700526" CI_START="0.8570255341136186" DF="0" EFFECT_SIZE="0.9855072463768116" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" I2="0.0" ID="CMP-004.03.03" LOG_CI_END="0.05432588250549179" LOG_CI_START="-0.0670062385675297" LOG_EFFECT_SIZE="-0.006340178031018977" MODIFIED="2015-01-09 10:47:22 +0000" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="1.0" P_Z="0.8377011942644578" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="24" WEIGHT="100.0" Z="0.20483480361957243">
<NAME>Healing at 7 days: thermocautery/interferon <I>versus</I> wiping/interferon</NAME>
<DICH_DATA CI_END="1.1332504038700526" CI_START="0.8570255341136185" EFFECT_SIZE="0.9855072463768116" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.05432588250549179" LOG_CI_START="-0.06700623856752976" LOG_EFFECT_SIZE="-0.006340178031018977" MODIFIED="2010-02-15 18:56:44 +0000" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.07127108852197857" STUDY_ID="STD-Sundmacher-1978a" TOTAL_1="18" TOTAL_2="24" VAR="0.005079568059107704" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.120919563972433" CI_START="0.6590547413632515" DF="0" EFFECT_SIZE="0.859504132231405" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" I2="0.0" ID="CMP-004.03.04" LOG_CI_END="0.049574449190634355" LOG_CI_START="-0.18107851122597382" LOG_EFFECT_SIZE="-0.06575203101766972" MODIFIED="2015-01-09 10:47:42 +0000" MODIFIED_BY="Anupa Shah" NO="4" P_CHI2="1.0" P_Z="0.2638018462732763" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="99.99999999999999" Z="1.1174503242639824">
<NAME>Healing at 7 days: iodinisation/panthenol <I>versus</I> cryotherapy/panthenol</NAME>
<DICH_DATA CI_END="1.1209195639724332" CI_START="0.6590547413632515" EFFECT_SIZE="0.859504132231405" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.04957444919063444" LOG_CI_START="-0.18107851122597382" LOG_EFFECT_SIZE="-0.06575203101766972" MODIFIED="2013-09-25 20:11:53 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="278" O_E="0.0" SE="0.13548669069928368" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="33" TOTAL_2="26" VAR="0.01835664335664336" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4618698604317377" CI_START="0.9242668588702802" DF="0" EFFECT_SIZE="1.1623931623931625" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" I2="0.0" ID="CMP-004.03.05" LOG_CI_END="0.16490871228529538" LOG_CI_START="-0.034202619037183545" LOG_EFFECT_SIZE="0.0653530466240559" MODIFIED="2015-01-09 10:47:59 +0000" MODIFIED_BY="Anupa Shah" NO="5" P_CHI2="1.0" P_Z="0.1982291962631059" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="34" WEIGHT="100.0" Z="1.286613040175637">
<NAME>Healing at 7 days: iodinisation/fluorophenylalanine <I>versus</I> cryotherapy/fluorophenylalanine</NAME>
<DICH_DATA CI_END="1.4618698604317375" CI_START="0.9242668588702802" EFFECT_SIZE="1.1623931623931625" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="26" LOG_CI_END="0.1649087122852953" LOG_CI_START="-0.034202619037183545" LOG_EFFECT_SIZE="0.0653530466240559" MODIFIED="2013-09-25 20:13:08 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="279" O_E="0.0" SE="0.11695898163580996" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="27" TOTAL_2="34" VAR="0.013679403385285734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.097173809993527" CI_START="0.9114326197832772" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" I2="0.0" ID="CMP-004.03.06" LOG_CI_END="0.04027543226183532" LOG_CI_START="-0.04027543226183533" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-01-09 10:48:09 +0000" MODIFIED_BY="Anupa Shah" NO="6" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="24" WEIGHT="99.99999999999999" Z="0.0">
<NAME>Healing at 14 days: thermocautery/interferon <I>versus</I> wiping/interferon</NAME>
<DICH_DATA CI_END="1.097173809993527" CI_START="0.9114326197832773" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.04027543226183532" LOG_CI_START="-0.04027543226183528" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-15 18:56:44 +0000" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.047315976554414184" STUDY_ID="STD-Sundmacher-1978a" TOTAL_1="18" TOTAL_2="24" VAR="0.002238801637297873" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9987242203307625" CI_START="0.7303349499753646" DF="0" EFFECT_SIZE="0.8540510543840177" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" I2="0.0" ID="CMP-004.03.07" LOG_CI_END="-5.544178032011868E-4" LOG_CI_START="-0.13647791581992974" LOG_EFFECT_SIZE="-0.06851616681156547" MODIFIED="2015-01-09 10:48:28 +0000" MODIFIED_BY="Anupa Shah" NO="7" P_CHI2="1.0" P_Z="0.04816010483261185" STUDIES="1" TAU2="0.0" TOTAL_1="33" TOTAL_2="26" WEIGHT="100.0" Z="1.9759529627891048">
<NAME>Healing at 14 days: iodinisation/panthenol <I>versus </I>cryotherapy/panthenol</NAME>
<DICH_DATA CI_END="0.9987242203307624" CI_START="0.7303349499753646" EFFECT_SIZE="0.8540510543840177" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="-5.544178032012351E-4" LOG_CI_START="-0.13647791581992974" LOG_EFFECT_SIZE="-0.06851616681156547" MODIFIED="2013-09-25 20:14:47 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="280" O_E="0.0" SE="0.07984213556719277" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="33" TOTAL_2="26" VAR="0.00637476661192999" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1443515705612004" CI_START="0.9147819254056766" DF="0" EFFECT_SIZE="1.0231481481481481" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" I2="0.0" ID="CMP-004.03.08" LOG_CI_END="0.058559469997362494" LOG_CI_START="-0.0386824249290029" LOG_EFFECT_SIZE="0.009938522534179796" MODIFIED="2015-01-09 10:48:38 +0000" MODIFIED_BY="Anupa Shah" NO="8" P_CHI2="1.0" P_Z="0.6886904955068635" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="34" WEIGHT="100.0" Z="0.4006327980605965">
<NAME>Healing at 14 days: iodinisation/fluorophenylalanine <I>versus</I> cryotherapy/fluorophenylalanine</NAME>
<DICH_DATA CI_END="1.1443515705612006" CI_START="0.9147819254056765" EFFECT_SIZE="1.0231481481481481" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="32" LOG_CI_END="0.05855946999736258" LOG_CI_START="-0.03868242492900295" LOG_EFFECT_SIZE="0.009938522534179796" MODIFIED="2013-09-25 20:16:02 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="281" O_E="0.0" SE="0.05712037043489018" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="27" TOTAL_2="34" VAR="0.003262736718619076" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4773270094878521" CI_START="0.4094816298083208" DF="0" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" I2="0.0" ID="CMP-004.03.09" LOG_CI_END="0.16947663796388213" LOG_CI_START="-0.3877655768140182" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2015-01-09 10:48:50 +0000" MODIFIED_BY="Anupa Shah" NO="9" P_CHI2="1.0" P_Z="0.44261893849956635" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="7" WEIGHT="100.0" Z="0.767778260554535">
<NAME>Healing at 14 days: photoinactivation <I>versus</I> carbolisation</NAME>
<DICH_DATA CI_END="1.477327009487852" CI_START="0.40948162980832087" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.16947663796388207" LOG_CI_START="-0.38776557681401813" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2013-09-25 19:37:11 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="276" O_E="0.0" SE="0.32732683535398854" STUDY_ID="STD-Bartholomew-1977" TOTAL_1="6" TOTAL_2="7" VAR="0.10714285714285712" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="38.04277211302071" CI_END="1.36339164368121" CI_START="0.961583013499644" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1449953036197182" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="140" I2="73.71379780029923" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.1346206278505986" LOG_CI_START="-0.017013217147211532" LOG_EFFECT_SIZE="0.05880370535169354" METHOD="MH" MODIFIED="2014-10-14 16:35:31 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="3.730665860790516E-5" P_Q="0.6870456965860745" P_Z="0.12847311512832052" Q="0.16230246952799615" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.028500237504576028" TOTALS="SUB" TOTAL_1="255" TOTAL_2="191" WEIGHT="200.0" Z="1.5201506582978097">
<NAME>Debridement with antiviral or interferon <I>versus</I> debridement</NAME>
<GROUP_LABEL_1>Physical/antiviral</GROUP_LABEL_1>
<GROUP_LABEL_2>Physical method</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Débridement</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débride/Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="21.476142101756267" CI_END="1.3621790707224788" CI_START="0.9351669092083047" DF="7" EFFECT_SIZE="1.128656188285778" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="105" I2="67.40569154910017" ID="CMP-004.04.01" LOG_CI_END="0.1342342032556744" LOG_CI_START="-0.029110869043065035" LOG_EFFECT_SIZE="0.05256166710630472" MODIFIED="2013-09-27 16:48:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0031257927999843726" P_Z="0.20717697416257586" STUDIES="8" TAU2="0.038014023228079424" TOTAL_1="199" TOTAL_2="148" WEIGHT="99.99999999999999" Z="1.2613661746383258">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.4554228022043114" CI_START="0.90816095953185" EFFECT_SIZE="1.1496774193548387" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="25" LOG_CI_END="0.16298917475880983" LOG_CI_START="-0.041837171697680905" LOG_EFFECT_SIZE="0.06057600153056449" MODIFIED="2013-09-27 16:48:40 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.12031600981530972" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="31" TOTAL_2="33" VAR="0.014475942217877708" WEIGHT="17.539248934603542">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5968374464185637" CI_START="0.9432383681166708" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.20326070842617652" LOG_CI_START="-0.025378541752614427" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2010-05-26 00:11:12 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.13430382733756335" STUDY_ID="STD-Sundmacher-1976a" TOTAL_1="22" TOTAL_2="18" VAR="0.018037518037518033" WEIGHT="16.424786004777264">
<FOOTNOTE>Interferon-&#945;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4306375401885152" CI_START="0.7137300833548526" EFFECT_SIZE="1.0104895104895104" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="13" LOG_CI_END="0.15552961682389915" LOG_CI_START="-0.14646599756888962" LOG_EFFECT_SIZE="0.004531809627504818" MODIFIED="2010-05-26 00:11:31 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.17739371879672483" STUDY_ID="STD-Sundmacher-1976b" TOTAL_1="22" TOTAL_2="17" VAR="0.031468531468531485" WEIGHT="13.249866452741198">
<FOOTNOTE>Interferon-&#945;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0678369538792396" CI_START="0.9364725545104977" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="22" LOG_CI_END="0.028504946104339565" LOG_CI_START="-0.028504946104339547" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 00:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.033487892886895874" STUDY_ID="STD-Coster-1977a" TOTAL_1="56" TOTAL_2="22" VAR="0.0011214389700042113" WEIGHT="23.524305548394967">
<FOOTNOTE>Interferon-&#945;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.1416418262738324" CI_START="0.8636364761413231" EFFECT_SIZE="1.36" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.3307468400347514" LOG_CI_START="-0.06366902329431634" LOG_EFFECT_SIZE="0.13353890837021754" MODIFIED="2010-05-26 00:11:37 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.23168183050950564" STUDY_ID="STD-Uchida-1981" TOTAL_1="20" TOTAL_2="17" VAR="0.0536764705882353" WEIGHT="10.040676325396445">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="8.284914975413653" CI_START="0.9462981845035238" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.9182880557972201" LOG_CI_START="-0.023971993112781843" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2010-05-26 00:11:41 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.5534882169922015" STUDY_ID="STD-Hung-1984" TOTAL_1="15" TOTAL_2="14" VAR="0.30634920634920637" WEIGHT="2.673440400868239">
<FOOTNOTE>Oral acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3468134459558745" CI_START="0.6915420867668596" EFFECT_SIZE="0.9650793650793651" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.12930744353079013" LOG_CI_START="-0.16018138389248363" LOG_EFFECT_SIZE="-0.015436970180846762" MODIFIED="2010-05-26 00:11:41 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.17004717022123778" STUDY_ID="STD-Yamazaki-1984a" TOTAL_1="21" TOTAL_2="19" VAR="0.028916040100250617" WEIGHT="13.755172559887534">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="3.8427321177945166" CI_START="0.4626338040961618" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.5846401102466411" LOG_CI_START="-0.3347626370300412" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2010-05-26 00:11:25 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.5400617248673217" STUDY_ID="STD-Parlato-1985" TOTAL_1="12" TOTAL_2="8" VAR="0.2916666666666667" WEIGHT="2.792503773330802">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.743865906473808" CI_END="2.0027071597815302" CI_START="0.7830783710019682" DF="2" EFFECT_SIZE="1.2523085323815768" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="35" I2="89.32984257367508" ID="CMP-004.04.02" LOG_CI_END="0.3016174504474977" LOG_CI_START="-0.10619477128757154" LOG_EFFECT_SIZE="0.09771133957996303" MODIFIED="2013-11-28 22:13:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="8.507920825717719E-5" P_Z="0.34762282604850947" STUDIES="3" TAU2="0.13251310062073043" TOTAL_1="56" TOTAL_2="43" WEIGHT="100.0" Z="0.9392102357457229">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.4708352670618612" CI_START="0.9134209422520496" EFFECT_SIZE="1.1590909090909092" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.1675640346498667" LOG_CI_START="-0.03932903542636876" LOG_EFFECT_SIZE="0.06411749961174897" MODIFIED="2013-11-28 22:13:51 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.12153001349999465" STUDY_ID="STD-Sundmacher-1976a" TOTAL_1="22" TOTAL_2="17" VAR="0.01476954418130888" WEIGHT="38.962256735754266">
<FOOTNOTE>Interferon-&#945;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1005291344024701" CI_START="0.908653818186238" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.041601544156739834" LOG_CI_START="-0.041601544156739834" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-11-28 22:08:43 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.048873905937267544" STUDY_ID="STD-Sundmacher-1976b" TOTAL_1="22" TOTAL_2="18" VAR="0.002388658681564876" WEIGHT="42.53809771775394">
<FOOTNOTE>Interferon-&#945;</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="5.648597079159474" CI_START="1.0822850376350053" EFFECT_SIZE="2.4725274725274726" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.751940597122852" LOG_CI_START="0.03434165445768579" LOG_EFFECT_SIZE="0.3931411257902689" MODIFIED="2010-05-26 00:11:57 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.4215211710935735" STUDY_ID="STD-Parlato-1985" TOTAL_1="12" TOTAL_2="8" VAR="0.17768009768009768" WEIGHT="18.49964554649179">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.093851126516857" CI_END="1.3659389985775714" CI_START="0.8943109872139061" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1052485034108313" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" I2="52.241112687724346" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.1354313046363587" LOG_CI_START="-0.04851143361418437" LOG_EFFECT_SIZE="0.04345993551108718" METHOD="MH" MODIFIED="2014-10-14 16:35:41 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.14789289919669757" P_Q="0.33587713646894446" P_Z="0.3543645132647105" Q="0.9261053781756962" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="26" TOTAL_2="24" WEIGHT="200.0" Z="0.9261567940360129">
<NAME>Debridement with different antivirals</NAME>
<GROUP_LABEL_1>Acyclovir/debride</GROUP_LABEL_1>
<GROUP_LABEL_2>IDU/debride</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Débride/IDU</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débride/Acyclovir</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.015329300648402" CI_START="0.7993466601432491" DF="0" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="0.30434601909737646" LOG_CI_START="-0.09726483528323744" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-08-28 00:40:19 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.31220347938693727" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="1.0106092943568186">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="2.015329300648402" CI_START="0.7993466601432491" EFFECT_SIZE="1.2692307692307692" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.30434601909737646" LOG_CI_START="-0.09726483528323744" LOG_EFFECT_SIZE="0.10354059190706949" MODIFIED="2013-08-28 00:40:19 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.23590820386896394" STUDY_ID="STD-Serifoglu-1987" TOTAL_1="13" TOTAL_2="12" VAR="0.055652680652680656" WEIGHT="100.0">
<FOOTNOTE>Débridement + idoxuridine <I>vs</I>. débridement + acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1598200223752566" CI_START="0.8622027389663849" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" I2="0.0" ID="CMP-004.05.02" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316099" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-28 00:40:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.1598200223752566" CI_START="0.8622027389663848" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.064390601853161" LOG_CI_START="-0.06439060185316105" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-28 00:40:38 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.07564671653433303" STUDY_ID="STD-Serifoglu-1987" TOTAL_1="13" TOTAL_2="12" VAR="0.0057224257224257336" WEIGHT="100.0">
<FOOTNOTE>Débridement + idoxuridine <I>vs</I>. débridement + acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="61.96002595844127" CI_END="1.1761058100613186" CI_START="0.9541108939892501" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0593089095554498" ESTIMABLE="YES" EVENTS_1="233" EVENTS_2="208" I2="79.01873054617577" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.07044639542940268" LOG_CI_START="-0.020401145370641124" LOG_EFFECT_SIZE="0.025022625029380807" METHOD="MH" MODIFIED="2014-12-13 19:19:27 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="2.3377767943699723E-8" P_Q="0.4257021220452196" P_Z="0.28028170463351876" Q="0.6345207968646412" RANDOM="YES" SCALE="6.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03301886524687741" TOTALS="SUB" TOTAL_1="318" TOTAL_2="321" WEIGHT="200.0" Z="1.0796867680586284">
<NAME>Debridement with antiviral <I>versus</I> antiviral: 7-day &amp; 14-day healing</NAME>
<GROUP_LABEL_1>Débride/Antiviral</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débride/Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="26.313594199185648" CI_END="1.790261168506158" CI_START="0.841645573699251" DF="6" EFFECT_SIZE="1.2275037222912428" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="81" I2="77.19809785549673" ID="CMP-004.06.01" LOG_CI_END="0.2529163917437784" LOG_CI_START="-0.07487075623426188" LOG_EFFECT_SIZE="0.08902281775475822" MODIFIED="2014-04-21 21:33:21 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.945981300809363E-4" P_Z="0.2870558418097736" STUDIES="7" TAU2="0.1604874783908455" TOTAL_1="153" TOTAL_2="152" WEIGHT="99.99999999999999" Z="1.064602548805777">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="7.500639654796631" CI_START="1.0465318301280575" EFFECT_SIZE="2.8017241379310347" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.8750983016187438" LOG_CI_START="0.01975244188516805" LOG_EFFECT_SIZE="0.44742537175195596" MODIFIED="2014-04-21 21:33:21 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.5024343920377936" STUDY_ID="STD-Daniel-1972" TOTAL_1="29" TOTAL_2="25" VAR="0.2524403183023873" WEIGHT="8.978110128031055">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6.181982712657025" CI_START="1.6928831032550544" EFFECT_SIZE="3.2350230414746544" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="7" LOG_CI_END="0.7911277862646271" LOG_CI_START="0.22862697029792448" LOG_EFFECT_SIZE="0.5098773782812758" MODIFIED="2014-04-21 21:33:21 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.3304157637227867" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="31" TOTAL_2="26" VAR="0.10917457691651239" WEIGHT="13.747989977349645">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2009875846792983" CI_START="0.9066262589201777" EFFECT_SIZE="1.0434782608695652" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="23" LOG_CI_END="0.07953851786656853" LOG_CI_START="-0.04257170647854227" LOG_EFFECT_SIZE="0.018483405694013133" MODIFIED="2010-05-26 14:07:54 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.07172815023567715" STUDY_ID="STD-Wilhelmus-1981a" TOTAL_1="25" TOTAL_2="25" VAR="0.005144927536231872" WEIGHT="22.382765092896562">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.8535307997056396" CI_START="0.29971669367466097" EFFECT_SIZE="0.7453416149068323" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.26799980699955533" LOG_CI_START="-0.5232890669680053" LOG_EFFECT_SIZE="-0.1276446299842249" MODIFIED="2010-05-26 14:07:54 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.46480700151164284" STUDY_ID="STD-Jensen-1982" TOTAL_1="23" TOTAL_2="20" VAR="0.21604554865424436" WEIGHT="9.845912489352791">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.3484766163037192" CI_START="0.363373004823123" EFFECT_SIZE="0.7" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.12984341982983522" LOG_CI_START="-0.4396473398013216" LOG_EFFECT_SIZE="-0.1549019599857432" MODIFIED="2010-05-26 14:07:52 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.3345216912320663" STUDY_ID="STD-Parlato-1985" TOTAL_1="12" TOTAL_2="14" VAR="0.11190476190476192" WEIGHT="13.610193996766528">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.2956568871443097" CI_START="0.7303938638305537" EFFECT_SIZE="0.9728" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="25" LOG_CI_END="0.11249000790134621" LOG_CI_START="-0.13644288404402674" LOG_EFFECT_SIZE="-0.011976438071340282" MODIFIED="2010-05-26 14:08:01 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.14622441296640046" STUDY_ID="STD-Richter-1986" TOTAL_1="25" TOTAL_2="32" VAR="0.021381578947368425" WEIGHT="20.38450788658753">
<FOOTNOTE>Brivudine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.837874370854859" CI_START="0.5505881500770327" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.45299316587405014" LOG_CI_START="-0.2591731398579374" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2010-05-26 14:08:01 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.4183300132670378" STUDY_ID="STD-Altinisik-1987" TOTAL_1="8" TOTAL_2="10" VAR="0.17500000000000002" WEIGHT="11.05052042901588">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="17.695472720669358" CI_END="1.1667376567043664" CI_START="0.9384727432721404" DF="6" EFFECT_SIZE="1.0463992972886857" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="127" I2="66.0930222395718" ID="CMP-004.06.02" LOG_CI_END="0.06697321503948366" LOG_CI_START="-0.027578336381371353" LOG_EFFECT_SIZE="0.01969743932905613" MODIFIED="2014-12-13 19:19:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.007040058790512949" P_Z="0.4141465037117542" STUDIES="7" TAU2="0.010229288805805583" TOTAL_1="165" TOTAL_2="169" WEIGHT="100.0" Z="0.8166184709286027">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.8125372542592126" CI_START="0.9225280881889086" EFFECT_SIZE="1.293103448275862" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="16" LOG_CI_END="0.2582869416722342" LOG_CI_START="-0.03502040201470864" LOG_EFFECT_SIZE="0.11163326982876277" MODIFIED="2014-12-13 18:27:01 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.17229018557647735" STUDY_ID="STD-Daniel-1972" TOTAL_1="29" TOTAL_2="25" VAR="0.029683908045977002" WEIGHT="7.728514186434031">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0790906478597926" CI_START="0.9267062058070317" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.03305792866041778" LOG_CI_START="-0.03305792866041775" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-13 18:27:01 +0000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.0388367818690308" STUDY_ID="STD-Wilhelmus-1981a" TOTAL_1="25" TOTAL_2="25" VAR="0.0015082956259426794" WEIGHT="26.280510260746265">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.5570284857644208" CI_START="0.48563252002776225" EFFECT_SIZE="0.8695652173913043" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.19229655803834167" LOG_CI_START="-0.313692238745565" LOG_EFFECT_SIZE="-0.0606978403536117" MODIFIED="2010-05-26 14:08:17 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.29722032391580594" STUDY_ID="STD-Jensen-1982" TOTAL_1="23" TOTAL_2="20" VAR="0.0883399209486166" WEIGHT="3.129473279368528">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1545422069486428" CI_START="0.8661441686423186" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.06240981417813003" LOG_CI_START="-0.06240981417813004" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-05-26 14:08:16 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.0733196675635924" STUDY_ID="STD-Parlato-1985" TOTAL_1="12" TOTAL_2="14" VAR="0.005375773651635704" WEIGHT="19.76728442684584">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0708667526722295" CI_START="0.9338229966563165" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="32" LOG_CI_END="0.029735435183576835" LOG_CI_START="-0.02973543518357687" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-12-13 18:27:03 +0000" MODIFIED_BY="[Empty name]" ORDER="261" O_E="0.0" SE="0.034933483639222225" STUDY_ID="STD-Richter-1986" TOTAL_1="25" TOTAL_2="32" VAR="0.0012203482791718068" WEIGHT="26.941439785865928">
<FOOTNOTE>Brivudine</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.4516866268925386" CI_START="0.8237930358496397" EFFECT_SIZE="1.0935672514619883" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.16187287607501252" LOG_CI_START="-0.08418188378632226" LOG_EFFECT_SIZE="0.03884549614434513" MODIFIED="2010-05-26 14:08:22 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.1445337839332529" STUDY_ID="STD-Altinisik-1987" TOTAL_1="8" TOTAL_2="10" VAR="0.02089001469806423" WEIGHT="9.912487535480231">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.0637783689094706" CI_START="0.9497143828654874" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.3146630561684448" LOG_CI_START="-0.022406984811968737" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-12-13 19:19:27 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="301" O_E="0.0" SE="0.19799661059550736" STUDY_ID="STD-Shen-2014" TOTAL_1="43" TOTAL_2="43" VAR="0.03920265780730897" WEIGHT="6.2402905252591685">
<FOOTNOTE>Ganciclovir and fibroblast growth factor and oral acyclovir; data reported for 21 days of treatment</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IPD_OUTCOME CHI2="18.69573608883947" CI_END="2.3534422679292764" CI_START="1.3208741692098571" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="1.7631225426595978" ESTIMABLE="YES" EVENTS_1="105" EVENTS_2="84" I2="73.25593399350144" I2_Q="0.0" ID="CMP-004.07" LOG_CI_END="0.371703549136236" LOG_CI_START="0.12086144727335743" LOG_EFFECT_SIZE="0.24628249820479672" MODIFIED="2014-10-14 16:35:47 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0021897229640728266" P_Q="1.0" P_Z="1.1875858447358728E-4" Q="0.0" SCALE="15.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="128" TOTAL_2="120" WEIGHT="99.99999999999999" Z="3.848674707468526">
<NAME>Debridement with antiviral <I>versus</I> antiviral: healing rate</NAME>
<GROUP_LABEL_1>Débride/Antiviral</GROUP_LABEL_1>
<GROUP_LABEL_2>Antiviral</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Débride/Antiviral</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IPD_DATA CI_END="4.533057638533569" CI_START="1.2975753485748434" EFFECT_SIZE="2.4252801581322623" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.6563912412157427" LOG_CI_START="0.11313258618920444" LOG_EFFECT_SIZE="0.38476191370247353" MODIFIED="2010-06-15 14:40:18 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="8.7" SE="0.31911282313630135" STUDY_ID="STD-Daniel-1972" TOTAL_1="29" TOTAL_2="25" VAR="9.82" WEIGHT="21.320017368649584">
<FOOTNOTE>Idoxuridine</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="8.904194921063604" CI_START="2.2857965396655944" EFFECT_SIZE="4.511449649400418" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="7" LOG_CI_END="0.949594658538664" LOG_CI_START="0.3590375709267301" LOG_EFFECT_SIZE="0.6543161147326971" MODIFIED="2014-04-27 16:48:18 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="12.52" SE="0.3468961565679801" STUDY_ID="STD-Fulhorst-1972" TOTAL_1="31" TOTAL_2="26" VAR="8.31" WEIGHT="18.041684759009986">
<FOOTNOTE>Idoxuridine; excluded from HR table analysis because of only one week of follow up</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="3.6332379875729495" CI_START="1.1285208243169071" EFFECT_SIZE="2.024891288112852" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="25" LOG_CI_END="0.560293846336301" LOG_CI_START="0.05250957741686401" LOG_EFFECT_SIZE="0.30640171187658244" MODIFIED="2010-06-15 14:40:39 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="7.93" SE="0.2982749931359468" STUDY_ID="STD-Wilhelmus-1981a" TOTAL_1="25" TOTAL_2="25" VAR="11.24" WEIGHT="24.402952670429872">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="1.799165234397833" CI_START="0.35973102340773266" EFFECT_SIZE="0.8044970795780093" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="12" LOG_CI_END="0.2550710505561574" LOG_CI_START="-0.44402210676364307" LOG_EFFECT_SIZE="-0.09447552810374278" MODIFIED="2010-06-15 14:40:47 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="-1.29" SE="0.41065078117659093" STUDY_ID="STD-Jensen-1982" TOTAL_1="23" TOTAL_2="20" VAR="5.93" WEIGHT="12.87451150673035">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="1.4775104055442885" CI_START="0.31451809990519086" EFFECT_SIZE="0.6816918404542757" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.16953054813505447" LOG_CI_START="-0.502354356696425" LOG_EFFECT_SIZE="-0.16641190428068525" MODIFIED="2010-06-15 14:40:55 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="-2.46" SE="0.3946685189819292" STUDY_ID="STD-Parlato-1985" TOTAL_1="12" TOTAL_2="14" VAR="6.42" WEIGHT="13.938341293964392">
<FOOTNOTE>Trifluridine</FOOTNOTE>
</IPD_DATA>
<IPD_DATA CI_END="3.0243961042144707" CI_START="0.46074331036060395" EFFECT_SIZE="1.180453418351393" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.48063866996707366" LOG_CI_START="-0.3365409616858103" LOG_EFFECT_SIZE="0.0720488541406316" MODIFIED="2010-06-15 14:41:07 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.72" SE="0.4800153607373193" STUDY_ID="STD-Altinisik-1987" TOTAL_1="8" TOTAL_2="10" VAR="4.34" WEIGHT="9.422492401215804">
<FOOTNOTE>Acyclovir</FOOTNOTE>
</IPD_DATA>
</IPD_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2015-01-09 11:00:20 +0000" MODIFIED_BY="Anupa Shah" NO="5">
<NAME>Adjunctive and alternative agents: lubricant, growth factor, nonsteroidal anti-inflammatory drug, immunomodulator</NAME>
<DICH_OUTCOME CHI2="3.737039171520398" CI_END="2.8576599544466283" CI_START="1.0283853072270668" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7142857142857142" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="10" I2="73.24084779145747" I2_Q="63.18594916191263" ID="CMP-005.01" LOG_CI_END="0.4560105489148471" LOG_CI_START="0.01215586315188886" LOG_EFFECT_SIZE="0.23408320603336796" METHOD="MH" MODIFIED="2013-08-12 17:20:51 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="1" P_CHI2="0.05321892865871669" P_Q="0.09932472043671059" P_Z="0.03870408782406478" Q="2.716354156183791" RANDOM="NO" SCALE="20.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="24" WEIGHT="200.0" Z="2.0673191831801043">
<NAME>Antiviral/lubricant <I>versus</I> antiviral</NAME>
<GROUP_LABEL_1>Ganciclovir/Hyaluronan</GROUP_LABEL_1>
<GROUP_LABEL_2>Ganciclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiv/Hyaluronan</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.0803964571505158E-31" CI_END="14.497169305397247" CI_START="1.0262383439827316" DF="0" EFFECT_SIZE="3.8571428571428568" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" I2="100.0" ID="CMP-005.01.01" LOG_CI_END="1.1612832108515894" LOG_CI_START="0.011248237437871423" LOG_EFFECT_SIZE="0.5862657241447304" MODIFIED="2013-08-12 16:37:24 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="1" P_CHI2="0.0" P_Z="0.04568371948128075" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="1.9983039320676363">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="14.497169305397252" CI_START="1.0262383439827318" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="1.1612832108515896" LOG_CI_START="0.011248237437871516" LOG_EFFECT_SIZE="0.5862657241447304" MODIFIED="2013-08-12 16:37:24 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="261" O_E="0.0" SE="0.6755362361481481" STUDY_ID="STD-Liu-2011" TOTAL_1="14" TOTAL_2="12" VAR="0.45634920634920645" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9135537286508992" CI_START="0.7258905728370624" DF="0" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.281840660827054" LOG_CI_START="-0.13912884375571752" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2013-08-12 16:37:44 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="2" P_CHI2="1.0" P_Z="0.5064071562204231" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="12" WEIGHT="100.0" Z="0.664442479997007">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.9135537286508992" CI_START="0.7258905728370624" EFFECT_SIZE="1.1785714285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="8" LOG_CI_END="0.281840660827054" LOG_CI_START="-0.13912884375571752" LOG_EFFECT_SIZE="0.07135590853566827" MODIFIED="2013-08-12 16:37:44 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="260" O_E="0.0" SE="0.2472795708245753" STUDY_ID="STD-Liu-2011" TOTAL_1="14" TOTAL_2="12" VAR="0.06114718614718616" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.237259953207567" CI_START="0.8082375877498692" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.09246095620373274" LOG_CI_START="-0.09246095620373274" LOG_EFFECT_SIZE="0.0" METHOD="MH" MODIFIED="2013-08-12 16:47:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="40" TOTAL_2="40" WEIGHT="200.0" Z="0.0">
<NAME>Antiviral/epidermal growth factor <I>versus</I> antiviral</NAME>
<GROUP_LABEL_1>Acyclovir/EGF</GROUP_LABEL_1>
<GROUP_LABEL_2>Acyclovir</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral/EGF</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8585470606953671" CI_START="0.5380547101270895" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.26917356244091883" LOG_CI_START="-0.26917356244091883" LOG_EFFECT_SIZE="0.0" NO="1" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.8585470606953671" CI_START="0.5380547101270895" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.26917356244091883" LOG_CI_START="-0.26917356244091883" LOG_EFFECT_SIZE="0.0" ORDER="65207" O_E="0.0" SE="0.31622776601683794" STUDY_ID="STD-Cellini-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.10000000000000002" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0990684440478304" CI_START="0.9098614425840807" DF="0" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.04102473878083397" LOG_CI_START="-0.04102473878083395" LOG_EFFECT_SIZE="0.0" NO="2" P_CHI2="1.0" P_Z="1.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.0">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.0990684440478307" CI_START="0.9098614425840805" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.04102473878083406" LOG_CI_START="-0.04102473878083406" LOG_EFFECT_SIZE="0.0" ORDER="65208" O_E="0.0" SE="0.04819626927118808" STUDY_ID="STD-Cellini-1994" TOTAL_1="20" TOTAL_2="20" VAR="0.002322880371660868" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.09736180029140756" CI_END="1.0675553135990394" CI_START="0.8745763011054168" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9662600982100427" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="107" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.028390386524683224" LOG_CI_START="-0.05820229515785695" LOG_EFFECT_SIZE="-0.014905954316586846" METHOD="MH" MODIFIED="2015-01-09 11:00:20 +0000" MODIFIED_BY="Anupa Shah" NO="3" P_CHI2="0.7550188679031283" P_Q="0.7809850716537404" P_Z="0.4998210020071192" Q="0.07730377121146538" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="118" TOTAL_2="122" WEIGHT="200.0" Z="0.6747714252069474">
<NAME>Panthenol <I>versus</I> <I>para</I>-fluorophenylalanine, with debridement</NAME>
<GROUP_LABEL_1>Panthenol</GROUP_LABEL_1>
<GROUP_LABEL_2>Fluorophenylalanine</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours <I>p</I>-FPA</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Panthenol</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1383176505789954" CI_START="0.794818251715083" DF="0" EFFECT_SIZE="0.9511864406779661" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="50" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="0.05626347000601129" LOG_CI_START="-0.0997321685776551" LOG_EFFECT_SIZE="-0.02173434928582189" MODIFIED="2010-02-22 21:52:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.5849625456871823" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="61" WEIGHT="99.99999999999999" Z="0.5461504207988167">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.1383176505789954" CI_START="0.794818251715083" EFFECT_SIZE="0.9511864406779661" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="50" LOG_CI_END="0.05626347000601129" LOG_CI_START="-0.0997321685776551" LOG_EFFECT_SIZE="-0.02173434928582189" MODIFIED="2010-02-22 21:52:15 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.09163261029491035" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="59" TOTAL_2="61" VAR="0.00839653526945891" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.084896224550041" CI_START="0.8843114681657678" DF="0" EFFECT_SIZE="0.9794826048171276" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="57" I2="0.0" ID="CMP-005.03.02" LOG_CI_END="0.03538819785206731" LOG_CI_START="-0.05339474281386739" LOG_EFFECT_SIZE="-0.009003272480900047" MODIFIED="2010-02-22 21:52:15 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.6909908096600109" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="61" WEIGHT="100.0" Z="0.39751082073214833">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.084896224550041" CI_START="0.8843114681657678" EFFECT_SIZE="0.9794826048171276" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="57" LOG_CI_END="0.03538819785206731" LOG_CI_START="-0.05339474281386739" LOG_EFFECT_SIZE="-0.009003272480900047" MODIFIED="2010-02-22 21:52:15 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.052151538829814235" STUDY_ID="STD-Matth_x00e4_us-1970" TOTAL_1="59" TOTAL_2="61" VAR="0.0027197830023176217" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19393403516912877" CI_END="1.4091265192542206" CI_START="0.7132211330660398" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0025062656641603" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="0.1489499882457522" LOG_CI_START="-0.14677579696332393" LOG_EFFECT_SIZE="0.0010870956412141369" METHOD="MH" MODIFIED="2013-11-28 16:28:26 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NO="4" P_CHI2="0.6596623350504545" P_Q="0.7136368186271599" P_Z="0.9885030754920936" Q="0.13467157941198998" RANDOM="NO" SCALE="6.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="40" WEIGHT="200.0" Z="0.014409756680661556">
<NAME>Interferon/methyl uracil <I>versus</I> interferon</NAME>
<GROUP_LABEL_1>IFN/Methacil</GROUP_LABEL_1>
<GROUP_LABEL_2>IFN</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours IFN</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours IFN/Methacil</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.6732974545566934" CI_START="0.2652683759637299" DF="0" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" I2="0.0" ID="CMP-005.04.01" LOG_CI_END="0.4270472848640239" LOG_CI_START="-0.5763145214578324" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2013-08-13 19:32:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="1" P_CHI2="1.0" P_Z="0.770609162233639" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.2915781784321153">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="2.6732974545566934" CI_START="0.2652683759637299" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4270472848640239" LOG_CI_START="-0.5763145214578324" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2013-08-13 19:32:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="266" O_E="0.0" SE="0.5893796917545019" STUDY_ID="STD-Maichuk-1980" TOTAL_1="19" TOTAL_2="20" VAR="0.3473684210526316" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4111810787706307" CI_START="0.785181475053866" DF="0" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" I2="0.0" ID="CMP-005.04.02" LOG_CI_END="0.14958274477144962" LOG_CI_START="-0.10502995534914522" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2013-08-13 19:32:30 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="2" P_CHI2="1.0" P_Z="0.7316288750378788" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="20" WEIGHT="100.0" Z="0.3429595720761557">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.4111810787706307" CI_START="0.785181475053866" EFFECT_SIZE="1.0526315789473684" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.14958274477144962" LOG_CI_START="-0.10502995534914522" LOG_EFFECT_SIZE="0.022276394711152208" MODIFIED="2013-08-13 19:32:30 +0100" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="267" O_E="0.0" SE="0.1495607604040297" STUDY_ID="STD-Maichuk-1980" TOTAL_1="19" TOTAL_2="20" VAR="0.02236842105263158" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1073137684325234" CI_START="0.5632504131362633" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7897435897435897" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.04427070000300503" LOG_CI_START="-0.2492984810551149" LOG_EFFECT_SIZE="-0.10251389052605496" METHOD="MH" MODIFIED="2013-08-20 16:52:36 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.17105160661766883" Q="0.0" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.3688326044440706">
<NAME>Antiviral/oxyphenbutazone <I>versus</I> antiviral</NAME>
<GROUP_LABEL_1>IDU/NSAID</GROUP_LABEL_1>
<GROUP_LABEL_2>IDU/Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Antiviral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Antiviral/NSAID</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1073137684325234" CI_START="0.5632504131362633" DF="0" EFFECT_SIZE="0.7897435897435897" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" I2="0.0" ID="CMP-005.05.01" LOG_CI_END="0.04427070000300503" LOG_CI_START="-0.2492984810551149" LOG_EFFECT_SIZE="-0.10251389052605496" MODIFIED="2010-03-17 19:23:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.17105160661766883" STUDIES="1" TAU2="0.0" TOTAL_1="15" TOTAL_2="14" WEIGHT="100.0" Z="1.3688326044440706">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="1.1073137684325234" CI_START="0.5632504131362632" EFFECT_SIZE="0.7897435897435897" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.04427070000300503" LOG_CI_START="-0.24929848105511498" LOG_EFFECT_SIZE="-0.10251389052605496" MODIFIED="2010-03-17 19:23:32 +0000" MODIFIED_BY="[Empty name]" ORDER="65209" O_E="0.0" SE="0.1724439901444227" STUDY_ID="STD-Norn-1973" TOTAL_1="15" TOTAL_2="14" VAR="0.02973692973692975" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.393937337420839" CI_END="1.8954533394081854" CI_START="1.0808293237234676" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4313146233382572" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="25" I2="59.42621822317927" I2_Q="47.69680323483264" ID="CMP-005.06" LOG_CI_END="0.27771309781707154" LOG_CI_START="0.03375711891417067" LOG_EFFECT_SIZE="0.15573510836562107" METHOD="MH" MODIFIED="2013-11-28 15:44:55 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.06034723961581134" P_Q="0.166749379897412" P_Z="0.012336165949657774" Q="1.9119290250839418" RANDOM="NO" SCALE="6.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="52" TOTAL_2="48" WEIGHT="200.0" Z="2.502379362848486">
<NAME>Oral inosine pranobex <I>versus</I> inactive control, with or without antiviral</NAME>
<GROUP_LABEL_1>Oral isoprinosine</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Inosine Pranobex</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.1181853954162797" CI_END="3.470186449193353" CI_START="1.0665257149973995" DF="1" EFFECT_SIZE="1.9238095238095239" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="52.78977930052844" ID="CMP-005.06.01" LOG_CI_END="0.5403528095691079" LOG_CI_START="0.027971331184263565" LOG_EFFECT_SIZE="0.2841620703766857" MODIFIED="2013-11-28 15:37:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.14555897286655195" P_Z="0.029708431246046236" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="2.173956113582712">
<NAME>Healing at 7 days</NAME>
<DICH_DATA CI_END="2.4538946151421293" CI_START="0.8316642100021105" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.389855907598397" LOG_CI_START="-0.08005198762691071" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-11-28 15:37:43 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="221" O_E="0.0" SE="0.2760262237369417" STUDY_ID="STD-Colin-1982" TOTAL_1="12" TOTAL_2="12" VAR="0.07619047619047618" WEIGHT="86.66666666666667">
<FOOTNOTE>Trifluridine used by both treatment groups</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="36.9366657623275" CI_START="0.7160629971861894" EFFECT_SIZE="5.142857142857143" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="1.5674576895238979" LOG_CI_START="-0.14504876801783698" LOG_EFFECT_SIZE="0.7112044607530305" MODIFIED="2013-11-28 15:37:43 +0000" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="1.0059347702036958" STUDY_ID="STD-Haut-1983" TOTAL_1="14" TOTAL_2="12" VAR="1.011904761904762" WEIGHT="13.333333333333334"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.121929130566964" CI_END="1.6172622005553063" CI_START="0.9050711016840329" DF="1" EFFECT_SIZE="1.2098501070663814" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="17" I2="10.867810385255574" ID="CMP-005.06.02" LOG_CI_END="0.20878043612346073" LOG_CI_START="-0.043317301616807836" LOG_EFFECT_SIZE="0.08273156725332645" MODIFIED="2013-11-28 15:37:48 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2895034784866224" P_Z="0.19829899521791658" STUDIES="2" TAU2="0.0" TOTAL_1="26" TOTAL_2="24" WEIGHT="100.0" Z="1.286412909965373">
<NAME>Healing at 14 days</NAME>
<DICH_DATA CI_END="1.3604268274035298" CI_START="0.8684586751395925" EFFECT_SIZE="1.0869565217391304" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.13367518756415273" LOG_CI_START="-0.061250842255263324" LOG_EFFECT_SIZE="0.03621217265444471" MODIFIED="2013-11-28 15:37:48 +0000" MODIFIED_BY="Kirk R. Wilhelmus" ORDER="222" O_E="0.0" SE="0.11450051481533431" STUDY_ID="STD-Colin-1982" TOTAL_1="12" TOTAL_2="12" VAR="0.013110367892976593" WEIGHT="64.02569593147751">
<FOOTNOTE>Trifluridine used by both treatment groups; data for day 14 carried forward from day 12</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.7519930944973865" CI_START="0.7415775608635164" EFFECT_SIZE="1.4285714285714286" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.43964733980132165" LOG_CI_START="-0.12984341982983522" LOG_EFFECT_SIZE="0.1549019599857432" MODIFIED="2013-11-28 15:37:48 +0000" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.3345216912320663" STUDY_ID="STD-Haut-1983" TOTAL_1="14" TOTAL_2="12" VAR="0.11190476190476191" WEIGHT="35.974304068522486"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-12-27 20:19:41 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-12-13 17:29:57 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<UL>
<LI>Study flow diagram.</LI>
</UL>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqkAAANOCAYAAAAyEJVJAACAAElEQVR42uy9D4RWzf///yFJkkSS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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Network of HSV trials.PNG" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-12-27 15:12:15 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Networks of clinical trials included in this systematic review. Left diagram shows a network of two-way comparisons among topical antiviral agents. Not shown in the left diagram are trials evaluating <I>para</I>-fluorophenylalanine, different trifluridine vehicles, and different ganciclovir concentrations. Right diagram illustrates a network of comparisons between topical antiviral agents and various interventions that included dual antiviral therapy, oral acyclovir, interferon without or with an antiviral, and debridement without or with an antiviral. Not shown in the right diagram are trials evaluating different interferon dosages or types, an interferon inducer, different methods of debridement, debridement with two different antivirals, and miscellaneous agents (hyaluronate, epidermal growth factor, panthenol, methyluracil, oxyphenbutazone, or inosine pranobex). Lines show direct treatment comparisons reporting outcomes at one week or two weeks. Circled numerals indicate the number of direct treatment comparisons that were included in this systematic review. The placebo groups consist of a variety of inactive controls. The number of acyclovir-idoxuridine (IDU) comparisons includes one trial using iododeoxycytidine (IDC), even though IDC was not pooled with IDU in the meta-analysis. The number of direct comparisons exceeds the number of studies because 21 studies compared more than two interventions.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAIcCAYAAADffZlTAACAAElEQVR42uydBZhcRfbF/7sQt4m7
u7vbxJ0hQFyIuxsxQhwm7iHuCUmIEhcSEgIxiJEQxxeHBXaxZbf+87vDa3o6PTPdM90zLfd8X33J
tL5+71XVqVvnnvt/RqFQKBQKhUKhULiM/9NToFAoFAqFQqFQKIFWKBQKhUKhUCiUQCsUCoVCoVAo
FEqgFQqFQqFQKBQKJdAKhUKhUCgUCoUSaIVCoVAoFAqFQgm0ngKFQqFQKBQKhUIJtEKhUCgUCoVC
oQRaoVAoFAqFQqFQAq1QKBQKhUKhUCiBVigUCoVCoVAolEArFAqFQqFQKBRKoPUUKBQKhUKhUCgU
SqAVCoVCoVAoFAol0AqFQqFQKBQKhRJohUKhUCgUCoVCCbRCoVAoFAqFQqEEWqFQKBQKhUKhUAKt
p0ChUCgUCoVCoVACrVAoFAqFQqFQKIFWKBQKhUKhUCiUQCsUCoVCoVAoFEqgFQqFQqFQKBQKJdAK
hUKhUCgUCoUSaD0FCoVCoVAoFAqFEmiFQqFQKBQKhUIJtEKhUCgUCoVCoQRaoVAoFAqFQqFQAq1Q
KBQKhUKhUCiBVigUCoVCoVAolEDrKVAoFAqFQqFQKJRAKxQKhUKhUCgUSqAVCoVCoVAoFAol0AqF
QqFQKBQKhRJohUKhUCgUCoVCCbRCoVAoFAqFQqEEWk+BQqFQKBQKhUKhBFqhUCgUCoVCoVACrVAo
FAqFQqFQKIFWKBQKhUKhUCiUQCsUCoVCoVAoFEqgFQqFQqFQKBQKJdB6ChQKhUKhUCgUCiXQCoVC
oVAoFAqFEmiFQqFQKBQKhUIJtEKhUCgUCoVCoQRaoVAoFAqFQqFQAq1QKBQKhUKhUCiB1lOgUCgU
imDAL7/8Yr766ivz6aefmo8//th88cUX5scff9QTo1AolEArFAqFInjxn//8x7z99ttm6dKlpm/f
vqZBgwYmf/78JkWKFOb//u//nLYkSZKYHDlymBo1a5ouXbqY8PBwc/ToUfPTTz/pCVUoFEqgFQqF
QhF4uHnzppkzZ45p3ry5SZ06tY0Ypw0JMSUqVDD1w540bXr3NT3HjDWDp043w18KNyPDZ5sh02ea
PuMnmvYDBpombdqastVrmCzZc9je/9hjj5nqNWqYiRMnmtOnT5v//ve/erIVCoUSaIVCoVD4J778
8kszf/58U65cORvhzVOokGnVpauZtHyF2Xb+ojn+4SdxanuuvWfCt2wzHQcNFgIOkebzc+bMacaO
HSuEXaFQKIFWKBQKhcIvcPXqVdO2bVsbqS1apqwZOGWqeeXi5TgT5tja/pu3zcSly021Bg1s31ut
WnWzf/9+87///U8vikKhBFqhUCgUCt/D+fPnTcuWLYW8pkqTxrTr19+sOXHKa6Q5urbznaum/6TJ
JnuePHIspUuXNtu3b1d5h0KhBFqhUCgUCt/A559/bjp27ChkNV36DKbbyNFm7/WbCU6cHduRBx+a
5+YvNHkLF5Zjq1Spkrl8+bJeMIVCCbRCoVAoFImDP/74wyxcuNCkSZPGJE2WzHQZOtzsv3Un0Ymz
Yzv2wcdm3IJFJmOWLOZvf/ubGTBggPn+++/1AioUSqAVCoVCoUg4fPLJJ2IpR2S3Smg9s+GNsz5H
nB3b3hu3TOvuPczf//53scQ7e/asXkiFQgm0QqFQKBTex8GDB02GDBlMytSpzbiFi32eODu25QcO
m1z5CwiRnjlzpiYZKhRKoBUKhUKh8B7wWybqXKhkKbP+9Bm/I8/2rh14T/NbmjZrpgVZFAol0AqF
QqFQeBbonbt37y6Es3n7Dubgnft+S57t27CZL4ntXYUKFaSEuEKhUAKtUCgUCkW88fPPP5tWrVoJ
ee46fERAEGf7NmPdRpMsRQpTqFAh8/DhQ73gCoUSaIVCoVAo4o7ffvvNNGjYUNwrhs54MeDIs9UW
7t5n0qZPL5UMP/74Y73wCoUSaIVCoVAo3AeFR9q1ayeR5zHzFgQsebbayiPHTOq0aU3RokXNN998
ozeAQqEEWqFQKBQK9zBo0CAhz33GTwx48my1+Tt3mWTJk5sqVaqYf//733oTKBRKoBUKhUKhcA1L
ly4V8tymT7+gIc9Wm7JqjVjctW3bVm8EhUIJtEKhUCgUsePdd981SZMmNVXrN5AqfsFGoGm9x42X
BcSyZcv0hlAolEArFAqFQhE9fvzxR1OwYEGTJXsOs+vK9aAkz1b5bxYQLCSuXLmiN4ZCoQRaoVAo
FArn6Natm/giL9i1J2jJs9VYQGTOnt0UKVJE3EgUCoUSaIVCoVAoouDMmTMiW+g4aHDQk2ervbRp
i5yTadOmBeQ1/+WXX6SAzKeffir2fV988YXsQigUSqAVCoVCoYgF//nPf0zJkiVNtly5zIHbd5U8
27W6LVqa5MmTmw8++MBvr+3bb78tiaF9+/Y1DRo0MPnz5zcpUqSQxYGzliRJEpMjRw5To2ZN06VL
FxMeHm6OHj2qJc8VSqAVCoVCobAwb948IU5TV69V0uzQtl24ZFKmSmWeeOIJv7meN2/eNHPmzDHN
mzc3qVOnthHjtCEhpkSFCqZ+2JOmTe++pueYsWbw1Olm+EvhZmT4bDNk+kyxLWw/YKBp0qatKVu9
hujhrfcj76leo4aZOHGiOX36tHiFKxRKoBUKhUIRdMDvOGPGjKZy3VAlzNG0ns+NEwJ58eJFn72O
X375pZk/f74pV66cjfDmKVTItOrS1UxavsJsO38xzr9/z7X3TPiWbSLvgYBDpPl8KjeOHTtWCLtC
oQRaoVAoFEEDK/pMOWsly87b/pu3pdR3WFiYz12/q1evime1RWqLlilrBk6Zal65eNmr52Pi0uWm
WoMGtu+tVq262b9/v/nf//6nnUqhBFqh8DWgwfvoo49k0jh//rwkPp09e9ZcuHDB3Lhxw3z22Wfm
119/1ROlULgA+kr27NlNuRo1lSjH0p4dMVKI4vXr133i2jH+tWzZUo4pVZo0pl2//mbNiVMJfl52
vnPV9J802WTPk0eOpXTp0mb79u0q71AogVYoEgNkg+/cudNMmDDBtG7dWhKc0kRMEtElvTi2TJky
mYoVK5pOnTqZGTNmmGPHjmkCjELhgLVr10p/mbX1FSXJLsgYUqZObbp27Zqo1+zzzz83HTt2lOuW
Ln0G023kaLP3+s1EPz9HHnxonpu/0OQtXFiOrVKlSuby5cvayRRKoBUKb+L77783GzduNN27dzeF
ChWyEWFK6mbLndtUqFXbtOrcRSqEjZw1x0xescrMXL9RJn60eTPWbTTPL3vZDJv5UsSEMso0fqaN
KVWpssmQOXOUBBhI9fDhw83BgwfN77//rideEdSoXaeO6GTjW3QkWCoWMgbhXpEYi/E//vjDLFy4
UAIJSZMlM12GDjf7b93xySI04xYsMhmzZDF/+9vfzIABA2R8VyiUQCsUHsIPP/xgNm3aJNuQ2CZZ
EZUajZuYvhOeN4v37jeH7j6I94C+98Yt8XPtPGSYKVe9hkn2p31TSEiI6dGjhzly5IhYPSkUwQRs
2egHPUY/FzcdbAR5w6khecqUEplt0bGTOXjnvtPXLtn3mll9/PV49+X8RYtJQlxc3//yoaMmWfLk
cX7/wl175ZytX78+Qa/VJ598IpZyfHeV0HpmwxtnfX6xwbjbunsPCYJgiYfUTqFQAq1QxAN37twx
/fv3t/mQZs2ZUyyVluw/kCADO6R8+toNptHTz4h2kGPIli2bSD2+/fZbvUCKoMDUqVPl3t/y1oU4
9aNnevcx2fPkNROWLJOt+4xZspoxc+c7fW2miP41Z9uOePddXCDiM07El0DTcubLZ+o3aJBg14nd
sgwZMsgiZdzCxX4XtV9+4LDJlb+AEOmZM2dqkqFCCbRC4S7eeOMNW9ILW5DN2nUwi/bsT9TBHTKN
9y0WXhwXpB5y/+DBA71gioBGqVKlTNlq1ePcdzJmzSYewtbfaHGr1m/g/LUR5HrOKzsSncx5gkB3
GTZcpAlff/21168RfsuMS4VKljLrT5/xaxcTvKf5LU2bNdN8FIUSaIXCFdy+fdu0atVKBs/0mTKZ
rsNHSOa2rw3yq4+fNM3bdxByj6QErfR3332nF1ARcKB8M/0Rf+O49JWjDz8yI8JnmR2X3rU9NnrO
PJOvSNFHXou047HHHzc58+eXPAUeYwcIOUaadCGmwZOtzb733pfHN519y1SqU9eMmbdAotbFK1SI
Ermu27KVLeERrS2yLMh5sXLlzITFS22vQ4PL5/D5/Lvq2AmPEWgW/Zw7kpy9BfTO5IPwPYxJ0Ulj
/K2Ro0IuSoWI68o9qFAogVYonAA5xKBBg2TARCrRa+w4v5gIIAVMWmw5pk+f3ixYsEA10oqAAjZj
kDO0yZ7qN6GtnjBhXbs98jj5B6nSppXqdutef8OsPHLM/D1iTOBv9MwQ6eoNG8lr1548bZIkTWpy
FShgXty42XQYOMikz5zZ7Lpy/RENNNZpqdOmE+LOQiBJxMKXqoGb33xbSDIJxxDxgiVLCsH2FIHG
bQI5BTtV3sDPP/9sCzgQbAi0REwSvslDIVn84cOH2hkVSqAVCnscOnRIdMWQ5ye6PGteffea3w30
K48el+gVE1nlypUlkq5QBAL69u0ri1rIoCf6Crpkosxzt++MVcLRpG07U7tZc9tzSBOQROBhDIGm
v0GyrOeLly8vhUEcCXS2XLmlBLX1ulpNm8nrhkybIdX3rMfDN281KVKl8hiBpiFVKVKkiMevy2+/
/WYaNGwo52PojBcD1s2Eoj0UpqGS4ccff6wdUqEEWqH417/+JZMzk2CBYsXNisPH/H6wZ9uZwT55
xMS7ePFiTYJR+D3wVY9Or+xu237xHZMlggi17NQ5er20HYEuUrqMRI3tn8dKj8p2EGh2fuyJPZFq
ixBbBPq19+/KGEO0ObrvPHzvoVmwa49p27e/vJbP9BSB7j1+gnymJ3XQFB5p166dfC6R80C3BGQn
InXatKZo0aLmm2++0U6pUAKtCF4QoWVbjugJVbE8YUHnKw2SAOFgciMR8scff9QLrvBLEOVkZwhH
i3gnh926IwlupSpXibG/2xNotM32EWZamWrVzMDJU4RAh2TKFOW5PuMnmsqhoVEI9Maz56QvOvNB
hlxbDjvIOkpUqBhJoO9/4DECTVSbz3z99dc9dl2Qu/GZ/N5gKU4zf+cuuR5VqlQx//73v7VzKpRA
K4IPx48fN+nSpZMkwXk7Xg3YAR/Xgccff1wiePjoKhT+BkreQ9TGL1oSr75AIiHaZWzdLI2yKwQ6
f7Fij3x3wRIlxKINAu1IcDsOGmLqh7WOQqCpCshveOXiZdvrdl+7IcmIT3brLgmLU1auFoK99LWD
8loi0p4i0CyoRUO+ZIlHrsnSpUvl89r06Rd0FR6nrFojuw5t27bVzqlQAq0ILixbtkwiWgWLlzBb
zp0P+AF/9tbtJk1IiJQLP3funN4ACr/C/v2RLhIUKorvYhKXC1fs1bC8s9wzajZpKiTXnvgSKcbd
wtJA86/1fMXadcQ6zlEDTQIhbh7W67DFpHAHZNzeXg+Paj6TBGZPEWgaiXAjR46M9/V49913TdKk
SWWHK1gqOj4iiRk3Xq4Rc4lCoQRaERQIDw+XgY9IFF6fwTLgrzt1xuQuUFB8o0+dOqU3gsJvYEU7
7S3o4tIyZ88upG/Yi+G25qhtti8+QjIxC+yZGzaZ5BH9BhkH5JnoMlFpy4WDY6tar75EtbGjezxJ
EluxF3sC/XSv3iIf4bnwLdvE6YNqh03btpfjohIeOtusuXLJZxK19iSBzlOwkGnTpk28rgVSsIIF
C5os2XPEGsUP5MbCgWvGQuLKlSvaSRVKoBWBjblz58rEhEG+p7L5/anhZY3vbcqUKc2ZM2f0hlD4
BSZPnmxLqovPApLPcGyQWGev7zR4qORG8C9/PztipLh28B7IteXTbBFoSHBkwaXkZuyChU5Lee+9
ftPmkhOSMaMUcuHxZQcOmbyFi4gsIF2GDCIRIFKOtMyTBLp0laomNDQ0XteiW7dusntHsmOwkmer
sYBgUYa7CTp9hUIJtCIgsWjRIpm4Qlu2CkrybPOMvnwlYrIubFKlSqVyDoVfYOjQoeJ+kBjV6Ejk
s/4+cPvuI5IvCDREm/+jbz54+55Lvu3OEhiJTHtTElGjcRNTpkyZOF8HFt2MoZ5I5gyUhmc452Ta
tGnaURVKoBWBB0tDiZer/YQYtCQ6YgJHzpExY0ZNLFT4PLCZzJA5s0/2JXsC7euNwjFx9YKmMBOJ
yNly5ZKFhJLnv1rdFi3FMlTHUoUSaEVA4datWyZNmjSmaJmyLkWHgqWRSJUmXTqJSKkdk8KXQYno
rDlyKoGOZ2v41NMmb758cboG8+bNkyDE1NVrdfx0aFSTTJkqlXniiSe0syqUQCsCA99//734PBO9
2nb+og72Do3Sw2rHpPB19O7d22TKmtUn+xBOGST++UN/J/eD8dBdsMBmt6py3VAdN6NplGZngXHx
4kXtsAol0Ar/R/v27SUjfuGuvTrIR9MogsDA//LLL+sNo/BJULCDypraX+PXKB2ODCOu0WfKWet5
jF4vzz2qUWiFEmiF32Pv3r0y6HcbOUoH+FhahVq1TOrUqc3HH3+sN47C5zBx4kRxfghWz2FPtXI1
apqaEX3dHfz6668me/bs8l49hzE3nFqYc65fv66dVqEEWuGf+O6770y2bNnEc1WTBmNvm99826RI
mdI0adpUbx6Fz2H+/Pk2X2Ttr3FvBYoVN2FhYW6d+7Vr18q5t4rKaIu+cX+mTJ3adO3aVTutQgm0
wj/Rq1cvKV+Nh6oO7K5XaWOi3Lx5s95ACp/Cjh075N5MLK3xmLnznfo6eyOxEI/p6WvXe+V3pA0J
MQMGDHDr3NeuU8fkKVQowc85VqP+WCW2VecuUqzqp59+0o6rUAKt8C/cvn1bEuOo+qXE2L3KWkVK
lzb5Iibw33//XW8khc/g0qVLQqApMJLQ/YL8CYqbWH/jgbxk/4EY34MfdONn2vgUgabKIedw9uzZ
Lp93bNl4T4/RzyXY+cYfu1WXriZ5ypTy3Vly5JCxPK7e/Z4sROPq/cJxr1+/XjuuQgm0wr+AowSW
Qq++e02JsZuNksUM/suWLdMbSeEz+OGHH+S+7DlmbIL3ifmv7o5CoL3dvEWgSQDkHOKJ7yqmTp0q
77HKkidEq1Q31KTPnFmqObLj0G/iJBOSKZNp07uvXxBo6xrWq19fO65CCbTCf3DlyhUZ8DsPGaaE
OB7lfkka+vnnn/WGUvgM8ubNK4VA4npfv/b+XYkeI8HIlC2bad6+gzl872FkIYyWrUz45q2mfI2a
Utq7flhrKRZC6e1cBQqYvz/2mClcqrRoXHktemCi4RTQsP+OvhOeN12GDTebzr5lipQuI48Nfync
9B4/QT67YMmSUv45pmOxJ9BrTpySSHaakBBTokJFs/Lo8Tj//qEzXpSx8cMPP3T5nJcqVcqUrVY9
wcYezivnmrLr9o/PeWWHPI7tpj8QaO4BJDxff/21dlyFEmiF/0SfKfnLdqWS4bi1udt3ahRa4XNo
166dyRyxsIvrfd3v+RdM3sJFzHPzF5puI0dHjBPphPBauuaMWbKaJm3bmYGTp5ikyZKbAS9MEY/n
joOGmBSpUpkx8xbI35YGmsRbSNLOd67+laRXvLhETu010DgzhGTMKASYUtpIpWI6FnsCXatpUyHz
U1aulvfmKVQ4zr+/wZOtTdasWV0+31999VVk1P+5cQlqs1eneQunz1UODTXP9O5jW/CMW7BI7ocn
u3WXx/i7Up26Jk26EPl31bETiUagF+2JrHy7c+dO7bgKJdAK38enn34qVlfWgKotftn6xYoV05tK
4TNYsWKFkBLH6KSrrWq9+hHEdIPtb6K+Tdu2txHoFh072Z5r2amzTcPsKOGwTyLMV6SoGbdwsU33
TO4FEWZHAg2psy9/HdOxWAQazW+SpEnN6uMn5fEdl96V44LEx+X3Z4wgzx06dHD5fG/fvl3O95J9
ryXcuBOxAEGy4ey5Nn36mYq169iuQYbMWYRIswBhMQNJ7j1uvCx0iPQXK1cu0Qg01w43jv79+2vH
VSiBVvg+pk+PdJGwIg/a4t4GTZ0m5/LNN9/UG0vhE7h3757ck0gR4nNv7752w0xescqUq15DIrwW
IRsRPuuvqnJjxprqDRvFSqDb9etvGj39jPx/1Oy5EmV2dOGAQJesWMnlY7GPQON+AanksynUEZ9y
4zI2rlrl8vnu27evSZUmTZyT9+LSiMRPWLw0WicUSLN1DShLbj03ZNoMSTy0/kaOw65BYhFoWSTV
b2CKFCmiHVehBFrh+yhcuHDERFVRCbAnMvav35RJp0+fPnpjKXwGuXLlMrWbNY/TPb3swCFTpmo1
iRKTpIYcAlmEM2s65BRV6tWLlUDP2/GqjdShz+4+aoxTAu14zDEdiz2BXn7gsJBoyC+uFGip47Mg
vn//vsvnmoqFkMCEHHf4jZOWr3T6HHIX6zpwDfpPmvzIa9CRL9i1x7Tt219+L+Q/sQg014pjUB20
Qgm0wqdB5ScGq2EvhisB9lCrH/akyZQpk/nvf/+rN5jCJzBw4EAhQ/vee99ti0Y0zpDcxXv3y99E
j+NLoCFoRE1XHD4mMg3Ld96RQCM1cPVYnLlwcAx8BmPc8oNH3O7LJStVMiVKlHD5PP/2228ihyPR
MSHHHCQx6MOdPceuAImc1jWYuHR5lARRdgKImCdJlkx2AoRA3/8g0Qg0UXCO4fXXX9eOq1ACrfBd
TJs2TSYsdIJKfj3TmKCYAM6ePas3mMIncOHCBbknR86a49a9vP70mcikLruEPyQa1Ro0jJVAE9GE
HEdXSKXeE2GSfIibhrNCKo4EOrZjsQg0z5evWStKQjTRbne9sDeeeVO+Lzw83OXzfOPGDXnP+EVL
EnjR3tpUb9TY6XMVatW2yWUcrwF5Lznz55dky/237pilrx2U4ycinVgEevvFdyI15EuWaMdVKIFW
+C6ollWkTBklvh4uvMAW86RJk/QGU/gM0JW6a60GkcIKDq0sSXij58wTggspi41AQ8AgQhOWLIvi
wmG9FtcNLNaad+joEoGO7VjsI9BFy5Yzrbv3MDsuX5HvJDGNaGtcLNVIsnYVeEXzm4mQJ2jRmj+9
qh0L1bCIsU9odLwGBUuUkEqq9nIPXs/5TSwCTUuWIoUZOXKkdlqFEmiFb+KXX34xSZMmlSxtJb6e
bUXLlJXFiULhK7CShde9/oZb9zK2dESSWRSS1EcUG/0xEoqYCDQkrFDJUrZS4o6vxXUDgkr00xUC
Hdux2BPoOdt2iKME3509T163EyiRMGTNmdM0aNjQrXO8dOlS+c7E2NFr2PopkWIgx0MDPmT6TFk4
EJ2ObhcABxP02iz6uUZZc+WS48e3OzEJdJ6ChUybNm200yqUQCt8E+fPn48s82s3gWnzTHuqR0+T
MmVK1UErfAb4E6dIkcI0adPW7fsZMhxXUggZ82TfcudYtl24FKfvwLmCsfHAgQNunePJkyfbkvAS
esw5+vAjibpT0IZjgEwzDvF4dASapEx8tVmQoFdH5sIChSTPxCTQFKUKDQ3VTqtQAq3wTSxfHqnV
3XLuvJJeDzdrAn7//ff1RlP4DIYNG2Yef/xx8f/Vfho9Ec1TsKApW7as2+d36NChUpAqsY8f/bY9
cY6tUXKcKL6vXAMSQ8uUKaMdVqEEWuGbGDJkiGzx6aTp+UZkBwK9e/duvdEUPgP0vEmSJIni/ast
akOzHddqeHhAZ8icWc9jPBtOK+oFrVACrfBZtGjRQjSK8R3sSAZiwrEaGkbspspUqxalOAuTNpXE
EkpCQSZ+YiYSci5mz56tN5rCpzBgwACxWtPCSU7kIbfvmWy5c4uXc1zkV927dzdZc+TUcxlfPfdT
T5u8+fJpZ1UogVb4Jtgis6qGeYJA40NK4QFa5yHDhJwnT5HCrDlxKugINI3oPlu6CoUv4dtvvzUZ
M2YUnamStait0+ChMpadPn06Tue2d+/eJlPWrHouPeClX6hQIe2sCiXQCt9E9uzZTbN2HTxGoB1t
ovgbAt173PigJNC4AnTs2FFvNIXPYc2aNdJnx8xboITtz7bu1BmTJGlS06VLlzif10GDBpm06dPr
+Yxnq9W0mewCKBRKoBU+CVwi2vTu6zUCbfmMWlZUjgR65vqNYr0UkjGjRKstom1feQwv1my5ckum
eL+JkyQD3zbhvf6GkGSyzYuVKyeep44Eus/4iSInwfJq6uq1Ua2qHnxo2g8YKNZNvCasa7conx/f
VqR0aZHJKBS+hv/973+mevUaJl36DGbb+YtBT9gYC0pVqmzSpk1rvvjiizif14kTJ4o8xpcS8vyx
latR09SsVUs7qkIJtMI34amSs9ERaCqCoYd+ulfvRwg0ZJfnkJD0GjtOCC6fMXnFKtv7OwwcJIUW
IPk0otnDX4osOU6BBOyWMmbNZrqPGiPVyChFu/r46zYCnTxigQAx7j1+glTpwpKJKJNNk925i0Sc
2vcfIJITXl+raVOPTQKUAW7opo+sQpFQuHv3rkmdOrUpXblKotiu+VJjIc34s23btnid0/nz59t8
lJUIx70VKFbchIWFaSdVKIFW+CYgsGj+PEWgiWTtvnbDvPruNfETxaCfxylq4EigMfDPU6hwlEgN
kWarqMve6zdNilSpJIJsPd9x0BDbeyD+PE/5WStaTfWxxs+0sRFo+wpcPF+8QgUpH8zfW9++aB57
/HEbIadRhIH34KDhiUmgVAQxqV+/vt5oCp/F1q1b5Z5nsRqsZG3mhk1yDvr06RPv87ljxw5b4Rhf
sNKMzv/ZWbMvYhMXuZpVxMYTLW1IiCS7KhRKoBU+ieTJk5u2fft73IXDviGLcObCAdHGe9Teu7Ri
7To2Agzp5v1UK7OvXEbkmtcWKV3GRoatRuWyzNmz2wh0geLFozw/cMpUkYLw/3ELF5ukyZI/Itng
/USsPTEJFIsg9M2aNdMbTeHTgDjS12IjWIGqe0bGUrp0aanMGl9cunQpsjjVqjWJ+rsW7torhVH+
Cj4MfqTMt2N75eJl2/ibmARaHYwUSqAVPo8MEQPsE12e9RiBfqZ3H5FDsB06ZNoMs3jv/iivc9RA
rz99RnTPlUNDJfGGzyD7mueem79QJBvRfWdIpkwiz4AkWw0tMxW12I6GQNdsElWOwaT2eJIk8jyy
EQZ9x88tU7VaFNIfn5avSBHz9NNP642m8GlAHGvUrClyJmu3KBgahDFbxJiROXNmc//+fY+cyx9+
+EHGsZ5jxibqb5v/6u4oBDohEqY9RaAX7t4n53D//v3aORVKoBW+CYzq67Zo6dUkwugI9EubtoiE
grKzJBlCmIlAWwR6ZPhseS66z0KvzOuf6tnrkYaXKwTaUc88Y91GOU6izkSrrWi0fatQq7bHikyk
z5hJCisoFL6O7777TlwPsF5cfvBIwJNnJGLobNGAv/POOx49l3nz5pVCIJ44TsZUosdIMDJly2aa
t+9gDt97KM8xboZv3mrK16gpY2X9sNbmwO278ttyFSgg+SOFS5UWPTavnbX1FQkiOI75fSc8L8na
m86+JTt7PIa0jZ04PrtgxH3B7l9Mx+JJAj10xosyTn/44YfaMRVKoBW+ibp163rECzYuBLp4+fKm
Ut1Qc+T+B39JHsqVs8kyLF2ivcRi19XrEtnh39wFCwoJdiyCYH0eBNqaDKw2InyWOH7w/1Gz55rU
adM9coxorHuMfi7e54SJhWj4Cy+8oDeawi9AlcI8efKYkAwZY93u9+dGjkbRMmWlIuPJkyc9fh7b
tWtnk5LFt+Gtz0KfAEO3kaNlzILwWrpmduGatG1nBk6eIpK0AS9MkTGTfBFyRLAp5G9LA00Jd3TO
JHjbEvaKF5cx3F4DzdjKWFmiQkUpq00OSUzH4kkC3eDJ1iZr1qzaIRVKoBW+C6pmEUlIDALN9qL9
Nie6N6JfVnSEJD8I6JSVq22vQRZCVGX/zdsS4SEy4jjwkkhoEWgmECZL63mcOqrUqyf/f/nQ0Uid
3dbttucp+MJjRKrje06Qp/BZGzZs0BtN4TdAypA/f36TImVKiW4GGnmGQOYuUFDyPw4cOOCVc7hi
xQrp+/aOP3FtjJfT126w/U3UlwRsi0C36NjJ9lzLTp1tGmZHCYd9EmG+IkUlB8SSsTDOEmF2JNC4
HBHRduVYPEmgM0aQ5w4dOmhnVCiBVvguZs6cKQP9vvfeT3AC3ejpZyTai0sGDc9mJB0WwaXVad7C
ZMmRw4Rv2SaDPxpny1OaCBnfyaQBGUZLzeBveT1DoCHbRLnRYqN55vV8lr1cI0vOnCInIekmf7Fi
EcdUyCMertPWrJPve+utt/RGU/gVPv/8c6lSSr4AfTtQyDPjBOQsJCTEnDt3zmvn7969e9L3kSJ4
6thJusbis1z1GjZpGqSYXTXrNQQkrMqyMRHodv36y/hr7cQRZXZ04YBAYy3q6rF4ikBzDJy7VatW
aUdUKIFW+C4OHjwog9W8Ha8mOIFefuCwSDZ4HxM1CYhsQ5IcaBFYpBpo8CxHD+Qm+D9bnzduwSKJ
WvNchsxZZGKwL6QCAYeQW9/Rf9LkKMfDZ5WtXt32+WxlbnjjrEcmPCYgJqOffvpJbzSF34FkuLqh
odIv6LeeLDCUGG3Yi+EmabJkJlfEIvzmzZteP398T+1mzeN93FhqkthMlDh95swSdEBS4cyaDjmF
FYCIiUAz3jNe8n928vDRd0agHY8/pmPxFIEeNHWa3HOeSupUKIFWKLwCKm6J/6md13JCty3nzot2
OabXbL/4jrwuugpibJVibRfTd8RE7iHSSEY8+bvwwC5YsKDeZAq/xX/+8x8zZswYGSOoFIosyd+I
M7tr5FXwG5o0bWq++uqrBDl3AwcOlMJN8dndI5CAxhmSyy4afxMkiC+BZsxEv7zi8DGRaRCZd0ag
rd0+V47FUwSa4lMlSpTQzqdQAq3wfRQuXFi0wVr9ynMNMo/+miSlRYsWmT/++ENvNIXfgp0qLC+T
p0gpUijLecHXGzKDLDlySsVV5GqUL08oXLhwQUj7yFlz4p1HYZ/wh0TDGq9jItD45UOOoyukwqKC
5EP7HJiYCHRsx+IJAr3xzJuRMrvwcO10CiXQCt9Hv379RAZx6O4DJb+eKmLwp49puT8lKhUqVJAC
CwqFvwKHjtatW8v9TJ6AL/tFbzx7zlYFlQIpb7/9dqKcM2xCy1arHi8nnzQhIZI8jYRm9Jx5QnDJ
3YiNQFtJ0hOWLIviwmEvuyNHpHmHji4R6NiOxRMEGis9PpN7TaFQAq3weZCJzkD74sbNSn491Cgk
8/jjj5vvv//ebN++3eTIkUN0g0OGDBFtqULhrzh06JApUKCAjBmVQ+uJVMBX+h0+xiQVUxAGf+f5
8+cn6u7P9OnTI904Xn8jzr8JWzoiyYwfJPUR0UZ/jIQiJgINyUV2Y5UVd3wtrhuQVXuXo5gIdGzH
El8Cjf1o1pw5TYOGDbWTKZRAK3wfbGlu2rRJtjjjWsJV26O6xey5c5uGjRrZzvOPP/5oBg0aJBNP
9uzZzc6dO/XmU/gtqFz40ksvSQU/CBpR1pnrN8aYh+Btd42GTz0t41jSCPLcv39/89lnnyX6eUJv
nSJFCtOkTdt4/T7I8I5L78bpvRRR8eS5js+xxNTGzJ0v95K3rAUVSqAVCo/h7NmzpkqVKpEOFhky
SMILFayUBMevYYkXnf/z5cuXTcWKFeX5pk2bmgcPHuiNqPBb/Pzzz2bhwoUmZ86cck9jEdemTz+z
8uhxr/czEouJuBYsXkK+O2XKlGbEiBHmH//4h0+do2HDhsluFP7TOj5GnzOSp2BBU7ZsWe1UCiXQ
Ct8FHqVPP/20TDpYLa1bt86cPh3pvYmFkA7o8Wu1m7eQ7ePo7Ov++9//mgULFpi0adNKdOrFF180
v//+u96YCr/Fb7/9Znbt2mXCwsKELDKWUKykVecu5vllL0cpZhTXRkEPCrsgjypWrrzs5vA9VatW
M0uXLjXffvutT54b9LwkE2MFqOOj84ZOWxIUdWdOoQRa4W3gY4q+j+hGjx49zLhx42Tr69///ne0
7/nmm2/k9QzmadKkMdOmTZMIkoVSpUqZAsWK64Aej8bWJgRi8ODBsV5DtpithQy2TWfOnHH6utu3
b5vFixeb4cOHS+XIsWPHmt27d4u+WqHwNTDOQGhbtmwp44zlsY5GlqIbEGA8mdHLkmy7+vhJ8V7H
gYFKoEtfOyj5GJSg7jp8hGnY+ilTsERJ8XEXP/eI/lWzVi0zefJkc+fOHb84JwMGDBB5yapjJ3Sc
dJSE3L5nsuXObUqWLCnBBYVCCbTCK7h+/bpp3LixyZMnj/iMzp0716xZs0aSVUJDQ0WTyMRib9f0
66+/mjlz5kj1LQbxPn36mC+//PKRz16/fr1MUPZJJdrcaxRv4RwT5XcVJGVROpnknZ49ewoBsRZJ
zZo1kwRErhnXcO3atRKx5h7ImDGjGTlypEavFT4LEvjOnz8v9+wzzzwjrhRWhNrVxi4Z/YAgwZEj
R8y//vUvvzsPRMfprxSC0nEyaus0eKhcZ3ZBFQol0AqvgAglEZ2VK1dG62eKphZZAJpEEn1wgMiX
L58MUM2bNze3bt2KcbJjgstXpGiiJQP5c9vy1gXJ/u/Vq5fb15adgOeee052BzJlymQmTpwo13r5
8uXRRmXQehYvXlyurTp7KPwF3M8ff/yxuXjxojl8+LDZsWOHqV27thDMV155xezfv1/KbLMIRRoS
KCDQQV8lsq7jZWSjABZjZpcuXbRjKJRAK7yD48ePy+D77rvvxvpayDVEmAIpvKd8+fLm5MmTLn0P
kxnvwSNUB3j3WrN2HcQBAHIQV7z33nsipeEauOob3ahRI1OmTBmfLRlOhJxoOvpGnBvYzsZPuG7d
unLc3KtE4KnayIKAJEsi7B06dJAqeEuWLDHHjh3zCVcFhXeANCl37twB/RsZl6tXr2HSpc9gtp2/
GPTjJdUQS1WqLLkgVMRVKJRA+xAgFEgVPvnkEyE1dNJ//vOfCVqNyhMgCgO5eO2112yPUWI3tsEa
coI+2h1dGe+j+Ad+nPtv3VFi7GJbfvCISDeGDh0a72tdqFAhs2/fPqfPR3fd27Zta1544QWfuF/R
ZqPRxvO6StWqsqiw35JPGxJi8hcrZspUrSZlgCkNjM61flhrU6d5C/GxLVGhgmhmkyZLFuW9ROdb
tGhhZsyYIdIArfAYGGCcQqoR6Lh7964kGJeuXEUIZLB75dOnt23bph1AoQQ6sQakLVu2mAkTJojG
rnLEwJQtW7YYdXZoTbFto0IViS4kZ61atUosxnxxQiZy18jOU/jzzz8XDbR9hO+pp56SRDRkGpZG
kG1QopnuLhjeeustOUdPdHlWybGLBQBIcuK+i29i36uvvmoaRlNIwPG624NFIuQysba8v/76a7Ni
xQpTr359mzsCfRC3hDa9+5pxCxbJIsPdRRme2iRmUvVu8NTpQrTx2Lb6cvr06UU3fvTo0VgXlQrf
BdcQ2VkwYOvWrXLvdhg4KGjHzJkbNsk5ILdDoVACnUBgKxjfUchy1qxZoxDjzNmymzLVqpmmbdvL
6rb3+AlSdnRE+CwzMny2GTJ9pun3/Aum85BhYilUOTTU5MyX3zxmR7ZTpUolZHXq1KmiOfaFrOBu
3boJwQeUpIUUo4+1gCXapEmT5P/jx4+XZDMLTEoffPCB29/JooLzMXf7TiXJsbRuI0fJuYouauzu
tUbj7ghn190RNWvWTNBEHBabSH4aNW4s0Xcp8VywoOk4aIiZvXW7ee39u14752yBj1+0RIpnpPrT
6QENLWXpb9y4oQOln4G8AZJlgwUQR+5Z+8qAwaR7RsZCAIs8HV8Bcz2Fb95//33R57/55pvCAdjp
InkfCVkgafKVQAcJsPGC0BJhtYiuVHqLmDyxQ6JMKR6h8dFiYaGEF2XYs90lmkgElu+BpFNBjqIj
iSX9gNCjAQU4ZRB1z5s3r+159KRoZ60FBhnrFmrUqCGRaHeBHR7lenNEfM/eG7eUKMcg3cBeC72u
J4D2l2iqI5xdd0d07NhRdmO8DRIWcX8hGk4f4R7pOGiwWXH4WOLYYN25b6asWiMSkGQpUsgxQepx
bFD4B3r37i0VOoMFEMcaEQteEujYXQmW8fKVi5dNtly5xC3q/v37iXb+kXMiHRk9erRp0qSJzHWu
usOw0KtVu7ZUu2TXDX6iUALtU2A7FjJQqVIlm+wCzSTbuAmRgAFppABA7WbNbZMyGr3w8PAE999F
nuFoMG9PpEi6spIw+LdChQq254haXrt2LU7fywqcQaVagwbqyuGkURwCrTj3hWU9541rHd11dwTa
YBwMvAWkQeis0XBa5Zunrl4rMgtfuSa7r90wPceMNZmyZZNj5P4/ePCgDqh+EJFFAhVM+O6778T7
OGVEf2IhHujjJVVuqTPA+PHOO+8kOJ9gHCAYZjkX0cixKBwxRtR7IkwkNRQSY2dr+toNUrRn1tZX
pEQ9OwXDZr4kvuSUZUfDnjpt2r8CehGLv86dO0ugQx2RlEAnGkjyg6RapWHzFCpkBrwwRVauidXx
0W1OWLzUVKhVy1Yylo6YUGWYsTezJBrOiFS9evXMw4cP5f8cEytqK4qcLl26eHXoZcsiK0QRYVTS
HFX3zIIuefLkHp0MKJLy/PPPx4lAExH2RjSErU38p5kkuBfqtmhplh847NPX5/C9h+Ikkyt/ATnm
ho0axXkhqfA++vbtK7t9wQaqFNJvQzJkNEv2HwjoYEPRMmXFptNVRyhPgLGZxG4i3owDKSLm7sqh
9UzvceOlYE98EzkpADT8pXAh4Bn+/A7mhPbt2wth1yRnJdAJAhLh0DaT3MdNWLFWbTNj3Uafim7R
kIuwAmXrzao456noY3RgS59tI/vOaE+k2IbavHmz/H/Tpk1CuAGkp2nTph6JDnFNxi1crOT5z9ai
Yyc5J56WTFy4cEEs3aJLiIuOQDMp8T5Pa/avXLkirixSLbFCBakc528LnYGTp5i06dPLLhbbrv5Y
iCPQgXY9S5YsQfnbkTLQdyF3RD0Dbazc/ObbUtYdYkm1XG8DqSX5KJUrV7ZFmXH3mbZmnSysvflb
l+x7zYR17SYab2vXetGiRVEq/iqUQHsUe/futXkWV6xdx7x86KhflGxu1bmLJE8R5SVxz9MJBnwe
WlM+n+IoRCedESlkG6x4ceCoU6eORJxxbKDyIITME8dRNzRUfuuk5SuDnjw/3au33KskbHoj2hsW
FhbtZzsj0Ow0sCvCMeEq8+GHH8b7OFiszZw5UxaJGbNmlfwAf75me669Z57q2UtINHrHuOQFKLwH
FjZECYMVjNfYjpJPEUge/MzljB/MRd7ucxBnCvFYPvrkZmAcQN9PjB0wKvpSeZJjYXHIzjpjtUIJ
tEeA9RWaT26wfEWKSMTZ3waI1cdfN1XrN7DpLa9evRrr70ZbHFtCIhUEiUrwuSQFMvgw8ROpiQ5W
5ySRELKLJZqngKc2SS8QqmAu9d22b3+5JvH1e44JaCMpLoI3risTL8RjypQpsthCXwiZnjVrVpxt
3ZABUfCB34lHM7riQLl+81/dbbLnySNWe5SGVus73wDFdbBhDGYQ+CBQQb/DJYrkWH/uayT4E/0l
Csuc5E3gksH8ZHEJFiG+4rM9f+cuU7lu5HWlWNCePXu0wyuBjh8oCsKqDCkEdnP+bipP0gErbTRe
L774Yoxb6bVq1RJ5RXTkumrVyFUrW+cnTpywPffrr7+KzR6JJzzuOPkTeZw8ebIQqtWrV3v8mv34
44+mWrXqEiWZuHR5UBFnkiityDP6d2+DqD8exxBpJDxInOxBGW8IM7pRqvtZwA+aCDbHiU2Uu1Gf
U6dOyfemCQkR3X8gXsv9N2+b5u07yDmq36CBLFgUiYuBAweKDWGwgzGd6pvcm4VKljLrT5/xu/61
7733RRPMb2jStKlYw3kLBHawXCVghI581Oy5Pif7tF+8Fywe6STGbrGVt6RQAu3WAEG0wRogVh07
ETAT866r101oy1by27C5oQqis+ieZY9nn9x379498bbmORIoIdjOSDhb6+hu0XdBdIh6Q8iRwECc
0St701aHY+a3cZzPjhgZFOSZJNIajRp7PfLsCK4/OxHVqlUTGQ8LJyQ6kGquPVnfaJSdATcO5B5I
FrgnXCGJeI2zw0AEZ+PZcwF/XcfMWyALePoOFoGKxAOLUvJfFJEgAY3zkTxFStNr7Diva3c91Sav
WGWy5MgphBYJmDetXxn7qNrKGNeyU2e/2CkjUEgtCpxX2C2kqI5CCbRLYBKnUhlEpE2ffn4zKLjb
qLqG9R3Z1Wwt2YOtdsv6ZtSoUebbb7+VFTSRazoUfteu6qR4L84CeFRDABLKp5ro6LPPPiu/gUjD
wdv3ApZkbXnrgkQNmBCWLl2aaH0HdxrupTfeeEMWSK5kd5Msxz0GKWa3Z968edFKFqyoV5XQekHl
+71g1x4TkjGjaDTZ/VEkDkjGZlGo+As4dODxb7lR+bJfNAtuS8rIzheFn7wJ3KGSRix+M2fPLpFd
fxt3tr59UazwrGqMvlRQRgm0DwKCR6SHiM9z8xcG/MSMzRedG1KMXMUCK2aLQEPKqCzHvxQSsLyc
/QVIB/gd+YsWS7QiGt5s+IDj3kD01ypk44+AeFuyIO5HknbtMXLkSHmO0u3+LqWKS9t09i2poMi5
oYy9IuExZMgQWcQoHsWhQ4ck/4U+igWbLxFG+g7RX+Z1+s/8+fO9at2GlI2dN84FhH3Xlev+a4Ua
MdbiPS2e+mXLiixPoQT6EVAljwQRIj1EfIKp6hLelyQssVXD5OxY1QjZhbcTLLwJqr1RAAFdNAUs
AqHgClnbDZ6MjPxUqVIlILb32Z0gAdWqsIkUBE07lof8/WS37kHtrLL94jviGc2C1hPONQr3gDSK
harCOYhQErCw/IwpYkSBj8Qab3HXoBIwwR8iwbioUOram2BHjQqj/P7uo8b4rNbZ3cZ1TJkqlUju
VEqmBDoKbt26JZ2eymD+mBAR3/ba+3dNueo1hERjU+SsNOjhw4f9+hojJWnbtq38luLlK4gXpr9e
L6pQsXOA7AE5TaAZ4d+5c8fm7mKVriXyrN7en5htFy6ZnPnymbRp07rkpqPwHIYNGybnXREz8BOm
XoJVaIzEdeSQK48eT5BFZt8Jz9sS4XD7GTFiRIJETnHsoioxhH30nHkBN/YsO3BIAowEGi9duqQ3
uhJoI1pNkuUyZsli1p06E7QTMyTa8oO0IoD2rWjRoo+4LPgjiLJzvcXdIOxJs+Xceb/SwhYrV16O
vXz58gleajah0aFDpAtFk7btAiaS4yltYpbsOSR/gUlbkTAgD4Tov8I1kIeybds20Y0TnBGLtAIF
pTYB0jMq/8W3Lxy4fVcKu7QfMFDGRut7qlatJvkgBE4SAiSuE3xKljy5mb52fcCOPQQYsdhkIalV
U4OcQFOdL1++fFLecu3J00E/MePkUDJiBU2yIBZ0JFngekDkpWHDhrZKgv4ObIUoRU3VKTxAW3fv
4dOODhDnGo2bRBrv58hhNmzYkGDJmIkFoqtEj0pWrGQO3X2gxNmhUeKXyRpPXvWJThgQyURDq3Ad
Vu4Cfv8QWooosQixAjPsptRq2lQIMJ7MkE8qia4+flJKUG8886ZZc+KU3O8vbtwsrjRdh48wDVs/
ZQqWKCmyPGunqmatWmKRyg5WQgLr1jp168qxBGKVxugW8MgiP/jgA73Jg5FAM+ngtgGB8uftfE83
bHYY1Ogc3taLJTbwI6YQCAsGIhe1mzX3meQXyjvjcVysbGSJauyipk2bFhRVoljYorVDpkI1Te2X
0TvpcG/gDqFIGDKIx73CNRCAQc6A9tgeSM7Onz8vtQiwRcXy0pJqudoofELxLgoNkeOC9jgxgI2n
VWgNaV2wjD0UZyN5HcMBb3poK4H2UZAQwk3PilYnY8fOcVISBvBxZnUd6EAfR1lqSKrYMRUsaDoP
GSbnIaELoWADxRYnWjOOhcll+fLlQVVeFekG0RyiTtofXSvZDolQeBfYLbIroogdJBQWK1ZMFsIk
ArtCRD/++GNz8eJFybfZsWOH2bRpk9m4caOUvsYznoJL1CJAGuIrYCeT/jdw8pSgG3vYKcAKN7Re
vRiLsikCjEDv3r1bbnomH52Enbcpq9bIOcK6KVgASUWyws6EpaWjYEeb3n2lNLg37IiQjoyZO980
a9dBpERW4kv79u2lUEGgSzUcgX0d56DbyFHaD11olFLOW7iwlN91hago4o7Ro0ebFBGEQRE70IuT
S2NfpTbQwG/jN5KjEazjDwFIxutJkybpTR8MBJqkAgo2FC5VSrbJdRKOvmEbRuegCEqwgQqNGOFD
ppMlS2bbOoSsoL9Dh8cW+uK9+83Od67G6E2Mhhfd2JxXdpgR4bNM+/4DRPeX8c9kRhqJNm3atDE7
d+6ULPZgxPfffy/SIbSN2jddb4v27JcFHxaACu+BQj7kTShiBlao3I+UPg9UfP7558IjCLCQyBjM
40+TNm0DfrGkBPpPYHCO3ioQi2p4w5mDjFt0TsFK6gBbhmwf4nHaokULSeRzpstLlSaNSZ8pk8kS
8Tz63fQZM0mZW8fXMblwTjt27CjyDDzIgy3S7AxoJembyw8e0f7nZmOXhHsLbanCO8CPnMW0Inow
TyA7IzmfZO1ABcmQjO1ogZUn3JWFRPaIOU93wQKYQKOtYpLpMmy4TrouNjS5nDMmD8VfoGz15cuX
RQ60ePFiyf7GrYQoIImJPXv2FEJI4tGMGTPMihUrRJIBWQ4GXbm7ePDggZBn9XuOu4MOizd2TBTe
wdixY6UghyJ6kFtENPL1118P2N9oycz6TZykY4+dKxDXnTlQEYAEmghf6dKlTa58+c3hew/1pnej
NX6mjURePv30U737FV5Bly5dJCGFQgja5+LWBrwwRSb2kydP6g3lBeD4gGOPwjnefPNN2V0L5LwZ
8mTwXy9QrLjKzBxaqy5d5fqrP3QAEmgM3YPNasZTbfObb4srQt++ffXuV3gclIknetGuX3/tb/FM
KMySI6cUkVB4Hjj1sEuieBRINwoXLmwKFCiQaJZyCYEJEyYIj/AVu1NfanuuvSfuUfhxKwKIQOP5
jOaU8p5a0SxuLezZ7uLpef/+fe0BCo/i2WefNSlSpjS7rl7XvhbPRjEKJvhTp07pjeUF8sQYqHgU
gwYNkkXw6dOnA/Y3YkCAD3i9J8J0rIlu/Jn5kow/x44d004RKASaCnpc1Kmr1+pNHsdGQQu22Hv1
6qU9QOExYMKPrhQbP+1nnknoIZmV4g4Kz2LixImyRa2IijNnzgSF/vWFF14QHrHq2Akda2JwnCKB
nsqMigAh0JWrVDE58ubV6LMH7GqwcWIlrlB4AvPmzZNJSauBelaLSKQUK8aYMGXKFCmrXKZMGVkY
79u3T8uCxwCKZkAUFX8BTXDBggWlBXKxJ9wlQkJCTM0mTXWMcTEXA028ws8J9JUrV+Ri9hwzVm9u
D1Qe4lwuWLBAe4HCIyhbtqz4Pmv/8lx7+dBRl/opTglEDbFmxIccX1ssG5FpaWWxR0GxCM6r4i8M
GDBAFhVEoQMZCxculGuv1VFjb/hio4Vu3bq1dhB/J9AjRoyQxA8kCHpzx7/lL1rMlC9fXnuBIt6A
qDEp9Z80WfuWhxuLEneSeYg837171/z++++SCFYr4r2UTVb8BWsLXxEJ9M6QZ+bYQAdzXpEyZWz9
i8JZW86d17EmBl96eNc333yjHcWfCXTOnDlNjUaN9ab2UOv3fOQkosmEivhi7ty5ci/h8qJ9y7MN
r3vIDRpzd0HOSIYMGWTLmgJCikjg9c79qkWPjDhtsNDCeSPQi2zh3c91Hzh5imh8kUglTxlZIIui
WU/36h1jJdrYdouSJU/ukT6PDC6+hV3WnoxcFMV3Byzpn9V7lyxZogOHvxLod955Ry7i6DnzdFL1
oKUd5xTyo1DEB02bNpUKVtqvPN+W7D8g/fSVV16J07X56KOPTLFixUzatGnjRMIDEWjGOacqbzFS
MIqEymDQuVJEjGjqq+9eM5Xqhpr0mTObsQsWmpVHjkkxlZBMmSTimtgEOlO2bFL4LD6f8crFy1L3
Ib4Emt/ELliVKlV14PBXAj1z5kwZ8Ha+c1UnVQ+2fEWKmsaNG2tPUMQZSAawhNLKg95pRMRSpk4t
RCeu+Prrr212VJo4bMzUqVNlPvnjjz+C+jygnSdKOWrUqKD4vVjgVqlX38za+or5+2OPmXWnzkSt
1vvKDnn8xY2bvUKg9964JRHvg7fvxfi6jFmyyrH4Qg4Gv6n3uPHSX7QAm58SaEgeml2dUD3vCZ0y
okNrxr4irrh69aoWNvJyq1SnriRpxhcQJaq4BnsJ+mnTpsk9G8zj3k8//WTy5ctnihQpEvDSDfDJ
J5/Y8jRqNW1m6jRv4bSvVQ4NNc/07iP/r9uylRm3YJHYuT3Zrbs8xt/0xzTpQuRfywrPJQJ9/aYc
Q0wEukXHTuaxxx83OfPnN88ve1kem752g/AfvrPBk63Nvvfel8c3nX1LjmHMvAUStS5eoYItcs1z
RUr/pfXecfmKqdagoXxGaKsnolj4xfabrGTmTZs26YTnbwQanRrbj606d9HJ1MNtwpJl0jHeffdd
7Q0OIAnriy++kOhdsEeqYsK6devkHlr3+hvap7zU2g8YKFvPOGvEB4cPH5ZrxVZ2MGP69OlyHujj
wYo+ffqIdOOtt94Kit+7YcMGuebINQoULy6SDadJc336mYq169gS7TNkziJEutvI0SJ7tCKykNaC
JUuaYuXKeZRAv7Rpi0kVwXfo84ypHC9Rcf6etHyFHFP1ho1sOuckSZOaXAUKSNS8w8BBIkvZdeX6
IxroEhUqmlKVq5jJK1aJhV+ZatVsUs7YfhO2wWnTpzfdu3fXCc/fCPSDBw/kphv+UrhOph5u60+f
kXO7Zs0a7Q0m0gt11apVpl69euKTnTVrVknCIkqPznfnzp0arXfA6NGjJdFEvdm918YtXCz9lFLp
8UWPHj2k4M0HH3wQdPcqfZdgQceOHeV8Hj9+PCij8SdOnBByNWbMmKD5zVRJDcmQUcap1GnTmQmL
lzrta2PmzhfSbBHohk89bXtuyLQZknho/R2+eatJkSpVrAR68NTpplbE/EEEmPuueqPG8jfVRmOT
cDRp287UbtY8ypzNtVtz4pSQZD5vxrqNtueLly9vBk6ZGoVAY9n3eJIkNgmslOrOlEmi1K7+Jo4h
T548OuH5G4Hev3+/3CSL9+7XydTDjcGEqoTBYF8UGyAnFBGAKL/22mtRon0Q6127dplyEStztj3Z
/lREAo/QvIULx3qvEQGpUKt2tM+zZck2Kdun5arXiPZ1K48ej9xOjBj8vdUvnurR05SvWSva52M7
Ro8nEu57TX4zY2F88dlnn5kUEX1+/PjxQXOPsoOE/y8EoESJEqZJkyamefPmpmbNmuKbzSIwWGy6
KCSSN29eSSz95ZdfguYewGUE0kp/Qoc8aflKp33tufkLTboMGWwE2pk15+F7D82CXXtM2779pV+S
pxATgSbajTSCMYPXM7bwN0Q3NgKNDMPRPCFPoUJm4tLlQpLZRbB3DiFSDSG2J9C8v2jZcjGOMbH9
JpxLePwf//iHTnr+RKDnz58vF45tiZhugJadOptCJUsl6sQbU9t/87Z8/7wdr7p0fAk1SecvWtSE
hYUFdUf48MMPXS4sg34yWbJk5uHDhzqCRKBixYqiG4ztPus9foJEQegHziyXOP/o9xjsuwwd7tME
OrZj9HRDv+hJK6n3338/aO5PZBqNGjWSPJobN2488jwyrfbt28v5DQYSTaVKqlu+/fbbQXMPEACB
THYdPsKWPI+Nq7O+RqG2wqVK2wg0RNV67rX375pGTz9jUqVJY5JEzAEEBYRs3v/AYxIORwKNttk+
wkxDfgGhZdwkkmz/XJ/xE2U8tifQvcaOM1Xq1XP6Xa7+prnbd0Y+fuSITnr+RKCJjqaIWDHGNsn4
OoGm07ACjs7f0fH4EmqSrlqvflAXVGECzZ49u2h5XQVEhkhWIJe8dRVE9RiAXZULvfDyo5Ef9Hdo
7FzxYPUFAp3Q7ejDj2QypACIpzBu3Djz8ssvB/S9iU0d0dZnnnkm1tcuXbrUZIsgK4EcYcOJhb4z
duzYoBqjrCrGaIjpT/XDWouMwllfY5fMGs8g0NZ7aOyQsVM2ZeVqs//WHZFG8LlEb71FoPMXK/ZI
gnbBiLkHWRck2fE7Ow4aIr/PnkAjFSlZsVKU1227cElIsqu/iQAmjxPQVPgRge7SpYvJnju33xNo
XyAGzlqTNm1Nzly5grYTMJkMHDjQ7fdRNnn58uVBP4ikTp3aPNWzl8u2iWj6HB9ncLceJ7IS1rXb
XwvPO/fFLYZJhdeRBGPfT/B0JcGHxBe2XsmwZ/KwoitoAsO3bDPZcuWWKAwTQ0zvsSfQRHOs7526
eq3teftjtL5j9fGTMimTAESyDhpF+9/YfdQYkz1PXtFXMmlxHO700zTp0pkhQ4Z47LpVr17dVKhQ
IaDvTXaUkCq4CnaXnnrqqYAssPLDDz/IYrd48eJBp/vevXu3jBnLDxyWvrRw977IHZ39B6L0MSQM
8vi+15wSaIgremZ7uYcQ4ogxyqMEOms2sdrj/yT8WQ4gtN3XbkikeNGe/badO/uxiwRIii/ZE2jG
P3TfHKcl10gTEmLmv7rbrd+EnaYnxyAl0AmAli1bmsKlSrlNoGObeIl2oRfKGkEeeQ0TonWD8S83
4rMjRkbZZpbJePNW6QjWpGk9v/HMm/IYBubOJu49f75n+cEjLh2f/STN/5nwR82ea3IXLCiTMMfm
mLgVl0ma6kv4+AYr0D1fu3YtymNs5XLfVa1aVSZUZ5Hmffv2mYYNG8b42UzERMFIXmIrmYkL3SGf
RwUw9IhMbN9//7357rvv5Htx/fjyyy8lMk40DM0qFkwff/yxSE1I/iKxlgqSlGy+c+eObMnfunVL
Km2xTc3vwV6OhCmKEF26dMlcvHjRnD9/XrZuqUpH4YQzZ86YN954w5w6dUo8YUkuIrHq6NGjslV3
6NAhc/DgQdGEo7/du3ev2bNnj+jBX331VbNjxw7ZDqYfuUICiY6QJW5/35LYwkA/bc06p9IlsuLZ
XmRrtVm7DjKI2/cTCiIw4XAM3PMQWLLs7WVTRFjQDRYpUzbW91gEGp0kfRPpCcSYicTyjbU/Rus7
+HyiRRwvdlD2FlL8bl5DIg59lOddidpHjUplEecET2HOnDlyTNxbgQj6XO7cuZ3KNqznnT3GbtTt
27cD7nyQPEpfvXDhQtCN8YsWLXpEBtqw9VMyrhCdhVgPmT5Txhait3/JG6MS6KZt25uq9RuInzPu
GHAHPpekPFcINOMeBDi2vp4zXz7x1afE+MwNm0zyFClExsF7OT7GGXvpG7vI/Dbs6JDJbXnrQhQC
DdfhWCkSw+sg2AQz3P1NFMtiPlT4EYFGv1aiYkW3CXRsEy+2eFjAtO8/wHQeMkwmTCvJgAZh5Xlu
Rv7GOoYOxc1obWfYJzbaR5CdTdyOGujYjs9+kub/fBYdqXmHjpKAwGunr10f70ka6xs62oQJE8zE
iRPlX7Z3icySpU2CzciRI0VKM2zYMDN06FAzePBgM2jQIDNgwADTv39/07dvX5nc0df17NlT7G66
detmunbtKjsInTp1ksx3tIbt2rUzbdq0kW1VOiNJaGiwn3jiCSGtRHabNWsmyXzoFrn+DRo0MPXr
1zehoaGmbt26pnbt2qZWrVqmRo0aEkmD6FapUsVUqlRJNLlIUkj4K1OmjPjelixZUiQXRKOKFi0q
CSWY6pMQiD2YI55//nnb9ja/1ZlLCQSXZCwammicDTj/wdhade7qEglcduDQI5EfFoX2xQXs7/vt
F9+JvDeXLLO9nnva6if0Tf5v/zxZ9DzGItbqc0wwlhQitvdYBNo+EsXEh8dqvSfCoiXQjB3WwgD5
FY/h18pExO+z9JeRvq7rJfmHRberBDprjpwetZFicRWfCoe+Dn4ffd4ZWCgyxjgDY9q8efMC6lyw
GBav9iBKHLXHpEmTZByh/9vLolp37yGLZ84NczH93v41jgSa8Stv4SLSd9m5mrJqjcyzzOmerETY
afBQOV7+5W+CZXhDC6eImLMsn2aLQEOC+TdpsuRSWdFZKW8i1gQEeB08ieCeu7+pbLXqpk6dOsqc
/YlAYylWukpVtwh0bBPv1rcvyg1pb43HpMbz3FDW1iw3HMbm6JF4zrrpXCXQ9hO3PYGO7ficEWie
44aWFeX9D0yOvPkkemzZ0sR1kkbCYREhXg+hhAxCCiGHWLixTZ8mYoBJly6dCQkJEWu3jBkzmsyZ
M5ssWbKIdpDITc6cOU2uiBUsW4VoD/NHkP4CBQoIWYW0Ql4hsUxskFrILSQXsgvphfxCgiHDkGLI
MSQZsgxphjxDoiHTkGorOQiyzYQI+YaEQ8Yh5ZBzSDpkHdIOeYfEQ+Yh9TzHb3AEDhxEo4gU83lE
XZ1FqzhXLDBYbLDosBYhDNjoVSkZTNUzfGdnzJhhXnzxRfPSSy+ZWbNmmdmzZ0sZdSZrtppxCVi8
eLHoq5ctWybykBUrVpiVK1ea1atXC4lHp71+/XqzceNGMbXfsmWL2bp1q5Cg7du3i80ekWG2LDlm
ouREjg8cOCCRZHyAmUzRQhJpPnnypESeT58+LZHos2fPSmQab1gi1USriFxfvnxZItloCYlsX79+
XSJ7LI64b8K6ul6FMEuOHBIBsf6u0bhJlKIG9vc9/Y1JwX4nZfbW7bZ+wmIWqYS9dpptSZ7H39Tq
c1g12Vf2i+k9FoG2j0jLLtCUqTLRREegif5YryWixWMbz56zjSv2PtnsPvG7RobPdvm8ZYi4T1mo
ego4U9C3uH8CEdz/jAOOoB8RmY6uAisaz0Dapv7nP/8pYzLjbbAW0CEIggQquvwC5kh74hxbYxHu
bdtOxhXmeevvA7fvSkTaMfnaIsnsfMcmDeGY4T5x/U3ISUqVKqXM2Z8INOSoWLnybhHo2CZeBPg8
b0k2rEbFIbZsrb9HhM+SLRG2O+yTDlwl0PYTtz2Bju34nEagI1ae9sdKRNzyqIzPJM0WNu+FGPMv
hPHevXtB0QGQU0RXiZHnWLwxYCCdcARSChYKgaiXdAVY+bGgYhFBJMfViYH7zZJSMOCzq2KfJGN/
3w+aOs1ky50nyvvpH/b9hPscfTI7M+j5mFCkL5w6Y+tzVPKKktAbw3ssAs1kYf8eIjOMBRBvZwTa
WlzbHyORIraG+XwIuX1Dx2i/kIitESFj90fhGrZt2yaLZUeweGVhGB2BZtHqSalMYoOdQPooMq5g
BdcTCVSg2dA6Rpm93diBIxCm8CMCTRTR0vy4SqBjm3ixdXEkpGIPU7ValAQmVqVEnbhJcRFwl0Db
T9z2BNoVYuBIoEtVqhzl9ZBny2A9PpM0OmwizhBJoqZUfeRvIqnB4HeMjpmobXQgetuqVatHHkdD
imQlWEG0nPuVnQfKy7o6CGNVx/t2XHpXFn6QUvR3zgg08iaqbNm/H8201U9YgJLsZ21LsuVJNS1H
Am1vHRnbeywCbS/noqFBtJJrnBFo+++wJ9AkIlKYgERLx0bmuyvnjEgUn8eOhicxc+ZMp1HaQAC7
Kvg8OwMa5+gINLtIkydPDohzQA4D9w1jeTAD6RMSKCXQ8WtwjrwRvEnhRwS6d+/eLq0e7Ql0bBMv
miJrO9bRwsa+Kg8RMraced/M9RsfIdDoiqzHbPXi7Qi0/aRq/1hsx+eMQDt6QiP5sAh0fCZpVpVs
acqxzZsn2t7OnTtLx8wR8dsDVSNpgYS4smXLSrKfBWQZSBsAsgeiOPYg+Y9zg7QhGEHUHTlOtWrV
TJWqVW2lb10igw8+lAxwdML0WUcPaft7nYxwcgOic6shwcaxn9FPrd0YZ/0wtvdYBNo+CdDajQrJ
mDFaCUd0BJqKZ1bk2v7z0Ee7es7YnhUXAQ+7vhCZYwEUiECuQJEUxjN3CDRSh0DwSCYxGUkdO2jx
LQGvEWjfbCzmSfzTCLQS6GhBRIDs4dg8Yu0JdGwTL4lL2Lo4fkaeQoVNj9HP2f4mUs3nkKVKQoGl
k2Lyc5w07SUYsRHo2I7PXQIdn0m6bMTn1qhZUzTGOFJYkgS2OdEic0xEckjKCUSgBUU/jc7afoKl
UtnTTz8tOyD2khakHZwTT+pR/TWyxTZ527ZtTa58+d0aiBs/00Yai0j7PATHex3PdKvAir1ntNVP
sF9CAmJ/37PjwvO811k/jO09FoFmQYrdnfUayvBaxQjcIdDorSV6vGpNlMgR+QaOBRKia5a9Fufd
k2ChyM5ToILf50yOER2BRh9duXLlgPjtJHAj3SB3IdgRkwZam+tNNdB+SKBJoHLFH9meQMc28VrR
Ykiv9bw10VmTGlFmdIdEq9na/XsEiScKZb2e7FQr49WykHOVQMd2fO4S6PhM0llz5pKIM0lofAaS
BftII0lsWbNmlc8iQx2btUCMVuHIwe//6KOPbI9jNWcPbOKI2AW7FpVSyETgseYjeZKEXPuEl9ia
ZHqHhMg9RZW9mMpkYzlHwuz8nbukCEuaP7X69BOS9Pg/jjn8PWzmS0KOLQcNZ/0wtvdYBJr+zncj
02Ihba9zdodAS7GiiAU41pJIVhhzcPSwqp250iyXECwLPQkkW3xuoOLbb7+VROZ+/frFSqCxauRc
+EP0mSqoyHkIbBD0IAEbvffmzZtlgc8YLkWLPFh4x5/hzIVDm/tNXTj8kECjZWMweHHjZrds7GKa
eC25RpacOc1Lm7aYhbv2is4ayzkrE5VkJ2xdrNLDWM3hymFZXeHdzOdDUEnU47NcJdCuHJ87BDqu
kzSZvQwsDMYk0rHlR9KmI/AqJjM9SZIksi2KSwSR20ACiwXIIO4iRJ6JRhHxw8mCrXN00DiOBHsl
JsgH9wzOIgAnEO5bdlBcHYi57yCtFBxxfM7xXkfaxL3Md6DpR+9v30/a9u0vC10ewyMdFx3K2xJp
dtYPY3uPRaBxBiHizGvY3ek/abLTY3SFQLMYR+bCY5y78jVqRsmfiK3xfckjFuye7nMQrujs3AIF
n3/+uZx3SLSzZGHATgquQzjQ+PoYhaUoY/CoUaPEOQc/eKRkOPSQz1GkSBEZp3A3YoGrcO4Drc39
pj7Qfkig0XJx8xMFcodAxzbxEvkqW726zcKNpLsNb5y1lR0mqtZv4qQoNi/4QltWcWiPLH00ZYit
5ChXCXRsx+cugY7LJM3zYpr+p00blbh4LwU6nIGCHURueA9bOZZOOJDA/bZhwwbz7LPPCrnAlYRk
QbTgWro70icXsvHVV1/Z7gnuBzTN3hy8sXCyFq+PaAFv33vE4ilW/aCL74npe91t9FGSJ+MS+alS
parOWHEEu2ZM/NhtWj7P+Lzji4zmGetMigz5Ohh7CXLEtAuIJWYg+3vHBVYlQsuiNqEbO0jReUt7
OjkQcwT7+hCebFqJ0A8JNGAbzp4semritYh0dN6IrjR3PSS9OUG7O0njBsLAQpU7QAU8HDhikyjg
WoG/M+9l69Be9qAIXOApiye4fUEPomJExDDz1yiN59uhuw9ELkYRI09j1apVkucQDOA+RQLDDhIe
8kT0KRTlLwmD5AIx3roSVSYAwGKBSqYKI/71nLvYiKs3Grvb7GT/VfBs8CMlxJ0lDZMj4ksE2jJO
CPYdWL8k0CREWBnw2jzX2KbGgcMe6KGxsovNwg7dMHZPJCFRcIUt/Z9//ll7VQCDwi8MokxI9njy
ySdN9jx5tE95obFjxTmnjLqnEega6OiwdOlS+d0EDPwBOIkgLfvss89cfg+RQqrHKozsHBLRtS80
llCNIk32BNrbzVsEeu72ndJnKMSl8DMCjb6Li7fi8DGdVD3UiJqnS59BpAr2YCuTc80k4wo++eQT
qfTHe6g+6I2JXpH4wOaPXQeqQToCjbi9i4U2zzX02uQekIegBNozIIeD3+3M4s5Xj5fAhiOpxiGI
apLIUxyLPT148EC00MFa6MkR2K85eru709glJnqMBCNTtmymefsOtkJodVu2MuGbt4psktLg9cNa
S57H3us3xWmIhGTykagYzGtnbX1FEqnrtmgZ5Tv6TnheHIGQcVo2mrgUUdyNzy5YsqREgmM6FnsC
jbkAkWzyq0pUqOhWnopjGzh5ivQZ3dXwQwLNYMEKstvIUTqpejiyRflnR2DlRLltd0BCC37KfCZb
pDhWKAIH6OQlEWfXrkee+/TTT+U5nGi0b3m2YREYnWexEui4wVrwkWDoD+jYsaMk69qD3T/LFxzJ
BpZ9jiChkBwFhZFAUUiGjHEuwd3v+RekdgQWtDj4YIML4bV0zRgMNGnbTogmFYAHvDBFfJo7Dhoi
lpgUa+JvSwO9+c23hdOQC2V9B3lYOHvZa6BxAWP3HQJco3ETOf6YjsWeQLNggMxTC4L3YtMb13EI
CS2VdxV+SKBB9YiVNiW1dVL1TKPiInpnioI4YuPGyMISJ06ccOsa4RJAxnOGDBnEg5QtRJLyFP4P
ypozgEbnBFGzVi2TM2++OE9Q2pxs/+7cFRnZX73aK9c0GFw4nIEEQn+KpoWGhj6SsA0xtmw2cQpy
5o7A+3CxUkQuMsQtKI6FR6rWqx+lsjBRXyvvA1LcomOnKIYGlobZUcJhn0QInxm3cLFN94ytJxFm
RwKdJl2IRLRdORaLQONzj+nB6uMnI3O9Lr0rxwWJd/e3M6ZjlGCf+6LwMwJt6dYW7t6nk2s8G50x
ddq0pk2bNk7PNfrmzJkzm7CwsDhdK/xXKWBAARw+Z+3atVEq/Sn8Czdu3Ij0TZ89O9rXrFixQl7D
9qT2MQ+Vzm39lDieeEO+Ecyw7lV3NMWJCcbp6Fw1cEzCEckxLwEUK1bM3Lx5Uy+4iZQacs3t7Sjj
0nZfu2Emr1glrliWJARSbF8jgkrD1Rs2ipVAt+vXX9y0+D/F3YgyO7pwQKCxzHX1WOwj0NjyEtXm
sy073rg0W5XlTZv0RvJXAv3NN99IxLRJm7Y6uXrAVsexaIojrAqQjto6d3D16lUxXue7KlasaM6d
O6e9zg/Rs2dPSRb97rvvon0NOxk4dIS2ekL7mAcaekncNxxzFDyJYHLhsAfFoRiTkB75A7AXdZYQ
ePHiRVO6dGnxgXYEfTVdunQSDFFEolAEoaxSr36c+iMWeGWqVpMocfrMmUUOgSzCmTUdcgqramlM
BBoZJbUb+D/jpiWBcyTQjg5kMR2LPYFefuCwkGju9eQR4zda6rj8dqvIm7/0FyXQ0YDJJFmKFCLO
10k27q1kpUpiDRhTVJgVOzIMrJ7iC7aKc+XKFalj79ZNExH8COwm4LLiWM3NGQYNGiRFR7adv6j9
LJ7NmrSckSNPIVg10Cwc+N2Mcf6Aa9euiVuSPRk+c+aMqVq1qs2C1BHs2JJkqPgLzz33nMxpr757
zW0JAxpnSC61E/ib6HF8CTQyC/TLmCMg0yDS64xAk3jo6rE4c+HgGPgM7vnlB4+4PRYVLFFSfegD
gUBbfo6JYUcTKG3OK5EFXzDcjw24a2CfRHnY+AIrobFjx8qWNJHKOXPmmN9++017oY9j5szIAj+u
JIXiB45jRPMOHbWvxaPte+99cchp4qQqqBLo+ANNub3/va8DJw00zgMHDrQ9RuSZnAQqDtI6depk
e85K6n3nnXd0ALMDYxjnhUQ/d/ojhdUk4d4u4Q+JRrUGDWMl0At27RFyHF0hlXpPhEnyIW4azgqp
OBLo2I7FItA8X75mLbP3xi3b64h24/7hzm9HM+6OK5cSaB8HZZapiKNlOeMefaaalSukGGcNOg9l
rT2Fhw8fSnU/PhdrIfWV9F1Q+pjIV6NGjVx+z+DBg0X6Y1X11OZ+w8rK29HnYCbQjGf8bn8qAEUR
oxw5csRaUAf7OqSOWonwUdCfKPpUOGLx4U5/xCIOK7gh02ZIEh5VVyG4FWrVjpVAW/rhCUuWRXHh
sF6L6wY2d/ZBh5gIdGzHYh+BLlq2nGndvYcUi+M74U3uFm1r07uvRO2R0CoCgEDfunVLbpg2ffrp
ZOtmI3NX/LRXrHD5fBPdKF++vMev49GjRyXJheNp0aJFtOXDFYmH7du3x6qVdwSWk+il64c9qX0u
jhW/mOgIFHgbwerCQVIz93V88jsSA+zYoeMtXry49El7R5wPPvhAilllypTJowGPQABuJcOHD5eF
PUXCJKL62kG3+iW2dESS0R2T1Ddy1hzRHyOhiIlAQ3ILlSxlcwBxfC39HT6D1ZwrBDq2Y7En0HO2
7RDvaL47e568ZuiMF902G8BCT6VAAUSgAZUJSbDZePacTrpurKLpvBTDILLoKqyEmzfffNPj15Gy
tLNmzZJBjajJ+PHjY62AqEg4UKShYMGCbjuoWGWHZ2/drn3PzUZWPhEfAgUK78AqzAXp9Dcg5eD+
qFatmuQmkFuSKlUqKd3dq1cvKVeu+AssNJC6QEjJ40DeEhISYmo2cb+oCmQYO7i4JgV7cpxw51i2
XbgUp++AqHtr7lcCnYigE0C6ytWoqb6zLjZ043SG1157za1zjXaZba927dp57XoStWRRxCCXPXt2
s3XrVq2glchAPym2kQsXuv1e5EHIcyjvvf/WHe1/LrYZ6yL9159//vkEucbB6sKxfv16Oc/IyfwJ
yDI47vDwcFtEmkRIZ17+wQ6K5DBncb6w+Xvrrbdsz1nSpVXHTui4E007dPeByRwxF9dxUnlW4ecE
GliJIO5uSwRjY+uIqIVjOVhXMXLkSEkO87ZvKrZMZJZzXYl+ahJM4qFLly4mTZo0cfYgJmrBgujJ
bt21D7rQSPZhwipZsmSCJdcGqwbaKqqBXthf8OWXX4o8g/ExumJGisiESySKWPglT55cZC3sdNoD
ZyGi9iTw6djjvA2b+ZL0kWPHjulNFYgEGjRs1MikjOgI1I7Xmz76lWSR0qVNlixZZOCIC4jUoLea
NGlSggyALI6yZs0q38m221dffaW9NYEna9xShgwZEq/P4f0MwjM3bNK+GEtDM879ziIyoRCsBNqq
tHr//n2/OWakGxBCLc0dPSgaU7NmTbm2DRo0MPfu3Yv2tRMnTpTXYfGm48+jchO0z1SXVQQwgSYJ
BD1TweIl3M4uDZbWrF0HGSgo9xoftGrVSkhtQkXHiHyScU7km2u8ZMkSt7Tbirhj8uTJEj2Ob2In
8p+yZctK1ct1p85of4zO83l8pGYcy8CERLASaCqq8btjIli+hC1btsRaCTSYgT82wR3yaIjSI9Fx
ZWxCG12gWHFz5P4HOg7ZtVZduspiHv9xRQATaICbAxe7TouWevM7tEFTp3lMU8l55rMYzBMSt2/f
Nk2aNJHvZnv75MmT2nO9CLY7SUjCGcVTi1wmNSpi4W+s/TJqIzrP+NW2bdsEv9bB6sLB72Y88Qfn
H/JD8OInadDdZN5gwKlTp0yRIkXkeiI7+/rrr11+7969e+V9/SZO0rHoz4Y7CcGT2OwSFQFCoAFF
OegI3UaO0k7wZ8MBAdueJ554wiMJeXxG0aJFZSBPDOzevVscIbjOkA1/s6Dyt+icJ7Vvp0+flnux
cmg9cYPR/vlXbgLReawiiYgpEjai6w+OFU8++aRINwgkKP4CcsQePXrIdcTa78SJE3H6HGoSJE+R
0qw+/nrQj0fs4ueLWIyQyK+JqUFEoAEuDnQmrFeCvSNQ/ShFypQSsfVkR1i0aJGc40uXLiXKNWar
burUqZIAgoUT///555+1J3sQlStXFp9ZT7ugWEm/lJxVEv1JxIR90oRkyCg2ZIm1GAxWFw5cfrgX
fZ2UWovZuXPn6sDksADKnDmzyPuobhufSrm4dZAfBHHE9ziYx6QmbdpK9DmuixEl0H4M9LGUnmbA
QboQrJ1g4e59kljJthaDgycBGceZ4dlnn03Ua42NIVFornXevHklOq2IP86dOyfndPny5V75/GXL
lsnn12raLKh1h2tOnDLpM2WSynKJqcMNVg30tm3b5Hf7ckIeY3eGDBnEjUilG5HANaVx48Zy7apX
r25u3Ljhkc+FMEIcKakdrGPSmHkL5LwmhFGAEmgfBfpNtrziUu8+EBoZxakiCC5bWv/4xz+8co4H
DRokDg2+4Ixx5swZU65cObne9erV89iAGqzAN5WETSp3eQvWLkaNRo2DMvEXjWGGzJlFZ57YEoJg
JdCWn7IvF6tBescum1ZojQyO4X3N+aD+Awnlnl5UkCcUrLyBoFuyiHNbNzRUF2vBTKAtEk3pSTpD
2LPdzZEHHwbNCjJJ0qQSeSZC6y0QtWG1PmPGDJ+43nR4BlQSbdDZkvzw/fffa+92E9wzeIWPHj3a
699FJJrEOUrcbn37YtBMVM8ve1kqqObLl88n5APBSqCtEvXYnvkiLJ/qBQsWBP24dOHCBckR4Hww
r3urFgHzCFaBfM+ExUuDSEr2ukmbPr0E3dQuVgm0rTOMGjVKOkOlOnXN3us3A7YDUImx/YCB8lvr
N2iQIOSxUaNGJnfu3D5l6E9SCZ7RkGhcH9Dc6mradYwbN07OXUKVNz5y5IhEkzJmyWIW790f8BPV
syNGSh/FW9UdpwBvIlhdOHbs2CHX4r333vO5Y2PnkMqvtSLuk2Aev5AL4iPPQps8gfjasLoCcmyI
wj6eJIkJ37w14MckghdZsueQ3TB/q8qpBDoBsHbtWkk0yJUvv2xTBFoHoMY9CwSx4okgjwnlk7x/
/375zldffdXnrjnelXXrRp6TChUqSEU8RcwgCYdFBxGYhARb6Pnz55cJq+dz48zRhx8FXh89f9HW
R8kdSCgfdUX02Llzp1wPX5R84QqRMmVKv/Go9gawl4M0Q54HDx5sfvrppwT7buoPEPFmp2j62vUB
S57Xnz5jsufJI0EM9XtWAh0tIFAkmtEZOw4aHDAOAOMXLTFp0qWTwXblypUJek6JjEB8QiNW674K
Mu2JkjNR4tDi7TLk/gzLIQO7uYQGOwdWQmjJSpXMhjfOBswkNW7hYlsfpbywryFYXThY+HO/Xb9+
3aeOa926dXJc5AkEI5CRWfJLCjAlZFVOe7BDVCliLGJHbvSceQFHnpcdOCSVBgmaJJajlhJoPwLb
QTbPyJKlzMJde/325t/y1gUpGsNvqVateqJFKqiK5atRHAt4644fP158VFOnTm1mzZqlEUAnYLIi
6pLYCx4SGLFf7DV2nDl4577f9lEWATWbNI10C6hRw2dLRgerBnrXrl3yu30p8gZ55P6vU6eOxy0k
fR0EZJYuXSrRUBabJAwmdtVZEqkb/en40X3UGJFKBkThpvUbxaWLoKImqCqBdgvoqLCOolPUjSCh
G8+e85sbnypuHQYOkq0lCCFlfxNTg/zdd99JVnSfPn18/rqj7yKr3TLdP3TokPb+P0ElL84Lcidf
IBFhYWFyPNly5fK7ZJ49194zT/fqLZIUvMohAr6UJ6AEOhLYXvK7r1696jPH1Lx5c7lnsGoLJrAL
ULVqVbkeVJz1JS0uhgSdO3eWY6tav4HZdeW63xJnzBTgD1Z031suXUqgAxxEJadMmSIrXVwrnurR
02w5d96niXO/518Q31irXOknn3ziE+eyV69ech79xfXi+PHjUiSE80jylDMbMSIfb7zxhvhhoisf
OHCgmTZtmjl//nxARoawfWQrLz7FCDyN119/3WZPWKxcefPCyyt9Wh/NxNpt5GiTJiREHGp69+7t
cQ92JdCew549e+R3X7lyxSeOZ82aNXI8uAkFCyiAReIyzj8UMiGh1VeBa1DS/2fvPaCkqrL27+8/
Ss4iOeecU5O7yRnJQVFyziBZlCDSiARJSg42SQmSJAgSBBVEkgERjOOoYxhnxuW8M+8763z1280t
q6urqqsr3lv3PGudRdNd4d5zT3jODs92cAUS7pCKtWKyYLV69WWMYfAy01qvCbRFwQlsyJAhMoGJ
j8Yi/eIB86gBvPL2O6rnsOGi68zAj09IUO+//76p+hALjtUqZUGQKf2eK1cuWRSpZGVUayROldju
OnXqCIGmoAjxiLymWrVqUtmRBJdYARXwiPObPXu26a4Nty4xoTwPxljhEiVEo/XQR7dNVRClY/9H
xSvENZIAZra4Wl+wqwoHc5jn9cEHH0T9WjCGsBaRT2KX0A0MGWXKlJHD5qBBgyQPwuxgrBjX3Pmx
AWr/jVuWsDpjfMuaPbuEMBImp6EJdMgXsOnTp0v8GYtquapVJQYzGuEduICnLFmq6jWPF1IPue/f
v7/piLMrmjZtKguL1SSXfvjhBzVw4EBZEAsVKqQaN26sKlasqN555x2v7zly5IiMESx3sYApU6bI
GAunbngoiDQxq40cz4e+J36vRdduav7GzerYnXtRUb4Z/fQ8SXjkeginwqpj5qp2GilBKB/P7urV
q1G/lnbt2knohtVkxJB8IxQO4wLrKPrxlB73pSVMch4eVPq+QoUKUUlaDgaogUyaNEmMDrkfyqum
Pv+CaWOjsZSXqVRZ+prwIC1Tpwl0WEHSAIkMDRrEyaCTSV69hrhmX9jzqjp6+7OQD3Lc0i8dOyGl
x4mxInaS7y1durRYBc0SquELhqYq5NKKIAu5SJEicg/+uLZwzUO658+fb+nxTigTh8a+ffta5pop
qgBZpWgOzwvvTKtu3eXQiSxTODYiSDqbETJ71eo3kGdvxBEuXrzYNJrOgcCuKhyGDGe0DRP0P9dB
iICVgGoPayZa1RTU2rp1q8wFZDDRsPZUKZDXMG/x+lH1DwJuVeBlMg70JcuXVzNWrDRNwbblr+4T
AxzXhgoV4UoamkBHFF999ZWoTNS9b2WiQW4r16kjSUITnn1OJSbtkjALf2Mz975/Ta3Yd0BNe2G5
enTcBFU/oYUzPIOGq3ratGmmtjZ7AiERLKYkgFgRWEFYaIjJ8xfff/+9euihhyydxcymzbjzZXE3
85g7ceKEKOsYZJpGieym7TtI1vwzL29QG06+KTkE/hYk2nP5qoRxIV3Va/hIiRvMmCmT8/MJ4yEe
PtoluEMFu8ZAHz58WO47mhJeX3/9tahOtGjRwlKhGxh2SMT2Zr3nQMl6WqBAAVE8Yo3kHulvvJVm
Lp+eHvDMKAlftWpVZ4jZ+IWLxIscadKMNO+89RvlgM+1EFNOAjNGEg1NoKMKEuSwrhLmgSRVJpcN
1SDWVFPjJFqxRk1VtW49VdWx8VZw/IwLpUDhIlJn3vU9hGdUrlxZktSSkpJkMbUyIBVY5qxILIhb
dU9g4ZkT1sHBgDZnzpxU78PyQoKhVUEyJQfEWNjIiE9ctmyZ6ElTJtt1rhlhH6h6lKlcRVWqWUvm
Z5U6dWW+Mm+Zv4b3x2jM8zqO1/CMmaNWSArUBNo/GKFY0dIZBm3atJG41EhV/gwFmGP0mz8xy5Bo
JPkIccLTRX5JLMZ4c0+EBNWrV0/6hgN3sw4d1YJNW8Jec2L164dV1ycGqVx5HpLvpvgMOTvpMQZp
aAIdUeCaQnuZRZiQDzKJybrv0aOHJOS0bNlSYqTQWUThgPgwYk1ZfBDwR3vUyu4rTyCeGNccpVet
BGSKUBFxD93AKo110xcYA5A1KwLrLQuumTPfgwGxilgXsRCh/U3cIlUAkTJsfN/1ijWZ+dqzZ0+Z
v8xj5jPzGquZmeXnNIEODkePHpX7JiQoGoBM8v0vvfSSpdZ4wjP8JfzMH0g0Vmc8dnYAVvkJEyao
fPnyyfNF075efIIaNmu2WnP4aNBhHujLT1qcqBK6dBVvm5GDQRgeY9oOa5Ym0DYArjk2bTsBvUzu
O5JlV4MFSixYmt2xYsUKIVTIS3300Uce38shiMXLilYVkkoKFixoy6IyuJDZePbs2WP7dcquKhwk
vzEGkKaMNFC+yUHsfqtWluoz6g64e9yo8ovBqFGjRuJNdSdwlEy3amhfMCDEDEI7duxYp2yqYZ1G
pAACjCYzuU9UFF64eZuEhC7ZuVsKncxd97KauGixenzSZNW2V28JJcvu2FuNz2HPYr8lrpzS4xqa
QGsCbXFgzWFyY8WzCiD7WKDdQZILEodsAK1bt/ZYhplYP+KgrQasq4TboIVuR2gCrfHGG29EJf6f
wzbEGQJNno2VgMzeyZMnU/3OUJ9Bjg7S6G5koNgWnj47Awv8rl271NSpU+VAgUgA6kfuoWaeGoXf
mjRtqkaNGiX70O3bt/UE1gRaE+hYBBn9nLitBCyxvtyShGp4ihWm2AcVtKyGcePGSbiNXdyq7sCj
wMaEeozdYVcVjuPHj8sYuHTpUkS/F115vnf9+vWW6zNk59zJm2vCO/sd8bfuwFqqq96lBqGgSP5x
ACEW/8KFC+r8+fPiFUHl49tvv7Wlh1ATaA2xMEyePNl29719+3bZIBDKtwpGjx6dKklw1qxZ6vTp
0/IzVhXi2N1BfDuWBCsVzsDdx9gkHtiu0AT6D9g1BtrIAbh48WLEvpNDOkmDJA9aEcg2eis8gyxg
rVq1nAWpXEGRmF9++UWTAg1NoDU0gfYFTsxI6HTt2tUy10xMIqWsXWWZcPNT4ACSTElpd8vLtm3b
JFGEEA4SRkmetMImsXz5clPo32oCrQl0NEEoAvdNDG8kQOgGUm54Jq2quMSa7insCS8GetCe9NCx
sJJ4aLUiWxoamkBrAh0VYM1Fps9K8kyGrJX7huopQcMgoYR2QJqxYEOiIeG4Zs26WbCJo9/KZmdn
fPjhh/L8iG/XBNqeBBoPGfeN2zwSoLAI30cBEquC+FsKpbhi6dKlqk+fPl4LUHHfVirUpKGhCbQJ
gKsO6To7grLQJEhQFMZKuHbtmmxyyNdBstyB1bZXr16qePHiqco2E8ZBQg3vx5UZqY05PTCqr9nd
8qoJ9B+wqwrHm2++KWOAmNNwgxLKlOrGo2Vl7Nu3T/Y1I7QNXfQMFBerXFlVr15dGupFBn799Vcx
JHkL+9DQ0ARaQxNoD4BoEt5gNUF3NgUUONB3RsOUBCsIMVW1SI6kOqUv2SB0hyHYbM7IDHGYMAvI
/kdoH4klTaA1gbYzIIGMgXPnzoX1e/D6cLAmDvibb76xZF+RbNyvXz/pL2obYBxJK+8D8kxyNuul
hoYm0BqaQKcDbExWd1kSgoI0H5ZniLC/es8cGghjQSMay9PixYujXjjHiPvlWuyOW7duSV9Q1Mju
sJMKBwluWIPJdVi1apVTcpP/83tPCXDBAlUKvmfz5s2W6y/WO9ZvYpipyjl//nzJccFqzz1RKvq3
335L8R7C10i6JlTMah5IjZSgGu/du3dl/yPZlj0d2Uc8tUgw6jLhmkCHFCwuuO6xbLHgUFY41ioO
pge49EjAsysg4CQhstmUKVNG4qyjheHDh4se608//WTrOUqsJnHqPJPp06dLcqidE5xiMQaaNZdK
ohT+IP6WdSinSxEKX43X8Xrex/v5nEDXcMgHB2iKFlkNhKhRhps+wYL+6aefpjqEEg+NoQid/Mcf
f1xCVEggr127toSLaVgDHILQRX/mmWekmjIhOdRG8Ge+4GWuU6eOPH/i4ZHgs1M1RE2gQwBOYySS
cVKPi4uThYXFpF69erKA4spnwbEbsG5FMlHHrCDekkWJvmBcRFoIn0RHFkTKVdt5jlIYB1c6xKBz
584iJ0aoDvq2VPTSBNq6gPA9++yzUhUPz4+zYluxYqpBi5aq6xODpJzyk0uXqXkbNqnntr+int+5
R/7l//yev/M6Xs/7jM/g8wh/4vPdcx+8Aest4yx37tyi52slIxBECp14yFFalnPC2ZAEZP5gebZq
mIrdgFWZUMVGjRs7C7pQXKtoqdKqUZu2qvuQoWrknLlq2rIVasGmLWrxjiSZL4u27VDz1m9UUxKf
V0Omz1SdHxug6jZrrh4uWNA5X4h779Spk1q2bJnligVpAh1h4M5Czgx3FZI97iAWbMGCBbZ0GRPK
wKECS7zdQdwxCwoEjsQbxks4XMaegKuV8WclvepQgphnYthnzJghbkl3oLyCJQ2ZLiuWZbcrgUY2
jVAMihwZm3eZSpVl82fTP3jzI3Xqy28Cbryfz+Hz+FzjO/g+vteXN4dkOl6L3KVVgIu+YsWKct2P
Pvqox/1Mw7rgcEMIn1FaHOWoSrVqq76jx6jEV3aqw5/cCWq+vHr1unpq7UtCqouVLuOcL/EJCWrL
li0R2+80gbYIsKwyQA4ePJjma3HncTLDKmsnULqUE66VrDDhBJsSKh/I/JFkQ+GZcJI23Gkk/qBB
a0cw75ijL730Upr9BDHi2dgJVlThuHfvnnhTOIjybMtWqapGPvW02nvlg6AIQFqNz+d7+D6+l+/n
OrgeVyBviccHK5wVgIdq6NChYoGkMBQWZY3YwfXr18WIxfNl3FarV19NfC5RHbjxYVjny44Ll9TA
KVPFqs334o1/8sknJVFfE2hNhCTeixg5f2EU7PDXDRgLIDkHsoi7SOMP4EJr2LChLCyE/Vy5ciUs
34PXg+94/fXXbdfHWP0hxVj+/X091hk79pUVQOgT4XCsJxkzZVJdBjyh1p84FVYS4K3xvXw/18H1
cF1GPD0663jerFC+eteuXeKdMWRHraaapOEdlAcnVE3Ia44cqt+YsWr7hYtRmS8r97+uWj7STeYK
+WFjx441lUKVJtARBoSQQZBeIOtDwL2dwCRmkSa+TuMPYHkmdrBQoUJiHcAK9MMPP4T0O5o2bapK
lSply0S548ePC4FOD0j05GBjF1hBhYMkJxI+IXlZsmZVvYaNUHsuX40KEXBvXAfXw3VxfSQfQlh2
7Nhh6j4lwZl8DK6V53/jxg29IMcICC0i34NnmyvPQ2rglCeDDmcKVdt+/m3VoW8/9WCGDOKlWbJk
iaVlVTWBDhA1atQQiTN3jBs3TjZgklkMwXlXQJDsVtrUKJuLu1gjNYgNI9SFxB1ipImfDMWiYhSG
8dcCG2uYMGGCxH97wqVLlyR50B30O/PTLmolZo+BPnDggGiXSwJu777qtQ9umIIIuDeui+vjOjEW
cN1mBKFKGHEgL4QUIrOny2zHjkGGAzHJnxzmeo8YpQ59/Kkp58srb78jyYrMFxLsw63Hrgm0yQDR
IXbMFYRzGGVLCV1o0KCB3++N9YlNcoq3/tBIBlJRhlWIUAIOHsFg4MCBkhxHIqsdQVLg/v37PR5Y
CJtBWtDb4dgu1dPMSqDRmCUe3UgMXLnvoCmJQCpXteM6jYRDrt9MWrmEiSEryrUhr6kVM2IHHPg7
duwoz7ZGXEO18dRpS8yXhZu3OhVvZs2aZTkJPE2gAwQB8e4i8sS8GclyZIjjmvcE4qD5u51gFC4I
V6xvLIEwAgoR0F9IInIYSy+I0SfWbMyYMbbtx7Zt20oYh6eDBZJb3gg0HiQs1JpARwcff/yxWKUI
a3ps/ER1/N6XliADRuN6uW6un/vgfqKJf/7zn2rixIkSf1qkSBGPh0oN64IiJ3hpMmTMqMYveNZS
c4V25PYd1aFff1mHmjRtaqnYaE2gA0T58uW9ajtDrNm8KdjgDqyBuM7sVk4Zqx/3bbf470BBvDiF
HLAgo0M7d+7cdFmzkE5kA4+05rSZAFF2V73Zs2ePhMsw/7wRaEgGCb92gNlUOFA0Irwgz8MPq8Sk
XZYjA66N6+c+uB9/lJrCAQqaFCtWTMgzh2l0mzViB2vXrhU5uiIlS6p1R96w9HyZuXKVypotm8qb
N69lDBiaQAcINmF0Zd1BjHOjRo1E99ATXn75ZdWzZ09b9hlJl1hFtb6o/8Cj0b9/8umcjXDv3r1p
vuc///mPKly4sOXkyUKNnTt3ilvTAOSBPmTTYR6i375v374U78FDQviM3fSgzQAOOxC9yrVrmyZJ
MBRJhtwP9xVJCVO8oewzIltWrZpUiNOILRjeo4atWqvXP/wkJubLljPnRPaOqrl4CTWBjlHgZuCk
hM6sK3mmrOVbb73l8T3EPaP9e/XqVVv2GdZQrKJU9NJIHyj2QYlcFszmzZv7zJpPSkqS11Ge1c6g
BDOuTcOagWcI3W0aB1xkKN1LDnP4XbNmja1IqxlUOFgTRBEioUXQBR3M1rgf7ov7C/fax8Fv3bp1
kmcDCXnuueds5+2MdZD0OXLkSGdirdVCnPwpyFK+enWxrJu9EJEm0EGATZiMfSSBAAocZMBWdzx8
o7GJA8TDGfALFy60dZ9RPhlSoxf1wBZOCoIQQ8/igkX/559/TvU6kjUJMdJWVCXxnsy7jz76KMXv
PYVwoNpBuIwxZ+1kxTIDeW7Vrbs6fveLmCIDzrhox31xf+Ek0VTc5AAofdmqVQrjjkbsgOI9PGMq
CMbiXKEd+ui2qtOkqenVuzSBDhLEVPKQly9f7jGDFBKDWH3JkiUlptXuwOJnx7LmoQTlqCHPSBXh
BYFUG1JUuGrp39WrV+uOcjno0ifeXILElhMfWq5cOVuRZzMQ6I0bNyYTvu491Mkvvo5ZQkDj/rhP
7pf7DhX+9a9/qdmzZ0tlRA7XeFg0YhPUn2D89B87PqbnCu3YnXuqVuPGss+Z1ZuqCXQIQNwksZaQ
mT59+qhJkyZJo3wmv6MylS6PmgyIHoU9CEPQCA4ksVKimwUVearz589LvDTuWzLvNVIe3LDKU1iF
hEwIDHq4TzzxhMxREg5JdLUbokmgqfhIbHD9+ISYtTx7skRzv9x3KCpeUmuAgx/PkLFsF/1yOwKj
CM+ZQiR2mCs0YrvLVa0qibie6m5oAh1DIEwDd8PSpUvFxd6hQwf19ddf645xA8SFheDmzZu6M0IA
EgtLlCghfUqMOS4+jdTAQ4RWOxUfCdVACxfr/VdffWXbPomWCscnn3wim2KlWrVjLubZn5ho7pv7
px8CAUQZwsych0B7KtqlETsgr4pDF8VHYi3mOa229/1rojJC/lioK/VqAm1SUFVu5syZuiM8gGRK
No/hw4frzggRfv/9dynbzYZK8hDhQnYLR/AXFEmhn0JhAdQIbKxWqVJF5c6bN2bUNgJR5+D+6Qf6
Iz0gRINQDUI2CN0ghEMjdgFphDwWL1vWtJUFw902nHxTZcqcWbVq3dpUlTM1gdYEOirASgqJJp5X
I3hAllGVaO1YYCi+AkEsXbp0KpUJDU2gXRENFQ48AHhKFu9IsiUZMBr3Tz/QH/6ApECSAxm7JAuS
NKgR2yCHqnWbNkIe1584Zev5MiXxedMJMWgCrQl0VIAMG5OBcBeN4GEkyp05c0b+j0sX6xa/o6iP
nQuquAMZSfpFHy4iHwNNQRG7JEH50+gH+sNXoRV03ZGjw7NEfgMydVphxx5YsWKFjI/JiUv0fHG0
lt26SyiLWaSANYEOE3CvUdtdwzuaNWsmVlIzuWSsilq1aqmqVaum+B1SbSzAuXPnlvFI8R9diUwT
6GgRaNROihcvrkpXrGSbpEF/kgrpD/rFU6XRd955Rwqh8IwojEKBFA17gGdN9V40xPVcSW4Hb32s
HsqXT7xmZjhEagKtCXTUsHLlSkm2REGiYsWKYjHFRbl48WIpVKPxBzhksJlCgnHfcvCg37p27aom
TpwoG6y3SmdUfsRNzMm9QIECauvWrba2YGkCHR0CjUdOJD9f26/JgEujP+gXV48lB12kFZmzVM/U
Y9V+6Nevn8qYKZPafv5tPU9cS36veFHmC9VkNYHWBNp2oCIciwOllMePHy9hB2Sjo8px/PhxKUiD
1RRiqF2VyeW8kasrW7aseuaZZ9TFixfVvXv3hAiiwNGjR/r8FZMAAIAASURBVA9x76ZVQY/XG4UW
KLZiRlmgSOD999+XPjh8+LDtx1akVDju3Lkja2Kbnr00CfDQ6Bf6h36i+E+RIkXEuMAaqCUp7QfU
glijBkycpOeHh1azYSMpYocggSbQmkDbBiS7sTBgOYVIe8OPP/4or0Oezc5Z5iRZIiQ/ffp0n9Ub
qbRHf5GV7wscSMjiL1y4sCQwDR48WH3//feaQGuEFUiuZc6SVSSpNAHwLNVFohjWZsYmIVnUF9Cw
J5o1b67yFyqsjn56V88PD42ESuYJHjRNoGMQkJ60yIwdyTOFLBo3buz3eyhQQ/UlO8ZJc4igyMfm
zZv9ej2n8Ro1aqglS5ak+VqsWtOmTZNk15w5c6ply5ZJspIm0PYCFuh69eqFVfLwiy++EGtqj6HD
9Obvo1WsWdMZyuGpqq2GPfD222/LOBjzzDw9L3y0Ju3ai6c6mgWwNIHWBDpiWL9+vYQiuCKtjeLf
//63qlSpkjp58qTt+mvGjBlqyJAh6XrP559/LhqxkG9/gMuYgj8s2MSh26FipibQf4A4QvoinMlp
I0eOVBkcB7Vd713RG7+Ptu3cBfVghgzSXxr2Rdt27UQj/MjtO3pe+GhrDh+VtYucKU2gNYGOeTRs
2DBFTXvcLxT8cD15t2zZUuJ02UQMco1sEzHTdgKhFoUKFUolP9e5c2cJv6Dxd0/W/L59+0qFvfTg
6NGjzpLAVOgjxjpWgWuc+zxy5Ijt5+S+ffukL65duxaWz//555/Fy9Hp0cf0pu9Ho5/oL/pNw35A
25v5OGT6TD0f/Gj1msdLkZloeWw0gQ4TcFnOmTNHd8R94CIm0Q1iiFWZ5EHCE1wJdHx8vLO07aBB
g4TUARQ5ihYtaquEwk8//VQIrS+grLFx48ZUv8ctH8iBg+fCaT579uwqU6ZMMn49SWtpAh07uHXr
lvTF7t27w/L5a9euTc6Yf+Ok3vD9aPQT/UW/adgPhNVhfHvtgxt6PvjR5m3YJPPl2LFjmkBrAh27
+OqrryQh0CDEuI7ZJFwJNK51A5MmTVIvvvii/Ez8M1YZO8VBnzt3TjVv3tzr3wlpIfTCE9566y05
jAQK3PmPPfaYJBlycAkXudIE2hwHW6QjwxUi1aBBnOgc+7MZPlywoKpWv0HYNttpLywP+jM2nz4r
8yKYz+g3Zqxq3aOn17/TX/Sbhr3A/oZnsWGr1qpx23ayRtEYb3kLFFTNOnRMVxJuiXLl1dMvrQ96
XPM3rsNMxHn164fVxlNn1Buffa5y5XlIvK6aQGsCHdMbdebMmVP8jjADVwJtAM1TstCN5AAIHQuL
nYAFukKFCl7/jpA8Jak9YdeuXSEJebl06ZKqU6eOLJ4Uvbl+/bpl+o8kSYgy5J+kSg5kKEGg/hIX
Fyf3hI42hxAKVAwfPlyStzjUQayJDbdTIlc4vDv0If08fNacNDfEdUePq4JFi6mMmTKHRalj5b6D
KtdDDwX9Obsvvx+0FF9aBJr+ot/oPw374NSpZGWJueteFgJdt3m8mr58pZr6/AtqwIRJKn+RInLI
PPzJnZATaF/j2owEmn5Yumuv/Nz18YHCLaJRJEwT6ACALi+DffXq1erJJ58UstK6dWtVu3ZtScSi
yAUE+uF8+UQVISEhQbR6CVugdPXrr7+uPvvsM9spS1SvXl2dP3/eJ4GmGEiTJk1SJMEhu9alSxdb
9RWSdQ85Nvyvv/461d8uX74sY8obSDx84YUXQmYVIfkTzW7G9OjRo00Xnwn54zCBkkifPn1UyZIl
ndYbo2XNlk0VKFJUlalcRVWqWUtVrVdfValTV1WoXsOx0ZRTefPnlwQu1/cQxlLH8RoKWiQlJanv
vvsuJscaZeBJPA31BkQ4kISHODbntDbEJyZPUe379FPVHYebic8lhqVYSSgIdChaWgSaZMtoJ0dp
RB7k/WTNnl2k6yDQ3QcPSTEutpw5p3LmyaOGzZodcgKdlnXabAQ6b/4CaunuZAK9cv/rYQ1D0wQ6
SAJx48YNIctszlhCXTdZSEXhEiVUZQd5bpDQQjXv2Em1fKSbatWtu2reqbNq2LqNuCXZpDNlyZLi
vZTpbNeunXr22WeFWMa63jEbgqurxZ1Ac7igj137AXKExTDWwgj8wYgRI0SJwx0kp3qrwmRI3335
5ZchvRb0qDkAEp8HscdSG00LLQcMFEPQseZ+jTlFmdem7TuoQVOnqWde3qA2nHxTvf7hJ34tyie/
+FrtuXxVvXjgkFh9eg0fqao5iDbVwIzPp6zyggULxEMQK6DCJfdG7Hwo0aZNG1WqQkW/+r684yDz
5NJlavCT08Xy5vo31tHEV3aqWo0aq2w5c6oWXbuJQsGxO/dUpVq11EvHTjhfu+PCJVXJsRbj2nWW
/735kSpaurT6k2OtLle1mjpw40N14vOvVN9Rox3jJb9Yvl0lwyYtTlRDZ8xUbXv1FsLC9++7ftP5
+eWrVU+h3xzXspXKkSu3iu/cRcaba8W0us2ay9/41/hbWgSaRr/Rfxr2ATkvjCWevycCTesy4IkU
42/ftZvyWuYFMoiuuQYQaMg2r8d6zZh2nVOMz3yFCqlHBg5KNa5nrlwl7y9WpoyanLgkBYH29Z0t
uj6iFm3boWo0bKjyONZivp/XM/4LFC2qRj+dUppv4JSpYk3mb+MXPJtiDo6cM1f1HDZcDr7M2/XH
k7+nY/9H1QOOfahIqVLqqbUvyVzO7rgWvIiaQJvEogWhxfJE6WNj88xfuIgMEBZbBgmyQ8fvfuH3
qYkNGuvCC3teVVMSn1edHxsgC6Xx+STZ9e7dW7322mvq999/j7l+xcJVxjEhKeHtTqCx7lF8pnLl
ymKppq1YsUKqpKHKYReNYlcQN54/f3518ODBFL8nDOHdd99N9XoILa6sKVOmhO2ayBJHKYXxineF
WO1IguqJLJQGac7mOIRyYJ2yZKnaevZ8WKwdWISwYA6ZNkMOw8QKGvfPodBfyUAzr3fkJ7hLTAYD
ElJZz7oNGuyX+5g+5fBCKAebI6TXlUxicWrbu4+svYR5GBsxFckGTnnS+Vo2YYi2+/PrP3a8ypIt
m5q2bIX8nwpvbMy4yI3P5GfDGs5rIRnP79wjzzyhS1ePsaKVa9cRbwaHNUgFFnR+/8rb70hhlGEz
Z8l3lqlSRciGvwSafqP/6EeN2Ad5QawpI5962ieBHjt/gRzqjP/jRWN+QIY7D3hcDmuGwQACjHwk
xJn1MXPWrJJ0Z8wpDo+MceaP67jeeOq0jF1CiTAk5MidOwWB9vWdjHOIMyQX8kspesY9/2de8TnM
cV7LHGb95tCM14k5N2/9RuccRMqP905ctFg+t2rdevK3xTuShLz3HT1GrPL8rlHrNsItNIGOMmEh
JAN5MHHhOhYwAvdnrFipki6+GzZ3xP4bt9SCTVvkdJnn4YeTiYFjMD366KMxV24ZnWLuD8u7r7hL
Ng4sMLw2Fg8T/gKiTB9QwtsXKKJC3Hg4ybMrOORBurg2vArffPNN2L4LLxBya40aN3aGY2CFZDOI
RqUuDsEs/lXq1pXr4dACqTcUZKwI4sS5F7xtoQAGCD7P2LB9NaxNZatUTeGeZc11JdBswK5Sb0a8
5ojZTwmBNf5GAha/8xXCgXWaTX/OmnXOv3M4KlWxonPzhjQYY4u1H3Kx98oHKYgGOrSE/bx69br8
H8t2bsf6jTUPIg+5MD4fCzoEwV8CbagLuIa8acQuCFN0VavxRqCX7NydnAB9+44zdIHxZvy9eNly
asy8+U4CjQfcdYwbBzzmVKvuPTwmEcJD8KAbf8MSbBDotL4Totuud1/n3wzvi+trjYMq1m8OmMbf
iPM2koiFQDvmkuFJ4r4zO/iYpxAOg4xzXZ5CHjWBjoBVi9ABwjFoDN7Zq9aoQx9/GvHNGXcEVg82
CdwSDIqGjRoJYYmVpCak0dAvpkDKqlWrhFRDkrFQQ0Kef/55sTBiaSUZzO7AOk9focpBvCpklRCG
n376ScYuyar0F6XjIyn1xzOD2GMpy5o1q1q4cGFIK9pBnLnfUqVKyTwgVApr4aGPbpsmFm/Tm28J
ucNiwzV26tRJ3bx503JjjBAdYshDdVg14p8xDqTVh5BeLMTG/9mAmzgO2K4EGjeyKxHgPcbGT2jG
wVsfS0gHVjaeiS8CzeYvhXRckrEIr8Badvzel7J5YzhxfX/hEiUlacmVaBByUqFGTZ/3BgFYse+A
6j1ilHwnn+8PgabfdBy0fUD8c45cucRL7YtAL9y8VazKjCMOaYQ+ML6MBmHu0Lefk0C7hm2gXIF1
2JhTo+Y+45FA12rcRMa28Tcs0gaBTus7IdCuoRiEUxGmYfwfAs/fkenjMzkoG58jFmkH5zEIdJ2m
zVIUGeL1xqHWnUBj1Y5GHLStCTTFA1rcd0dDVlnkdr5z2TSbMwSek13h+5a+smXLiiUuFgA5evPN
N0XvuXjx4kLC0B/mHnEla+tLSkBM8Y7QRyT0Ee6SJ08eUZKYOnVqyGOe0+u5QcmCZ0YCrXvISSA4
c+aM3JtUSKxZS5JhOFyaVY+UOD9coVguIWLDhg2zXNIhhy/Kxp8+fTroz+rfv78kbabVb1jSOHxA
giEGNH7mdwbBZbNHmcB4Dxbm+gkJzv8XKl5CQigwPBDPnFYSIYocEG3Xv2NFZqxhZWbzJrPf9e8Q
ZdzgrkQDcuJ6Ha6Na4ck46LOkCmThHoIgb77hV8Emkb/0Y+xBoo0zZs3T4wouN3xnOHF2rFjR8zn
AXkDRrLqDeKcz94bgcYabHhKOHS6J0vTyMUyCDThDsZ7t59PLhF+9PZnMqdcPTCu47pgseLiETf+
ZpBdf74TAk38tGu4h+vhl/AqCLShd+6psSYwB8knM96XdOm9FIdedwLN4Zn8HIxImkCHGahoQNwY
MLkfyisnsWhYm9NjlWaDKFm+ggyiJk2bikRXrAIrGIlqxINr/AFCWooUKSLWZzMWlYH0Vq1aVcYo
1xpISAOxgHge+IyCRYuKJ8hKwv648XsMHSaufcKwEhMTLeM54pBGDgLa31ikgwGHH2/k0t2iBsmc
9eJqZyO2kv4zFATSItAkQREuQVIg7ue0CLShKuCaaEj8vBRkcGzEbN7ukl4kIRKf6Uo0iNuEILiH
90CSuSaSnHgPe4tRdpjv9JdAc4/0Y6wAowlykqztGAPIn7h7967o/2/dulW1bdtWVKzwSNoNuR0H
b9eQH28EGksvccv8TIIeBzus1q7NNYmQJDunlfbIG3Iw9TSnXMc1JNg1hIoQJoNAp/WdvNd1zfZG
oMkRkMRlx7+ePksI9P379IdAJ99vOdWtWzdNoMNpYaE4B+5mLB1YnF2TVczecNuwaBtx0sRdxmqI
AwssJ0oOOxpKyCgLHIotZgZkkTmGdRwr+eTJk/2WR9u5c6dsJFkc8xPrXjTim0PVcDkaxRCwLkEU
rICrV6/KcyN5l4NaoMiVK1cqK66nRviLa7iG0Wo3aSrJof4Q6Oe2vyLGBZKMFm7e5vF7cBETj2lY
vSHoy1/d90eRlWUrVP7ChZ2bt2HlMyxwJDbiynYlGolJu1T2nLmc41Riqx3jF7JexnEQGTd/ofMz
iPs0XND+Emj6j36MFRCCVqxYMQk984Y1a9ZIP7kW1Yp1/Prrr6n00j0RaEKTSHY1FGM4YDIWXasW
krjHWDYItGv4xPiFi5zj2heBxvLLAdAZj+84BBoEOq3v9JdAc8jEMzPh2eecf8PqTaKwXwS6QEGJ
i3btnwYtWkpitybQYQBxoy1btZKHENeyZYogeKs1YkCR2GIgEx/69ttvx9zz+uKLL8QV/tRTT2n2
7MCoUaMkWc0qig9cJwc8niFKNoQGeLOaoyuNt4G5SWIe5DNWSs3iziS2kUO7N+lBs4Hy8DyLp59+
OqD3c6jn/a4JQl71XB0boSfdZyMeElKaFoGGlJKghyUbcuzpe5C645pmr14rryfOGtkuLGAQY0I/
2LSNzZvXEj5HLDIJVYYCgCvRwKBBPGivYSMkhAdlD4i8EcfNhk5sNvJbvI7PxEPhL4Gm/3hPLBhJ
MIhwL/54Y4hjRX0onInJZsKtW8nx7q4hFRBoyCZzA+UNxhNWV2LxCcEwwhb4XZN27WXNxHPDQc9Q
I4JAc8BbdfCQqFVwQOSz0iLQHAwJcSLmn4Nnkfs5KP58p78Emp9RIeN+OAAzP/HyGGtGWgS6SMmS
4m1yFXfAgo93QxPoEGPPnj1ykseyRcZ3rGzOWDqIj2bgE/sTa4VZKJ4C+bK7lBPudMIB0Dy2Gihw
0vi+egbVE93l9z7++GM5BGIRHDJ9pqnjnANW7Xj3siTE0AdUQ7TCeKZ4Docg3OlYyNJ7+OVekcDy
1S9rjxyT17E5uv9t+4WL8jfkQtMi0JKI2LqNqhcf71OKEKUPPhNCi64zVm4j7hINZ2NzZvNG2YMN
nb9BIIxDnbuMHZrhEArJUXF8PuTDuDcIDAdIQkdQ1cACvmzva34TaPqPz6U/rQy8iCQ5//DDD36/
h7yOcePG2WJ9f+utt+Q5G5X1DALtWsobYoq0oftcQRUDHWVex2HUVYGG8YfUW4b7OvaobhhhS74I
NO2x8RNl7NL42VXGztd3podAc5hkzvI5WNZJ3HWdg74I9KPjJsj18q+rige/iyQPimkCjcVr7ty5
TssWi3Ksbc7E1xEXxT127NjRWf46FnDyZHKiAckldgYFZugHK5XSdgdFOihCxAI3cOBA9f3336vj
x4+rnDlzShVArCSxNjc9VdvjOTZ2q7RpVmAtJCYat/uxY8fSdWjyV8IuVA0CjYvanxh11/+TNOiu
FGJs3sRjYuFyjfH0pu/vLfmcjT+t96clZUd/WhkoLXFwdEXnzp1lPaAhG8sh2xUkRVMd0w7Vevfv
359Cwi69zRin3owPkE4K/qT3c/GeeFPRSes709MIB/G32JW7J961DochZYekqybQQYJENMMtjPvD
NWEkFhti40jwVXGcAKOpyBBqkFTSoEED25JnNhAstMQPWh24oqmsmDFjRglHgUxjtTOT8k24G0k9
JPJQbvz27dumf2bEorKmsI7WrVvXr+TlS5eSZeJwzYa7PyEHSFgRwmHoMYfioONq/YpWo//oR5SX
WNOt2kgKTkpK8jpehg4dKmFD7qAyH0pNVr53fxqFxXjORlEQ3QLnQPTjX/7yF02ggwFJS5AuNmhP
ovqx2giqJ94SmTPiqmIBlFBnUly+fNmWBPrAgQPJerr798fMPRHXLsl1rVqbWv0mXA1FBkqOFyxY
0BIlwVHnYJNHopAQHFzOHOoaNmwo1kV3oK7A80VWLtx9SRwl3+VJscDqBJr+8yb1ZaWGl4kx483L
2KFDB49/q1atWkzcv78tFj3kkWzITNKPyKpqAh0gCGGIi2soCg5Iv9ltEHGKJT4JEk18aSw8zxw5
cqgBAwbYkkDHx8dLxb9YKaKzdu3aZCnGdu1TuN/s1sioR00HF/Znn31m6mdGzDbKKpBmLIkQZK67
Tp06Hgl0JC3QaNvyPST0heozcXeHs/Jsei3QFEpC5s2qrUmTJl4LXJAX4S1EhZoAixYtsvS9+9Mo
oqIt0NoCHXX89ttvEl9oV/LsJNFvnVd5CxSQBDwruInTAskkmTJlUn/9619tRZ6paCeWvOefj4n7
MdQdGrVpG/MhVf40qt+hQ4/uslnDrgjZMLS969WrJ1rfaQEpPF4/f+NmvbEH0eg/+pH+tDLQQkdF
yB14FRMSEjy+hxwJEv//85//xPw6T4iOkdyqx33gDXk/+hFVJ02g0wksdK3btJE44Lnr1tt+MJFV
i5sYS1EkT2ThAIcAwnEoFW0nDBkyROTPIpkUES6cPXtW5ma9+ARNnl0amyZVUKtXry4l7s0GEpPT
m0RIpTk2smkvLNfPOIhG/9GP9KeVcefOHTHmuMvxzZ4926u0I5Znu3gdqfzJc35hz6t63AfRHp80
WfoxGP162xJoCjbQecTB6MH0x+aMdB8hLVaXgqOyHZa6SE6OaIJiAyTa4d6zOoyM+uJlywaUbR3r
Dak25KLMVHlz2bJl6saNGyKh6G8hHANGYQg75Z+Eo9F/9GN6ZQTNCFQ4unfvnuJ3JBe6y1qCDz/8
UO47kEqmVgTqStyvNvwF17o+MSjihYdigkBv375dBiA6iXogpWxMSvoGa6aVcfjwYbmPV1991RaL
KhYY7tfqcexYVakOhZWV0CI9J70UzZg1O1n32PHco40NGzbItUyYMCHgz0C3PJSJfYG21a8fVhtP
nUlXcqC7Rq6/jWIQRqnkUDT6j36MBZCISnVSxpUvY87Fi8n63+fPn7eNpxFjCfc8au4zplybkH40
JCnd9aLNNIcIDUQxSBPodIA4UeJjazZqbOukJF/NEEKnOIJVgZwbKgDNmjWL+QUVKzvWdqzuVsf4
8eOdBTH0XPTdWnR9RCzR0VScIaGLUt4oIwTj7SFuGm3maPcpCdVGgQpIgGt5bW+t/9hxavWhI1En
0PQf/RgrYA3v1q2bSDhSshu1BGKc0UQnxGvEiBGiTJOecKFYQfbs2U1rAOw+ZKhU+ePn3ZffV216
9jLlHCpTqbLoi2sC7SeIe65du7Zks7vWZtctteh57SZNZJJGUuIl1DAKiuBajmWQsc59HjlyxNL3
QYl5rBWPDByk56GfhQvyFSokVpRohFyxnvLdHN6Cjbvv1auXlNuNdp9SJXDp7r0R+a5QE2j6j36M
NWBdppgSsfVowlN+OS4uTi1YsMB2ieIG0Fhnjw5knDy5dJlU8QvXuIbYGwTarHMIFZ6MmTJJyXhN
oP2E4ebWsUNpt1fefkfiodu0bWvZ582mTlLdsGHDYnoxbdSokUg4UUnTqvjXv/4lhRAKFS9uS63n
QNuzW5LD0dDKjgaQoOPgEyzmz58vh6dQPfuZK15UdZs1l3LY/IuCCb/fceGSapDQQhQripUpI4R5
wrPPyd869n9UPfDgg1KKmwI2kxYnSmljKpiVr15D3mt8PlXgqtVvIJXVCPNAU5/f8zPfzcHGOAh6
u5ZQEmiukf6jHzViH4MHD1Z58j4c0FhhXDdo0TIsc4gwjNx580o5+g79+stry1ernhxz/PhANfG5
xBTfUbd5vFr+2v6IzyHCtERLe/t2TaD9AQkGnF6bd+ykN14/GzXoRW9yyxbLLjSQ51hRpvAEZMN4
RujuWhlk2EeqmEastdY9eooUZyTj30lUQ2rsz3/+c0g+jwIZodKC5vDPpjps5iw1bdkKVaZKFVWx
Zk1nTGbmLFlUwaLF1JDpM1Xb3n0kDIbqlot3JKlsOXMKaUZj1zUGukKNmilKfw+aOs0ZcuIav8nP
D+XLL+8bOOVJn9cSSgJtaEDTjxqxD8IrA9WC9odABzqHuJ46TZupWo0ay3xyjYEmb6Nmw0Yp5HMf
zJBBDn+RnkOGBjSKL5pA+4EuXbpIYlKoyrfaJZSjat16IilkRsksf2BoIxPOEYt47LHHpHAMBWSs
CjRcOeQQ06vnXfrbvms3Vdbs2VWPHj0i9syWLFki8wpFgFCA9YVY6j4jR4Xk4O/qQk58ZaeU7jY2
f647MWmXc43DWoYl3z2Ew5VAI3lF0pHxmVXr1ZdN2BOBbtW9h1/XEkoCTb/Rf1ZdpzXSh7t378o4
dj3UpZ0z0U01addOla1SVeXJl09+pq0/cSqkc8g1hMOVQFMMSgjzfS8TOsy1GjeJyhxiXhcpUiTi
z82SBBrpGx744Cen6w03nW3FvuTS0IsXL7bsYtO8eXNJKCQpJZYA8cSrEoz6gRlA4iCaz9vOXdBz
LsA2YOKkiBXRIFSIapctW7YM6ec2bdZMVaheI2R9gn4461fvEaOkb4h7NDZ/4sedyURVqqjpy1f6
JNCUU+eQQuL5wZsfSajHrncve9z8PakjeLqWUBJo+q2pDRKmNf4AMeHpiWXmAEj4Q4ly5YXw8jON
cRjKOeSNQNMKFiuuFm7eKj/XT0hQI596OipziDCTxx9/XBNof9DCsdCTOKhjKwNruHuQFLKqvihS
dkw4pO1iCU8//bQsTmYv7ewLJKlyCCBeTs+1wBt62bnyPKTatmsX9mf2zjvvyHzasWNHyMczruB9
128G1ReHP7kjYS3ZcuRQGTJlUpVr10necB3k19j8XV9fqVYtSazyRaCxsuFWXv7qPsmhKV2pkkcJ
Ln6es2adX9cSKgJNf9Fv9J+GfYBWNnM+vWXp/QnhCGYO+SLQaC8T13z007sy9g2p0kjOIfIXohWa
ajkCfe7cOems0U/P0xttEJmu9OG8efMsudDEksybAVQXCK3p1KmTpe9j7Nix4tYzrHm6BaENPXOW
zNP3338/rM/s6NGjqk6dOukumJIWrl27lm63tKfGBk0i4Lz1G8VogvWYz8WC5UmX1h8CTWvXu69I
fHLY6zdmrFcC7apn6+taQkWg6S8+k/7TsA8OHEj2Di/auj3kBDqYOeSLQCNPSuIhYRiuqjuRnEOE
O+HxjIaCi+UINDqSOXLlUkdvf6Y32SBavebxQtisWqGQst5MZMp8xwKMYkCnTp2y7D0Qt41UYnzn
LnqOhaiAAZsJlimrAh3jKg5yHkw/lKlcOYV+M65l5gpWrzQJdIGCTjUAdwL99EvrRXmjcImS4kr2
Z/P3dS2hItD0VyzpP2v4b0RB0i+9uSP+EOhg5hAFfVC08USgeT8JiCQeuhZOitQcQjUHdY9I6z9b
kkCTIY5rS+vKBt/YPBi0aA5bEZw2KaAzbty4mFg80QGt7FhYrIyXX35ZxpRBWHQLvrXq1l3Geait
w66bdqlSpdTOnTvD8vlGcmIw8fBYiiEIxGiuP35SFShaVD6TA0Zamz9WsS4DnlBJF99NRaBRC2Dz
z5E7t2zE/mz+vq4lFASafpI55Og3Dfth9OjRKpNjTBLC5e+YgXgylsM1h/DOEOK06uAhj69FveZP
DzwgVuhIzyESH3nv3r17NYFOC4mJickV9TxkmeqWTuHxu1+oh/LlU+3bt7fsYkPSgNUVK4BRvval
l16y9H00atxYFSlRUuJL9RwLTSNGl7GxcePGsDwzQ9UmXAfpb7/9VoweJAoF2gdrjxyTRCk+h2Qp
KgqiH7ts72tpbv6Pjpsgf+dfT6W8UQ1AzcBbGWL3zd/XtYSCQNNPfDb9pmE/GAIJwYY9hXIOQZwz
Z80qoRqeXosWNH8/dudexOcQMsa5cuWSUvGaQKeBGjVqOB5sbb2xhqj1HTVaBvFPP/1kycWGkscs
NqtWrbL0otm7d29J6rSyZBXeIZ4Ferp6boW2FS1VOmzx/vv27Qt7vG2/fv1U1mzZ1P4bt4Lqh6RL
7wV0OMM6h8EglM8k0Gvx1egf+qmx4yB64sQJzSZtiri4hqpQsWIhH7PBjFvik0Mt2hDsHEKjGjI/
c+bMqD0ryxDoL7/8Uhb64bPm6E01RM0I3t+2bZtlF5sGDRqoihUrWrZq3zfffCNFMyJdgjTUWLdu
XbKl9NQZPbdC3LBKogkcjjAOI+wmnBbPW7duyXegvayfp/dG/9BPGIr4d8iQIWEL3dEwL44cOSLP
f9oLy/W88NHa9uqtsmTJEtXy75Yh0GvXrk2WKrkvk6JbaNrDBQuqPn36WHaxeeUVa1fs4vRMBjEH
RCvjkUcekbLdek6FvuHaFJ3WgwdD/txQ4MBCHO5k4q5du0qscXpiO+0mW0j/0E+4o6dNmybrAmpD
x44d06zSZuAQVbxMmRSx+bqlrKyI4SnaNRMsQ6Bxc+cvVFgPnjAkKeXPn9+yC40h/0ZlSqvhX//6
l8qbN6/q3r27pRd7rP+EoJAcoudU6BuxhcQFTpw40bJjBCk+DgG9ho3Qz9RDo1/cC+dcuXJF1DgM
a/Tf/vY3zSxtgv3798tzHzt/gZ4fHlrTDh3F+kzooCbQfqBw4cKpkj10C74hgcNEtXLxjqeeekpi
uT///HNLXTeJYfQ92uZWxieffCL3YSSd6Bb6ViOuoapfv0HIn92LL76oypYtG5FxMnz4cLGqbjj5
pn6mLo3+oF/oH08GArxUWNsoVYx7X8MeaN2mjcqeM6fae+UDPU9cGtrTope9aFHUn5ElCPQPP/wg
HWaUidQtdG3d0ePSt3v27LHsQkP8JhvM1KlTQ/J5n376qRSZoWQ48dVVqlRRrVq1kvLnoTzxVq9e
XdWsWdPyC31SUpJWxwlz6zlsuMqcObP6v//7v5A+O6rd8ewigZ9//lk8Lmgv62f6R6M/6Bf6xxuw
TLNe8KwGDhyofvnlF80wYxx37tyRqq54ifU8+UOyr2jJUqp8+fKmqGFhCQJNcQkWjqW79upBFOJG
di3Wj9mzZ1t6sSHEBxH633//PeDP+O233yQelJCWKVOmqDNnzoh1Famv48ePi+Z07ty5xZUebNIi
n82Y3rx5s+UXeonjdhxgwpE17qvtfOey2nr2vC3iBEkoYrxwuLMqgXb1uoyZN1+vv45GP9AfmzZt
SrPv/vOf/6g5c+ZIQmmhQoXU66+/rllmjIPnzfhYsGmLni/3DQn0x5tvvmmK52MJAo0+Lp0WSHng
3A8/LO81Wm7HSb9u83ixvKb1oGo2bBS2gdCkXXupBx+J70qrUWygb9++ll5oLlxILkCwYcOGgN5P
4g7vJ4kHIu0NP/74o7yuRIkSEsMcKEi6y5cvX1CfYabDC1YBv2Luu/dIMR/dW42GDf2aj8RbG+9p
36evapDQIuDxj8wZn0OynlnnK5XyuMZQJ5RFmkADqoZlyJhR9GDtTAa4f/ohvVXUkBzEcyXKJo8/
7tNyrWFtYGWtXbu2JJgi+2bn+cIhQuLCx441zfOxBIGeMWOGetBx6g5EMxACTdUbgvE57Q+YMEmV
r1ZdZcuRw+eAJJ6T10aCQIf7u9JqtZs0VQ3i4iy/2LCpkL0cCHmmEiD6q/6iY8eOEnv93//+N93f
R6w2MdtYF2IB9Rs0UHWaNvO7chRzkfbY+ImyIFIC1vjdvPUb05yPKBbwPipkQUI6D3g8KAJ99PZn
jvnYzqcEX7Tn6+7LyUl4yAWGEuhAP/rooxEdLxA+1CU4uFONzI5kgPvm/umHQAgw1ui5c+eKNbpg
wYLqwIEDmm3GKO7evSsFwyjxHmkvn1kaXC1nnjyqVq1aUSuaYlkCPXjwYKl3HkjHQ6AHTpma4ndH
bt9RGTNlVmOemRe1AeG6IUe7tXykm5TztToM9/D58+fT9b7169erFi1apNsyUKlSpYDk8yZPniwb
X6xUGyvpIAKMoUCE8CU0a3f6QrOIteZ9Oy5ckv8HS6CtMF/ZOLlnYvNjAVTfJHQsrmUrdfzel/aq
Auu4X+6b+6cfgsGNGzfEQsnY4CBk1aJYGr5BqWqecefHBtiOPFPApUL1GnKI4DBhJliCQONWL1Op
csgINC1Pvnxq1NxnkuPQHER64JQnVbdBg1X+woWl7CS/6/r4QKfEUP+x41K8n5KTlRwL177rN9WI
2U+p7kOGpqzyN3qMlI51Wt5e2amqx8Wph/Lll+tx3ZBdv+vwJ3ekjObGU6elxny2nDlV1Xr11aY3
30rx+VR8K1S8hHzeIwMHSSxzoAOU+87p+B6rg/hn4qB79eqVrvc1bNhQvfHGGyl+x0bUqVMnKdSC
zJynKoFYA4mZTg8IDyGOOr3vMzMYO1iRQ0Wgfc3HJTt3q1IVK8r7ylWtpobOmJmCQB+8+ZFz/hif
t/382/I7rLjG/MISXrBoMVU/IUEduP8e17AuM85XvGah1j2NpAqHp/nDc2zbu4+9CkA47pf7JjQx
FPjf//1fOViRcEb+BhJoGrEHPPGMG1deYYccrbrNmsth04wKNJYg0G3btg24hLcnAs2GjAvdkFMi
prFIqVIqc5Ysqmjp0mrOmnUp4hwh2nyOawgJVaNKlq8gP7OZ1ouP92qxInabjZXNmkqKbKRZs2f3
GFNpxGMWd2xqEIVew0dKnXjCTozP7j92vLymafsOsjHz92CsY5T0RsXi7Nmzlm/EcjPZXn31Vb9e
jwU5U6ZMqZICCc8wNjiSBz0l+aDIgQb1W2+95ff1kYDIs1uzZk1M9DeNscMYChWB9jUfmbMd+vaT
90Gw523YlIJA77t2M7m8+8FDHi3Wxvzi85lj5avXSBUDbdb5+pDj0D9ixIiQrq3RiIF2xTPPPCPf
j8HBDoSA++R+ue9Qg4qPhKLx+eQlRLNCm0Z4gAILz3fiosUxP1fgW3g2pYDeli2mfB6WINAJjo0s
UOkjiC+Nza1UhYoqb4GC8kDGL3g2VWbn6kNH5P9k9btuktvOJSeorTvyhvM9WJ0M0pAWgcbtwncb
rkosYtRw97UhE5NpEHZiLvkdsZ8HbnyoMmfNmqIs7sLNW+VAwOcG0kdGLKpdG1ZrTyEaWHawPGOJ
9hRjSPwz/W7nvjMaYyiUBNrXfHz5jZPydyzK7iEc/hJo4/V8tjuBNut8LVC4iBo0aFBMEWgwcuRI
uQYOGrFMCIyDFPcbLiBzuHDhQjEKkKT82muvadYZQ2BPYj9iPYplEk3IWpuevWS+IB9rVliCQLdp
00ZVrh24BZpy1RBeGm5bBh8WIkPVgw0RdQ5fWf/FypRRQ6bNSN6kr9+Uz1j+2n6/CHTVuvXEJe2u
/elrQ5654sU/tJodxJ3fbb9wUTZfOZE5yIerNiIx3VMSnw/YKhIrFmhao0aNJEwC+UN/LdCegEIG
hzeqgXkqtf2Xv/xFXKb+XteSJUvk2ZE8GCt97bRAB2BB9EWgfc3HUBBo1wO0O4E263zN6xhrnopt
WJ1AcxDlvriODv36x1xMNPfDfXF/3GcgicfpxUcffaTq168v39mjRw+ppaARGyBUERIdq+Ec5KjF
tWwp9zd//nxTPwtLEGjKNJetUjVkIRxspMRWNu/U2bkh4sr1RaBxzVZvECc/z3pxtcjKGAt9WgSa
7NFpy1ak+Dt/87UhE6Pper0i0XbyTTV+4SIh76UrVUrRMjhI4ICJgSkDEL9NgH6swNAN37Fjh1+v
p0CBr8RDYq88SU1t3749XSXE27dvL/qtZNDHErJnz54qByBYAu1rPoaCQC/cvM0rgTbrfM2RK5ca
P358SJ9dNFQ4vMHQvG3ctp3ElscCGeA+uB/j4BxJYI1+7rnnpADPw4590MrFsjRSW6KNcI4uA56I
GXWO1z64oarUrStr5ssvv2z652AJAv3EE0+I+zKUSYQkBRpWLk+6ru6/e2HPq1IsArcsWrauZcUh
0GhLu76/UZu2zg0XrU9It+vf2fR9bciumrSuGzIxmVmyZRPC4t68SYD5o81bvHjxmFpgUMjAAuMP
cBG562A/+eSTUuwEkGDIYuUKYqbj4uLU7t27/foOCmCwKJj9RB0IGDuBxPT6ItC+5qM/BPrFA4dS
JPy6E2jX+eX+OzPOV0JNGD9YjGMZq1atkvskptzqJb+5fu6D++G+ogWKQbFWSd5At27q+++/1ww0
RjB9+nR5rpBOCktZeb6whhItgEeYg70VYAkCDZnJ5DhFh5JAE46BG5WTmz8Emtdlz5lLxLxR8HDd
YHsMHZbq/a4uX5KQUOrwpzBDWhvy7FVrRBPb3c0JsQ904EL+ST6JJaxevVr67L333kvztX//+99V
mTJl1MqVK52/u337turQoYO4P9l0Pvvss1TWZEJF/LUmI/7OwhCLrtQ6deqk8sBEi0AbGtGu8+f5
nXvSRaDNOF/3vn8tOS7cMa5DiWiqcHgDB1eSczNlyaKmLFlqSTLAdXP93IdxEI8mCBtJTEwUazQ5
Hzt37tTsM0aAZwEPMp4zV8+alZIFBz85XfJCypUrp65fv26ZvrcEgeb0zuax98oHIdOBrlizpshN
+WuBpiV06SqZ+X964AFJDjJ+P2zmLBHFd/18JKeMDbd5x07O8A+jcINrJn56NmTksUQPdsMm5983
nz4rg+/ZLdsDGsDFy5RVPXv2jKlF5Z///KfIqw0YMMCv11PchH5t165dCkUO96qEJBcSk89r/S0b
DkEnzAFPSiwCmb8SjoXPDASaxmF7xoqVKSTk0kOgzThfV79+WD7n0KFDIX12ZoiB9gSspC1btZJr
Ix6SeHIrkAGus0GLFnLdXL/ZrL14wjj4i+u/SxfJ49CwPjDwGNUpWadevXrdEvMF7yAFYiSJuH9/
2betBEsQaFzodLCRtJdeAo1eMzq1NEoA41aTxJ+Vq9JFoEkU4n2um6uhGSvSQSNGCRlAD9Z1w8Wd
bGSZs/kTew0JD2RD5v9UVkRPlgQlrGvcH5q4gSa44LLGFRRrIF40PVZfFDeoRkj4B4c2SDUkGQKM
G/SFF15QRYoUEV3y9Ez05cuXy/P74IMPYnLxxkOU0dHP6a0UGi4CXaVOXVW4REkhqCTq5Xc8s/QQ
aDPOV9YqPpPkMDsQaMNqytzh8MmhCEPIsTv3TEkEuC6uj7WUkI1Zs2ZFJFkw0H5dunSpypIli8qT
J4/fuSIa5gYV+mbPni1FuiRfYuEiCf0y43zBAwcfw5CAWoxVx6AlCPQ333wji/y4+QsDItCuclsQ
WwokTHthud8bttFQ3+CBD5s1O9X3EMhPjDTfQXw0SYeucaGTFidK4pBBwNv26h3whkycJ6WT+R2L
da1GjVMkTaWnUQAiPQl3VoIRd4ysU3o2lzfffFPkwojtZZNhA8fNjfzUlStX0r1ZER7SpEmTmF24
0eh0V5qIJoFef/ykJAnzGtyaS3ftTReBNuN8NZRy8IDYhUAboGJnnz7JxUfyFy4iJd/xCpiBCHAd
XA/XxfVxuGbNSG8xp2jgzp07si5x3ag6xEplVLuD8EPDe4NnEG+cWZRtKGGPRzBXnodkLRw9erT6
29/+Ztm+/v+scqFkEZu9YhVV0Hy5TlhsjfLDoWhszIGEtbg21AaYaB9++GFMLiYU4cFqTNZyNIDL
nf6lsEusgpg17tE98S7q7vTzbwdlgTHTfKUaFy7aUMNMKhxp4fTp06rxfcJHURkMGRg1ojG2+F6+
n+sQ5RDHdXF9gCIpkIP0HrajAcLVsPJnzZpVpD+3bdumGWiMAA3watWqyfgsXKKEmvhcohz4ozFf
dr13RTx6hLYaB7arV69avo8tQ6CJ1ypaspTt6sCHu1HVjYXTrO7GYHH4cHLs6N69e6Py/S1btlTF
ihUTSalYBYeTbNmyiRdGz6nw6AhTCTGcBTishHPnzqlWrVvLvCZBE5m4Z17eEPbwDj6f7+H7+F6+
n+vgelzxj3/8Q/ThW7RoYZk+vXv3rmrevLncEwnSeH01rA8OSK+//rqqV6+ePNvMWbKqVt26S9hp
uMM7Dn38qZq+fKWq06SpHChpeGauXbsWM/1rGQK9bFlydS+rS7WYrXEyTY+WsdXAwaB06dKqWbNm
Ef9urPpmr6QUKpB8WbJ8eT2nwtCoyCghK35KJqYHZlTh8Bc3b95UU6ZMUQULJleXzZ4zp8iHjn56
nmh/h6Lv+Rw+j8/l8/kevo/v5fu9Yc2aNfLao0ePWopsMR44DOfKlUtt3rw5zfeQH3L8+HG1detW
uVdNvM2LS5cuqREjRkiIkRHeFt+5i1imqbYc7FyBkLNWDZ0xUzxmme5/T6lSpSRU7N69ezHXp5Yh
0CRxuVcQ0y24tvHUmeQS5evWxfTCQfIf93njxo2Ifi9Vx1isfv7555hfnI0+fuXtd/TcCnGj4ArW
mx9//DHkz80KMdBpAe8OJG7YsGFyWDbyXXLmzq1qNGwkOv3IEs5d97LE2xNDT/w9ihn8y//5PX/n
dbye9/F+47P4XD6f7/HHm4S8JbkPNWrUsJx3j+RpKrBy34TAff3116lec+vWLVHfIT8EVSJ08jlE
Y3mvXbt2yNViNEIHEuUJa0ShqvD9XBEjLArii0b9mGfmibeF3A4OkVveOi/zBQUhlDNIhkaiE7Lc
sf+jokOd1XHwMj6rSpUqksR/4cKFmO5LS62caATWbtJEb6ohapQrZrD/+c9/julBTpICMX5Dhw6N
2HdCmiHPoS69bFbgAmYsjZr7jJ5bIW5lKleRGNtwIBYItDu++uorSWxl7jWIixM5S9dE8rQar+d9
vJ/P4fMCAWFjfB7WWasBazSa4xBk+mPDhg3Ov508eVKUEzg0u8t8cljAEi05EbNmabZqwsMRh3Eq
VBog2R4jGoegWrVqyV6ZnvmSN29e1bRZM6l1gJfMTmXjLbVyPvXUU/LArKIJanbx8kLFi8vAtwPY
DFkYfvnll4h8H2EbjFUsNXYB1jbInp5fodVJZRytWLFCE+ggD9GEXFDUhMRJ5L64b/YU/s/v+Xso
FQEgoRSoKlGihEiMWRFffvml5HFIvHerVurgwYPy81tvveXzfch8kvsRi5VXrQTi8fG8YglGK5oE
V5TE0gq1+etf/yqxyihSkYyYlJQkCaa7du1SBw4cUGfPnhVJTT7fzrDUyskAYPL2GzNWb65BtsU7
kqQvN27caIuBzubI/T7//PNh/y5cvEjgsfHYCUaeAkU/9BwLTUOi74EHHgibVcdKKhyhBIoZjNXz
589H5Hsise6EE1gosUZjhPA3PIPDCPHisap/b2ZwwOHAQyx71apVRa6QMCS8CXjyf/31V91JdiPQ
gEGRN39+Ka2tN9jAW7OOnWQyubvgYhlkmZPQEO6YRCTr2DTJfrYTsFpkzJhRte/TT8+xELTDnyRX
NCXWVCO0wLLGHI1EjGaHDh2kfLbVSQtufxQ6XMFa6lq5FbhKhhIG0rdvXz3gIgi8Klj/X3nlFSkO
5goS25GQY+xHyhurCbSJYOjqol+sN9nA9XGxak2ePNlWgx1XVDjKIbujadOmctqPVWlAX6BceZas
WaOmzxtLjex4f9zlwcDKKhzB4NSpU9K3b7/9dti/C5103ObTpk2zdJ9RJGbPnj3O/+NpQ6oPdQcD
3333nXjfXA/VVDu041oYDaCcUqhQIVFH8YW1a9eqHI7DeaznP2kC7QZOu2T5Er/7xmef6402gNby
kW6S4MZiZyew4BctWlS1bt06bN+Bu1LKzi9fbssFhbg4klT6jByl51owFe4+vSvV7Ro0iAvr87JL
DLQ7SITjvi9evBi5g6VjzbUyYSHHwQjH+Mtf/iIhapBjg0C/8847Ei4AMXMFYQTa2hl+EJfMmPY3
LnnRokXyDGO5RoEm0B6AlJCWtAusUV4YgjNjxgxbDvhnn31W7p9yp+HaKIkVTMsCEMtAHgkN0D2X
r+o5F2BDe5g1zqhupwl0aHHiRHJypqv1NJwgGS9Tpkxq0KBBlu2zChUqONdNki4JgyE8w+hD1EYo
D07SpCuwiEK4NcILwltJ9vMXeAV4ppE6RGoCbSI0adpU5S1QIGqlKa3a4lq2kthnu1oEcCmykSG5
E2qQ6BWuz7YSEMx/8MEHdWXCICp45Xn4YZUQgUp2diXQhhEGq2mkMHXqVAmdw0tjRcTHx4vl3hWu
BNqAK4FGfQTLO7rYGuEDVmf2dfeYZ6QUCSkk/8dTNV7mv12NabYm0O+++65YEvUm7X97au1LMZER
Hiwef/xxcTOGWoIHySbGJLqadseoUaOERK87elzPvXS2XsNGyDxljQs37KrC8cYbb0Ssjw2gDU84
A0lcVgQu/zFjxqSLQJNQTTEWjfAClSmKl7iCcFd+R/IqHtHKlSunikUnL6hbt266A+1GoMGkSZNk
EaSKlN54fbd9126q3Hnzii6p3WOerly54tTWJZlo5cqVYjWmpDnx9SVKlpSNDmsyhJgEoMyZM0sm
PQlXcQ0bqt69e4tFiQIDbCCombBxuGep2xWGhBW60Foxx//24oFDMt5GjhypB1EYcezYMVkD3nvv
vYh+b2JiYsTUP0INPGzEPBOO4g+BZp9B9chK5cytCsZTEw/FlipVqqSuXr0qBLt8+fKpCDRhOHaT
W9UE+j5+//13KZda2DFhkXzSG7D3ltClq8qQIYPI2NgVlKTdvn27lOQlU9y1mlKGjBlVcQc5rp+Q
oFp176G6DRosiXCPjpug+o8dr3qPGCXeDvqxVuPGqmDRokKujfdjba3lIN9DhgwR+Tqts6mcRRcG
Tpmq56CfiYMlypUTCapIFSiwqwqHUS3v8uXLEd+zKKPc0HEItyIMrXes6WkRaBQ6CN+gYqFW4Qgv
qJHBYcUdGIn4fcmSJeU5uIPiKHb0QGkCfR/nzp0TIgOx0Zuw5zbh2edk0Vu4cKEtSTMLR/369Z1k
N0euXCrOceoeOmOmSkzapZIuvqtOfP5Vuvv12J17avPps2r+xs1S3KdavfoqY6ZMyYTccVjBVbtj
xw5bJxT269dPPejoizWHj+q5mEbrMXSYjB3icyMFu8ZAHzlyRO4bb1SkgdQY3034jBXx5JNPyvVj
2fSEH3/8US1YsEC8eUjf8VoODOFK3DYj6APkJylUhi4zlXB79OghHkoOFlh90QfHk0m4GxUCIbPI
KgZqfIEou8bXUwWXfY9QDlqjRo1SFbXp2bOnJUvNawIdQhhusSHTZ+qN2K0tf3Wf+tMDD0g4AmTO
DsB1SMIEiaYGaS5frZoaNnOWWn/ilJQxD6cVkT4njrVAkSLy3RQXYaGMVMa/mfDTTz+JRerhggXV
3isf6Dnppc1c8aKMlXHjxkX0+diVQB8+fFju+/3334/K+kQ8asWKFS0bTgcxxJLeuHFjUTbiULB4
8WKJpyXMg/BKI3EQZYi8efNKGBz5N7EYQvj555+rTZs2iTW3yP1132gkjj6UL58qWb68qlijpqpa
r76qWreeqlC9hipRtqzK/VDeFN5MGnUE8GbSd/4qmHBocS1agyKKa7w9hB1SbeDjjz9WDz/8sPaW
2p1AG5YuBuGzW7brDfl+S7r0nsQ9E9Nbr149mZicfmM1yQ1LLy5GIzyjaMlSasi0GVI4Jhr9D1Ff
uf911X3wELF6c03o+kLu7RKHjtoLsnb/709/UpVr19ba7R4a1vlMDnLRPD4+RRU3TaDDB6Mglzcr
aqQI/EsvvWTZPkRhg2TMmTNnqoEDB4plmup3KB25g/hpKmomr4ENhLxZHYRNzJ07V8JIDeILUcYb
PmL2UyrxlZ3qlbffUcfvfemXN3Pr2fNq4eZtYghs3LadypE7t/Nzq1WrppYsWeJTRxwiTDiWa8Ee
Etsh1Y888oiaM2dOCgs5n7tq1SrNgjWBTo4tq1mzplRBW/7afttvylj7ijsmNtI2uM5w4VB9KLdj
UmKNnjdvniyAsQAsHcR65b6/4FR3kNR5GzYFFJYRzrLM4+YvFFLPNaK/ySYaq/j3v/8tzwRrFBYY
Dm7cd9vefcLqAbBa2/nOZZW/UGE59LGpRRp2VeEgT4Hx6O7SjiRI+kIj2V16LJaxe/dusXqyB2Gx
tpohgXUNSzOJ5IwfEn7rNG2mxs5foDaeOhPStYH9a92RN9TwWXNUlTp15PswErZq3VrUTTzFlUOw
ed3o0aOdf+dQ7iojyOGFdRljk4Ym0E58//33QkyyZssmlj/bkuf3r0kyUjZHP7iXqsUSgLWeSVbO
8RqycK2MAwcOyKmb+6nbrLlae+SYqZ8Ni+LTL62Xw414BFq2lFK/sQSkkQyrTJs2bZxuQ+L8+J2W
nkxuu967ooqULCmH3FgbA2aHkeB67dq1qF0DIV1cA653OwELNbG3smbXrWuJxHYMdCTcUsmW6y5V
oaIaNmu22n35/YitF9vOXVADJkySKsyGEYa4aXevFQmexFhzKMc7ANlmnyfWmX7nAMO9aGgCnQrE
C0EMs2bPLpJQdtuUX716XZUs7zhEZM0qCZbewISin5iIuNgh1lZ7zu3at5fr534XbdthqeeEtBtW
i1x5HhKrAu5Pq3sEIAQkqogXoHr1VEUXwPTp0+XvjwwcZGvyTJXGoqVKix55JLWI3WFXFQ4O3ozD
aB9cCGvgABUN70O0AbHLnz+/5IgQRx3p8CV/gBWXMJt8+fI5vZuLdyRF3QgzZ806kQiV/c9xCMdo
4QpC5+hXQjcZYxDqxx57TEi0jnnWBNoncGNgAaOcMMVD7FSmu1CxYiIdRAZwWoCwkSGMOw2Xzvr1
6yXUwxf+9a9/ibIFkzCt14YLxBCjyczzHfPMPL9izMzaDt78SHV69DFZCKtWrRr1DZ0Ng8WXA4q/
1cOoPNinTx+5h8KFC4s2ti/ZqilTpjgt0VZ+doE24iLxQFDyPdqJpXaNgd6/f7/c940bN6J6HZ98
8omEOI0fP96WBISDg7F2oNqBXrFZQIKpkTtUs2EjU4aGLty8VZWtUjXZ29e2rcRlA9bgaKnMaAId
A8BN1KhxY9vo0JI8idWdmLr0ZpaTVGjEqCI35L6poKRAFSrcbWRSo1OL5QzS3atXr4iRANxoWMu5
zoo1a6ktb52Pmee3aOt2KU2P/F00YtOIBSW0h2dKERnGEQcxqoh5K4QA0aaYDJYOwoUgY/7Gc5Lo
wnOsH5+gDt762DbkecW+A5LYS7y+e3iVJtCRA7Hf3LcZCNuIESNkDqHkYFdwoCngWP/oBxLfommN
Js554sSJ4hnMmz+/mrlylbm9mfe+VGPmzVfZHHsy/cdeTXw9RVQ0NIEOaiJQtpmFsnnHTurAjQ9j
bkNm8gyaOk2SGWrVquUzSzctEE+FS42iIBAcquvhhmdhI8v67NmzKazOHFKQM6LiHEQrnBZpLKIQ
eBa1xydNjknL5b7rN1XT9h1kvA4ePNhvC3CwYMPiGZKR7ZpBj4cCNyveHNx/xvM1EgTxAmA941q/
++67dH8vVhLGGvJO2y9cjHnyPG3ZCinYQ+gUElNmgF0JNC5v7ttV1itaYG0j5I4DrJ1B7G7//v2T
Lb41a0bFG3f37l3ZR7mGrk8MstThHuGA+E6dncmGs2fP1gxXE+jggfwLG3W+QoWiHr8U6qQCIzuX
hScU2dxYFYcOHSoTEOLMZ3uKZXUF1oL4+HhxdxHiEWqQ6IO2JgorFC2JZZKFQgWJIvR7s+bNxfof
TnBowqNA6W1vIFO+Xbt2Ki4uTu3Zs8djgmCgINQIqzeSTbNXrYnJZ3roo9uqQ7/+zqRR5piZLLF2
VOHgYMjzMEsCGxJjrLnRVAUxC0jwxAOGN47E40gZEhgTeFZZixZs2mLZ9WZy4hI5qOfLn1+MXhqa
QAcNFibE643YSyu7jUkiQBItc5as4gretWtXyPsLPU8WMNfKRmkBS6SncqHB4Pz582KdyV+4iHr5
jZO2cfXPenG1VDUsX758QNZdf2Bo4f7zn//06/UdO3YUFyEJgidOnAjZdRBDHReXLAsV37mL2n/j
VuwUMnptv2TN4yEiI96MiVJ2BHkUjLf0rG/hBBr2qCO0bt1aP5z7hhy8XkZCcrgPFhR44bswSFE/
werrDgXDipctK3t4OPiBhs0INMA6OnnyZDnpU/1n/IJnLRcKgAW9dMVKzqSBb7/9Nix9RWIHi4ov
q6Q7iFHGchCqTenixYsSW8tCYMcqdpAvJBmpWIZEY6hB0o63+GZPIOEHC004roXxROweniJiwWev
XmvpZ0e4WPchyZ4cqooxls0Iu6pw4ElhDTVTQY+VK1fKNYXycGp1oJVPYjLrAgnvhI+FEoSlkcdh
HN4paBIr+wdGwhr3DROMLQ1NoENmjY5PSJCBhV7yvPUbTV/cYd3R45JwZZT5dJetCfVBg0QyYtI8
gbhJyI4ncEAhpjZYIO0FWStWuoxIftm5FDueBrwnnip8BYpvvvlG4t09qWUQO+et7DuSSOEsCU+4
DvGPjHMqF1pNzx15QpRhcubJI+R51KhRkktgVtg1BpqCHtw3KhhmAeSwVKlScrCNlsKRGUF42RNP
POFUKgpV+XX6eNCgQU5ZzVgs8HT007vOvBrmuoYm0CED1ahwkUvZ51KlxSJNxTgzxcMSi4WEDtdI
uAYhEqE+hbsDCzJWT08LPHJLefPm9Uqg2ZhQ5ggGSPFwr1Tti6RQvVnb0t17RbKPJMpQxZhjeSau
2R0oAWDx8UaSqR6GZnU4AanfvHmzeDOMBGAqcpn5GVGifMaKlbKOcM1UC4u2RJom0N6BW5v7pkqr
mbBz5065LkLoNFLi2LFjkguDNXrWrFlB6+ZPmpSca0JSeizvH4R8tuvdV1uiNYEOPYhJxJ1Xv359
GWAkEPQYOkytOhi9IiwoEgyZPtO5GZPktXTpUomTiwSIO27atGmq36Pw8fLLL0tJcG8E+syZMyoh
ISHg7/7HP/4h8jsUGNlx4ZKuWHe/kTxpFL0JBRDUR6HGHfwOkuxtA+d9KLJEAlhuIXjoJXPvuCPp
BzNZiojXHjJthnq4YEGnhSw9YTGaQEeXqCLhaSZgFUUFAkt0uA0lVgT1B8i1EQ9V5crq8uXLAX3O
c889J59BmJUd9g9ItGGJZuxraAIdchCniPWURCkGWsGiRVWv4SMlFjWcsVEQAoqgUBq0QvUa8t00
dKwh957ijcMJpHxYwL2BykzeCDSqDoFm9bN5PPLIIyKNtnTXXk2c3Rp65oyLUOhEE2fpnrBEdUoU
a7A+eyPQVAybMWNGRMcjB0c8L8Xvl7AtXKKE6j92nFp//GTU3KLzNmxSLbp2E88A19S6TRt1/Phx
y615dlXhSEpKkudmFjlBV6B6xLUtX75cb8pewFzDsMReQXXT9FijWdvo35aPdIvJsA1f6xbebCz4
/hRa09AEOuANe/v27aI6QBYrkw1FhGr1G6h+Y8aKFWzz6bMBkWpOgkkX31VLdu5Ww2bOUnEtW6mc
uXM7STNScFibv/rqq6j2AXHW3jKffRHozp07S98FgsTEROkDROE1YfZ80GraoaMoOgSblMYYJ0HT
NT4X8X28C0OGDBEpQ08lX3kNrtRogIMkB0rCI9g4GStU9Ht03AT1/M49YQ2/2vXuZVFGadW9hxQs
4LsJZRo5cqQptIQ10geDRBmV28wGJCJR5YiU19Gq+/SwYcPkOeK1JG8mLZA0iqoTRJKwK7vtISQW
kpSPRG04ksE1gdZIARIYiJUmU7e+g0BzejPILklCWKlrNW6sErp0FXm83iNGqf5jx8um3mfkKNVt
0GDZdOsnJCTLyty3bhutQoUKsghAOqNNml0BiYcMp4dA407D3R4IwSKZB8s/BFGTZd+awow5YvcD
jYdmTDOeeVYcWgwg7cU4pDIazX3zvnr1qsQgBht7GAqgCEI4UUKLFnKgYC4xNyvVqq16DRuhZq54
URJvD338aboPKSi+EHeOVGSrbt1VoWLFnPMVzWoOGFjwY0GSzq4qHHhZeJ5428wI5hr7C7G+Gmlb
7EuUKCGHavIzvK2L1Ekg7COP42Bi58R0vN14zlq2auUxiVxDE+iwgUmI9Y8qapAQQj7iGjaUTYjK
bJS6ZkNn8cuUKZOoWRR3TG4yq7t06aLGjh0rgfynTp0SEmDm+0R/01OcrCcCTXw0GxLKDlI+feBA
v++PSYwOMMoFe9+/polyGi0xKTkBCtdlekBBAsYe45Qx2q1bN7GiurvzPIVwoMjCdzLuzXjIpRQw
Ca716td3hmAZDQ9PqYoVVfUGcapRm7YiVwUxJgSDBMUGCS1E8aNIyZLiaXJ9L1ZAPFGErmDhinQ4
Vbhh1xhoDorcNxrkZgWhNVhLqVSo4RvkznDoZ9/FKOXJQ2cUCGP9tPseMmXJUhn/Cxcu1INHE2iN
cAAxeyMxypcrEWtczpw51ZYtW+T0j9UEEgNR27RpU5qSTJSF5ntmrlylCbKfjcp2kGB/JZ2IdeWQ
J/G6rVurmzdvOq03/I6iKt7w5ZdfymvCrb4RKnBQQEmGymIkRI4ePVoOC82bN1fVqlUT671xuEVt
pk6dOtInlFLmHlevXi39wqEw1mFXAk2uBveN6oxZwbWxjuKh1PAPp0+fViUdB2HWRiRVqU0AqMjH
8+47eozeP+43vOaEqJotkVYTaI2YAZngWJOxVKLFiWWSZDN0qEk4Q62D+DN38X9izSAsLFrEzXor
mUucLZJ19eIT9KKWzlg2XJGEMPgCVtPGjRvLc4A8ekp0e++99yRBr0ePHhJjTOw78l6QyDFjxkjY
QigSF80ENlnGs91hVwKNmgz3/cUXX5j6OidOnCihSWaT2zMzqKzKoRlrc7ly5cTDxh5FRdCjtz/T
+8f9hrc3e86cklOioQm0Rhjx9ddfqzVr1ohbsWXLlmLRY3E/cuSIzzgq9Hxxg3PSpZSxYREwMGfO
HNnIXjp2Qi9q6WwU7KDvONB4sl717Zus/YmeMqEXvp4Tmw4xxV27dlU1atQQN2h8fLyE6vzwww8x
N541gU6GXVU48JYxN/CumBmEweHdQ51II32AOJMMD5GWcIXN2/S+4dbI86BvMJxoaAKtYUL89NNP
UvGJhQx5PEMnl8p6KEHEd+qsF7MAGiow+QsXkeRWA0aCICEK9O3cuXNNXQlPE2iNaICDPcTBTInb
3kD8Pdd66dIl/eACMPyQuN+odRu9Z3hRBStfrZp4IAl909AEWsOkoEALWdBsBiRf4mYjVm3LmXN6
MQs0GSTxeenPw4cPp0gQpNiATj7SBDot2FWFg9wM5g0Ey+wgoRsvkqfiVhq+gQGB57zx1Gm9X3hp
i7YmJ9RyqNTQBFrDxOCUi0XFUCtp3LadXsSCLCGdy0GaydZ3TxDU0AQ6Ldg1Bnrjxo1y3998840l
rnf9+vVyvUiqavgHlDnIr2nSrr3eK9JoWKGJF9eydppAa1gAJCCyITy7ZbtewIJsaI/TlyRGaWgC
rQl02iAngPu2itIKmuPkJeDBizUpxXABBR6e8dojx/Q+kUZ7+qXkA9ru3bv1wNEEWsPsiE9IkPhd
YrD0AhZc23r2vCx+8+bN0wNLE2hNoP2AYdH99ttvLXPNBw4cSA5H2LhRT2A/QAIhRc70HuFfASl0
8NNSddLQBFojyvjuu+9kIxgwcZJevELUasQ1FE1jDU2g0wO7qnCgOMMaZLU8gYYNG0o1UHc1I42U
ePvtt+X5Tlu2Qu8PfrYnJk+RRH8r5AVoAq1hWxjWn/UnTumFK1SSdvPmS5/euXNHDzBNoDXSANVU
mS8c5q2ECxcuOIsa4XFC471MmTKqVq1aIluJTr+3UtZ2wvDhw1XmLFnVoY8/1fuDn23HhUsyttyr
DGtoAq1hIqAhXbBoUb1ohbC98vY7svihxKGhCbS/sKsKx7p162S+fP/995a6bqq6EgudJUsWNWXK
FHXu3Dl19+5dqUiKtnWrVq2kaIjZC8SEEySqU2W0Vfceem9IZ6tWv4HE2WtoAq1h0g0AqbW2vfvo
BSvEjUpbHE40vI+9Tz75RBLIyM6vW7eu2rt3r+iU2xV2jYFeu3at3LfVigS1adNGFS5cWAqseAOH
aO7t+vXrthzTRvjGMy9v0PtCOtvIp562VHKtJtAatgIERlyQS5fpBSvErXWPnip//vx6kHkACiXE
iBcrVkwNHTpUTZ8+XXTIOXBApnv37i3l5zWBtgeoqsp9U8zJKpg9e7Zcsz8FL7Zt26YKFixoSy34
+fPnSyzv/hu39L6QzkZFYMbY9u3b9aahCbSG2ZCUlJQc/3z8pF6wwlTa20rKAuEGVmdiQ+vXry+l
fT3hf/7nf2TTpe9Onz6tCbQNsHr1arlvX5ZcM4FQk7x586Zrbo8fP15NnjzZds+2eXy8Kle1qt4T
AlTjyJXnITVw4EC9eWgCrWE2zJw5Uz2YIYM6fvcLvWCFuC3b+5qQghMnTuiBdp88ExNKBTd0dNPC
jRs3pPw5cmF2gV1VOFatWiVzxSrhO4ScPPbYYx7/Rolv4qLdce/ePfFIMQ/sAg7DGTNmVL2GjdB7
QoCtafsOqkSJEnoD0QRaw2yghHfRUqWDnuTEULMBrjp4KGILS+cBj6sGCS1C8lk9hw1XNRs2Cun1
7b78vvQJ7mmN5GpzLdKpawqJLlCggKVc+xrpB8mTzJWff/7ZEtfbv39/8d65g2p7cXFxosThCeXL
l5ewObvg2rVr8lznrFmnyXCAbdjMWdKHf/vb3/RCoQm0hplQr159VbdZ86AmOMVXKF9dpFSpiFoa
QkmgiQEfMCH0OtgZM2VS06ZNs/04w+KM0sYHH3zg9TXeKrpNmDBBzZkzxzZE0k4qHIwLxsTgwYOF
JBw+fFislmZHfHy8OnPmTKrf42o/evSoVwLN+86ePWub50vsLs918+mzmgwH2BZtTe7D8+fPa8Ki
CbSGmVDCQWpadesedKhCtpw5hYQWiKAcXigJdLha/sKF1aBBg2w/zq5evaqqVKni9e/E/nrTO71y
5YqqVq2aLfrJLjHQHJZQpyhevLjIdLVr10516NBBNWrUSOXJk0d0lc0czoHnzr3M8p49e9TUqVPl
UOCNQJM4+9FHH9lm3jOeSSB847PPNRkOsG0/n6xigiyihibQGiZCjhw5VPfBQ4IOf2jUpq3ad/2m
+tOf/qRWv3441Ws2njqtajRsqHLkyq1aPtJNrTl8VH6P1bfLgCdSCchXqlVL7Xr3siRRUCGxYNFi
qkS58mrknLnq6Kd3PRLo4/e+VH1HjxESnzd/AdX18YHO12IZ7z92XKoM50q1a8t1k/DH6/n94U/u
yPcnJu2S762fkBDwBlCmchXVpUsX248z4pg99cO///1vSa4iIcsbgcZ1mdNxQLMDII5Zs2aN6XtE
taJ169YiAXfr1q1UfydBj0RTM8dEL1iwIEVC4N///ndRlCE2mqqK+fLlk3h2V/zyyy+ih2wFC3uo
gLZ7gcJFUqzRPFejZciUSUpWD35yungy/VlT2Q8SunT1ew0uVaGimrvuZY9/GzhlqsQYm4UsH7jx
oZq3YVOK37H3sK9yGNHQBFrDRMiQIYPqO2p0kHrHJdTERYvl56r16qcK43j16nWxUJevVl0NnzVH
VaxZU+UvUkQW0ymJz6uMmTKro7c/c75+3PyF8nd+7jdmrPrTAw/IZ9IyZ8miJi1O9EigOz82QGXI
mFHu57HxE1VmBxFp0q6d/G3U3GdU7ocfFkJuvP7xSZNVyfIVUsVAH/rotizuhKQUL1tWla9eI+C+
qVSrthAFu+PVV19VPXv2TPV79E0hHBAPbwT6t99+k2RCO2DEiBEidxar+O9//ytWZ09jwR3kDphV
+o3YfAizQYYZo4Qr0LAUkix46NChVPdjN114PAsVa9RMRaBZn6cvX6nGL1ykuj4xSAhix/6PhoVA
YzhZfeiIJQh09yFDZV9z/32evA+rkSNHasKiCbSGqQbc/cUs0AlP+W8+Y+c7l+X/Q6bPTBXGwedD
Xo0yrgdvfiREePbqtWrvlQ/k/c9tf8X5+gYtWsoiwuuyOIgTpPuPxXC8g9SWEyLsSqD5/gcefNBJ
rmkLN2+Vz1575Jjadi655O66I2+4kNtazsODJwJtfLa/lhFvlaQSEhJsP84uXrwohVK8gVLO3gj0
hx9+KMlXdgDka+zYsTF7fytWrJAwhvRYert372465Qquh+saM2ZMqr95CuHgoMiaQiiTnVCnTh3x
4LkT6JX7DqZYJzHAYChhnQ41gfbVzEaguw0a7JFAlyhXzq9DpybQGhoRRMb7FttgFqBSjg3RSaiP
n5QF0jWMo3qDOGd4hNFePHBIVCr4GQsvJ29+JuQiU+bMDvK7TS3dtVc+a9+1m8738fOKfQeE1LoS
6JkrVyVbsu+HbBgtX6FCatis2fJzMcemNmTajOTPuX5TYvOWv7bfK4Eev+DZoBdELNBt27a1/TiD
VBRyPIs7d+6km0BTsIIyyRrWHwNYbV3DNtKSMzTGze3bt013P7/++qtUIZw4caLP1yFfxzrrHjNt
B3BYat6xU5oEmpY7b141dMbMFHvLwwULikHGdS2GQDfr0FGUn3LmyaPiO3dxFmkh/I89gVA/3rtg
0xbVvFNntWTnbuf3sxdh0OF1eDVdCfTS3XtVmSpVVPacuSQ3iHA+w0BTLz5ezVu/UUJOCAthD8Pw
w76C59XYS3x9jnF98zdulvcRajjh2efkb4SZ0Ack5Hfo1z9F32DFb9++vV5ENIHWMBOCjYEuV7Wa
KlO5ssQeS3OQcSzBvYaPTBHiYZBYT41QCkIl+HnxjiQhwkdu3xEXH5Zqf5IIWXhZ2Nxf40reuSb+
z8+zXlytcuTOLQuqNwINiQ+WQOsY6D/wwgsviEs3PQQa8kGp+W+++Sbm+4fEOggZVtpYBGobJAwa
ePPNNz2SgsTERDVkyBDn/6lQuWzZMlPeEzH8aD7jXTly5EgKJZkvvvhCzZ07V+L3N23aZMs5X7p0
acl58YdAszYb1tfRT89T2Rx7E7HRE59LFE8k5NUg0FirybvhdxhgjO9A7YPXFixWXIg7pNY1Btrw
kM5dt16svexVBoGG3BKT3aLrI+rpl9bL5/Izf8MyjmGHnBhk5SDMhPgVddwfHlKs7Mb+4+tzuD72
ND6Ha+EQQPgKBH3LmXOqTtNmqlajxrIPuvZN1br1VMuWLfUmogm0hpkQjApH0qX3ZDHMmj27xDgb
DQLMAuFqBSYG2dvnEGLB5yRdfFcs0QYpJj6az/OHQD8xeYokGbq/pnaTps5F+YU9r8qC+fqHn6hW
3Xs4FrVuHnWgDQKNusj/3957gElVZd/b/28UyTmnJjQ55xyaHAVBsiAooCAgUaLkICBIDiKSg4Dk
IIKJJIggSRQxjo6jMuOog2HG38ycr97d3PJ2UVVdVV3dXWGv5zmP2JXvPWGdfdZeW104ggf0ohRR
sZMobwSaqKNIcFaujIrrA8Hk90ZqpNKeSAqhJBrtmh/ANSjkIDh2Ar1o0SJJNA1VkBS5efNmkWql
d5Ajvj+affTbSI9ICiUxUgm0dwLd/qHeIt9znhw6iKoz6jx8pMjh7ATaiupueOukvOfL710Rgsq/
iTy7SyIkwmt/jCRyi0A/OGBggnyXF469JuR2+zvvOiWAczZulsdIMOf/R82b73wu/88JqLf3sb4f
r3dWGsyRw8xev8mrhEMJtBJoRQgiKT7QQ6bPEPLs6lDBZCAyjjuJG6I1fmJIgudMXrnaOWnQOMoa
PX+BKV62rPO4jsnKmpScEo7LV0WGwX/tBHrMswvluMz1O6KXJoohk/cnn8tzmECz584tUejkJtDq
A50Qv/32m8mWLZtElT/77DOPz9u5c6c8Z82aNVFzbRYsWCD9LlKj7du3bxd3DTB//nzzzjvvJCDQ
v/76q2ywSMSzE2iSTB977LGw+I1EpLl/FFQBH3/8sSRqDx48OCrHuz8SjhYPdpFILUSY54xfvETk
ejSJSN8JpkCgSUhPEKgoWNAs2rXbSVAteaCdQONwIV7jd4i39V4Wga5Up45EhK3PpLG+EQ22CDTf
zZJ0iLXcGyfk/63vjMTQ2/tY32/ftQ/+OKUsX15OW70RaJVwKIFWhCCSUomQo6b6rVrf9XccNTim
6vb4YPl/squRedgLr+TIncd0HzTY+be2PXrKe6FL3nL6rHOSYuduHd3RINdEHyC5dgKNJR0T07Pb
djif++Jrb8rf7ESd5BOO23gPJtTkJNBaidA9SMCaNm2aWNc1atTIzJgxw7zwwgtyTI+elKhdrVq1
3BaqiGTUrVvXVKtWLWJ/HwVE6tev7/x/ThjsBBqpBoVUjh8/noBAo4Gnv4QrSAq99957Per/Ixm+
JhFagRZ0z8+/ciyB1Z29Ie2D9LJe2F9bonwFM/a5xU6Candbsgg01qlIK+yvYz2xCDRyDHefSX0D
i0Bbkj9rbuc0k/9Hg20RaG/vY30/19/NY5pEqARaEWaYMGGCuTdNGonO+kMOmTAgoejT3D2OPs2S
cVjHW5BU5Boc1fFaEg6t5+N9CXm2bOWsRrIIMgiOvJgE0a+RFOLOxg65BpEIdvpM0CQ3oq22T6YT
FseXDLa00MlJoJGM8D6vvvqqdjQ3+OWXX8yRI0ekymCuXLmkWAr6V2/VCiMZOHAQpY1UIOGhSIol
Z7AT6BMnTsj9p9w7/soNGjQwb7/9tjxGAZ6zZ8+G7e/+7rvvTKZMmaKSAHmysXMl0MzR1AhgjieA
wnP4L3+3N3sSoauVKq5LEFTWEXc+0BYJPnLzU+dj6JctAl3a8T3J1XH3mdZrrf/3RqC9vY+77+cL
gVYbOyXQihDE1q1bZeDbyawvjSMnu32da0OOYZdxQFyJSvM3kjHQN9ufz7Ea0QF7VNqSbBDptnbx
6OB2XrjklkDzd4q1WM9FDuJqi2QVe3FNakwOAk1xFt7n66+/1o6WCCjzTdGFaAXR2du3b0f876RQ
jCXHsBNokkUtH2UkT40bNxaJB1rpmjVrhv3vnj49fi7gN0UTPBVScSXQzMcEVcirIZjDWmC5U9CQ
3SGLsAi03fkJK1Rei5zCG4FGCsj72t0ykIxYBJrTSWsNsOxWkTduOnXGLwLt7X0SI9Ak9Lv6YWsh
FSXQihDFhx9+KAMfDXFye1wyMSKr4BjO9TE8okk+RC/m7rU7zl+UJENfPgci7YnYp2RD00dBBYUS
aG9gg0XyGUVUIh3ff/+9KVasmETTXCUcFiwJB3IO5qZwjj5bYHOUN29eExcXF1V927WUt0WgCZRw
eokTRd0WLeUU1O4GRVGsAkWKik0c8jxkEVZSIQSa9yB6DGGFBFsnit4ItEgFe/aSxEES+ghwUHjL
ItDI/0gyh8xTBbdV127OZEB/CLS390mMQFM4jMDPsn0HtJS3EmhFqAM9Ksla1u4+tRrZzGRe2+UW
4d7yx8REXeUxJdD+49FHHxWfYGzPogHffPONEAJItCcfaKQsadOmNadPn46Y342bjCRFHz4cNX2b
EwV+M4ETd6W8qRaL9A6yaS9YRX4Kvss8h8AKkg0r+Q8CjfczPso8DrmGZPpCoCG6nGLyOtwvqIJo
94GG0EPmeRwphhUp94dAe3ufxAg0xJlrwm+zHp+zIf4anjx5UhcKJdCKUAMkL59L9cCUakysJICw
Y7eb6Id7s3R8S5Ys0Q6mBNojjh49Gu84MH58VP3uv/3tb1LJD6s3y+cZK8OJEyeK5hlf5XPnzkXU
b2azULJkSdF6U9I8GnDp0iXp30+vWBXQPIq7hUVSXRtkllPJQIIuRIY95f0g9SBCndQ1IND3IVpv
Ve0VecuEiXINf/jhB10olEArQg1YhYkO+tXjKU402bkTaaAAS1JKZodaw+KPaxqNmfdKoP0be1Wr
VpUEu2gDp18fffSR+DzjzpEuXTo58o8EyYYn7NoVn1i8YcOGqLjH9GtOV6j4Fylze0o3IuRFihTR
RUIJtCIUYR2pcjSmE1ZwWuU6dcUDVaEE2lMEFn9jQCGOaIeVZAepjnRg0RgTEyOe6NGAuCZNTMkK
FXRdCKBJoZXsObQYlxJoRSijSdOmJk+BghEVBU6tZlXGwt9YoQTaFV9++aVsrqhQpycU8cDnmTET
DXjzzXh/+meffTYqfu/MmTNF98tpo64P/jWrvgGVLhVKoBUhCo4UXYuOaAusUUCGa+mt0p4iOgn0
tm3bxAs5a9asEZUgl1Qg3YgWAg3atm0r/SAadK30c+7t1NVrdH3wsw16eopcu7/85S86SSiBVoQq
KKPLhO6usqA2/xJAsuXMKQUEFEqgwX/+8x9z4cIF+XeLFi1E7/vJJ5/oTbdhypQpEqWMFly9Gu9H
j+d1pAOJEhvG5p0f1DXCz4ZjSLly5XSCUAKtCHWMGzdOJnUM6XXyCqxRIIaIwSuvvKIdKooJ9OXL
l6Usebt27WRjSinnr776yty6dStqHBj8weTJk2XuiSbQ30mcpF9EOvA4T5c+QwJ3CW3e2+ZTb8ta
8swzz+gEoQRaEepgcc+YMaOJu1MqW5t/jRKx6Mhr1aqtnSnKCTRSjSxZsphKlSqZAQMGmP3792uy
oBdQzv2ee+6Jqt/85z//WQh0NCSIWTKOsc8t1rXCx9Z31Gg5lSFnQqEEWhEmCxkTHckLOokFVrr7
tdde044U5QRa4R8mTZokUfpow5gxYyTy/v7770f8by1evLipWr++rhU+um8UdMyJJPcrlEArwgQ/
/vijyZYtm6kZ10QnMj/avmsfmOy5cpnGcXHm9ddf147kBli3vfPOO+KFS4EZEseGDx8ux7uZMmWS
IhMU1YBUzJkzR2zejhw5IuQiWiy/ohUUUEmTJk3U/e5//OMfMt+2b98+4n/r3LlzJcCw8tARXTMS
aSRccq1eeuklnRyUQCvCCYsXL5bBO2HJMp3MfGxte/SUSBLkj2vXu3dvIYzRiu+//97s2bNHdPX4
wOZybC7sJXxpHE9mypLF5Mid2+TMm9fkyJPHZMuR06RNn/6u53JtS5QoYbp27Sr2X2+//bbHMtCK
8MOECROk4EY0Yt68edLHT5w4EdG/85///KdsFhq0bqNrRiKtVMWKElDQfAkl0MkOOtnHH39sDh06
ZFasWCGT8cCBA82DDz5o2rRpY5o1a2aaNm0qzggPPPCAaM5Gjx4t5WNffvllc+XKlaisBObtetap
U9dkyZ7d7LxwSSe0RNq8rdtlAYQs/vvf/5bIKmQA0rh169ao6TdUlcPztVq1akKOLeJbqlIl2WAM
mjzVzFq3waw5eszsvnzVq+e4lME9d94s2bPfTFq2wvQZPlIqcuXJX8BJqolad+zY0WzZskUWZ0X4
glLmadOmjcrfzulKoUKFTO3akZ87gdsKY3ft8dd17fDQ5mzYJNdo3bp1OjEogQ4+8M6ELENY6tar
JxOvPVp1b5o0JmeePKZoqVKmTOUqpkKNmqZCzVqmTJWqJrZsOZO3QMG7olws9OXLlzeDBg0S0hPt
wn2OzdEkNmzbTic1L+3A9Rsmn2PxK+Xoa3aZwfXr103dunWlb+H5SsJQJOLrr7+WLPHKlSs7o8qM
t4eGDTdzN2+V6xPsa77l9FkzbtES067XQ5K0yecyB3Tq1Mns2LFDk/XCEMzlJNRFKyBL9GMCOpEM
TqZIVK/XspWuH24aQQWiz1Sq1HlMCXTQAAHh6LZGjRoJiHK56tXNgwMGmuGzn5FIIIurr9X0iK4u
3r3XjF24SBZ8dL8ZM2d2vn+xYsXEp9PycI0WHDx4ULwnWdC4DkOmz9DJzUOiBxsMNl9nzpxxG8lf
unSpREppy5Yti5gjuUuXLpk+ffrIJos+Ut4xDgdPmWa2v/Nuit+DJbv3mc6P9je58uWT71KgQAHR
W6IvVYQHmGfTp08ftb+feaFChQqyEQ9UmvTTTz+Zd9991+zcudMsWrRIEsKHDh0qp7GcupJrQM4B
VR85qWWeJ1DCqVlKwpKszFq3UdcRlzZsxiy5NgQCFEqgk4Sff/5ZBnrt2nWcpLZ0pcqm3+inzMId
u8zhGx8nyw4QB4qhM2aa2k2bOQkCGcRkikdyRSAm37i4uPjrXLq0aFiRvGAvtWD7Tp3gXFq/0fF6
Z6RAiW3+kBLxXKLSRKfDFeg00TTzWzJkzCjEddOpMyGzoeH4s3qDhvHfL0MG8+STT5rvvvtOJ9MQ
x1NPPSX3K5oBoaXfrlq1yqfnI1sk0bZ79+6mSJEid+UNMG8jw8uVN6+cupJrQM6Bu+dx+grBhrhh
Z5qcILJatmxZkz8mJlnW8HBtBPS4P81btNAJQQl04ICkcqRHwgEDvKRjZz5g/IRUWaj3XLlmRs9f
YGo2jpNII4S6V69eERWV/vzzz+U3cfyeJ08e2bRYURC0pUx2WbPnEGN3neji24y18UeuRGF9BVpd
dNHoo6dPn+4x8kPlumvXrol38MaNG83Ro0fN3//+91TtIyzWSCT4zeiQH5v4tDiPhOr9WfPqcdOq
W3cZr5kzZxaZiTp5hC5IvuVoP9rRqFEjky9fPgkeuQMuNkOGDBHNtEWAc+fPb+Lu72D6jx1vpr/w
onn+lWNm75X3ZUPpbmwc/fQLs/Pd98yyfQfMxKXLTa+hwyRYZD99rVixouQzsDYkB9566y35nB5P
DNH15E5r0qGjONGQS6JQAu03/vrXv5r+/fvLogdZbdyuvVm690DIdHDkIV0GPuacaPBoTG0iTQLk
ggULpOrZo48+KnZQEC9fkqo44iaZEv0o0R+O/Ny9DvLEZqZQ0WLmpfMXon6iW/DSTtHQIyfyl5Th
zMFmRWQP5cubs2fPOh/75ZdfRHpQ6I6mGmurhx9+2LRs2VJIICWgiVKl9CnQyJEjZUwScX70qXFh
FTVa/+ZJ0VtyvdEVRrrGNFzBPITMKdpx7tw56aszZsxw/o2I8KxZs2ROEL1/unSSUItskf4drLEC
sV6+/6DpP26CqVynrpNMN3SQejTawU60p8AQQRukl1FfwXb+gnhZi+M+K5RA+wWIAxE5SFya++6T
Y+GtZ86FbGff//6H4iiQ/Y41F1HIlC7HykTbuHFjkZagc1u4cKF58cUXzezZs8V1JGfOnKIrJJrp
CiZCSDclhjm+g3iTDJbY50HiChePNTvOX4zaiW7Rrt1SkhaNeFKOOvE3htCxUURmQKSHSH+PHj3M
jRs37no+x567d++W/gap/t///pfsfQyrOPoXixwJe+HsyMKmh5Msrh8bGBKRFaGDUaNGyfyiMOIe
xbUgOEJgJP2dhHdILUSL9SclxszWt9+RDXNMiRLy+fnz5xdtNet1MPDrr7/KPMo6Gs1rygvHXpOA
TLPmzdW2Tgm0fzhw4IAk/TBAiTiHip7SVyLdc8hQiQiQcEfxB3eENdggikZEcNOmTR6fA6EnCZLr
evv2bfkbpIsSw1R94+/ocpEK+AoS5ThmZULlCDDqyPPLeyQKW6ZMGfPtt98m+T5yX4YNG+a0fCNJ
NjGw+alataps2pKLREPWOcmA3KNTZNMQCfePCBu6dcZOwYIFzfHjx3XFCRFwykHpc0W8TIM5wZIM
turazax/40Sqjp35214yVerVl3kKGRp5H8HwYf/ggw8kcFalbj3zysefRWUBLtbTvHnzBmVNUQId
JUAqQOSTAVmifAXJpA/XQcBOvZGD/PNb8E9G8pBcwGKPzyEi7AuaNGkihIuIZ/Xq1eW1+PQGWi3v
5MmTMuFhH4bWLlomOrSC96VNK8eo33zzTdDuJxsupCBo/n0FUQruZXL4hJJwV+fO8W2b7j2TxYYu
tRuV0IqULHnXUbki9UCkNWvWrFF9DdgQc4rI6SEEumWXriIbDKWxgy87+UCWBI31IKkgN4T3a/ZA
J4+67UhseN2zcWCT9Oabb+okoATaN5w+fVqyhtlhk8AQKTtPSFZmxyIAwVyzZk3Qrxua5dy5c5uL
Fy/69bp27drJIOWab968OcmRSyzMiOCld/xOkuki3aqOIh5M8I0aNw56Mh8bGRJ2PN0TT1EeHFOQ
VwSzGt/Vq1dFVsJx4pRVz0f24nXjY9PiwS5OSYcWUkpdYK9GnkW04ubNm6bOHd/4irVqy7F+qCdR
57uTyNivX78kFzKyynx37j8gavye0bHzmzkVViiB9glEzcg0JSGN3WykDQx8cGs0aiwDg6IswSQ4
6JxJsgQvvPCCJJU1aNDALF++XP5Gwle3bt3k71gbWdINbNSI7gSzWhsJn0ROiZT0HTVajscj7V5S
LY+ys9xLTkuSw9ge/TOLhzsQ6YbQegL6wffeey8o3+Pw4cOSxIWXMhHaaIkCkTDF/cUqM7ntuxTe
xwE5GdEICBRjD6ejsc8tDpuxc+jGTZEwkkcTGxub5LkIGY/keIwcFfHkuXW3HvJblyxZooNfCXTi
4NgZr086DQRz39XrER21xJ6H39q0WbOgJSwhxzh27JgQYUz3sUGDoBPBpMLT+vXrxasaTJ482axd
u9b52nr16ol1UDBBEghaXH4nVR6DmREeCuVUc+bNK5u9xHyekwJKUeO37QrcObjH3hKrPL3WX+Da
wgkFJbej0WVl2vMvSNSdI2lcUhQpD3IBcuTIEVW/GQefxx57LD7qXLOWlK4P19wQrC2x51y5cmXA
14NTOAq+cD0e6PdIRMo5kG1YkeepU6fqwFcCnTiI3Fkesh37PhKR0Up3jWgCriLoZoNRgKVkyZJy
1Eek2e7UgMaZ43fkGb179xYyTaTaTqA5pkY/nRyg8hWLHySEqoXhfH/Z2LV/qLf0VQjs5cuXk3Vs
IK+hLL0rNmzYIPca2Y0ndOnSxezatSvJkWc2CWyAQtnXOdldOrbHWxOyGU1tz+1oBE5CaH+jBcjx
6tWPT8ojihvua+LuS1fFS5rfw70M1E0CEo0nOO+Dt/WRm59GVMKgZQ+okWcl0D6BCCnV7KQk9LTp
UencgG90iRIlRPaQFJD8h/bVDiLOkGOAFV2VKlVM7dq1JZpm/zyIGo4nyQU+q/WdantFS5U2czZu
Di+Hhk8+l+qTHKMiS+G0JCV0sUSgKPHtCd4INImEWM0FildffVWiRlT3jOQTIV8bfrQ46jCG1OYu
ZUFxENwdogEEU5ifCa5EUq4BEeOujw2SNQAJYVJKhONIJImKjjmOJP1wvzYUdsJtg2DF9u3bdcAr
gfaNPBMlk12pg5xE68KM1hv7M8pjJ8XBoWfPnpKlbV1boszorC3rPPxDiSha5KhDhw7OXT1EzJ2/
cLCxd+9e2SxYUp1Q19My6U9dvcbExMY6JTfJHXW2g+hznTp1/CbQVKvClzVQjT32UeguccChaplW
Aotvz2zaYu51LHItW7VKEUtKRTyeeOIJSZCOdHzyySeS15DBMfY49YjEMUSVUnHVaN5cZH6BgtM1
JGyZs2UzM19cH7bXY9S8+bIxp8JksGWUiggm0BR8YCA9MXV61C/Mi3fvFdcKIg+BJvMhlSBpEEKM
/tVVm4t84/z58/JvvETZvAD8bjmaTimTdiQ7GO6TFGQVAKDELMkToXI/Dn540wybMUuSWfmObG5S
usqftbnhZMGTvMYTga5UqZKJi4vzWPLXG4iussnJ4SAs4aq7TNaqYPPio1+cQihSBoMHDzZ58uSJ
6N9I8ARv/mw5cppVh49GvHyRk7z7778/SRtRNhxIFC35ZzjJzKiVENf+fvnuzVu0EItQhRJon0Cl
O7G4GT1GF+U77dltOyRjmchwIFZyGK0XLlxYbIMovw2JshrWgB9++KHp2rWrVLODYKOLhmBhD0Vk
OKXx008/CcmHBNIXIKv9x443m06eTrV7QGl4Kl1iN2i5L7AxSc1oIxXH2Gy4KzPtSqDpN23btpVi
LixQPH706FGfP4tNVKvWrSXKyqZOx6X71vHhftI/kitvQJEQnKRRTCJSwVxYuXJlCaIsP3AoKsYQ
pcYZQyQGJgVI6fAJZ77L6dhkTViyLOQLNpELhHQTiRwF1rTCoBJon4F8AI9niovoYpywEfVkUnn6
6af9mkDmz58vRJjrSjXAKVOmeHy+VWoVrR2JOfPmzUvV/gA5leh5w4by22k4PgycMFG0YcmZbU3W
M5X0ug583OQtWFA+m0kNu7+k6IeDjS+++EK+G7IcFlt3wP+bMu2tHQSYa0plSMp/W+XkfUl+s/xW
R86dp+MxEU08JyeUUf700091ZUpmPP7443LEHYlAZtU4Lk42rfO2bIuqcYQlnb/rnSdcuHDB1KxZ
U96PAiTkF4Xa7521boPI4viOyMCSs6iaIgIJNEQAohdbtpwck+tifHejwhsDDPswbyDaSJUmK4JL
IuD169dFAsJuHB9mNFWu0VPKeEOUOBLlJCCU8OWXX4qftTUR0ogG13EQwwHjJ0jJ2K1nzgUk9yBj
e93rb4nJP5ntWENRPZDPIHmjffv24lTiiaCmNjhh4Cgbz+6WLVtKYhUbpYEDB4qTC9rJpUuXJji9
IFGH5/D70JB6M+VHA8/JRcO27XQc+uLpfu68RJHimjRJtrLpiniQTIumPxIxduxYmYPGL14SleOo
bY/49c6d25C/IJK7evVqmet4z0q165i5m7emuq/z5JWrTWy58vFJ9EWLuj1NVCiBThRofUiY23zq
bV2EvRC9UhUrCsHFcs4dqFCHNlaS8RxE2bXUJzpjfJ9xYuD4H40z+mis7rCUQ+aBhCOUAZnetGmT
EEQ0yBahFsJ7332StVzLQV6ad37QdHrkUdN90GDz0LDhptfQJ023xwebDn36miYdOpqq9etLVSw2
Fdbr8TVGnoElEhuVH3/8MWzGEN8VPTZkefr06eb555+XIgXeZCbXrl0T9xVro8W1dV146tarZ7I4
+srOC5d0HPqRAMQ1XbVqla5OQQQJYkQl8atnA8hcR8IY/Z3y6jNnzhT5V7gncpLUTf+5v8/DUTuG
OAUkKsu6RHAnGCA5kfmx0J1qiMVKlzEDJ05KUR/7jSdOmT4jRpr8MTHOPJqNGzcGtXiaIooINL7D
dCS0T7r4JmJrc/SYkDwS/1yJEBpXayeLBjOx6BdH9zhHnDp1StwZwjVaRhELEh7xyMRLFK04C2tM
kSISlSV6CklGxpIuXTqZkEmGowQukgzIMhUakWZYMpZoAiR58eLFIvGBjFCh0uoLWOXRpyYsXqrj
z89WvUFDcSzBJlIRHCAvI+Js3zTbG+M8qR7nofAbZY5ykEdIZDSPoQ1vnRTnEbyvg7kp4gQOZ6o6
d/yVWRuqN2wkrl9rj78R9EjzqkOviMtI+Ro1nP2UoCF9VXXOSqCTNFlkyZLFVKlXPyIrCCVHY/fK
ICTayOKM/pUkQyLKSC9SwodYEXlARtWqVSvpW5R1xzscj91qDRrouAugbTp1RvSrJLopggecgtgI
uyPQRKDDHRQPS5c+g5BHHUdfSfJfchYRQW/MaUbsHUtSGk5DnFIOenqK6M+3nD7rU9GaVz7+TO7b
rHUbTf9xE0z9Vq3FTs96X058yUsKRoE0hRJosazD65DFRicL3xqDlKMnNM5EDImwjh49WqpUKRRJ
BfIYkkjRRzPpL99/UMddgA25ECdGn332mXasIIIcD1fy/NBDD4X97zpy5Ij8FvI6dPz80WrFNZG1
Lin1EHwB45TINH2p4J3kcasRpIJYFy1VypSpXMVUqFnLVKhRUwpKFSlRQmwG7XJAGgmuxYsXlxPh
pBZEUyiBTgCKMtDhqEKkk4S/WbsbZYCyAfn88891BCiCCsqB4yRBBEXHW+Btx/mLUuqbcaoILsaP
H+8kKnXr1g37k7fffvtNyBY5HARJdPwk1A2T2G1Vz00pIA8kjwiZKbp7klYpPNamTRvTtGlTcTdC
OokNLInc06ZNMxs2bBB7WHJSLAmcyriUQAcddET0TbsvXdVJIoCGnopdMhOvQhFMTJ06VTa3Lxx7
TcdaEhuJq1xLijsokgb0ordu3RLv+nPnzkn5dKRrRG5JfoaoJKUUdGrCsoqM1EqDSZYuDo+XLnLf
wwUQ6WA5iSiUQDtx6dKl+AjqyFE6OQTYFry0U64hCWAKRbAAAcHphZLqOs6CY2tHktLIkSO1c/kB
7Bm3b98ulR3R5hOdRQ7jKYHQ3goUKCD+8UQFcaPBijGUgTsEFms145romPHQDnzwkcmaPYfYioYD
cNWgEBlSOIrhYDHat29fsQzVoJcS6CSBjsTR5r6r13VySGIUmjKvmsmrCBZ27NghJGTKqjU6xoLU
6jRrLj73muDrnXBg34aTjlXoRwoYpU1rSlaoIEld+LTjlDBx6XKRsZHghQf8nA2bHP31eTNizlwJ
yrTq2k383DNlyeJ8H9w7cC/iiD3UPN1JkOM7hmKRj1Bq/UY/JdcJ96hQxvvvvy82srRnnnlGiDSF
4nB7wi6UysC7d+/WQa8E2n/gYUxVNyY5nRSS1sYuXKRHRIqgggk+e65cqsMMYqNID+M03C3WkgNU
yhw+fLizyAVlq4nEUnF0xcHDPrkfJKafpYImBDzHnc/AxaNHjx5C2FPbM5oTH6R4VLDUseK9EXCj
SBH2o6EKXD3oX2zUPOHEiRPSD0nYViiB9gsrVqyIt6XZs18nhSS2QzduSpSFJAaFIqnAyYVsc3S7
Or6CWOLbQQJz5skjeR+K+GqpFCqyKosSZW7Utp2Z+eL6ZN+44SrT8eF+IgfgsymqQXENZBSpASKR
fA+i6DpWEm8UxmKOQuITavjzn/8s9/KVV15J9LmYKOD3feDAAZ0QlED7DiqbFS1VWieDIDUWAyL6
lOpWKJICyx5s2b4DOraC3O7v3UeK1USzjAPi/NJLL5kKFSrEa5WLFDFPzppj9l55P1XsQKevWWsq
1oqvxInuf968eSleTKljx44mZ968UnBDx0ni7cXX3oyXuyxaFHL9m5oMI0aM8Pn5R48eNaVKlQr7
yplKoFMI7BrJSO83eoxOBkFqz+18WSaUnTt36khQJAn4nyLf0KJGwW+z12+ScUrVzGgELhlUlJNq
qQ7SMH7xkiTLM4LVFu3abWo2jpPvhj4VzWpKgGqwJEaqlat/De9lHFhCCSQGUvn2hx9+SPD3YcOG
ic0ilnevv/76Xa9DJ/3WW2/p4qMEOnGsX79eJqnnXzmmE0EQS4VyHElipkKRFOBeEHd/Bx1XyeEi
cP2GHD1PmjQpqvrU7du3xYGE306xiTHPLgzZDRpJfLFly8kahb9vchfAseSMa149rmPEjzZk+gy5
btevXw+Zfs7GuEmTJgn+BjFGaw/oS7Vr177rdTNmzDATJ07UxUcJdOKgoEC2nDl1EghyQz9I5ESh
CBQU5GFR4khdx1TyNCqYNY6Li5o+hV1piRIl5NSx/UO9zZ4r18JCrz5o8lSpUZDJ0bAdSy5gyVa4
eKyODT/bS+cvxHtmL1gQMn198+bN4vJiB9UHrSIqFGXBCcYVFGlB+qFQAp0oihYtahq2aauTQJAb
1k5MKF9++aWOBkVA2LNnj5buTm4ddJ+HTZYsWUQLHOlYuXKl5GbkdpCGcLRn23b2vFjhMSaoQBds
7150r5SnRhuvY8P/RsVGTglCBSQD4mDkDj///LN4ma9Zs+aux9gEqEe8EuhEQYY/k9GA8RN0Aghy
I+mLa5tS2r1w6W8bN26UU4/WrVvL5DZgwABJYkrpRKFwAGVoiRQevvGxjqlkaiOemSfj9IsvvojY
fvT7779LJI7fWbtps7CuNEs0Gu9pfgvFMIgoBgtU1ON9J69crWMjgNahT185IcA/PBRAsR4ChK74
7rvvTL169US+6g79+vUzq1at0gVICbR3oAdiwnhm0xa/fB83nTqjE4YPdnaQH0hQtIOiMhMmTDC5
cuUS27B169aJrRARgtWrV5v7779fPGdDMYs7NQHpyVuwkN99r8KdKJ27Nva5xRE75ijm4a/lGmWa
uS6vvfZaRPYhIm0tWraU3/jImLERk4yKxVyGjBlNkSJFzM2bN4NyrSiwwXV6+b0ruoYF0Cicw/U7
e/ZsyKw7pUuXlvLddvJcvXp18+abb7p9DYGcnDlziv2dQgm0V6D1ocNvPvV2ooNj0NNTTNlq1aQE
Lq/JnC2b6f3kiBSz+iHhh8/F4SKx5+66eDn+6PvAoSR/bpeBj5kqdesF9FrIj6sGKxrJc2xsrPjL
epuUSD7hnnXq1EmrON4BDgmVA+h7EOjSlauIjMi1rXv9rYh2vvE3Wr/1THzUkYpkkQY0njgKkCz4
1ILnIu6erzx0RPJ32Ji/++67Sb5eXbp0MQWLFlUyHGDbfu68jCUSMUMFFE9h7bFs6XDgwOu5UqVK
zma3sWzevLlEoBVKoBMF2edMrolZF/UZPtLcc++9ptMjj5qpq9eYZ7ftEPKc5r77TNuevVJkcLIw
Nmjd2qw9/kaKEmgWHn5/IK+F/ECCohVMWm3atBHdpS9A01iyZEkzePBgnUEcINmLam2BEOjmnTpH
1eJN+Wgh0B994t+84ng+r5s9e3ZE9R1KY0MO0qZLZ2at2xCx933DWydN/pgY0bFfuXIlSdcM/1/W
GCXDgbcs2bKZxx9/PORO8ho0aJCotATHDuaC1CrgowgzAj1w4ECpxuVtQExYskw6lbsIBr6hEOvt
77wbUoM4mAQ6KQ3yAwmKVpAExyLuKaLszqye4jNYt124cCHqJ5FsjsWoY99HkoVAs2nu8cQQk7dQ
IccckFeK/9jJ5+ojr5o23XuaLNmzm5IVKkpFOvvr1x5/3bFBrGsyXvqB1QAANV1JREFUZ81mmj3Q
SUo8W49xBN5v9FOmTJUqJmuOHA5S0sYZ+T744U1TtmpVM2/rdpOvUGFTy7Fo7b16Xf7Ge9Zt0dJk
dJAhfgMFGuyfiQQhf0wRkyN3HvNAv0eccg021TElSsqY5zN5b3+uF1KASEoaIqLWqHFjc2+aNGbe
lm0RT9pILsyTv4DJly+fONcEelKG/zNjItR/79a33wlZHXu5atXEXzmUQIIwlYGRZhw6dOguIs3p
RcuWLU2tWrVk46lQAu0TOC4vVqZMoiSwWoOGHitHEZW2a6LRprF4c7RWonwFM3DCxD+8IqdNl4UV
39HCsbGyEPYdNTqBLo9/9xkxUhbXIiVLiXSEhd1aeFcdPproIu5KoL2RBRZ23tdVxsJz+O58Z/7t
afH3prmE/ECCohUch7388stuH5s6daqZM2eO28cWLlyoNkIOpE2bVsrkJgeBxmmAE6Qeg5+Q06R0
GTIkiL5RmbRqvfrm8UmTTY3GcSLd2njilHN8QXJLVaxkHpv4tJDWPAULOk+yeH7OvPlkzEF0eW7x
smUTSLEKFismWfulKlV2/o3/Zz6iiAVjmve3vk+voU/Kc3AMgkjzeIsHuziPjpt27CSP83v89fCl
UM2gQYMios9ABDt37izXAk14tEQ+2USx2SNgcevWLb+vG25JXDOSSv397GEzZvlcyZcKj9NfeDHg
31m/VWv5njXj4kLyPjTt+IAp5hjboYh9+/ZJARXWZAI7VR1rOYVWOPVEdhLNFUmVQAcAnBDKVKma
qDUNOmBfBs/i3Xslca5u8xbi7FG+eg0Z7NOef8GpJ2bhTJc+vUg/ajRqLI/bjxjJsP7TPfeYrgMf
l8ZzR86dd5cG2tsi7kqgvZEFno+e+8mZsxPIRe5Lm06SIuwaaHeLv7frAflBvoBh+6effmo+/vhj
SXj56KOPzIcffmg++OAD0f5eu3ZNqoJxBIlP63vvvWcuXrwoUdjz58+bd955RzLE3377bXPmzBlJ
ijh58qQ5ceKEJIK+8cYbUlGJRKhjx46ZV199VUqSkqh3+PBh2XUfPHjQ7N+/XyYRnEF2794t5HbX
rl1mx44d4oSxfft2s3XrVikfjYfmpk2bRENGtjKJf2jm0Ypi/UPyH5nKWGMtX77cLFu2zCxdutQs
XrxYkgEpwQsBdN3t//vf/zZPPvmkRAM8EWiiSDw+btw4M3bsWPPUU45N15gxZtSoURIppDQr74Ge
bejQoeaJJ54Q2QckCHsrTlZw94CEP/LII6Jpo6hNnz595DiP6n49e/YUQ/3u3btLdAL9IwmObCof
eOABKefboUMH8YXFLQR7JsYL1kdEK9gcEGlp2rSpiXMsZo0bNzaNGjWSo8L69etLljeTNUb9RDbQ
4ZG8Uq1aNZm4cRBgEq9YsaIpX768KVeunCnrIJkkvXCUzKROX3to2PCACDQbRYisvVHswIrYcXLE
uLJewxjk89CVrjr0ihBmEoYtmQN93nInYAxlc5DOAx985EwsZpxOWr5SomO8D/+23nvswkXyNzag
1hiq3aSps+iQ9TfGpLWZ5sSLv+1//0MhHYzZh0eOSvB9+Y6bTp5OkoSDlqdAAfPoo49GxMIzefJk
uQ5s/KNNPrBkz36T1tEP45o08TuPgnnWdS1KDgLduf8AsU4M5PcxFmRsLVthdr77XkjeA9bs9I57
EMqg2iTrrJUDxkmpQgm030DzU7FWba9OEixSo+cv8GnwtO7WQ45S7RFlIrVWWVTIKB2W42Ehr598
bgoUKWoeHDDQuRCnz5hRCLE98sR7WpOHRaC9LeJ2Ap0YWeD/iV5D+p1R9I2b5fiTz3RHoO2Lv7fr
Afnx5IYQDS179ux39bm//OUv5vnnnxfi7YlAQ7rR5rP5YDLO4CBPGR39Ao9WtI5EDXhvkkEg2jh4
5MmTx+TNm1eM8ZGAFHRspgoVKmRiYmIkUx87o+LFi0tCI1EqSCpktUyZMkJeIbEVKlQQUgu5pSwt
RBfSSyIWBBgyXKdOHSHGkGTIcsOGDYU8Q6IZT5BqyHWLFi2EaEO60YFDwCHjOI5AzCHpkHWihZB3
SHy3bt2E1EPue/XqJWOPDWUgBJqxADG0N+t4GlkWG0RXsok/8MCJk8yao8fk/kFYrfFlb5Vq13Ge
ylht6d4DUkyBDSnSC3teBZ7DvN+W02edY8i+YbX+NmHxUuffIPH8jdMta7yuf+NEAu0yv2H0vGeT
TKBzOfoNm65wBxtoAhitunWPWg0uLjP0gylTpvh17Qg28DpIeHISaE5sAyXQnJYyJ6RU4n4grf/Y
8XIdg+3RnRxA68w6w2moQgm032CRL+cgCJ4GA4sXg8FV/0hkGWKMJILWa+gw+TtVrYhA2UtaV2/Y
yLTs0vWPCLRLljPEtXnnBxNYStn1XfybyPa+ax8kINDeFnE7gU6MLPBvdvREuCw5RudH+5uq9Rvc
5cLhbvH31iSaztH3xo0SzSWyS4SXSlpEfIn87ty5UyLBRITZCRMhJlKMxRtRYyLIR44ckQmeyDIR
ZkqUEnEm8owdD5FoItKnTp2SCDWRaqyEiFoTWUHjRTSbyDY778uXL0vEm8j3+++/L5FwIuL4ZhIh
J1L+ySefSNScaDAeuThofPXVV0KAqeT0zTffmG+//VZsgcj2Z1f//fffmx9++MH8+OOP8pi35EEi
2J4INK+FFEc72DT4evrjj4SD0yF3bgPWmGLc1rqTUMO4YHza8wnQIVtjx1Ni3oy16+SUKdaxOYHU
CQF+86RzDM1at/EuAm3XLiOpEneMY69JJUbeAxmIvaVJm1bkXkkl0Bz9c5IRzmA8soks6tgYEviI
5kS2Vl27SX/xx5qQeZj+gywwKQSafkuAhf6PTJGToOGzn3HavCFtJC/ASr5nfUOWwWkqp6jPv3LM
+b6N298vm0rWquaOjbal8ycnYeGOXfKcfqPHmFz58sk6bF+XCBgxRpFhxZYvL59DrhLjOmPmzPJZ
VgDJ+iz08jyf74IkKpB+xLXgOwYio0kNcOrHaSNrHmvyzJkzpU4BJ4s1HfMojxN44aSwbr16Eghh
rliyZImc8rLWKaKUQBMRK1mhgsfBwEJKJMuaAKxGxBZiTGMwUhLWnhWNdhiNFgsTgwldlEVGK9So
meC9WJytSojjFi2Rz/PFxs7bIm4n0ImRBSt6jWwEAs//F3IMGErHeiLQ9sXfWyOyDgmKVhDt9ZQZ
741As4EgihvtIJLOqU6wCTR5B+QXuP6dXAcrOgYRZdyz0NLn2QhyMmNtPgdPmeYxL4LNJ68hB4JT
GCsqaCfQdjtKd3+zE2hOpDiZ4vjbtU1fszZJBJrTMqJQOBKFM5jL06XP4JNLUaQ3pEJsJDiNIinZ
FyBZo/9YOv9ACTRRYtYwAkz9x02Q0wDGDiehnKCwZkJS527e6gxGFStdRogyYw9tPyefPMbfyROC
3PYcMkzej/diPPF+T0ydLuvvo0+NE+02Y8QaD4xxyHq5atVNvZatZC238hp4DkEtnm95XvNZkH2+
L/Ifgk68v7/XAuLOdSTQEsrAH51gFqeTadKkSXBySkIqPAUO06htO+E7bHKYH0s5iHQmxwbDei4b
NU4rkReGiv+1EugUAprQ/IULJ5JVW110TZ4eJ6nOItBMCsgl2MEy6CHETBh2Au3qqUwikEWgOY7l
tb4QaG+LuJ1A+0IW4i3n6opG2oq6sxHwRKB98aK2IiEFCxWK2kEwfvx4M2TIEL8JNJpjrQRlREpi
lxYFi0CTxJspS1Y3+Q4lZTG2NpV2Rw7yC1iIrTHv6laAPnr2+k1Csl3HCInFlgQjEALNCRGSKle7
TYtoJIVAc2rG69Duhys4teI3kHCtVmrxjYRyyA35Er6AE0KRDN3R1CeFQNtPU9igEXFmbLhKOJCL
uNZhYAxauQqQWut01kqUZH1NcIpqS9LHbtWSZLLuQcatKDLjEsJsHzNscIlgW5/VrtdDzsdY062T
Y38aazi/iaTMUAT5Q8jkkAbyPdmgEG0fMWeuSNd89ZFn40HAjetctX59x4YjrbwfhJw8BE5RFRFO
oNk1pc+QwXu2vmOwMwGwq0+MQPNvkpXQNluPE8GyvGwTI9DW4mtfBHdfviq6qi1vn0uwyHpbxO0E
2heyQMNtgKMxjouJQLsrpOIvgeYoDx1ttIJJhCgQchRfCTSkG02ylvaO30iwyAWbQEOI6cf4uVt/
Q7csfsiO8WNJmuyLLQs5m0z+zUKLNMN+UsVCRNIsZIIInJ3sIrOIPx5/IyACbX03u3uBpQe1iMmC
l+KP4O3E35fGkTmvI5k2HME4QedfvEzZBPOutvi1iz7iiz80x/f0A1frxEAJNJJD63EkFASTXAk0
kgukF0gUrYaNY9sePZ2k1h4kshNoCByfg5Ws9VqJSN8JQEHsiG5br4VoW7k7dsJNhNX6rFHz5ifQ
MgeyeWf95HuFGoFkDapTp658N07GKTu+aNfuoFXmZK7kZKBmXBPZuCFfJK8CAwFFhBJo3BJcNceu
jV2ZuGY4BrXrBM2ixS7XItAQbQaes+y3YxLJkCmTadyuvU8EmmMpJjzrGMqaZJBX7Dh/McEi620R
txPoxMiC9TeiY3w2ziB23WlSCHSx0qVFXxXNsLLbOSJNDLho8Fz01AojTiOMn+SwseMEhqgyp0ZL
du8T+zicZVhQ2MCSoMvJEXkFuGgQvbJcMCC13CfGBjpKxj9jlLnCOsHBrhISTGQn3Z1oz/L9BwMi
0LIZbdpMxjcJhYxlqqKy4XVNOkSW5Q8JmrJqjbyO/IBwBNITvj+Jmkqa77aMQ8ZQv0EDnwiWVNGz
+ZknhUC7BpmsOgp2Am1ZM7o2i+hCap9escotgbY2fu4aUWcItLWuWu4fnIi6fm/mCuuz0GjbA0ro
pf29Fsit+A6+SmeSG2yemjRtKt+pQJEi8puTO0eA02vuMUWMINITJkwwt2/f1gUt0gi0NWks23fA
pxr32LYxMNEHc5zLTotjJBZZiwwT2WWhpKGFZMBbAzExAk1jR4xjAEdgfC47dOQgroust0Xc1cbO
G1mwfxe00rzO0kInhUDz3lgqEeWPdvz1r38V5wx0zSRGYmVnj6CRQInLBY1kKEU88Calv7GxDDaB
3nnhkkSUrUWXpDy7/pOxxwbVehyLOfvCg2bTIsYsFJYbBq3b44NFm8ljJFJJyWUHIWfxCpRAs8lH
DmbpDtFy2ucttNfkNfC4twRH18YRNu8XjgscSbvkWARSrTJaGhs4+gTJ195A8jXPe2bTliQTaPqT
LwSaflq6chVZK+ztjwBMQlJrJ9A42ljONu5ezzrNumnv5+h4XQsTWbKsYBFoToXRFKc2fv/9d7FB
JSiWNXsOCcQlVnE52A1DA/gN94mT2MT6oCLMCDQuC9xcu8Wbt5LWEMl77wjuiTyzSKMhtEeBrKQj
ngf5JCGBxZOB7QuBRrLB4mgt3Gi6WOzdLbKeFnFXAp0YWbDv0jkCs0faAyXQ7ELlSPDFF3U03CHK
+G5i9ZbOca9wDMCKDos6rN44Qk+s1Gq0gaQUV+lCsBtjwxtBRxPKeHJbzdAxToj2uovooCXceuZc
0L8vRNqbBy7zhz82X5AKLA3DEdhv2TcZ2u5uR25+KkEeKjN6Ay4MXEtOW5KTQOPwZGmNp65eI8+1
Evms9QYpQGIEmrGHC409wR+3LMvC0JVAU1QHtw47ieRUxzptDRaBJspN8nNqAjcppJPcT9xOOIlI
zT5IMJGkVuFaI0cmCCApwphAU+ISX10KjfjaGfCFhRx60w6xcPoqxvfUkGz4sgB7W8T9JQvBbPhR
h/PRcHJHB7C/Q6rhrpy3Ih74lEp54cFPKBlKppYjd24prhNu4IicimquUUVtdze0wczFJJB5AqQG
Mmsv1pMcBBprUwI4nJ5A7nG+oNQ9AR0CQhBkK4HdG4G2CoRRR4GoOVJFcnespEJXAs16jJyF0yHy
BCDpnNhari3BItCV69Yz9erXT7VxgXUhnCZbjpzJGnjwt3H9qcoq1VQbNZLTI0WYE2hAsQcGj060
wW2U8Sa6qlFVRVLAYlS2ajUdU8nQLL0q1TXDDfjQBqrZjbZGcAXySOEib6DwUmLSp6QSaIgzCbpI
mywnDiLD3MucefMJcfVFwmFpvLFa47XYziF/tJL9XQm0FDTatVvyCKzn20+eg0WgsYDD3Ss1QLVc
Ag4k1KZUoCyQwBqOHVSaRQGgCHMCjROCZKF7OKbVFlhjQmVzolAkBVRUQ8fnLdFXW2ANhwPmvnDM
lOeIulSlSiF5XTkVJKKa1FPIYJeYRpvrLUGZiqGx5con+3dBr2+v8MlpLqetgVYYRAJid8xJLDeH
RF+raFiwkzbFwm/evFQhz3x2zcZxPl+LVCs5v3uf6LILFy4sBcoUYUygL16Md7ewdsjakt6sBI+F
CxfqSFAkCVSQDFSbqc17I7eBEu7hBqqH0ifIL0mOctNoNgMtyLL93HmTPXdu+X6j5y8ImXttladf
vny5x+uKWwK5O9FeyTHQRuI/15iKuSkJLAiJ+kOekcWEw7VCcpM5a1YpNkaSvSJMCTQoSJGEFi11
EghSw6WEiYRy2ApFUkGkAicZHVvBa1vffkcWXSL84QbcBTiqtiefBZNAIymwOxH5W0gD5yQIK0nX
oXTPiS7XqlXb43WlNLNEULds0zESQOs1dJhU9fTmaIOkEYI9bNgw06FDBzml7du3r9m2bZv57bff
/B4L2KRiFVe5Tt2w2/gg58mQMaOpXbuOJhaGM4HGao0J2Vt2uzbfG3qyaC6gogguJk6cGF8l7dQZ
HV9BahSR4JrevHkz7PpDiRIlTC2XohjBJNAktuHxH8h1Fe3tHd//UGsk2HkrM015Z0nadSnQpc23
Vq5aNVO3Xj2vJyc1atSQNn/+fLN3714h0+QgUDSKQAGWpr7i1q1bolunmjLuO+F4zXBioU8+/vjj
utCFK4G+dOmS3ER7ERRtAeqb7pRnDefSwIrQAiSPPkUGv46xpDe0prnzF0hVt4BA8dVXX0lfsFeo
85dAkzxG2W8szCh+RUEaIsZWgSoS1QoWKyaVXa2CWVTTo6IrSXZWohpe3RT94L2IWuPFT5IaFqck
zlm2gziFYA+KxSkFQKzvRJIbzhPYzOFQwN9mrdsoAQjeo9kDnZx6VuuzZqxdJwl4kHy7hZuvx+aJ
FXWi6EqZKlV1nPjZOG0g+vz000+7va7YBGJfumHDBo/X/sSJE/GBgk2bfBoL999/v9jXrjp8NKyv
HRs2KWjnx+ZBCXSIoWatWlKpJ1ilLaO14YPJRKE2NYpgolXr1g7SkCdsNH6h3CBhLFhoJ8MNGzdu
lO9uEd5ACDRRYlwpILQUGoEcV6hRUx6j2BRkl0Wd6qwQV/yGqUpJtIxiWvzbcpygQmW+wjESdR7z
7EIpuEOVSEpM8xzKSUOIIcoUEIEYW6SYv0O4IdJUruQ3Ya3GZ+MIweNWOWk+C8//fIUKm/7jJojf
Mcm1/rgtsLZRxvmRRx7xeH2nTZsm74uNqo4V3xsVE+mXb7311l3XlEQ5HnvllVcS7d8ffPCByeHY
1FHkzRus0uvIJcP92uHNXbJCBZPPsQn94YcfdLELRwK9ZcsW6ZAsLjohBFiU4t33pPrggAEDdAQo
ggr8TSVxbPoMHWtJbLhXFC1aVPzIww3oRfG49TfQcReBzpXL6cQwf9tLQk7dSTgeHDBQSLP1GEVb
IJjb33nXaQNIAQ/rcXyULYJtncZBwq3HqVRr9WEIcvPOD/4RfHCQYntRLfyQ0anj8299FolqFhkm
ej57/Sa/rgPvHxMT4/H6fvTRR/FH6jY7OW2Jt9pNm4r8BV3z7NmzZb768ccf5Zr279/fjBgxwuc+
jhad4kaeagT89NNPJnfu3KZM5SoBO5eEWiOKTgR/0KBButiFI4FG3I+2LrZsOY1CJ8H7mUGgyYOK
5EDjuDgp/GEdoWsLXHPo7Sg5lIF/LFHepHgVQ6Api249huUc1+TwR5/cRaAr1akjxHbx7r3OliFT
JolUW6SWksXuCDTlk0kotL+2bouWpm2Pnk4CbZeilKpY6S43qBjHmkR00/qsfdc++CMpsHx5M27R
Er+uA84lvI835wOSulgHdbz41rDAZVNVoUIFU6ZMGdn0cI35b+nSpaUegmtkdciQIaZu3bqOa13b
7XqJTtpdNBtMnx5/D1ceOhJR1xEZk/KHMCXQYPv2eBsayn7qxOC/dR0WSJoMoEgunDlzJj5XYdwE
HXMBap8pqcsiH44VMH/55ZegVMtzTfTDkYR+ZW3M7ASa6nY85toguhaptQdc7AS619An3b629p0E
SAg05Nju/uEaUYbAQ3qtz/JUoMTXtnDHLnkfopyesGLFCnkOmmkdN777qV+/fl2uH5Hn48ePm1mz
Zpk6jvvnmlD/+uuvmx49esi/0f26K7wyY8YMSZ52BUScSoNUb4zUE2xOmZRAhyEo7V2xYkVTqGix
ZDFaj+TWsktXkzZtWo8Z3gpFMEC2Ov6hqtH0v5F0JkWjdu0Ky3tvJXvbK8YFTKBtVeq8EejSlauY
gRMnCUm2N09V9+wEmtfxenevdVf9rphjY+MavIktV85MWLIs0Qp/vjaSGvmtixYt8nidyV8hamqX
l2jzrN/NHxPjIMp13V5LEjZ79+6d4G///e9/za+//iqbWEj28OHD73rd2rVrRfrhCoq0BJIDEC6N
xF6i+V9//bUS6HAEQn86aJ8RI3WC8LHhmco1w59VoUhO4MhBkirOBjr2/PN9RnrQrHnzsL33e/bs
kXlm1aFXkpdA580numj+3aRDRyk4Yz1339XrpkajxmKpmBiBRi7D43a/agjC2OcWuyXQ9GnLjYO2
58o1SWBcuvdA0Ag0jX7w5JNPer3WWLtynG7Xb2u7uyGhoe94Svrj72z63YF7QOLcm2++eddjCxYs
kCJHy5YtE69nyycZbXTFmrUi9npacioqRCuBDlOwYyQhwG45pM19Y9FhB442kV21QpHcYHFhkp20
bIWOQR8bVcoyZsxoPv/887C970uXLo23uwqgrLs/BLpg0aKmQ5++Ul762W07xNaOaDJVBnEZspIK
EyPQOMYQzea4HWKAEwfvRXKgOwI9Z+NmSWZExgF5btqxk0SlPX1WoAQaGU/nzp29Xms00hTowJpP
x49nV5MijnWPU2tOr93hxo0bkrDrCX/7299MgQIFJAfLju7du5usWbM6ZT+c7pYrVy4qqiZTFIYK
hUqgwxQcYeXJk0esVY5+8rlOFokI/xnUp06dUmanSBFw9FmrVi1xY1ApR+Jt1Lz5iZZxDgdQNRES
GYjzgD8E+qFhw+Vz+C//j+ae/A6egyRjye59PhFoy4kDbTOvJbJtd7dwJdDWd4Nk83yIPK4fwSbQ
EJRGjRoler0HDx5s0jhI9KaTp3UcuWlsiLhPO3bs8HgNkWuQSHj69OkEJylWhBWuQfKhPScBrX/O
nDnF/g7fc3TSY8eOlaIp/9+f/mQOfPBRRF9XfNrtmnIl0GF8XIiNkU4W7tv0F16Ua5TYcaBCEWzg
l4pOs3z16uoN7aUtP3DI3Jc2rUg3PEXJwgWUP0b/nlKFMezBExw6sK4LNFJJNNtX4k9JZp6fXL8N
qQikLTGgQ82UKZOp3bSZjiWXhhsKvvS4ZUCSvQHHm5o1azpJMnIMIsxdunQxbdq0MYcPH07w/OaO
sdqvX7+73qdSpUqmSr36USE3S0ynrwQ6DIC4nxtpada0/dHWHn9d6tgzMfzrX/9SRqdIcbz88ssy
Ptt076lj0kNWO1XuOEL++9//Hvb3+7HHHhPSovc2aQ1dN5I7XwCJYYxNe/4FvXa21umRR+VE4MKF
Cz5dR2ShDRo0SCDVoHS6K5o0aSLX21UOidQjmhyIChePNe3bt1cCHc6gszdp2lQiOMv3H9SJw5bc
wvEiCRDRni2rSF1QOlcLrNzdiJiWr1FDovRXrlyJiHtNBb28BQrq/U1iw12jiBddrh1ETdH45nFc
d6uCYrQ3klhxinjiiSd87ruc/nTt2lWkGYcOHbpL8/zuu++ali1bijSNQimuwPqOec5KbnVtVLC0
9NJ8N2RD9rLzPYcMNS0e7JJs1wTTBTZmQeujju+OZEUJdJiDyA0RHAo4oEOL9skD/RVlb9OkSWPO
nj2rDE6RqmBh6tixo0SDxi5cpAv8neS1Wk2ayjUJV8s6jUCHRgQaMM/jyBFMghS269/1G6ZQseKS
+BdI2el9+/ZJAZVs2bKJJAOf6IIFC5qyZcuK/7an01zyF0Rv7SHnwyoBjysI8+CjT42TMvH1WrYK
SwLdf+x4+b23b99WAh3uIJM2b968Mnmvf/NkVDtuVKpdRyZTjs8VilDAb7/9Zlq0bCmEkcSeaF7g
8a+v06y5LD54yUYSUlIDHcnNVw20Hc88E+8hPuKZeVF97UgQJcKb1KR5AnP4mrM5+eKLLxLNT6Dv
Z8yc2eP3gkDjGONadRRXF7T84UagkQzR3y5evKgEOhJA0hL15zkasWyIoo0844fK5OEt61ihSA2g
GURuRf+MVhKNbIOIk1SRW7064u5xUlw4tPnvwuF60tOqdWuRM0ZrhcIRc+ammkcxGuoCRYr4RaDX
vHpcvi/Jr64EmjkSP/PMWbPJfy23F8mduHBJNuE8Fnd/hwSP9Rs9RjgQJeopVW8n0I3atpOy91my
Z5fXIfW0Huc71GrSRDYBZapUSbQM+aJdu+W7v/baa0qgIwXvv/++yZUrl8mWM6dZvHtv1EwcL52/
YEpXqizkZNu2bcrWFCEJ7J/i7iThYAcWVQmDjkWvXLVq8ts5Co5EJMUHWpt/PtDucOvWLdGl5syb
12w5fTaqrhne3Jy8tm7TJlXcbDp06GBKlK/gF4HGMrFwbOxdEg7uXdp06czACRPFICG2fHkhtdbr
ylWrbirUrCVRYE4rKCfP35+YOl0IMPIQTiLSZ8xopq9Z6yTQfAc28PwNr/RmD3RyutBgIVm1Xn15
jKrFvNZeYMi1UYODsY4bmhLoCAKV0NCP4Y+J3igaEibI5MfO6ODBg8rSFCENLKKwgGLy5Ujx8I2P
I36MUtY3b8GCkjC4d+/eiL23lrVoYtGrVLMM3H/QrD3+hluvaU/NnRe0Ly0pR/K+VCL0BLx50e/i
kuCNAEVSw8s7bfr0pppjg5pamtxmzZpJ7pE3Am1poMc8u1D6BveZypeu/YXI8f19Hna+dt6WbUJo
+feKg4fF83zXxcvy/3uvvG+y5colFSnhAZBuZ9R5+EhTsVbtBATaSlrklJ6xSh+hQBDvb09CZTNA
NDuxioSUQlcCHWH4xz/+IcfF3OCujw0S3WGkGsUzccTExJirV68qO1OEDebNmyfH/ZycRHLeAhGk
9A7iTCLSe++9F9H3FM0oc24ghDMlGkfbC7bvdHrkU7wlsdf0GjpMvLpTikATvU+qx+6ZM2dMunTp
ZGxR2jzSN6dIEkqUKCER+NQClm6lKlb0SqAtFw4ahJUN3O7LVz32F3gLJ+ndHh8srzn66RdSmIdi
Qa7vDxHmOeMXL5HX0CQinSWLk0CXqlgpwWvyOOYkpBiQ7tpNmibUTA+Pl3x4vO535CfRmmv1/yL9
B2JDg40NN5ndlF0nFO6NQRfnGHz8tgYNG5rvvvtOGZki7LB//36TI0cO2QT6QmbCqbGgNWzTVsZo
w0aNpPRypAOJDpsiqv0Fcs0gB94W7aQ2ynYveGlnitz/QAn0wh274snS0aNJuhdYseHEVLxMWZH4
RSJ5hvxlchBENqefffZZqvb9Xr16mULFinkl0CQNMi9YpNlTfyFKzL+RY6ShRHi16vF94pPPzYDx
E0Sr7ElS4a5R+AcC3bZHQj9+eBEb/M79B5hWXbvdVRkUmYin3wNB572PHTumBDqSgayBst9IOgZO
nCS7uHCeNGat2ygaNyZHMq8Tq7KkUIQyIJboFpmMSZbhKDLcF3YWSmw173PMOc8++2xUjVHkcw1a
tw64RHBiVfUgF0SFkVYQUYYUWCeMvH7Q01PkWDyrY2NWskJFiVDyWLteD0kJ7oIOkjN55Wp5Lkfq
2J6hB7X3O8gIR98kQxIlxNuXx4nS8f587swX13v9LoES6CHTpstYCMaGC29ipH35ChWKuFMeThDQ
CVOGm5LaqQ2CdUTC/dFAeyLQD/R7RPopemRsaZFt0CfoW2iby1evkeC1JABakgr002ia7c2eRGh/
Xf6YIg4+sUGkGmip7Y89Mmas02LPXZuxdp183vnz55VARzqoEkRSBjecBA0SDsKvsuAbsrjwG7A4
unz5srIvRcQAVwo0wmx0ObKkFG845iPghMMYrVy5srl27VrU3ce+ffuabDlyOhfuYBPoQZOnmiIl
S4mWtN/op0ymLFklGcvSNZNATsIVjgwkX1m61Lmbt8pxNqR5/RsnEmigORJ/ctacBOShbouWCTTQ
1Bjg2D1f4RjTuF17s+jlPV6/S6AEmlMLJHnBAjZjuFNlzZ5DtK7hTpzpV0gOSJinqEmoVPC0KkJ6
SqD1h0DHliuX4ESO/sV74+Izb+t26Wf825J5ZM6WzSzYsUui1cNnP+N8HZs8XDcsAl2sTJkEVVD5
ToyFiUuXywbQHlxkHFr6bHftsYnxBbIC8dpWAh2mwCSdCAk3vnrDRmFh90NHv793H8kwzpo1q1mw
YIEkYikUkQaqZlLNDhkAJGzojJlhkWRIdJLMdb43LkCrVq2SCnHRiI0bN8r8akV+ffPu7SRRa46U
szvIHv+mobN0fS5RYE7hrP8n6tu6W48/CLTj+ltRYCLH+Oy6k3DYCTSSE3u0jaNrCLgrgeZ3QUp8
+S6BEGjIIVFMxkAw8cknn0i1Qr4/G4hwPYWFnFpBpG7duolkKFSA5Ibv9dzOl5NMoOlD/E6CCJKA
XKiQvDcJg9w7/r/rwMflekCMcdDgdfCEAkWKmmc2bRFuU6h4cWdSIc/jPSC+vA6/bGpGiL2mY45l
4ymBi6vXRdbB97USbt01iDm1N6IV/y9af/jvv/9ulixZYrI7Jioh0g0aSkQ6kIhJcidHoEsiInfv
vfeKUXuo7LYViuQEyWiW3R1EuveTI8QGLuSy/3fvMw3btpNoGHKNcePGuS3zG0346quv5L4NnjLN
5+sIeUW+QzQX6QX/pnkLcOBhi40XEX9LMgIpJjDi6hRgRes8EWiOyHFEQGMKgUDqsf3cebcE2p2e
2N13CYRA83uTy9mAYkZUipQTzBo1w07SwQkCLhOMs5UrV4bk5t9bv/eHQONiw1hgXmE8IFfB89ki
50v3HpC+bOV3EZW2HDlqxsXJ3+9Lm04kG5brBgQa72ds83gccr3p5OkEenIqI1qv5TTI2/2ILVfe
tGjRQgl0tOLHH38UJwASEOg0MSVKiP4sNRMu0DtNWrbCVGvQQL4TR9pDhw41n376qbIqRdThxIkT
zjLgbCRZYFhIUzOCRvQGHWKZKlVljLIRnzhxYlQkCfoKHBFquWT1B0vCAbkgcga5IFodU6KkM3os
pLhde+dzt779jtwji0R4ItAETyAPkIgpq9aY4mXL3mVjZxFoe6DF23cJhEATLeQz/vKXvyTbvdm+
fbvJkiWLjKeHhg0P+RMe9L3cU65LqVKlZHMdquD7JdZ//Wn0X0+BPf6+7ex5jwnMdks619dtPXPO
7fvyt02nziTqWkYwg/tBDpYS6CgHEemtW7eaGjVqSKdgsWZSRINkRSGSs3FMQ1ILu0XcCGR3WKiQ
mTt3btTqixQKOz7++GMzZMgQkzlzZmdUmqQwIi8pQQDYVI+e96xERe+5Y0dVpkwZKYgSSsfIoQIi
8Zya+etDnBiBZoGHBBNJW7bvgPx/90GDExJom7ezrwTaOjbnpKNtz15Cft0RaNYGX79LIASaqF6t
WrWT/f58++23pk+fPnJt8sfEmKdXrAq56pEkd/YfN8FkyJhRLPlmzpwZ8tJFgl3p0mcwR25+GtHW
gdjn0ncuXLigBFrxB27cuGFmzJhhypUr57SAyV+4sGne+UGJOiGrSMqCTeSMYxMmrI59H5EJk0mZ
z0FPxAA8efJkqlRSUihCHf/6178kjwHLqIyOhZVxQ1GB8o7NL+SFjHIiVklZHIi+rD3+uhBmdM0F
ixZ1zgWxsbESbb5y5YreDC+gIizXixO9YBJoq/iDVUSCVrd5Cylr7BOBzptPdNHunotzCs4baEjt
VWw9EejEvou/BJq1JaWrVL711lumfPny8Sewjr49duEikbGkJjlDhsC9yXJHYkmFv9S2qPMVlg6a
U4xIJtD08QIFCkQ1T1ECnQio6IRWukuXLmKDZ/dVzJ0vv5TPJGpBUgb2eFQPGjVvviy8ZHSToU1E
g4pC6JIKFi0m2jrrPSAAaIimT58upFnt6BQK3/Hrr7+KReXw4cNNxUqV5BjdGlt4w5Zy/A09KhtV
igKgTSRDnfEJUWO8Mm4Zv22695TockxsCYmcWu9DxJsxymlQKB8dhyKqVq0q98CfhRmtMpFHb5sb
HAe4dzwX32hIbbUGDX0i0GyGOvTpK0fYrs/lc0k45P3t0VhPBDqx7+IvgSYpDGvSlM5zYd3ZtWuX
uMZIIKdgQdHL2vWxKZVPQBIcWnSLOIebRRrXktPjQORL4dI4jWOuJZAQzVAC7ScoEY7UY9KkSUKq
a9SoafLly5dgwXVtTKgUiiADmkpFI0aMMC+88IJ59913ozZLX6FIDvz888+imSaCh9yjtYM8ly1b
VsoaexqfNEgL47hmzVoyrlkYGOdsoHVTGzgIPkhE9eDhoC7gVFcjoYpFHD/c0fMXiP4YCUViBBrN
L3My/3VXyrtq/QbiCOKulLcrgU7su/hDoCl0gQtCp06dUvWeUXylWfPmzlNRTnZwwuG3B5uIcRpL
MhxkvVDRYvHV+RwbmIcffjisq+pOnjxZ+gNa4kgk0DjWcK9wdlECrQgKbt++LdUAyUD/8ssvRWNG
kqJKMRSK0IgM/eMf/zDffPONjE+StBivkG5F8uCf//ynbF5cCzQEoxHxxd4zUG1tMGUKSfkudiIO
KTl9+nRI3DvGBwn2dikjxbuaPdBJTnGW7Nnvt0/7jvMXzbwt2+TUp06zZs5IM2S9qeP/N2zYIOto
uINk4rRp0zr9lyOp4VCTOWtWSeyOdiiBVigUCkWyYerUqUKSXjj2WkRrQpPSSDjDnq1R48YheQ+J
NHJq2rNnT8nTsZ/eZHFskGLLljNV69U3DVq3EW9h8oVIrCSZEk05sigrOd5quFUMHjxYpCMUOYs0
jBw5UpKN0clHUl9FCsf9UzmbEmiFQqFQJCO+//57yfVo0qGjkmUPjYItYo937FhY3NMvvvjCHDhw
QErUU76aaGS9+vUlGRH7wiJFiwpBrlSpkomLizNdu3Y1o0aNMsuXLzdvvPFGRBJmV3ACTQn1mo3j
IqafoolnI0QBG4USaIVCoVAkM55+Or7kL6WvlTDf7TiB9rl+gwbaUSIMbBjo95ThjoS+Sm0K/MMp
GKNQAq1QKBSKZAY+2TExMaZ4mbKpbpEWag2HJhLO1BYx8kDeRd169cSpZfOpt8O6n2JHyWZg9erV
emOVQCsUCoUipYB3NwvwoKenKHG+03AnIYEOZyZFZIIKwiTSUm4bp5Vw7KdU58RpDKmOmiIogVYo
FApFCgMbT6q0rT3+RtSTZ2z1ipYqZfLnzy9uJYrIxZEjR2SjRDnyUKv2mFjbeOKUyZ4rl2jaf/rp
J72ZSqAVCoVCkdLAQpCCVBDHcI3GBau16tpNSNVrr72mHSMKsHDhQjmB4b7jER4OfZRiQ3kKFDS5
HASaCs0KJdAKhUKhSCVAGCGOkeiR62sb+9zi+HLPU6Zoh4giUHFYSLSj74d6LgD2e/ljYkR+cvny
Zb15SqAVCoVCkdqgUhtEgsSkaCPPFCDBCqxxXJxWuYxCTJs2Tfp+9QYN/S5Ek5Ka5yzZs0vkmYrJ
CiXQCoVCoQgBQBw7d+4sRGLSshVRQ57RfkNM8Eq+deuWdoQoBRUXScorXDw26GXuk9KQlpDke2+a
NKZ06dLms88+05ulBFqhUCgUoYR//etfEoVlsaa8c6ST521nz5s8+QuYfPnyKTFRmJMnT5pChQoJ
kX70qXGpLunY+vY74vPMprZTp07mhx9+0JukBFqhUCgUoQiy+qlWlzZdOjNr3YaIJc+WnpQiFOr3
rLAASe3evbuQ1pjYWDN7/aZUcYOhPDdjMEOGDFKyXaEEWqFQKBQhDso616hRw9xzzz3mqQXPRRx5
XnnoiFQaVD2pwhMOHz4sNnEQ6cp16jo2kxuT3alj39XrZuCEiSZn3rzyuT179jRffvml3gwl0AqF
QqEIF/z888+mRcuWspA/MmZs2Nh8JdbmbNhkMmTMaIoUKWJu3rypN1rhEb///rtZunSpKVy4sIyD
IiVLmoETJ4m0Ipga5+d2vmzu791H+iWf07xFC3PmzBm9AUqgFQqFQhGuBKJ3796yqNdu2szsvnQ1
bInz0U+/MD2HDI2PKFaubP7617/qDVb4hP/7v/8zW7ZsMbVr15H+QytXrZrpNXSYeWbTFr+dOygh
jm1im+49Te78+eX9kGr06dPHXLp0SS+4EmiFQqFQRAJWrlxp7rvvPkm4W/TynrBMFqxYs5YQlcce
e8z89ttvelMVAYEy4LNnzxYyTbKhRahz5skjfazZA50kmtzt8cEOgv2k6dx/gGnbo6dp0LqNiS1X
Xqp+Wq/Jnj27ON9s375dTnwUSqAVCoVCEWF47733TGxsrBRcgSDsuXItLKLOgyZPNRkyZTKZHG3b
tm16IxVBA6T3+PHjZu7cuaZ///6mYaNGplixYiZ37twmXbp05k9/+pPJnDmzlIYvW7asad++vRk5
cqRZvXq1uXr1qvnf//6nF1EJtEKhUCgiHbdv3xYCQHJhthw5zZhnF4asNppIeWzZchLpa9u2rdrU
KRRKoBUKhUKhSD0QPatXv76Q06KlSpnxi5dItDdUKrbVbBwn343kr7179+oNUyiUQCsUCoVCkfrg
+Pmll14yFSpUELJaoEgR8+SsOWbvlfdTnDS/8vFnZvqataZirdryXfLkyWPmzZtnfvnlF71RCoUS
aIVCoVAoQo9I79+/39SsWVPI631p05pGbduZmS+uF2KbnMR5+f6DpmPfR0zW7Dnks6kih+3Yr7/+
qjdGoVACrVAoFApF6OPixYtm+PDhkkQFoU2fIYOpGddEvHNXHDycZJnHxhOnzMi580yTDh1Njjuf
QbJWjx49pPDFf/7zH70JCoUSaIVCoVAowg/45kJohw4dKu4Dlm0X0emSFSoIAcaTeeiMmWbi0uVS
5W3e1u1m/raXpNDJlFXPmxFz5pqHR44yrbp2E3uwTFmyON8HVwP8qTds2CClxxUKhUIJtEKhUCgi
Ct9++6143Y4ZM8a0atXKFC9ePIGHrrdWoEAB06BhQzN48GDz/PPPmxs3bugFVSgUSqAVCoVCEX34
73//a27dumU+/PBDc/78eXPq1Clz8uRJc+7cOXH5+Prrr82///1vvVAKhUIJtEKhUCgUCoVCoQRa
oVAoFAqFQqFQAq1QKBQKhUKhUCiBVigUCoVCoVAolEArFAqFQqFQKBRKoBUKhUKhUCgUCoUSaIVC
oVAoFAqFQgm0QqFQKBQKhUKhBFqhUCgUCoVCoVACrVAoFAqFQqFQKIFWKBQKhUKhUCiUQCsUCoVC
oVAoFAol0AqFQqFQKBQKhRJohUKhUCgUCoVCCbRCoVAoFAqFQqEEWqFQKBQKhUKhUAKtUCgUCoVC
oVAogVYoFAqFQqFQKBRKoBUKhUKhUCgUCiXQCoVCoVAoFAqFEmiFQqFQKBQKhUIJtEKhUCgUCoVC
oQRaoVAoFAqFQqFQAq1QKBQKhUKhUCiUQCsUCoVCoVAoFEqgFQqFQqFQKBQKJdAKhUKhUCgUCoUS
aIVCoVAoFAqFQgm0QqFQKBQKhUKhBFqhUCgUCoVCoVAogVYoFAqFQqFQKJRAKxQKhUKhUCgUSqAV
CoVCoVAoFAol0AqFQqFQKBQKhRJohUKhUCgUCoVCCbRCoVAoFAqFQqFQAq1QKBQKhUKhUCiBVigU
CoVCoVAolEArFAqFQqFQKBRKoBUKhUKhUCgUCiXQCoVCoVAoFAqFEmiFQqFQKBQKhUKhBFqhUCgU
CoVCoVACrVAoFAqFQqFQKIFWKBQKhUKhUCiUQCsUCoVCoVAoFEqgFQqFQqFQKBQKJdAKhUKhUCgU
CoVCCbRCoVAoFAqFQqEEWqFQKBQKhUKhSGX8/xU+bWx0rQVhAAAAAElFTkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-12-27 15:49:59 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review author's judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-12-13 17:34:48 +0000" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.22" SETTINGS="SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_CI_LINES:NO;SHOW_STUDY_NAMES:NO;DISTINGUISH_SUBGROUPS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of studies comparing ganciclovir to acyclovir.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGsCAMAAAA2Uyl8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Slide2.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-12-13 17:34:48 +0000" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Cumulative healing data from trials evaluating idoxuridine, vidarabine, trifluridine, acyclovir, or interferon plus an antiviral agent. Antiviral healing curves were blended from 24 studies (<LINK REF="STD-Abe-1987" TYPE="STUDY">Abe 1987</LINK>; <LINK REF="STD-Altinisik-1987" TYPE="STUDY">Altinisik 1987</LINK>; <LINK REF="STD-Blake-1977" TYPE="STUDY">Blake 1977</LINK>; <LINK REF="STD-Colin-1981" TYPE="STUDY">Colin 1981</LINK>; <LINK REF="STD-Collum-1980" TYPE="STUDY">Collum 1980</LINK>; <LINK REF="STD-Collum-1985" TYPE="STUDY">Collum 1985</LINK>; <LINK REF="STD-Coster-1976" TYPE="STUDY">Coster 1976</LINK>; <LINK REF="STD-Coster-1979" TYPE="STUDY">Coster 1979</LINK>; <LINK REF="STD-Coster-1980" TYPE="STUDY">Coster 1980</LINK>; <LINK REF="STD-Denis-1983" TYPE="STUDY">Denis 1983</LINK>; <LINK REF="STD-Hart-1965" TYPE="STUDY">Hart 1965</LINK>; <LINK REF="STD-Hoang_x002d_Xuan-1984" TYPE="STUDY">Hoang-Xuan 1984</LINK>; <LINK REF="STD-H_x00f8_vding-1989" TYPE="STUDY">Høvding 1989</LINK>; <LINK REF="STD-Jackson-1984" TYPE="STUDY">Jackson 1984</LINK>; <LINK REF="STD-Klauber-1982" TYPE="STUDY">Klauber 1982</LINK>; <LINK REF="STD-Kumar-1987" TYPE="STUDY">Kumar 1987</LINK>; <LINK REF="STD-La-Lau-1982" TYPE="STUDY">La Lau 1982</LINK>; <LINK REF="STD-Luntz-1963" TYPE="STUDY">Luntz 1963</LINK>; <LINK REF="STD-Markham-1977" TYPE="STUDY">Markham 1977</LINK>; <LINK REF="STD-McCulley-1982" TYPE="STUDY">McCulley 1982</LINK>; <LINK REF="STD-van-Bijsterveld-1980" TYPE="STUDY">van Bijsterveld 1980</LINK>; <LINK REF="STD-Wellings-1972" TYPE="STUDY">Wellings 1972</LINK>; <LINK REF="STD-Yeakley-1981" TYPE="STUDY">Yeakley 1981</LINK>; <LINK REF="STD-Young-1982" TYPE="STUDY">Young 1982</LINK>) that reported healing data for idoxuridine (278 eyes), vidarabine (262 eyes), trifluridine (279 eyes), or acyclovir (480 eyes). Corneal healing with combined interferon-antiviral was estimated from seven studies (<LINK REF="STD-Carmassi-1993" TYPE="STUDY">Carmassi 1993</LINK>; <LINK REF="STD-Colin-1983" TYPE="STUDY">Colin 1983</LINK>; <LINK REF="STD-de-Koning-1982" TYPE="STUDY">de Koning 1982</LINK>; <LINK REF="STD-de-Koning-1983" TYPE="STUDY">de Koning 1983</LINK>; <LINK REF="STD-Meurs-1985" TYPE="STUDY">Meurs 1985</LINK>; <LINK REF="STD-Sundmacher-1981b" TYPE="STUDY">Sundmacher 1981b</LINK>; <LINK REF="STD-van-Bijsterveld-1989" TYPE="STUDY">van Bijsterveld 1989</LINK>) that evaluated 196 participants who received interferon with trifluridine (75), acyclovir (102), or brivudine (19). (ACV, acyclovir; ARA, vidarabine; IDU, idoxuridine; IFN+, interferon with an antiviral (trifluridine, acyclovir, or brivudine); TFT, trifluridine).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASAAAAErCAYAAAB+RF5DAAA9MklEQVR42u1dB3hTZ5ad3Z3ZmVRK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</FILE>
</FIGURE>
<FIGURE FILENAME="Incl.Excl.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-12-27 20:19:41 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Histograms of publication year for included studies and excluded studies. Most of the studies during the late 20<SUP>th</SUP> century took place in Europe or North America. An upswing in studies reported since 2005 is due to trials conducted in China.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAtAAAAIcCAYAAADffZlTAABH3klEQVR42u3dCZRU5Z3w/8zMO5NZ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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2014-05-01 19:16:21 +0100" MODIFIED_BY="Kirk R. Wilhelmus"/>
<APPENDICES MODIFIED="2014-12-07 21:25:07 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-08-20 14:38:21 +0100" MODIFIED_BY=" Iris Gordon" NO="1">
<TITLE MODIFIED="2010-05-25 23:41:38 +0100" MODIFIED_BY="[Empty name]">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-20 14:38:21 +0100" MODIFIED_BY=" Iris Gordon">
<P>#1 MeSH descriptor Keratitis, Herpetic<BR/>#2 MeSH descriptor Keratitis, Dendritic<BR/>#3 (herpe* or simplex) near (cornea* or kerati* or dendr* or ocular) <BR/>#4 (#1 OR #2 OR #3)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-08-14 14:45:42 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-08-07 15:40:44 +0100" MODIFIED_BY="[Empty name]">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-08-14 14:45:42 +0100" MODIFIED_BY="[Empty name]">
<P>((randomized controlled trial [pt]) OR (controlled clinical trial [pt]) OR (clinical trial [pt]) OR (random allocation [mh]) OR (randomized controlled trials [mh])) AND ((herpes OR herpetic OR simplex) AND (cornea OR corneal OR keratitis OR ocular))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2014-07-31 21:20:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-07-31 21:18:48 +0100" MODIFIED_BY="[Empty name]">EMBASE.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-31 21:20:19 +0100" MODIFIED_BY="[Empty name]">
<P>#1 'randomized controlled trial'/exp<BR/>#2 'randomization'/exp<BR/>#3 'double blind procedure'/exp<BR/>#4 'single blind procedure'/exp<BR/>#5 random*:ab,ti<BR/>#6 #1 OR #2 OR #3 OR #4 OR #5<BR/>#7 'animal'/exp OR 'animal experiment'/exp<BR/>#8 'human'/exp<BR/>#9 #7 AND #8<BR/>#10 #7 NOT #9<BR/>#11 #6 NOT #10<BR/>#12 'clinical trial'/exp<BR/>#13 (clin* NEAR/3 trial*):ab,ti<BR/>#14 ((singl* OR doubl* OR trebl* OR tripl*) NEAR/3 (blind* OR mask*)):ab,ti<BR/>#15 'placebo'/exp<BR/>#16 placebo*:ab,ti<BR/>#17 random*:ab,ti<BR/>#18 'experimental design'/exp<BR/>#19 'crossover procedure'/exp<BR/>#20 'control group'/exp<BR/>#21 'latin square design'/exp<BR/>#22 #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21<BR/>#23 #22 NOT #10<BR/>#24 #23 NOT #11<BR/>#25 'comparative study'/exp<BR/>#26 'evaluation'/exp<BR/>#27 'prospective study'/exp<BR/>#28 control*:ab,ti OR prospectiv*:ab,ti OR volunteer*:ab,ti<BR/>#29 #25 OR #26 OR #27 OR #28<BR/>#30 #29 NOT #10<BR/>#31 #30 NOT (#11 OR #23)<BR/>#32 #11 OR #24 OR #31<BR/>#33 'herpes simplex keratitis'/exp<BR/>#34 ((herpe* OR simplex) NEAR/4 (cornea* OR kerati* OR dendr* OR ocular)):ab,ti<BR/>#35 #33 OR #34<BR/>#36 #32 AND #35</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2014-12-07 20:57:03 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-11-01 13:24:41 +0000" MODIFIED_BY=" Iris Gordon">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-07 20:57:03 +0000" MODIFIED_BY="[Empty name]">
<P>English Language Search Terms: (herpe$ or simplex) and (cornea$ or kerati$ or dendr$ or ocular)</P>
<P>Spanish Language Search Terms: (herpes simplex) and (dendrítica or queratitis)</P>
<P>Portuguese Language Search Terms (herpes simples) and (dendr$ or ceratite)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2014-07-31 21:26:54 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2013-08-16 21:45:35 +0100" MODIFIED_BY=" Iris Gordon">OpenGrey search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-31 21:21:06 +0100" MODIFIED_BY="[Empty name]">
<P>(herpe* OR simplex) AND (cornea* OR kerati* OR dendr* OR ocular)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-06" MODIFIED="2014-07-31 21:21:52 +0100" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2010-11-01 13:26:35 +0000" MODIFIED_BY=" Iris Gordon">BIOSIS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-31 21:21:52 +0100" MODIFIED_BY="[Empty name]">
<P>TS=(herpe* OR simplex) AND TS=(cornea* OR kerati* OR dendr* OR ocular) AND TS=(random* OR trial*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-07" MODIFIED="2014-04-19 16:56:20 +0100" MODIFIED_BY="Kirk R. Wilhelmus" NO="7">
<TITLE MODIFIED="2014-04-19 16:49:18 +0100" MODIFIED_BY="Kirk R. Wilhelmus">Scopus search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-04-19 16:56:00 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Article Title, Abstract, Keywords=(herpe* OR simplex) AND (keratitis OR cornea*) AND (trial* OR RCT* OR random* OR blind*)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-08" MODIFIED="2014-04-19 16:56:20 +0100" MODIFIED_BY=" Iris Gordon" NO="8">
<TITLE MODIFIED="2013-08-30 20:37:51 +0100" MODIFIED_BY=" Iris Gordon">J-Global search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-11-03 19:25:02 +0000" MODIFIED_BY=" Iris Gordon">
<P>English Language Search Terms: (herpes OR simplex OR dendritic) AND (keratitis OR cornea)</P>
<P>Japanese Language Individual Search Terms: (&#12504;&#12523;&#12506;&#12473; OR &#21336;&#32020;&#12504;&#12523;&#12506;&#12473; OR &#27193;&#26525;&#29366;&#12398; OR &#27193;&#26408;&#29366;&#12398;) AND (&#35282;&#33180;&#28814; OR &#35282;&#33180;)</P>
<P>Japanese Language Combined Search Terms: &#12504;&#12523;&#12506;&#12473;&#24615;&#35282;&#33180;&#28814; OR &#35282;&#33180;&#12504;&#12523;&#12506;&#12473; OR &#32020;&#12504;&#12523;&#12506;&#12473;&#24615;&#35282;&#33180;&#28814; OR &#27193;&#26525;&#29366;&#35282;&#33180;&#28814;</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-09" MODIFIED="2014-12-06 19:26:14 +0000" MODIFIED_BY=" Iris Gordon" NO="9">
<TITLE MODIFIED="2013-08-16 21:47:45 +0100" MODIFIED_BY=" Iris Gordon">CNKI search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-06 19:26:14 +0000" MODIFIED_BY="[Empty name]">
<P>English Language Search Term (subject, precise): herpes simplex keratitis</P>
<P>Chinese Language Search Term (subject, precise): &#21333;&#32431;&#30129;&#30137;&#24615;&#35282;&#33180;&#28814;</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-10" MODIFIED="2014-07-31 21:23:36 +0100" MODIFIED_BY="[Empty name]" NO="10">
<TITLE MODIFIED="2010-11-01 13:24:54 +0000" MODIFIED_BY=" Iris Gordon">ZETOC search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-31 21:23:36 +0100" MODIFIED_BY="[Empty name]">
<P>herpe* simplex kerati* random*</P>
<P>herpe* simplex kerati* trial*</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-11" MODIFIED="2014-04-19 16:56:11 +0100" MODIFIED_BY=" Iris Gordon" NO="11">
<TITLE MODIFIED="2010-11-01 13:30:05 +0000" MODIFIED_BY=" Iris Gordon">
<I>meta</I>Register of Controlled Trials search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-01 13:39:01 +0000" MODIFIED_BY=" Iris Gordon">
<P>herpe* simplex AND keratitis</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-12" MODIFIED="2014-07-31 21:32:10 +0100" MODIFIED_BY="[Empty name]" NO="12">
<TITLE MODIFIED="2014-07-31 21:28:18 +0100" MODIFIED_BY="[Empty name]">ClinicalTrials.gov search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-07-31 21:29:54 +0100" MODIFIED_BY="[Empty name]">
<P>Condition: (herpes OR simplex) AND (corneal OR keratitis OR dendritic OR ocular)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-13" MODIFIED="2014-07-31 21:32:10 +0100" MODIFIED_BY="[Empty name]" NO="13">
<TITLE MODIFIED="2013-08-16 21:58:35 +0100" MODIFIED_BY="Kirk R. Wilhelmus">ICTRP search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-16 21:59:17 +0100" MODIFIED_BY="Kirk R. Wilhelmus">
<P>keratitis</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-14" MODIFIED="2014-12-07 21:25:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus" NO="14">
<TITLE MODIFIED="2014-12-07 21:25:07 +0000" MODIFIED_BY="Kirk R. Wilhelmus">ChiCTR search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-12-07 21:10:52 +0000" MODIFIED_BY="Kirk R. Wilhelmus">
<P>Target disease=eye or cornea or keratitis</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-15" MODIFIED="2014-12-07 21:13:47 +0000" MODIFIED_BY="[Empty name]" NO="15">
<TITLE MODIFIED="2014-09-05 15:47:39 +0100" MODIFIED_BY="[Empty name]">U.S. Food and Drug Administration search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-05 15:05:50 +0100" MODIFIED_BY="[Empty name]">
<P>"herpes simplex keratitis" and "dendritic keratitis"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-16" MODIFIED="2014-12-07 21:13:44 +0000" MODIFIED_BY="[Empty name]" NO="16">
<TITLE MODIFIED="2014-09-05 15:05:25 +0100" MODIFIED_BY="[Empty name]">National Institute for Health and Clinical Excellence search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-05 15:18:30 +0100" MODIFIED_BY="[Empty name]">
<P>"herpes simplex keratitis" and "dendritic keratitis"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-17" MODIFIED="2014-12-07 21:13:41 +0000" MODIFIED_BY="[Empty name]" NO="17">
<TITLE MODIFIED="2014-09-05 15:04:49 +0100" MODIFIED_BY="[Empty name]">European Medicines Agency search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2014-09-05 15:12:00 +0100" MODIFIED_BY="[Empty name]">
<P>"herpes simplex keratitis" and "dendritic keratitis"</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;137 studies (8,333 eyes) included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="285">
<FLOWCHARTBOX TEXT="&lt;p&gt;194 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="156">
<FLOWCHARTBOX TEXT="&lt;p&gt;280 studies' full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="151">
<FLOWCHARTBOX TEXT="&lt;p&gt;2,430 records screened&lt;/p&gt;" WIDTH="162">
<FLOWCHARTBOX TEXT="&lt;p&gt;2,430 records after duplicates removed&lt;/p&gt;" WIDTH="270">
<FLOWCHARTBOX TEXT="&lt;p&gt;2,800 records identified through database searching: MEDLINE/EMBASE/SCOPUS/BIOSIS (1671), LILACS (54), CNKI (902), J-Global (113), OpenGrey (7), mRCT (45), ZETOC (7), ICTRP (1)&lt;/p&gt;" WIDTH="228"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;145 additional records identified through other sources&lt;/p&gt;" WIDTH="154"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;2,152 records excluded because:&lt;/p&gt;&lt;p&gt;-2,079 records not treatment trial of HSV epithelial keratitis&lt;/p&gt;&lt;p&gt;-60 ancillary reports of same study&lt;/p&gt;&lt;p&gt;-2 unpublished studies without available data&lt;/p&gt;" WIDTH="288"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;86 studies excluded because:&lt;/p&gt;&lt;p&gt;-50 studies of traditional or botanical medicines&lt;/p&gt;&lt;p&gt;-25 studies with non-concurrent/non-randomised allocation&lt;/p&gt;&lt;p&gt;-7 studies with varied eligibility criteria&lt;/p&gt;&lt;p&gt;-4 studies using outcome other than corneal healing&lt;/p&gt;" WIDTH="285"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;57 studies excluded because of insufficient outcome data&lt;/p&gt;" WIDTH="284"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>